<!DOCTYPE html>
<html lang="en">
  <head>
    <title>US20190240354A1 - Compositions and methods for delivering messenger rna 
      - Google Patents</title>

    <meta name="viewport" content="width=device-width, initial-scale=1">
    <meta charset="UTF-8">
    <meta name="referrer" content="origin-when-crossorigin">
    <link rel="canonical" href="https://patents.google.com/patent/US20190240354A1/en">
    <meta name="description" content="
     The present invention provides compositions comprising nucleic acid molecules, such as mRNA molecules, encapsulated within lipid particles. The compositions are useful, for example, to introduce the mRNA molecules into a human subject where they are translated to produce a polypeptide that functions to ameliorate one or more symptoms of a disease. 
   
   ">
    <meta name="DC.type" content="patent">
    <meta name="DC.title" content="Compositions and methods for delivering messenger rna 
     ">
    <meta name="DC.date" content="2017-06-30" scheme="dateSubmitted">
    <meta name="DC.description" content="
     The present invention provides compositions comprising nucleic acid molecules, such as mRNA molecules, encapsulated within lipid particles. The compositions are useful, for example, to introduce the mRNA molecules into a human subject where they are translated to produce a polypeptide that functions to ameliorate one or more symptoms of a disease. 
   
   ">
    <meta name="citation_patent_application_number" content="US:16/312,162">
    <meta name="citation_pdf_url" content="https://patentimages.storage.googleapis.com/de/63/43/bb3e4ad0ff8479/US20190240354A1.pdf">
    <meta name="citation_patent_publication_number" content="US:20190240354:A1">
    <meta name="DC.date" content="2019-08-08">
    <meta name="DC.contributor" content="Michael J. Abrams" scheme="inventor">
    <meta name="DC.contributor" content="James Heyes" scheme="inventor">
    <meta name="DC.contributor" content="Adam Judge" scheme="inventor">
    <meta name="DC.contributor" content="Kieu Mong LAM" scheme="inventor">
    <meta name="DC.contributor" content="Lorne Ralph PALMER" scheme="inventor">
    <meta name="DC.contributor" content="Stephen P. REID" scheme="inventor">
    <meta name="DC.contributor" content="Edward D. YAWORSKI" scheme="inventor">
    <meta name="DC.contributor" content="Arbutus Biopharma Corp" scheme="assignee">
    <link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Roboto:400,400italic,500,500italic,700">
    <link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Product+Sans">
    <link rel="stylesheet" href="https://fonts.googleapis.com/css2?family=Google+Sans:wght@400;500;700">

    <style>
      
      #gb { top: 15px; left: auto; right: 0; width: auto; min-width: 135px !important; }   
      body { transition: none; }
    </style>
    <script></script>

    <script>
      window.version = 'patent-search.search_20250707_RC00';

      function sendFeedback() {
        userfeedback.api.startFeedback({
          'productId': '713680',
          'bucket': 'patent-search-web',
          'productVersion': window.version,
        });
      }

      window.experiments = {};
      window.experiments.patentCountries = "ae,ag,al,am,ao,ap,ar,at,au,aw,az,ba,bb,bd,be,bf,bg,bh,bj,bn,bo,br,bw,bx,by,bz,ca,cf,cg,ch,ci,cl,cm,cn,co,cr,cs,cu,cy,cz,dd,de,dj,dk,dm,do,dz,ea,ec,ee,eg,em,ep,es,fi,fr,ga,gb,gc,gd,ge,gh,gm,gn,gq,gr,gt,gw,hk,hn,hr,hu,ib,id,ie,il,in,ir,is,it,jo,jp,ke,kg,kh,km,kn,kp,kr,kw,kz,la,lc,li,lk,lr,ls,lt,lu,lv,ly,ma,mc,md,me,mg,mk,ml,mn,mo,mr,mt,mw,mx,my,mz,na,ne,ng,ni,nl,no,nz,oa,om,pa,pe,pg,ph,pl,pt,py,qa,ro,rs,ru,rw,sa,sc,sd,se,sg,si,sk,sl,sm,sn,st,su,sv,sy,sz,td,tg,th,tj,tm,tn,tr,tt,tw,tz,ua,ug,us,uy,uz,vc,ve,vn,wo,yu,za,zm,zw";
      
      
      window.experiments.keywordWizard = true;
      
      
      
      window.experiments.definitions = true;
      window.experiments.plogs = true;

      window.Polymer = {
        dom: 'shady',
        lazyRegister: true,
      };
    </script>

    <script src="//www.gstatic.com/patent-search/frontend/patent-search.search_20250707_RC00/scs/compiled_dir/webcomponentsjs/webcomponents-lite.min.js"></script>
    <link rel="import" href="//www.gstatic.com/patent-search/frontend/patent-search.search_20250707_RC00/scs/compiled_dir/search-app-vulcanized.html">
  </head>
  <body unresolved>
    
    
    <script></script>
    <script src="//www.gstatic.com/patent-search/frontend/patent-search.search_20250707_RC00/scs/compiled_dir/search-app-vulcanized.js"></script>
    <search-app>
      
      

      <article class="result" itemscope itemtype="http://schema.org/ScholarlyArticle">
  <h1 itemprop="pageTitle">US20190240354A1 - Compositions and methods for delivering messenger rna 
      - Google Patents</h1>
  <span itemprop="title">Compositions and methods for delivering messenger rna 
     </span>

  <meta itemprop="type" content="patent">
  <a href="https://patentimages.storage.googleapis.com/de/63/43/bb3e4ad0ff8479/US20190240354A1.pdf" itemprop="pdfLink">Download PDF</a>
  <h2>Info</h2>

  <dl>
    <dt>Publication number</dt>
    <dd itemprop="publicationNumber">US20190240354A1</dd>
    <meta itemprop="numberWithoutCodes" content="20190240354">
    <meta itemprop="kindCode" content="A1">
    <meta itemprop="publicationDescription" content="Patent application publication">
    <span>US20190240354A1</span>
    <span>US16/312,162</span>
    <span>US201716312162A</span>
    <span>US2019240354A1</span>
    <span>US 20190240354 A1</span>
    <span>US20190240354 A1</span>
    <span>US 20190240354A1</span>
    <span>  </span>
    <span> </span>
    <span> </span>
    <span>US 201716312162 A</span>
    <span>US201716312162 A</span>
    <span>US 201716312162A</span>
    <span>US 2019240354 A1</span>
    <span>US2019240354 A1</span>
    <span>US 2019240354A1</span>

    <dt>Authority</dt>
    <dd itemprop="countryCode">US</dd>
    <dd itemprop="countryName">United States</dd>

    <dt>Prior art keywords</dt>
    <dd itemprop="priorArtKeywords" repeat>lipid</dd>
    <dd itemprop="priorArtKeywords" repeat>mol</dd>
    <dd itemprop="priorArtKeywords" repeat>peg</dd>
    <dd itemprop="priorArtKeywords" repeat>mrna</dd>
    <dd itemprop="priorArtKeywords" repeat>population</dd>

    <dt>Prior art date</dt>
    <dd><time itemprop="priorArtDate" datetime="2016-06-30">2016-06-30</time></dd>

    <dt>Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)</dt>
    <dd itemprop="legalStatusIfi" itemscope>
      <span itemprop="status">Granted</span>
    </dd>
  </dl>

  <dt>Application number</dt>
  <dd itemprop="applicationNumber">US16/312,162</dd>

  

  <dt>Other versions</dt>
  <dd itemprop="directAssociations" itemscope repeat>
    <a href="/patent/US11191849B2/en">
      <span itemprop="publicationNumber">US11191849B2</span>
      (<span itemprop="primaryLanguage">en</span>
    </a>
  </dd>

  <dt>Inventor</dt>
  <dd itemprop="inventor" repeat>Michael J. Abrams</dd>
  <dd itemprop="inventor" repeat>James Heyes</dd>
  <dd itemprop="inventor" repeat>Adam Judge</dd>
  <dd itemprop="inventor" repeat>Kieu Mong LAM</dd>
  <dd itemprop="inventor" repeat>Lorne Ralph PALMER</dd>
  <dd itemprop="inventor" repeat>Stephen P. REID</dd>
  <dd itemprop="inventor" repeat>Edward D. YAWORSKI</dd>

  <dt>Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)</dt>
  <dd itemprop="assigneeCurrent" repeat>
    Arbutus Biopharma Corp
  </dd>

  <dt>Original Assignee</dt>
  <dd itemprop="assigneeOriginal" repeat>Arbutus Biopharma Corp</dd>

  <dt>Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)</dt>
  <dd><time itemprop="priorityDate" datetime="2016-06-30">2016-06-30</time></dd>

  <dt>Filing date</dt>
  <dd><time itemprop="filingDate" datetime="2017-06-30">2017-06-30</time></dd>

  <dt>Publication date</dt>
  <dd><time itemprop="publicationDate" datetime="2019-08-08">2019-08-08</time></dd>

  
  <dd itemprop="events" itemscope repeat>
    <time itemprop="date" datetime="2017-06-30">2017-06-30</time>
    <span itemprop="title">Application filed by Arbutus Biopharma Corp</span>
    <span itemprop="type">filed</span>
    <span itemprop="critical" content="true" bool>Critical</span>
    
    
    
    <span itemprop="assigneeSearch">Arbutus Biopharma Corp</span>
  </dd>
  <dd itemprop="events" itemscope repeat>
    <time itemprop="date" datetime="2017-06-30">2017-06-30</time>
    <span itemprop="title">Priority to US16/312,162</span>
    <span itemprop="type">priority</span>
    <span itemprop="critical" content="true" bool>Critical</span>
    
    
    <span itemprop="documentId">patent/US11191849B2/en</span>
    
  </dd>
  <dd itemprop="events" itemscope repeat>
    <time itemprop="date" datetime="2019-03-05">2019-03-05</time>
    <span itemprop="title">Assigned to ARBUTUS BIOPHARMA CORPORATION</span>
    <span itemprop="type">reassignment</span>
    
    
    
    
    <span itemprop="assigneeSearch">ARBUTUS BIOPHARMA CORPORATION</span>
    <span itemprop="description" repeat>ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS).</span>
    <span itemprop="description" repeat>Assignors: LAM, Kieu Mong, JUDGE, ADAM, ABRAMS, MICHAEL J., HEYES, JAMES, PALMER, Lorne Ralph, REID, Stephen P., YAWORSKI, Edward D.</span>
  </dd>
  <dd itemprop="events" itemscope repeat>
    <time itemprop="date" datetime="2019-08-08">2019-08-08</time>
    <span itemprop="title">Publication of US20190240354A1</span>
    <span itemprop="type">publication</span>
    <span itemprop="critical" content="true" bool>Critical</span>
    
    
    <span itemprop="documentId">patent/US20190240354A1/en</span>
    
  </dd>
  <dd itemprop="events" itemscope repeat>
    <time itemprop="date" datetime="2021-12-07">2021-12-07</time>
    <span itemprop="title">Application granted</span>
    <span itemprop="type">granted</span>
    <span itemprop="critical" content="true" bool>Critical</span>
    
    
    
    
  </dd>
  <dd itemprop="events" itemscope repeat>
    <time itemprop="date" datetime="2021-12-07">2021-12-07</time>
    <span itemprop="title">Publication of US11191849B2</span>
    <span itemprop="type">publication</span>
    <span itemprop="critical" content="true" bool>Critical</span>
    
    
    <span itemprop="documentId">patent/US11191849B2/en</span>
    
  </dd>
  <dd itemprop="events" itemscope repeat>
    <time itemprop="date">Status</time>
    <span itemprop="title">Active</span>
    <span itemprop="type">legal-status</span>
    <span itemprop="critical" content="true" bool>Critical</span>
    <span itemprop="current" content="true" bool>Current</span>
    
    
    
  </dd>
  <dd itemprop="events" itemscope repeat>
    <time itemprop="date" datetime="2037-06-30">2037-06-30</time>
    <span itemprop="title">Anticipated expiration</span>
    <span itemprop="type">legal-status</span>
    <span itemprop="critical" content="true" bool>Critical</span>
    
    
    
    
  </dd>

  <h2>Links</h2>
  <ul>
    <li itemprop="links" itemscope repeat>
          <meta itemprop="id" content="usptoLink">
          <a href="https://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&p=1&u=/netahtml/PTO/srchnum.html&r=1&f=G&l=50&d=PG01&s1=20190240354.PGNR." itemprop="url" target="_blank"><span itemprop="text">USPTO</span></a>
        </li>
        
        <li itemprop="links" itemscope repeat>
          <meta itemprop="id" content="usptoPatentCenterLink">
          <a href="https://patentcenter.uspto.gov/applications/16312162" itemprop="url" target="_blank"><span itemprop="text">USPTO PatentCenter</span></a>
        </li>
        <li itemprop="links" itemscope repeat>
          <meta itemprop="id" content="usptoAssignmentLink">
          <a href="https://assignment.uspto.gov/patent/index.html#/patent/search/resultFilter?searchInput=20190240354" itemprop="url" target="_blank"><span itemprop="text">USPTO Assignment</span></a>
        </li>

    <li itemprop="links" itemscope repeat>
        <meta itemprop="id" content="espacenetLink">
        <a href="https://worldwide.espacenet.com/publicationDetails/biblio?CC=US&amp;NR=2019240354A1&amp;KC=A1&amp;FT=D" itemprop="url" target="_blank"><span itemprop="text">Espacenet</span></a>
      </li>
      

    

    <li itemprop="links" itemscope repeat>
      <meta itemprop="id" content="globalDossierLink">
      <a href="https://globaldossier.uspto.gov/result/application/US/16312162/1" itemprop="url" target="_blank"><span itemprop="text">Global Dossier</span></a>
    </li>

    

      

      

      <li itemprop="links" itemscope repeat>
        <meta itemprop="id" content="stackexchangeLink">
        <a href="https://patents.stackexchange.com/questions/tagged/US20190240354" itemprop="url"><span itemprop="text">Discuss</span></a>
      </li>
      
  </ul>

  <ul itemprop="concept" itemscope>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">0</span>
      <span itemprop="name">*CC(C)OC(COC)COP(C)(=O)O</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">*CC(C)OC(COC)COP(C)(=O)O</span>
      <span itemprop="inchi_key"></span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">11</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">NRLNQCOGCKAESA-KWXKLSQISA-N</span>
      <span itemprop="name">CCCCC/C=C\C/C=C\CCCCCCCCC(CCCCCCCC/C=C\C/C=C\CCCCC)OC(=O)CCCN(C)C</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCC/C=C\C/C=C\CCCCCCCCC(CCCCCCCC/C=C\C/C=C\CCCCC)OC(=O)CCCN(C)C</span>
      <span itemprop="inchi_key">NRLNQCOGCKAESA-KWXKLSQISA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">2</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">DIIXYZRGUJMAPE-KWXKLSQISA-N</span>
      <span itemprop="name">CCCCC/C=C\C/C=C\CCCCCCCCC(CCCCCCCC/C=C\C/C=C\CCCCC)OCCCN(C)C</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCC/C=C\C/C=C\CCCCCCCCC(CCCCCCCC/C=C\C/C=C\CCCCC)OCCCN(C)C</span>
      <span itemprop="inchi_key">DIIXYZRGUJMAPE-KWXKLSQISA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">2</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">FHCUZLOJBZEFJY-HWPCFPMLSA-N</span>
      <span itemprop="name">CC(C)CCCC(C)CCC(CCC(C)CCCC(C)C)C(CCC(C)CCCC(C)C)OC(=O)CCCCN(C)C.CCCCC/C=C\CCCC(CCC/C=C\CCCCC)C(CCC(C)CCCC(C)C)OC(=O)CCCCN(C)C.CCCCC/C=C\CCCC(CCC/C=C\CCCCC)C(CCC/C=C\CCCCC)OCCCCCN(C)C.CCCCC/C=C\CCCC(CCC/C=C\CCCCC)C(CCC/C=C\CCCCC)OCCCCN(C)C.CCCCC/C=C\CCCC(OC(=O)CCCCN(C)C)C(CCCCCCCCCC)CCCCCCCCCC.CCCCCC1CC1CCCC(CCCC1CC1CCCCC)C(CCCC1CC1CCCCC)OC(=O)CCCCCN(C)C</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CC(C)CCCC(C)CCC(CCC(C)CCCC(C)C)C(CCC(C)CCCC(C)C)OC(=O)CCCCN(C)C.CCCCC/C=C\CCCC(CCC/C=C\CCCCC)C(CCC(C)CCCC(C)C)OC(=O)CCCCN(C)C.CCCCC/C=C\CCCC(CCC/C=C\CCCCC)C(CCC/C=C\CCCCC)OCCCCCN(C)C.CCCCC/C=C\CCCC(CCC/C=C\CCCCC)C(CCC/C=C\CCCCC)OCCCCN(C)C.CCCCC/C=C\CCCC(OC(=O)CCCCN(C)C)C(CCCCCCCCCC)CCCCCCCCCC.CCCCCC1CC1CCCC(CCCC1CC1CCCCC)C(CCCC1CC1CCCCC)OC(=O)CCCCCN(C)C</span>
      <span itemprop="inchi_key">FHCUZLOJBZEFJY-HWPCFPMLSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">NCBHETHFUGYBNA-SYLYGHNVSA-N</span>
      <span itemprop="name">CC/C=C\CCC(CC/C=C\CC)CC(OC(=O)CCCCN(C)C)C(CC/C=C\CCC)CC/C=C\CCC.CC/C=C\CCC(CC/C=C\CC)CC(OC(=O)CCCCN(C)C)C(CC/C=C\CCCCC)CC/C=C\CCCCC.CCCCC/C=C\CCCC(CCC/C=C\CCCCC)C(CC(CCCC)CCCCCC)OC(=O)CCCCN(C)C.CCCCCCCCC(CCCCCC)CC(CC(CCCCCC)CCCCCCCC)OC(=O)CCCCCN(C)C.CCCCCCCCC(CCCCCC)CC(CC(CCCCCC)CCCCCCCC)OC(=O)CCCCN(C)C</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CC/C=C\CCC(CC/C=C\CC)CC(OC(=O)CCCCN(C)C)C(CC/C=C\CCC)CC/C=C\CCC.CC/C=C\CCC(CC/C=C\CC)CC(OC(=O)CCCCN(C)C)C(CC/C=C\CCCCC)CC/C=C\CCCCC.CCCCC/C=C\CCCC(CCC/C=C\CCCCC)C(CC(CCCC)CCCCCC)OC(=O)CCCCN(C)C.CCCCCCCCC(CCCCCC)CC(CC(CCCCCC)CCCCCCCC)OC(=O)CCCCCN(C)C.CCCCCCCCC(CCCCCC)CC(CC(CCCCCC)CCCCCCCC)OC(=O)CCCCN(C)C</span>
      <span itemprop="inchi_key">NCBHETHFUGYBNA-SYLYGHNVSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">OZZIBOWRJCNZAT-UEADRGIISA-N</span>
      <span itemprop="name">CCCCC/C=C\C/C=C\C/C=C\CCCCCOCC(CN(C)C)OCCCCC/C=C\C/C=C\C/C=C\CCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCC/C=C\C/C=C\C/C=C\CCCCCOCC(CN(C)C)OCCCCC/C=C\C/C=C\C/C=C\CCCCC</span>
      <span itemprop="inchi_key">OZZIBOWRJCNZAT-UEADRGIISA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">LRFJOIPOPUJUMI-KWXKLSQISA-N</span>
      <span itemprop="name">CCCCC/C=C\C/C=C\CCCCCCCCC1(CCCCCCCC/C=C\C/C=C\CCCCC)OCC(CCN(C)C)O1</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCC/C=C\C/C=C\CCCCCCCCC1(CCCCCCCC/C=C\C/C=C\CCCCC)OCC(CCN(C)C)O1</span>
      <span itemprop="inchi_key">LRFJOIPOPUJUMI-KWXKLSQISA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">NFQBIAXADRDUGK-KWXKLSQISA-N</span>
      <span itemprop="name">CCCCC/C=C\C/C=C\CCCCCCCCOCC(CN(C)C)OCCCCCCCC/C=C\C/C=C\CCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCC/C=C\C/C=C\CCCCCCCCOCC(CN(C)C)OCCCCCCCC/C=C\C/C=C\CCCCC</span>
      <span itemprop="inchi_key">NFQBIAXADRDUGK-KWXKLSQISA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">WZUMXOSHBRRSQK-MGMQGUCPSA-N</span>
      <span itemprop="name">CCCCC/C=C\CCC(CC/C=C\CCCCC)C(CC/C=C\CCCCC)OC(=O)CCCCN(C)C.CCCCC/C=C\CCC(CC/C=C\CCCCC)C(CC/C=C\CCCCC)OC(=O)CCCN(C)C.CCCCC/C=C\CCCC(CCC/C=C\CCCCC)C(CC/C=C\CCCCC)OC(=O)N(C)CCCN(C)C.CCCCC/C=C\CCCC(CCC/C=C\CCCCC)C(CC/C=C\CCCCC)OC(=O)NCCCN(C)C.CCCCC/C=C\CCCC(CCC/C=C\CCCCC)C(CC/C=C\CCCCC)OC(=O)NCCN(C)C.CCCCC/C=C\CCCC(OC(=O)CCCN(C)C)C(O)(CCC/C=C\CCCCC)CCC/C=C\CCCCC.CCCCC/C=C\CCCC(OC(=O)CCN(C)C)C(O)(CCC/C=C\CCCCC)CCC/C=C\CCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCC/C=C\CCC(CC/C=C\CCCCC)C(CC/C=C\CCCCC)OC(=O)CCCCN(C)C.CCCCC/C=C\CCC(CC/C=C\CCCCC)C(CC/C=C\CCCCC)OC(=O)CCCN(C)C.CCCCC/C=C\CCCC(CCC/C=C\CCCCC)C(CC/C=C\CCCCC)OC(=O)N(C)CCCN(C)C.CCCCC/C=C\CCCC(CCC/C=C\CCCCC)C(CC/C=C\CCCCC)OC(=O)NCCCN(C)C.CCCCC/C=C\CCCC(CCC/C=C\CCCCC)C(CC/C=C\CCCCC)OC(=O)NCCN(C)C.CCCCC/C=C\CCCC(OC(=O)CCCN(C)C)C(O)(CCC/C=C\CCCCC)CCC/C=C\CCCCC.CCCCC/C=C\CCCC(OC(=O)CCN(C)C)C(O)(CCC/C=C\CCCCC)CCC/C=C\CCCCC</span>
      <span itemprop="inchi_key">WZUMXOSHBRRSQK-MGMQGUCPSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">LLWQKLOBPZIJEN-VNKKGPJPSA-N</span>
      <span itemprop="name">CCCCC/C=C\CCCC(CCC/C=C\CCCCC)C(CC/C=C\CCCCC)OC(=O)CCCCCN(C)C.CCCCC/C=C\CCCC(CCC/C=C\CCCCC)C(CC/C=C\CCCCC)OC(=O)CCCCN(C)C.CCCCC/C=C\CCCC(CCC/C=C\CCCCC)C(CC/C=C\CCCCC)OC(=O)CCCN(C)C.CCCCC/C=C\CCCC(CCC/C=C\CCCCC)C(CCC/C=C\CCCCC)OC(=O)CCCN(C)C.CCCCC/C=C\CCCC(CCC/C=C\CCCCC)C(CCC/C=C\CCCCC)OC(=O)N(C)CCCN(C)C.CCCCC/C=C\CCCC(CCC/C=C\CCCCC)C(CCC/C=C\CCCCC)OC(=O)NCCCN(C)C.CCCCC/C=C\CCCC(CCC/C=C\CCCCC)C(CCC/C=C\CCCCC)OC(=O)NCCN(C)C</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCC/C=C\CCCC(CCC/C=C\CCCCC)C(CC/C=C\CCCCC)OC(=O)CCCCCN(C)C.CCCCC/C=C\CCCC(CCC/C=C\CCCCC)C(CC/C=C\CCCCC)OC(=O)CCCCN(C)C.CCCCC/C=C\CCCC(CCC/C=C\CCCCC)C(CC/C=C\CCCCC)OC(=O)CCCN(C)C.CCCCC/C=C\CCCC(CCC/C=C\CCCCC)C(CCC/C=C\CCCCC)OC(=O)CCCN(C)C.CCCCC/C=C\CCCC(CCC/C=C\CCCCC)C(CCC/C=C\CCCCC)OC(=O)N(C)CCCN(C)C.CCCCC/C=C\CCCC(CCC/C=C\CCCCC)C(CCC/C=C\CCCCC)OC(=O)NCCCN(C)C.CCCCC/C=C\CCCC(CCC/C=C\CCCCC)C(CCC/C=C\CCCCC)OC(=O)NCCN(C)C</span>
      <span itemprop="inchi_key">LLWQKLOBPZIJEN-VNKKGPJPSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">MIWVIQZZPZZRJA-IUAZUQLVSA-N</span>
      <span itemprop="name">CCCCC/C=C\CCCC(CCC/C=C\CCCCC)C(CCC/C=C/CCCCC)OC(=O)CCCCN(C)C.CCCCC/C=C\CCCC(OC(=O)CCCCCN(C)C)C(CCCCCCCC)CCCCCCCCCC.CCCCCC1CC1CCCC(CCCC1CC1CCCCC)C(CCCC1CC1CCCCC)OCCCCCN(C)C</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCC/C=C\CCCC(CCC/C=C\CCCCC)C(CCC/C=C/CCCCC)OC(=O)CCCCN(C)C.CCCCC/C=C\CCCC(OC(=O)CCCCCN(C)C)C(CCCCCCCC)CCCCCCCCCC.CCCCCC1CC1CCCC(CCCC1CC1CCCCC)C(CCCC1CC1CCCCC)OCCCCCN(C)C</span>
      <span itemprop="inchi_key">MIWVIQZZPZZRJA-IUAZUQLVSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">WLCODOOBPYTABW-ASSJVFBPSA-N</span>
      <span itemprop="name">CCCCC/C=C\CCCC(CCC/C=C\CCCCC)C(CCC/C=C\CCCCC)OC(=O)CCCCCN(C)C</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCC/C=C\CCCC(CCC/C=C\CCCCC)C(CCC/C=C\CCCCC)OC(=O)CCCCCN(C)C</span>
      <span itemprop="inchi_key">WLCODOOBPYTABW-ASSJVFBPSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">ARJCMRWHZPDQJG-ASSJVFBPSA-N</span>
      <span itemprop="name">CCCCC/C=C\CCCC(CCC/C=C\CCCCC)C(CCC/C=C\CCCCC)OC(=O)CCCCN(C)C</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCC/C=C\CCCC(CCC/C=C\CCCCC)C(CCC/C=C\CCCCC)OC(=O)CCCCN(C)C</span>
      <span itemprop="inchi_key">ARJCMRWHZPDQJG-ASSJVFBPSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">CCMLONQLTCOTKY-FRRVGIRPSA-N</span>
      <span itemprop="name">CCCCC/C=C\CCCC(CCC/C=C\CCCCC)C(CCCCCCCCCC)OC(=O)CCCCN(C)C</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCC/C=C\CCCC(CCC/C=C\CCCCC)C(CCCCCCCCCC)OC(=O)CCCCN(C)C</span>
      <span itemprop="inchi_key">CCMLONQLTCOTKY-FRRVGIRPSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">GVPMIJDBOCDKAB-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCCCC(CCCCCCCCCC)C(CCCCCCCCCC)OC(=O)CCCCN(C)C</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCCC(CCCCCCCCCC)C(CCCCCCCCCC)OC(=O)CCCCN(C)C</span>
      <span itemprop="inchi_key">GVPMIJDBOCDKAB-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">GKCPKAOFSUIWHT-SKRAEFHRSA-N</span>
      <span itemprop="name">CCCCCCCCCCCCCCOCC(CNC(=O)OCCOCCOC)OCCCCCCCCCCCCCC.CCCCCCCCCCCCCCOC[C@H](COC(=O)NCCOCCOC)OCCCCCCCCCCCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCCCCCCOCC(CNC(=O)OCCOCCOC)OCCCCCCCCCCCCCC.CCCCCCCCCCCCCCOC[C@H](COC(=O)NCCOCCOC)OCCCCCCCCCCCCCC</span>
      <span itemprop="inchi_key">GKCPKAOFSUIWHT-SKRAEFHRSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
  </ul>

  

  <section>
    <h2>Classifications</h2>
    <ul>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A</span>&mdash;<span itemprop="Description">HUMAN NECESSITIES</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61</span>&mdash;<span itemprop="Description">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K</span>&mdash;<span itemprop="Description">PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K48/00</span>&mdash;<span itemprop="Description">Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K48/0083</span>&mdash;<span itemprop="Description">Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the administration regime</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="FirstCode" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A</span>&mdash;<span itemprop="Description">HUMAN NECESSITIES</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61</span>&mdash;<span itemprop="Description">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K</span>&mdash;<span itemprop="Description">PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K31/00</span>&mdash;<span itemprop="Description">Medicinal preparations containing organic active ingredients</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K31/56</span>&mdash;<span itemprop="Description">Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K31/57</span>&mdash;<span itemprop="Description">Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K31/573</span>&mdash;<span itemprop="Description">Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A</span>&mdash;<span itemprop="Description">HUMAN NECESSITIES</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61</span>&mdash;<span itemprop="Description">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K</span>&mdash;<span itemprop="Description">PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K31/00</span>&mdash;<span itemprop="Description">Medicinal preparations containing organic active ingredients</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K31/56</span>&mdash;<span itemprop="Description">Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K31/58</span>&mdash;<span itemprop="Description">Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A</span>&mdash;<span itemprop="Description">HUMAN NECESSITIES</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61</span>&mdash;<span itemprop="Description">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K</span>&mdash;<span itemprop="Description">PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K31/00</span>&mdash;<span itemprop="Description">Medicinal preparations containing organic active ingredients</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K31/70</span>&mdash;<span itemprop="Description">Carbohydrates; Sugars; Derivatives thereof</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K31/7088</span>&mdash;<span itemprop="Description">Compounds having three or more nucleosides or nucleotides</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K31/7105</span>&mdash;<span itemprop="Description">Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3&#39;-5&#39; phosphodiester links</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A</span>&mdash;<span itemprop="Description">HUMAN NECESSITIES</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61</span>&mdash;<span itemprop="Description">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K</span>&mdash;<span itemprop="Description">PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K31/00</span>&mdash;<span itemprop="Description">Medicinal preparations containing organic active ingredients</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K31/70</span>&mdash;<span itemprop="Description">Carbohydrates; Sugars; Derivatives thereof</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K31/7088</span>&mdash;<span itemprop="Description">Compounds having three or more nucleosides or nucleotides</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K31/713</span>&mdash;<span itemprop="Description">Double-stranded nucleic acids or oligonucleotides</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A</span>&mdash;<span itemprop="Description">HUMAN NECESSITIES</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61</span>&mdash;<span itemprop="Description">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K</span>&mdash;<span itemprop="Description">PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K45/00</span>&mdash;<span itemprop="Description">Medicinal preparations containing active ingredients not provided for in groups A61K31/00Â -Â A61K41/00</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K45/06</span>&mdash;<span itemprop="Description">Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A</span>&mdash;<span itemprop="Description">HUMAN NECESSITIES</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61</span>&mdash;<span itemprop="Description">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K</span>&mdash;<span itemprop="Description">PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K47/00</span>&mdash;<span itemprop="Description">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K47/50</span>&mdash;<span itemprop="Description">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K47/51</span>&mdash;<span itemprop="Description">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K47/54</span>&mdash;<span itemprop="Description">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K47/543</span>&mdash;<span itemprop="Description">Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K47/544</span>&mdash;<span itemprop="Description">Phospholipids</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A</span>&mdash;<span itemprop="Description">HUMAN NECESSITIES</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61</span>&mdash;<span itemprop="Description">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K</span>&mdash;<span itemprop="Description">PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K47/00</span>&mdash;<span itemprop="Description">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K47/50</span>&mdash;<span itemprop="Description">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K47/51</span>&mdash;<span itemprop="Description">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K47/56</span>&mdash;<span itemprop="Description">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K47/59</span>&mdash;<span itemprop="Description">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K47/60</span>&mdash;<span itemprop="Description">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A</span>&mdash;<span itemprop="Description">HUMAN NECESSITIES</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61</span>&mdash;<span itemprop="Description">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K</span>&mdash;<span itemprop="Description">PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K47/00</span>&mdash;<span itemprop="Description">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K47/50</span>&mdash;<span itemprop="Description">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K47/69</span>&mdash;<span itemprop="Description">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K47/6905</span>&mdash;<span itemprop="Description">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K47/6907</span>&mdash;<span itemprop="Description">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a microemulsion, nanoemulsion or micelle</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K47/6909</span>&mdash;<span itemprop="Description">Micelles formed by phospholipids</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A</span>&mdash;<span itemprop="Description">HUMAN NECESSITIES</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61</span>&mdash;<span itemprop="Description">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K</span>&mdash;<span itemprop="Description">PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K47/00</span>&mdash;<span itemprop="Description">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K47/50</span>&mdash;<span itemprop="Description">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K47/69</span>&mdash;<span itemprop="Description">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K47/6905</span>&mdash;<span itemprop="Description">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K47/6911</span>&mdash;<span itemprop="Description">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A</span>&mdash;<span itemprop="Description">HUMAN NECESSITIES</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61</span>&mdash;<span itemprop="Description">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K</span>&mdash;<span itemprop="Description">PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K9/00</span>&mdash;<span itemprop="Description">Medicinal preparations characterised by special physical form</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K9/0012</span>&mdash;<span itemprop="Description">Galenical forms characterised by the site of application</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K9/0019</span>&mdash;<span itemprop="Description">Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A</span>&mdash;<span itemprop="Description">HUMAN NECESSITIES</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61</span>&mdash;<span itemprop="Description">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K</span>&mdash;<span itemprop="Description">PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K9/00</span>&mdash;<span itemprop="Description">Medicinal preparations characterised by special physical form</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K9/48</span>&mdash;<span itemprop="Description">Preparations in capsules, e.g. of gelatin, of chocolate</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K9/50</span>&mdash;<span itemprop="Description">Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K9/51</span>&mdash;<span itemprop="Description">Nanocapsules; Nanoparticles</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K9/5107</span>&mdash;<span itemprop="Description">Excipients; Inactive ingredients</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K9/5123</span>&mdash;<span itemprop="Description">Organic compounds, e.g. fats, sugars</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A</span>&mdash;<span itemprop="Description">HUMAN NECESSITIES</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61</span>&mdash;<span itemprop="Description">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61P</span>&mdash;<span itemprop="Description">SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61P43/00</span>&mdash;<span itemprop="Description">Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">B</span>&mdash;<span itemprop="Description">PERFORMING OPERATIONS; TRANSPORTING</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">B82</span>&mdash;<span itemprop="Description">NANOTECHNOLOGY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">B82Y</span>&mdash;<span itemprop="Description">SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">B82Y5/00</span>&mdash;<span itemprop="Description">Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C</span>&mdash;<span itemprop="Description">CHEMISTRY; METALLURGY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C12</span>&mdash;<span itemprop="Description">BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C12N</span>&mdash;<span itemprop="Description">MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C12N15/00</span>&mdash;<span itemprop="Description">Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C12N15/09</span>&mdash;<span itemprop="Description">Recombinant DNA-technology</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C12N15/11</span>&mdash;<span itemprop="Description">DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C12N15/111</span>&mdash;<span itemprop="Description">General methods applicable to biologically active non-coding nucleic acids</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C</span>&mdash;<span itemprop="Description">CHEMISTRY; METALLURGY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C12</span>&mdash;<span itemprop="Description">BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C12N</span>&mdash;<span itemprop="Description">MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C12N2320/00</span>&mdash;<span itemprop="Description">Applications; Uses</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C12N2320/30</span>&mdash;<span itemprop="Description">Special therapeutic applications</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C12N2320/32</span>&mdash;<span itemprop="Description">Special delivery means, e.g. tissue-specific</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="Additional" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
    </ul>
  </section>

  

  

  <section>
    <h2>Definitions</h2>
    <ul>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Some diseases in humans</span>
        <span itemprop="definition">are caused by the absence, or impairment, of a functional protein in a cell type where the protein is normally present and active.</span>
        <meta itemprop="num_attr" content="0002">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the functional protein</span>
        <span itemprop="definition">can be completely or partially absent due, for example, to transcriptional inactivity of the encoding gene, or due to the presence of a mutation in the encoding gene that renders the protein completely or partially non-functional.</span>
        <meta itemprop="num_attr" content="0002">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">X-SCID</span>
        <span itemprop="definition">X-linked severe combined immunodeficiency</span>
        <meta itemprop="num_attr" content="0003">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">X-ALD</span>
        <span itemprop="definition">adrenoleukodystrophy</span>
        <meta itemprop="num_attr" content="0003">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">X-SCID</span>
        <span itemprop="definition">is caused by one or more mutations in the gene encoding the common gamma chain protein that is a component of the receptors for several interleukins that are involved in the development and maturation of B and T cells within the immune system.</span>
        <meta itemprop="num_attr" content="0003">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">X-ALD</span>
        <span itemprop="definition">is caused by one or more mutations in a peroxisomal membrane transporter protein gene called ABCD1. Individuals afflicted with X-ALD have very high levels of long chain fatty acids in tissues throughout the body, which causes a variety of symptoms that may lead to mental impairment or death.</span>
        <meta itemprop="num_attr" content="0003">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Gene therapy</span>
        <span itemprop="definition">typically involves introduction of a vector that includes a gene encoding a functional form of the affected protein, into a diseased person, and expression of the functional protein to treat the disease.</span>
        <meta itemprop="num_attr" content="0004">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">gene therapy</span>
        <span itemprop="definition">has met with limited success.</span>
        <meta itemprop="num_attr" content="0004">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">compositions and methods for expressing a functional form of a protein within a human who suffers from a disease caused by the complete or partial absence of the functional protein</span>
        <span itemprop="definition">there is a need for delivery of nucleic acids (e.g., mRNA) via a methods and compositions that trigger less of an immune response to the therapy.</span>
        <meta itemprop="num_attr" content="0005">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">nucleic acids</span>
        <span itemprop="definition">e.g., mRNA</span>
        <meta itemprop="num_attr" content="0005">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the present invention</span>
        <span itemprop="definition">provides in certain embodiments compositions and methods that can be used to deliver nucleic acids, e.g., so as to express one or more mRNA molecules in a living cell (e.g., cells within a human body).</span>
        <meta itemprop="num_attr" content="0006">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the mRNA molecules</span>
        <span itemprop="definition">can encode one or more polypeptides that is/are expressed within the living cells.</span>
        <meta itemprop="num_attr" content="0006">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the polypeptides</span>
        <span itemprop="definition">are expressed within a diseased organism (e.g., mammal, such as a human being), and expression of the polypeptide ameliorates one or more symptoms of the disease.</span>
        <meta itemprop="num_attr" content="0006">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the compositions and methods of certain embodiments of the invention</span>
        <span itemprop="definition">are particularly useful for treating human diseases caused by the absence, or reduced levels, of a functional polypeptide within the human body.</span>
        <meta itemprop="num_attr" content="0006">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the present invention</span>
        <span itemprop="definition">provides a lipid nanoparticle (LNP) comprising: (a) a cationic lipid; (b) a non-cationic lipid; (c) a corticosteroid and; (d) a nucleic acid, wherein the nucleic acid and the corticosteroid are encapsulated within the lipid nanoparticle.</span>
        <meta itemprop="num_attr" content="0007">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">LNP</span>
        <span itemprop="definition">lipid nanoparticle</span>
        <meta itemprop="num_attr" content="0007">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Certain embodiments of the invention</span>
        <span itemprop="definition">provide a population of lipid nanoparticles comprising the lipid nanoparticles.</span>
        <meta itemprop="num_attr" content="0007">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Certain embodiments of the invention</span>
        <span itemprop="definition">provide a population of lipid particles comprising a multiplicity of lipid nanoparticles.</span>
        <meta itemprop="num_attr" content="0007">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid</span>
        <span itemprop="definition">is HPLC-purified mRNA.</span>
        <meta itemprop="num_attr" content="0007">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the LNP</span>
        <span itemprop="definition">comprises a PEG-lipid conjugate present in an amount of at least 3 mole percent. In certain embodiments, the LNP comprises less than 0.5 mole percent phospholipid.</span>
        <meta itemprop="num_attr" content="0007">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Certain embodiments of the invention</span>
        <span itemprop="definition">provide a population of lipid nanoparticles, comprising at least one population of lipid nanoparticle selected from: (a) a first population of lipid nanoparticles that each comprise a cationic lipid, a non-cationic lipid, and a corticosteroid; and (b) a second population of lipid nanoparticles that each comprise a cationic lipid, a non-cationic lipid, and a nucleic acid, wherein the first population of lipid nanoparticles does not comprise a nucleic acid, and wherein the second population of lipid nanoparticles does not comprise a corticosteroid. Certain embodiments of the invention provide a population of lipid nanoparticles comprising the first and second populations of lipid nanoparticles.</span>
        <meta itemprop="num_attr" content="0008">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid</span>
        <span itemprop="definition">is HPLC-purified mRNA.</span>
        <meta itemprop="num_attr" content="0008">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">lipid nanoparticle</span>
        <span itemprop="definition">comprising: (a) a cationic lipid; (b) a PEG-lipid conjugate present in an amount of at least 3 mole percent; and (c) mRNA encapsulated within the lipid particle; provided that the lipid particle comprises less than 0.5 mole percent phospholipid.</span>
        <meta itemprop="num_attr" content="0009">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the LNP</span>
        <span itemprop="definition">comprises a corticosteroid.</span>
        <meta itemprop="num_attr" content="0009">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the mRNA</span>
        <span itemprop="definition">is HPLC-purified mRNA.</span>
        <meta itemprop="num_attr" content="0009">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">each lipid nanoparticle in the population</span>
        <span itemprop="definition">comprises: (a) a cationic lipid; (b) a PEG-lipid conjugate present in an amount of at least 3 mole percent; and (c) mRNA encapsulated within the lipid nanoparticle; provided that the lipid nanoparticle comprises less than 0.5 mole percent phospholipid.</span>
        <meta itemprop="num_attr" content="0010">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the population of LNPs</span>
        <span itemprop="definition">comprises LNPs that comprise a corticosteroid.</span>
        <meta itemprop="num_attr" content="0010">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the mRNA</span>
        <span itemprop="definition">is HPLC-purified mRNA.</span>
        <meta itemprop="num_attr" content="0010">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">lipid nanoparticle formulation</span>
        <span itemprop="definition">comprising a multiplicity of lipid nanoparticles, wherein each lipid nanoparticle comprises: (a) a cationic lipid; (b) a non-cationic lipid; and (c) mRNA encapsulated within the lipid particle, wherein the lipid nanoparticle formulation has an IFIT response that is no more than 30 fold greater than a reference IFIT response of phosphate buffered saline.</span>
        <meta itemprop="num_attr" content="0011">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the mRNA</span>
        <span itemprop="definition">is HPLC-purified mRNA.</span>
        <meta itemprop="num_attr" content="0011">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the LNP</span>
        <span itemprop="definition">comprises a PEG-lipid conjugate present in an amount of at least 3 mole percent. In certain embodiments, the LNP comprises less than 0.5 mole percent phospholipid. In certain embodiments, the LNP comprises a corticosteroid.</span>
        <meta itemprop="num_attr" content="0011">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Certain embodiments of the invention</span>
        <span itemprop="definition">provide a method of making a lipid nanoparticle, comprising combining: (a) a cationic lipid; (b) a non-cationic lipid; and (c) purified mRNA so as to form a lipid nanoparticle, wherein the mRNA is encapsulated within the lipid nanoparticle, and wherein the lipid nanoparticle has an IFIT response that is no more than 30 fold greater than a reference IFIT response of phosphate buffered saline.</span>
        <meta itemprop="num_attr" content="0012">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the mRNA</span>
        <span itemprop="definition">is HPLC-purified mRNA.</span>
        <meta itemprop="num_attr" content="0012">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the LNP</span>
        <span itemprop="definition">comprises a PEG-lipid conjugate present in an amount of at least 3 mole percent. In certain embodiments, the LNP comprises less than 0.5 mole percent phospholipid. In certain embodiments, the LNP comprises a corticosteroid.</span>
        <meta itemprop="num_attr" content="0012">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Certain embodiments of the invention</span>
        <span itemprop="definition">provide a method of making a lipid nanoparticle formulation comprising a multiplicity of lipid nanoparticles, the method comprising the step of combining: (a) a cationic lipid; (b) a non-cationic lipid; and (c) purified mRNA so as to form a lipid nanoparticle formulation comprising a multiplicity of lipid nanoparticles, wherein the mRNA is encapsulated within the lipid particles in the lipid nanoparticle formulation, and wherein the lipid nanoparticle formulation has an IFIT response that is no more than 30 fold greater than a reference IFIT response of phosphate buffered saline.</span>
        <meta itemprop="num_attr" content="0013">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the LNP</span>
        <span itemprop="definition">comprises a PEG-lipid conjugate present in an amount of at least 3 mole percent. In certain embodiments, the LNP comprises less than 0.5 mole percent phospholipid. In certain embodiments, the LNP comprises a corticosteroid.</span>
        <meta itemprop="num_attr" content="0013">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Certain embodiments of the invention</span>
        <span itemprop="definition">provide a lipid nanoparticle formulation comprising a multiplicity of lipid nanoparticles made by a process comprising the steps of combining: (a) a cationic lipid; (b) a non-cationic lipid; and (c) purified mRNA so as to form a lipid nanoparticle formulation comprising a multiplicity of lipid nanoparticles, wherein the mRNA is encapsulated within the lipid particles in the lipid nanoparticle formulation, and wherein the lipid nanoparticle formulation has an IFIT response that is no more than 30 fold greater than a reference IFIT response of phosphate buffered saline.</span>
        <meta itemprop="num_attr" content="0014">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the LNP</span>
        <span itemprop="definition">comprises a PEG-lipid conjugate present in an amount of at least 3 mole percent. In certain embodiments, the LNP comprises less than 0.5 mole percent phospholipid. In certain embodiments, the LNP comprises a corticosteroid.</span>
        <meta itemprop="num_attr" content="0014">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the present invention</span>
        <span itemprop="definition">provides a lipid particle comprising a cationic lipid, a non-cationic lipid, and an mRNA molecule that is encapsulated within the lipid particle.</span>
        <meta itemprop="num_attr" content="0015">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the present invention</span>
        <span itemprop="definition">also provides nucleic acid-lipid particles that each include (a) a lipid particle comprising a cationic lipid, a PEG-lipid, and a phospholipid; and (b) an mRNA molecule, wherein the mRNA molecule is encapsulated within the lipid particle.</span>
        <meta itemprop="num_attr" content="0016">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the lipid particles</span>
        <span itemprop="definition">can optionally include cholesterol.</span>
        <meta itemprop="num_attr" content="0016">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the mRNA</span>
        <span itemprop="definition">can be completely or partially encapsulated within the lipid particle.</span>
        <meta itemprop="num_attr" content="0016">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid-lipid particle</span>
        <span itemprop="definition">has a lipid:mRNA mass ratio of from about 9:1 to about 20:1. In a specific embodiment, the nucleic acid-lipid particle has a lipid:mRNA mass ratio of about 12:1.</span>
        <meta itemprop="num_attr" content="0016">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the mRNA</span>
        <span itemprop="definition">can be chemically modified, such as by the incorporation of pseudouridine instead of uridine, and/or the incorporation of 5-methylcytidine instead of cytidine.</span>
        <meta itemprop="num_attr" content="0016">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the present invention</span>
        <span itemprop="definition">also provides pharmaceutical compositions that include nucleic acid-lipid particles of the present invention. Typically, the pharmaceutical compositions include an excipient.</span>
        <meta itemprop="num_attr" content="0016">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the present invention</span>
        <span itemprop="definition">provides methods for introducing an mRNA that encodes a protein into a cell.</span>
        <meta itemprop="num_attr" content="0017">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the methods</span>
        <span itemprop="definition">each include the step of contacting the cell with a nucleic acid-lipid particle of the present invention (typically, a multiplicity of nucleic acid-lipid particles of the present invention) under conditions whereby the mRNA is introduced into the cell and expressed therein to produce the protein.</span>
        <meta itemprop="num_attr" content="0017">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the methods</span>
        <span itemprop="definition">can be practiced in vivo or in vitro.</span>
        <meta itemprop="num_attr" content="0017">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the cell</span>
        <span itemprop="definition">is within a living body (e.g., a mammalian body, such as a human body), and the nucleic acid-lipid particle can be introduced into the living body by injection.</span>
        <meta itemprop="num_attr" content="0017">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the present invention</span>
        <span itemprop="definition">provides methods for treating and/or ameliorating one or more symptoms associated with a disease, in a human, caused by impaired expression of a protein in the human.</span>
        <meta itemprop="num_attr" content="0018">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the methods of this aspect of the invention</span>
        <span itemprop="definition">include the step of administering to the human a therapeutically effective amount of a nucleic acid-lipid particle of the present invention (typically, a multiplicity of nucleic acid-lipid particles of the present invention), wherein the mRNA encapsulated within the nucleic acid-lipid particle encodes the protein.</span>
        <meta itemprop="num_attr" content="0018">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the encoded protein</span>
        <span itemprop="definition">is expressed within the human being, thereby ameliorating at least one symptom of the disease.</span>
        <meta itemprop="num_attr" content="0018">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the ratio of lipid to nucleic acid (e.g., mRNA) in the lipid particles used in the practice of the present invention</span>
        <span itemprop="definition">is about 13:1.</span>
        <meta itemprop="num_attr" content="0019">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">compositions of the invention</span>
        <span itemprop="definition">can be used, for example, to treat any disease that is caused, at least in part, by the absence of a polypeptide, or the reduced level of a polypeptide, or the expression of a non-functional (or partially functional, or aberrantly functional) form of a polypeptide, in a cell, tissue, and/or organ of a human body.</span>
        <meta itemprop="num_attr" content="0020">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">nucleic acid-lipid particles, methods, and pharmaceutical formulations, described herein</span>
        <span itemprop="definition">advantageously provide significant new compositions and methods for expressing proteins in a mammalian organism, such as a human being.</span>
        <meta itemprop="num_attr" content="0022">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Embodiments of the present invention</span>
        <span itemprop="definition">can be administered, for example, once per day, once per week, or once every several weeks (e.g., once every two, three, four, five or six weeks), or once per month, or once per year.</span>
        <meta itemprop="num_attr" content="0022">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Encapsulation of mRNA within lipid particles</span>
        <span itemprop="definition">confers one or more advantages, such as protecting the mRNA from nuclease degradation in the bloodstream, allowing preferential accumulation of the mRNA in target tissue and providing a means of mRNA entry into the cellular cytoplasm where the mRNA can express the encoded protein.</span>
        <meta itemprop="num_attr" content="0022">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the present invention</span>
        <span itemprop="definition">provides a lipid nanoparticle comprising: (a) a cationic lipid; (b) a non-cationic lipid; (c) a corticosteroid and; (d) a nucleic acid, wherein the nucleic acid and the corticosteroid are encapsulated within the lipid nanoparticle.</span>
        <meta itemprop="num_attr" content="0023">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Certain embodiments of the invention</span>
        <span itemprop="definition">provide a population of lipid nanoparticles comprising the lipid nanoparticles.</span>
        <meta itemprop="num_attr" content="0023">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Certain embodiments of the invention</span>
        <span itemprop="definition">provide a population of lipid particles comprising a multiplicity of lipid nanoparticles.</span>
        <meta itemprop="num_attr" content="0023">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid</span>
        <span itemprop="definition">is HPLC-purified mRNA.</span>
        <meta itemprop="num_attr" content="0023">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the LNP</span>
        <span itemprop="definition">comprises a PEG-lipid conjugate present in an amount of at least 3 mole percent. In certain embodiments, the LNP comprises less than 0.5 mole percent phospholipid.</span>
        <meta itemprop="num_attr" content="0023">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Certain embodiments of the invention</span>
        <span itemprop="definition">provide a population of lipid nanoparticles, comprising at least one population of lipid nanoparticles selected from: (a) a first population of lipid nanoparticles that each comprise a cationic lipid, a non-cationic lipid, and a corticosteroid; and (b) a second population of lipid nanoparticles that each comprise a cationic lipid, a non-cationic lipid, and a nucleic acid, wherein the first population of lipid nanoparticles does not comprise a nucleic acid, and wherein the second population of lipid nanoparticles does not comprise a corticosteroid. Certain embodiments of the invention provide a population of lipid nanoparticles comprising the first and second populations of lipid nanoparticles.</span>
        <meta itemprop="num_attr" content="0024">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid</span>
        <span itemprop="definition">is HPLC-purified mRNA.</span>
        <meta itemprop="num_attr" content="0024">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">lipid nanoparticle</span>
        <span itemprop="definition">comprising: (a) a cationic lipid; (b) a PEG-lipid conjugate present in an amount of at least 3 mole percent; and (c) mRNA encapsulated within the lipid particle; provided that the lipid particle comprises less than 0.5 mole percent phospholipid.</span>
        <meta itemprop="num_attr" content="0025">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the LNP</span>
        <span itemprop="definition">comprises a corticosteroid.</span>
        <meta itemprop="num_attr" content="0025">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the mRNA</span>
        <span itemprop="definition">is HPLC-purified mRNA.</span>
        <meta itemprop="num_attr" content="0025">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">each lipid nanoparticle in the population</span>
        <span itemprop="definition">comprises: (a) a cationic lipid; (b) a PEG-lipid conjugate present in an amount of at least 3 mole percent; and (c) mRNA encapsulated within the lipid nanoparticle; provided that the lipid nanoparticle comprises less than 0.5 mole percent phospholipid.</span>
        <meta itemprop="num_attr" content="0026">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the population of LNPs</span>
        <span itemprop="definition">comprises LNPs that comprise a corticosteroid.</span>
        <meta itemprop="num_attr" content="0026">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the mRNA</span>
        <span itemprop="definition">is HPLC-purified mRNA.</span>
        <meta itemprop="num_attr" content="0026">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">lipid nanoparticle formulation</span>
        <span itemprop="definition">comprising a multiplicity of lipid nanoparticles, wherein each lipid nanoparticle comprises: (a) a cationic lipid; (b) a non-cationic lipid; and (c) mRNA encapsulated within the lipid particle, wherein the lipid nanoparticle formulation has an IFIT response that is no more than 30 fold greater than a reference IFIT response of phosphate buffered saline.</span>
        <meta itemprop="num_attr" content="0027">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the mRNA</span>
        <span itemprop="definition">is purified mRNA.</span>
        <meta itemprop="num_attr" content="0027">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the mRNA</span>
        <span itemprop="definition">is HPLC-purified mRNA.</span>
        <meta itemprop="num_attr" content="0027">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the LNP</span>
        <span itemprop="definition">comprises a PEG-lipid conjugate present in an amount of at least 3 mole percent.</span>
        <meta itemprop="num_attr" content="0027">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the LNP</span>
        <span itemprop="definition">comprises a PEG-lipid conjugate present in an amount of at least 3.5 mole percent. In certain embodiments, the LNP comprises less than 0.5 mole percent phospholipid. In certain embodiments, the LNP comprises less than 0.05 mole percent phospholipid. In certain embodiments, the LNP comprises a corticosteroid. In certain embodiments, substantially all of the lipid nanoparticles in the formulation comprise a corticosteroid encapsulated within the lipid nanoparticle. For example, in certain embodiments, at least about 80% of the lipid nanoparticles in the formulation further comprise a corticosteroid encapsulated within the lipid nanoparticle.</span>
        <meta itemprop="num_attr" content="0027">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">lipid nanoparticles in the formulation</span>
        <span itemprop="definition">further comprise a corticosteroid encapsulated within the lipid nanoparticle.</span>
        <meta itemprop="num_attr" content="0027">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">lipid nanoparticle formulation</span>
        <span itemprop="definition">comprising a multiplicity of lipid nanoparticles, wherein each lipid nanoparticle comprises: (a) a cationic lipid; (b) a non-cationic lipid; and (c) mRNA encapsulated within the lipid particle, wherein the lipid nanoparticle formulation has an IFIT response that is no more than 30 fold greater than a reference IFIT response of phosphate buffered saline, wherein the non-cationic lipid is a PEG-lipid conjugate present in an amount of at least 3 mole percent, provided that the lipid nanoparticle comprises less than 0.5 mole percent phospholipid, and wherein at least 90% of the lipid nanoparticles in the formulation further comprise a corticosteroid encapsulated within the lipid nanoparticle.</span>
        <meta itemprop="num_attr" content="0028">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">lipid nanoparticles</span>
        <span itemprop="definition">that each comprise a cationic lipid, a non-cationic lipid, and a mRNA encapsulated within the lipid nanoparticle</span>
        <meta itemprop="num_attr" content="0031">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the first population of lipid nanoparticles</span>
        <span itemprop="definition">does not comprise a mRNA</span>
        <meta itemprop="num_attr" content="0032">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the second population of lipid nanoparticles</span>
        <span itemprop="definition">does not comprise a corticosteroid</span>
        <meta itemprop="num_attr" content="0032">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the lipid nanoparticle formulation</span>
        <span itemprop="definition">has an IFIT response that is no more than 30 fold greater than a reference IFIT response of phosphate buffered saline.</span>
        <meta itemprop="num_attr" content="0032">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Certain embodiments of the invention</span>
        <span itemprop="definition">provide a method of making a lipid nanoparticle, comprising combining: (a) a cationic lipid; (b) a non-cationic lipid; and (c) purified mRNA so as to form a lipid nanoparticle, wherein the mRNA is encapsulated within the lipid nanoparticle, and wherein the lipid nanoparticle has an IFIT response that is no more than 30 fold greater than a reference IFIT response of phosphate buffered saline.</span>
        <meta itemprop="num_attr" content="0033">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the mRNA</span>
        <span itemprop="definition">is HPLC-purified mRNA.</span>
        <meta itemprop="num_attr" content="0033">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the LNP</span>
        <span itemprop="definition">comprises a PEG-lipid conjugate present in an amount of at least 3 mole percent. In certain embodiments, the LNP comprises less than 0.5 mole percent phospholipid. In certain embodiments, the LNP comprises a corticosteroid.</span>
        <meta itemprop="num_attr" content="0033">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the method</span>
        <span itemprop="definition">further comprises purifying mRNA to provide the purified mRNA.</span>
        <meta itemprop="num_attr" content="0033">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Certain embodiments of the invention</span>
        <span itemprop="definition">provide a method of making a lipid nanoparticle formulation comprising a multiplicity of lipid nanoparticles, the method comprising the step of combining: (a) a cationic lipid; (b) a non-cationic lipid; and (c) purified mRNA so as to form a lipid nanoparticle formulation comprising a multiplicity of lipid nanoparticles, wherein the mRNA is encapsulated within the lipid particles in the lipid nanoparticle formulation, and wherein the lipid nanoparticle formulation has an IFIT response that is no more than 30 fold greater than a reference IFIT response of phosphate buffered saline.</span>
        <meta itemprop="num_attr" content="0034">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the LNP</span>
        <span itemprop="definition">comprises a PEG-lipid conjugate present in an amount of at least 3 mole percent. In certain embodiments, the LNP comprises less than 0.5 mole percent phospholipid. In certain embodiments, the LNP comprises a corticosteroid. In certain embodiments, the method further comprises purifying mRNA (e.g., via HPLC) to provide the purified mRNA.</span>
        <meta itemprop="num_attr" content="0034">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Certain embodiments of the invention</span>
        <span itemprop="definition">provide a lipid nanoparticle formulation comprising a multiplicity of lipid nanoparticles made by a process comprising the steps of combining: (a) a cationic lipid; (b) a non-cationic lipid; and (c) purified mRNA so as to form a lipid nanoparticle formulation comprising a multiplicity of lipid nanoparticles, wherein the mRNA is encapsulated within the lipid particles in the lipid nanoparticle formulation, and wherein the lipid nanoparticle formulation has an IFIT response that is no more than 30 fold greater than a reference IFIT response of phosphate buffered saline.</span>
        <meta itemprop="num_attr" content="0035">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the LNP</span>
        <span itemprop="definition">comprises a PEG-lipid conjugate present in an amount of at least 3 mole percent. In certain embodiments, the LNP comprises less than 0.5 mole percent phospholipid. In certain embodiments, the LNP comprises a corticosteroid. In certain embodiments, the method further comprises purifying mRNA (e.g., via HPLC) to provide the purified mRNA.</span>
        <meta itemprop="num_attr" content="0035">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid</span>
        <span itemprop="definition">is mRNA.</span>
        <meta itemprop="num_attr" content="0036">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid</span>
        <span itemprop="definition">is purified mRNA.</span>
        <meta itemprop="num_attr" content="0037">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the mRNA</span>
        <span itemprop="definition">is HPLC-purified mRNA.</span>
        <meta itemprop="num_attr" content="0038">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the corticosteroid</span>
        <span itemprop="definition">has a log P greater than 3.0.</span>
        <meta itemprop="num_attr" content="0039">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">substantially all lipid nanoparticles in a formulation/population</span>
        <span itemprop="definition">comprise a corticosteroid encapsulated within the lipid nanoparticle.</span>
        <meta itemprop="num_attr" content="0040">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">at least about 80% of the lipid nanoparticles in a formulation/population</span>
        <span itemprop="definition">further comprise a corticosteroid encapsulated within the lipid nanoparticle.</span>
        <meta itemprop="num_attr" content="0040">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">at least about 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% of the lipid nanoparticles in the formulation/population</span>
        <span itemprop="definition">further comprise a corticosteroid encapsulated within the lipid nanoparticle.</span>
        <meta itemprop="num_attr" content="0040">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the corticosteroid</span>
        <span itemprop="definition">is a glucocorticoid.</span>
        <meta itemprop="num_attr" content="0041">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the corticosteroid</span>
        <span itemprop="definition">is a mineralocorticoid.</span>
        <meta itemprop="num_attr" content="0042">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the corticosteroid</span>
        <span itemprop="definition">is clobetasol.</span>
        <meta itemprop="num_attr" content="0043">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the glucocorticoid</span>
        <span itemprop="definition">is selected from hydrocortisone, cortisone, corticosterone, deoxycorticosterone, prednisone, prednisolone, methylprednisolone, dexamethasone, betamethasone, mometasone, triamcinolone, beclomethasone, fludrocortisone, aldosterone, fluticasone, clobetasone, clobetasol, and loteprednol, and pharmaceutically acceptable salts thereof, and mixtures thereof.</span>
        <meta itemprop="num_attr" content="0044">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the non-cationic lipid</span>
        <span itemprop="definition">is selected from a PEG-lipid conjugate and a phospholipid.</span>
        <meta itemprop="num_attr" content="0045">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the non-cationic lipid</span>
        <span itemprop="definition">is selected from a PEG-lipid conjugate, a phospholipid, or a mixture of a PEG-lipid conjugate and a phospholipid.</span>
        <meta itemprop="num_attr" content="0046">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the non-cationic lipid</span>
        <span itemprop="definition">comprises a phospholipid.</span>
        <meta itemprop="num_attr" content="0047">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the non-cationic lipid</span>
        <span itemprop="definition">comprises a PEG-lipid conjugate.</span>
        <meta itemprop="num_attr" content="0048">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the non-cationic lipid</span>
        <span itemprop="definition">comprises a mixture of a PEG-lipid conjugate and a phospholipid.</span>
        <meta itemprop="num_attr" content="0049">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the non-cationic lipid</span>
        <span itemprop="definition">is a phospholipid.</span>
        <meta itemprop="num_attr" content="0050">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the non-cationic lipid</span>
        <span itemprop="definition">is a PEG-lipid conjugate.</span>
        <meta itemprop="num_attr" content="0051">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the non-cationic lipid</span>
        <span itemprop="definition">is a mixture of a PEG-lipid conjugate and a phospholipid.</span>
        <meta itemprop="num_attr" content="0052">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the lipid nanoparticle</span>
        <span itemprop="definition">further comprises cholesterol.</span>
        <meta itemprop="num_attr" content="0053">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the phospholipid</span>
        <span itemprop="definition">comprises dipalmitoylphosphatidylcholine (DPPC), distearoylphosphatidylcholine (DSPC), or a mixture thereof.</span>
        <meta itemprop="num_attr" content="0054">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">DPPC</span>
        <span itemprop="definition">dipalmitoylphosphatidylcholine</span>
        <meta itemprop="num_attr" content="0054">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">DSPC</span>
        <span itemprop="definition">distearoylphosphatidylcholine</span>
        <meta itemprop="num_attr" content="0054">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the PEG-lipid conjugate</span>
        <span itemprop="definition">is selected from the group consisting of a PEG-diacylglycerol (PEG-DAG) conjugate, a PEG-dialkyloxypropyl (PEG-DAA) conjugate, a PEG-phospholipid conjugate, a PEG-ceramide (PEG-Cer) conjugate, and a mixture thereof.</span>
        <meta itemprop="num_attr" content="0055">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">PEG-DAG</span>
        <span itemprop="definition">PEG-diacylglycerol</span>
        <meta itemprop="num_attr" content="0055">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">PEG-DAA</span>
        <span itemprop="definition">PEG-dialkyloxypropyl</span>
        <meta itemprop="num_attr" content="0055">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">PEG-phospholipid conjugate</span>
        <span itemprop="definition">a PEG-ceramide conjugate</span>
        <meta itemprop="num_attr" content="0055">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">PEG-Cer</span>
        <span itemprop="definition">PEG-ceramide conjugate</span>
        <meta itemprop="num_attr" content="0055">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the PEG-lipid conjugate</span>
        <span itemprop="definition">is selected from the group consisting of a PEG-2000-C-DMA, PEG-diacylglycerol (PEG-DAG) conjugate, a PEG-dialkyloxypropyl (PEG-DAA) conjugate, a PEG-phospholipid conjugate, a PEG-ceramide (PEG-Cer) conjugate, and a mixture thereof.</span>
        <meta itemprop="num_attr" content="0056">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the PEG-lipid conjugate</span>
        <span itemprop="definition">is a PEG-DAA conjugate.</span>
        <meta itemprop="num_attr" content="0057">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the PEG-DAA conjugate</span>
        <span itemprop="definition">is selected from the group consisting of a PEG-didecyloxypropyl (C 10 ) conjugate, a PEG-dilauryloxypropyl (C 12 ) conjugate, a PEG-dimyristyloxypropyl (C 14 ) conjugate, a PEG-dipalmityloxypropyl (C 16 ) conjugate, a PEG-distearyloxypropyl (C 18 ) conjugate, and a mixture thereof.</span>
        <meta itemprop="num_attr" content="0058">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the lipid nanoparticle</span>
        <span itemprop="definition">has a lipid:nucleic mass ratio of from about 9:1 to about 20:1.</span>
        <meta itemprop="num_attr" content="0059">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the multiplicity of lipid nanoparticles in the lipid nanoparticle formulation</span>
        <span itemprop="definition">has a lipid:nucleic mass ratio of from about 9:1 to about 20:1.</span>
        <meta itemprop="num_attr" content="0060">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the mRNA</span>
        <span itemprop="definition">is chemically modified.</span>
        <meta itemprop="num_attr" content="0061">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the lipid nanoparticle</span>
        <span itemprop="definition">comprises an electron dense core.</span>
        <meta itemprop="num_attr" content="0062">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the lipid nanoparticle</span>
        <span itemprop="definition">comprises an electron dense core and wherein the mRNA is located within the electron dense core.</span>
        <meta itemprop="num_attr" content="0063">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Certain embodiments</span>
        <span itemprop="definition">provide a pharmaceutical composition</span>
        <meta itemprop="num_attr" content="0064">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a pharmaceutical composition</span>
        <span itemprop="definition">comprising a lipid nanoparticle or population thereof as described herein, and a pharmaceutically acceptable carrier.</span>
        <meta itemprop="num_attr" content="0064">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Certain embodiments</span>
        <span itemprop="definition">provide a method for introducing an mRNA that encodes a protein into a cell, the method comprising contacting the cell with a lipid nanoparticle or population thereof as described herein, under conditions whereby the mRNA is introduced into the cell and expressed therein to produce the protein.</span>
        <meta itemprop="num_attr" content="0065">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Certain embodiments</span>
        <span itemprop="definition">provide a method for treating and/or ameliorating one or more symptoms associated with a disease in a human, caused by impaired expression of a protein in the human, the method comprising administering to the human a therapeutically effective amount of a lipid nanoparticle or population thereof as described herein, wherein the mRNA encapsulated within the lipid nanoparticle encodes the protein.</span>
        <meta itemprop="num_attr" content="0066">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the phospholipid</span>
        <span itemprop="definition">is distearoylphosphatidylcholine (DSPC).</span>
        <meta itemprop="num_attr" content="0067">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the PEG-lipid conjugate</span>
        <span itemprop="definition">is PEG-2000-C-DMA.</span>
        <meta itemprop="num_attr" content="0068">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the LNP</span>
        <span itemprop="definition">comprises at least 3.5 mole percent of the PEG-lipid conjugate (e.g., at least about 3.5, 4, 4.5, 5, 5.5, or 6 mole percent).</span>
        <meta itemprop="num_attr" content="0069">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the amount of PEG-lipid conjugate</span>
        <span itemprop="definition">is at least 3 mole percent (e.g., at least 3.1 mole percent, at least 3.2 mole percent, at least 3.3 mole percent, at least 3.4 mole percent, at least 3.5 mole percent, at least 3.6 mole percent, at least 3.7 mole percent, at least 3.8 mole percent, at least 3.9 mole percent, at least 4 mole percent).</span>
        <meta itemprop="num_attr" content="0070">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">no phospholipid</span>
        <span itemprop="definition">is used in the practice of the invention.</span>
        <meta itemprop="num_attr" content="0070">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the lipid particle</span>
        <span itemprop="definition">comprises less than 2 mole percent phospholipid, e.g., 1.9 mol % phospholipid, 1.8 mol % phospholipid, 1.7 mol % phospholipid, 1.6 mol % phospholipid, 1.5 mol % phospholipid, 1.4 mol % phospholipid, 1.3 mol % phospholipid, 1.2 mol % phospholipid, 1.1 mol % phospholipid, 1.0 mol % phospholipid, 0.9 mol % phospholipid, 0.8 mol % phospholipid, 0.7 mol % phospholipid, 0.6 mol % phospholipid, 0.5 mol % phospholipid, 0.4 mol % phospholipid, 0.3 mol % phospholipid, 0.2 mol % phospholipid, 0.1 mol % phospholipid, or 0.0% phospholipid, e.g., less than 1.9 mol % phospholipid, less than 1.8 mol % phospholipid, less than</span>
        <meta itemprop="num_attr" content="0070">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the LNP</span>
        <span itemprop="definition">comprises a PEG-lipid conjugate present in an amount of at least 3 mole percent, provided that the LNP comprises less than 0.5 mole percent phospholipid. In certain embodiments, the PEG-lipid conjugate is present in an amount of at least 3.5 mole percent (e.g., at least about 3.5, 4, 4.5, 5, 5.5, or 6 mole percent). In certain embodiments, the LNP comprises less than 0.05 mole percent phospholipid.</span>
        <meta itemprop="num_attr" content="0071">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the lipid nanoparticle</span>
        <span itemprop="definition">has a lipid:mRNA mass ratio of from about 9:1 to about 20:1.</span>
        <meta itemprop="num_attr" content="0072">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Certain embodiments</span>
        <span itemprop="definition">provide a lipid nanoparticle prepared according to the methods described herein.</span>
        <meta itemprop="num_attr" content="0073">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Certain embodiments</span>
        <span itemprop="definition">provide a lipid nanoparticle formulation comprising a multiplicity of lipid nanoparticles as described herein.</span>
        <meta itemprop="num_attr" content="0074">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">lipid nanoparticle formulation</span>
        <span itemprop="definition">comprising a multiplicity of lipid nanoparticles as described herein, wherein the lipid nanoparticle formulation has an IFIT response that is no more than 30 fold greater than a phosphate buffered saline control response.</span>
        <meta itemprop="num_attr" content="0075">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the lipid nanoparticle formulation</span>
        <span itemprop="definition">has an IFIT response that is no more than about 29, 28, 2, 26, 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1 fold greater than a phosphate buffered saline control response.</span>
        <meta itemprop="num_attr" content="0075">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">an âeffective amountâ or âtherapeutically effective amountâ of a therapeutic nucleic acid such as an mRNA</span>
        <span itemprop="definition">is an amount sufficient to produce the desired effect, e.g., mRNA-directed expression of an amount of a protein that causes a desirable biological effect in the organism within which the protein is expressed.</span>
        <meta itemprop="num_attr" content="0077">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the expressed protein</span>
        <span itemprop="definition">is an active form of a protein that is normally expressed in a cell type within the body</span>
        <meta itemprop="num_attr" content="0077">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the therapeutically effective amount of the mRNA</span>
        <span itemprop="definition">is an amount that produces an amount of the encoded protein that is at least 50% (e.g., at least 60%, or at least 70%, or at least 80%, or at least 90%) of the amount of the protein that is normally expressed in the cell type of a healthy individual.</span>
        <meta itemprop="num_attr" content="0077">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Suitable assays for measuring the expression of an mRNA or protein</span>
        <span itemprop="definition">include, but are not limited to dot blots, Northern blots, in situ hybridization, ELISA, immunoprecipitation, enzyme function, as well as phenotypic assays known to those of skill in the art.</span>
        <meta itemprop="num_attr" content="0077">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a detectable decrease of an immune response to a given mRNA</span>
        <span itemprop="definition">e.g., a modified mRNA.</span>
        <meta itemprop="num_attr" content="0078">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the amount of decrease of an immune response by a modified mRNA</span>
        <span itemprop="definition">may be determined relative to the level of an immune response in the presence of an unmodified mRNA.</span>
        <meta itemprop="num_attr" content="0078">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a detectable decrease</span>
        <span itemprop="definition">can be about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 100%, or more lower than the immune response detected in the presence of the unmodified mRNA.</span>
        <meta itemprop="num_attr" content="0078">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a decrease in the immune response to mRNA</span>
        <span itemprop="definition">is typically measured by a decrease in cytokine production (e.g., IFN â , IFN â , TNF â , IL-6, or IL-12) by a responder cell in vitro or a decrease in cytokine production in the sera of a mammalian subject after administration of the mRNA.</span>
        <meta itemprop="num_attr" content="0078">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">cytokine production</span>
        <span itemprop="definition">e.g., IFN â , IFN â , TNF â , IL-6, or IL-12</span>
        <meta itemprop="num_attr" content="0078">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Substantial identity</span>
        <span itemprop="definition">refers to a sequence that hybridizes to a reference sequence under stringent conditions, or to a sequence that has a specified percent identity over a specified region of a reference sequence.</span>
        <meta itemprop="num_attr" content="0079">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">stringent hybridization conditions</span>
        <span itemprop="definition">refers to conditions under which a nucleic acid will hybridize to its target sequence, typically in a complex mixture of nucleic acids, but to no other sequences. Stringent conditions are sequence-dependent and will be different in different circumstances. Longer sequences hybridize specifically at higher temperatures. An extensive guide to the hybridization of nucleic acids is found in Tijssen, Techniques in Biochemistry and Molecular BiologyâHybridization with Nucleic Probes, âOverview of principles of hybridization and the strategy of nucleic acid assaysâ (1993). Generally, stringent conditions are selected to be about 5-10Â° C. lower than the thermal melting point (T m ) for the specific sequence at a defined ionic strength pH.</span>
        <meta itemprop="num_attr" content="0080">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">T m</span>
        <span itemprop="definition">thermal melting point</span>
        <meta itemprop="num_attr" content="0080">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the T m</span>
        <span itemprop="definition">is the temperature (under defined ionic strength, pH, and nucleic concentration) at which 50% of the probes complementary to the target hybridize to the target sequence at equilibrium (as the target sequences are present in excess, at T m , 50% of the probes are occupied at equilibrium).</span>
        <meta itemprop="num_attr" content="0080">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Stringent conditions</span>
        <span itemprop="definition">may also be achieved with the addition of destabilizing agents such as formamide.</span>
        <meta itemprop="num_attr" content="0080">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a positive signal</span>
        <span itemprop="definition">is at least two times background, preferably 10 times background hybridization.</span>
        <meta itemprop="num_attr" content="0080">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Exemplary stringent hybridization conditions</span>
        <span itemprop="definition">can be as follows: 50% formamide, 5 â SSC, and 1% SDS, incubating at 42Â° C., or, 5 â SSC, 1% SDS, incubating at 65Â° C., with wash in 0.2 â SSC, and 0.1% SDS at 65Â° C.</span>
        <meta itemprop="num_attr" content="0081">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a temperature of about 36Â° C.</span>
        <span itemprop="definition">is typical for low stringency amplification, although annealing temperatures may vary between about 32Â° C. and 48Â° C. depending on primer length.</span>
        <meta itemprop="num_attr" content="0081">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a temperature of about 62Â° C.</span>
        <span itemprop="definition">is typical, although high stringency annealing temperatures can range from about 50Â° C. to about 65Â° C., depending on the primer length and specificity.</span>
        <meta itemprop="num_attr" content="0081">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Typical cycle conditions for both high and low stringency amplifications</span>
        <span itemprop="definition">include a denaturation phase of 90Â° C.-95Â° C. for 30 sec. to 2 min., an annealing phase lasting 30 sec. to 2 min., and an extension phase of about 72Â° C. for 1 to 2 min. Protocols and guidelines for low and high stringency amplification reactions are provided, e.g., in Innis et al., PCR Protocols, A Guide to Methods and Applications, Academic Press, Inc. N.Y. (1990).</span>
        <meta itemprop="num_attr" content="0081">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Nucleic acids that do not hybridize to each other under stringent conditions</span>
        <span itemprop="definition">are still substantially identical if the polypeptides which they encode are substantially identical. This occurs, for example, when a copy of a nucleic acid is created using the maximum codon degeneracy permitted by the genetic code. In such cases, the nucleic acids typically hybridize under moderately stringent hybridization conditions.</span>
        <meta itemprop="num_attr" content="0082">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Exemplary âmoderately stringent hybridization conditionsâ</span>
        <span itemprop="definition">include a hybridization in a buffer of 40% formamide, 1 M NaCl, 1% SDS at 37Â° C., and a wash in 1 â SSC at 45Â° C. A positive hybridization is at least twice background.</span>
        <meta itemprop="num_attr" content="0082">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Those of ordinary skill</span>
        <span itemprop="definition">will readily recognize that alternative hybridization and wash conditions can be utilized to provide conditions of similar stringency. Additional guidelines for determining hybridization parameters are provided in numerous references, e.g., Current Protocols in Molecular Biology, Ausubel et al., eds.</span>
        <meta itemprop="num_attr" content="0082">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">substantially identical</span>
        <span itemprop="definition">or âsubstantial identity,â in the context of two or more nucleic acids, refer to two or more sequences or subsequences that are the same or have a specified percentage of nucleotides that are the same (i.e., at least about 60%, preferably at least about 65%, 70%, 75%, 80%, 85%, 90%, or 95% identity over a specified region), when compared and aligned for maximum correspondence over a comparison window, or designated region as measured using one of the following sequence comparison algorithms or by manual alignment and visual inspection.</span>
        <meta itemprop="num_attr" content="0083">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">This definition</span>
        <span itemprop="definition">when the context indicates, also refers analogously to the complement of a sequence.</span>
        <meta itemprop="num_attr" content="0083">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the substantial identity</span>
        <span itemprop="definition">exists over a region that is at least about 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, or 60 nucleotides in length.</span>
        <meta itemprop="num_attr" content="0083">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">sequence comparison</span>
        <span itemprop="definition">typically one sequence acts as a reference sequence, to which test sequences are compared.</span>
        <meta itemprop="num_attr" content="0084">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">test and reference sequences</span>
        <span itemprop="definition">are entered into a computer, subsequence coordinates are designated, if necessary, and sequence algorithm program parameters are designated. Default program parameters can be used, or alternative parameters can be designated.</span>
        <meta itemprop="num_attr" content="0084">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">sequence comparison algorithm</span>
        <span itemprop="definition">then calculates the percent sequence identities for the test sequences relative to the reference sequence, based on the program parameters.</span>
        <meta itemprop="num_attr" content="0084">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a âcomparison window,â as used herein,</span>
        <span itemprop="definition">includes reference to a segment of any one of a number of contiguous positions selected from the group consisting of from about 5 to about 60, usually about 10 to about 45, more usually about 15 to about 30, in which a sequence may be compared to a reference sequence of the same number of contiguous positions after the two sequences are optimally aligned.</span>
        <meta itemprop="num_attr" content="0085">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Methods of alignment of sequences for comparison</span>
        <span itemprop="definition">are well known in the art. Optimal alignment of sequences for comparison can be conducted, e.g., by the local homology algorithm of Smith and Waterman, Adv. Appl. Math., 2:482 (1981), by the homology alignment algorithm of Needleman and Wunsch, J. Mol.</span>
        <meta itemprop="num_attr" content="0085">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Non-limiting examples of algorithms that are suitable for determining percent sequence identity and sequence similarity</span>
        <span itemprop="definition">are the BLAST and BLAST 2.0 algorithms, which are described in Altschul et al., Nuc. Acids Res., 25:3389-3402 (1977) and Altschul et al., J. Mol. Biol., 215:403-410 (1990), respectively.</span>
        <meta itemprop="num_attr" content="0086">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">BLAST and BLAST 2.0</span>
        <span itemprop="definition">are used, with the parameters described herein, to determine percent sequence identity for the nucleic acids of the invention.</span>
        <meta itemprop="num_attr" content="0086">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Software for performing BLAST analyses</span>
        <span itemprop="definition">is publicly available through the National Center for Biotechnology Information (http://www.ncbi.nlm.nih.gov/).</span>
        <meta itemprop="num_attr" content="0086">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Another example</span>
        <span itemprop="definition">is a global alignment algorithm for determining percent sequence identity such as the Needleman-Wunsch algorithm for aligning protein or nucleotide (e.g., RNA) sequences.</span>
        <meta itemprop="num_attr" content="0086">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the BLAST algorithm</span>
        <span itemprop="definition">also performs a statistical analysis of the similarity between two sequences (see, e.g., Karlin and Altschul, Proc. Natl. Acad. Sci. USA, 90:5873-5787 (1993)).</span>
        <meta itemprop="num_attr" content="0087">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">One measure of similarity provided by the BLAST algorithm</span>
        <span itemprop="definition">is the smallest sum probability (P(N)), which provides an indication of the probability by which a match between two nucleotide sequences would occur by chance.</span>
        <meta itemprop="num_attr" content="0087">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">P(N)</span>
        <span itemprop="definition">the smallest sum probability</span>
        <meta itemprop="num_attr" content="0087">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a nucleic acid</span>
        <span itemprop="definition">is considered similar to a reference sequence if the smallest sum probability in a comparison of the test nucleic acid to the reference nucleic acid is less than about 0.2, more preferably less than about 0.01, and most preferably less than about 0.001.</span>
        <meta itemprop="num_attr" content="0087">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">nucleic acid</span>
        <span itemprop="definition">refers to a polymer containing at least two deoxyribonucleotides or ribonucleotides in either single- or double-stranded form and includes DNA and RNA.</span>
        <meta itemprop="num_attr" content="0088">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">DNA</span>
        <span itemprop="definition">may be in the form of, e.g., antisense molecules, plasmid DNA, pre-condensed DNA, a PCR product, vectors (e.g., P1, PAC, BAC, YAC, artificial chromosomes), expression cassettes, chimeric sequences, chromosomal DNA, or derivatives and combinations of these groups.</span>
        <meta itemprop="num_attr" content="0088">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">RNA</span>
        <span itemprop="definition">may be in the form of small interfering RNA (siRNA), Dicer-substrate dsRNA, small hairpin RNA (shRNA), asymmetrical interfering RNA (aiRNA), microRNA (miRNA), mRNA, tRNA, rRNA, tRNA, viral RNA (vRNA), and combinations thereof.</span>
        <meta itemprop="num_attr" content="0088">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Nucleic acids</span>
        <span itemprop="definition">include nucleic acids containing known nucleotide analogs or modified backbone residues or linkages, which are synthetic, naturally occurring, and non-naturally occurring, and which have similar binding properties as the reference nucleic acid.</span>
        <meta itemprop="num_attr" content="0088">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">nucleic acid sequence</span>
        <span itemprop="definition">may in certain embodiments include an âunlocked nucleobase analogueâ (abbreviated as âUNAâ).</span>
        <meta itemprop="num_attr" content="0088">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">unlocked nucleobase analogue</span>
        <span itemprop="definition">refers to an acyclic nucleobase in which the C2â² and C3â² atoms of the ribose ring are not covalently linked.</span>
        <meta itemprop="num_attr" content="0089">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">unlocked nucleobase analogue</span>
        <span itemprop="definition">includes nucleobase analogues having the following structure identified as Structure A:</span>
        <meta itemprop="num_attr" content="0089">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Base</span>
        <span itemprop="definition">is any natural or unnatural base such as, for example, adenine (A), cytosine (C), guanine (G) and thymine (T).</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">UNA useful in the practice of the present invention</span>
        <span itemprop="definition">include the molecules identified as acyclic 2â²-3â²-seco-nucleotide monomers in U.S. Pat. No. 8,314,227 which is incorporated by reference herein in its entirety.</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">nucleic acid sequence</span>
        <span itemprop="definition">also implicitly encompasses conservatively modified variants thereof (e.g., degenerate codon substitutions), alleles, orthologs, SNPs, and complementary sequences as well as the sequence explicitly indicated.</span>
        <meta itemprop="num_attr" content="0090">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">degenerate codon substitutions</span>
        <span itemprop="definition">may be achieved by generating sequences in which the third position of one or more selected (or all) codons is substituted with mixed-base and/or deoxyinosine residues (Batzer et al., Nucleic Acid Res., 19:5081 (1991); Ohtsuka et al., J. Biol. Chem., 260:2605-2608 (1985); Rossolini et al., Mol. Cell. Probes, 8:91-98 (1994)).</span>
        <meta itemprop="num_attr" content="0090">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">small-interfering RNA</span>
        <span itemprop="definition">refers to double stranded RNA (i.e., duplex RNA) that is capable of reducing or inhibiting the expression of a target gene or sequence (e.g., by mediating the degradation or inhibiting the translation of mRNAs which are complementary to the siRNA sequence) when the siRNA is in the same cell as the target gene or sequence.</span>
        <meta itemprop="num_attr" content="0091">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the siRNA</span>
        <span itemprop="definition">may have substantial or complete identity to the target gene or sequence, or may comprise a region of mismatch (i.e., a mismatch motif).</span>
        <meta itemprop="num_attr" content="0091">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the siRNAs</span>
        <span itemprop="definition">may be about 19-25 (duplex) nucleotides in length, and is preferably about 20-24, 21-22, or 21-23 (duplex) nucleotides in length.</span>
        <meta itemprop="num_attr" content="0091">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">siRNA duplexes</span>
        <span itemprop="definition">may comprise 3â² overhangs of about 1 to about 4 nucleotides or about 2 to about 3 nucleotides and 5â² phosphate termini.</span>
        <meta itemprop="num_attr" content="0091">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Examples of siRNA</span>
        <span itemprop="definition">include, without limitation, a double-stranded polynucleotide molecule assembled from two separate stranded molecules, wherein one strand is the sense strand and the other is the complementary antisense strand.</span>
        <meta itemprop="num_attr" content="0091">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">siRNA</span>
        <span itemprop="definition">are chemically synthesized.</span>
        <meta itemprop="num_attr" content="0092">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">siRNA</span>
        <span itemprop="definition">can also be generated by cleavage of longer dsRNA (e.g., dsRNA greater than about 25 nucleotides in length) with the E. coli RNase III or Dicer. These enzymes process the dsRNA into biologically active siRNA (see, e.g., Yang et al., Proc. Natl. Acad. Sci. USA, 99:9942-9947 (2002); Calegari et al., Proc. Natl. Acad. Sci.</span>
        <meta itemprop="num_attr" content="0092">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">dsRNA</span>
        <span itemprop="definition">are at least 50 nucleotides to about 100, 200, 300, 400, or 500 nucleotides in length.</span>
        <meta itemprop="num_attr" content="0092">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a dsRNA</span>
        <span itemprop="definition">may be as long as 1000, 1500, 2000, 5000 nucleotides in length, or longer.</span>
        <meta itemprop="num_attr" content="0092">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the dsRNA</span>
        <span itemprop="definition">can encode for an entire gene transcript or a partial gene transcript.</span>
        <meta itemprop="num_attr" content="0092">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">siRNA</span>
        <span itemprop="definition">may be encoded by a plasmid (e.g., transcribed as sequences that automatically fold into duplexes with hairpin loops).</span>
        <meta itemprop="num_attr" content="0092">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Nucleotides</span>
        <span itemprop="definition">contain a sugar deoxyribose (DNA) or ribose (RNA), a base, and a phosphate group. Nucleotides are linked together through the phosphate groups.</span>
        <meta itemprop="num_attr" content="0093">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Bases</span>
        <span itemprop="definition">include purines and pyrimidines, which further include natural compounds adenine, thymine, guanine, cytosine, uracil, inosine, and natural analogs, and synthetic derivatives of purines and pyrimidines, which include, but are not limited to, modifications which place new reactive groups such as, but not limited to, amines, alcohols, thiols, carboxylates, and alkylhalides.</span>
        <meta itemprop="num_attr" content="0093">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">gene</span>
        <span itemprop="definition">refers to a nucleic acid (e.g., DNA or RNA) sequence that comprises partial length or entire length coding sequences necessary for the production of a polypeptide or precursor polypeptide.</span>
        <meta itemprop="num_attr" content="0094">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Gene product</span>
        <span itemprop="definition">refers to a product of a gene such as an RNA transcript or a polypeptide.</span>
        <meta itemprop="num_attr" content="0095">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">lipid</span>
        <span itemprop="definition">refers to a group of organic compounds that include, but are not limited to, esters of fatty acids and are characterized by being insoluble in water, but soluble in many organic solvents. They are usually divided into at least three classes: (1) âsimple lipids,â which include fats and oils as well as waxes; (2) âcompound lipids,â which include phospholipids and glycolipids; and (3) âderived lipidsâ such as steroids.</span>
        <meta itemprop="num_attr" content="0096">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">lipid particle</span>
        <span itemprop="definition">includes a lipid formulation that can be used to deliver a therapeutic nucleic acid (e.g., mRNA or siRNA) to a target site of interest (e.g., cell, tissue, organ, and the like).</span>
        <meta itemprop="num_attr" content="0097">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a therapeutic nucleic acid</span>
        <span itemprop="definition">e.g., mRNA or siRNA</span>
        <meta itemprop="num_attr" content="0097">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the lipid particle of the invention</span>
        <span itemprop="definition">is a nucleic acid-lipid particle, which is typically formed from a cationic lipid, a non-cationic lipid (e.g., a phospholipid), a conjugated lipid that prevents aggregation of the particle (e.g., a PEG-lipid), and optionally cholesterol.</span>
        <meta itemprop="num_attr" content="0097">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the therapeutic nucleic acid</span>
        <span itemprop="definition">e.g., mRNA</span>
        <meta itemprop="num_attr" content="0097">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">lipid particle of the present invention</span>
        <span itemprop="definition">refers to the dark appearance of the interior portion of a lipid particle when visualized using cryo transmission electron microscopy (âcryoTEMâ).</span>
        <meta itemprop="num_attr" content="0098">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">cryoTEM</span>
        <span itemprop="definition">cryo transmission electron microscopy</span>
        <meta itemprop="num_attr" content="0098">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Some lipid particles of the present invention</span>
        <span itemprop="definition">have an electron dense core and lack a lipid bilayer structure.</span>
        <meta itemprop="num_attr" content="0098">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Some lipid particles of the present invention</span>
        <span itemprop="definition">have an electron dense core, lack a lipid bilayer structure, and have an inverse Hexagonal or Cubic phase structure.</span>
        <meta itemprop="num_attr" content="0098">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the non-bilayer lipid packing</span>
        <span itemprop="definition">provides a 3-dimensional network of lipid cylinders with water and nucleic on the inside, i.e., essentially, a lipid droplet interpenetrated with aqueous channels containing the nucleic acid.</span>
        <meta itemprop="num_attr" content="0098">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">SNALP</span>
        <span itemprop="definition">refers to a stable nucleic acid-lipid particle.</span>
        <meta itemprop="num_attr" content="0099">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a SNALP</span>
        <span itemprop="definition">is a particle made from lipids (e.g., a cationic lipid, a non-cationic lipid, and a conjugated lipid that prevents aggregation of the particle), wherein the nucleic acid (e.g., mRNA) is fully encapsulated within the lipid.</span>
        <meta itemprop="num_attr" content="0099">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">lipids</span>
        <span itemprop="definition">e.g., a cationic lipid, a non-cationic lipid, and a conjugated lipid that prevents aggregation of the particle</span>
        <meta itemprop="num_attr" content="0099">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid</span>
        <span itemprop="definition">e.g., mRNA</span>
        <meta itemprop="num_attr" content="0099">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">SNALP</span>
        <span itemprop="definition">are extremely useful for systemic applications, as they can exhibit extended circulation lifetimes following intravenous (i.v.) injection, they can accumulate at distal sites (e.g., sites physically separated from the administration site), and they can mediate mRNA expression at these distal sites.</span>
        <meta itemprop="num_attr" content="0099">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid</span>
        <span itemprop="definition">may be complexed with a condensing agent and encapsulated within a SNALP as set forth in PCT Publication No. WO 00/03683, the disclosure of which is herein incorporated by reference in its entirety for all purposes.</span>
        <meta itemprop="num_attr" content="0099">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the lipid particles of the invention</span>
        <span itemprop="definition">typically have a mean diameter of from about 30 nm to about 150 nm, from about 40 nm to about 150 nm, from about 50 nm to about 150 nm, from about 60 nm to about 130 nm, from about 70 nm to about 110 nm, from about 70 nm to about 100 nm, from about 80 nm to about 100 nm, from about 90 nm to about 100 nm, from about 70 to about 90 nm, from about 80 nm to about 90 nm, from about 70 nm to about 80 nm, or about 30 nm, 35 nm, 40 nm, 45 nm, 50 nm, 55 nm, 60 nm, 65 nm, 70 nm, 75 nm, 80 nm, 85 nm, 90 nm, 95 nm, 100 nm, 105 nm, 110 nm, 115</span>
        <meta itemprop="num_attr" content="0100">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">nucleic acids</span>
        <span itemprop="definition">when present in the lipid particles of the present invention, are resistant in aqueous solution to degradation with a nuclease.</span>
        <meta itemprop="num_attr" content="0100">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Nucleic acid-lipid particles and their method of preparation</span>
        <span itemprop="definition">are disclosed in, e.g., U.S. Patent Publication Nos. 20040142025 and 20070042031, the disclosures of which are herein incorporated by reference in their entirety for all purposes.</span>
        <meta itemprop="num_attr" content="0100">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">lipid encapsulated</span>
        <span itemprop="definition">can refer to a lipid particle that provides a therapeutic nucleic acid such as an mRNA with full encapsulation, partial encapsulation, or both.</span>
        <meta itemprop="num_attr" content="0101">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid</span>
        <span itemprop="definition">e.g., mRNA</span>
        <meta itemprop="num_attr" content="0101">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the lipid particle</span>
        <span itemprop="definition">e.g., to form a SNALP or other nucleic acid-lipid particle.</span>
        <meta itemprop="num_attr" content="0101">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">lipid conjugate</span>
        <span itemprop="definition">refers to a conjugated lipid that inhibits aggregation of lipid particles.</span>
        <meta itemprop="num_attr" content="0102">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">lipid conjugates</span>
        <span itemprop="definition">include, but are not limited to, PEG-lipid conjugates such as, e.g., PEG coupled to dialkyloxypropyls (e.g., PEG-DAA conjugates), PEG coupled to diacylglycerols (e.g., PEG-DAG conjugates), PEG coupled to cholesterol, PEG coupled to phosphatidylethanolamines, and PEG conjugated to ceramides (see, e.g., U.S. Pat. No.</span>
        <meta itemprop="num_attr" content="0102">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">PEG-lipid conjugates</span>
        <span itemprop="definition">such as, e.g., PEG coupled to dialkyloxypropyls (e.g., PEG-DAA conjugates), PEG coupled to diacylglycerols (e.g., PEG-DAG conjugates), PEG coupled to cholesterol, PEG coupled to phosphatidylethanolamines, and PEG conjugated to ceramides (see</span>
        <meta itemprop="num_attr" content="0102">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">PEG or POZ</span>
        <span itemprop="definition">can be conjugated directly to the lipid or may be linked to the lipid via a linker moiety. Any linker moiety suitable for coupling the PEG or the POZ to a lipid can be used including, e.g., non-ester containing linker moieties and ester-containing linker moieties. In certain preferred embodiments, non-ester containing linker moieties, such as amides or carbamates, are used.</span>
        <meta itemprop="num_attr" content="0102">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">amphipathic lipid</span>
        <span itemprop="definition">refers, in part, to any suitable material wherein the hydrophobic portion of the lipid material orients into a hydrophobic phase, while the hydrophilic portion orients toward the aqueous phase.</span>
        <meta itemprop="num_attr" content="0103">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Hydrophilic characteristics</span>
        <span itemprop="definition">derive from the presence of polar or charged groups such as carbohydrates, phosphate, carboxylic, sulfato, amino, sulfhydryl, nitro, hydroxyl, and other like groups. Hydrophobicity can be conferred by the inclusion of apolar groups that include, but are not limited to, long-chain saturated and unsaturated aliphatic hydrocarbon groups and such groups substituted by one or more aromatic, cycloaliphatic, or heterocyclic group(s). Examples of amphipathic compounds include, but are not limited to, phospholipids, aminolipids, and sphingolipids.</span>
        <meta itemprop="num_attr" content="0103">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">phospholipids</span>
        <span itemprop="definition">include, but are not limited to, phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, phosphatidylinositol, phosphatidic acid, palmitoyloleoyl phosphatidylcholine, lysophosphatidylcholine, lysophosphatidylethanolamine, dipalmitoylphosphatidylcholine, dioleoylphosphatidylcholine, distearoylphosphatidylcholine, and dilinoleoylphosphatidylcholine.</span>
        <meta itemprop="num_attr" content="0104">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">amphipathic lipids</span>
        <span itemprop="definition">Other compounds lacking in phosphorus, such as sphingolipid, glycosphingolipid families, diacylglycerols, and  â -acyloxyacids, are also within the group designated as amphipathic lipids. Additionally, the amphipathic lipids described above can be mixed with other lipids including triglycerides and sterols.</span>
        <meta itemprop="num_attr" content="0104">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">neutral lipid</span>
        <span itemprop="definition">refers to any of a number of lipid species that exist either in an uncharged or neutral zwitterionic form at a selected pH.</span>
        <meta itemprop="num_attr" content="0105">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">lipids</span>
        <span itemprop="definition">include, for example, diacylphosphatidylcholine, diacylphosphatidylethanolamine, ceramide, sphingomyelin, cephalin, cholesterol, cerebrosides, and diacylglycerols.</span>
        <meta itemprop="num_attr" content="0105">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">non-cationic lipid</span>
        <span itemprop="definition">refers to any amphipathic lipid as well as any other neutral lipid or anionic lipid.</span>
        <meta itemprop="num_attr" content="0106">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">anionic lipid</span>
        <span itemprop="definition">refers to any lipid that is negatively charged at physiological pH. These lipids include, but are not limited to, phosphatidylglycerols, cardiolipins, diacylphosphatidylserines, diacylphosphatidic acids, N-dodecanoyl phosphatidylethanolamines, N-succinyl phosphatidylethanolamines, N-glutarylphosphatidylethanolamines, lysylphosphatidylglycerols, palmitoyloleyolphosphatidylglycerol (POPG), and other anionic modifying groups joined to neutral lipids.</span>
        <meta itemprop="num_attr" content="0107">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">phosphatidylglycerols</span>
        <span itemprop="definition">cardiolipins</span>
        <meta itemprop="num_attr" content="0107">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">diacylphosphatidylserines</span>
        <span itemprop="definition">diacylphosphatidic acids</span>
        <meta itemprop="num_attr" content="0107">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">N-dodecanoyl phosphatidylethanolamines</span>
        <span itemprop="definition">N-succinyl phosphatidylethanolamines</span>
        <meta itemprop="num_attr" content="0107">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">hydrophobic lipid</span>
        <span itemprop="definition">refers to compounds having apolar groups that include, but are not limited to, long-chain saturated and unsaturated aliphatic hydrocarbon groups and such groups optionally substituted by one or more aromatic, cycloaliphatic, or heterocyclic group(s). Suitable examples include, but are not limited to, diacylglycerol, dialkylglycerol, N-N-dialkylamino, 1,2-diacyloxy-3-aminopropane, and 1,2-dialkyl-3-aminopropane.</span>
        <meta itemprop="num_attr" content="0108">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">cationic lipid</span>
        <span itemprop="definition">and âamino lipidâ are used interchangeably herein to include those lipids and salts thereof having one, two, three, or more fatty acid or fatty alkyl chains and a pH-titratable amino head group (e.g., an alkylamino or dialkylamino head group).</span>
        <meta itemprop="num_attr" content="0109">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the cationic lipid</span>
        <span itemprop="definition">is typically protonated (i.e., positively charged) at a pH below the pK a of the cationic lipid and is substantially neutral at a pH above the pK a .</span>
        <meta itemprop="num_attr" content="0109">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the cationic lipids of the invention</span>
        <span itemprop="definition">may also be termed titratable cationic lipids.</span>
        <meta itemprop="num_attr" content="0109">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the cationic lipids</span>
        <span itemprop="definition">comprise: a protonatable tertiary amine (e.g., pH-titratable) head group; C 18 alkyl chains, wherein each alkyl chain independently has 0 to 3 (e.g., 0, 1, 2, or 3) double bonds; and ether, ester, or ketal linkages between the head group and alkyl chains.</span>
        <meta itemprop="num_attr" content="0109">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a protonatable tertiary amine</span>
        <span itemprop="definition">e.g., pH-titratable</span>
        <meta itemprop="num_attr" content="0109">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">C 18 alkyl chains</span>
        <span itemprop="definition">wherein each alkyl chain independently has 0 to 3 (e.g., 0, 1, 2, or 3) double bonds</span>
        <meta itemprop="num_attr" content="0109">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">ether, ester, or ketal linkages between the head group and alkyl chains</span>
        <span itemprop="definition">e.g., 1, 2, or 3</span>
        <meta itemprop="num_attr" content="0109">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Such cationic lipids</span>
        <span itemprop="definition">include, but are not limited to, DSDMA, DODMA, DLinDMA, DLenDMA,  â -DLenDMA, DLin-K-DMA, DLin-K-C2-DMA (also known as DLin-C2K-DMA, XTC2, and C2K), DLin-K-C3-DMA, DLin-K-C4-DMA, DLen-C2K-DMA,  â -DLen-C2K-DMA, DLin-M-C2-DMA (also known as MC2), DLin-M-C3-DMA (also known as MC3) and (DLin-MP-DMA) (also known as 1-B11).</span>
        <meta itemprop="num_attr" content="0109">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">alkylamino</span>
        <span itemprop="definition">includes a group of formula âN(H)R, wherein R is an alkyl as defined herein.</span>
        <meta itemprop="num_attr" content="0110">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">dialkylamino</span>
        <span itemprop="definition">includes a group of formula âNR 2 , wherein each R is independently an alkyl as defined herein.</span>
        <meta itemprop="num_attr" content="0111">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">salts</span>
        <span itemprop="definition">includes any anionic and cationic complex, such as the complex formed between a cationic lipid and one or more anions.</span>
        <meta itemprop="num_attr" content="0112">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">anions</span>
        <span itemprop="definition">include inorganic and organic anions, e.g., hydride, fluoride, chloride, bromide, iodide, oxalate (e.g., hemioxalate), phosphate, phosphonate, hydrogen phosphate, dihydrogen phosphate, oxide, carbonate, bicarbonate, nitrate, nitrite, nitride, bisulfate, sulfide, sulfite, bisulfate, sulfate, thiosulfate, hydrogen sulfate, borate, formate, acetate, benzoate, citrate, tartrate, lactate, acrylate, polyacrylate, fumarate, maleate, itaconate, glycolate, gluconate, malate, mandelate, tiglate, ascorbate,</span>
        <meta itemprop="num_attr" content="0112">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">alkyl</span>
        <span itemprop="definition">includes a straight chain or branched, noncyclic or cyclic, saturated aliphatic hydrocarbon containing from 1 to 24 carbon atoms.</span>
        <meta itemprop="num_attr" content="0113">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Representative saturated straight chain alkyls</span>
        <span itemprop="definition">include, but are not limited to, methyl, ethyl, n-propyl, n-butyl, n-pentyl, n-hexyl, and the like, while saturated branched alkyls include, without limitation, isopropyl, sec-butyl, isobutyl, tert-butyl, isopentyl, and the like.</span>
        <meta itemprop="num_attr" content="0113">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">saturated cyclic alkyls</span>
        <span itemprop="definition">include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and the like, while unsaturated cyclic alkyls include, without limitation, cyclopentenyl, cyclohexenyl, and the like.</span>
        <meta itemprop="num_attr" content="0113">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">alkenyl</span>
        <span itemprop="definition">includes an alkyl, as defined above, containing at least one double bond between adjacent carbon atoms. Alkenyls include both cis and trans isomers. Representative straight chain and branched alkenyls include, but are not limited to, ethylenyl, propylenyl, 1-butenyl, 2-butenyl, isobutylenyl, 1-pentenyl, 2-pentenyl, 3-methyl-1-butenyl, 2-methyl-2-butenyl, 2,3-dimethyl-2-butenyl, and the like.</span>
        <meta itemprop="num_attr" content="0114">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">alkynyl</span>
        <span itemprop="definition">includes any alkyl or alkenyl, as defined above, which additionally contains at least one triple bond between adjacent carbons.</span>
        <meta itemprop="num_attr" content="0115">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Representative straight chain and branched alkynyls</span>
        <span itemprop="definition">include, without limitation, acetylenyl, propynyl, 1-butynyl, 2-butynyl, 1-pentynyl, 2-pentynyl, 3-methyl-1 butynyl, and the like.</span>
        <meta itemprop="num_attr" content="0115">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">acyl</span>
        <span itemprop="definition">includes any alkyl, alkenyl, or alkynyl wherein the carbon at the point of attachment is substituted with an oxo group, as defined below.</span>
        <meta itemprop="num_attr" content="0116">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">acyl groups</span>
        <span itemprop="definition">include âC( â O)alkyl, âC( â O)alkenyl, and âC( â O)alkynyl.</span>
        <meta itemprop="num_attr" content="0116">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">heterocycle</span>
        <span itemprop="definition">includes a 5- to 7-membered monocyclic, or 7- to 10-membered bicyclic, heterocyclic ring which is either saturated, unsaturated, or aromatic, and which contains from 1 or 2 heteroatoms independently selected from nitrogen, oxygen and sulfur, and wherein the nitrogen and sulfur heteroatoms may be optionally oxidized, and the nitrogen heteroatom may be optionally quaternized, including bicyclic rings in which any of the above heterocycles are fused to a benzene ring.</span>
        <meta itemprop="num_attr" content="0117">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the heterocycle</span>
        <span itemprop="definition">may be attached via any heteroatom or carbon atom.</span>
        <meta itemprop="num_attr" content="0117">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Heterocycles</span>
        <span itemprop="definition">include, but are not limited to, heteroaryls as defined below, as well as morpholinyl, pyrrolidinonyl, pyrrolidinyl, piperidinyl, piperizynyl, hydantoinyl, valerolactamyl, oxiranyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydropyridinyl, tetrahydroprimidinyl, tetrahydrothiophenyl, tetrahydrothiopyranyl, tetrahydropyrimidinyl, tetrahydrothiophenyl, tetrahydrothiopyranyl, and the like.</span>
        <meta itemprop="num_attr" content="0117">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">optionally substituted alkyl</span>
        <span itemprop="definition">means that, when substituted, at least one hydrogen atom is replaced with a substituent. In the case of an oxo substituent ( â O), two hydrogen atoms are replaced.</span>
        <meta itemprop="num_attr" content="0118">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">substituents</span>
        <span itemprop="definition">include, but are not limited to, oxo, halogen, heterocycle, âCN, âOR x , âNR x R y , âNR x C( â O)R y , âNR x SO 2 R y , âC( â O)R x , âC( â O)OR x , âC( â O)NR x R y , âSO n R x , and âSO n NR x R y , wherein n is 0, 1, or 2, R x and R y are the same or different and are independently hydrogen, alkyl, or heterocycle, and each of the alkyl and heterocycle substituents may be further substituted with one or more of oxo, halogen, âOH, âCN, alkyl, âOR x , heterocycle, âNR x R y , âNR x C( â O)R y , âNR</span>
        <meta itemprop="num_attr" content="0118">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">halogen</span>
        <span itemprop="definition">includes fluoro, chloro, bromo, and iodo.</span>
        <meta itemprop="num_attr" content="0119">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">lipid particle</span>
        <span itemprop="definition">such as a SNALP</span>
        <meta itemprop="num_attr" content="0120">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the membranes</span>
        <span itemprop="definition">can be either the plasma membrane or membranes surrounding organelles, e.g., endosome, nucleus, etc.</span>
        <meta itemprop="num_attr" content="0120">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">aqueous solution</span>
        <span itemprop="definition">refers to a composition comprising in whole, or in part, water.</span>
        <meta itemprop="num_attr" content="0121">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">organic lipid solution</span>
        <span itemprop="definition">refers to a composition comprising in whole, or in part, an organic solvent having a lipid.</span>
        <meta itemprop="num_attr" content="0122">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Distal site</span>
        <span itemprop="definition">refers to a physically separated site, which is not limited to an adjacent capillary bed, but includes sites broadly distributed throughout an organism.</span>
        <meta itemprop="num_attr" content="0123">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">âSerum-stableâ in relation to nucleic acid-lipid particles such as SNALP</span>
        <span itemprop="definition">means that the particle is not significantly degraded after exposure to a serum or nuclease assay that would significantly degrade free DNA or RNA.</span>
        <meta itemprop="num_attr" content="0124">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Suitable assays</span>
        <span itemprop="definition">include, for example, a standard serum assay, a DNAse assay, or an RNAse assay.</span>
        <meta itemprop="num_attr" content="0124">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Systemic delivery</span>
        <span itemprop="definition">refers to delivery of lipid particles that leads to a broad biodistribution of an active agent such as an mRNA within an organism. Some techniques of administration can lead to the systemic delivery of certain agents, but not others. Systemic delivery means that a useful, preferably therapeutic, amount of an agent is exposed to most parts of the body. To obtain broad biodistribution generally requires a blood lifetime such that the agent is not rapidly degraded or cleared (such as by first pass organs (liver, lung, etc.) or by rapid, nonspecific cell binding) before reaching a disease site distal to the site of administration.</span>
        <meta itemprop="num_attr" content="0125">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Systemic delivery of lipid particles</span>
        <span itemprop="definition">can be by any means known in the art including, for example, intravenous, subcutaneous, and intraperitoneal. In a preferred embodiment, systemic delivery of lipid particles is by intravenous delivery.</span>
        <meta itemprop="num_attr" content="0125">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">âLocal delivery,â as used herein,</span>
        <span itemprop="definition">refers to delivery of an active agent such as an mRNA directly to a target site within an organism.</span>
        <meta itemprop="num_attr" content="0126">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">an agent</span>
        <span itemprop="definition">can be locally delivered by direct injection into a disease site, other target site, or a target organ such as the liver, heart, pancreas, kidney, and the like.</span>
        <meta itemprop="num_attr" content="0126">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">mammal</span>
        <span itemprop="definition">refers to any mammalian species such as a human, mouse, rat, dog, cat, hamster, guinea pig, rabbit, livestock, and the like.</span>
        <meta itemprop="num_attr" content="0127">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">lipid</span>
        <span itemprop="definition">refers to the total lipid in the particle.</span>
        <meta itemprop="num_attr" content="0128">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the present invention</span>
        <span itemprop="definition">provides nucleic acid-lipid particles that each include (a) a lipid particle comprising a cationic lipid; and (b) an mRNA molecule encapsulated within the lipid particle.</span>
        <meta itemprop="num_attr" content="0130">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a population of mRNA molecules</span>
        <span itemprop="definition">is encapsulated within the lipid particle.</span>
        <meta itemprop="num_attr" content="0130">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the lipid particles</span>
        <span itemprop="definition">typically include an outer layer defining an interior portion, wherein the mRNA molecule(s) is located within the interior portion.</span>
        <meta itemprop="num_attr" content="0130">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the mRNA molecule(s)</span>
        <span itemprop="definition">is typically completely encapsulated within the lipid particle.</span>
        <meta itemprop="num_attr" content="0130">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the lipid particles</span>
        <span itemprop="definition">can be spherical or non-spherical.</span>
        <meta itemprop="num_attr" content="0130">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the lipid particles</span>
        <span itemprop="definition">can have an electron dense core when visualized using cryo TEM.</span>
        <meta itemprop="num_attr" content="0130">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the electron dense core</span>
        <span itemprop="definition">is mainly composed of lipid, although aqueous material may be present in an amount that is less than the amount of the lipid.</span>
        <meta itemprop="num_attr" content="0130">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the present invention</span>
        <span itemprop="definition">provides a lipid particle comprising a PEG lipid, a non-cationic lipid, a cationic lipid selected from a trialkyl cationic lipid and a tetra alkyl cationic lipid, and an mRNA; wherein the lipid particle has an electron dense core and the mRNA is encapsulated within the electron dense core.</span>
        <meta itemprop="num_attr" content="0131">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the lipid particles</span>
        <span itemprop="definition">include (a) a lipid particle comprising a cationic lipid, a PEG-lipid, and a phospholipid; and (b) an mRNA molecule, wherein the mRNA molecule is encapsulated within the lipid particle.</span>
        <meta itemprop="num_attr" content="0132">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the lipid particles</span>
        <span itemprop="definition">can optionally include cholesterol.</span>
        <meta itemprop="num_attr" content="0132">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the mRNA</span>
        <span itemprop="definition">can be completely or partially encapsulated within the lipid particle.</span>
        <meta itemprop="num_attr" content="0132">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the formation of the particle 100</span>
        <span itemprop="definition">includes, in one or more embodiments, disposing a lipid into a first fluid, such as ethanol, disposing mRNA into a second fluid, such as an aqueous buffer, and mixing the first and second fluids under controlled conditions to form particle 100.</span>
        <meta itemprop="num_attr" content="0133">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the resulting particle 100</span>
        <span itemprop="definition">includes an electron dense core within the lipid particle when viewed by Cryo Transmission Electron Microscopy.</span>
        <meta itemprop="num_attr" content="0133">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">mRNA useful in the practice of the present invention</span>
        <span itemprop="definition">may comprise at least one, two, three, four, five, six, seven, eight, nine, ten, or more modified nucleotides such as 2â²OMe nucleotides.</span>
        <meta itemprop="num_attr" content="0134">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">modified nucleotides</span>
        <span itemprop="definition">such as 2â²OMe nucleotides.</span>
        <meta itemprop="num_attr" content="0134">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">uridine and/or guanosine nucleotides in the mRNA</span>
        <span itemprop="definition">are modified with 2â²OMe nucleotides.</span>
        <meta itemprop="num_attr" content="0134">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the mRNA</span>
        <span itemprop="definition">may further comprise modified (e.g., 2â²OMe-modified) adenosine and/or modified (e.g., 2â²OMe-modified) cytosine nucleotides.</span>
        <meta itemprop="num_attr" content="0134">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the present invention</span>
        <span itemprop="definition">provides a nucleic acid-lipid particle (e.g., SNALP) that includes an mRNA.</span>
        <meta itemprop="num_attr" content="0135">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid-lipid particles</span>
        <span itemprop="definition">typically comprise one or more (e.g., a cocktail) mRNA(s), a cationic lipid, and a non-cationic lipid.</span>
        <meta itemprop="num_attr" content="0135">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid-lipid particles</span>
        <span itemprop="definition">e.g., SNALP</span>
        <meta itemprop="num_attr" content="0135">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid-lipid particles</span>
        <span itemprop="definition">comprise one or more (e.g., a cocktail) mRNAs, a cationic lipid, a non-cationic lipid, and a conjugated lipid that inhibits aggregation of particles.</span>
        <meta itemprop="num_attr" content="0135">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the mRNA(s)</span>
        <span itemprop="definition">are fully encapsulated in the nucleic acid-lipid particle (e.g., SNALP).</span>
        <meta itemprop="num_attr" content="0136">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the different types of mRNA species present in the cocktail</span>
        <span itemprop="definition">e.g., mRNA having different sequences</span>
        <meta itemprop="num_attr" content="0136">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">each type of mRNA species present in the cocktail</span>
        <span itemprop="definition">may be encapsulated in a separate particle.</span>
        <meta itemprop="num_attr" content="0136">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the mRNA cocktail</span>
        <span itemprop="definition">may be formulated in the particles described herein using a mixture of two or more individual mRNAs (each having a unique sequence) at identical, similar, or different concentrations or molar ratios.</span>
        <meta itemprop="num_attr" content="0136">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a cocktail of mRNAs</span>
        <span itemprop="definition">(corresponding to a plurality of mRNAs with different sequences) is formulated using identical, similar, or different concentrations or molar ratios of each mRNA species, and the different types of mRNAs are co-encapsulated in the same particle.</span>
        <meta itemprop="num_attr" content="0136">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">each type of mRNA species present in the cocktail</span>
        <span itemprop="definition">is encapsulated in different particles at identical, similar, or different mRNA concentrations or molar ratios, and the particles thus formed (each containing a different mRNA payload) are administered separately (e.g., at different times in accordance with a therapeutic regimen), or are combined and administered together as a single unit dose (e.g., with a pharmaceutically acceptable carrier).</span>
        <meta itemprop="num_attr" content="0136">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the particles described herein</span>
        <span itemprop="definition">are serum-stable, are resistant to nuclease degradation, and are substantially non-toxic to mammals such as humans.</span>
        <meta itemprop="num_attr" content="0136">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the cationic lipid in the nucleic acid-lipid particles of the invention</span>
        <span itemprop="definition">may comprise, e.g., one or more cationic lipids of Formula I-III described herein or any other cationic lipid species.</span>
        <meta itemprop="num_attr" content="0137">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the cationic lipid</span>
        <span itemprop="definition">is selected from the group consisting of 1,2-dilinoleyloxy-N,N-dimethylaminopropane (DLinDMA), 1,2-dilinolenyloxy-N,N-dimethylaminopropane (DLenDMA), 1,2-di- â -linolenyloxy-N,N-dimethylaminopropane ( â -DLenDMA), 2,2-dilinoleyl-4-(2-dimethylaminoethyl)-[1,3]-dioxolane (DLin-K-C2-DMA), 2,2-dilinoleyl-4-dimethylaminomethyl-[1,3]-dioxolane (DLin-K-DMA), dilinoleylmethyl-3-dimethylaminopropionate (DLin-M-C2-DMA), (6Z,9Z,28Z,31Z)-heptatriaconta-6,9,</span>
        <meta itemprop="num_attr" content="0137">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the non-cationic lipid in the nucleic acid-lipid particles of the present invention</span>
        <span itemprop="definition">may comprise, e.g., one or more anionic lipids and/or neutral lipids.</span>
        <meta itemprop="num_attr" content="0138">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the non-cationic lipid</span>
        <span itemprop="definition">comprises one of the following neutral lipid components: (1) a mixture of a phospholipid and cholesterol or a derivative thereof; (2) cholesterol or a derivative thereof; or (3) a phospholipid.</span>
        <meta itemprop="num_attr" content="0138">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the phospholipid</span>
        <span itemprop="definition">comprises dipalmitoylphosphatidylcholine (DPPC), distearoylphosphatidylcholine (DSPC), or a mixture thereof.</span>
        <meta itemprop="num_attr" content="0138">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the non-cationic lipid</span>
        <span itemprop="definition">is a mixture of DPPC and cholesterol.</span>
        <meta itemprop="num_attr" content="0138">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the lipid conjugate in the nucleic acid-lipid particles of the invention</span>
        <span itemprop="definition">inhibits aggregation of particles and may comprise, e.g., one or more of the lipid conjugates described herein.</span>
        <meta itemprop="num_attr" content="0139">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the lipid conjugate</span>
        <span itemprop="definition">comprises a PEG-lipid conjugate.</span>
        <meta itemprop="num_attr" content="0139">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">PEG-lipid conjugates</span>
        <span itemprop="definition">include, but are not limited to, PEG-DAG conjugates, PEG-DAA conjugates, and mixtures thereof.</span>
        <meta itemprop="num_attr" content="0139">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the PEG-DAA conjugate in the lipid particle</span>
        <span itemprop="definition">may comprise a PEG-didecyloxypropyl (C 10 ) conjugate, a PEG-dilauryloxypropyl (C 12 ) conjugate, a PEG-dimyristyloxypropyl (C 14 ) conjugate, a PEG-dipalmityloxypropyl (C 16 ) conjugate, a PEG-distearyloxypropyl (C 18 ) conjugate, or mixtures thereof.</span>
        <meta itemprop="num_attr" content="0139">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the lipid conjugate</span>
        <span itemprop="definition">comprises a POZ-lipid conjugate such as a POZ-DAA conjugate.</span>
        <meta itemprop="num_attr" content="0139">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the present invention</span>
        <span itemprop="definition">provides nucleic acid-lipid particles (e.g., SNALP) comprising: (a) one or more (e.g., a cocktail) mRNA molecule(s) that each encode a protein; (b) one or more cationic lipids or salts thereof comprising from about 50 mol % to about 85 mol % of the total lipid present in the particle; (c) one or more non-cationic lipids comprising from about 13 mol % to about 49.5 mol % of the total lipid present in the particle; and (d) one or more conjugated lipids that inhibit aggregation of particles comprising from about 0.5 mol % to about 2 mol % of the total lipid present in the particle.</span>
        <meta itemprop="num_attr" content="0140">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">SNALP</span>
        <span itemprop="definition">nucleic acid-lipid particles</span>
        <meta itemprop="num_attr" content="0140">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid-lipid particle</span>
        <span itemprop="definition">comprises: (a) one or more (e.g., a cocktail) mRNA molecule(s) that each encode a protein; (b) a cationic lipid or a salt thereof comprising from about 52 mol % to about 62 mol % of the total lipid present in the particle; (c) a mixture of a phospholipid and cholesterol or a derivative thereof comprising from about 36 mol % to about 47 mol % of the total lipid present in the particle; and (d) a PEG-lipid conjugate comprising from about 1 mol % to about 2 mol % of the total lipid present in the particle.</span>
        <meta itemprop="num_attr" content="0141">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a cocktail</span>
        <span itemprop="definition">mRNA molecule(s) that each encode a protein</span>
        <meta itemprop="num_attr" content="0141">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a cationic lipid or a salt thereof</span>
        <span itemprop="definition">comprising from about 52 mol % to about 62 mol % of the total lipid present in the particle</span>
        <meta itemprop="num_attr" content="0141">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a mixture of a phospholipid and cholesterol or a derivative thereof</span>
        <span itemprop="definition">comprising from about 36 mol % to about</span>
        <meta itemprop="num_attr" content="0141">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">nucleic acid-lipid particle</span>
        <span itemprop="definition">is generally referred to herein as the â1:57â formulation.</span>
        <meta itemprop="num_attr" content="0141">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the 1:57 formulation</span>
        <span itemprop="definition">is a four-component system comprising about 1.4 mol % PEG-lipid conjugate (e.g., PEG2000-C-DMA), about 57.1 mol % cationic lipid (e.g., DLin-K-C2-DMA) or a salt thereof, about 7.1 mol % DPPC (or DSPC), and about 34.3 mol % cholesterol (or derivative thereof).</span>
        <meta itemprop="num_attr" content="0141">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid-lipid particle</span>
        <span itemprop="definition">comprises: (a) one or more (e.g., a cocktail) mRNA molecule(s) that each encode a protein; (b) a cationic lipid or a salt thereof comprising from about 56.5 mol % to about 66.5 mol % of the total lipid present in the particle; (c) cholesterol or a derivative thereof comprising from about 31.5 mol % to about 42.5 mol % of the total lipid present in the particle; and (d) a PEG-lipid conjugate comprising from about 1 mol % to about 2 mol % of the total lipid present in the particle.</span>
        <meta itemprop="num_attr" content="0142">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">This embodiment of nucleic acid-lipid particle</span>
        <span itemprop="definition">is generally referred to herein as the â1:62â formulation.</span>
        <meta itemprop="num_attr" content="0142">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the 1:62 formulation</span>
        <span itemprop="definition">is a three-component system which is phospholipid-free and comprises about 1.5 mol % PEG-lipid conjugate (e.g., PEG2000-C-DMA), about 61.5 mol % cationic lipid (e.g., DLin-K-C2-DMA) or a salt thereof, and about 36.9 mol % cholesterol (or derivative thereof).</span>
        <meta itemprop="num_attr" content="0142">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">PEG-lipid conjugate</span>
        <span itemprop="definition">e.g., PEG2000-C-DMA</span>
        <meta itemprop="num_attr" content="0142">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">61.5 mol % cationic lipid</span>
        <span itemprop="definition">e.g., DLin-K-C2-DMA</span>
        <meta itemprop="num_attr" content="0142">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a salt thereof</span>
        <span itemprop="definition">e.g., DLin-K-C2-DMA</span>
        <meta itemprop="num_attr" content="0142">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the present invention</span>
        <span itemprop="definition">provides nucleic acid-lipid particles (e.g., SNALP) comprising: (a) one or more (e.g., a cocktail) mRNA molecule(s) that each encode a protein; (b) one or more cationic lipids or salts thereof comprising from about 2 mol % to about 50 mol % of the total lipid present in the particle; (c) one or more non-cationic lipids comprising from about 5 mol % to about 90 mol % of the total lipid present in the particle; and (d) one or more conjugated lipids that inhibit aggregation of particles comprising from about 0.5 mol % to about 20 mol % of the total lipid present in the particle.</span>
        <meta itemprop="num_attr" content="0144">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">SNALP</span>
        <span itemprop="definition">nucleic acid-lipid particles</span>
        <meta itemprop="num_attr" content="0144">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid-lipid particle</span>
        <span itemprop="definition">comprises: (a) one or more (e.g., a cocktail) mRNA molecule(s) that each encode a protein; (b) a cationic lipid or a salt thereof comprising from about 30 mol % to about 50 mol % of the total lipid present in the particle; (c) a mixture of a phospholipid and cholesterol or a derivative thereof comprising from about 47 mol % to about 69 mol % of the total lipid present in the particle; and (d) a PEG-lipid conjugate comprising from about 1 mol % to about 3 mol % of the total lipid present in the particle.</span>
        <meta itemprop="num_attr" content="0145">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a cocktail</span>
        <span itemprop="definition">mRNA molecule(s) that each encode a protein</span>
        <meta itemprop="num_attr" content="0145">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a cationic lipid or a salt thereof</span>
        <span itemprop="definition">comprising from about 30 mol % to about 50 mol % of the total lipid present in the particle</span>
        <meta itemprop="num_attr" content="0145">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a mixture of a phospholipid and cholesterol or a derivative thereof</span>
        <span itemprop="definition">comprising from about 47 mol % to about</span>
        <meta itemprop="num_attr" content="0145">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the 2:40 formulation</span>
        <span itemprop="definition">is a four-component system which comprises about 2 mol % PEG-lipid conjugate (e.g., PEG2000-C-DMA), about 40 mol % cationic lipid (e.g., DLin-K-C2-DMA) or a salt thereof, about 10 mol % DPPC (or DSPC), and about 48 mol % cholesterol (or derivative thereof).</span>
        <meta itemprop="num_attr" content="0145">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">PEG-lipid conjugate</span>
        <span itemprop="definition">e.g., PEG2000-C-DMA</span>
        <meta itemprop="num_attr" content="0145">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">40 mol % cationic lipid</span>
        <span itemprop="definition">e.g., DLin-K-C2-DMA</span>
        <meta itemprop="num_attr" content="0145">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a salt thereof</span>
        <span itemprop="definition">e.g., DLin-K-C2-DMA</span>
        <meta itemprop="num_attr" content="0145">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">10 mol % DPPC</span>
        <span itemprop="definition">or DSPC</span>
        <meta itemprop="num_attr" content="0145">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">48 mol % cholesterol</span>
        <span itemprop="definition">or derivative thereof.</span>
        <meta itemprop="num_attr" content="0145">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the present invention</span>
        <span itemprop="definition">provides nucleic acid-lipid particles (e.g., SNALP) comprising: (a) one or more (e.g., a cocktail) mRNA molecule(s) that each encode a protein; (b) one or more cationic lipids or salts thereof comprising from about 50 mol % to about 65 mol % of the total lipid present in the particle; (c) one or more non-cationic lipids comprising from about 25 mol % to about 45 mol % of the total lipid present in the particle; and (d) one or more conjugated lipids that inhibit aggregation of particles comprising from about 5 mol % to about 10 mol % of the total lipid present in the particle.</span>
        <meta itemprop="num_attr" content="0146">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">SNALP</span>
        <span itemprop="definition">nucleic acid-lipid particles</span>
        <meta itemprop="num_attr" content="0146">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid-lipid particle</span>
        <span itemprop="definition">comprises: (a) one or more (e.g., a cocktail) mRNA molecule(s) that each encode a protein; (b) a cationic lipid or a salt thereof comprising from about 50 mol % to about 60 mol % of the total lipid present in the particle; (c) a mixture of a phospholipid and cholesterol or a derivative thereof comprising from about 35 mol % to about 45 mol % of the total lipid present in the particle; and (d) a PEG-lipid conjugate comprising from about 5 mol % to about 10 mol % of the total lipid present in the particle.</span>
        <meta itemprop="num_attr" content="0147">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a cocktail</span>
        <span itemprop="definition">mRNA molecule(s) that each encode a protein</span>
        <meta itemprop="num_attr" content="0147">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a cationic lipid or a salt thereof</span>
        <span itemprop="definition">comprising from about 50 mol % to about 60 mol % of the total lipid present in the particle</span>
        <meta itemprop="num_attr" content="0147">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a mixture of a phospholipid and cholesterol or a derivative thereof</span>
        <span itemprop="definition">comprising from about 35 mol % to about 45</span>
        <meta itemprop="num_attr" content="0147">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the non-cationic lipid mixture in the 7:54 formulation</span>
        <span itemprop="definition">comprises: (i) a phospholipid of from about 5 mol % to about 10 mol % of the total lipid present in the particle; and (ii) cholesterol or a derivative thereof of from about 25 mol % to about 35 mol % of the total lipid present in the particle.</span>
        <meta itemprop="num_attr" content="0147">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the 7:54 formulation</span>
        <span itemprop="definition">is a four-component system which comprises about 7 mol % PEG-lipid conjugate (e.g., PEG750-C-DMA), about 54 mol % cationic lipid (e.g., DLin-K-C2-DMA) or a salt thereof, about 7 mol % DPPC (or DSPC), and about 32 mol % cholesterol (or derivative thereof).</span>
        <meta itemprop="num_attr" content="0147">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">PEG-lipid conjugate</span>
        <span itemprop="definition">e.g., PEG750-C-DMA</span>
        <meta itemprop="num_attr" content="0147">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">54 mol % cationic lipid</span>
        <span itemprop="definition">e.g., DLin-K-C2-DMA</span>
        <meta itemprop="num_attr" content="0147">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a salt thereof</span>
        <span itemprop="definition">e.g., DLin-K-C2-DMA</span>
        <meta itemprop="num_attr" content="0147">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">7 mol DPPC</span>
        <span itemprop="definition">or DSPC</span>
        <meta itemprop="num_attr" content="0147">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">32 mol % cholesterol</span>
        <span itemprop="definition">or derivative thereof.</span>
        <meta itemprop="num_attr" content="0147">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid-lipid particle</span>
        <span itemprop="definition">comprises: (a) one or more (e.g., a cocktail) mRNA molecule(s) that each encode a protein; (b) a cationic lipid or a salt thereof comprising from about 55 mol % to about 65 mol % of the total lipid present in the particle; (c) cholesterol or a derivative thereof comprising from about 30 mol % to about 40 mol % of the total lipid present in the particle; and (d) a PEG-lipid conjugate comprising from about 5 mol % to about 10 mol % of the total lipid present in the particle.</span>
        <meta itemprop="num_attr" content="0148">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">This embodiment of nucleic acid-lipid particle</span>
        <span itemprop="definition">is generally referred to herein as the â7:58â formulation.</span>
        <meta itemprop="num_attr" content="0148">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the 7:58 formulation</span>
        <span itemprop="definition">is a three-component system which is phospholipid-free and comprises about 7 mol % PEG-lipid conjugate (e.g., PEG750-C-DMA), about 58 mol % cationic lipid (e.g., DLin-K-C2-DMA) or a salt thereof, and about 35 mol % cholesterol (or derivative thereof).</span>
        <meta itemprop="num_attr" content="0148">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">PEG-lipid conjugate</span>
        <span itemprop="definition">e.g., PEG750-C-DMA</span>
        <meta itemprop="num_attr" content="0148">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">58 mol % cationic lipid</span>
        <span itemprop="definition">e.g., DLin-K-C2-DMA</span>
        <meta itemprop="num_attr" content="0148">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a salt thereof</span>
        <span itemprop="definition">e.g., DLin-K-C2-DMA</span>
        <meta itemprop="num_attr" content="0148">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the present invention</span>
        <span itemprop="definition">also provides pharmaceutical compositions comprising a nucleic acid-lipid particle such as a SNALP and a pharmaceutically acceptable carrier.</span>
        <meta itemprop="num_attr" content="0150">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid-lipid particles of the present invention</span>
        <span itemprop="definition">are useful for the therapeutic delivery of mRNAs that express one or more proteins (such as full length proteins, or biologically active fragments of full length proteins).</span>
        <meta itemprop="num_attr" content="0151">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">mRNAs that express one or more proteins</span>
        <span itemprop="definition">such as full length proteins, or biologically active fragments of full length proteins.</span>
        <meta itemprop="num_attr" content="0151">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a cocktail of mRNAs that express different proteins</span>
        <span itemprop="definition">is formulated into the same or different nucleic acid-lipid particles, and the particles are administered to a mammal (e.g., a human) requiring such treatment.</span>
        <meta itemprop="num_attr" content="0151">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a therapeutically effective amount of the nucleic acid-lipid particles</span>
        <span itemprop="definition">can be administered to the mammal.</span>
        <meta itemprop="num_attr" content="0151">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the present invention</span>
        <span itemprop="definition">provides a method for introducing one or more mRNA molecules into a cell by contacting the cell with a nucleic acid-lipid particle described herein (e.g., a SNALP formulation).</span>
        <meta itemprop="num_attr" content="0152">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a nucleic acid-lipid particle described herein</span>
        <span itemprop="definition">e.g., a SNALP formulation.</span>
        <meta itemprop="num_attr" content="0152">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the cell</span>
        <span itemprop="definition">is a reticuloendothelial cell (e.g., monocyte or macrophage), fibroblast cell, endothelial cell, or platelet cell.</span>
        <meta itemprop="num_attr" content="0152">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid-lipid particles described herein</span>
        <span itemprop="definition">are administered by one of the following routes of administration: oral, intranasal, intravenous, intraperitoneal, intramuscular, intra-articular, intralesional, intratracheal, subcutaneous, and intradermal.</span>
        <meta itemprop="num_attr" content="0153">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid-lipid particles</span>
        <span itemprop="definition">are administered systemically, e.g., via enteral or parenteral routes of administration.</span>
        <meta itemprop="num_attr" content="0153">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid-lipid particles of the invention</span>
        <span itemprop="definition">can preferentially deliver a payload such as an mRNA to the liver as compared to other tissues.</span>
        <meta itemprop="num_attr" content="0154">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the present invention</span>
        <span itemprop="definition">provides methods for expressing a protein in a mammal (e.g., human) in need thereof, the method comprising administering to the mammal a therapeutically effective amount of a nucleic acid-lipid particle (e.g., a SNALP formulation) comprising one or more mRNAs that encode one or more proteins under conditions that enable expression of the protein(s) in the mammal.</span>
        <meta itemprop="num_attr" content="0155">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a nucleic acid-lipid particle</span>
        <span itemprop="definition">e.g., a SNALP formulation</span>
        <meta itemprop="num_attr" content="0155">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the level of expression of the protein encoded by the mRNA encapsulated within the SNALP</span>
        <span itemprop="definition">is at least 10%, or at least 20%, or at least 30%, or at least 40%, or at least 50%, or at least 60%, or at least 70%, or at least 80%, or at least 90%, or at least 100%, or greater than 100%, of the level of the protein that is normally expressed in a healthy mammalian subject.</span>
        <meta itemprop="num_attr" content="0155">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the present invention</span>
        <span itemprop="definition">provides methods for treating, preventing, reducing the risk or likelihood of developing (e.g., reducing the susceptibility to), delaying the onset of, and/or ameliorating one or more symptoms associated with a disease in a mammal (e.g., human) in need thereof, wherein the disease is caused (at least in part) by reduced or aberrant expression of a protein.</span>
        <meta itemprop="num_attr" content="0156">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the methods</span>
        <span itemprop="definition">each include the step of administering to the mammal a therapeutically effective amount of a nucleic acid-lipid particle (e.g., a SNALP formulation) comprising one or more mRNA molecules that encode a protein that is absent, or present at reduced levels, within the treated subject.</span>
        <meta itemprop="num_attr" content="0156">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a nucleic acid-lipid particle</span>
        <span itemprop="definition">e.g., a SNALP formulation</span>
        <meta itemprop="num_attr" content="0156">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">mRNA molecules useful in the present invention</span>
        <span itemprop="definition">may be chemically modified or unmodified. Typically mRNA molecules are chemically modified in order to reduce their ability to induce the innate immune response of a cell into which the mRNA is introduced.</span>
        <meta itemprop="num_attr" content="0157">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">mRNA used in the practice of the present invention</span>
        <span itemprop="definition">can include one, two, or more than two nucleoside modifications.</span>
        <meta itemprop="num_attr" content="0158">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the modified mRNA</span>
        <span itemprop="definition">exhibits reduced degradation in a cell into which the mRNA is introduced, relative to a corresponding unmodified mRNA.</span>
        <meta itemprop="num_attr" content="0158">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">modified nucleosides</span>
        <span itemprop="definition">include pyridin-4-one ribonucleoside, 5-aza-uridine, 2-thio-5-aza-uridine, 2-thiouridine, 4-thio-pseudouridine, 2-thio-pseudouridine, 5-hydroxyuridine, 3-methyluridine, 5-carboxymethyl-uridine, 1-carboxymethyl-pseudouridine, 5-propynyl-uridine, 1-propynyl-pseudouridine, 5-taurinomethyluridine, 1-taurinomethyl-pseudouridine, 5-taurinomethyl-2-thio-uridine, 1-taurinomethyl-4-thio-uridine, 5-methyl-uridine, 1-methyl-pseudouridine, 4-thio-1-methyl-pseudouridine, 2-thio-1-methyl-pseudouridine, 1-methyl-1-deaza-pseudouridine, 2-thio-1-methyl-1-methyl-1-</span>
        <meta itemprop="num_attr" content="0159">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">modified nucleosides</span>
        <span itemprop="definition">include 5-aza-cytidine, pseudoisocytidine, 3-methyl-cytidine, N4-acetylcytidine, 5-formylcytidine, N4-methylcytidine, 5-hydroxymethylcytidine, 1-methyl-pseudoisocytidine, pyrrolo-cytidine, pyrrolo-pseudoisocytidine, 2-thio-cytidine, 2-thio-5-methyl-cytidine, 4-thio-pseudoisocytidine, 4-thio-1-methyl-pseudoisocytidine, 4-thio-1-methyl-1-deaza-pseudoisocytidine, 1-methyl-1-deaza-pseudoisocytidine, zebularine, 5-aza-zebularine, 5-methyl-zebularine, 5-aza-2-thio-zebularine, 2-thio-zebula</span>
        <meta itemprop="num_attr" content="0160">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">modified nucleosides</span>
        <span itemprop="definition">include 2-aminopurine, 2,6-diaminopurine, 7-deaza-adenine, 7-deaza-8-aza-adenine, 7-deaza-2-aminopurine, 7-deaza-8-aza-2-aminopurine, 7-deaza-2,6-diaminopurine, 7-deaza-8-aza-2,6-diaminopurine, 1-methyl adenosine, N6-methyladenosine, N6-isopentenyladenosine, N6-(cis-hydroxyisopentenyl)adenosine, 2-methylthio-N6-(cis-hydroxyisopentenyl) adenosine, N6-glycinylcarbamoyladenosine, N6-threonylcarbamoyladenosine, 2-methylthio-N6-threonyl carbamoyladenosine, N6,N6-d</span>
        <meta itemprop="num_attr" content="0161">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a modified nucleoside</span>
        <span itemprop="definition">is 5â²-0-(1-Thiophosphate)-Adenosine, 5â²-0-(1-Thiophosphate)-Cytidine, 5â²-0-(1-Thiophosphate)-Guanosine, 5â²-0-(1-Thiophosphate)-Uridine or 5â²-0-(1-Thiophosphate)-Pseudouridine.</span>
        <meta itemprop="num_attr" content="0162">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the  â -thio substituted phosphate moiety</span>
        <span itemprop="definition">is provided to confer stability to RNA polymers through the unnatural phosphorothioate backbone linkages.</span>
        <meta itemprop="num_attr" content="0162">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Phosphorothioate RNA</span>
        <span itemprop="definition">have increased nuclease resistance and subsequently a longer half-life in a cellular environment.</span>
        <meta itemprop="num_attr" content="0162">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Phosphorothioate linked nucleic acids</span>
        <span itemprop="definition">are expected to also reduce the innate immune response through weaker binding/activation of cellular innate immune molecules.</span>
        <meta itemprop="num_attr" content="0162">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the invention</span>
        <span itemprop="definition">provides a modified nucleic acid containing a degradation domain, which is capable of being acted on in a directed manner within a cell.</span>
        <meta itemprop="num_attr" content="0163">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">modified nucleosides</span>
        <span itemprop="definition">include inosine, 1-methyl-inosine, wyosine, wybutosine, 7-deaza-guanosine, 7-deaza-8-aza-guanosine, 6-thio-guanosine, 6-thio-7-deaza-guanosine, 6-thio-7-deaza-8-aza-guanosine, 7-methyl-guanosine, 6-thio-7-methyl-guanosine, 7-methylinosine, 6-methoxy-guanosine, 1-methylguanosine, N2-methylguanosine, N2,N2-dimethylguanosine, 8-oxo-guanosine, 7-methyl-8-oxo-guanosine, 1-methyl-6-thio-guanosine, N2-methyl-6-thio-guanosine, and N2,N2-dimethyl-6-thio-guanosine.</span>
        <meta itemprop="num_attr" content="0164">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the modified nucleic acids</span>
        <span itemprop="definition">may include other optional components, which can be beneficial in some embodiments.</span>
        <meta itemprop="num_attr" content="0165">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">These optional components</span>
        <span itemprop="definition">include, but are not limited to, untranslated regions, kozak sequences, intronic nucleotide sequences, internal ribosome entry site (IRES), caps and polyA tails.</span>
        <meta itemprop="num_attr" content="0165">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a 5â² untranslated region (UTR) and/or a 3â² UTR</span>
        <span itemprop="definition">may be provided, wherein either or both may independently contain one or more different nucleoside modifications.</span>
        <meta itemprop="num_attr" content="0165">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">nucleoside modifications</span>
        <span itemprop="definition">may also be present in the translatable region.</span>
        <meta itemprop="num_attr" content="0165">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">nucleic acids containing a Kozak sequence</span>
        <span itemprop="definition">are also be present in the translatable region.</span>
        <meta itemprop="num_attr" content="0165">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">nucleic acids</span>
        <span itemprop="definition">containing one or more intronic nucleotide sequences capable of being excised from the nucleic acid.</span>
        <meta itemprop="num_attr" content="0166">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Untranslated regions (UTRs) of a gene</span>
        <span itemprop="definition">are transcribed but not translated.</span>
        <meta itemprop="num_attr" content="0167">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the 5â²UTR</span>
        <span itemprop="definition">starts at the transcription start site and continues to the start codon but does not include the start codon; whereas, the 3â²UTR starts immediately following the stop codon and continues until the transcriptional termination signal.</span>
        <meta itemprop="num_attr" content="0167">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the regulatory features of a UTR</span>
        <span itemprop="definition">can be incorporated into the mRNA used in the present invention to increase the stability of the molecule.</span>
        <meta itemprop="num_attr" content="0167">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the specific features</span>
        <span itemprop="definition">can also be incorporated to ensure controlled down-regulation of the transcript in case they are misdirected to undesired organs sites.</span>
        <meta itemprop="num_attr" content="0167">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the 5â² cap structure of an mRNA</span>
        <span itemprop="definition">is involved in nuclear export, increasing mRNA stability and binds the mRNA Cap Binding Protein (CBP), which is responsible for mRNA stability in the cell and translation competency through the association of CBP with poly(A) binding protein to form the mature cyclic mRNA species.</span>
        <meta itemprop="num_attr" content="0168">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">CBP</span>
        <span itemprop="definition">mRNA Cap Binding Protein</span>
        <meta itemprop="num_attr" content="0168">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the cap</span>
        <span itemprop="definition">further assists the removal of 5â² proximal introns removal during mRNA splicing.</span>
        <meta itemprop="num_attr" content="0168">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Endogenous mRNA molecules</span>
        <span itemprop="definition">may be 5â²-end capped generating a 5â²-ppp-5â²-triphosphate linkage between a terminal guanosine cap residue and the 5â²-terminal transcribed sense nucleotide of the mRNA molecule.</span>
        <meta itemprop="num_attr" content="0169">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">This 5â²-guanylate cap</span>
        <span itemprop="definition">may then be methylated to generate an N7-methyl-guanylate residue.</span>
        <meta itemprop="num_attr" content="0169">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the ribose sugars of the terminal and/or anteterminal transcribed nucleotides of the 5â² end of the mRNA</span>
        <span itemprop="definition">may optionally also be 2â²-0-methylated.</span>
        <meta itemprop="num_attr" content="0169">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">5â²-decapping through hydrolysis and cleavage of the guanylate cap structure</span>
        <span itemprop="definition">may target a nucleic acid molecule, such as an mRNA molecule, for degradation.</span>
        <meta itemprop="num_attr" content="0169">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">IRES</span>
        <span itemprop="definition">internal ribosome entry site</span>
        <meta itemprop="num_attr" content="0170">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">An IRES</span>
        <span itemprop="definition">may act as the sole ribosome binding site, or may serve as one of multiple ribosome binding sites of an mRNA.</span>
        <meta itemprop="num_attr" content="0170">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">An mRNA containing more than one functional ribosome binding site</span>
        <span itemprop="definition">may encode several peptides or polypeptides that are translated independently by the ribosomes (âmulticistronic mRNAâ).</span>
        <meta itemprop="num_attr" content="0170">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">multicistronic mRNA</span>
        <span itemprop="definition">When mRNA are provided with an IRES, further optionally provided is a second translatable region.</span>
        <meta itemprop="num_attr" content="0170">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">IRES sequences</span>
        <span itemprop="definition">that can be used according to the invention include without limitation, those from picornaviruses (e.g.</span>
        <meta itemprop="num_attr" content="0170">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">FMDV</span>
        <span itemprop="definition">pest viruses</span>
        <meta itemprop="num_attr" content="0170">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">CFFV</span>
        <span itemprop="definition">pest viruses</span>
        <meta itemprop="num_attr" content="0170">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">PV</span>
        <span itemprop="definition">polio viruses</span>
        <meta itemprop="num_attr" content="0170">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">ECMV</span>
        <span itemprop="definition">encephalomyocarditis viruses</span>
        <meta itemprop="num_attr" content="0170">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">FMDV</span>
        <span itemprop="definition">foot-and-mouth disease viruses</span>
        <meta itemprop="num_attr" content="0170">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">HCV</span>
        <span itemprop="definition">hepatitis C viruses</span>
        <meta itemprop="num_attr" content="0170">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">CSFV</span>
        <span itemprop="definition">classical swine fever viruses</span>
        <meta itemprop="num_attr" content="0170">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">MLV</span>
        <span itemprop="definition">murine leukemia virus</span>
        <meta itemprop="num_attr" content="0170">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">S1V</span>
        <span itemprop="definition">simian immune deficiency viruses</span>
        <meta itemprop="num_attr" content="0170">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">CrPV</span>
        <span itemprop="definition">cricket paralysis viruses</span>
        <meta itemprop="num_attr" content="0170">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a long chain of adenine nucleotides</span>
        <span itemprop="definition">may be added to a polynucleotide such as an mRNA molecules in order to increase stability.</span>
        <meta itemprop="num_attr" content="0171">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a polynucleotide</span>
        <span itemprop="definition">such as an mRNA molecules</span>
        <meta itemprop="num_attr" content="0171">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the 3â² end of the transcript</span>
        <span itemprop="definition">may be cleaved to free a 3â² hydroxyl.</span>
        <meta itemprop="num_attr" content="0171">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">poly-A polymerase</span>
        <span itemprop="definition">adds a chain of adenine nucleotides to the RNA.</span>
        <meta itemprop="num_attr" content="0171">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the process</span>
        <span itemprop="definition">called polyadenylation, adds a poly-A tail that can be between 100 and 250 residues long.</span>
        <meta itemprop="num_attr" content="0171">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the length of a poly-A tail</span>
        <span itemprop="definition">is greater than 30 nucleotides in length. In another embodiment, the poly-A tail is greater than 35 nucleotides in length (e.g., at least or greater than about 35, 40, 45, 50, 55, 60, 70, 80, 90, 100, 120, 140, 160, 180, 200, 250, 300, 350, 400, 450, 500, 600, 700, 800, 900, 1000, 1100, 1200, 1300, 1400, 1500, 1600, 1700, 1800, 1900, 2,000, 2,500, and 3,000 nucleotides).</span>
        <meta itemprop="num_attr" content="0172">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the poly-A tail</span>
        <span itemprop="definition">is greater than 35 nucleotides in length (e.g., at least or greater than about 35, 40, 45, 50, 55, 60, 70, 80, 90, 100, 120, 140, 160, 180, 200, 250, 300, 350, 400, 450, 500, 600, 700, 800, 900, 1000, 1100, 1200, 1300, 1400, 1500, 1600, 1700, 1800, 1900, 2,000</span>
        <meta itemprop="num_attr" content="0172">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the poly-A tail</span>
        <span itemprop="definition">may be 10, 20, 30, 40, 50, 60, 70, 80, 90, or 100% greater in length than the modified mRNA.</span>
        <meta itemprop="num_attr" content="0173">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the poly-A tail</span>
        <span itemprop="definition">may also be designed as a fraction of modified nucleic acids to which it belongs.</span>
        <meta itemprop="num_attr" content="0173">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the poly-A tail</span>
        <span itemprop="definition">may be 10, 20, 30, 40, 50, 60, 70, 80, or 90% or more of the total length of the modified mRNA or the total length of the modified mRNA minus the poly-A tail.</span>
        <meta itemprop="num_attr" content="0173">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">RNA, synthesizing RNA, hybridizing nucleic acids, making and screening cDNA libraries, and performing PCR</span>
        <span itemprop="definition">are well known in the art (see, e.g., Gubler and Hoffman, Gene, 25:263-269 (1983); Sambrook et al., Molecular Cloning, A Laboratory Manual (2nd ed. 1989)); as are PCR methods (see, U.S. Pat. Nos. 4,683,195 and 4,683,202; PCR Protocols: A Guide to Methods and Applications (Innis et al., eds, 1990)). Expression libraries are also well known to those of skill in the art.</span>
        <meta itemprop="num_attr" content="0174">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">siRNA</span>
        <span itemprop="definition">can be provided in several forms including, e.g., as one or more isolated small-interfering RNA (siRNA) duplexes, as longer double-stranded RNA (dsRNA), or as siRNA or dsRNA transcribed from a transcriptional cassette in a DNA plasmid.</span>
        <meta itemprop="num_attr" content="0175">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">siRNA</span>
        <span itemprop="definition">may be produced enzymatically or by partial/total organic synthesis, and modified ribonucleotides can be introduced by in vitro enzymatic or organic synthesis.</span>
        <meta itemprop="num_attr" content="0175">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">each strand</span>
        <span itemprop="definition">is prepared chemically. Methods of synthesizing RNA molecules are known in the art, e.g., the chemical synthesis methods as described in Verma and Eckstein (1998) or as described herein.</span>
        <meta itemprop="num_attr" content="0175">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">RNA, synthesizing RNA, hybridizing nucleic acids, making and screening cDNA libraries, and performing PCR</span>
        <span itemprop="definition">are well known in the art (see, e.g., Gubler and Hoffman, Gene, 25:263-269 (1983); Sambrook et al., supra; Ausubel et al., supra), as are PCR methods (see, U.S. Pat. Nos. 4,683,195 and 4,683,202; PCR Protocols: A Guide to Methods and Applications (Innis et al., eds, 1990)).</span>
        <meta itemprop="num_attr" content="0176">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Expression libraries</span>
        <span itemprop="definition">are also well known to those of skill in the art.</span>
        <meta itemprop="num_attr" content="0176">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">siRNA</span>
        <span itemprop="definition">are chemically synthesized.</span>
        <meta itemprop="num_attr" content="0177">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the oligonucleotides that comprise the siRNA molecules of the invention</span>
        <span itemprop="definition">can be synthesized using any of a variety of techniques known in the art, such as those described in Usman et al., J. Am. Chem. Soc., 109:7845 (1987); Scaringe et al., Nucl. Acids Res., 18:5433 (1990); Wincott et al., Nucl. Acids Res., 23:2677-2684 (1995); and Wincott et al., Methods Mol. Bio., 74:59 (1997).</span>
        <meta itemprop="num_attr" content="0177">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">oligonucleotides</span>
        <span itemprop="definition">makes use of common nucleic acid protecting and coupling groups, such as dimethoxytrityl at the 5â²-end and phosphoramidites at the 3â²-end.</span>
        <meta itemprop="num_attr" content="0177">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">small scale syntheses</span>
        <span itemprop="definition">can be conducted on an Applied Biosystems synthesizer using a 0.2  â mol scale protocol.</span>
        <meta itemprop="num_attr" content="0177">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">syntheses at the 0.2  â mol scale</span>
        <span itemprop="definition">can be performed on a 96-well plate synthesizer from Protogene (Palo Alto, Calif.).</span>
        <meta itemprop="num_attr" content="0177">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a larger or smaller scale of synthesis</span>
        <span itemprop="definition">is also within the scope of this invention.</span>
        <meta itemprop="num_attr" content="0177">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Suitable reagents for oligonucleotide synthesis, methods for RNA deprotection, and methods for RNA purification</span>
        <span itemprop="definition">are known to those of skill in the art.</span>
        <meta itemprop="num_attr" content="0177">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">siRNA molecules</span>
        <span itemprop="definition">can be assembled from two distinct oligonucleotides, wherein one oligonucleotide comprises the sense strand and the other comprises the antisense strand of the siRNA.</span>
        <meta itemprop="num_attr" content="0178">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">each strand</span>
        <span itemprop="definition">can be synthesized separately and joined together by hybridization or ligation following synthesis and/or deprotection.</span>
        <meta itemprop="num_attr" content="0178">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the present invention</span>
        <span itemprop="definition">provides lipid particles comprising one or more therapeutic mRNA molecules encapsulated within the lipid particles.</span>
        <meta itemprop="num_attr" content="0179">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the mRNA</span>
        <span itemprop="definition">is fully encapsulated within the lipid portion of the lipid particle such that the mRNA in the lipid particle is resistant in aqueous solution to nuclease degradation.</span>
        <meta itemprop="num_attr" content="0180">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the lipid particles described herein</span>
        <span itemprop="definition">are substantially non-toxic to mammals such as humans.</span>
        <meta itemprop="num_attr" content="0180">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the lipid particles of the invention</span>
        <span itemprop="definition">typically have a mean diameter of from about 30 nm to about 150 nm, from about 40 nm to about 150 nm, from about 50 nm to about 150 nm, from about 60 nm to about 130 nm, from about 70 nm to about 110 nm, or from about 70 to about 90 nm.</span>
        <meta itemprop="num_attr" content="0180">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the lipid particles of the invention</span>
        <span itemprop="definition">also typically have a lipid:mRNA ratio (mass/mass ratio) of from about 1:1 to about 100:1, from about 1:1 to about 50:1, from about 2:1 to about 25:1, from about 3:1 to about 20:1, from about 5:1 to about 15:1, or from about 5:1 to about 10:1, or from about 10:1 to about 14:1, or from about 9:1 to about 20:1.</span>
        <meta itemprop="num_attr" content="0180">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the lipid particles of the invention</span>
        <span itemprop="definition">have a lipid:mRNA ratio (mass/mass ratio) of about 12:1, such as 12:1.</span>
        <meta itemprop="num_attr" content="0180">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the lipid particles of the invention</span>
        <span itemprop="definition">have a lipid:mRNA ratio (mass/mass ratio) of about 13:1, such as 13:1.</span>
        <meta itemprop="num_attr" content="0180">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the lipid particles of the invention</span>
        <span itemprop="definition">are serum-stable nucleic acid-lipid particles (SNALP) which comprise an mRNA, a cationic lipid (e.g., one or more cationic lipids of Formula I-III or salts thereof as set forth herein), a phospholipid, and a conjugated lipid that inhibits aggregation of the particles (e.g., one or more PEG-lipid conjugates).</span>
        <meta itemprop="num_attr" content="0181">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">SNALP</span>
        <span itemprop="definition">serum-stable nucleic acid-lipid particles</span>
        <meta itemprop="num_attr" content="0181">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the lipid particles</span>
        <span itemprop="definition">can also include cholesterol.</span>
        <meta itemprop="num_attr" content="0181">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the SNALP</span>
        <span itemprop="definition">may comprise at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more unmodified and/or modified mRNA that express one or more polypeptides. Nucleic acid-lipid particles and their method of preparation are described in, e.g., U.S. Pat. Nos.</span>
        <meta itemprop="num_attr" content="0181">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the mRNA</span>
        <span itemprop="definition">may be fully encapsulated within the lipid portion of the particle, thereby protecting the nucleic acid from nuclease degradation.</span>
        <meta itemprop="num_attr" content="0182">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a SNALP comprising an mRNA</span>
        <span itemprop="definition">is fully encapsulated within the lipid portion of the particle, thereby protecting the nucleic acid from nuclease degradation.</span>
        <meta itemprop="num_attr" content="0182">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the mRNA in the SNALP</span>
        <span itemprop="definition">is not substantially degraded after exposure of the particle to a nuclease at 37Â° C. for at least about 20, 30, 45, or 60 minutes. In certain other instances, the mRNA in the SNALP is not substantially degraded after incubation of the particle in serum at 37Â° C.</span>
        <meta itemprop="num_attr" content="0182">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the mRNA</span>
        <span itemprop="definition">is complexed with the lipid portion of the particle.</span>
        <meta itemprop="num_attr" content="0182">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid-lipid particle compositions</span>
        <span itemprop="definition">are substantially non-toxic to mammals such as humans.</span>
        <meta itemprop="num_attr" content="0182">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">nucleic acid (mRNA) in the nucleic acid-lipid particle</span>
        <span itemprop="definition">is not significantly degraded after exposure to serum or a nuclease assay that would significantly degrade free RNA.</span>
        <meta itemprop="num_attr" content="0183">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a fully encapsulated system</span>
        <span itemprop="definition">preferably less than about 25% of the nucleic acid in the particle is degraded in a treatment that would normally degrade 100% of free nucleic acid, more preferably less than about 10%, and most preferably less than about 5% of the nucleic acid in the particle is degraded.</span>
        <meta itemprop="num_attr" content="0183">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">âFully encapsulatedâ</span>
        <span itemprop="definition">also indicates that the nucleic acid-lipid particles are serum-stable, that is, that they do not rapidly decompose into their component parts upon in vivo administration.</span>
        <meta itemprop="num_attr" content="0183">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">full encapsulation</span>
        <span itemprop="definition">may be determined by performing a membrane-impermeable fluorescent dye exclusion assay, which uses a dye that has enhanced fluorescence when associated with nucleic acid.</span>
        <meta itemprop="num_attr" content="0184">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Specific dyes</span>
        <span itemprop="definition">such as OliGreenÂ® and RiboGreenÂ® (Invitrogen Corp.; Carlsbad, Calif.) are available for the quantitative determination of plasmid DNA, single-stranded deoxyribonucleotides, and/or single- or double-stranded ribonucleotides.</span>
        <meta itemprop="num_attr" content="0184">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Encapsulation</span>
        <span itemprop="definition">is determined by adding the dye to a liposomal formulation, measuring the resulting fluorescence, and comparing it to the fluorescence observed upon addition of a small amount of nonionic detergent.</span>
        <meta itemprop="num_attr" content="0184">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the present invention</span>
        <span itemprop="definition">provides a nucleic acid-lipid particle (e.g., SNALP) composition comprising a plurality of nucleic acid-lipid particles.</span>
        <meta itemprop="num_attr" content="0185">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a nucleic acid-lipid particle</span>
        <span itemprop="definition">e.g., SNALP</span>
        <meta itemprop="num_attr" content="0185">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the SNALP composition</span>
        <span itemprop="definition">comprises mRNA that is fully encapsulated within the lipid portion of the particles, such that from about 30% to about 100%, from about 40% to about 100%, from about 50% to about 100%, from about 60% to about 100%, from about 70% to about 100%, from about 80% to about 100%, from about 90% to about 100%, from about 30% to about 95%, from about 40% to about 95%, from about 50% to about 95%, from about 60% to about 95%, from about 70% to about 95%, from about 80% to about 95%, from about 85% to about 95%, from about 90% to about 95%, from about 30% to about 90%, from about 40% to about 90%, from about 50% to about 90%, from about 60% to about 90%, from about 70% to about 90%, from about 80% to about 90%, or at least about 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% (</span>
        <meta itemprop="num_attr" content="0186">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the proportions of the components</span>
        <span itemprop="definition">can be varied and the delivery efficiency of a particular formulation can be measured using, e.g., an endosomal release parameter (ERP) assay.</span>
        <meta itemprop="num_attr" content="0187">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">ERP</span>
        <span itemprop="definition">endosomal release parameter</span>
        <meta itemprop="num_attr" content="0187">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">cationic lipids or salts thereof</span>
        <span itemprop="definition">may be used in the lipid particles of the present invention (e.g., SNALP), either alone or in combination with one or more other cationic lipid species or non-cationic lipid species.</span>
        <meta itemprop="num_attr" content="0188">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the cationic lipids</span>
        <span itemprop="definition">include the (R) and/or (S) enantiomers thereof.</span>
        <meta itemprop="num_attr" content="0188">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the cationic lipids</span>
        <span itemprop="definition">contain a portion (i.e. a hydrophobic moiety) that comprises unsaturated and/or saturated hydrocarbon chains.</span>
        <meta itemprop="num_attr" content="0188">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">cationic lipids of Formula I</span>
        <span itemprop="definition">having the following structure are useful in the present invention:</span>
        <meta itemprop="num_attr" content="0189">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 1 and R 2</span>
        <span itemprop="definition">are either the same or different and are independently hydrogen (H) or an optionally substituted C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl, or R 1 and R 2 may join to form an optionally substituted heterocyclic ring of 4 to 6 carbon atoms and 1 or 2 heteroatoms selected from the group consisting of nitrogen (N), oxygen (O), and mixtures thereof;</span>
        <meta itemprop="num_attr" content="0191">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 3</span>
        <span itemprop="definition">is either absent or is hydrogen (H) or a C 1 -C 6 alkyl to provide a quaternary amine</span>
        <meta itemprop="num_attr" content="0192">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 4 and R 5</span>
        <span itemprop="definition">are either the same or different and are independently an optionally substituted C 10 -C 24 alkyl, C 10 -C 24 alkenyl, C 10 -C 24 alkynyl, or C 10 -C 24 acyl, wherein at least one of R 4 and R 5 comprises at least two sites of unsaturation;</span>
        <meta itemprop="num_attr" content="0192">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">n</span>
        <span itemprop="definition">0, 1, 2, 3, or 4.</span>
        <meta itemprop="num_attr" content="0193">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 1 and R 2</span>
        <span itemprop="definition">are independently an optionally substituted C 1 -C 4 alkyl, C 2 -C 4 alkenyl, or C 2 -C 4 alkynyl. In one preferred embodiment, R 1 and R 2 are both methyl groups. In other preferred embodiments, n is 1 or 2. In other embodiments, R 3 is absent when the pH is above the pK a of the cationic lipid and R 3 is hydrogen when the pH is below the pK a of the cationic lipid such that the amino head group is protonated. In an alternative embodiment, R 3 is an optionally substituted C 1 -C 4 alkyl to provide a quaternary amine.</span>
        <meta itemprop="num_attr" content="0194">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 4 and R 5</span>
        <span itemprop="definition">are independently an optionally substituted C 12 -C 20 or C 14 -C 22 alkyl, C 12 -C 20 or C 14 -C 22 alkenyl, C 12 -C 20 or C 14 -C 22 alkynyl, or C 12 -C 20 or C 14 -C 22 acyl, wherein at least one of R 4 and R 5 comprises at least two sites of unsaturation.</span>
        <meta itemprop="num_attr" content="0194">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 4 and R 5</span>
        <span itemprop="definition">are independently selected from the group consisting of a dodecadienyl moiety, a tetradecadienyl moiety, a hexadecadienyl moiety, an octadecadienyl moiety, an icosadienyl moiety, a dodecatrienyl moiety, a tetradectrienyl moiety, a hexadecatrienyl moiety, an octadecatrienyl moiety, an icosatrienyl moiety, an arachidonyl moiety, and a docosahexaenoyl moiety, as well as acyl derivatives thereof (e.g., linoleoyl, linolenoyl,  â -linolenoyl, etc.).</span>
        <meta itemprop="num_attr" content="0195">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">acyl derivatives thereof</span>
        <span itemprop="definition">e.g., linoleoyl, linolenoyl,</span>
        <meta itemprop="num_attr" content="0195">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">one of R 4 and R 5</span>
        <span itemprop="definition">comprises a branched alkyl group (e.g., a phytanyl moiety) or an acyl derivative thereof (e.g., a phytanoyl moiety).</span>
        <meta itemprop="num_attr" content="0195">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the octadecadienyl moiety</span>
        <span itemprop="definition">is a linoleyl moiety.</span>
        <meta itemprop="num_attr" content="0195">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the octadecatrienyl moiety</span>
        <span itemprop="definition">is a linolenyl moiety or a  â -linolenyl moiety.</span>
        <meta itemprop="num_attr" content="0195">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 4 and R 5</span>
        <span itemprop="definition">are both linoleyl moieties, linolenyl moieties, or  â -linolenyl moieties.</span>
        <meta itemprop="num_attr" content="0195">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the cationic lipid of Formula I</span>
        <span itemprop="definition">is 1,2-dilinoleyloxy-N,N-dimethylaminopropane (DLinDMA), 1,2-dilinolenyloxy-N,N-dimethylaminopropane (DLenDMA), 1,2-dilinoleyloxy-(N,N-dimethyl)-butyl-4-amine (C2-DLinDMA), 1,2-dilinoleoyloxy-(N,N-dimethyl)-butyl-4-amine (C2-DLinDAP), or mixtures thereof.</span>
        <meta itemprop="num_attr" content="0195">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">DLinDMA</span>
        <span itemprop="definition">1,2-dilinoleyloxy-N,N-dimethylaminopropane</span>
        <meta itemprop="num_attr" content="0195">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">DLenDMA</span>
        <span itemprop="definition">1,2-dilinolenyloxy-N,N-dimethylaminopropane</span>
        <meta itemprop="num_attr" content="0195">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">C2-DLinDMA</span>
        <span itemprop="definition">1,2-dilinoleyloxy-(N,N-dimethyl)-butyl-4-amine</span>
        <meta itemprop="num_attr" content="0195">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">C2-DLinDAP</span>
        <span itemprop="definition">1,2-dilin</span>
        <meta itemprop="num_attr" content="0195">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the cationic lipid of Formula I</span>
        <span itemprop="definition">forms a salt (preferably a crystalline salt) with one or more anions.</span>
        <meta itemprop="num_attr" content="0196">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the cationic lipid of Formula I</span>
        <span itemprop="definition">is the oxalate (e.g., hemioxalate) salt thereof, which is preferably a crystalline salt.</span>
        <meta itemprop="num_attr" content="0196">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">cationic lipids</span>
        <span itemprop="definition">such as DLinDMA and DLenDMA, as well as additional cationic lipids</span>
        <meta itemprop="num_attr" content="0197">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">U.S. Patent Publication No. 20060083780</span>
        <span itemprop="definition">the disclosure of which is herein incorporated by reference in its entirety for all purposes.</span>
        <meta itemprop="num_attr" content="0197">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the synthesis of cationic lipids such as C2-DLinDMA and C2-DLinDAP, as well as additional cationic lipids,</span>
        <span itemprop="definition">is described in international patent application number WO2011/000106 the disclosure of which is herein incorporated by reference in its entirety for all purposes.</span>
        <meta itemprop="num_attr" content="0197">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">cationic lipids of Formula II</span>
        <span itemprop="definition">having the following structure (or salts thereof) are useful in the present invention:</span>
        <meta itemprop="num_attr" content="0198">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 1 and R 2</span>
        <span itemprop="definition">are either the same or different and are independently an optionally substituted C 12 -C 24 alkyl, C 12 -C 24 alkenyl, C 12 -C 24 alkynyl, or C 12 -C 24 acyl;</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 3 and R 4</span>
        <span itemprop="definition">are either the same or different and are independently an optionally substituted C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl, or R 3 and R 4 may join to form an optionally substituted heterocyclic ring of 4 to 6 carbon atoms and 1 or 2 heteroatoms chosen from nitrogen and oxygen;</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 5</span>
        <span itemprop="definition">is either absent or is hydrogen (H) or a C 1 -C 6 alkyl to provide a quaternary amine;</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">m, n, and p</span>
        <span itemprop="definition">are either the same or different and are independently either 0, 1, or 2, with the proviso that m, n, and p are not simultaneously 0; q is 0, 1, 2, 3, or 4; and Y</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the cationic lipid of Formula II</span>
        <span itemprop="definition">is 2,2-dilinoleyl-4-(2-dimethylaminoethyl)-[1,3]-dioxolane, 2,2-dilinoleyl-4-(3-dimethylaminopropyl)-[1,3]-dioxolane, 2,2-dilinoleyl-4-(4-dimethylaminobutyl)-[1,3]-dioxolane, 2,2-dilinoleyl-5-dimethylaminomethyl-[1,3]-dioxane, 2,2-dilinoleyl-4-N-methylpepiazino-[1,3]-dioxolane, 2,2-dilinoleyl-4-dimethylaminomethyl-[1,3]-dioxolane, 2,2-dioleoyl-4-dimethylaminomethyl-[1,3]-dioxolane, 2,2-distearoyl-4</span>
        <meta itemprop="num_attr" content="0199">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the cationic lipid of Formula II</span>
        <span itemprop="definition">forms a salt (preferably a crystalline salt) with one or more anions.</span>
        <meta itemprop="num_attr" content="0200">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the cationic lipid of Formula II</span>
        <span itemprop="definition">is the oxalate (e.g., hemioxalate) salt thereof, which is preferably a crystalline salt.</span>
        <meta itemprop="num_attr" content="0200">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">cationic lipids</span>
        <span itemprop="definition">such as 2,2-dilinoleyl-4-dimethylaminomethyl-[1,3]-dioxolane, as well as additional cationic lipids, is described in PCT Publication No. WO 09/086558, the disclosure of which is herein incorporated by reference in its entirety for all purposes, and in PCT Application No. PCT/US2009/060251, entitled âImproved Amino Lipids and Methods for the Delivery of Nucleic Acids,â the disclosure of which is incorporated herein by reference in its entirety for all purposes.</span>
        <meta itemprop="num_attr" content="0201">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">cationic lipids of Formula III</span>
        <span itemprop="definition">having the following structure are useful in the present invention:</span>
        <meta itemprop="num_attr" content="0202">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 1 and R 2</span>
        <span itemprop="definition">are either the same or different and are independently an optionally substituted C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl, or R 1 and R 2 may join to form an optionally substituted heterocyclic ring of 4 to 6 carbon atoms and 1 or 2 heteroatoms selected from the group consisting of nitrogen (N), oxygen (O), and mixtures thereof;</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 3</span>
        <span itemprop="definition">is either absent or is hydrogen (H) or a C 1 -C 6 alkyl to provide a quaternary amine;</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 4 and R 5</span>
        <span itemprop="definition">are either absent or present and when present are either the same or different and are independently an optionally substituted C 1 -C 10 alkyl or C 2 -C 10 alkenyl; and n is 0, 1, 2, 3, or 4.</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 1 and R 2</span>
        <span itemprop="definition">are independently an optionally substituted C 1 -C 4 alkyl, C 2 -C 4 alkenyl, or C 2 -C 4 alkynyl. In a preferred embodiment, R 1 and R 2 are both methyl groups. In another preferred embodiment, R 4 and R 5 are both butyl groups. In yet another preferred embodiment, n is 1. In other embodiments, R 3 is absent when the pH is above the pK a of the cationic lipid and R 3 is hydrogen when the pH is below the pK a of the cationic lipid such that the amino head group is protonated. In an alternative embodiment, R 3 is an optionally substituted C 1 -C 4 alkyl to provide a quaternary amine. In further embodiments, R 4 and R 5 are independently an optionally substituted C 2 -C 6 or C 2 -C 4 alkyl or C 2 -C 6 or C 2 -C 4 alkenyl.</span>
        <meta itemprop="num_attr" content="0203">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the cationic lipid of Formula III</span>
        <span itemprop="definition">comprises ester linkages between the amino head group and one or both of the alkyl chains.</span>
        <meta itemprop="num_attr" content="0204">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the cationic lipid of Formula III</span>
        <span itemprop="definition">forms a salt (preferably a crystalline salt) with one or more anions.</span>
        <meta itemprop="num_attr" content="0204">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the cationic lipid of Formula III</span>
        <span itemprop="definition">is the oxalate (e.g., hemioxalate) salt thereof, which is preferably a crystalline salt.</span>
        <meta itemprop="num_attr" content="0204">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">each of the alkyl chains in Formula III</span>
        <span itemprop="definition">contains cis double bonds at positions 6, 9, and 12 (i.e., cis,cis,cis- â  6 , â  9 , â  12 ), in an alternative embodiment, one, two, or three of these double bonds in one or both alkyl chains may be in the trans configuration.</span>
        <meta itemprop="num_attr" content="0205">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the cationic lipid of Formula III</span>
        <span itemprop="definition">has the structure:</span>
        <meta itemprop="num_attr" content="0206">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">cationic lipids</span>
        <span itemprop="definition">such as  â -DLenDMA, as well as additional cationic lipids, is described in International Patent Application WO2011/000106, the disclosure of which is herein incorporated by reference in its entirety for all purposes.</span>
        <meta itemprop="num_attr" content="0207">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a cationic lipid having the following structure</span>
        <span itemprop="definition">is useful in the present invention:</span>
        <meta itemprop="num_attr" content="0208">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a trialkyl cationic lipid</span>
        <span itemprop="definition">can be used to prepare the lipid particles described herein.</span>
        <meta itemprop="num_attr" content="0211">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Such trialkyl cationic lipids</span>
        <span itemprop="definition">typically comprise three saturated or unsaturated hydrocarbon chains having six or more carbons in each chain.</span>
        <meta itemprop="num_attr" content="0211">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Trialkyl cationic lipids that can be incorporated into the compositions described herein</span>
        <span itemprop="definition">can be prepared as described in International Patent Application Publication Number WO 2013/126803.</span>
        <meta itemprop="num_attr" content="0211">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">lipid particles of the present invention</span>
        <span itemprop="definition">For example, a trialkyl cationic lipid of the following Formula B can be used to make lipid particles of the present invention:</span>
        <meta itemprop="num_attr" content="0212">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">X</span>
        <span itemprop="definition">is âN(H)R or âNR 2 ;</span>
        <meta itemprop="num_attr" content="0214">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">A</span>
        <span itemprop="definition">is absent, C 1 to C 6 alkyl, C 2 to C 6 alkenyl, or C 2 to C 6 alkynyl, which C 1 to C 6 alkyl, C 2 to C 6 alkenyl, and C 2 to C 6 alkynyl is optionally substituted with one or more groups independently selected from oxo, halogen, heterocycle, âCN, âOR x , âNR x R y , âNR x C( â O)R y , âNR x SO 2 R y , âC( â O)R x , âC( â O)OR x , âC( â O)NR x R y , âSO n R x , and âSO n NR x R y , wherein n is 0, 1, or 2, and R x and R y are each independently hydrogen, alkyl, or heterocycle, wherein each alkyl and heterocycle of R x and R y may be further substitute</span>
        <meta itemprop="num_attr" content="0215">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Y</span>
        <span itemprop="definition">is selected from the group consisting of absent, âC( â O)â, âOâ, âOC( â O)â, âC( â O)Oâ, âN(R b )C( â O)â, âC( â O)N(R b )â, âN(R b )C( â O)Oâ, and âOC( â O)N(R b )â;</span>
        <meta itemprop="num_attr" content="0216">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Z</span>
        <span itemprop="definition">is a hydrophobic moiety comprising three chains wherein each of the chains is independently selected from C 8 to C 11 alkyl, C 8 to C 11 alkenyl, and C 8 to C 11 alkynyl, which C 8 to C 11 alkyl, C 8 to C 11 alkenyl, and C 8 to C 11 alkynyl is optionally substituted with one or more groups independently selected from oxo, halogen, heterocycle, âCN, âOR x , âNR x R y , âNR x C( â O)R y , âNR x SO 2 R y , âC( â O)R x , âC( â O)OR x , âC( â O)NR x R y , âSO n R x , and âSO n NR x R y , wherein n is 0, 1, or 2, and R x and R y are each independently hydrogen, alkyl, or heterocycle, wherein</span>
        <meta itemprop="num_attr" content="0217">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">each R</span>
        <span itemprop="definition">is independently alkyl, alkenyl, or alkynyl, that is optionally substituted with one or more groups independently selected from oxo, halogen, heterocycle, âCN, âOR x , âNR x R y , âNR x C( â O)R y , âNR x SO 2 R y , âC( â O)R x , âC( â O)OR x , âC( â O)NR x R y , âSO n R x , and âSO n NR x R y , wherein n is 0, 1, or 2, and R x and R y are each independently hydrogen, alkyl, or heterocycle, wherein any alkyl and heterocycle of R x and R y may be further substituted with one or more groups independently selected from oxo, halogen, âOH, âCN, alkyl, âOR xâ² , heterocycle, âNR</span>
        <meta itemprop="num_attr" content="0218">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">each R b</span>
        <span itemprop="definition">is H or C 1 to C 6 alkyl.</span>
        <meta itemprop="num_attr" content="0219">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Z in Formula B</span>
        <span itemprop="definition">has the structure:</span>
        <meta itemprop="num_attr" content="0220">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 1 , R 2 , and R 3</span>
        <span itemprop="definition">are each independently C 8 to C 11 alkyl, C 8 to C 11 alkenyl, or C 8 to C 11 alkynyl, which C 8 to C 11 alkyl, C 8 to C 11 alkenyl, and C 8 to C 11 alkynyl is optionally substituted with one or more groups independently selected from oxo, halogen, heterocycle, âCN, âOR x , âNR x R y , âNR x C( â O)R y , âNR x SO 2 R y , âC( â O)R x , âC( â O)OR x , âC( â O)NR x R y , âSO n R x , and âSO n NR x R y , wherein n is 0, 1, or 2, and R x and R y are each independently hydrogen, alkyl, or heterocycle, wherein any alkyl and heterocycle, where</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">cationic lipids of the following Formula C</span>
        <span itemprop="definition">are used to make lipid particles of the present invention:</span>
        <meta itemprop="num_attr" content="0221">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">X</span>
        <span itemprop="definition">is âN(H)R or âNR 2 ;</span>
        <meta itemprop="num_attr" content="0223">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">A</span>
        <span itemprop="definition">is absent, C 1 to C 6 alkyl, C 2 to C 6 alkenyl, or C 2 to C 6 alkynyl, which C 1 to C 6 alkyl, C 2 to C 6 alkenyl, and C 2 to C 6 alkynyl is optionally substituted with one or more groups independently selected from oxo, halogen, heterocycle, âCN, âOR x , âNR x R y , âNR x C( â O)R y , âNR x SO 2 R y , âC( â O)R x , âC( â O)OR x , âC( â O)NR x R y , âSO n R x , and âSO n NR x R y , wherein n is 0, 1, or 2, and R x and R y are each independently hydrogen, alkyl, or heterocycle, wherein each alkyl and heterocycle of R x and R y may be further substitute</span>
        <meta itemprop="num_attr" content="0224">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Y</span>
        <span itemprop="definition">is selected from the group consisting of absent, âC( â O)â, âOâ, âOC( â O)â, âC( â O)Oâ, âN(R b )C( â O)â, âC( â O)N(R b )â, âN(R b )C( â O)Oâ, and âOC( â O)N(R b )â;</span>
        <meta itemprop="num_attr" content="0225">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Z 1</span>
        <span itemprop="definition">is a C 1 to C 6 alkyl that is substituted with three or four R x groups, wherein each R x is independently selected from C 6 to C 11 alkyl, C 6 to C 11 alkenyl, and C 6 to C 11 alkynyl, which C 6 to C 11 alkyl, C 6 to C 11 alkenyl, and C 6 to C 11 alkynyl is optionally substituted with one or more groups independently selected from oxo, halogen, heterocycle, âCN, âOR x , âNR x R y , âNR x C( â O)R y , âNR x SO 2 R y , âC( â O)R x , âC( â O)OR x , âC( â O)NR x R y , âSO n R x , and âSO n NR x R y , wherein n is 0, 1, or 2, and R x and R y are each</span>
        <meta itemprop="num_attr" content="0226">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">each R</span>
        <span itemprop="definition">is independently alkyl, alkenyl, or alkynyl, that is optionally substituted with one or more groups independently selected from oxo, halogen, heterocycle, âCN, âOR x , âNR x R y , âNR x C( â O)R y , âNR x SO 2 R y , âC( â O)R x , âC( â O)OR x , âC( â O)NR x R y , âSO n R x , and âSO n NR x R y , wherein n is 0, 1, or 2, and R x and R y are each independently hydrogen, alkyl, or heterocycle, wherein any alkyl and heterocycle of R x and R y may be further substituted with one or more groups independently selected from oxo, halogen, âOH, âCN, alkyl, âOR xâ² , heterocycle, âNR</span>
        <meta itemprop="num_attr" content="0227">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">each R b</span>
        <span itemprop="definition">is H or C 1 to C 6 alkyl.</span>
        <meta itemprop="num_attr" content="0228">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Z 1 in Formula C</span>
        <span itemprop="definition">has the structure:</span>
        <meta itemprop="num_attr" content="0229">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 1 , R 2 , and R 3</span>
        <span itemprop="definition">are each independently C 8 to C 11 alkyl, C 8 to C 11 alkenyl, or C 8 to C 11 alkynyl, which C 8 to C 11 alkyl, C 8 to C 11 alkenyl, and C 8 to C 11 alkynyl is optionally substituted with one or more groups independently selected from oxo, halogen, heterocycle, âCN, âOR x , âNR x R y , âNR x C( â O)R y , âNR x SO 2 R y , âC( â O)R x , âC( â O)OR x , âC( â O)NR x R y , âSO n R x , and âSO n NR x R y , wherein n is 0, 1, or 2, and R x and R y are each independently hydrogen, alkyl, or heterocycle, wherein any alkyl and heterocycle, where</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Z 1 in Formula C</span>
        <span itemprop="definition">has the structure:</span>
        <meta itemprop="num_attr" content="0230">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 1z and R 2z</span>
        <span itemprop="definition">are selected from the group consisting of:</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 1z and R 2z</span>
        <span itemprop="definition">is selected from the group consisting of:</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">each R 3z , R 4z , R 5z , R 6z , and R 7z</span>
        <span itemprop="definition">is independently selected from C 6 to C 11 alkyl, C 6 to C 11 alkenyl, and C 6 to C 11 alkynyl, which C 6 to C 11 alkyl, C 6 to C 11 alkenyl, and C 6 to C 11 alkynyl is optionally substituted with one or more groups independently selected from oxo, halogen, heterocycle, âCN, âOR x , âNR x R y , âNR x C( â O)R y , âNR x SO 2 R y , âC( â O)R x , âC( â O)OR x , âC( â O)NR x R y , âSO n R x , and âSO n NR x R y , wherein n is 0, 1, or 2, and R x and R y are each independently hydrogen, alkyl,</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Z 1 in Formula C</span>
        <span itemprop="definition">has the structure:</span>
        <meta itemprop="num_attr" content="0231">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">each R 3z , R 4z , R 5z , and R 6z</span>
        <span itemprop="definition">is independently selected from C 6 to C 11 alkyl, C 6 to C 11 alkenyl, and C 6 to C 11 alkynyl, which C 6 to C 11 alkyl, C 6 to C 11 alkenyl, and C 6 to C 11 alkynyl is optionally substituted with one or more groups independently selected from oxo, halogen, heterocycle, âCN, âOR x , âNR x R y , âNR x C( â O)R y , âNR x SO 2 R y , âC( â O)R x , âC( â O)OR x , âC( â O)NR x R y , âSO n R x , and âSO n NR x R y , wherein n is 0, 1, or 2, and R x and R y are each independently hydrogen, alkyl, or heterocycle,</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">cationic lipids</span>
        <span itemprop="definition">such as CLinDMA, as well as additional cationic lipids</span>
        <meta itemprop="num_attr" content="0233">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">cationic lipids</span>
        <span itemprop="definition">such as DLin-C-DAP, DLinDAC, DLinMA, DLinDAP, DLin-S-DMA, DLin-2-DMAP, DLinTMA.Cl, DLinTAP.Cl, DLinMPZ, DLinAP, DOAP, and DLin-EG-DMA, as well as additional cationic lipids, is described in PCT Publication No.</span>
        <meta itemprop="num_attr" content="0233">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">WO 09/086558</span>
        <span itemprop="definition">the disclosure of which is herein incorporated by reference in its entirety for all purposes.</span>
        <meta itemprop="num_attr" content="0233">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">cationic lipids</span>
        <span itemprop="definition">such as DO-C-DAP, DMDAP, DOTAP.Cl, DLin-M-C2-DMA, as well as additional cationic lipids, is described in PCT Application No. PCT/US2009/060251, entitled âImproved Amino Lipids and Methods for the Delivery of Nucleic Acids,â filed Oct. 9, 2009, the disclosure of which is incorporated herein by reference in its entirety for all purposes.</span>
        <meta itemprop="num_attr" content="0233">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the synthesis of a number of other cationic lipids and related analogs</span>
        <span itemprop="definition">has been described in U.S. Pat. Nos.</span>
        <meta itemprop="num_attr" content="0233">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">cationic lipids</span>
        <span itemprop="definition">can be used, such as, e.g., LIPOFECTINÂ® (including DOTMA and DOPE, available from Invitrogen); LIPOFECTAMINEÂ® (including DOSPA and DOPE, available from Invitrogen); and TRANSFECTAMÂ® (including DOGS, available from Promega Corp.).</span>
        <meta itemprop="num_attr" content="0233">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">LIPOFECTINÂ®</span>
        <span itemprop="definition">including DOTMA and DOPE, available from Invitrogen</span>
        <meta itemprop="num_attr" content="0233">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">LIPOFECTAMINEÂ®</span>
        <span itemprop="definition">including DOSPA and DOPE, available from Invitrogen</span>
        <meta itemprop="num_attr" content="0233">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">TRANSFECTAMÂ®</span>
        <span itemprop="definition">including DOGS, available from Promega Corp.</span>
        <meta itemprop="num_attr" content="0233">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the cationic lipid</span>
        <span itemprop="definition">comprises from about 50 mol % to about 90 mol %, from about 50 mol % to about 85 mol %, from about 50 mol % to about 80 mol %, from about 50 mol % to about 75 mol %, from about 50 mol % to about 70 mol %, from about 50 mol % to about 65 mol %, from about 50 mol % to about 60 mol %, from about 55 mol % to about 65 mol %, or from about 55 mol % to about 70 mol % (or any fraction thereof or range therein) of the total lipid present in the particle.</span>
        <meta itemprop="num_attr" content="0234">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the cationic lipid</span>
        <span itemprop="definition">comprises about 50 mol %, 51 mol %, 52 mol %, 53 mol %, 54 mol %, 55 mol %, 56 mol %, 57 mol %, 58 mol %, 59 mol %, 60 mol %, 61 mol %, 62 mol %, 63 mol %, 64 mol %, or 65 mol % (or any fraction thereof) of the total lipid present in the particle.</span>
        <meta itemprop="num_attr" content="0234">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the cationic lipid</span>
        <span itemprop="definition">comprises from about 2 mol % to about 60 mol %, from about 5 mol % to about 50 mol %, from about 10 mol % to about 50 mol %, from about 20 mol % to about 50 mol %, from about 20 mol % to about 40 mol %, from about 30 mol % to about 40 mol %, or about 40 mol % (or any fraction thereof or range therein) of the total lipid present in the particle.</span>
        <meta itemprop="num_attr" content="0235">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the percentage of cationic lipid present in the lipid particles of the invention</span>
        <span itemprop="definition">is a target amount, and that the actual amount of cationic lipid present in the formulation may vary, for example, by  â 5 mol %.</span>
        <meta itemprop="num_attr" content="0237">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the target amount of cationic lipid</span>
        <span itemprop="definition">is 57.1 mol %, but the actual amount of cationic lipid may be  â 5 mol %,  â 4 mol %,  â 3 mol %,  â 2 mol %, 1 mol %, 0.75 mol %, 0.5 mol %,  â 0.25 mol %, or  â 0.1 mol % of that target amount, with the balance of the formulation being made up of other lipid components (adding up to 100 mol % of total lipids present in the particle).</span>
        <meta itemprop="num_attr" content="0237">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">cationic lipids</span>
        <span itemprop="definition">include the following compounds:</span>
        <meta itemprop="num_attr" content="0238">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the non-cationic lipids used in the lipid particles of the invention</span>
        <span itemprop="definition">can be any of a variety of neutral uncharged, zwitterionic, or anionic lipids capable of producing a stable complex.</span>
        <meta itemprop="num_attr" content="0247">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Non-limiting examples of non-cationic lipids</span>
        <span itemprop="definition">include phospholipids such as lecithin, phosphatidylethanolamine, lysolecithin, lysophosphatidylethanolamine, phosphatidylserine, phosphatidylinositol, sphingomyelin, egg sphingomyelin (ESM), cephalin, cardiolipin, phosphatidic acid, cerebrosides, dicetylphosphate, di stearoylphosphatidylcholine (DSPC), dioleoylphosphatidylcholine (DOPC), dipalmitoylphosphatidylcholine (DPPC), dioleoylphosphatidylglycerol (DOPG), dipalmitoylphosphatidylglycerol (DPPG), dioleoylphosphatidylethanolamine (DOPE), palmitoyloleoyl-phosphatidylcholine (POPC), palmitoy</span>
        <meta itemprop="num_attr" content="0248">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">acyl groups in these lipids</span>
        <span itemprop="definition">are preferably acyl groups derived from fatty acids having C 10 -C 24 carbon chains, e.g., lauroyl, myristoyl, palmitoyl, stearoyl, or oleoyl.</span>
        <meta itemprop="num_attr" content="0248">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">non-cationic lipids</span>
        <span itemprop="definition">include sterols such as cholesterol and derivatives thereof.</span>
        <meta itemprop="num_attr" content="0249">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">cholesterol derivatives</span>
        <span itemprop="definition">include polar analogues such as 5 â -cholestanol, 5 â -coprostanol, cholesteryl-(2â²-hydroxy)-ethyl ether, cholesteryl-(4â²-hydroxy)-butyl ether, and 6-ketocholestanol; non-polar analogues such as 5 â -cholestane, cholestenone, 5 â -cholestanone, 5 â -cholestanone, and cholesteryl decanoate; and mixtures thereof.</span>
        <meta itemprop="num_attr" content="0249">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the cholesterol derivative</span>
        <span itemprop="definition">is a polar analogue such as cholesteryl-(4â²-hydroxy)-butyl ether.</span>
        <meta itemprop="num_attr" content="0249">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">cholesteryl-(2â²-hydroxy)-ethyl ether</span>
        <span itemprop="definition">is described in PCT Publication No. WO 09/127060, the disclosure of which is herein incorporated by reference in its entirety for all purposes.</span>
        <meta itemprop="num_attr" content="0249">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the non-cationic lipid present in the lipid particles</span>
        <span itemprop="definition">comprises or consists of a mixture of one or more phospholipids and cholesterol or a derivative thereof.</span>
        <meta itemprop="num_attr" content="0250">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the non-cationic lipid present in the lipid particles</span>
        <span itemprop="definition">comprises or consists of one or more phospholipids, e.g., a cholesterol-free lipid particle formulation.</span>
        <meta itemprop="num_attr" content="0250">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the non-cationic lipid present in the lipid particles</span>
        <span itemprop="definition">comprises or consists of cholesterol or a derivative thereof, e.g., a phospholipid-free lipid particle formulation.</span>
        <meta itemprop="num_attr" content="0250">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">non-cationic lipids suitable for use in the present invention</span>
        <span itemprop="definition">include nonphosphorous containing lipids such as, e.g., stearylamine, dodecylamine, hexadecylamine, acetyl palmitate, glycerolricinoleate, hexadecyl stereate, isopropyl myristate, amphoteric acrylic polymers, triethanolamine-lauryl sulfate, alkyl-aryl sulfate polyethyloxylated fatty acid amides, dioctadecyldimethyl ammonium bromide, ceramide, sphingomyelin, and the like.</span>
        <meta itemprop="num_attr" content="0251">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">nonphosphorous containing lipids</span>
        <span itemprop="definition">such as, e.g., stearylamine, dodecylamine, hexadecylamine, acetyl palmitate, glycerolricinoleate, hexadecyl stereate,</span>
        <meta itemprop="num_attr" content="0251">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the non-cationic lipid</span>
        <span itemprop="definition">comprises from about 10 mol % to about 60 mol %, from about 20 mol % to about 55 mol %, from about 20 mol % to about 45 mol %, from about 20 mol % to about 40 mol %, from about 25 mol % to about 50 mol %, from about 25 mol % to about 45 mol %, from about 30 mol % to about 50 mol %, from about 30 mol % to about 45 mol %, from about 30 mol % to about 40 mol %, from about 35 mol % to about 45 mol %, from about 37 mol % to about 42 mol %, or about 35 mol %, 36 mol %, 37 mol %, 38 mol %, 39 mol %, 40 mol %, 41 mol %, 42 mol %, 43 mol %, 44 mol %, or 45 mol % (or any fraction thereof or range therein</span>
        <meta itemprop="num_attr" content="0252">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the lipid particles</span>
        <span itemprop="definition">contain a mixture of phospholipid and cholesterol or a cholesterol derivative</span>
        <meta itemprop="num_attr" content="0253">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the mixture</span>
        <span itemprop="definition">may comprise up to about 40 mol %, 45 mol %, 50 mol %, 55 mol %, or 60 mol % of the total lipid present in the particle.</span>
        <meta itemprop="num_attr" content="0253">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the phospholipid component in the mixture</span>
        <span itemprop="definition">may comprise from about 2 mol % to about 20 mol %, from about 2 mol % to about 15 mol %, from about 2 mol % to about 12 mol %, from about 4 mol % to about 15 mol %, or from about 4 mol % to about 10 mol % (or any fraction thereof or range therein) of the total lipid present in the particle.</span>
        <meta itemprop="num_attr" content="0254">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the phospholipid component in the mixture</span>
        <span itemprop="definition">comprises from about 5 mol % to about 10 mol %, from about 5 mol % to about 9 mol %, from about 5 mol % to about 8 mol %, from about 6 mol % to about 9 mol %, from about 6 mol % to about 8 mol %, or about 5 mol %, 6 mol %, 7 mol %, 8 mol %, 9 mol %, or 10 mol % (or any fraction thereof or range therein) of the total lipid present in the particle.</span>
        <meta itemprop="num_attr" content="0254">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a 1:57 lipid particle formulation comprising a mixture of phospholipid and cholesterol</span>
        <span itemprop="definition">may comprise a phospholipid such as DPPC or DSPC at about 7 mol % (or any fraction thereof), e.g., in a mixture with cholesterol or a cholesterol derivative at about 34 mol % (or any fraction thereof) of the total lipid present in the particle.</span>
        <meta itemprop="num_attr" content="0254">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a phospholipid</span>
        <span itemprop="definition">such as DPPC or DSPC at about 7 mol % (or any fraction thereof), e.g., in a mixture with cholesterol or a cholesterol derivative at about 34 mol % (or any fraction thereof) of the total lipid present in the particle.</span>
        <meta itemprop="num_attr" content="0254">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a 7:54 lipid particle formulation comprising a mixture of phospholipid and cholesterol</span>
        <span itemprop="definition">may comprise a phospholipid such as DPPC or DSPC at about 7 mol % (or any fraction thereof), e.g., in a mixture with cholesterol or a cholesterol derivative at about 32 mol % (or any fraction thereof) of the total lipid present in the particle.</span>
        <meta itemprop="num_attr" content="0254">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the cholesterol component in the mixture</span>
        <span itemprop="definition">may comprise from about 25 mol % to about 45 mol %, from about 25 mol % to about 40 mol %, from about 30 mol % to about 45 mol %, from about 30 mol % to about 40 mol %, from about 27 mol % to about 37 mol %, from about 25 mol % to about 30 mol %, or from about 35 mol % to about 40 mol % (or any fraction thereof or range therein) of the total lipid present in the particle.</span>
        <meta itemprop="num_attr" content="0255">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the cholesterol component in the mixture</span>
        <span itemprop="definition">comprises from about 25 mol % to about 35 mol %, from about 27 mol % to about 35 mol %, from about 29 mol % to about 35 mol %, from about 30 mol % to about 35 mol %, from about 30 mol % to about 34 mol %, from about 31 mol % to about 33 mol %, or about 30 mol %, 31 mol %, 32 mol %, 33 mol %, 34 mol %, or 35 mol % (or any fraction thereof or range therein) of the total lipid present in the particle.</span>
        <meta itemprop="num_attr" content="0255">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a 1:57 lipid particle formulation comprising a mixture of phospholipid and cholesterol</span>
        <span itemprop="definition">may comprise cholesterol or a cholesterol derivative at about 34 mol % (or any fraction thereof), e.g., in a mixture with a phospholipid such as DPPC or DSPC at about 7 mol % (or any fraction thereof) of the total lipid present in the particle.</span>
        <meta itemprop="num_attr" content="0255">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a 7:54 lipid particle formulation comprising a mixture of phospholipid and cholesterol</span>
        <span itemprop="definition">may comprise cholesterol or a cholesterol derivative at about 32 mol % (or any fraction thereof), e.g., in a mixture with a phospholipid such as DPPC or DSPC at about 7 mol % (or any fraction thereof) of the total lipid present in the particle.</span>
        <meta itemprop="num_attr" content="0255">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the cholesterol or derivative thereof</span>
        <span itemprop="definition">may comprise up to about 25 mol %, 30 mol %, 35 mol %, 40 mol %, 45 mol %, 50 mol %, 55 mol %, or 60 mol % of the total lipid present in the particle.</span>
        <meta itemprop="num_attr" content="0256">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the cholesterol or derivative thereof in the phospholipid-free lipid particle formulation</span>
        <span itemprop="definition">may comprise from about 25 mol % to about 45 mol %, from about 25 mol % to about 40 mol %, from about 30 mol % to about 45 mol %, from about 30 mol % to about 40 mol %, from about 31 mol % to about 39 mol %, from about 32 mol % to about 38 mol %, from about 33 mol % to about 37 mol %, from about 35 mol % to about 45 mol %, from about 30 mol % to about 35 mol %, from about 35 mol % to about 40 mol %, or about 30 mol %, 31 mol %, 32 mol %, 33 mol %, 34 mol %, 35 mol %, 36 mol %, 37 mol %, 38 mol %, 39 mol %, or 40 mol % (or any fraction thereof or range therein) of the total mol %,</span>
        <meta itemprop="num_attr" content="0257">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a 1:62 lipid particle formulation</span>
        <span itemprop="definition">may comprise cholesterol at about 37 mol % (or any fraction thereof) of the total lipid present in the particle.</span>
        <meta itemprop="num_attr" content="0257">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a 7:58 lipid particle formulation</span>
        <span itemprop="definition">may comprise cholesterol at about 35 mol % (or any fraction thereof) of the total lipid present in the particle.</span>
        <meta itemprop="num_attr" content="0257">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the non-cationic lipid</span>
        <span itemprop="definition">comprises from about 5 mol % to about 90 mol %, from about 10 mol % to about 85 mol %, from about 20 mol % to about 80 mol %, about 10 mol % (e.g., phospholipid only), or about 60 mol % (e.g., phospholipid and cholesterol or derivative thereof) (or any fraction thereof or range therein) of the total lipid present in the particle.</span>
        <meta itemprop="num_attr" content="0258">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the percentage of non-cationic lipid present in the lipid particles of the invention</span>
        <span itemprop="definition">is a target amount, and that the actual amount of non-cationic lipid present in the formulation may vary, for example, by  â 5 mol %.</span>
        <meta itemprop="num_attr" content="0260">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the target amount of phospholipid</span>
        <span itemprop="definition">is 7.1 mol % and the target amount of cholesterol is 34.3 mol %, but the actual amount of phospholipid may be  â 2 mol %, 1.5 mol %, 1 mol %, 0.75 mol %, 0.5 mol %, 0.25 mol %, or  â 0.1 mol % of that target amount</span>
        <meta itemprop="num_attr" content="0260">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the actual amount of cholesterol</span>
        <span itemprop="definition">may be  â 3 mol %,  â 2 mol %,  â 1 mol %,  â 0.75 mol %,  â 0.5 mol %,  â 0.25 mol %, or  â 0.1 mol % of that target amount, with the balance of the formulation being made up</span>
        <meta itemprop="num_attr" content="0260">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the target amount of phospholipid</span>
        <span itemprop="definition">is 6.75 mol % and the target amount of cholesterol is 32.43 mol %, but the actual amount of phospholipid may be  â 2 mol %,  â 1.5 mol %,  â 1 mol %,  â 0.75 mol %,  â 0.5 mol %,  â 0.25 mol %, or  â 0.1 mol % of that target amount, and the actual amount of cholesterol may be  â 3 mol %,  â 2 mol %,  â 1 mol %,  â 0.75 mol %,  â 0.5 mol %,  â 0.25 mol %, or  â 0.1 mol % of that target amount, with the balance of the formulation being made up of other lipid components (adding up to 100 mol % of total lipids present in the particle).</span>
        <meta itemprop="num_attr" content="0260">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the lipid particles of the invention</span>
        <span itemprop="definition">may further comprise a lipid conjugate.</span>
        <meta itemprop="num_attr" content="0261">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the conjugated lipid</span>
        <span itemprop="definition">is useful in that it prevents the aggregation of particles.</span>
        <meta itemprop="num_attr" content="0261">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Suitable conjugated lipids</span>
        <span itemprop="definition">include, but are not limited to, PEG-lipid conjugates, POZ-lipid conjugates, ATTA-lipid conjugates, cationic-polymer-lipid conjugates (CPLs), and mixtures thereof.</span>
        <meta itemprop="num_attr" content="0261">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the particles</span>
        <span itemprop="definition">comprise either a PEG-lipid conjugate or an ATTA-lipid conjugate together with a CPL.</span>
        <meta itemprop="num_attr" content="0261">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the lipid conjugate</span>
        <span itemprop="definition">is a PEG-lipid.</span>
        <meta itemprop="num_attr" content="0262">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">PEG-lipids</span>
        <span itemprop="definition">include, but are not limited to, PEG coupled to dialkyloxypropyls (PEG-DAA) as described in, e.g., PCT Publication No. WO 05/026372, PEG coupled to diacylglycerol (PEG-DAG) as described in, e.g., U.S. Patent Publication Nos. 20030077829 and 2005008689, PEG coupled to phospholipids such as phosphatidylethanolamine (PEG-PE), PEG conjugated to ceramides as described in, e.g., U.S. Pat. No.</span>
        <meta itemprop="num_attr" content="0262">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">PEG-lipids</span>
        <span itemprop="definition">include, but are not limited to, PEG coupled to dialkyloxypropyls (PEG-DAA) as described in, e.g., PCT Publication No. WO 05/026372, PEG coupled to diacylglycerol (PEG-DAG) as described in,</span>
        <meta itemprop="num_attr" content="0262">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">PEG conjugated to cholesterol or a derivative thereof</span>
        <span itemprop="definition">and mixtures thereof.</span>
        <meta itemprop="num_attr" content="0262">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the disclosures of these patent documents</span>
        <span itemprop="definition">are herein incorporated by reference in their entirety for all purposes.</span>
        <meta itemprop="num_attr" content="0262">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Additional PEG-lipids suitable for use in the invention</span>
        <span itemprop="definition">include, without limitation, mPEG2000-1,2-di-O-alkyl-sn3-carbomoylglyceride (PEG-C-DOMG).</span>
        <meta itemprop="num_attr" content="0262">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">PEG-C-DOMG</span>
        <span itemprop="definition">mPEG2000-1,2-di-O-alkyl-sn3-carbomoylglyceride</span>
        <meta itemprop="num_attr" content="0262">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the synthesis of PEG-C-DOMG</span>
        <span itemprop="definition">is described in PCT Publication No. WO 09/086558, the disclosure of which is herein incorporated by reference in its entirety for all purposes.</span>
        <meta itemprop="num_attr" content="0262">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">PEG-lipid conjugates</span>
        <span itemprop="definition">include, without limitation, 1-[8â²-(1,2-dimyristoyl-3-propanoxy)-carboxamido-3â²,6â²-dioxaoctanyl]carbamoyl- â -methyl-poly(ethylene glycol) (2KPEG-DMG).</span>
        <meta itemprop="num_attr" content="0262">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">2KPEG-DMG</span>
        <span itemprop="definition">1-[8â²-(1,2-dimyristoyl-3-propanoxy)-carboxamido-3â²,6â²-dioxaoctanyl]carbamoyl- â -methyl-poly(ethylene glycol)</span>
        <meta itemprop="num_attr" content="0262">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">PEG</span>
        <span itemprop="definition">is a linear, water-soluble polymer of ethylene PEG repeating units with two terminal hydroxyl groups. PEGs are classified by their molecular weights; for example, PEG 2000 has an average molecular weight of about 2,000 daltons, and PEG 5000 has an average molecular weight of about 5,000 daltons. PEGs are commercially available from Sigma Chemical Co.</span>
        <meta itemprop="num_attr" content="0263">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">MePEG-OH</span>
        <span itemprop="definition">monomethoxypolyethylene glycol</span>
        <meta itemprop="num_attr" content="0263">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">MePEG-S</span>
        <span itemprop="definition">monomethoxypolyethylene glycol-succinate</span>
        <meta itemprop="num_attr" content="0263">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">MePEG-S-NHS</span>
        <span itemprop="definition">monomethoxypolyethylene glycol-succinimidyl succinate</span>
        <meta itemprop="num_attr" content="0263">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">MePEG-NH 2</span>
        <span itemprop="definition">monomethoxypolyethylene glycol-amine</span>
        <meta itemprop="num_attr" content="0263">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">MePEG-TRES</span>
        <span itemprop="definition">monomethoxypolyethylene glycol-tresylate</span>
        <meta itemprop="num_attr" content="0263">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">MePEG-IM</span>
        <span itemprop="definition">monomethoxypolyethylene glycol-imidazolyl-carbonyl</span>
        <meta itemprop="num_attr" content="0263">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">PEGs</span>
        <span itemprop="definition">such as those described in U.S. Pat. Nos. 6,774,180 and 7,053,150 (e.g., mPEG (20 KDa) amine) are also useful for preparing the PEG-lipid conjugates of the present invention.</span>
        <meta itemprop="num_attr" content="0263">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">mPEG (20 KDa) amine</span>
        <span itemprop="definition">e.g., mPEG (20 KDa) amine</span>
        <meta itemprop="num_attr" content="0263">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">monomethoxypolyethyleneglycol-acetic acid</span>
        <span itemprop="definition">MePEG-CH 2 COOH</span>
        <meta itemprop="num_attr" content="0263">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">PEG-DAA conjugates</span>
        <span itemprop="definition">e.g., PEG-DAA conjugates.</span>
        <meta itemprop="num_attr" content="0263">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the PEG moiety of the PEG-lipid conjugates described herein</span>
        <span itemprop="definition">may comprise an average molecular weight ranging from about 550 daltons to about 10,000 daltons. In certain instances, the PEG moiety has an average molecular weight of from about 750 daltons to about 5,000 daltons (e.g., from about 1,000 daltons to about 5,000 daltons, from about 1,500 daltons to about 3,000 daltons, from about 750 daltons to about 3,000 daltons, from about 750 daltons to about 2,000 daltons, etc.). In preferred embodiments, the PEG moiety has an average molecular weight of about 2,000 daltons or about 750 daltons.</span>
        <meta itemprop="num_attr" content="0264">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the PEG</span>
        <span itemprop="definition">can be optionally substituted by an alkyl, alkoxy, acyl, or aryl group.</span>
        <meta itemprop="num_attr" content="0265">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the PEG</span>
        <span itemprop="definition">can be conjugated directly to the lipid or may be linked to the lipid via a linker moiety.</span>
        <meta itemprop="num_attr" content="0265">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Any linker moiety suitable for coupling the PEG to a lipid</span>
        <span itemprop="definition">can be used including, e.g., non-ester containing linker moieties and ester-containing linker moieties.</span>
        <meta itemprop="num_attr" content="0265">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the linker moiety</span>
        <span itemprop="definition">is a non-ester containing linker moiety.</span>
        <meta itemprop="num_attr" content="0265">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">non-ester containing linker moiety</span>
        <span itemprop="definition">refers to a linker moiety that does not contain a carboxylic ester bond (âOC(O)â).</span>
        <meta itemprop="num_attr" content="0265">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Suitable non-ester containing linker moieties</span>
        <span itemprop="definition">include, but are not limited to, amido (âC(O)NHâ), amino (âNRâ), carbonyl (âC(O)â), carbamate (âNHC(O)Oâ), urea (âNHC(O)NHâ), disulphide (âSâSâ), ether (âOâ), succinyl (â(O)CCH 2 CH 2 C(O)â), succinamidyl (âNHC(O)CH 2 CH 2 C(O)NHâ), ether, disulphide, as well as combinations thereof (such as a linker containing both a carbamate linker moiety and an amido linker moiety).</span>
        <meta itemprop="num_attr" content="0265">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a carbamate linker</span>
        <span itemprop="definition">is used to couple the PEG to the lipid.</span>
        <meta itemprop="num_attr" content="0265">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">an ester containing linker moiety</span>
        <span itemprop="definition">is used to couple the PEG to the lipid.</span>
        <meta itemprop="num_attr" content="0266">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Suitable ester containing linker moieties</span>
        <span itemprop="definition">include, e.g., carbonate (âOC(O)Oâ), succinoyl, phosphate esters (âOâ(O)POHâOâ), sulfonate esters, and combinations thereof.</span>
        <meta itemprop="num_attr" content="0266">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Phosphatidylethanolamines having a variety of acyl chain groups of varying chain lengths and degrees of saturation</span>
        <span itemprop="definition">can be conjugated to PEG to form the lipid conjugate.</span>
        <meta itemprop="num_attr" content="0267">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Such phosphatidylethanolamines</span>
        <span itemprop="definition">are commercially available, or can be isolated or synthesized using conventional techniques known to those of skilled in the art.</span>
        <meta itemprop="num_attr" content="0267">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Phosphatidyl-ethanolamines containing saturated or unsaturated fatty acids with carbon chain lengths in the range of C 10 to C 20</span>
        <span itemprop="definition">are preferred.</span>
        <meta itemprop="num_attr" content="0267">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Phosphatidylethanolamines with mono- or diunsaturated fatty acids and mixtures of saturated and unsaturated fatty acids</span>
        <span itemprop="definition">can also be used.</span>
        <meta itemprop="num_attr" content="0267">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Suitable phosphatidylethanolamines</span>
        <span itemprop="definition">include, but are not limited to, dimyristoyl-phosphatidylethanolamine (DMPE), dipalmitoyl-phosphatidylethanolamine (DPPE), dioleoylphosphatidylethanolamine (DOPE), and distearoyl-phosphatidylethanolamine (DSPE).</span>
        <meta itemprop="num_attr" content="0267">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">DMPE</span>
        <span itemprop="definition">dimyristoyl-phosphatidylethanolamine</span>
        <meta itemprop="num_attr" content="0267">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">DPPE</span>
        <span itemprop="definition">dipalmitoyl-phosphatidylethanolamine</span>
        <meta itemprop="num_attr" content="0267">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">DOPE</span>
        <span itemprop="definition">dioleoylphosphatidylethanolamine</span>
        <meta itemprop="num_attr" content="0267">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">DSPE</span>
        <span itemprop="definition">distearoyl-phosphatidylethanolamine</span>
        <meta itemprop="num_attr" content="0267">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R</span>
        <span itemprop="definition">is a member selected from the group consisting of hydrogen, alkyl and acyl</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 1</span>
        <span itemprop="definition">is a member selected from the group consisting of hydrogen and alkyl; or optionally, R and R 1 and the nitrogen to which they are bound form an azido moiety</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 2</span>
        <span itemprop="definition">is a member of the group selected from hydrogen, optionally substituted alkyl, optionally substituted aryl and a side chain of an amino acid</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 3</span>
        <span itemprop="definition">is a member selected from the group consisting of hydrogen, halogen, hydroxy, alkoxy, mercapto, hydrazino, amino and NR 4 R 5 , wherein R 4 and R 5 are independently hydrogen or alkyl</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">n</span>
        <span itemprop="definition">is 4 to 80</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">m</span>
        <span itemprop="definition">is 2 to 6</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">p</span>
        <span itemprop="definition">is 1 to 4</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">q</span>
        <span itemprop="definition">is 0 or 1.</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">diacylglycerol</span>
        <span itemprop="definition">or âDAGâ includes a compound having 2 fatty acyl chains, R 1 and R 2 , both of which have independently between 2 and 30 carbons bonded to the 1- and 2-position of glycerol by ester linkages.</span>
        <meta itemprop="num_attr" content="0269">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the acyl groups</span>
        <span itemprop="definition">can be saturated or have varying degrees of unsaturation. Suitable acyl groups include, but are not limited to, lauroyl (C 12 ), myristoyl (C 14 ), palmitoyl (C 16 ), stearoyl (C 18 ), and icosoyl (C 20 ).</span>
        <meta itemprop="num_attr" content="0269">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 1 and R 2</span>
        <span itemprop="definition">are the same, i.e., R 1 and R 2 are both myristoyl (i.e., dimyristoyl), R 1 and R 2 are both stearoyl (i.e., distearoyl), etc.</span>
        <meta itemprop="num_attr" content="0269">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Diacylglycerols</span>
        <span itemprop="definition">have the following general formula:</span>
        <meta itemprop="num_attr" content="0269">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">dialkyloxypropyl</span>
        <span itemprop="definition">includes a compound having 2 alkyl chains, R 1 and R 2 , both of which have independently between 2 and 30 carbons.</span>
        <meta itemprop="num_attr" content="0270">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the alkyl groups</span>
        <span itemprop="definition">can be saturated or have varying degrees of unsaturation.</span>
        <meta itemprop="num_attr" content="0270">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Dialkyloxypropyls</span>
        <span itemprop="definition">have the following general formula:</span>
        <meta itemprop="num_attr" content="0270">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the PEG-lipid</span>
        <span itemprop="definition">is a PEG-DAA conjugate having the following formula:</span>
        <meta itemprop="num_attr" content="0271">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 1 and R 2</span>
        <span itemprop="definition">are independently selected and are long-chain alkyl groups having from about 10 to about 22 carbon atoms; PEG is a polyethyleneglycol; and L is a non-ester containing linker moiety or an ester containing linker moiety as described above.</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the long-chain alkyl groups</span>
        <span itemprop="definition">can be saturated or unsaturated. Suitable alkyl groups include, but are not limited to, decyl (C 10 ), lauryl (C 12 ), myristyl (C 14 ), palmityl (C 16 ), stearyl (C 18 ), and icosyl (C 20 ).</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 1 and R 2</span>
        <span itemprop="definition">are the same, i.e., R 1 and R 2 are both myristyl (i.e., dimyristyl), R 1 and R 2 are both stearyl (i.e., distearyl), etc.</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the PEG</span>
        <span itemprop="definition">has an average molecular weight ranging from about 550 daltons to about 10,000 daltons. In certain instances, the PEG has an average molecular weight of from about 750 daltons to about 5,000 daltons (e.g., from about 1,000 daltons to about 5,000 daltons, from about 1,500 daltons to about 3,000 daltons, from about 750 daltons to about 3,000 daltons, from about 750 daltons to about 2,000 daltons, etc.). In preferred embodiments, the PEG has an average molecular weight of about 2,000 daltons or about 750 daltons.</span>
        <meta itemprop="num_attr" content="0272">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the PEG</span>
        <span itemprop="definition">can be optionally substituted with alkyl, alkoxy, acyl, or aryl groups. In certain embodiments, the terminal hydroxyl group is substituted with a methoxy or methyl group.</span>
        <meta itemprop="num_attr" content="0272">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">âLâ</span>
        <span itemprop="definition">is a non-ester containing linker moiety.</span>
        <meta itemprop="num_attr" content="0273">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Suitable non-ester containing linkers</span>
        <span itemprop="definition">include, but are not limited to, an amido linker moiety, an amino linker moiety, a carbonyl linker moiety, a carbamate linker moiety, a urea linker moiety, an ether linker moiety, a disulphide linker moiety, a succinamidyl linker moiety, and combinations thereof.</span>
        <meta itemprop="num_attr" content="0273">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the non-ester containing linker moiety</span>
        <span itemprop="definition">is a carbamate linker moiety (i.e., a PEG-C-DAA conjugate).</span>
        <meta itemprop="num_attr" content="0273">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the non-ester containing linker moiety</span>
        <span itemprop="definition">is an amido linker moiety (i.e., a PEG-A-DAA conjugate). In yet another preferred embodiment, the non-ester containing linker moiety is a succinamidyl linker moiety (i.e., a PEG-S-DAA conjugate).</span>
        <meta itemprop="num_attr" content="0273">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the PEG-lipid conjugate</span>
        <span itemprop="definition">is selected from:</span>
        <meta itemprop="num_attr" content="0274">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the PEG-DAA conjugates</span>
        <span itemprop="definition">are synthesized using standard techniques and reagents known to those of skill in the art. It will be recognized that the PEG-DAA conjugates will contain various amide, amine, ether, thio, carbamate, and urea linkages. Those of skill in the art will recognize that methods and reagents for forming these bonds are well known and readily available. See, e.g., March, ADVANCED ORGANIC CHEMISTRY (Wiley 1992); Larock, COMPREHENSIVE ORGANIC TRANSFORMATIONS (VCH 1989); and Furniss, VOGEL&#39;S TEXTBOOK OF PRACTICAL ORGANIC CHEMISTRY, 5th ed. (Longman 1989).</span>
        <meta itemprop="num_attr" content="0275">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the PEG-DAA conjugate</span>
        <span itemprop="definition">is a PEG-didecyloxypropyl (C 10 ) conjugate, a PEG-dilauryloxypropyl (C 12 ) conjugate, a PEG-dimyristyloxypropyl (C 14 ) conjugate, a PEG-dipalmityloxypropyl (C 16 ) conjugate, or a PEG-distearyloxypropyl (C 18 ) conjugate.</span>
        <meta itemprop="num_attr" content="0276">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the PEG</span>
        <span itemprop="definition">preferably has an average molecular weight of about 750 or about 2,000 daltons.</span>
        <meta itemprop="num_attr" content="0276">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the PEG-lipid conjugate</span>
        <span itemprop="definition">comprises PEG2000-C-DMA, wherein the â2000â denotes the average molecular weight of the PEG, the âCâ denotes a carbamate linker moiety, and the âDMAâ denotes dimyristyloxypropyl.</span>
        <meta itemprop="num_attr" content="0276">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the PEG-lipid conjugate</span>
        <span itemprop="definition">comprises PEG750-C-DMA, wherein the â750â denotes the average molecular weight of the PEG, the âCâ denotes a carbamate linker moiety, and the âDMAâ denotes dimyristyloxypropyl.</span>
        <meta itemprop="num_attr" content="0276">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the terminal hydroxyl group of the PEG</span>
        <span itemprop="definition">is substituted with a methyl group.</span>
        <meta itemprop="num_attr" content="0276">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">hydrophilic polymers</span>
        <span itemprop="definition">can be used in place of PEG.</span>
        <meta itemprop="num_attr" content="0277">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">suitable polymers</span>
        <span itemprop="definition">include, but are not limited to, polyvinylpyrrolidone, polymethyloxazoline, polyethyloxazoline, polyhydroxypropyl methacrylamide, polymethacrylamide and polydimethylacrylamide, polylactic acid, polyglycolic acid, and derivatized celluloses such as hydroxymethylcellulose or hydroxyethylcellulose.</span>
        <meta itemprop="num_attr" content="0277">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the lipid particles (e.g., SNALP) of the present invention</span>
        <span itemprop="definition">can further comprise cationic poly(ethylene glycol) (PEG) lipids or CPLs (see, e.g., Chen et al., Bioconj. Chem., 11:433-437 (2000); U.S. Pat. No. 6,852,334; PCT Publication No. WO 00/62813, the disclosures of which are herein incorporated by reference in their entirety for all purposes).</span>
        <meta itemprop="num_attr" content="0278">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">PEG</span>
        <span itemprop="definition">poly(ethylene glycol)</span>
        <meta itemprop="num_attr" content="0278">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Suitable CPLs</span>
        <span itemprop="definition">include compounds of Formula VIII:</span>
        <meta itemprop="num_attr" content="0279">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">A</span>
        <span itemprop="definition">is a lipid moiety such as an amphipathic lipid, a neutral lipid, or a hydrophobic lipid that acts as a lipid anchor.</span>
        <meta itemprop="num_attr" content="0280">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Suitable lipid examples</span>
        <span itemprop="definition">include, but are not limited to, diacylglycerolyls, dialkylglycerolyls, N-N-dialkylaminos, 1,2-diacyloxy-3-aminopropanes, and 1,2-dialkyl-3-aminopropanes.</span>
        <meta itemprop="num_attr" content="0280">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">âWâ</span>
        <span itemprop="definition">is a polymer or an oligomer such as a hydrophilic polymer or oligomer.</span>
        <meta itemprop="num_attr" content="0281">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the hydrophilic polymer</span>
        <span itemprop="definition">is a biocompatible polymer that is nonimmunogenic or possesses low inherent immunogenicity.</span>
        <meta itemprop="num_attr" content="0281">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the hydrophilic polymer</span>
        <span itemprop="definition">can be weakly antigenic if used with appropriate adjuvants.</span>
        <meta itemprop="num_attr" content="0281">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Suitable nonimmunogenic polymers</span>
        <span itemprop="definition">include, but are not limited to, PEG, polyamides, polylactic acid, polyglycolic acid, polylactic acid/polyglycolic acid copolymers, and combinations thereof.</span>
        <meta itemprop="num_attr" content="0281">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the polymer</span>
        <span itemprop="definition">has a molecular weight of from about 250 to about 7,000 daltons.</span>
        <meta itemprop="num_attr" content="0281">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Y</span>
        <span itemprop="definition">is a polycationic moiety.</span>
        <meta itemprop="num_attr" content="0282">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">polycationic moiety</span>
        <span itemprop="definition">refers to a compound, derivative, or functional group having a positive charge, preferably at least 2 positive charges at a selected pH, preferably physiological pH.</span>
        <meta itemprop="num_attr" content="0282">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Suitable polycationic moieties</span>
        <span itemprop="definition">include basic amino acids and their derivatives such as arginine, asparagine, glutamine, lysine, and histidine; spermine; spermidine; cationic dendrimers; polyamines; polyamine sugars; and amino polysaccharides.</span>
        <meta itemprop="num_attr" content="0282">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the polycationic moieties</span>
        <span itemprop="definition">can be linear, such as linear tetralysine, branched or dendrimeric in structure.</span>
        <meta itemprop="num_attr" content="0282">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Polycationic moieties</span>
        <span itemprop="definition">have between about 2 to about 15 positive charges, preferably between about 2 to about 12 positive charges, and more preferably between about 2 to about 8 positive charges at selected pH values.</span>
        <meta itemprop="num_attr" content="0282">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the selection of which polycationic moiety to employ</span>
        <span itemprop="definition">may be determined by the type of particle application which is desired.</span>
        <meta itemprop="num_attr" content="0282">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the charges on the polycationic moieties</span>
        <span itemprop="definition">can be either distributed around the entire particle moiety, or alternatively, they can be a discrete concentration of charge density in one particular area of the particle moiety e.g., a charge spike. If the charge density is distributed on the particle, the charge density can be equally distributed or unequally distributed. All variations of charge distribution of the polycationic moiety are encompassed by the present invention.</span>
        <meta itemprop="num_attr" content="0283">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the lipid âAâ and the nonimmunogenic polymer âWâ</span>
        <span itemprop="definition">can be attached by various methods and preferably by covalent attachment. Methods known to those of skill in the art can be used for the covalent attachment of âAâ and âW.â Suitable linkages include, but are not limited to, amide, amine, carboxyl, carbonate, carbamate, ester, and hydrazone linkages. It will be apparent to those skilled in the art that âAâ and âWâ must have complementary functional groups to effectuate the linkage. The reaction of these two groups, one on the lipid and the other on the polymer, will provide the desired linkage.</span>
        <meta itemprop="num_attr" content="0284">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the lipid</span>
        <span itemprop="definition">is a diacylglycerol and the terminal hydroxyl is activated, for instance with NHS and DCC, to form an active ester, and is then reacted with a polymer which contains an amino group, such as with a polyamide (see, e.g., U.S. Pat. Nos. 6,320,017 and 6,586,559, the disclosures of which are herein incorporated by reference in their entirety for all purposes), an amide bond will form between the two groups.</span>
        <meta itemprop="num_attr" content="0284">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a polyamide</span>
        <span itemprop="definition">see, e.g., U.S. Pat. Nos. 6,320,017 and 6,586,559, the disclosures of which are herein incorporated by reference in their entirety for all purposes</span>
        <meta itemprop="num_attr" content="0284">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the polycationic moiety</span>
        <span itemprop="definition">can have a ligand attached, such as a targeting ligand or a chelating moiety for complexing calcium.</span>
        <meta itemprop="num_attr" content="0285">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a ligand attached</span>
        <span itemprop="definition">such as a targeting ligand or a chelating moiety for complexing calcium.</span>
        <meta itemprop="num_attr" content="0285">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the cationic moiety</span>
        <span itemprop="definition">maintains a positive charge.</span>
        <meta itemprop="num_attr" content="0285">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the ligand that is attached</span>
        <span itemprop="definition">has a positive charge.</span>
        <meta itemprop="num_attr" content="0285">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Suitable ligands</span>
        <span itemprop="definition">include, but are not limited to, a compound or device with a reactive functional group and include lipids, amphipathic lipids, carrier compounds, bioaffinity compounds, biomaterials, biopolymers, biomedical devices, analytically detectable compounds, therapeutically active compounds, enzymes, peptides, proteins, antibodies, immune stimulators, radiolabels, fluorogens, biotin, drugs, haptens, DNA, RNA, polysaccharides, liposomes, virosomes, micelles, immunoglobulins, functional groups, other targeting moieties, or toxins.</span>
        <meta itemprop="num_attr" content="0285">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the lipid conjugate</span>
        <span itemprop="definition">(e.g., PEG-lipid) comprises from about 0.1 mol % to about 2 mol %, from about 0.5 mol % to about 2 mol %, from about 1 mol % to about 2 mol %, from about 0.6 mol % to about 1.9 mol %, from about 0.7 mol % to about 1.8 mol %, from about 0.8 mol % to about 1.7 mol %, from about 0.9 mol % to about 1.6 mol %, from about 0.9 mol % to about 1.8 mol %, from about 1 mol % to about 1.8 mol %, from about 1 mol % to about 1.7 mol %, from about 1.2 mol % to about 1.8 mol %, from about 1.2 mol % to about 1.7 mol %, from about 1.3 mol % to about 1.6 mol %, or from about 1.4 mol % to about 1.5 mol % (or</span>
        <meta itemprop="num_attr" content="0286">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the lipid conjugate</span>
        <span itemprop="definition">(e.g., PEG-lipid) comprises from about 0 mol % to about 20 mol %, from about 0.5 mol % to about 20 mol %, from about 2 mol % to about 20 mol %, from about 1.5 mol % to about 18 mol %, from about 2 mol % to about 15 mol %, from about 4 mol % to about 15 mol %, from about 2 mol % to about 12 mol %, from about 5 mol % to about 12 mol %, or about 2 mol % (or any fraction thereof or range therein) of the total lipid present in the particle.</span>
        <meta itemprop="num_attr" content="0287">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">PEG-lipid</span>
        <span itemprop="definition">comprises from about 0 mol % to about 20 mol %, from about 0.5 mol % to about 20 mol %, from about 2 mol % to about 20 mol %, from about 1.5 mol % to about 18 mol %, from about 2 mol % to about 15 mol %, from about 4</span>
        <meta itemprop="num_attr" content="0287">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the lipid conjugate</span>
        <span itemprop="definition">(e.g., PEG-lipid) comprises from about 4 mol % to about 10 mol %, from about 5 mol % to about 10 mol %, from about 5 mol % to about 9 mol %, from about 5 mol % to about 8 mol %, from about 6 mol % to about 9 mol %, from about 6 mol % to about 8 mol %, or about 5 mol %, 6 mol %, 7 mol %, 8 mol %, 9 mol %, or 10 mol % (or any fraction thereof or range therein) of the total lipid present in the particle.</span>
        <meta itemprop="num_attr" content="0288">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">PEG-lipid</span>
        <span itemprop="definition">comprises from about 4 mol % to about 10 mol %, from about 5 mol % to about 10 mol %, from about 5 mol % to about 9 mol %, from about 5 mol % to about 8 mol %, from about 6 mol % to about 9 mol %, from about 6 mol %</span>
        <meta itemprop="num_attr" content="0288">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the percentage of lipid conjugate (e.g., PEG-lipid) present in the lipid particles of the invention</span>
        <span itemprop="definition">is a target amount, and that the actual amount of lipid conjugate present in the formulation may vary, for example, by  â 2 mol %.</span>
        <meta itemprop="num_attr" content="0290">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the target amount of lipid conjugate</span>
        <span itemprop="definition">is 1.4 mol %, but the actual amount of lipid conjugate may be  â 0.5 mol %,  â 0.4 mol %,  â 0.3 mol %,  â 0.2 mol %,  â 0.1 mol %, or  â 0.05 mol % of that target amount, with the balance of the formulation being made up of other lipid components (adding up to 100 mol % of total lipids present in the particle).</span>
        <meta itemprop="num_attr" content="0290">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the target amount of lipid conjugate</span>
        <span itemprop="definition">is 6.76 mol %, but the actual amount of lipid conjugate may be  â 2 mol %,  â 1.5 mol %,  â 1 mol %,  â 0.75 mol %,  â 0.5 mol %,  â 0.25 mol %, or  â 0.1 mol % of that target amount, with the balance of the formulation being made up of other lipid components (adding up to 100 mol % of total lipids present in the particle).</span>
        <meta itemprop="num_attr" content="0290">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">concentration of the lipid conjugate</span>
        <span itemprop="definition">can be varied depending on the lipid conjugate employed and the rate at which the lipid particle is to become fusogenic.</span>
        <meta itemprop="num_attr" content="0291">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the rate at which the lipid conjugate exchanges out of the lipid particle</span>
        <span itemprop="definition">can be controlled, for example, by varying the concentration of the lipid conjugate, by varying the molecular weight of the PEG, or by varying the chain length and degree of saturation of the alkyl groups on the PEG-DAA conjugate.</span>
        <meta itemprop="num_attr" content="0292">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">other variables</span>
        <span itemprop="definition">including, for example, pH, temperature, ionic strength, etc. can be used to vary and/or control the rate at which the lipid particle becomes fusogenic.</span>
        <meta itemprop="num_attr" content="0292">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">lipid particle</span>
        <span itemprop="definition">e.g., SNALP</span>
        <meta itemprop="num_attr" content="0292">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the lipid particles of the present invention</span>
        <span itemprop="definition">e.g., SNALP, in which an mRNA is entrapped within the lipid portion of the particle and is protected from degradation, can be formed by any method known in the art including, but not limited to, a continuous mixing method, a direct dilution process, and an in-line dilution process.</span>
        <meta itemprop="num_attr" content="0293">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the present invention</span>
        <span itemprop="definition">provides nucleic acid-lipid particles (e.g., SNALP) produced via a continuous mixing method, e.g., a process that includes providing an aqueous solution comprising a nucleic acid (e.g., mRNA) in a first reservoir, providing an organic lipid solution in a second reservoir (wherein the lipids present in the organic lipid solution are solubilized in an organic solvent, e.g., a lower alkanol such as ethanol), and mixing the aqueous solution with the organic lipid solution such that the organic lipid solution mixes with the aqueous solution so as to substantially instantaneously produce a lipid vesicle (e.g., liposome) encapsulating the nucleic acid within the lipid vesicle.</span>
        <meta itemprop="num_attr" content="0294">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a lipid vesicle</span>
        <span itemprop="definition">e.g., liposome</span>
        <meta itemprop="num_attr" content="0294">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">lipid and buffer solutions</span>
        <span itemprop="definition">into a mixing environment, such as in a mixing chamber, causes a continuous dilution of the lipid solution with the buffer solution, thereby producing a lipid vesicle substantially instantaneously upon mixing.</span>
        <meta itemprop="num_attr" content="0295">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">continuous diluting a lipid solution with a buffer solution</span>
        <span itemprop="definition">generally means that the lipid solution is diluted sufficiently rapidly in a hydration process with sufficient force to effectuate vesicle generation.</span>
        <meta itemprop="num_attr" content="0295">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the organic lipid solution</span>
        <span itemprop="definition">undergoes a continuous stepwise dilution in the presence of the buffer solution (i.e., aqueous solution) to produce a nucleic acid-lipid particle.</span>
        <meta itemprop="num_attr" content="0295">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the buffer solution</span>
        <span itemprop="definition">i.e., aqueous solution</span>
        <meta itemprop="num_attr" content="0295">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid-lipid particles formed using the continuous mixing method</span>
        <span itemprop="definition">typically have a size of from about 30 nm to about 150 nm, from about 40 nm to about 150 nm, from about 50 nm to about 150 nm, from about 60 nm to about 130 nm, from about 70 nm to about 110 nm, from about 70 nm to about 100 nm, from about 80 nm to about 100 nm, from about 90 nm to about 100 nm, from about 70 to about 90 nm, from about 80 nm to about 90 nm, from about 70 nm to about 80 nm, less than about 120 nm, 110 nm, 100 nm, 90 nm, or 80 nm, or about 30 nm, 35 nm, 40 nm, 45 nm, 50 nm, 55 nm, 60 nm, 65 nm, 70 nm, 75 nm, 80 nm, 85 nm, 90 n</span>
        <meta itemprop="num_attr" content="0296">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the present invention</span>
        <span itemprop="definition">provides nucleic acid-lipid particles (e.g., SNALP) produced via a direct dilution process that includes forming a lipid vesicle (e.g., liposome) solution and immediately and directly introducing the lipid vesicle solution into a collection vessel containing a controlled amount of dilution buffer.</span>
        <meta itemprop="num_attr" content="0297">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the collection vessel</span>
        <span itemprop="definition">includes one or more elements configured to stir the contents of the collection vessel to facilitate dilution.</span>
        <meta itemprop="num_attr" content="0297">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the amount of dilution buffer present in the collection vessel</span>
        <span itemprop="definition">is substantially equal to the volume of lipid vesicle solution introduced thereto.</span>
        <meta itemprop="num_attr" content="0297">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a lipid vesicle solution in 45% ethanol when introduced into the collection vessel containing an equal volume of dilution buffer</span>
        <span itemprop="definition">will advantageously yield smaller particles.</span>
        <meta itemprop="num_attr" content="0297">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the present invention</span>
        <span itemprop="definition">provides nucleic acid-lipid particles (e.g., SNALP) produced via an in-line dilution process in which a third reservoir containing dilution buffer is fluidly coupled to a second mixing region.</span>
        <meta itemprop="num_attr" content="0298">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the lipid vesicle (e.g., liposome) solution formed in a first mixing region</span>
        <span itemprop="definition">is immediately and directly mixed with dilution buffer in the second mixing region.</span>
        <meta itemprop="num_attr" content="0298">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the second mixing region</span>
        <span itemprop="definition">includes a T-connector arranged so that the lipid vesicle solution and the dilution buffer flows meet as opposing 180Â° flows; however, connectors providing shallower angles can be used, e.g., from about 27Â° to about 180Â° (e.g., about 90Â°).</span>
        <meta itemprop="num_attr" content="0298">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a pump mechanism</span>
        <span itemprop="definition">delivers a controllable flow of buffer to the second mixing region.</span>
        <meta itemprop="num_attr" content="0298">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the flow rate of dilution buffer provided to the second mixing region</span>
        <span itemprop="definition">is controlled to be substantially equal to the flow rate of lipid vesicle solution introduced thereto from the first mixing region.</span>
        <meta itemprop="num_attr" content="0298">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">This embodiment</span>
        <span itemprop="definition">advantageously allows for more control of the flow of dilution buffer mixing with the lipid vesicle solution in the second mixing region, and therefore also the concentration of lipid vesicle solution in buffer throughout the second mixing process.</span>
        <meta itemprop="num_attr" content="0298">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Such control of the dilution buffer flow rate</span>
        <span itemprop="definition">advantageously allows for small particle size formation at reduced concentrations.</span>
        <meta itemprop="num_attr" content="0298">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid-lipid particles formed using the direct dilution and in-line dilution processes</span>
        <span itemprop="definition">typically have a size of from about 30 nm to about 150 nm, from about 40 nm to about 150 nm, from about 50 nm to about 150 nm, from about 60 nm to about 130 nm, from about 70 nm to about 110 nm, from about 70 nm to about 100 nm, from about 80 nm to about 100 nm, from about 90 nm to about 100 nm, from about 70 to about 90 nm, from about 80 nm to about 90 nm, from about 70 nm to about 80 nm, less than about 120 nm, 110 nm, 100 nm, 90 nm, or 80 nm, or about 30 nm, 35 nm, 40 nm, 45 nm, 50 nm, 55 nm, 60 nm, 65 nm, 70 nm, 75 nm, 80</span>
        <meta itemprop="num_attr" content="0300">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the lipid particles of the invention</span>
        <span itemprop="definition">can be sized by any of the methods available for sizing liposomes.</span>
        <meta itemprop="num_attr" content="0301">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the sizing</span>
        <span itemprop="definition">may be conducted in order to achieve a desired size range and relatively narrow distribution of particle sizes.</span>
        <meta itemprop="num_attr" content="0301">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Extrusion of the particles through a small-pore polycarbonate membrane or an asymmetric ceramic membrane</span>
        <span itemprop="definition">is also an effective method for reducing particle sizes to a relatively well-defined size distribution.</span>
        <meta itemprop="num_attr" content="0303">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the suspension</span>
        <span itemprop="definition">is cycled through the membrane one or more times until the desired particle size distribution is achieved.</span>
        <meta itemprop="num_attr" content="0303">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the particles</span>
        <span itemprop="definition">may be extruded through successively smaller-pore membranes, to achieve a gradual reduction in size.</span>
        <meta itemprop="num_attr" content="0303">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the methods</span>
        <span itemprop="definition">may further comprise adding non-lipid polycations which are useful to effect the lipofection of cells using the present compositions.</span>
        <meta itemprop="num_attr" content="0304">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">suitable non-lipid polycations</span>
        <span itemprop="definition">include, hexadimethrine bromide (sold under the brand name POLYBRENEÂ®, from Aldrich Chemical Co., Milwaukee, Wis., USA) or other salts of hexadimethrine.</span>
        <meta itemprop="num_attr" content="0304">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">suitable polycations</span>
        <span itemprop="definition">include, for example, salts of poly-L-ornithine, poly-L-arginine, poly-L-lysine, poly-D-lysine, polyallylamine, and polyethyleneimine. Addition of these salts is preferably after the particles have been formed.</span>
        <meta itemprop="num_attr" content="0304">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid to lipid ratios (mass/mass ratios) in a formed nucleic acid-lipid particle</span>
        <span itemprop="definition">will range from about 0.01 to about 0.2, from about 0.05 to about 0.2, from about 0.02 to about 0.1, from about 0.03 to about 0.1, or from about 0.01 to about 0.08.</span>
        <meta itemprop="num_attr" content="0305">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the ratio of the starting materials (input)</span>
        <span itemprop="definition">also falls within this range.</span>
        <meta itemprop="num_attr" content="0305">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the particle preparation</span>
        <span itemprop="definition">uses about 400  â g nucleic acid per 10 mg total lipid or a nucleic acid to lipid mass ratio of about 0.01 to about 0.08 and, more preferably, about 0.04, which corresponds to 1.25 mg of total lipid per 50  â g of nucleic acid.</span>
        <meta itemprop="num_attr" content="0305">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the particle</span>
        <span itemprop="definition">has a nucleic acid:lipid mass ratio of about 0.08.</span>
        <meta itemprop="num_attr" content="0305">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the lipid to nucleic acid ratios (mass/mass ratios) in a formed nucleic acid-lipid particle</span>
        <span itemprop="definition">will range from about 1 (1:1) to about 100 (100:1), from about 5 (5:1) to about 100 (100:1), from about 1 (1:1) to about 50 (50:1), from about 2 (2:1) to about 50 (50:1), from about 3 (3:1) to about 50 (50:1), from about 4 (4:1) to about 50 (50:1), from about 5 (5:1) to about 50 (50:1), from about 1 (1:1) to about 25 (25:1), from about 2 (2:1) to about 25 (25:1), from about 3 (3:1) to about 25 (25:1), from about 4 (4:1) to about 25 (25:1), from about 5 (5:1) to about 25 (25:1), from about 5 (5:1) to about 20 (20:1), from about 5 (5:1) to about 15 (15:1), from about 5 (5:1) to about 10 (10:1), or</span>
        <meta itemprop="num_attr" content="0306">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the conjugated lipid</span>
        <span itemprop="definition">may further include a CPL.</span>
        <meta itemprop="num_attr" content="0307">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">CPL-containing SNALP</span>
        <span itemprop="definition">A variety of general methods for making SNALP-CPLs (CPL-containing SNALP) are discussed herein.</span>
        <meta itemprop="num_attr" content="0307">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Two general techniques</span>
        <span itemprop="definition">include the âpost-insertionâ technique, that is, insertion of a CPL into, for example, a pre-formed SNALP, and the âstandardâ technique, wherein the CPL is included in the lipid mixture during, for example, the SNALP formation steps.</span>
        <meta itemprop="num_attr" content="0307">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the post-insertion technique</span>
        <span itemprop="definition">results in SNALP having CPLs mainly in the external face of the SNALP bilayer membrane, whereas standard techniques provide SNALP having CPLs on both internal and external faces.</span>
        <meta itemprop="num_attr" content="0307">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the method</span>
        <span itemprop="definition">is especially useful for vesicles made from phospholipids (which can contain cholesterol) and also for vesicles containing PEG-lipids (such as PEG-DAAs and PEG-DAGs).</span>
        <meta itemprop="num_attr" content="0307">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">PEG-lipids</span>
        <span itemprop="definition">such as PEG-DAAs and PEG-DAGs.</span>
        <meta itemprop="num_attr" content="0307">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the lipid particles of the invention</span>
        <span itemprop="definition">are particularly useful for the introduction of nucleic acids (e.g., mRNA) into cells.</span>
        <meta itemprop="num_attr" content="0308">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the present invention</span>
        <span itemprop="definition">also provides methods for introducing a nucleic acid (e.g., mRNA) into a cell.</span>
        <meta itemprop="num_attr" content="0308">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid</span>
        <span itemprop="definition">e.g., mRNA</span>
        <meta itemprop="num_attr" content="0308">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid</span>
        <span itemprop="definition">is introduced into an infected cell such as reticuloendothelial cells (e.g., macrophages, monocytes, etc.) as well as other cell types, including fibroblasts, endothelial cells (such as those lining the interior surface of blood vessels), and/or platelet cells.</span>
        <meta itemprop="num_attr" content="0308">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the methods</span>
        <span itemprop="definition">may be carried out in vitro or in vivo by first forming the particles as described herein and then contacting the particles with the cells for a period of time sufficient for delivery of the mRNA to the cells to occur.</span>
        <meta itemprop="num_attr" content="0308">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the lipid particles of the invention</span>
        <span itemprop="definition">can be adsorbed to almost any cell type with which they are mixed or contacted. Once adsorbed, the particles can either be endocytosed by a portion of the cells, exchange lipids with cell membranes, or fuse with the cells. Transfer or incorporation of the nucleic acid (e.g., mRNA) portion of the particle can take place via any one of these pathways. In particular, when fusion takes place, the particle membrane is integrated into the cell membrane and the contents of the particle combine with the intracellular fluid.</span>
        <meta itemprop="num_attr" content="0309">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">SNALP</span>
        <span itemprop="definition">lipid particles of the invention</span>
        <meta itemprop="num_attr" content="0309">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the lipid particles of the invention</span>
        <span itemprop="definition">can be administered either alone or in a mixture with a pharmaceutically acceptable carrier (e.g., physiological saline or phosphate buffer) selected in accordance with the route of administration and standard pharmaceutical practice.</span>
        <meta itemprop="num_attr" content="0310">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a pharmaceutically acceptable carrier</span>
        <span itemprop="definition">e.g., physiological saline or phosphate buffer</span>
        <meta itemprop="num_attr" content="0310">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">physiological saline or phosphate buffer</span>
        <span itemprop="definition">e.g., physiological saline or phosphate buffer</span>
        <meta itemprop="num_attr" content="0310">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">suitable carriers</span>
        <span itemprop="definition">include, e.g., water, buffered water, 0.4% saline, 0.3% glycine, and the like, including glycoproteins for enhanced stability, such as albumin, lipoprotein, globulin, etc.</span>
        <meta itemprop="num_attr" content="0310">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">carrier</span>
        <span itemprop="definition">includes any and all solvents, dispersion media, vehicles, coatings, diluents, antibacterial and antifungal agents, isotonic and absorption delaying agents, buffers, carrier solutions, suspensions, colloids, and the like.</span>
        <meta itemprop="num_attr" content="0310">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">pharmaceutically acceptable</span>
        <span itemprop="definition">refers to molecular entities and compositions that do not produce an allergic or similar untoward reaction when administered to a human.</span>
        <meta itemprop="num_attr" content="0310">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the pharmaceutically acceptable carrier</span>
        <span itemprop="definition">is generally added following lipid particle formation.</span>
        <meta itemprop="num_attr" content="0311">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the lipid particle</span>
        <span itemprop="definition">e.g., SNALP</span>
        <meta itemprop="num_attr" content="0311">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the particle</span>
        <span itemprop="definition">can be diluted into pharmaceutically acceptable carriers such as normal buffered saline.</span>
        <meta itemprop="num_attr" content="0311">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the concentration of particles in the pharmaceutical formulations</span>
        <span itemprop="definition">can vary widely, i.e., from less than about 0.05%, usually at or at least about 2 to 5%, to as much as about 10 to 90% by weight, and will be selected primarily by fluid volumes, viscosities, etc., in accordance with the particular mode of administration selected.</span>
        <meta itemprop="num_attr" content="0312">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the concentration</span>
        <span itemprop="definition">may be increased to lower the fluid load associated with treatment. This may be particularly desirable in patients having atherosclerosis-associated congestive heart failure or severe hypertension.</span>
        <meta itemprop="num_attr" content="0312">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">particles composed of irritating lipids</span>
        <span itemprop="definition">may be diluted to low concentrations to lessen inflammation at the site of administration.</span>
        <meta itemprop="num_attr" content="0312">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">compositions of the present invention</span>
        <span itemprop="definition">may be sterilized by conventional, well-known sterilization techniques.</span>
        <meta itemprop="num_attr" content="0313">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Aqueous solutions</span>
        <span itemprop="definition">can be packaged for use or filtered under aseptic conditions and lyophilized, the lyophilized preparation being combined with a sterile aqueous solution prior to administration.</span>
        <meta itemprop="num_attr" content="0313">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the compositions</span>
        <span itemprop="definition">can contain pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions, such as pH adjusting and buffering agents, tonicity adjusting agents and the like, for example, sodium acetate, sodium lactate, sodium chloride, potassium chloride, and calcium chloride.</span>
        <meta itemprop="num_attr" content="0313">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the particle suspension</span>
        <span itemprop="definition">may include lipid-protective agents which protect lipids against free-radical and lipid-peroxidative damages on storage. Lipophilic free-radical quenchers, such as alphatocopherol, and water-soluble iron-specific chelators, such as ferrioxamine, are suitable.</span>
        <meta itemprop="num_attr" content="0313">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the lipid particles of the invention</span>
        <span itemprop="definition">are particularly useful in methods for the therapeutic delivery of one or more mRNA.</span>
        <meta itemprop="num_attr" content="0314">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">nucleic acid-lipid particles</span>
        <span itemprop="definition">such as those described in PCT Publication Nos. WO 05/007196, WO 05/121348, WO 05/120152, and WO 04/002453, the disclosures of which are herein incorporated by reference in their entirety for all purposes.</span>
        <meta itemprop="num_attr" content="0315">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the present invention</span>
        <span itemprop="definition">also provides fully encapsulated lipid particles that protect the nucleic acid from nuclease degradation in serum, are non-immunogenic, are small in size, and are suitable for repeat dosing.</span>
        <meta itemprop="num_attr" content="0315">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">administration</span>
        <span itemprop="definition">can be in any manner known in the art, e.g., by injection, oral administration, inhalation (e.g., intransal or intratracheal), transdermal application, or rectal administration.</span>
        <meta itemprop="num_attr" content="0316">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Administration</span>
        <span itemprop="definition">can be accomplished via single or divided doses.</span>
        <meta itemprop="num_attr" content="0316">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the pharmaceutical compositions</span>
        <span itemprop="definition">can be administered parenterally, i.e., intraarticularly, intravenously, intraperitoneally, subcutaneously, or intramuscularly.</span>
        <meta itemprop="num_attr" content="0316">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the pharmaceutical compositions</span>
        <span itemprop="definition">are administered intravenously or intraperitoneally by a bolus injection (see, e.g., U.S. Pat. No. 5,286,634).</span>
        <meta itemprop="num_attr" content="0316">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Intracellular nucleic acid delivery</span>
        <span itemprop="definition">has also been discussed in Straubringer et al., Methods Enzymol., 101:512 (1983); Mannino et al., Biotechniques, 6:682 (1988); Nicolau et al., Crit. Rev. Ther. Drug Carrier Syst., 6:239 (1989); and Behr, Acc. Chem. Res., 26:274 (1993). Still other methods of administering lipid-based therapeutics are described in, for example, U.S. Pat. Nos. 3,993,754; 4,145,410; 4,235,871; 4,224,179; 4,522,803; and 4,588,578.</span>
        <meta itemprop="num_attr" content="0316">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the lipid particles</span>
        <span itemprop="definition">can be administered by direct injection at the site of disease or by injection at a site distal from the site of disease (see, e.g., Culver, HUMAN GENE THERAPY, MaryAnn Liebert, Inc., Publishers, New York. pp. 70-71 (1994)).</span>
        <meta itemprop="num_attr" content="0316">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Culver</span>
        <span itemprop="definition">HUMAN GENE THERAPY</span>
        <meta itemprop="num_attr" content="0316">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">MaryAnn Liebert, Inc.</span>
        <span itemprop="definition">Publishers, New York. pp. 70-71 (1994)</span>
        <meta itemprop="num_attr" content="0316">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the disclosures of the above-described references</span>
        <span itemprop="definition">are herein incorporated by reference in their entirety for all purposes.</span>
        <meta itemprop="num_attr" content="0316">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the lipid particles of the present invention</span>
        <span itemprop="definition">e.g., SNALP</span>
        <meta itemprop="num_attr" content="0317">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">at least about 5%, 10%, 15%, 20%, or 25% of the total injected dose of the particles</span>
        <span itemprop="definition">is present in plasma about 8, 12, 24, 36, or 48 hours after injection.</span>
        <meta itemprop="num_attr" content="0317">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">more than about 20%, 30%, 40% and as much as about 60%, 70% or 80% of the total injected dose of the lipid particles</span>
        <span itemprop="definition">is present in plasma about 8, 12, 24, 36, or 48 hours after injection.</span>
        <meta itemprop="num_attr" content="0317">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">more than about 10% of a plurality of the particles</span>
        <span itemprop="definition">is present in the plasma of a mammal about 1 hour after administration.</span>
        <meta itemprop="num_attr" content="0317">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the presence of the lipid particles</span>
        <span itemprop="definition">is detectable at least about 1 hour after administration of the particle.</span>
        <meta itemprop="num_attr" content="0317">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the presence of a therapeutic nucleic acid such as an mRNA molecule</span>
        <span itemprop="definition">is detectable in cells at about 8, 12, 24, 36, 48, 60, 72 or 96 hours after administration.</span>
        <meta itemprop="num_attr" content="0317">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">expression of a polypeptide encoded by an mRNA introduced into a living body in accordance with the present invention</span>
        <span itemprop="definition">is detectable at about 8, 12, 24, 36, 48, 60, 72 or 96 hours after administration.</span>
        <meta itemprop="num_attr" content="0317">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the presence or effect of an mRNA in cells at a site proximal or distal to the site of administration</span>
        <span itemprop="definition">is detectable at about 12, 24, 48, 72, or 96 hours, or at about 6, 8, 10, 12, 14, 16, 18, 19, 20, 22, 24, 26, or 28 days after administration.</span>
        <meta itemprop="num_attr" content="0317">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the lipid particles (e.g., SNALP) of the invention</span>
        <span itemprop="definition">are administered parenterally or intraperitoneally.</span>
        <meta itemprop="num_attr" content="0317">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">compositions of the present invention</span>
        <span itemprop="definition">can be made into aerosol formulations (i.e., they can be ânebulizedâ) to be administered via inhalation (e.g., intranasally or intratracheally) (see, Brigham et al., Am. J. Sci., 298:278 (1989)). Aerosol formulations can be placed into pressurized acceptable propellants, such as dichlorodifluoromethane, propane, nitrogen, and the like.</span>
        <meta itemprop="num_attr" content="0318">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the pharmaceutical compositions</span>
        <span itemprop="definition">may be delivered by intranasal sprays, inhalation, and/or other aerosol delivery vehicles.</span>
        <meta itemprop="num_attr" content="0319">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Methods for delivering nucleic acid compositions directly to the lungs via nasal aerosol sprays</span>
        <span itemprop="definition">have been described, e.g., in U.S. Pat. Nos. 5,756,353 and 5,804,212.</span>
        <meta itemprop="num_attr" content="0319">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the delivery of drugs using intranasal microparticle resins and lysophosphatidyl-glycerol compounds</span>
        <span itemprop="definition">(U.S. Pat. No. 5,725,871) are also known in the pharmaceutical arts.</span>
        <meta itemprop="num_attr" content="0319">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">transmucosal drug delivery in the form of a polytetrafluoroetheylene support matrix</span>
        <span itemprop="definition">is described in U.S. Pat. No. 5,780,045.</span>
        <meta itemprop="num_attr" content="0319">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the disclosures of the above-described patents</span>
        <span itemprop="definition">are herein incorporated by reference in their entirety for all purposes.</span>
        <meta itemprop="num_attr" content="0319">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Formulations suitable for parenteral administration</span>
        <span itemprop="definition">include aqueous and non-aqueous, isotonic sterile injection solutions, which can contain antioxidants, buffers, bacteriostats, and solutes that render the formulation isotonic with the blood of the intended recipient, and aqueous and non-aqueous sterile suspensions that can include suspending agents, solubilizers, thickening agents, stabilizers, and preservatives.</span>
        <meta itemprop="num_attr" content="0320">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">compositions</span>
        <span itemprop="definition">are preferably administered, for example, by intravenous infusion, orally, topically, intraperitoneally, intravesically, or intrathecally.</span>
        <meta itemprop="num_attr" content="0320">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the lipid particle formulations</span>
        <span itemprop="definition">are formulated with a suitable pharmaceutical carrier.</span>
        <meta itemprop="num_attr" content="0321">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a suitable pharmaceutical carrier</span>
        <span itemprop="definition">may be employed in the compositions and methods of the present invention. Suitable formulations for use in the present invention are found, for example, in REMINGTON&#39;S PHARMACEUTICAL SCIENCES, Mack Publishing Company, Philadelphia, Pa., 17th ed. (1985).</span>
        <meta itemprop="num_attr" content="0321">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a variety of aqueous carriers</span>
        <span itemprop="definition">may be used, for example, water, buffered water, 0.4% saline, 0.3% glycine, and the like, and may include glycoproteins for enhanced stability, such as albumin, lipoprotein, globulin, etc.</span>
        <meta itemprop="num_attr" content="0321">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">compositions</span>
        <span itemprop="definition">can be sterilized by conventional liposomal sterilization techniques, such as filtration.</span>
        <meta itemprop="num_attr" content="0321">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the compositions</span>
        <span itemprop="definition">may contain pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions, such as pH adjusting and buffering agents, tonicity adjusting agents, wetting agents and the like, for example, sodium acetate, sodium lactate, sodium chloride, potassium chloride, calcium chloride, sorbitan monolaurate, triethanolamine oleate, etc.</span>
        <meta itemprop="num_attr" content="0321">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">These compositions</span>
        <span itemprop="definition">can be sterilized using the techniques referred to above or, alternatively, they can be produced under sterile conditions.</span>
        <meta itemprop="num_attr" content="0321">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the resulting aqueous solutions</span>
        <span itemprop="definition">may be packaged for use or filtered under aseptic conditions and lyophilized, the lyophilized preparation being combined with a sterile aqueous solution prior to administration.</span>
        <meta itemprop="num_attr" content="0321">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the lipid particles disclosed herein</span>
        <span itemprop="definition">may be delivered via oral administration to the individual.</span>
        <meta itemprop="num_attr" content="0322">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the particles</span>
        <span itemprop="definition">may be incorporated with excipients and used in the form of ingestible tablets, buccal tablets, troches, capsules, pills, lozenges, elixirs, mouthwash, suspensions, oral sprays, syrups, wafers, and the like (see, e.g., U.S. Pat. Nos. 5,641,515, 5,580,579, and 5,792,451, the disclosures of which are herein incorporated by reference in their entirety for all purposes).</span>
        <meta itemprop="num_attr" content="0322">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">These oral dosage forms</span>
        <span itemprop="definition">may also contain the following: binders, gelatin; excipients, lubricants, and/or flavoring agents.</span>
        <meta itemprop="num_attr" content="0322">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the unit dosage form</span>
        <span itemprop="definition">When the unit dosage form is a capsule, it may contain, in addition to the materials described above, a liquid carrier. Various other materials may be present as coatings or to otherwise modify the physical form of the dosage unit. Of course, any material used in preparing any unit dosage form should be pharmaceutically pure and substantially non-toxic in the amounts employed.</span>
        <meta itemprop="num_attr" content="0322">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">these oral formulations</span>
        <span itemprop="definition">may contain at least about 0.1% of the lipid particles or more, although the percentage of the particles may, of course, be varied and may conveniently be between about 1% or 2% and about 60% or 70% or more of the weight or volume of the total formulation.</span>
        <meta itemprop="num_attr" content="0323">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the amount of particles in each therapeutically useful composition may be prepared</span>
        <span itemprop="definition">is such a way that a suitable dosage will be obtained in any given unit dose of the compound.</span>
        <meta itemprop="num_attr" content="0323">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Factors</span>
        <span itemprop="definition">such as solubility, bioavailability, biological half-life, route of administration, product shelf life, as well as other pharmacological considerations will be contemplated by one skilled in the art of preparing such pharmaceutical formulations, and as such, a variety of dosages and treatment regimens may be desirable.</span>
        <meta itemprop="num_attr" content="0323">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Formulations suitable for oral administration</span>
        <span itemprop="definition">can consist of: (a) liquid solutions, such as an effective amount of a packaged therapeutic nucleic acid (e.g., mRNA) suspended in diluents such as water, saline, or PEG 400; (b) capsules, sachets, or tablets, each containing a predetermined amount of a therapeutic nucleic acid (e.g., mRNA), as liquids, solids, granules, or gelatin; (c) suspensions in an appropriate liquid; and (d) suitable emulsions.</span>
        <meta itemprop="num_attr" content="0324">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a packaged therapeutic nucleic acid</span>
        <span itemprop="definition">e.g., mRNA</span>
        <meta itemprop="num_attr" content="0324">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">diluents</span>
        <span itemprop="definition">such as water, saline, or PEG 400</span>
        <meta itemprop="num_attr" content="0324">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">capsules, sachets, or tablets</span>
        <span itemprop="definition">each containing a predetermined amount of a therapeutic nucleic acid (e.g., mRNA), as liquids, solids, granules, or gelatin</span>
        <meta itemprop="num_attr" content="0324">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">suspensions in an appropriate liquid</span>
        <span itemprop="definition">and (d) suitable emulsions</span>
        <meta itemprop="num_attr" content="0324">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Tablet forms</span>
        <span itemprop="definition">can include one or more of lactose, sucrose, mannitol, sorbitol, calcium phosphates, corn starch, potato starch, microcrystalline cellulose, gelatin, colloidal silicon dioxide, talc, magnesium stearate, stearic acid, and other excipients, colorants, fillers, binders, diluents, buffering agents, moistening agents, preservatives, flavoring agents, dyes, disintegrating agents, and pharmaceutically compatible carriers.</span>
        <meta itemprop="num_attr" content="0324">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Lozenge forms</span>
        <span itemprop="definition">can comprise a therapeutic nucleic acid (e.g., mRNA) in a flavor, e.g., sucrose, as well as pastilles comprising the therapeutic nucleic acid in an inert base, such as gelatin and glycerin or sucrose and acacia emulsions, gels, and the like containing, in addition to the therapeutic nucleic acid, carriers known in the art.</span>
        <meta itemprop="num_attr" content="0324">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a therapeutic nucleic acid</span>
        <span itemprop="definition">e.g., mRNA</span>
        <meta itemprop="num_attr" content="0324">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a flavor</span>
        <span itemprop="definition">e.g., sucrose</span>
        <meta itemprop="num_attr" content="0324">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">an inert base</span>
        <span itemprop="definition">such as gelatin and glycerin or sucrose and acacia emulsions, gels, and the like containing, in addition to the therapeutic nucleic acid, carriers known in the art.</span>
        <meta itemprop="num_attr" content="0324">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">lipid particles</span>
        <span itemprop="definition">can be incorporated into a broad range of topical dosage forms.</span>
        <meta itemprop="num_attr" content="0325">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a suspension containing nucleic acid-lipid particles such as SNALP</span>
        <span itemprop="definition">can be formulated and administered as gels, oils, emulsions, topical creams, pastes, ointments, lotions, foams, mousses, and the like.</span>
        <meta itemprop="num_attr" content="0325">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">lipid particles of the invention</span>
        <span itemprop="definition">When preparing pharmaceutical preparations of the lipid particles of the invention, it is preferable to use quantities of the particles which have been purified to reduce or eliminate empty particles or particles with therapeutic agents such as nucleic acid associated with the external surface.</span>
        <meta itemprop="num_attr" content="0326">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">hosts</span>
        <span itemprop="definition">include mammalian species, such as primates (e.g., humans and chimpanzees as well as other nonhuman primates), canines, felines, equines, bovines, ovines, caprines, rodents (e.g., rats and mice), lagomorphs, and swine.</span>
        <meta itemprop="num_attr" content="0327">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the amount of particles administered</span>
        <span itemprop="definition">will depend upon the ratio of therapeutic nucleic acid (e.g., mRNA) to lipid, the particular therapeutic nucleic acid used, the disease or disorder being treated, the age, weight, and condition of the patient, and the judgment of the clinician, but will generally be between about 0.01 and about 50 mg per kilogram of body weight, preferably between about 0.1 and about 5 mg/kg of body weight, or about 10 8 -10 10 particles per administration (e.g., injection).</span>
        <meta itemprop="num_attr" content="0328">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">therapeutic nucleic acid</span>
        <span itemprop="definition">e.g., mRNA</span>
        <meta itemprop="num_attr" content="0328">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the delivery of therapeutic nucleic acids</span>
        <span itemprop="definition">can be to any cell grown in culture, whether of plant or animal origin, vertebrate or invertebrate, and of any tissue or type.</span>
        <meta itemprop="num_attr" content="0329">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the cells</span>
        <span itemprop="definition">are animal cells, more preferably mammalian cells, and most preferably human cells.</span>
        <meta itemprop="num_attr" content="0329">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the concentration of particles</span>
        <span itemprop="definition">varies widely depending on the particular application, but is generally between about 1  â mol and about 10 mmol.</span>
        <meta itemprop="num_attr" content="0330">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Treatment of the cells with the lipid particles</span>
        <span itemprop="definition">is generally carried out at physiological temperatures (about 37Â° C.) for periods of time of from about 1 to 48 hours, preferably of from about 2 to 4 hours.</span>
        <meta itemprop="num_attr" content="0330">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a lipid particle suspension</span>
        <span itemprop="definition">is added to 60-80% confluent plated cells having a cell density of from about 10 3 to about 10 5 cells/ml, more preferably about 2 â 10 4 cells/ml.</span>
        <meta itemprop="num_attr" content="0331">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the concentration of the suspension added to the cells</span>
        <span itemprop="definition">is preferably of from about 0.01 to 0.2  â g/ml, more preferably about 0.1  â g/ml.</span>
        <meta itemprop="num_attr" content="0331">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">tissue culture of cells</span>
        <span itemprop="definition">may be required, it is well-known in the art.</span>
        <meta itemprop="num_attr" content="0332">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Freshney</span>
        <span itemprop="definition">Culture of Animal Cells, a Manual of Basic Technique, 3rd Ed., Wiley-Liss, New York (1994), Kuchler et al., Biochemical Methods in Cell Culture and Virology, Dowden, Hutchinson and Ross, Inc. (1977), and the references cited therein provide a general guide to the culture of cells.</span>
        <meta itemprop="num_attr" content="0332">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Cultured cell systems</span>
        <span itemprop="definition">often will be in the form of monolayers of cells, although cell suspensions are also used.</span>
        <meta itemprop="num_attr" content="0332">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">an ERP assay</span>
        <span itemprop="definition">is described in detail in U.S. Patent Publication No. 20030077829, the disclosure of which is herein incorporated by reference in its entirety for all purposes. More particularly, the purpose of an ERP assay is to distinguish the effect of various cationic lipids and helper lipid components of SNALP or other lipid particle based on their relative effect on binding/uptake or fusion with/destabilization of the endosomal membrane. This assay allows one to determine quantitatively how each component of the SNALP or other lipid particle affects delivery efficiency, thereby optimizing the SNALP or other lipid particle.</span>
        <meta itemprop="num_attr" content="0333">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">an ERP assay</span>
        <span itemprop="definition">measures expression of a reporter protein (e.g., luciferase,  â -galactosidase, green fluorescent protein (GFP), etc.), and in some instances, a SNALP formulation optimized for an expression plasmid will also be appropriate for encapsulating an mRNA.</span>
        <meta itemprop="num_attr" content="0333">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a reporter protein</span>
        <span itemprop="definition">e.g., luciferase,  â -galactosidase, green fluorescent protein (GFP), etc.</span>
        <meta itemprop="num_attr" content="0333">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">GFP</span>
        <span itemprop="definition">green fluorescent protein</span>
        <meta itemprop="num_attr" content="0333">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the present invention</span>
        <span itemprop="definition">can be practiced on a wide variety of cell types from any vertebrate species, including mammals, such as, e.g, canines, felines, equines, bovines, ovines, caprines, rodents (e.g., mice, rats, and guinea pigs), lagomorphs, swine, and primates (e.g. monkeys, chimpanzees, and humans).</span>
        <meta itemprop="num_attr" content="0334">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">mammals</span>
        <span itemprop="definition">such as, e.g, canines, felines, equines, bovines, ovines, caprines, rodents (e.g., mice, rats, and guinea pigs), lagomorphs, swine, and primates (e.g. monkeys, chimpanzees, and humans).</span>
        <meta itemprop="num_attr" content="0334">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the lipid particles of the present invention</span>
        <span itemprop="definition">are detectable in the subject at about 1, 2, 3, 4, 5, 6, 7, 8 or more hours. In other embodiments, the lipid particles of the present invention (e.g., SNALP) are detectable in the subject at about 8, 12, 24, 48, 60, 72, or 96 hours, or about 6, 8, 10, 12, 14, 16, 18, 19, 22, 24, 25, or 28 days after administration of the particles.</span>
        <meta itemprop="num_attr" content="0335">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the presence of the particles</span>
        <span itemprop="definition">can be detected in the cells, tissues, or other biological samples from the subject.</span>
        <meta itemprop="num_attr" content="0335">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the particles</span>
        <span itemprop="definition">may be detected, e.g., by direct detection of the particles, and/or detection of an mRNA sequence encapsulated within the lipid particles, and/or detection of a polypeptide expressed from an mRNA.</span>
        <meta itemprop="num_attr" content="0335">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Lipid particles of the invention</span>
        <span itemprop="definition">such as SNALP can be detected using any method known in the art.</span>
        <meta itemprop="num_attr" content="0336">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a label</span>
        <span itemprop="definition">can be coupled directly or indirectly to a component of the lipid particle using methods well-known in the art.</span>
        <meta itemprop="num_attr" content="0336">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a wide variety of labels</span>
        <span itemprop="definition">can be used, with the choice of label depending on sensitivity required, ease of conjugation with the lipid particle component, stability requirements, and available instrumentation and disposal provisions.</span>
        <meta itemprop="num_attr" content="0336">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Suitable labels</span>
        <span itemprop="definition">include, but are not limited to, spectral labels such as fluorescent dyes (e.g., fluorescein and derivatives, such as fluorescein isothiocyanate (FITC) and Oregon GreenTM; rhodamine and derivatives such Texas red, tetrarhodimine isothiocynate (TRITC), etc., digoxigenin, biotin, phycoerythrin, AMCA, CyDyesTM, and the like; radiolabels such as 3 H, 125 I, 35 S, 14 C, 32 P, 33 P, etc.; enzymes such as horse radish peroxidase, alkaline phosphatase, etc.; spectral colorimetric labels such as colloidal gold or colored glass or plastic beads such as polystyrene, polypropylene, latex, etc.</span>
        <meta itemprop="num_attr" content="0336">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the label</span>
        <span itemprop="definition">can be detected using any means known in the art.</span>
        <meta itemprop="num_attr" content="0336">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Nucleic acids</span>
        <span itemprop="definition">are detected and quantified herein by any of a number of means well-known to those of skill in the art.</span>
        <meta itemprop="num_attr" content="0337">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the detection of nucleic acids</span>
        <span itemprop="definition">may proceed by well-known methods such as Southern analysis, Northern analysis, gel electrophoresis, PCR, radiolabeling, scintillation counting, and affinity chromatography. Additional analytic biochemical methods such as spectrophotometry, radiography, electrophoresis, capillary electrophoresis, high performance liquid chromatography (HPLC), thin layer chromatography (TLC), and hyperdiffusion chromatography may also be employed.</span>
        <meta itemprop="num_attr" content="0337">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">HPLC</span>
        <span itemprop="definition">high performance liquid chromatography</span>
        <meta itemprop="num_attr" content="0337">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">TLC</span>
        <span itemprop="definition">thin layer chromatography</span>
        <meta itemprop="num_attr" content="0337">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">nucleic acid hybridization format</span>
        <span itemprop="definition">is not critical.</span>
        <meta itemprop="num_attr" content="0338">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a variety of nucleic acid hybridization formats</span>
        <span itemprop="definition">are known to those skilled in the art.</span>
        <meta itemprop="num_attr" content="0338">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">common formats</span>
        <span itemprop="definition">include sandwich assays and competition or displacement assays.</span>
        <meta itemprop="num_attr" content="0338">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Hybridization techniques</span>
        <span itemprop="definition">are generally described in, e.g., âNucleic Acid Hybridization, A Practical Approach,â Eds. Hames and Higgins, IRL Press (1985).</span>
        <meta itemprop="num_attr" content="0338">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the sensitivity of the hybridization assays</span>
        <span itemprop="definition">may be enhanced through the use of a nucleic acid amplification system which multiplies the target nucleic acid being detected.</span>
        <meta itemprop="num_attr" content="0339">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a nucleic acid amplification system</span>
        <span itemprop="definition">which multiplies the target nucleic acid being detected.</span>
        <meta itemprop="num_attr" content="0339">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">In vitro amplification techniques suitable for amplifying sequences for use as molecular probes or for generating nucleic acid fragments for subsequent subcloning</span>
        <span itemprop="definition">are known.</span>
        <meta itemprop="num_attr" content="0339">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">RNA polymerase mediated techniques</span>
        <span itemprop="definition">e.g., NASBATM</span>
        <meta itemprop="num_attr" content="0339">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">PCR</span>
        <span itemprop="definition">polymerase chain reaction</span>
        <meta itemprop="num_attr" content="0339">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">LCR</span>
        <span itemprop="definition">ligase chain reaction</span>
        <meta itemprop="num_attr" content="0339">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Q â -replicase amplification</span>
        <span itemprop="definition">e.g., Q â -replicase mediated techniques</span>
        <meta itemprop="num_attr" content="0339">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">NASBATM</span>
        <span itemprop="definition">RNA polymerase mediated techniques</span>
        <meta itemprop="num_attr" content="0339">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">PCR or LCR primers</span>
        <span itemprop="definition">are designed to be extended or ligated only when a select sequence is present.</span>
        <meta itemprop="num_attr" content="0339">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">select sequences</span>
        <span itemprop="definition">can be generally amplified using, for example, nonspecific PCR primers and the amplified target region later probed for a specific sequence indicative of a mutation.</span>
        <meta itemprop="num_attr" content="0339">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Nucleic acids for use as probes</span>
        <span itemprop="definition">are typically synthesized chemically according to the solid phase phosphoramidite triester method described by Beaucage et al., Tetrahedron Letts., 22:1859 1862 (1981), e.g., using an automated synthesizer, as described in Needham VanDevanter et al., Nucleic Acids Res., 12:6159 (1984).</span>
        <meta itemprop="num_attr" content="0340">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Purification of polynucleotides, where necessary,</span>
        <span itemprop="definition">is typically performed by either native acrylamide gel electrophoresis or by anion exchange HPLC as described in Pearson et al., J. Chrom., 255:137 149 (1983). The sequence of the synthetic polynucleotides can be verified using the chemical degradation method of Maxam and Gilbert (1980) in Grossman and Moldave (eds.) Academic Press, New York, Methods in Enzymology, 65:499.</span>
        <meta itemprop="num_attr" content="0340">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">In situ hybridization assays</span>
        <span itemprop="definition">are well-known and are generally described in Angerer et al., Methods Enzymol., 152:649 (1987).</span>
        <meta itemprop="num_attr" content="0341">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">in situ hybridization assay</span>
        <span itemprop="definition">cells are fixed to a solid support, typically a glass slide. If DNA is to be probed, the cells are denatured with heat or alkali. The cells are then contacted with a hybridization solution at a moderate temperature to permit annealing of specific probes that are labeled.</span>
        <meta itemprop="num_attr" content="0341">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the probes</span>
        <span itemprop="definition">are preferably labeled with radioisotopes or fluorescent reporters.</span>
        <meta itemprop="num_attr" content="0341">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Corticosteroids</span>
        <span itemprop="definition">are a class of steroid hormones that are produced in the adrenal cortex of vertebrates, as well as the synthetic analogues of these hormones. Corticosteroids are involved in a wide range of physiological processes, including stress response, immune response, and regulation of inflammation, carbohydrate metabolism, protein catabolism, blood electrolyte levels, and behavior.</span>
        <meta itemprop="num_attr" content="0343">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">corticosteroids</span>
        <span itemprop="definition">there are two classes of corticosteroids. Glucocorticoids such as cortisol control carbohydrate, fat and protein metabolism, and are anti-inflammatory by preventing phospholipid release, decreasing eosinophil action and a number of other mechanisms. Mineralocorticoids such as aldosterone control electrolyte and water levels, mainly by promoting sodium retention in the kidney.</span>
        <meta itemprop="num_attr" content="0344">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">glucocorticoid</span>
        <span itemprop="definition">refers to any of a group of natural or synthetic steroid hormones that control carbohydrate, protein, and fat metabolism and have anti-inflammatory and/or immunosuppressive properties.</span>
        <meta itemprop="num_attr" content="0345">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Suitable glucocorticoids for use in certain embodiments of the present invention</span>
        <span itemprop="definition">include, but are not limited to, hydrocortisone, cortisone, corticosterone, deoxycorticosterone, prednisone, prednisolone, methylprednisolone, dexamethasone, betamethasone, mometasone, triamcinolone, beclomethasone, fludrocortisone, aldosterone, fluticasone, clobetasone, clobetasol, and loteprednol, and pharmaceutically acceptable salts thereof, and mixtures thereof.â</span>
        <meta itemprop="num_attr" content="0345">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Steroids</span>
        <span itemprop="definition">are often used in the treatment of various diseases as they can help with treatment in a number of ways.</span>
        <meta itemprop="num_attr" content="0346">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">cancer treatment</span>
        <span itemprop="definition">for example, steroids can reduce nausea associated with chemotherapy and radiation, decrease inflammation, reduce allergic reactions (before transfusions, for example), or simply to help improve quality of life by enabling the patient to sleep, eat, and feel better.</span>
        <meta itemprop="num_attr" content="0346">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Lipid nanoparticles</span>
        <span itemprop="definition">were made by either direct dilution or in-line dilution methods described by Jeffs et al. (see U.S. Pat. No. 9,005,654).</span>
        <meta itemprop="num_attr" content="0349">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Lipid composition</span>
        <span itemprop="definition">typically contained the following lipids in the respective molar ratios, except where otherwise noted: PEG-lipid (PEG2000-C-DMA, 1.1 mol %); Cationic lipid (Compound 13, 54.9 mol %); cholesterol (33.0 mol %); and 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC, 11.0 mol %).</span>
        <meta itemprop="num_attr" content="0349">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Nucleic acid</span>
        <span itemprop="definition">was solubilized in 20 mM EDTA, pH 4.5.</span>
        <meta itemprop="num_attr" content="0349">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the solutions</span>
        <span itemprop="definition">were combined in a T-connector at a flow rate of 400 mL/min, diluting (in-line or directly into) with PBS at pH 7.4. Ethanol was then removed and carrier buffer replaced with PBS, pH 7.4 by tangential flow ultrafilitration using Midgee hoop cartridges (MW cut off of 500K, GE Healthcare).</span>
        <meta itemprop="num_attr" content="0349">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the LNP</span>
        <span itemprop="definition">were sterile filtered (0.2  â m syringe filter) and sample concentration determined by either DENAX-HPLC or RiboGreen Assay. Particle size and polydispersity were determined using a Malvern Nano Series Zetasizer. Final lipid and steroid concentrations were determined by UPLC.</span>
        <meta itemprop="num_attr" content="0349">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">LPS</span>
        <span itemprop="definition">lipopolysaccharide</span>
        <meta itemprop="num_attr" content="0350">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">blood</span>
        <span itemprop="definition">is collected into tubes containing 50 mM EDTA via tail nicks and processed to plasma by centrifugation at 16000 â g for 5 min at 16Â° C.</span>
        <meta itemprop="num_attr" content="0351">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">terminal blood samples</span>
        <span itemprop="definition">are collected into sodium EDTA microtainer tubes and are processed to plasma using the same procedure as above. Plasma samples are analyzed by ELISA for Interleukin-6 (IL-6) and Monocyte Chemotactic Protein 1 (MCP-1) cytokine levels.</span>
        <meta itemprop="num_attr" content="0351">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">IL-6</span>
        <span itemprop="definition">Interleukin-6</span>
        <meta itemprop="num_attr" content="0351">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">MCP-1</span>
        <span itemprop="definition">Monocyte Chemotactic Protein 1</span>
        <meta itemprop="num_attr" content="0351">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the left liver lobe</span>
        <span itemprop="definition">is collected into RNAlater and assayed for ApoB levels by QuantiGene 2.0 analysis. Results are normalized to the house keeping gene GAPDH.</span>
        <meta itemprop="num_attr" content="0352">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Dexamethasone 21-palmitate</span>
        <span itemprop="definition">(Dex-P) is effectively a pro-drug of dexamethasone, requiring enzymatic action to release the steroid (Dexamethasone). This is less favorable compared to the steroid in its free form (since it requires conversion to the active form in vivo); however, dexamethasone 21-palmitate has a higher log P than free dexamethasone, facilitating better incorporation into LNP.</span>
        <meta itemprop="num_attr" content="0353">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">cytokine data</span>
        <span itemprop="definition">MCP-1</span>
        <meta itemprop="num_attr" content="0356">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the cytokine levels</span>
        <span itemprop="definition">were highest for the group treated with the Base Formulation in the absence of steroid.</span>
        <meta itemprop="num_attr" content="0356">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Co-formulating Dex-P with the LNP</span>
        <span itemprop="definition">reduced cytokine levels significantly.</span>
        <meta itemprop="num_attr" content="0356">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the cytokine levels</span>
        <span itemprop="definition">were similar between the low (0.5 mol %) and high (5 mol %) steroid doses when co-formulated in LNP, indicating a potentially saturating effect.</span>
        <meta itemprop="num_attr" content="0356">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the equivalent dose of free dexamethasone administered in a single intravenous injection</span>
        <span itemprop="definition">was 0.3 mg/kg.</span>
        <meta itemprop="num_attr" content="0356">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the cytokine levels achieved with Dex-P LNP at this dose</span>
        <span itemprop="definition">was similar to co-administering the control LNP with 0.3 mg/kg of free dexamethasone in two separate, consecutive injections.</span>
        <meta itemprop="num_attr" content="0356">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">MCP-1</span>
        <span itemprop="definition">cytokine readout</span>
        <meta itemprop="num_attr" content="0364">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Ciclesonide</span>
        <span itemprop="definition">has a log P of  â 5.3 and incorporated readily into the particle.</span>
        <meta itemprop="num_attr" content="0368">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the Ciclesonide LNP</span>
        <span itemprop="definition">were tested in the LPS-primed mouse model, and compared to the Base formulation as well as Dex-P LNP.</span>
        <meta itemprop="num_attr" content="0370">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the Ciclesonide LNP</span>
        <span itemprop="definition">also exhibited a significantly reduced inflammatory cytokine response, compared to the Base formulation.</span>
        <meta itemprop="num_attr" content="0370">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Data for a representative cytokine (MCP-1)</span>
        <span itemprop="definition">is shown in Table 15.</span>
        <meta itemprop="num_attr" content="0370">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Ciclesonide LNP</span>
        <span itemprop="definition">were also assessed in the Activity Model described in General Procedures. Like Dex-P LNP, the Ciclesonide LNP exhibited similar potency to the Base Formulation (Table 16).</span>
        <meta itemprop="num_attr" content="0371">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">LNP formulation</span>
        <span itemprop="definition">was administered to a group of four cynomolgus monkeys (Cambodian origin; 2 males, 2 females, 2-5 years of age) via a 60 minute intravenous infusion at a dose of 2.0 mg/kg total siRNA. Blood draws at pre-dose and 2, 6, and 24 h post-infusion were tested for a panel of inflammatory markers.</span>
        <meta itemprop="num_attr" content="0373">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the clobetasol LNP</span>
        <span itemprop="definition">demonstrated a significant reduction in a number of inflammatory markers, further confirming the effectiveness of this strategy.</span>
        <meta itemprop="num_attr" content="0373">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Table 18</span>
        <span itemprop="definition">compares MCP-1, IL-6, and IL-1ra (Interleukin-1 receptor antagonist) levels between the two compositions at 6 hours post-infusion.</span>
        <meta itemprop="num_attr" content="0373">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">na â ve mini-pigs</span>
        <span itemprop="definition">were surgically instrumented and baseline data was collected prior to a single administration of vehicle (saline), base LNP, or clobetasol LNP via a 60 minute intravenous infusion.</span>
        <meta itemprop="num_attr" content="0375">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">LNP formulations</span>
        <span itemprop="definition">were administered at a dose of 0.3 mg/kg total nucleic acid.</span>
        <meta itemprop="num_attr" content="0375">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a blood sample</span>
        <span itemprop="definition">was taken, processed to plasma and serum, and analyzed for cytokines and thromboxane (11-dehydrothromboxane B2). Hemodynamic data was collected continuously throughout the experiment, for a total time period of 4 hours. At 4 hours post-infusion, pigs were euthanized under anesthesia via barbiturate overdose.</span>
        <meta itemprop="num_attr" content="0375">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">LNP</span>
        <span itemprop="definition">LNP (PL-containing &amp; PL-free) were prepared by the direct dilution method described by Jeffs et al. In brief, lipid stocks were prepared in 100% ethanol at a total lipid concentration of 6-7 mg/mL. An mRNA transcript encoding Luciferase (TriLink BioTechnologies), a reporter gene, was solubilized in 40 mM EDTA, pH 4.5 at 0.366 mg/mL. Equal volumes of these solutions were combined in a T-connector at a flow rate of 250 mL/min, immediately diluting into PBS (4 â  volume of lipid stock) at pH 7.4.</span>
        <meta itemprop="num_attr" content="0378">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">TriLink BioTechnologies</span>
        <span itemprop="definition">TriLink BioTechnologies</span>
        <meta itemprop="num_attr" content="0378">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Ethanol</span>
        <span itemprop="definition">was then removed and carrier buffer was replaced with PBS by dialysis (Slide-A-Lyzer unit, MWCO 10 k), dialyzing overnight against 100 volumes of PBS. Following dialysis the formulations were concentrated to  â 0.3 mg/mL using VivaSpin concentrator units (MWCO 100,000). As with siRNA formulations, the low log P of clobetasol necessitated it being input at  â 8 â  the amount desired in the final composition, as only  â 15% incorporates in the LNP particles. The remainder is lost during dialysis. The LNP samples were sterile filtered (0.2  â m syringe filter) and sample concentration determined by RiboGreen Assay. Particle size and polydispersity were determined using a Malvern Nano Series Zetasizer. The amount of clobetasol and other lipids in the final composition was determined by UPLC and is displayed in Table 23.</span>
        <meta itemprop="num_attr" content="0378">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">mice</span>
        <span itemprop="definition">Prior to injection formulations were diluted to 0.05 mg/mL.</span>
        <meta itemprop="num_attr" content="0379">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a small amount (20  â L) of the terminal blood</span>
        <span itemprop="definition">was collected into a tube containing 5  â L of 50 mg/L heparin, while the rest of the blood was collected into sodium EDTA microtainer tubes. All of these tubes were centrifuged for 5 min at 16000 â g &amp; 16Â° C. to isolate plasma.</span>
        <meta itemprop="num_attr" content="0379">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a small portion (  â 200 mg) of the left lateral lobe of the liver</span>
        <span itemprop="definition">was collected and stored overnight in RNALater @4Â° C.</span>
        <meta itemprop="num_attr" content="0379">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the heparin plasma</span>
        <span itemprop="definition">(diluted 1:4000 with ELISA Diluent) was used in a standard Murine EPO ELISA analysis (kit from R&amp;D Systems).</span>
        <meta itemprop="num_attr" content="0380">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">kit</span>
        <span itemprop="definition">from R&amp;D Systems</span>
        <meta itemprop="num_attr" content="0380">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the incorporation of clobetasol within the mRNA-LNP</span>
        <span itemprop="definition">possibly resulted in a slight reduction in potency, though likely within the boundary of experimental variability.</span>
        <meta itemprop="num_attr" content="0380">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the regular level of EPO seen within the plasma of these mice</span>
        <span itemprop="definition">is 0.1-0.2 ng/mL. Therefore, the incorporation of clobetasol within the mRNA-LNP does not really affect the efficacy of the formulation.</span>
        <meta itemprop="num_attr" content="0380">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">EDTA plasma samples</span>
        <span itemprop="definition">were diluted (1:8) and analyzed for cytokines (MCP-1 and IL-6) by ELISA (ELISA assays and capture &amp; detection antibodies from BD Biosciences).</span>
        <meta itemprop="num_attr" content="0381">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Table 25</span>
        <span itemprop="definition">demonstrates that cytokine production is significantly reduced when clobetasol is incorporated in the formulation.</span>
        <meta itemprop="num_attr" content="0381">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the liver IFIT</span>
        <span itemprop="definition">Interferon Induced proteins with Tetratricopeptide repeats</span>
        <meta itemprop="num_attr" content="0382">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the IFIT biomarker</span>
        <span itemprop="definition">indicates a type I interferon response to the payload.</span>
        <meta itemprop="num_attr" content="0382">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Liver samples (20-25 mg)</span>
        <span itemprop="definition">were homogenized and the QuantiGene 2.0 assay (Affymetrix) used to assess IFIT levels in the liver (normalized to the housekeeping gene GAPDH). Results are plotted as a fold increase over the PBS control group, and demonstrate that clobetasol co-formulation is also effective in suppressing the IFIT response to the mRNA payload (Table 26).</span>
        <meta itemprop="num_attr" content="0382">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">This example</span>
        <span itemprop="definition">demonstrates how a steroid pro-drug, dexamethasone 21-palmitate (Dex-P), can also be used to reduce inflammatory responses to LNP bearing and mRNA payload.</span>
        <meta itemprop="num_attr" content="0384">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">An mRNA-LNP containing Dex-P</span>
        <span itemprop="definition">was formulated as described in Example 12, with the compositions described in Table 27.</span>
        <meta itemprop="num_attr" content="0384">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a murine EPO mRNA transcript</span>
        <span itemprop="definition">(TriLink BioTechnologies) was used for the payload.</span>
        <meta itemprop="num_attr" content="0384">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the heparin plasma</span>
        <span itemprop="definition">(diluted 1:4000 with ELISA Diluent) was analyzed by ELISA for EPO levels (kit from R&amp;D Systems). As shown in Table 28, the incorporation of Dex-P within the mRNA-LNP possibly resulted in an increase in potency, though possibly within experimental variability.</span>
        <meta itemprop="num_attr" content="0386">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">EDTA plasma</span>
        <span itemprop="definition">was analyzed by ELISA (BD Biosciences) for cytokine levels (MCP-1 &amp; IL-6). Table 29 demonstrates that incorporation of Dex-P into the mRNA-LNP yields a marked reduction in cytokine levels.</span>
        <meta itemprop="num_attr" content="0387">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">LNPs</span>
        <span itemprop="definition">lipid nanoparticles</span>
        <meta itemprop="num_attr" content="0389">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Most or all the phospholipid</span>
        <span itemprop="definition">was removed from LNPs to test the effect on shelf-life of LNP comprising mRNA.</span>
        <meta itemprop="num_attr" content="0389">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">certain embodiments of the present invention</span>
        <span itemprop="definition">are directed to LNPs possessing the combination of low or absent phospholipid and higher than usual PEG.</span>
        <meta itemprop="num_attr" content="0389">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the combination of low phospholipid and high mol percent PEG</span>
        <span itemprop="definition">reduces immunostimulation for mRNA more effectively than for siRNA.</span>
        <meta itemprop="num_attr" content="0389">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the amount of PEG</span>
        <span itemprop="definition">is at least 3 mole percent (e.g., at least 3.1 mole percent, at least 3.2 mole percent, at least 3.3 mole percent, at least 3.4 mole percent, at least 3.5 mole percent, at least 3.6 mole percent, at least 3.7 mole percent, at least 3.8 mole percent, at least 3.9 mole percent, at least 4 mole percent).</span>
        <meta itemprop="num_attr" content="0390">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">no phospholipid</span>
        <span itemprop="definition">is used in the practice of the invention.</span>
        <meta itemprop="num_attr" content="0390">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the lipid particle</span>
        <span itemprop="definition">comprises less than 2 mole percent phospholipid, e.g., 1.9 mol % phospholipid, 1.8 mol % phospholipid, 1.7 mol % phospholipid, 1.6 mol % phospholipid, 1.5 mol % phospholipid, 1.4 mol % phospholipid, 1.3 mol % phospholipid, 1.2 mol % phospholipid, 1.1 mol % phospholipid, 1.0 mol % phospholipid, 0.9 mol % phospholipid, 0.8 mol % phospholipid, 0.7 mol % phospholipid, 0.6 mol % phospholipid, 0.5 mol % phospholipid, 0.4 mol % phospholipid, 0.3 mol % phospholipid, 0.2 mol % phospholipid, 0.1 mol % phospholipid, or 0.0% phospholipid, e.g., less than 1.9 mol % phospholipid, less than 1.8 mol % phospholipid, less than</span>
        <meta itemprop="num_attr" content="0390">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">LNP formulations</span>
        <span itemprop="definition">were prepared by the LipoMixer method described by Jeffs et al, using either direct dilution or in-line dilution. Lipid compositions were as described, typically comprising 3 or 4 lipids in the molar ratios described. Lipids were solubilized in 100% ethanol at a total lipid concentration of approx. 12 mg/mL. Nucleic acid was solubilized in 20 mM EDTA, pH 4.5 when phospholipid is present in the LNP and in 40 mM EDTA, pH 4.5 in the absence of phospholipid.</span>
        <meta itemprop="num_attr" content="0392">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Equal volumes of these solutions</span>
        <span itemprop="definition">were combined in a T-connector at a flow rate of 400 mL/min, immediately diluting (in-line or directly into) with PBS (4 â  volume of lipid stock) at pH 7.4. Ethanol was then removed and carrier buffer was replaced with PBS by either dialysis (Slide-A-Lyzer unit, MWCO 10 k) or tangential flow ultrafilitration using Midgee hoop cartridges (MWCO 500 k, GE Healthcare).</span>
        <meta itemprop="num_attr" content="0392">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the LNP samples</span>
        <span itemprop="definition">were sterile filtered (0.2  â m syringe filter) and sample concentration determined by either DENAX-HPLC or RiboGreen Assay. Particle size and polydispersity were determined using a Malvern Nano Series Zetasizer. Final lipid were determined by UPLC.</span>
        <meta itemprop="num_attr" content="0392">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">LPS</span>
        <span itemprop="definition">lipopolysaccharide</span>
        <meta itemprop="num_attr" content="0395">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">blood</span>
        <span itemprop="definition">is collected into tubes containing 50 mM EDTA via tail nicks and processed to plasma by centrifugation at 16000 â g for 5 min at 16Â° C.</span>
        <meta itemprop="num_attr" content="0397">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">terminal blood samples</span>
        <span itemprop="definition">are collected into sodium EDTA microtainer tubes and are processed to plasma using the same procedure as above. Plasma samples are analyzed by ELISA for IL-6 and MCP-1 cytokine levels.</span>
        <meta itemprop="num_attr" content="0397">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">LNP</span>
        <span itemprop="definition">formulated with a siRNA targeting Apolipoprotein B.</span>
        <meta itemprop="num_attr" content="0399">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Terminal time point</span>
        <span itemprop="definition">is at 48 hours post-intravenous administration of LNP.</span>
        <meta itemprop="num_attr" content="0399">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the left liver lobe</span>
        <span itemprop="definition">is collected into RNAlater and assayed for ApoB levels by QuantiGene 2.0 analysis. Results are normalized to the house keeping gene GAPDH, and expressed as a % of the PBS control.</span>
        <meta itemprop="num_attr" content="0399">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a group with an ApoB readout that is â20% of PBSâ</span>
        <span itemprop="definition">has experienced more profound gene silencing activity than one with â80% of PBSâ.</span>
        <meta itemprop="num_attr" content="0399">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Two LNP formulations</span>
        <span itemprop="definition">were made with an oligonucleotide siRNA payload targeting Apolipoprotein B (ApoB).</span>
        <meta itemprop="num_attr" content="0400">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Composition details</span>
        <span itemprop="definition">are outlined in Table 30.</span>
        <meta itemprop="num_attr" content="0400">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">This example</span>
        <span itemprop="definition">demonstrates how a reduction in mRNA-LNP immune stimulation can be achieved by removing the phospholipid from the LNP composition (i.e. production of a PL-free mRNA-LNP).</span>
        <meta itemprop="num_attr" content="0406">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the mRNA-LNP formulations</span>
        <span itemprop="definition">were made with the lipid compositions shown in Table 41.</span>
        <meta itemprop="num_attr" content="0406">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Two different base formulations</span>
        <span itemprop="definition">(1.1:55 and 1.6:55) had their phospholipid content removed (âPL-freeâ compositions), whilst either maintaining or slightly increasing the cholesterol content.</span>
        <meta itemprop="num_attr" content="0406">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">LNP</span>
        <span itemprop="definition">Prior to injection, LNP were diluted to 0.05 mg/mL.</span>
        <meta itemprop="num_attr" content="0408">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">livers</span>
        <span itemprop="definition">were homogenized in 1 â  Cell Culture Lysis Reagent (CCLR) buffer, then analyzed for luciferase activity using the Luciferase Assay (Promega). As seen in Table 42, there is no detrimental effect on potency when phospholipid was removed from the compositions.</span>
        <meta itemprop="num_attr" content="0409">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">CCLR</span>
        <span itemprop="definition">Cell Culture Lysis Reagent</span>
        <meta itemprop="num_attr" content="0409">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Example 17</span>
        <span itemprop="definition">was further corroborated with a subset of the compositions formulated with two different mRNA transcripts, mLuc (Table 44a) &amp; mEPO (Table 44b).</span>
        <meta itemprop="num_attr" content="0412">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Transcripts used</span>
        <span itemprop="definition">encoded either luciferase (reporter gene) or erythropoietin (a hormone that controls erythropoiesis, or red blood cell production).</span>
        <meta itemprop="num_attr" content="0412">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the mRNA-LNP</span>
        <span itemprop="definition">were prepared as described in Example 17.</span>
        <meta itemprop="num_attr" content="0413">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Female Balb/C (n</span>
        <span itemprop="definition">4) received a 0.5 mg/kg (mRNA) intravenous dose of LNP.</span>
        <meta itemprop="num_attr" content="0413">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a small amount (75  â L) of the terminal blood</span>
        <span itemprop="definition">was collected into a tube containing 18.8  â L of 50 mg/L heparin, while the rest of the blood was collected into sodium EDTA microtainer tubes. All of these tubes were centrifuged for 5 min at 16000 â g &amp; 16Â° C. and plasma was isolated. Also, part of the liver was collected into FastPrep tubes which were placed at  â 80Â° C. until analysis.</span>
        <meta itemprop="num_attr" content="0413">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the livers</span>
        <span itemprop="definition">were homogenized in 1 â CCLR buffer and were analyzed for luciferase activity using the Luciferase Assay (Promega).</span>
        <meta itemprop="num_attr" content="0414">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the efficacy of the PL-free mRNA-LNP formulations</span>
        <span itemprop="definition">are similar to those of the Base (PL-containing) formulation.</span>
        <meta itemprop="num_attr" content="0414">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the heparin plasma</span>
        <span itemprop="definition">(diluted 1:4000 with ELISA Diluent) was used in a standard Murine EPO ELISA analysis (R&amp;D Systems).</span>
        <meta itemprop="num_attr" content="0415">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the efficacy trend for the mEPO-LNP</span>
        <span itemprop="definition">was similar to that seen with the mLuc-LNP where the efficacies of the PL-free Luc mRNA-LNP are similar to those of the Base (PL-containing) formulation.</span>
        <meta itemprop="num_attr" content="0415">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">ketamine/xylazine</span>
        <span itemprop="definition">was euthanized with ketamine/xylazine.</span>
        <meta itemprop="num_attr" content="0421">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the animals</span>
        <span itemprop="definition">were euthanized with a lethal dose of ketamine/xylazine.</span>
        <meta itemprop="num_attr" content="0421">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a small amount (20  â L) of the terminal blood</span>
        <span itemprop="definition">was collected into a tube containing 5  â L of 50 mg/L heparin, while the rest of the blood was collected into sodium EDTA microtainer tubes. Tubes were centrifuged for 5 min at 16000 â g &amp; 16Â° C. and to isolate plasma.</span>
        <meta itemprop="num_attr" content="0421">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Heparin plasma analyzed by ELISA (kit from R&amp;D Systems) for EPO concentrations</span>
        <span itemprop="definition">As seen in Table 51, at all the time points the efficacy of the PL-containing mRNA-LNP and the 3.3:55 PL-free formulation are equivalent.</span>
        <meta itemprop="num_attr" content="0422">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Plasma samples</span>
        <span itemprop="definition">were analyzed by ELISA for cytokines MCP-1 and IL-6 (ELISA assays and capture/detection antibodies from BD Biosciences). Results in Table 52 corroborate the data in Example 19, and show again how the inflammatory response to the high PEG, PL-free LNP compositions is markedly reduced compared to the Base composition.</span>
        <meta itemprop="num_attr" content="0423">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">This example</span>
        <span itemprop="definition">demonstrates how a reduction in mRNA-LNP immune stimulation can be achieved by replacing regular silica membrane purified mRNA with Reverse Phase (RP) HPLC-purified mRNA in LNP.</span>
        <meta itemprop="num_attr" content="0425">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">RP</span>
        <span itemprop="definition">Reverse Phase</span>
        <meta itemprop="num_attr" content="0425">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">EPO</span>
        <span itemprop="definition">Murine erythropoietin</span>
        <meta itemprop="num_attr" content="0425">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">mRNA purified by either method</span>
        <span itemprop="definition">was formulated in LNP and injected via the iv route into Balb/C mice. Four hours following injection the animals were sacrificed and plasma &amp; liver tissue were analyzed for efficacy and immune stimulation.</span>
        <meta itemprop="num_attr" content="0425">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">LNP</span>
        <span itemprop="definition">were prepared by the regular LipoMixer technology.</span>
        <meta itemprop="num_attr" content="0426">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a 7.36 mg/mL lipid solution in 100% ethanol</span>
        <span itemprop="definition">was prepared containing the lipids DSPC:Chol:PEG 2000 -C-DMA:Compound 13 in the following molar ratios: 10.9:32.8:1.64:54.6, mol %.</span>
        <meta itemprop="num_attr" content="0426">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the mRNA payload</span>
        <span itemprop="definition">was solubilized in 40 mM EDTA (pH 4.5) at a concentration of 0.366 mg/mL.</span>
        <meta itemprop="num_attr" content="0426">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Equal volumes of each solution (1.6 mL)</span>
        <span itemprop="definition">were blended at 250 mL/min through a T-connector using the Direct Dilution method described by Jeffs et al.</span>
        <meta itemprop="num_attr" content="0426">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the resulting mixture</span>
        <span itemprop="definition">was subsequently collected directly into a tube containing  â 4 volumes (5.9 mL) of PBS, pH 7.4. These formulations were placed in Slide-A-Lyzer dialysis units (MWCO 10,000) and were dialyzed overnight against 100 volumes of PBS, pH 7.4. Following dialysis the formulations were concentrated to  â 0.6 mg/mL using VivaSpin concentrator units (MWCO 100,000).</span>
        <meta itemprop="num_attr" content="0426">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">EPO</span>
        <span itemprop="definition">mouse erythropoietin</span>
        <meta itemprop="num_attr" content="0427">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Each animal</span>
        <span itemprop="definition">received a dose corresponding to 0.5 mg/kg mRNA.</span>
        <meta itemprop="num_attr" content="0427">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Four hours following injection</span>
        <span itemprop="definition">the animals were euthanized with a lethal dose of ketamine/xylazine.</span>
        <meta itemprop="num_attr" content="0427">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a small amount (20  â L) of the terminal blood</span>
        <span itemprop="definition">was collected into a tube containing 5  â L of 50 mg/L heparin, while the rest of the blood was collected into Na EDTA microtainer tubes. All tubes were centrifuged for 5 min at 16000 â g &amp; 16Â° C. to isolate plasma.</span>
        <meta itemprop="num_attr" content="0427">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Half of the left lateral lobe</span>
        <span itemprop="definition">was collected into 1.5 mL of RNALater and stored at 4Â° C. for at least 16</span>
        <meta itemprop="num_attr" content="0427">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the heparin plasma</span>
        <span itemprop="definition">(diluted 1:4000 with ELISA Diluent) was used in a standard Murine EPO ELISA analysis (kit from R&amp;D Systems).</span>
        <meta itemprop="num_attr" content="0428">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the efficacy of the LNP containing the highly (HPLC) purified EPO mRNA</span>
        <span itemprop="definition">is very similar to that of the regular (Silica Membrane) purified EPO mRNA.</span>
        <meta itemprop="num_attr" content="0428">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the regular level of EPO seen within the plasma of mice treated with PBS</span>
        <span itemprop="definition">is 100-200 pg/mL. Therefore, regardless of the purity of the EPO mRNA incorporated the level of liver gene expression of EPO from the encapsulated mEPO is extremely high.</span>
        <meta itemprop="num_attr" content="0428">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the fold increase of IFIT mRNA within the livers for the LNP treated animals (over the PBS treated animals)</span>
        <span itemprop="definition">was determined. This is one example of an assay the art worker can use to assess the the level of immune stimulation caused by mRNA-LNP.</span>
        <meta itemprop="num_attr" content="0429">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the HPLC-purified mRNA-LNP</span>
        <span itemprop="definition">induces significantly less immune stimulation than a control, which in certain embodiments is characterized by the IFIT response.</span>
        <meta itemprop="num_attr" content="0429">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">IFIT1 mRNA induction in both liver and spleen</span>
        <span itemprop="definition">can be observed in mice treated with LNP bearing nucleic acids, even in the absence of detectable plasma IFN protein. This likely reflects local IFN induction that does not manifest as a systemic cytokine response.</span>
        <meta itemprop="num_attr" content="0429">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">IFIT1 assay</span>
        <span itemprop="definition">the amount of IFIT1 mRNA in hepatocytes was quantified and normalized to mRNA levels of a housekeeping gene (usually GAPD), which typically remains constant.</span>
        <meta itemprop="num_attr" content="0429">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">GAPD</span>
        <span itemprop="definition">housekeeping gene</span>
        <meta itemprop="num_attr" content="0429">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the lipid nanoparticle formulation having HPLC-purified mRNA</span>
        <span itemprop="definition">has an IFIT response that is no more than 30 fold greater than a reference IFIT response of phosphate buffered saline. In certain embodiments, the lipid nanoparticle formulation having HPLC-purified mRNA has an IFIT response that is no more than 10 or 20 or 30 or 40 or 50 or 60 or 70 or 80 or 90 or 100 fold greater than a reference IFIT response of phosphate buffered saline.</span>
        <meta itemprop="num_attr" content="0430">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">cytokine</span>
        <span itemprop="definition">MCP-1 and IL-6 ELISA assays.</span>
        <meta itemprop="num_attr" content="0431">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Plasma</span>
        <span itemprop="definition">was diluted (1:8 or 1:80) in ELISA diluent and was analyzed for levels of MCP-1 &amp; IL-6 presence using ELISA assays with capture &amp; detection antibodies from BD Biosciences.</span>
        <meta itemprop="num_attr" content="0431">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the level of MCP-1</span>
        <span itemprop="definition">is dramatically reduced (37106 pg/mL down to 105 pg/mL) with the incorporation of the HPLC purified mRNA.</span>
        <meta itemprop="num_attr" content="0431">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">another cytokine</span>
        <span itemprop="definition">IL-6 is also dramatically reduced (4805 pg/mL reduced to 22 pg/mL) when using the HPLC purified mRNA. Results are shown in Table 55.</span>
        <meta itemprop="num_attr" content="0431">
      </li>
    </ul>
  </section>

  <section>
    <h2>Landscapes</h2>
    <ul>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Health &amp; Medical Sciences</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Life Sciences &amp; Earth Sciences</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Chemical &amp; Material Sciences</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Engineering &amp; Computer Science</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">General Health &amp; Medical Sciences</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Pharmacology &amp; Pharmacy</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Medicinal Chemistry</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Veterinary Medicine</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Animal Behavior &amp; Ethology</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Public Health</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Epidemiology</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Bioinformatics &amp; Cheminformatics</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Molecular Biology</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Biomedical Technology</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Genetics &amp; Genomics</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Biotechnology</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Biochemistry</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Nanotechnology</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Biophysics</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">General Engineering &amp; Computer Science</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Organic Chemistry</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Physics &amp; Mathematics</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Zoology</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Wood Science &amp; Technology</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Dispersion Chemistry</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Plant Pathology</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Microbiology</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Optics &amp; Photonics</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Dermatology</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Medical Informatics</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Crystallography &amp; Structural Chemistry</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">General Chemical &amp; Material Sciences</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Chemical Kinetics &amp; Catalysis</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Nuclear Medicine, Radiotherapy &amp; Molecular Imaging</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Pharmaceuticals Containing Other Organic And Inorganic Compounds</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Medicines That Contain Protein Lipid Enzymes And Other Medicines</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Medicinal Preparation</span>
        (<span itemprop="type">AREA</span>)
      </li>
    </ul>
  </section>


  <section itemprop="abstract" itemscope>
    <h2>Abstract</h2>
    
    <div itemprop="content" html><abstract mxw-id="PA305886881" lang="EN" source="national office" load-source="docdb">
    <div class="abstract">The present invention provides compositions comprising nucleic acid molecules, such as mRNA molecules, encapsulated within lipid particles. The compositions are useful, for example, to introduce the mRNA molecules into a human subject where they are translated to produce a polypeptide that functions to ameliorate one or more symptoms of a disease.</div>
  </abstract>
  </div>
  </section>

  <section itemprop="description" itemscope>
    <h2>Description</h2>
    
    <div itemprop="content" html><ul mxw-id="PDES198164695" lang="EN" load-source="patent-office" class="description">
    
    <heading id="h-0001">CROSS-REFERENCE TO RELATED APPLICATIONS</heading>
    <li> <para-num num="[0001]"> </para-num> <div id="p-0002" num="0001" class="description-line">This patent application claims the benefit of priority of U.S. application Ser. No. 62/357,189, filed Jun. 30, 2016, and of U.S. application Ser. No. 62/375,292, filed Aug. 15, 2016, which applications are herein incorporated by reference.</div>
    
    
    </li> <heading id="h-0002">BACKGROUND</heading>
    <li> <para-num num="[0002]"> </para-num> <div id="p-0003" num="0002" class="description-line">Some diseases in humans are caused by the absence, or impairment, of a functional protein in a cell type where the protein is normally present and active. The functional protein can be completely or partially absent due, for example, to transcriptional inactivity of the encoding gene, or due to the presence of a mutation in the encoding gene that renders the protein completely or partially non-functional.</div>
    </li> <li> <para-num num="[0003]"> </para-num> <div id="p-0004" num="0003" class="description-line">Examples of human diseases that are caused by complete or partial inactivation of a protein include X-linked severe combined immunodeficiency (X-SCID), and adrenoleukodystrophy (X-ALD). X-SCID is caused by one or more mutations in the gene encoding the common gamma chain protein that is a component of the receptors for several interleukins that are involved in the development and maturation of B and T cells within the immune system. X-ALD is caused by one or more mutations in a peroxisomal membrane transporter protein gene called ABCD1. Individuals afflicted with X-ALD have very high levels of long chain fatty acids in tissues throughout the body, which causes a variety of symptoms that may lead to mental impairment or death.</div>
    </li> <li> <para-num num="[0004]"> </para-num> <div id="p-0005" num="0004" class="description-line">Attempts have been made to use gene therapy to treat some diseases caused by the absence, or impairment, of a functional protein in a cell type where the protein is normally present and active. Gene therapy typically involves introduction of a vector that includes a gene encoding a functional form of the affected protein, into a diseased person, and expression of the functional protein to treat the disease. Thus far, gene therapy has met with limited success.</div>
    </li> <li> <para-num num="[0005]"> </para-num> <div id="p-0006" num="0005" class="description-line">As such, there is a continuing need for compositions and methods for expressing a functional form of a protein within a human who suffers from a disease caused by the complete or partial absence of the functional protein, and there is a need for delivery of nucleic acids (e.g., mRNA) via a methods and compositions that trigger less of an immune response to the therapy.</div>
    </li> <heading id="h-0003">BRIEF SUMMARY</heading>
    <li> <para-num num="[0006]"> </para-num> <div id="p-0007" num="0006" class="description-line">In accordance with the foregoing, the present invention provides in certain embodiments compositions and methods that can be used to deliver nucleic acids, e.g., so as to express one or more mRNA molecules in a living cell (e.g., cells within a human body). The mRNA molecules can encode one or more polypeptides that is/are expressed within the living cells. In some embodiments, the polypeptides are expressed within a diseased organism (e.g., mammal, such as a human being), and expression of the polypeptide ameliorates one or more symptoms of the disease. The compositions and methods of certain embodiments of the invention are particularly useful for treating human diseases caused by the absence, or reduced levels, of a functional polypeptide within the human body.</div>
    </li> <li> <para-num num="[0007]"> </para-num> <div id="p-0008" num="0007" class="description-line">In one aspect, the present invention provides a lipid nanoparticle (LNP) comprising: (a) a cationic lipid; (b) a non-cationic lipid; (c) a corticosteroid and; (d) a nucleic acid, wherein the nucleic acid and the corticosteroid are encapsulated within the lipid nanoparticle. Certain embodiments of the invention provide a population of lipid nanoparticles comprising the lipid nanoparticles. Certain embodiments of the invention provide a population of lipid particles comprising a multiplicity of lipid nanoparticles. In certain embodiments, the nucleic acid is HPLC-purified mRNA. In certain embodiments, the LNP comprises a PEG-lipid conjugate present in an amount of at least 3 mole percent. In certain embodiments, the LNP comprises less than 0.5 mole percent phospholipid.</div>
    </li> <li> <para-num num="[0008]"> </para-num> <div id="p-0009" num="0008" class="description-line">Certain embodiments of the invention provide a population of lipid nanoparticles, comprising at least one population of lipid nanoparticle selected from: (a) a first population of lipid nanoparticles that each comprise a cationic lipid, a non-cationic lipid, and a corticosteroid; and (b) a second population of lipid nanoparticles that each comprise a cationic lipid, a non-cationic lipid, and a nucleic acid, wherein the first population of lipid nanoparticles does not comprise a nucleic acid, and wherein the second population of lipid nanoparticles does not comprise a corticosteroid. Certain embodiments of the invention provide a population of lipid nanoparticles comprising the first and second populations of lipid nanoparticles. In certain embodiments, the nucleic acid is HPLC-purified mRNA.</div>
    </li> <li> <para-num num="[0009]"> </para-num> <div id="p-0010" num="0009" class="description-line">Certain embodiments of the invention provide a lipid nanoparticle comprising: (a) a cationic lipid; (b) a PEG-lipid conjugate present in an amount of at least 3 mole percent; and (c) mRNA encapsulated within the lipid particle; provided that the lipid particle comprises less than 0.5 mole percent phospholipid. In certain embodiments, the LNP comprises a corticosteroid. In certain embodiments, the mRNA is HPLC-purified mRNA.</div>
    </li> <li> <para-num num="[0010]"> </para-num> <div id="p-0011" num="0010" class="description-line">Certain embodiments provide a population of lipid nanoparticles wherein each lipid nanoparticle in the population comprises: (a) a cationic lipid; (b) a PEG-lipid conjugate present in an amount of at least 3 mole percent; and (c) mRNA encapsulated within the lipid nanoparticle; provided that the lipid nanoparticle comprises less than 0.5 mole percent phospholipid. In certain embodiments, the population of LNPs comprises LNPs that comprise a corticosteroid. In certain embodiments, the mRNA is HPLC-purified mRNA.</div>
    </li> <li> <para-num num="[0011]"> </para-num> <div id="p-0012" num="0011" class="description-line">Certain embodiments of the invention provide a lipid nanoparticle formulation comprising a multiplicity of lipid nanoparticles, wherein each lipid nanoparticle comprises: (a) a cationic lipid; (b) a non-cationic lipid; and (c) mRNA encapsulated within the lipid particle, wherein the lipid nanoparticle formulation has an IFIT response that is no more than 30 fold greater than a reference IFIT response of phosphate buffered saline. In certain embodiments, the mRNA is HPLC-purified mRNA. In certain embodiments, the LNP comprises a PEG-lipid conjugate present in an amount of at least 3 mole percent. In certain embodiments, the LNP comprises less than 0.5 mole percent phospholipid. In certain embodiments, the LNP comprises a corticosteroid.</div>
    </li> <li> <para-num num="[0012]"> </para-num> <div id="p-0013" num="0012" class="description-line">Certain embodiments of the invention provide a method of making a lipid nanoparticle, comprising combining: (a) a cationic lipid; (b) a non-cationic lipid; and (c) purified mRNA so as to form a lipid nanoparticle, wherein the mRNA is encapsulated within the lipid nanoparticle, and wherein the lipid nanoparticle has an IFIT response that is no more than 30 fold greater than a reference IFIT response of phosphate buffered saline. In certain embodiments, the mRNA is HPLC-purified mRNA. In certain embodiments, the LNP comprises a PEG-lipid conjugate present in an amount of at least 3 mole percent. In certain embodiments, the LNP comprises less than 0.5 mole percent phospholipid. In certain embodiments, the LNP comprises a corticosteroid.</div>
    </li> <li> <para-num num="[0013]"> </para-num> <div id="p-0014" num="0013" class="description-line">Certain embodiments of the invention provide a method of making a lipid nanoparticle formulation comprising a multiplicity of lipid nanoparticles, the method comprising the step of combining: (a) a cationic lipid; (b) a non-cationic lipid; and (c) purified mRNA so as to form a lipid nanoparticle formulation comprising a multiplicity of lipid nanoparticles, wherein the mRNA is encapsulated within the lipid particles in the lipid nanoparticle formulation, and wherein the lipid nanoparticle formulation has an IFIT response that is no more than 30 fold greater than a reference IFIT response of phosphate buffered saline. In certain embodiments, the LNP comprises a PEG-lipid conjugate present in an amount of at least 3 mole percent. In certain embodiments, the LNP comprises less than 0.5 mole percent phospholipid. In certain embodiments, the LNP comprises a corticosteroid.</div>
    </li> <li> <para-num num="[0014]"> </para-num> <div id="p-0015" num="0014" class="description-line">Certain embodiments of the invention provide a lipid nanoparticle formulation comprising a multiplicity of lipid nanoparticles made by a process comprising the steps of combining: (a) a cationic lipid; (b) a non-cationic lipid; and (c) purified mRNA so as to form a lipid nanoparticle formulation comprising a multiplicity of lipid nanoparticles, wherein the mRNA is encapsulated within the lipid particles in the lipid nanoparticle formulation, and wherein the lipid nanoparticle formulation has an IFIT response that is no more than 30 fold greater than a reference IFIT response of phosphate buffered saline. In certain embodiments, the LNP comprises a PEG-lipid conjugate present in an amount of at least 3 mole percent. In certain embodiments, the LNP comprises less than 0.5 mole percent phospholipid. In certain embodiments, the LNP comprises a corticosteroid.</div>
    </li> <li> <para-num num="[0015]"> </para-num> <div id="p-0016" num="0015" class="description-line">Thus, in one aspect, the present invention provides a lipid particle comprising a cationic lipid, a non-cationic lipid, and an mRNA molecule that is encapsulated within the lipid particle.</div>
    </li> <li> <para-num num="[0016]"> </para-num> <div id="p-0017" num="0016" class="description-line">The present invention also provides nucleic acid-lipid particles that each include (a) a lipid particle comprising a cationic lipid, a PEG-lipid, and a phospholipid; and (b) an mRNA molecule, wherein the mRNA molecule is encapsulated within the lipid particle. The lipid particles can optionally include cholesterol. The mRNA can be completely or partially encapsulated within the lipid particle. In some embodiments, the nucleic acid-lipid particle has a lipid:mRNA mass ratio of from about 9:1 to about 20:1. In a specific embodiment, the nucleic acid-lipid particle has a lipid:mRNA mass ratio of about 12:1. The mRNA can be chemically modified, such as by the incorporation of pseudouridine instead of uridine, and/or the incorporation of 5-methylcytidine instead of cytidine. The present invention also provides pharmaceutical compositions that include nucleic acid-lipid particles of the present invention. Typically, the pharmaceutical compositions include an excipient.</div>
    </li> <li> <para-num num="[0017]"> </para-num> <div id="p-0018" num="0017" class="description-line">In another aspect, the present invention provides methods for introducing an mRNA that encodes a protein into a cell. The methods each include the step of contacting the cell with a nucleic acid-lipid particle of the present invention (typically, a multiplicity of nucleic acid-lipid particles of the present invention) under conditions whereby the mRNA is introduced into the cell and expressed therein to produce the protein. The methods can be practiced in vivo or in vitro. For example, the cell is within a living body (e.g., a mammalian body, such as a human body), and the nucleic acid-lipid particle can be introduced into the living body by injection.</div>
    </li> <li> <para-num num="[0018]"> </para-num> <div id="p-0019" num="0018" class="description-line">In a further aspect, the present invention provides methods for treating and/or ameliorating one or more symptoms associated with a disease, in a human, caused by impaired expression of a protein in the human. The methods of this aspect of the invention include the step of administering to the human a therapeutically effective amount of a nucleic acid-lipid particle of the present invention (typically, a multiplicity of nucleic acid-lipid particles of the present invention), wherein the mRNA encapsulated within the nucleic acid-lipid particle encodes the protein. The encoded protein is expressed within the human being, thereby ameliorating at least one symptom of the disease.</div>
    </li> <li> <para-num num="[0019]"> </para-num> <div id="p-0020" num="0019" class="description-line">In one embodiment, the ratio of lipid to nucleic acid (e.g., mRNA) in the lipid particles used in the practice of the present invention is about 13:1.</div>
    </li> <li> <para-num num="[0020]"> </para-num> <div id="p-0021" num="0020" class="description-line">The methods and compositions of the invention can be used, for example, to treat any disease that is caused, at least in part, by the absence of a polypeptide, or the reduced level of a polypeptide, or the expression of a non-functional (or partially functional, or aberrantly functional) form of a polypeptide, in a cell, tissue, and/or organ of a human body.</div>
    </li> <li> <para-num num="[0021]"> </para-num> <div id="p-0022" num="0021" class="description-line">Other objects, features, and advantages of the present invention will be apparent to one of skill in the art from the following detailed description and figures.</div>
    
    
    </li> <heading id="h-0004">DETAILED DESCRIPTION</heading>
    <li> <para-num num="[0022]"> </para-num> <div id="p-0023" num="0022" class="description-line">The nucleic acid-lipid particles, methods, and pharmaceutical formulations, described herein advantageously provide significant new compositions and methods for expressing proteins in a mammalian organism, such as a human being. Embodiments of the present invention can be administered, for example, once per day, once per week, or once every several weeks (e.g., once every two, three, four, five or six weeks), or once per month, or once per year. Encapsulation of mRNA within lipid particles confers one or more advantages, such as protecting the mRNA from nuclease degradation in the bloodstream, allowing preferential accumulation of the mRNA in target tissue and providing a means of mRNA entry into the cellular cytoplasm where the mRNA can express the encoded protein.</div>
    </li> <li> <para-num num="[0023]"> </para-num> <div id="p-0024" num="0023" class="description-line">In one aspect, the present invention provides a lipid nanoparticle comprising: (a) a cationic lipid; (b) a non-cationic lipid; (c) a corticosteroid and; (d) a nucleic acid, wherein the nucleic acid and the corticosteroid are encapsulated within the lipid nanoparticle. Certain embodiments of the invention provide a population of lipid nanoparticles comprising the lipid nanoparticles. Certain embodiments of the invention provide a population of lipid particles comprising a multiplicity of lipid nanoparticles. In certain embodiments, the nucleic acid is HPLC-purified mRNA. In certain embodiments, the LNP comprises a PEG-lipid conjugate present in an amount of at least 3 mole percent. In certain embodiments, the LNP comprises less than 0.5 mole percent phospholipid.</div>
    </li> <li> <para-num num="[0024]"> </para-num> <div id="p-0025" num="0024" class="description-line">Certain embodiments of the invention provide a population of lipid nanoparticles, comprising at least one population of lipid nanoparticles selected from: (a) a first population of lipid nanoparticles that each comprise a cationic lipid, a non-cationic lipid, and a corticosteroid; and (b) a second population of lipid nanoparticles that each comprise a cationic lipid, a non-cationic lipid, and a nucleic acid, wherein the first population of lipid nanoparticles does not comprise a nucleic acid, and wherein the second population of lipid nanoparticles does not comprise a corticosteroid. Certain embodiments of the invention provide a population of lipid nanoparticles comprising the first and second populations of lipid nanoparticles. In certain embodiments, the nucleic acid is HPLC-purified mRNA.</div>
    </li> <li> <para-num num="[0025]"> </para-num> <div id="p-0026" num="0025" class="description-line">Certain embodiments of the invention provide a lipid nanoparticle comprising: (a) a cationic lipid; (b) a PEG-lipid conjugate present in an amount of at least 3 mole percent; and (c) mRNA encapsulated within the lipid particle; provided that the lipid particle comprises less than 0.5 mole percent phospholipid. In certain embodiments, the LNP comprises a corticosteroid. In certain embodiments, the mRNA is HPLC-purified mRNA.</div>
    </li> <li> <para-num num="[0026]"> </para-num> <div id="p-0027" num="0026" class="description-line">Certain embodiments provide a population of lipid nanoparticles wherein each lipid nanoparticle in the population comprises: (a) a cationic lipid; (b) a PEG-lipid conjugate present in an amount of at least 3 mole percent; and (c) mRNA encapsulated within the lipid nanoparticle; provided that the lipid nanoparticle comprises less than 0.5 mole percent phospholipid. In certain embodiments, the population of LNPs comprises LNPs that comprise a corticosteroid. In certain embodiments, the mRNA is HPLC-purified mRNA.</div>
    </li> <li> <para-num num="[0027]"> </para-num> <div id="p-0028" num="0027" class="description-line">Certain embodiments of the invention provide a lipid nanoparticle formulation comprising a multiplicity of lipid nanoparticles, wherein each lipid nanoparticle comprises: (a) a cationic lipid; (b) a non-cationic lipid; and (c) mRNA encapsulated within the lipid particle, wherein the lipid nanoparticle formulation has an IFIT response that is no more than 30 fold greater than a reference IFIT response of phosphate buffered saline. In certain embodiments, the mRNA is purified mRNA. In certain embodiments, the mRNA is HPLC-purified mRNA. In certain embodiments, the LNP comprises a PEG-lipid conjugate present in an amount of at least 3 mole percent. In certain embodiments, the LNP comprises a PEG-lipid conjugate present in an amount of at least 3.5 mole percent. In certain embodiments, the LNP comprises less than 0.5 mole percent phospholipid. In certain embodiments, the LNP comprises less than 0.05 mole percent phospholipid. In certain embodiments, the LNP comprises a corticosteroid. In certain embodiments, substantially all of the lipid nanoparticles in the formulation comprise a corticosteroid encapsulated within the lipid nanoparticle. For example, in certain embodiments, at least about 80% of the lipid nanoparticles in the formulation further comprise a corticosteroid encapsulated within the lipid nanoparticle. In certain embodiments, at least about 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% of the lipid nanoparticles in the formulation further comprise a corticosteroid encapsulated within the lipid nanoparticle.</div>
    </li> <li> <para-num num="[0028]"> </para-num> <div id="p-0029" num="0028" class="description-line">Certain embodiments of the invention provide a lipid nanoparticle formulation comprising a multiplicity of lipid nanoparticles, wherein each lipid nanoparticle comprises: (a) a cationic lipid; (b) a non-cationic lipid; and (c) mRNA encapsulated within the lipid particle, wherein the lipid nanoparticle formulation has an IFIT response that is no more than 30 fold greater than a reference IFIT response of phosphate buffered saline, wherein the non-cationic lipid is a PEG-lipid conjugate present in an amount of at least 3 mole percent, provided that the lipid nanoparticle comprises less than 0.5 mole percent phospholipid, and wherein at least 90% of the lipid nanoparticles in the formulation further comprise a corticosteroid encapsulated within the lipid nanoparticle.</div>
    </li> <li> <para-num num="[0029]"> </para-num> <div id="p-0030" num="0029" class="description-line">Certain embodiments of the invention provide a lipid nanoparticle formulation comprising:</div>
    </li> <li> <para-num num="[0030]"> </para-num> <div id="p-0031" num="0030" class="description-line">(a) a first population of lipid nanoparticles that each comprise a cationic lipid, a non-cationic lipid, and a corticosteroid encapsulated with the lipid nanoparticle; and</div>
    </li> <li> <para-num num="[0031]"> </para-num> <div id="p-0032" num="0031" class="description-line">(b) a second population of lipid nanoparticles that each comprise a cationic lipid, a non-cationic lipid, and a mRNA encapsulated within the lipid nanoparticle,</div>
    </li> <li> <para-num num="[0032]"> </para-num> <div id="p-0033" num="0032" class="description-line">wherein the first population of lipid nanoparticles does not comprise a mRNA, wherein the second population of lipid nanoparticles does not comprise a corticosteroid, and wherein the lipid nanoparticle formulation has an IFIT response that is no more than 30 fold greater than a reference IFIT response of phosphate buffered saline.</div>
    </li> <li> <para-num num="[0033]"> </para-num> <div id="p-0034" num="0033" class="description-line">Certain embodiments of the invention provide a method of making a lipid nanoparticle, comprising combining: (a) a cationic lipid; (b) a non-cationic lipid; and (c) purified mRNA so as to form a lipid nanoparticle, wherein the mRNA is encapsulated within the lipid nanoparticle, and wherein the lipid nanoparticle has an IFIT response that is no more than 30 fold greater than a reference IFIT response of phosphate buffered saline. In certain embodiments, the mRNA is HPLC-purified mRNA. In certain embodiments, the LNP comprises a PEG-lipid conjugate present in an amount of at least 3 mole percent. In certain embodiments, the LNP comprises less than 0.5 mole percent phospholipid. In certain embodiments, the LNP comprises a corticosteroid. In certain embodiments, the method further comprises purifying mRNA to provide the purified mRNA.</div>
    </li> <li> <para-num num="[0034]"> </para-num> <div id="p-0035" num="0034" class="description-line">Certain embodiments of the invention provide a method of making a lipid nanoparticle formulation comprising a multiplicity of lipid nanoparticles, the method comprising the step of combining: (a) a cationic lipid; (b) a non-cationic lipid; and (c) purified mRNA so as to form a lipid nanoparticle formulation comprising a multiplicity of lipid nanoparticles, wherein the mRNA is encapsulated within the lipid particles in the lipid nanoparticle formulation, and wherein the lipid nanoparticle formulation has an IFIT response that is no more than 30 fold greater than a reference IFIT response of phosphate buffered saline. In certain embodiments, the LNP comprises a PEG-lipid conjugate present in an amount of at least 3 mole percent. In certain embodiments, the LNP comprises less than 0.5 mole percent phospholipid. In certain embodiments, the LNP comprises a corticosteroid. In certain embodiments, the method further comprises purifying mRNA (e.g., via HPLC) to provide the purified mRNA.</div>
    </li> <li> <para-num num="[0035]"> </para-num> <div id="p-0036" num="0035" class="description-line">Certain embodiments of the invention provide a lipid nanoparticle formulation comprising a multiplicity of lipid nanoparticles made by a process comprising the steps of combining: (a) a cationic lipid; (b) a non-cationic lipid; and (c) purified mRNA so as to form a lipid nanoparticle formulation comprising a multiplicity of lipid nanoparticles, wherein the mRNA is encapsulated within the lipid particles in the lipid nanoparticle formulation, and wherein the lipid nanoparticle formulation has an IFIT response that is no more than 30 fold greater than a reference IFIT response of phosphate buffered saline. In certain embodiments, the LNP comprises a PEG-lipid conjugate present in an amount of at least 3 mole percent. In certain embodiments, the LNP comprises less than 0.5 mole percent phospholipid. In certain embodiments, the LNP comprises a corticosteroid. In certain embodiments, the method further comprises purifying mRNA (e.g., via HPLC) to provide the purified mRNA.</div>
    </li> <li> <para-num num="[0036]"> </para-num> <div id="p-0037" num="0036" class="description-line">In certain embodiments, the nucleic acid is mRNA.</div>
    </li> <li> <para-num num="[0037]"> </para-num> <div id="p-0038" num="0037" class="description-line">In certain embodiments, the nucleic acid is purified mRNA.</div>
    </li> <li> <para-num num="[0038]"> </para-num> <div id="p-0039" num="0038" class="description-line">In certain embodiments, the mRNA is HPLC-purified mRNA.</div>
    </li> <li> <para-num num="[0039]"> </para-num> <div id="p-0040" num="0039" class="description-line">In certain embodiments, the corticosteroid has a log P greater than 3.0.</div>
    </li> <li> <para-num num="[0040]"> </para-num> <div id="p-0041" num="0040" class="description-line">In certain embodiments, substantially all lipid nanoparticles in a formulation/population comprise a corticosteroid encapsulated within the lipid nanoparticle. For example, in certain embodiments, at least about 80% of the lipid nanoparticles in a formulation/population further comprise a corticosteroid encapsulated within the lipid nanoparticle. In certain embodiments, at least about 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% of the lipid nanoparticles in the formulation/population further comprise a corticosteroid encapsulated within the lipid nanoparticle.</div>
    </li> <li> <para-num num="[0041]"> </para-num> <div id="p-0042" num="0041" class="description-line">In certain embodiments, the corticosteroid is a glucocorticoid.</div>
    </li> <li> <para-num num="[0042]"> </para-num> <div id="p-0043" num="0042" class="description-line">In certain embodiments, the corticosteroid is a mineralocorticoid.</div>
    </li> <li> <para-num num="[0043]"> </para-num> <div id="p-0044" num="0043" class="description-line">In certain embodiments, the corticosteroid is clobetasol.</div>
    </li> <li> <para-num num="[0044]"> </para-num> <div id="p-0045" num="0044" class="description-line">In certain embodiments, the glucocorticoid is selected from hydrocortisone, cortisone, corticosterone, deoxycorticosterone, prednisone, prednisolone, methylprednisolone, dexamethasone, betamethasone, mometasone, triamcinolone, beclomethasone, fludrocortisone, aldosterone, fluticasone, clobetasone, clobetasol, and loteprednol, and pharmaceutically acceptable salts thereof, and mixtures thereof.</div>
    </li> <li> <para-num num="[0045]"> </para-num> <div id="p-0046" num="0045" class="description-line">In certain embodiments, the non-cationic lipid is selected from a PEG-lipid conjugate and a phospholipid.</div>
    </li> <li> <para-num num="[0046]"> </para-num> <div id="p-0047" num="0046" class="description-line">In certain embodiments, the non-cationic lipid is selected from a PEG-lipid conjugate, a phospholipid, or a mixture of a PEG-lipid conjugate and a phospholipid.</div>
    </li> <li> <para-num num="[0047]"> </para-num> <div id="p-0048" num="0047" class="description-line">In certain embodiments, the non-cationic lipid comprises a phospholipid.</div>
    </li> <li> <para-num num="[0048]"> </para-num> <div id="p-0049" num="0048" class="description-line">In certain embodiments, the non-cationic lipid comprises a PEG-lipid conjugate.</div>
    </li> <li> <para-num num="[0049]"> </para-num> <div id="p-0050" num="0049" class="description-line">In certain embodiments, the non-cationic lipid comprises a mixture of a PEG-lipid conjugate and a phospholipid.</div>
    </li> <li> <para-num num="[0050]"> </para-num> <div id="p-0051" num="0050" class="description-line">In certain embodiments, the non-cationic lipid is a phospholipid.</div>
    </li> <li> <para-num num="[0051]"> </para-num> <div id="p-0052" num="0051" class="description-line">In certain embodiments, the non-cationic lipid is a PEG-lipid conjugate.</div>
    </li> <li> <para-num num="[0052]"> </para-num> <div id="p-0053" num="0052" class="description-line">In certain embodiments, the non-cationic lipid is a mixture of a PEG-lipid conjugate and a phospholipid.</div>
    </li> <li> <para-num num="[0053]"> </para-num> <div id="p-0054" num="0053" class="description-line">In certain embodiments, the lipid nanoparticle further comprises cholesterol.</div>
    </li> <li> <para-num num="[0054]"> </para-num> <div id="p-0055" num="0054" class="description-line">In certain embodiments, the phospholipid comprises dipalmitoylphosphatidylcholine (DPPC), distearoylphosphatidylcholine (DSPC), or a mixture thereof.</div>
    </li> <li> <para-num num="[0055]"> </para-num> <div id="p-0056" num="0055" class="description-line">In certain embodiments, the PEG-lipid conjugate is selected from the group consisting of a PEG-diacylglycerol (PEG-DAG) conjugate, a PEG-dialkyloxypropyl (PEG-DAA) conjugate, a PEG-phospholipid conjugate, a PEG-ceramide (PEG-Cer) conjugate, and a mixture thereof.</div>
    </li> <li> <para-num num="[0056]"> </para-num> <div id="p-0057" num="0056" class="description-line">In certain embodiments, the PEG-lipid conjugate is selected from the group consisting of a PEG-2000-C-DMA, PEG-diacylglycerol (PEG-DAG) conjugate, a PEG-dialkyloxypropyl (PEG-DAA) conjugate, a PEG-phospholipid conjugate, a PEG-ceramide (PEG-Cer) conjugate, and a mixture thereof.</div>
    </li> <li> <para-num num="[0057]"> </para-num> <div id="p-0058" num="0057" class="description-line">In certain embodiments, the PEG-lipid conjugate is a PEG-DAA conjugate.</div>
    </li> <li> <para-num num="[0058]"> </para-num> <div id="p-0059" num="0058" class="description-line">In certain embodiments, the PEG-DAA conjugate is selected from the group consisting of a PEG-didecyloxypropyl (C<sub>10</sub>) conjugate, a PEG-dilauryloxypropyl (C<sub>12</sub>) conjugate, a PEG-dimyristyloxypropyl (C<sub>14</sub>) conjugate, a PEG-dipalmityloxypropyl (C<sub>16</sub>) conjugate, a PEG-distearyloxypropyl (C<sub>18</sub>) conjugate, and a mixture thereof.</div>
    </li> <li> <para-num num="[0059]"> </para-num> <div id="p-0060" num="0059" class="description-line">In certain embodiments, the lipid nanoparticle has a lipid:nucleic mass ratio of from about 9:1 to about 20:1.</div>
    </li> <li> <para-num num="[0060]"> </para-num> <div id="p-0061" num="0060" class="description-line">In certain embodiments, the multiplicity of lipid nanoparticles in the lipid nanoparticle formulation has a lipid:nucleic mass ratio of from about 9:1 to about 20:1.</div>
    </li> <li> <para-num num="[0061]"> </para-num> <div id="p-0062" num="0061" class="description-line">In certain embodiments, the mRNA is chemically modified.</div>
    </li> <li> <para-num num="[0062]"> </para-num> <div id="p-0063" num="0062" class="description-line">In certain embodiments, the lipid nanoparticle comprises an electron dense core.</div>
    </li> <li> <para-num num="[0063]"> </para-num> <div id="p-0064" num="0063" class="description-line">In certain embodiments, the lipid nanoparticle comprises an electron dense core and wherein the mRNA is located within the electron dense core.</div>
    </li> <li> <para-num num="[0064]"> </para-num> <div id="p-0065" num="0064" class="description-line">Certain embodiments provide a pharmaceutical composition comprising a lipid nanoparticle or population thereof as described herein, and a pharmaceutically acceptable carrier.</div>
    </li> <li> <para-num num="[0065]"> </para-num> <div id="p-0066" num="0065" class="description-line">Certain embodiments provide a method for introducing an mRNA that encodes a protein into a cell, the method comprising contacting the cell with a lipid nanoparticle or population thereof as described herein, under conditions whereby the mRNA is introduced into the cell and expressed therein to produce the protein.</div>
    </li> <li> <para-num num="[0066]"> </para-num> <div id="p-0067" num="0066" class="description-line">Certain embodiments provide a method for treating and/or ameliorating one or more symptoms associated with a disease in a human, caused by impaired expression of a protein in the human, the method comprising administering to the human a therapeutically effective amount of a lipid nanoparticle or population thereof as described herein, wherein the mRNA encapsulated within the lipid nanoparticle encodes the protein.</div>
    </li> <li> <para-num num="[0067]"> </para-num> <div id="p-0068" num="0067" class="description-line">In certain embodiments, the phospholipid is distearoylphosphatidylcholine (DSPC).</div>
    </li> <li> <para-num num="[0068]"> </para-num> <div id="p-0069" num="0068" class="description-line">In certain embodiments, the PEG-lipid conjugate is PEG-2000-C-DMA.</div>
    </li> <li> <para-num num="[0069]"> </para-num> <div id="p-0070" num="0069" class="description-line">In certain embodiments, the LNP comprises at least 3.5 mole percent of the PEG-lipid conjugate (e.g., at least about 3.5, 4, 4.5, 5, 5.5, or 6 mole percent).</div>
    </li> <li> <para-num num="[0070]"> </para-num> <div id="p-0071" num="0070" class="description-line">In certain embodiments, the amount of PEG-lipid conjugate is at least 3 mole percent (e.g., at least 3.1 mole percent, at least 3.2 mole percent, at least 3.3 mole percent, at least 3.4 mole percent, at least 3.5 mole percent, at least 3.6 mole percent, at least 3.7 mole percent, at least 3.8 mole percent, at least 3.9 mole percent, at least 4 mole percent).With respect to phospholipid, in certain embodiments, no phospholipid is used in the practice of the invention. In certain embodiments, the lipid particle comprises less than 2 mole percent phospholipid, e.g., 1.9 mol % phospholipid, 1.8 mol % phospholipid, 1.7 mol % phospholipid, 1.6 mol % phospholipid, 1.5 mol % phospholipid, 1.4 mol % phospholipid, 1.3 mol % phospholipid, 1.2 mol % phospholipid, 1.1 mol % phospholipid, 1.0 mol % phospholipid, 0.9 mol % phospholipid, 0.8 mol % phospholipid, 0.7 mol % phospholipid, 0.6 mol % phospholipid, 0.5 mol % phospholipid, 0.4 mol % phospholipid, 0.3 mol % phospholipid, 0.2 mol % phospholipid, 0.1 mol % phospholipid, or 0.0% phospholipid, e.g., less than 1.9 mol % phospholipid, less than 1.8 mol % phospholipid, less than 1.7 mol % phospholipid, less than 1.6 mol % phospholipid, less than 1.5 mol % phospholipid, less than 1.4 mol % phospholipid, less than 1.3 mol % phospholipid, less than 1.2 mol % phospholipid, less than 1.1 mol % phospholipid, less than 1.0 mol % phospholipid, less than 0.9 mol % phospholipid, less than 0.8 mol % phospholipid, less than 0.7 mol % phospholipid, less than 0.6 mol % phospholipid, less than 0.5 mol % phospholipid, less than 0.4 mol % phospholipid, less than 0.3 mol % phospholipid, less than 0.2 mol % phospholipid, less than 0.1 mol % phospholipid.</div>
    </li> <li> <para-num num="[0071]"> </para-num> <div id="p-0072" num="0071" class="description-line">In certain embodiments, the LNP comprises a PEG-lipid conjugate present in an amount of at least 3 mole percent, provided that the LNP comprises less than 0.5 mole percent phospholipid. In certain embodiments, the PEG-lipid conjugate is present in an amount of at least 3.5 mole percent (e.g., at least about 3.5, 4, 4.5, 5, 5.5, or 6 mole percent). In certain embodiments, the LNP comprises less than 0.05 mole percent phospholipid.</div>
    </li> <li> <para-num num="[0072]"> </para-num> <div id="p-0073" num="0072" class="description-line">In certain embodiments, the lipid nanoparticle has a lipid:mRNA mass ratio of from about 9:1 to about 20:1.</div>
    </li> <li> <para-num num="[0073]"> </para-num> <div id="p-0074" num="0073" class="description-line">Certain embodiments provide a lipid nanoparticle prepared according to the methods described herein.</div>
    </li> <li> <para-num num="[0074]"> </para-num> <div id="p-0075" num="0074" class="description-line">Certain embodiments provide a lipid nanoparticle formulation comprising a multiplicity of lipid nanoparticles as described herein.</div>
    </li> <li> <para-num num="[0075]"> </para-num> <div id="p-0076" num="0075" class="description-line">Certain embodiments provide a lipid nanoparticle formulation comprising a multiplicity of lipid nanoparticles as described herein, wherein the lipid nanoparticle formulation has an IFIT response that is no more than 30 fold greater than a phosphate buffered saline control response. In certain embodiments, the lipid nanoparticle formulation has an IFIT response that is no more than about 29, 28, 2, 26, 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1 fold greater than a phosphate buffered saline control response.</div>
    </li> <li> <para-num num="[0076]"> </para-num> <div id="p-0077" num="0076" class="description-line">As used herein, the following terms have the meanings ascribed to them unless specified otherwise.</div>
    </li> <li> <para-num num="[0077]"> </para-num> <div id="p-0078" num="0077" class="description-line">An âeffective amountâ or âtherapeutically effective amountâ of a therapeutic nucleic acid such as an mRNA is an amount sufficient to produce the desired effect, e.g., mRNA-directed expression of an amount of a protein that causes a desirable biological effect in the organism within which the protein is expressed. For example, in some embodiments, the expressed protein is an active form of a protein that is normally expressed in a cell type within the body, and the therapeutically effective amount of the mRNA is an amount that produces an amount of the encoded protein that is at least 50% (e.g., at least 60%, or at least 70%, or at least 80%, or at least 90%) of the amount of the protein that is normally expressed in the cell type of a healthy individual. Suitable assays for measuring the expression of an mRNA or protein include, but are not limited to dot blots, Northern blots, in situ hybridization, ELISA, immunoprecipitation, enzyme function, as well as phenotypic assays known to those of skill in the art.</div>
    </li> <li> <para-num num="[0078]"> </para-num> <div id="p-0079" num="0078" class="description-line">By âdecrease,â âdecreasing,â âreduce,â or âreducingâ of an immune response by an mRNA is intended to mean a detectable decrease of an immune response to a given mRNA (e.g., a modified mRNA). The amount of decrease of an immune response by a modified mRNA may be determined relative to the level of an immune response in the presence of an unmodified mRNA. A detectable decrease can be about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 100%, or more lower than the immune response detected in the presence of the unmodified mRNA. A decrease in the immune response to mRNA is typically measured by a decrease in cytokine production (e.g., IFNÎ³, IFNÎ±, TNFÎ±, IL-6, or IL-12) by a responder cell in vitro or a decrease in cytokine production in the sera of a mammalian subject after administration of the mRNA.</div>
    </li> <li> <para-num num="[0079]"> </para-num> <div id="p-0080" num="0079" class="description-line">âSubstantial identityâ refers to a sequence that hybridizes to a reference sequence under stringent conditions, or to a sequence that has a specified percent identity over a specified region of a reference sequence.</div>
    </li> <li> <para-num num="[0080]"> </para-num> <div id="p-0081" num="0080" class="description-line">The phrase âstringent hybridization conditionsâ refers to conditions under which a nucleic acid will hybridize to its target sequence, typically in a complex mixture of nucleic acids, but to no other sequences. Stringent conditions are sequence-dependent and will be different in different circumstances. Longer sequences hybridize specifically at higher temperatures. An extensive guide to the hybridization of nucleic acids is found in Tijssen, <i>Techniques in Biochemistry and Molecular BiologyâHybridization with Nucleic Probes, </i>âOverview of principles of hybridization and the strategy of nucleic acid assaysâ (1993). Generally, stringent conditions are selected to be about 5-10Â° C. lower than the thermal melting point (T<sub>m</sub>) for the specific sequence at a defined ionic strength pH. The T<sub>m </sub>is the temperature (under defined ionic strength, pH, and nucleic concentration) at which 50% of the probes complementary to the target hybridize to the target sequence at equilibrium (as the target sequences are present in excess, at T<sub>m</sub>, 50% of the probes are occupied at equilibrium). Stringent conditions may also be achieved with the addition of destabilizing agents such as formamide. For selective or specific hybridization, a positive signal is at least two times background, preferably 10 times background hybridization.</div>
    </li> <li> <para-num num="[0081]"> </para-num> <div id="p-0082" num="0081" class="description-line">Exemplary stringent hybridization conditions can be as follows: 50% formamide, 5ÃSSC, and 1% SDS, incubating at 42Â° C., or, 5ÃSSC, 1% SDS, incubating at 65Â° C., with wash in 0.2ÃSSC, and 0.1% SDS at 65Â° C. For PCR, a temperature of about 36Â° C. is typical for low stringency amplification, although annealing temperatures may vary between about 32Â° C. and 48Â° C. depending on primer length. For high stringency PCR amplification, a temperature of about 62Â° C. is typical, although high stringency annealing temperatures can range from about 50Â° C. to about 65Â° C., depending on the primer length and specificity. Typical cycle conditions for both high and low stringency amplifications include a denaturation phase of 90Â° C.-95Â° C. for 30 sec. to 2 min., an annealing phase lasting 30 sec. to 2 min., and an extension phase of about 72Â° C. for 1 to 2 min. Protocols and guidelines for low and high stringency amplification reactions are provided, e.g., in Innis et al., <i>PCR Protocols, A Guide to Methods and Applications, </i>Academic Press, Inc. N.Y. (1990).</div>
    </li> <li> <para-num num="[0082]"> </para-num> <div id="p-0083" num="0082" class="description-line">Nucleic acids that do not hybridize to each other under stringent conditions are still substantially identical if the polypeptides which they encode are substantially identical. This occurs, for example, when a copy of a nucleic acid is created using the maximum codon degeneracy permitted by the genetic code. In such cases, the nucleic acids typically hybridize under moderately stringent hybridization conditions. Exemplary âmoderately stringent hybridization conditionsâ include a hybridization in a buffer of 40% formamide, 1 M NaCl, 1% SDS at 37Â° C., and a wash in 1ÃSSC at 45Â° C. A positive hybridization is at least twice background. Those of ordinary skill will readily recognize that alternative hybridization and wash conditions can be utilized to provide conditions of similar stringency. Additional guidelines for determining hybridization parameters are provided in numerous references, e.g., Current Protocols in Molecular Biology, Ausubel et al., eds.</div>
    </li> <li> <para-num num="[0083]"> </para-num> <div id="p-0084" num="0083" class="description-line">The terms âsubstantially identicalâ or âsubstantial identity,â in the context of two or more nucleic acids, refer to two or more sequences or subsequences that are the same or have a specified percentage of nucleotides that are the same (i.e., at least about 60%, preferably at least about 65%, 70%, 75%, 80%, 85%, 90%, or 95% identity over a specified region), when compared and aligned for maximum correspondence over a comparison window, or designated region as measured using one of the following sequence comparison algorithms or by manual alignment and visual inspection. This definition, when the context indicates, also refers analogously to the complement of a sequence. Preferably, the substantial identity exists over a region that is at least about 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, or 60 nucleotides in length.</div>
    </li> <li> <para-num num="[0084]"> </para-num> <div id="p-0085" num="0084" class="description-line">For sequence comparison, typically one sequence acts as a reference sequence, to which test sequences are compared. When using a sequence comparison algorithm, test and reference sequences are entered into a computer, subsequence coordinates are designated, if necessary, and sequence algorithm program parameters are designated. Default program parameters can be used, or alternative parameters can be designated. The sequence comparison algorithm then calculates the percent sequence identities for the test sequences relative to the reference sequence, based on the program parameters.</div>
    </li> <li> <para-num num="[0085]"> </para-num> <div id="p-0086" num="0085" class="description-line">A âcomparison window,â as used herein, includes reference to a segment of any one of a number of contiguous positions selected from the group consisting of from about 5 to about 60, usually about 10 to about 45, more usually about 15 to about 30, in which a sequence may be compared to a reference sequence of the same number of contiguous positions after the two sequences are optimally aligned. Methods of alignment of sequences for comparison are well known in the art. Optimal alignment of sequences for comparison can be conducted, e.g., by the local homology algorithm of Smith and Waterman, <i>Adv. Appl. Math., </i>2:482 (1981), by the homology alignment algorithm of Needleman and Wunsch, <i>J. Mol. Biol., </i>48:443 (1970), by the search for similarity method of Pearson and Lipman, <i>Proc. Natl. Acad. Sci. USA, </i>85:2444 (1988), by computerized implementations of these algorithms (GAP, BESALDHIT, FASTA, and ALDHASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Dr., Madison, Wis.), or by manual alignment and visual inspection (see, e.g., <i>Current Protocols in Molecular Biology, </i>Ausubel et al., eds. (1995 supplement)).</div>
    </li> <li> <para-num num="[0086]"> </para-num> <div id="p-0087" num="0086" class="description-line">Non-limiting examples of algorithms that are suitable for determining percent sequence identity and sequence similarity are the BLAST and BLAST 2.0 algorithms, which are described in Altschul et al., <i>Nuc. Acids Res., </i>25:3389-3402 (1977) and Altschul et al., <i>J. Mol. Biol., </i>215:403-410 (1990), respectively. BLAST and BLAST 2.0 are used, with the parameters described herein, to determine percent sequence identity for the nucleic acids of the invention. Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information (http://www.ncbi.nlm.nih.gov/). Another example is a global alignment algorithm for determining percent sequence identity such as the Needleman-Wunsch algorithm for aligning protein or nucleotide (e.g., RNA) sequences.</div>
    </li> <li> <para-num num="[0087]"> </para-num> <div id="p-0088" num="0087" class="description-line">The BLAST algorithm also performs a statistical analysis of the similarity between two sequences (see, e.g., Karlin and Altschul, <i>Proc. Natl. Acad. Sci. USA, </i>90:5873-5787 (1993)). One measure of similarity provided by the BLAST algorithm is the smallest sum probability (P(N)), which provides an indication of the probability by which a match between two nucleotide sequences would occur by chance. For example, a nucleic acid is considered similar to a reference sequence if the smallest sum probability in a comparison of the test nucleic acid to the reference nucleic acid is less than about 0.2, more preferably less than about 0.01, and most preferably less than about 0.001.</div>
    </li> <li> <para-num num="[0088]"> </para-num> <div id="p-0089" num="0088" class="description-line">The term ânucleic acidâ as used herein refers to a polymer containing at least two deoxyribonucleotides or ribonucleotides in either single- or double-stranded form and includes DNA and RNA. DNA may be in the form of, e.g., antisense molecules, plasmid DNA, pre-condensed DNA, a PCR product, vectors (e.g., P1, PAC, BAC, YAC, artificial chromosomes), expression cassettes, chimeric sequences, chromosomal DNA, or derivatives and combinations of these groups. RNA may be in the form of small interfering RNA (siRNA), Dicer-substrate dsRNA, small hairpin RNA (shRNA), asymmetrical interfering RNA (aiRNA), microRNA (miRNA), mRNA, tRNA, rRNA, tRNA, viral RNA (vRNA), and combinations thereof. Nucleic acids include nucleic acids containing known nucleotide analogs or modified backbone residues or linkages, which are synthetic, naturally occurring, and non-naturally occurring, and which have similar binding properties as the reference nucleic acid. Examples of such analogs include, without limitation, phosphorothioates, phosphoramidates, methyl phosphonates, chiral-methyl phosphonates, 2â²-O-methyl ribonucleotides, and peptide-nucleic acids (PNAs). Unless specifically limited, the term encompasses nucleic acids containing known analogues of natural nucleotides that have similar binding properties as the reference nucleic acid. Nucleic acid sequence may in certain embodiments include an âunlocked nucleobase analogueâ (abbreviated as âUNAâ).</div>
    </li> <li> <para-num num="[0089]"> </para-num> <div id="p-0090" num="0089" class="description-line">The term âunlocked nucleobase analogueâ (abbreviated as âUNAâ) refers to an acyclic nucleobase in which the C2â² and C3â² atoms of the ribose ring are not covalently linked. The term âunlocked nucleobase analogueâ includes nucleobase analogues having the following structure identified as Structure A:</div>
    </li> <li> <div id="p-0091" num="0000" class="description-line">
      <chemistry id="CHEM-US-00001" num="00001">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/94/64/83/23ebb27c5053a0/US20190240354A1-20190808-C00001.png"><img id="EMI-C00001" he="35.48mm" wi="69.93mm" file="US20190240354A1-20190808-C00001.TIF" alt="Figure US20190240354A1-20190808-C00001" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="280" height="142" alt="Figure US20190240354A1-20190808-C00001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/94/64/83/23ebb27c5053a0/US20190240354A1-20190808-C00001.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00001" attachment-type="cdx" file="US20190240354A1-20190808-C00001.CDX"> </attachment>
          <attachment idref="CHEM-US-00001" attachment-type="mol" file="US20190240354A1-20190808-C00001.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <div id="p-0092" num="0000" class="description-line">wherein R is hydroxyl, and Base is any natural or unnatural base such as, for example, adenine (A), cytosine (C), guanine (G) and thymine (T). UNA useful in the practice of the present invention include the molecules identified as acyclic 2â²-3â²-seco-nucleotide monomers in U.S. Pat. No. 8,314,227 which is incorporated by reference herein in its entirety.</div>
    </li> <li> <para-num num="[0090]"> </para-num> <div id="p-0093" num="0090" class="description-line">Unless otherwise indicated, a particular nucleic acid sequence also implicitly encompasses conservatively modified variants thereof (e.g., degenerate codon substitutions), alleles, orthologs, SNPs, and complementary sequences as well as the sequence explicitly indicated. Specifically, degenerate codon substitutions may be achieved by generating sequences in which the third position of one or more selected (or all) codons is substituted with mixed-base and/or deoxyinosine residues (Batzer et al., <i>Nucleic Acid Res., </i>19:5081 (1991); Ohtsuka et al., <i>J. Biol. Chem., </i>260:2605-2608 (1985); Rossolini et al., <i>Mol. Cell. Probes, </i>8:91-98 (1994)).</div>
    </li> <li> <para-num num="[0091]"> </para-num> <div id="p-0094" num="0091" class="description-line">The term âsmall-interfering RNAâ or âsiRNAâ as used herein refers to double stranded RNA (i.e., duplex RNA) that is capable of reducing or inhibiting the expression of a target gene or sequence (e.g., by mediating the degradation or inhibiting the translation of mRNAs which are complementary to the siRNA sequence) when the siRNA is in the same cell as the target gene or sequence. The siRNA may have substantial or complete identity to the target gene or sequence, or may comprise a region of mismatch (i.e., a mismatch motif). In certain embodiments, the siRNAs may be about 19-25 (duplex) nucleotides in length, and is preferably about 20-24, 21-22, or 21-23 (duplex) nucleotides in length. siRNA duplexes may comprise 3â² overhangs of about 1 to about 4 nucleotides or about 2 to about 3 nucleotides and 5â² phosphate termini. Examples of siRNA include, without limitation, a double-stranded polynucleotide molecule assembled from two separate stranded molecules, wherein one strand is the sense strand and the other is the complementary antisense strand.</div>
    </li> <li> <para-num num="[0092]"> </para-num> <div id="p-0095" num="0092" class="description-line">Preferably, siRNA are chemically synthesized. siRNA can also be generated by cleavage of longer dsRNA (e.g., dsRNA greater than about 25 nucleotides in length) with the <i>E. coli </i>RNase III or Dicer. These enzymes process the dsRNA into biologically active siRNA (see, e.g., Yang et al., <i>Proc. Natl. Acad. Sci. USA, </i>99:9942-9947 (2002); Calegari et al., <i>Proc. Natl. Acad. Sci. USA, </i>99:14236 (2002); Byrom et al., <i>Ambion TechNotes, </i>10(1):4-6 (2003); Kawasaki et al., <i>Nucleic Acids Res., </i>31:981-987 (2003); Knight et al., <i>Science, </i>293:2269-2271 (2001); and Robertson et al., <i>J. Biol. Chem., </i>243:82 (1968)). Preferably, dsRNA are at least 50 nucleotides to about 100, 200, 300, 400, or 500 nucleotides in length. A dsRNA may be as long as 1000, 1500, 2000, 5000 nucleotides in length, or longer. The dsRNA can encode for an entire gene transcript or a partial gene transcript. In certain instances, siRNA may be encoded by a plasmid (e.g., transcribed as sequences that automatically fold into duplexes with hairpin loops).</div>
    </li> <li> <para-num num="[0093]"> </para-num> <div id="p-0096" num="0093" class="description-line">âNucleotidesâ contain a sugar deoxyribose (DNA) or ribose (RNA), a base, and a phosphate group. Nucleotides are linked together through the phosphate groups. âBasesâ include purines and pyrimidines, which further include natural compounds adenine, thymine, guanine, cytosine, uracil, inosine, and natural analogs, and synthetic derivatives of purines and pyrimidines, which include, but are not limited to, modifications which place new reactive groups such as, but not limited to, amines, alcohols, thiols, carboxylates, and alkylhalides.</div>
    </li> <li> <para-num num="[0094]"> </para-num> <div id="p-0097" num="0094" class="description-line">The term âgeneâ refers to a nucleic acid (e.g., DNA or RNA) sequence that comprises partial length or entire length coding sequences necessary for the production of a polypeptide or precursor polypeptide.</div>
    </li> <li> <para-num num="[0095]"> </para-num> <div id="p-0098" num="0095" class="description-line">âGene product,â as used herein, refers to a product of a gene such as an RNA transcript or a polypeptide.</div>
    </li> <li> <para-num num="[0096]"> </para-num> <div id="p-0099" num="0096" class="description-line">The term âlipidâ refers to a group of organic compounds that include, but are not limited to, esters of fatty acids and are characterized by being insoluble in water, but soluble in many organic solvents. They are usually divided into at least three classes: (1) âsimple lipids,â which include fats and oils as well as waxes; (2) âcompound lipids,â which include phospholipids and glycolipids; and (3) âderived lipidsâ such as steroids.</div>
    </li> <li> <para-num num="[0097]"> </para-num> <div id="p-0100" num="0097" class="description-line">The term âlipid particleâ includes a lipid formulation that can be used to deliver a therapeutic nucleic acid (e.g., mRNA or siRNA) to a target site of interest (e.g., cell, tissue, organ, and the like). In preferred embodiments, the lipid particle of the invention is a nucleic acid-lipid particle, which is typically formed from a cationic lipid, a non-cationic lipid (e.g., a phospholipid), a conjugated lipid that prevents aggregation of the particle (e.g., a PEG-lipid), and optionally cholesterol. Typically, the therapeutic nucleic acid (e.g., mRNA) may be encapsulated in the lipid portion of the particle, thereby protecting it from enzymatic degradation.</div>
    </li> <li> <para-num num="[0098]"> </para-num> <div id="p-0101" num="0098" class="description-line">The term âelectron dense coreâ, when used to describe a lipid particle of the present invention, refers to the dark appearance of the interior portion of a lipid particle when visualized using cryo transmission electron microscopy (âcryoTEMâ). Some lipid particles of the present invention have an electron dense core and lack a lipid bilayer structure. Some lipid particles of the present invention have an electron dense core, lack a lipid bilayer structure, and have an inverse Hexagonal or Cubic phase structure. While not wishing to be bound by theory, it is thought that the non-bilayer lipid packing provides a 3-dimensional network of lipid cylinders with water and nucleic on the inside, i.e., essentially, a lipid droplet interpenetrated with aqueous channels containing the nucleic acid.</div>
    </li> <li> <para-num num="[0099]"> </para-num> <div id="p-0102" num="0099" class="description-line">As used herein, the term âSNALPâ refers to a stable nucleic acid-lipid particle. A SNALP is a particle made from lipids (e.g., a cationic lipid, a non-cationic lipid, and a conjugated lipid that prevents aggregation of the particle), wherein the nucleic acid (e.g., mRNA) is fully encapsulated within the lipid. In certain instances, SNALP are extremely useful for systemic applications, as they can exhibit extended circulation lifetimes following intravenous (i.v.) injection, they can accumulate at distal sites (e.g., sites physically separated from the administration site), and they can mediate mRNA expression at these distal sites. The nucleic acid may be complexed with a condensing agent and encapsulated within a SNALP as set forth in PCT Publication No. WO 00/03683, the disclosure of which is herein incorporated by reference in its entirety for all purposes.</div>
    </li> <li> <para-num num="[0100]"> </para-num> <div id="p-0103" num="0100" class="description-line">The lipid particles of the invention (e.g., SNALP) typically have a mean diameter of from about 30 nm to about 150 nm, from about 40 nm to about 150 nm, from about 50 nm to about 150 nm, from about 60 nm to about 130 nm, from about 70 nm to about 110 nm, from about 70 nm to about 100 nm, from about 80 nm to about 100 nm, from about 90 nm to about 100 nm, from about 70 to about 90 nm, from about 80 nm to about 90 nm, from about 70 nm to about 80 nm, or about 30 nm, 35 nm, 40 nm, 45 nm, 50 nm, 55 nm, 60 nm, 65 nm, 70 nm, 75 nm, 80 nm, 85 nm, 90 nm, 95 nm, 100 nm, 105 nm, 110 nm, 115 nm, 120 nm, 125 nm, 130 nm, 135 nm, 140 nm, 145 nm, or 150 nm, and are substantially non-toxic. In addition, nucleic acids, when present in the lipid particles of the present invention, are resistant in aqueous solution to degradation with a nuclease. Nucleic acid-lipid particles and their method of preparation are disclosed in, e.g., U.S. Patent Publication Nos. 20040142025 and 20070042031, the disclosures of which are herein incorporated by reference in their entirety for all purposes.</div>
    </li> <li> <para-num num="[0101]"> </para-num> <div id="p-0104" num="0101" class="description-line">As used herein, âlipid encapsulatedâ can refer to a lipid particle that provides a therapeutic nucleic acid such as an mRNA with full encapsulation, partial encapsulation, or both. In a preferred embodiment, the nucleic acid (e.g., mRNA) is fully encapsulated in the lipid particle (e.g., to form a SNALP or other nucleic acid-lipid particle).</div>
    </li> <li> <para-num num="[0102]"> </para-num> <div id="p-0105" num="0102" class="description-line">The term âlipid conjugateâ refers to a conjugated lipid that inhibits aggregation of lipid particles. Such lipid conjugates include, but are not limited to, PEG-lipid conjugates such as, e.g., PEG coupled to dialkyloxypropyls (e.g., PEG-DAA conjugates), PEG coupled to diacylglycerols (e.g., PEG-DAG conjugates), PEG coupled to cholesterol, PEG coupled to phosphatidylethanolamines, and PEG conjugated to ceramides (see, e.g., U.S. Pat. No. 5,885,613), cationic PEG lipids, polyoxazoline (POZ)-lipid conjugates, polyamide oligomers (e.g., ATTA-lipid conjugates), and mixtures thereof. Additional examples of POZ-lipid conjugates are described in PCT Publication No. WO 2010/006282. PEG or POZ can be conjugated directly to the lipid or may be linked to the lipid via a linker moiety. Any linker moiety suitable for coupling the PEG or the POZ to a lipid can be used including, e.g., non-ester containing linker moieties and ester-containing linker moieties. In certain preferred embodiments, non-ester containing linker moieties, such as amides or carbamates, are used. The disclosures of each of the above patent documents are herein incorporated by reference in their entirety for all purposes.</div>
    </li> <li> <para-num num="[0103]"> </para-num> <div id="p-0106" num="0103" class="description-line">The term âamphipathic lipidâ refers, in part, to any suitable material wherein the hydrophobic portion of the lipid material orients into a hydrophobic phase, while the hydrophilic portion orients toward the aqueous phase. Hydrophilic characteristics derive from the presence of polar or charged groups such as carbohydrates, phosphate, carboxylic, sulfato, amino, sulfhydryl, nitro, hydroxyl, and other like groups. Hydrophobicity can be conferred by the inclusion of apolar groups that include, but are not limited to, long-chain saturated and unsaturated aliphatic hydrocarbon groups and such groups substituted by one or more aromatic, cycloaliphatic, or heterocyclic group(s). Examples of amphipathic compounds include, but are not limited to, phospholipids, aminolipids, and sphingolipids.</div>
    </li> <li> <para-num num="[0104]"> </para-num> <div id="p-0107" num="0104" class="description-line">Representative examples of phospholipids include, but are not limited to, phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, phosphatidylinositol, phosphatidic acid, palmitoyloleoyl phosphatidylcholine, lysophosphatidylcholine, lysophosphatidylethanolamine, dipalmitoylphosphatidylcholine, dioleoylphosphatidylcholine, distearoylphosphatidylcholine, and dilinoleoylphosphatidylcholine. Other compounds lacking in phosphorus, such as sphingolipid, glycosphingolipid families, diacylglycerols, and Î²-acyloxyacids, are also within the group designated as amphipathic lipids. Additionally, the amphipathic lipids described above can be mixed with other lipids including triglycerides and sterols.</div>
    </li> <li> <para-num num="[0105]"> </para-num> <div id="p-0108" num="0105" class="description-line">The term âneutral lipidâ refers to any of a number of lipid species that exist either in an uncharged or neutral zwitterionic form at a selected pH. At physiological pH, such lipids include, for example, diacylphosphatidylcholine, diacylphosphatidylethanolamine, ceramide, sphingomyelin, cephalin, cholesterol, cerebrosides, and diacylglycerols.</div>
    </li> <li> <para-num num="[0106]"> </para-num> <div id="p-0109" num="0106" class="description-line">The term ânon-cationic lipidâ refers to any amphipathic lipid as well as any other neutral lipid or anionic lipid.</div>
    </li> <li> <para-num num="[0107]"> </para-num> <div id="p-0110" num="0107" class="description-line">The term âanionic lipidâ refers to any lipid that is negatively charged at physiological pH. These lipids include, but are not limited to, phosphatidylglycerols, cardiolipins, diacylphosphatidylserines, diacylphosphatidic acids, N-dodecanoyl phosphatidylethanolamines, N-succinyl phosphatidylethanolamines, N-glutarylphosphatidylethanolamines, lysylphosphatidylglycerols, palmitoyloleyolphosphatidylglycerol (POPG), and other anionic modifying groups joined to neutral lipids.</div>
    </li> <li> <para-num num="[0108]"> </para-num> <div id="p-0111" num="0108" class="description-line">The term âhydrophobic lipidâ refers to compounds having apolar groups that include, but are not limited to, long-chain saturated and unsaturated aliphatic hydrocarbon groups and such groups optionally substituted by one or more aromatic, cycloaliphatic, or heterocyclic group(s). Suitable examples include, but are not limited to, diacylglycerol, dialkylglycerol, N-N-dialkylamino, 1,2-diacyloxy-3-aminopropane, and 1,2-dialkyl-3-aminopropane.</div>
    </li> <li> <para-num num="[0109]"> </para-num> <div id="p-0112" num="0109" class="description-line">The terms âcationic lipidâ and âamino lipidâ are used interchangeably herein to include those lipids and salts thereof having one, two, three, or more fatty acid or fatty alkyl chains and a pH-titratable amino head group (e.g., an alkylamino or dialkylamino head group). The cationic lipid is typically protonated (i.e., positively charged) at a pH below the pK<sub>a </sub>of the cationic lipid and is substantially neutral at a pH above the pK<sub>a</sub>. The cationic lipids of the invention may also be termed titratable cationic lipids. In some embodiments, the cationic lipids comprise: a protonatable tertiary amine (e.g., pH-titratable) head group; C<sub>18 </sub>alkyl chains, wherein each alkyl chain independently has 0 to 3 (e.g., 0, 1, 2, or 3) double bonds; and ether, ester, or ketal linkages between the head group and alkyl chains. Such cationic lipids include, but are not limited to, DSDMA, DODMA, DLinDMA, DLenDMA, Î³-DLenDMA, DLin-K-DMA, DLin-K-C2-DMA (also known as DLin-C2K-DMA, XTC2, and C2K), DLin-K-C3-DMA, DLin-K-C4-DMA, DLen-C2K-DMA, Î³-DLen-C2K-DMA, DLin-M-C2-DMA (also known as MC2), DLin-M-C3-DMA (also known as MC3) and (DLin-MP-DMA) (also known as 1-B11).</div>
    </li> <li> <para-num num="[0110]"> </para-num> <div id="p-0113" num="0110" class="description-line">The term âalkylaminoâ includes a group of formula âN(H)R, wherein R is an alkyl as defined herein.</div>
    </li> <li> <para-num num="[0111]"> </para-num> <div id="p-0114" num="0111" class="description-line">The term âdialkylaminoâ includes a group of formula âNR<sub>2</sub>, wherein each R is independently an alkyl as defined herein.</div>
    </li> <li> <para-num num="[0112]"> </para-num> <div id="p-0115" num="0112" class="description-line">The term âsaltsâ includes any anionic and cationic complex, such as the complex formed between a cationic lipid and one or more anions. Non-limiting examples of anions include inorganic and organic anions, e.g., hydride, fluoride, chloride, bromide, iodide, oxalate (e.g., hemioxalate), phosphate, phosphonate, hydrogen phosphate, dihydrogen phosphate, oxide, carbonate, bicarbonate, nitrate, nitrite, nitride, bisulfate, sulfide, sulfite, bisulfate, sulfate, thiosulfate, hydrogen sulfate, borate, formate, acetate, benzoate, citrate, tartrate, lactate, acrylate, polyacrylate, fumarate, maleate, itaconate, glycolate, gluconate, malate, mandelate, tiglate, ascorbate, salicylate, polymethacrylate, perchlorate, chlorate, chlorite, hypochlorite, bromate, hypobromite, iodate, an alkylsulfonate, an arylsulfonate, arsenate, arsenite, chromate, dichromate, cyanide, cyanate, thiocyanate, hydroxide, peroxide, permanganate, and mixtures thereof. In particular embodiments, the salts of the cationic lipids disclosed herein are crystalline salts.</div>
    </li> <li> <para-num num="[0113]"> </para-num> <div id="p-0116" num="0113" class="description-line">The term âalkylâ includes a straight chain or branched, noncyclic or cyclic, saturated aliphatic hydrocarbon containing from 1 to 24 carbon atoms. Representative saturated straight chain alkyls include, but are not limited to, methyl, ethyl, n-propyl, n-butyl, n-pentyl, n-hexyl, and the like, while saturated branched alkyls include, without limitation, isopropyl, sec-butyl, isobutyl, tert-butyl, isopentyl, and the like. Representative saturated cyclic alkyls include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and the like, while unsaturated cyclic alkyls include, without limitation, cyclopentenyl, cyclohexenyl, and the like.</div>
    </li> <li> <para-num num="[0114]"> </para-num> <div id="p-0117" num="0114" class="description-line">The term âalkenylâ includes an alkyl, as defined above, containing at least one double bond between adjacent carbon atoms. Alkenyls include both cis and trans isomers. Representative straight chain and branched alkenyls include, but are not limited to, ethylenyl, propylenyl, 1-butenyl, 2-butenyl, isobutylenyl, 1-pentenyl, 2-pentenyl, 3-methyl-1-butenyl, 2-methyl-2-butenyl, 2,3-dimethyl-2-butenyl, and the like.</div>
    </li> <li> <para-num num="[0115]"> </para-num> <div id="p-0118" num="0115" class="description-line">The term âalkynylâ includes any alkyl or alkenyl, as defined above, which additionally contains at least one triple bond between adjacent carbons. Representative straight chain and branched alkynyls include, without limitation, acetylenyl, propynyl, 1-butynyl, 2-butynyl, 1-pentynyl, 2-pentynyl, 3-methyl-1 butynyl, and the like.</div>
    </li> <li> <para-num num="[0116]"> </para-num> <div id="p-0119" num="0116" class="description-line">The term âacylâ includes any alkyl, alkenyl, or alkynyl wherein the carbon at the point of attachment is substituted with an oxo group, as defined below. The following are non-limiting examples of acyl groups: âC(âO)alkyl, âC(âO)alkenyl, and âC(âO)alkynyl.</div>
    </li> <li> <para-num num="[0117]"> </para-num> <div id="p-0120" num="0117" class="description-line">The term âheterocycleâ includes a 5- to 7-membered monocyclic, or 7- to 10-membered bicyclic, heterocyclic ring which is either saturated, unsaturated, or aromatic, and which contains from 1 or 2 heteroatoms independently selected from nitrogen, oxygen and sulfur, and wherein the nitrogen and sulfur heteroatoms may be optionally oxidized, and the nitrogen heteroatom may be optionally quaternized, including bicyclic rings in which any of the above heterocycles are fused to a benzene ring. The heterocycle may be attached via any heteroatom or carbon atom. Heterocycles include, but are not limited to, heteroaryls as defined below, as well as morpholinyl, pyrrolidinonyl, pyrrolidinyl, piperidinyl, piperizynyl, hydantoinyl, valerolactamyl, oxiranyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydropyridinyl, tetrahydroprimidinyl, tetrahydrothiophenyl, tetrahydrothiopyranyl, tetrahydropyrimidinyl, tetrahydrothiophenyl, tetrahydrothiopyranyl, and the like.</div>
    </li> <li> <para-num num="[0118]"> </para-num> <div id="p-0121" num="0118" class="description-line">The terms âoptionally substituted alkylâ, âoptionally substituted alkenylâ, âoptionally substituted alkynylâ, âoptionally substituted acylâ, and âoptionally substituted heterocycleâ mean that, when substituted, at least one hydrogen atom is replaced with a substituent. In the case of an oxo substituent (âO), two hydrogen atoms are replaced. In this regard, substituents include, but are not limited to, oxo, halogen, heterocycle, âCN, âOR<sup>x</sup>, âNR<sup>x</sup>R<sup>y</sup>, âNR<sup>x</sup>C(âO)R<sup>y</sup>, âNR<sup>x</sup>SO<sub>2</sub>R<sup>y</sup>, âC(âO)R<sup>x</sup>, âC(âO)OR<sup>x</sup>, âC(âO)NR<sup>x</sup>R<sup>y</sup>, âSO<sub>n</sub>R<sup>x</sup>, and âSO<sub>n</sub>NR<sup>x</sup>R<sup>y</sup>, wherein n is 0, 1, or 2, R<sup>x </sup>and R<sup>y </sup>are the same or different and are independently hydrogen, alkyl, or heterocycle, and each of the alkyl and heterocycle substituents may be further substituted with one or more of oxo, halogen, âOH, âCN, alkyl, âOR<sup>x</sup>, heterocycle, âNR<sup>x</sup>R<sup>y</sup>, âNR<sup>x</sup>C(âO)R<sup>y</sup>, âNR<sup>x</sup>SO<sub>2</sub>R<sup>y</sup>, âC(âO)R<sup>x</sup>, âC(âO)OR<sup>x</sup>, âC(âO)NR<sup>x</sup>R<sup>y</sup>, and âSO<sub>n</sub>NR<sup>x</sup>R<sup>y</sup>. The term âoptionally substituted,â when used before a list of substituents, means that each of the substituents in the list may be optionally substituted as described herein.</div>
    </li> <li> <para-num num="[0119]"> </para-num> <div id="p-0122" num="0119" class="description-line">The term âhalogenâ includes fluoro, chloro, bromo, and iodo.</div>
    </li> <li> <para-num num="[0120]"> </para-num> <div id="p-0123" num="0120" class="description-line">The term âfusogenicâ refers to the ability of a lipid particle, such as a SNALP, to fuse with the membranes of a cell. The membranes can be either the plasma membrane or membranes surrounding organelles, e.g., endosome, nucleus, etc.</div>
    </li> <li> <para-num num="[0121]"> </para-num> <div id="p-0124" num="0121" class="description-line">As used herein, the term âaqueous solutionâ refers to a composition comprising in whole, or in part, water.</div>
    </li> <li> <para-num num="[0122]"> </para-num> <div id="p-0125" num="0122" class="description-line">As used herein, the term âorganic lipid solutionâ refers to a composition comprising in whole, or in part, an organic solvent having a lipid.</div>
    </li> <li> <para-num num="[0123]"> </para-num> <div id="p-0126" num="0123" class="description-line">âDistal site,â as used herein, refers to a physically separated site, which is not limited to an adjacent capillary bed, but includes sites broadly distributed throughout an organism.</div>
    </li> <li> <para-num num="[0124]"> </para-num> <div id="p-0127" num="0124" class="description-line">âSerum-stableâ in relation to nucleic acid-lipid particles such as SNALP means that the particle is not significantly degraded after exposure to a serum or nuclease assay that would significantly degrade free DNA or RNA. Suitable assays include, for example, a standard serum assay, a DNAse assay, or an RNAse assay.</div>
    </li> <li> <para-num num="[0125]"> </para-num> <div id="p-0128" num="0125" class="description-line">âSystemic delivery,â as used herein, refers to delivery of lipid particles that leads to a broad biodistribution of an active agent such as an mRNA within an organism. Some techniques of administration can lead to the systemic delivery of certain agents, but not others. Systemic delivery means that a useful, preferably therapeutic, amount of an agent is exposed to most parts of the body. To obtain broad biodistribution generally requires a blood lifetime such that the agent is not rapidly degraded or cleared (such as by first pass organs (liver, lung, etc.) or by rapid, nonspecific cell binding) before reaching a disease site distal to the site of administration. Systemic delivery of lipid particles can be by any means known in the art including, for example, intravenous, subcutaneous, and intraperitoneal. In a preferred embodiment, systemic delivery of lipid particles is by intravenous delivery.</div>
    </li> <li> <para-num num="[0126]"> </para-num> <div id="p-0129" num="0126" class="description-line">âLocal delivery,â as used herein, refers to delivery of an active agent such as an mRNA directly to a target site within an organism. For example, an agent can be locally delivered by direct injection into a disease site, other target site, or a target organ such as the liver, heart, pancreas, kidney, and the like.</div>
    </li> <li> <para-num num="[0127]"> </para-num> <div id="p-0130" num="0127" class="description-line">The term âmammalâ refers to any mammalian species such as a human, mouse, rat, dog, cat, hamster, guinea pig, rabbit, livestock, and the like.</div>
    </li> <li> <para-num num="[0128]"> </para-num> <div id="p-0131" num="0128" class="description-line">When used herein to describe the ratio of lipid:mRNA, the term âlipidâ refers to the total lipid in the particle.</div>
    </li> <li> <para-num num="[0129]"> </para-num> <div id="p-0132" num="0129" class="description-line">Unless stated otherwise herein, the term âaboutâ, when used in connection with a value or range of values, means plus or minus 5% of the stated value or range of values.</div>
    </li> <heading id="h-0005">DESCRIPTION OF CERTAIN EMBODIMENTS</heading>
    <li> <para-num num="[0130]"> </para-num> <div id="p-0133" num="0130" class="description-line">In one aspect, the present invention provides nucleic acid-lipid particles that each include (a) a lipid particle comprising a cationic lipid; and (b) an mRNA molecule encapsulated within the lipid particle. Typically, a population of mRNA molecules is encapsulated within the lipid particle. The lipid particles typically include an outer layer defining an interior portion, wherein the mRNA molecule(s) is located within the interior portion. The mRNA molecule(s) is typically completely encapsulated within the lipid particle. The lipid particles can be spherical or non-spherical. The lipid particles can have an electron dense core when visualized using cryo TEM. Typically, the electron dense core is mainly composed of lipid, although aqueous material may be present in an amount that is less than the amount of the lipid.</div>
    </li> <li> <para-num num="[0131]"> </para-num> <div id="p-0134" num="0131" class="description-line">In one aspect, the present invention provides a lipid particle comprising a PEG lipid, a non-cationic lipid, a cationic lipid selected from a trialkyl cationic lipid and a tetra alkyl cationic lipid, and an mRNA; wherein the lipid particle has an electron dense core and the mRNA is encapsulated within the electron dense core.</div>
    </li> <li> <para-num num="[0132]"> </para-num> <div id="p-0135" num="0132" class="description-line">In some embodiments of the invention the lipid particles include (a) a lipid particle comprising a cationic lipid, a PEG-lipid, and a phospholipid; and (b) an mRNA molecule, wherein the mRNA molecule is encapsulated within the lipid particle. The lipid particles can optionally include cholesterol. The mRNA can be completely or partially encapsulated within the lipid particle.</div>
    </li> <li> <para-num num="[0133]"> </para-num> <div id="p-0136" num="0133" class="description-line">The formation of the particle 100 includes, in one or more embodiments, disposing a lipid into a first fluid, such as ethanol, disposing mRNA into a second fluid, such as an aqueous buffer, and mixing the first and second fluids under controlled conditions to form particle 100. The resulting particle 100 includes an electron dense core within the lipid particle when viewed by Cryo Transmission Electron Microscopy.</div>
    </li> <li> <div id="p-0137" num="0000" class="description-line">mRNA</div>
    </li> <li> <para-num num="[0134]"> </para-num> <div id="p-0138" num="0134" class="description-line">mRNA useful in the practice of the present invention may comprise at least one, two, three, four, five, six, seven, eight, nine, ten, or more modified nucleotides such as 2â²OMe nucleotides. Preferably, uridine and/or guanosine nucleotides in the mRNA are modified with 2â²OMe nucleotides. In some embodiments, the mRNA may further comprise modified (e.g., 2â²OMe-modified) adenosine and/or modified (e.g., 2â²OMe-modified) cytosine nucleotides.</div>
    </li> <li> <para-num num="[0135]"> </para-num> <div id="p-0139" num="0135" class="description-line">In one aspect, the present invention provides a nucleic acid-lipid particle (e.g., SNALP) that includes an mRNA. The nucleic acid-lipid particles (e.g., SNALP) typically comprise one or more (e.g., a cocktail) mRNA(s), a cationic lipid, and a non-cationic lipid. In certain instances, the nucleic acid-lipid particles (e.g., SNALP) further comprise a conjugated lipid that inhibits aggregation of particles. Preferably, the nucleic acid-lipid particles (e.g., SNALP) comprise one or more (e.g., a cocktail) mRNAs, a cationic lipid, a non-cationic lipid, and a conjugated lipid that inhibits aggregation of particles.</div>
    </li> <li> <para-num num="[0136]"> </para-num> <div id="p-0140" num="0136" class="description-line">In some embodiments, the mRNA(s) are fully encapsulated in the nucleic acid-lipid particle (e.g., SNALP). With respect to formulations comprising an mRNA cocktail, the different types of mRNA species present in the cocktail (e.g., mRNA having different sequences) may be co-encapsulated in the same particle, or each type of mRNA species present in the cocktail may be encapsulated in a separate particle. The mRNA cocktail may be formulated in the particles described herein using a mixture of two or more individual mRNAs (each having a unique sequence) at identical, similar, or different concentrations or molar ratios. In one embodiment, a cocktail of mRNAs (corresponding to a plurality of mRNAs with different sequences) is formulated using identical, similar, or different concentrations or molar ratios of each mRNA species, and the different types of mRNAs are co-encapsulated in the same particle. In another embodiment, each type of mRNA species present in the cocktail is encapsulated in different particles at identical, similar, or different mRNA concentrations or molar ratios, and the particles thus formed (each containing a different mRNA payload) are administered separately (e.g., at different times in accordance with a therapeutic regimen), or are combined and administered together as a single unit dose (e.g., with a pharmaceutically acceptable carrier). The particles described herein are serum-stable, are resistant to nuclease degradation, and are substantially non-toxic to mammals such as humans.</div>
    </li> <li> <para-num num="[0137]"> </para-num> <div id="p-0141" num="0137" class="description-line">The cationic lipid in the nucleic acid-lipid particles of the invention (e.g., SNALP) may comprise, e.g., one or more cationic lipids of Formula I-III described herein or any other cationic lipid species. In one particular embodiment, the cationic lipid is selected from the group consisting of 1,2-dilinoleyloxy-N,N-dimethylaminopropane (DLinDMA), 1,2-dilinolenyloxy-N,N-dimethylaminopropane (DLenDMA), 1,2-di-Î³-linolenyloxy-N,N-dimethylaminopropane (Î³-DLenDMA), 2,2-dilinoleyl-4-(2-dimethylaminoethyl)-[1,3]-dioxolane (DLin-K-C2-DMA), 2,2-dilinoleyl-4-dimethylaminomethyl-[1,3]-dioxolane (DLin-K-DMA), dilinoleylmethyl-3-dimethylaminopropionate (DLin-M-C2-DMA), (6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-tetraen-19-yl 4-(dimethylamino)butanoate (DLin-M-C3-DMA), salts thereof, and mixtures thereof.</div>
    </li> <li> <para-num num="[0138]"> </para-num> <div id="p-0142" num="0138" class="description-line">The non-cationic lipid in the nucleic acid-lipid particles of the present invention (e.g., SNALP) may comprise, e.g., one or more anionic lipids and/or neutral lipids. In some embodiments, the non-cationic lipid comprises one of the following neutral lipid components: (1) a mixture of a phospholipid and cholesterol or a derivative thereof; (2) cholesterol or a derivative thereof; or (3) a phospholipid. In certain preferred embodiments, the phospholipid comprises dipalmitoylphosphatidylcholine (DPPC), distearoylphosphatidylcholine (DSPC), or a mixture thereof. In a particularly preferred embodiment, the non-cationic lipid is a mixture of DPPC and cholesterol.</div>
    </li> <li> <para-num num="[0139]"> </para-num> <div id="p-0143" num="0139" class="description-line">The lipid conjugate in the nucleic acid-lipid particles of the invention (e.g., SNALP) inhibits aggregation of particles and may comprise, e.g., one or more of the lipid conjugates described herein. In one particular embodiment, the lipid conjugate comprises a PEG-lipid conjugate. Examples of PEG-lipid conjugates include, but are not limited to, PEG-DAG conjugates, PEG-DAA conjugates, and mixtures thereof. In certain embodiments, the PEG-DAA conjugate in the lipid particle may comprise a PEG-didecyloxypropyl (C<sub>10</sub>) conjugate, a PEG-dilauryloxypropyl (C<sub>12</sub>) conjugate, a PEG-dimyristyloxypropyl (C<sub>14</sub>) conjugate, a PEG-dipalmityloxypropyl (C<sub>16</sub>) conjugate, a PEG-distearyloxypropyl (C<sub>18</sub>) conjugate, or mixtures thereof. In another embodiment, the lipid conjugate comprises a POZ-lipid conjugate such as a POZ-DAA conjugate.</div>
    </li> <li> <para-num num="[0140]"> </para-num> <div id="p-0144" num="0140" class="description-line">In some embodiments, the present invention provides nucleic acid-lipid particles (e.g., SNALP) comprising: (a) one or more (e.g., a cocktail) mRNA molecule(s) that each encode a protein; (b) one or more cationic lipids or salts thereof comprising from about 50 mol % to about 85 mol % of the total lipid present in the particle; (c) one or more non-cationic lipids comprising from about 13 mol % to about 49.5 mol % of the total lipid present in the particle; and (d) one or more conjugated lipids that inhibit aggregation of particles comprising from about 0.5 mol % to about 2 mol % of the total lipid present in the particle.</div>
    </li> <li> <para-num num="[0141]"> </para-num> <div id="p-0145" num="0141" class="description-line">In one aspect of this embodiment, the nucleic acid-lipid particle comprises: (a) one or more (e.g., a cocktail) mRNA molecule(s) that each encode a protein; (b) a cationic lipid or a salt thereof comprising from about 52 mol % to about 62 mol % of the total lipid present in the particle; (c) a mixture of a phospholipid and cholesterol or a derivative thereof comprising from about 36 mol % to about 47 mol % of the total lipid present in the particle; and (d) a PEG-lipid conjugate comprising from about 1 mol % to about 2 mol % of the total lipid present in the particle. This embodiment of nucleic acid-lipid particle is generally referred to herein as the â1:57â formulation. In one particular embodiment, the 1:57 formulation is a four-component system comprising about 1.4 mol % PEG-lipid conjugate (e.g., PEG2000-C-DMA), about 57.1 mol % cationic lipid (e.g., DLin-K-C2-DMA) or a salt thereof, about 7.1 mol % DPPC (or DSPC), and about 34.3 mol % cholesterol (or derivative thereof).</div>
    </li> <li> <para-num num="[0142]"> </para-num> <div id="p-0146" num="0142" class="description-line">In another aspect of this embodiment, the nucleic acid-lipid particle comprises: (a) one or more (e.g., a cocktail) mRNA molecule(s) that each encode a protein; (b) a cationic lipid or a salt thereof comprising from about 56.5 mol % to about 66.5 mol % of the total lipid present in the particle; (c) cholesterol or a derivative thereof comprising from about 31.5 mol % to about 42.5 mol % of the total lipid present in the particle; and (d) a PEG-lipid conjugate comprising from about 1 mol % to about 2 mol % of the total lipid present in the particle. This embodiment of nucleic acid-lipid particle is generally referred to herein as the â1:62â formulation. In one particular embodiment, the 1:62 formulation is a three-component system which is phospholipid-free and comprises about 1.5 mol % PEG-lipid conjugate (e.g., PEG2000-C-DMA), about 61.5 mol % cationic lipid (e.g., DLin-K-C2-DMA) or a salt thereof, and about 36.9 mol % cholesterol (or derivative thereof).</div>
    </li> <li> <para-num num="[0143]"> </para-num> <div id="p-0147" num="0143" class="description-line">Additional embodiments related to the 1:57 and 1:62 formulations are described in PCT Publication No. WO 09/127060 and published US patent application publication number US 2011/0071208 A1, the disclosures of which are herein incorporated by reference in their entirety for all purposes.</div>
    </li> <li> <para-num num="[0144]"> </para-num> <div id="p-0148" num="0144" class="description-line">In other embodiments, the present invention provides nucleic acid-lipid particles (e.g., SNALP) comprising: (a) one or more (e.g., a cocktail) mRNA molecule(s) that each encode a protein; (b) one or more cationic lipids or salts thereof comprising from about 2 mol % to about 50 mol % of the total lipid present in the particle; (c) one or more non-cationic lipids comprising from about 5 mol % to about 90 mol % of the total lipid present in the particle; and (d) one or more conjugated lipids that inhibit aggregation of particles comprising from about 0.5 mol % to about 20 mol % of the total lipid present in the particle.</div>
    </li> <li> <para-num num="[0145]"> </para-num> <div id="p-0149" num="0145" class="description-line">In one aspect of this embodiment, the nucleic acid-lipid particle comprises: (a) one or more (e.g., a cocktail) mRNA molecule(s) that each encode a protein; (b) a cationic lipid or a salt thereof comprising from about 30 mol % to about 50 mol % of the total lipid present in the particle; (c) a mixture of a phospholipid and cholesterol or a derivative thereof comprising from about 47 mol % to about 69 mol % of the total lipid present in the particle; and (d) a PEG-lipid conjugate comprising from about 1 mol % to about 3 mol % of the total lipid present in the particle. This embodiment of nucleic acid-lipid particle is generally referred to herein as the â2:40â formulation. In one particular embodiment, the 2:40 formulation is a four-component system which comprises about 2 mol % PEG-lipid conjugate (e.g., PEG2000-C-DMA), about 40 mol % cationic lipid (e.g., DLin-K-C2-DMA) or a salt thereof, about 10 mol % DPPC (or DSPC), and about 48 mol % cholesterol (or derivative thereof).</div>
    </li> <li> <para-num num="[0146]"> </para-num> <div id="p-0150" num="0146" class="description-line">In further embodiments, the present invention provides nucleic acid-lipid particles (e.g., SNALP) comprising: (a) one or more (e.g., a cocktail) mRNA molecule(s) that each encode a protein; (b) one or more cationic lipids or salts thereof comprising from about 50 mol % to about 65 mol % of the total lipid present in the particle; (c) one or more non-cationic lipids comprising from about 25 mol % to about 45 mol % of the total lipid present in the particle; and (d) one or more conjugated lipids that inhibit aggregation of particles comprising from about 5 mol % to about 10 mol % of the total lipid present in the particle.</div>
    </li> <li> <para-num num="[0147]"> </para-num> <div id="p-0151" num="0147" class="description-line">In one aspect of this embodiment, the nucleic acid-lipid particle comprises: (a) one or more (e.g., a cocktail) mRNA molecule(s) that each encode a protein; (b) a cationic lipid or a salt thereof comprising from about 50 mol % to about 60 mol % of the total lipid present in the particle; (c) a mixture of a phospholipid and cholesterol or a derivative thereof comprising from about 35 mol % to about 45 mol % of the total lipid present in the particle; and (d) a PEG-lipid conjugate comprising from about 5 mol % to about 10 mol % of the total lipid present in the particle. This embodiment of nucleic acid-lipid particle is generally referred to herein as the â7:54â formulation. In certain instances, the non-cationic lipid mixture in the 7:54 formulation comprises: (i) a phospholipid of from about 5 mol % to about 10 mol % of the total lipid present in the particle; and (ii) cholesterol or a derivative thereof of from about 25 mol % to about 35 mol % of the total lipid present in the particle. In one particular embodiment, the 7:54 formulation is a four-component system which comprises about 7 mol % PEG-lipid conjugate (e.g., PEG750-C-DMA), about 54 mol % cationic lipid (e.g., DLin-K-C2-DMA) or a salt thereof, about 7 mol % DPPC (or DSPC), and about 32 mol % cholesterol (or derivative thereof).</div>
    </li> <li> <para-num num="[0148]"> </para-num> <div id="p-0152" num="0148" class="description-line">In another aspect of this embodiment, the nucleic acid-lipid particle comprises: (a) one or more (e.g., a cocktail) mRNA molecule(s) that each encode a protein; (b) a cationic lipid or a salt thereof comprising from about 55 mol % to about 65 mol % of the total lipid present in the particle; (c) cholesterol or a derivative thereof comprising from about 30 mol % to about 40 mol % of the total lipid present in the particle; and (d) a PEG-lipid conjugate comprising from about 5 mol % to about 10 mol % of the total lipid present in the particle. This embodiment of nucleic acid-lipid particle is generally referred to herein as the â7:58â formulation. In one particular embodiment, the 7:58 formulation is a three-component system which is phospholipid-free and comprises about 7 mol % PEG-lipid conjugate (e.g., PEG750-C-DMA), about 58 mol % cationic lipid (e.g., DLin-K-C2-DMA) or a salt thereof, and about 35 mol % cholesterol (or derivative thereof).</div>
    </li> <li> <para-num num="[0149]"> </para-num> <div id="p-0153" num="0149" class="description-line">Additional embodiments related to the 7:54 and 7:58 formulations are described in published US patent application publication number US 2011/0076335 A1, the disclosure of which is herein incorporated by reference in its entirety for all purposes.</div>
    </li> <li> <para-num num="[0150]"> </para-num> <div id="p-0154" num="0150" class="description-line">The present invention also provides pharmaceutical compositions comprising a nucleic acid-lipid particle such as a SNALP and a pharmaceutically acceptable carrier.</div>
    </li> <li> <para-num num="[0151]"> </para-num> <div id="p-0155" num="0151" class="description-line">The nucleic acid-lipid particles of the present invention (e.g., SNALP) are useful for the therapeutic delivery of mRNAs that express one or more proteins (such as full length proteins, or biologically active fragments of full length proteins). In some embodiments, a cocktail of mRNAs that express different proteins is formulated into the same or different nucleic acid-lipid particles, and the particles are administered to a mammal (e.g., a human) requiring such treatment. In certain instances, a therapeutically effective amount of the nucleic acid-lipid particles can be administered to the mammal.</div>
    </li> <li> <para-num num="[0152]"> </para-num> <div id="p-0156" num="0152" class="description-line">In certain embodiments, the present invention provides a method for introducing one or more mRNA molecules into a cell by contacting the cell with a nucleic acid-lipid particle described herein (e.g., a SNALP formulation). In one particular embodiment, the cell is a reticuloendothelial cell (e.g., monocyte or macrophage), fibroblast cell, endothelial cell, or platelet cell.</div>
    </li> <li> <para-num num="[0153]"> </para-num> <div id="p-0157" num="0153" class="description-line">In some embodiments, the nucleic acid-lipid particles described herein (e.g., SNALP) are administered by one of the following routes of administration: oral, intranasal, intravenous, intraperitoneal, intramuscular, intra-articular, intralesional, intratracheal, subcutaneous, and intradermal. In particular embodiments, the nucleic acid-lipid particles are administered systemically, e.g., via enteral or parenteral routes of administration.</div>
    </li> <li> <para-num num="[0154]"> </para-num> <div id="p-0158" num="0154" class="description-line">In particular embodiments, the nucleic acid-lipid particles of the invention (e.g., SNALP) can preferentially deliver a payload such as an mRNA to the liver as compared to other tissues.</div>
    </li> <li> <para-num num="[0155]"> </para-num> <div id="p-0159" num="0155" class="description-line">In certain aspects, the present invention provides methods for expressing a protein in a mammal (e.g., human) in need thereof, the method comprising administering to the mammal a therapeutically effective amount of a nucleic acid-lipid particle (e.g., a SNALP formulation) comprising one or more mRNAs that encode one or more proteins under conditions that enable expression of the protein(s) in the mammal. For example, in embodiments in which the mRNA encodes a protein that is normally expressed in a healthy mammalian subject, the level of expression of the protein encoded by the mRNA encapsulated within the SNALP is at least 10%, or at least 20%, or at least 30%, or at least 40%, or at least 50%, or at least 60%, or at least 70%, or at least 80%, or at least 90%, or at least 100%, or greater than 100%, of the level of the protein that is normally expressed in a healthy mammalian subject.</div>
    </li> <li> <para-num num="[0156]"> </para-num> <div id="p-0160" num="0156" class="description-line">In other aspects, the present invention provides methods for treating, preventing, reducing the risk or likelihood of developing (e.g., reducing the susceptibility to), delaying the onset of, and/or ameliorating one or more symptoms associated with a disease in a mammal (e.g., human) in need thereof, wherein the disease is caused (at least in part) by reduced or aberrant expression of a protein. The methods each include the step of administering to the mammal a therapeutically effective amount of a nucleic acid-lipid particle (e.g., a SNALP formulation) comprising one or more mRNA molecules that encode a protein that is absent, or present at reduced levels, within the treated subject.</div>
    </li> <li> <para-num num="[0157]"> </para-num> <div id="p-0161" num="0157" class="description-line">mRNA molecules useful in the present invention may be chemically modified or unmodified. Typically mRNA molecules are chemically modified in order to reduce their ability to induce the innate immune response of a cell into which the mRNA is introduced.</div>
    </li> <li> <div id="p-0162" num="0000" class="description-line">Modifications to mRNA</div>
    </li> <li> <para-num num="[0158]"> </para-num> <div id="p-0163" num="0158" class="description-line">mRNA used in the practice of the present invention can include one, two, or more than two nucleoside modifications. In some embodiments, the modified mRNA exhibits reduced degradation in a cell into which the mRNA is introduced, relative to a corresponding unmodified mRNA.</div>
    </li> <li> <para-num num="[0159]"> </para-num> <div id="p-0164" num="0159" class="description-line">In some embodiments, modified nucleosides include pyridin-4-one ribonucleoside, 5-aza-uridine, 2-thio-5-aza-uridine, 2-thiouridine, 4-thio-pseudouridine, 2-thio-pseudouridine, 5-hydroxyuridine, 3-methyluridine, 5-carboxymethyl-uridine, 1-carboxymethyl-pseudouridine, 5-propynyl-uridine, 1-propynyl-pseudouridine, 5-taurinomethyluridine, 1-taurinomethyl-pseudouridine, 5-taurinomethyl-2-thio-uridine, 1-taurinomethyl-4-thio-uridine, 5-methyl-uridine, 1-methyl-pseudouridine, 4-thio-1-methyl-pseudouridine, 2-thio-1-methyl-pseudouridine, 1-methyl-1-deaza-pseudouridine, 2-thio-1-methyl-1-deaza-pseudouridine, dihydrouridine, dihydropseudouridine, 2-thio-dihydrouridine, 2-thio-dihydropseudouridine, 2-methoxyuridine, 2-methoxy-4-thio-uridine, 4-methoxy-pseudouridine, and 4-methoxy-2-thio-pseudouridine.</div>
    </li> <li> <para-num num="[0160]"> </para-num> <div id="p-0165" num="0160" class="description-line">In some embodiments, modified nucleosides include 5-aza-cytidine, pseudoisocytidine, 3-methyl-cytidine, N4-acetylcytidine, 5-formylcytidine, N4-methylcytidine, 5-hydroxymethylcytidine, 1-methyl-pseudoisocytidine, pyrrolo-cytidine, pyrrolo-pseudoisocytidine, 2-thio-cytidine, 2-thio-5-methyl-cytidine, 4-thio-pseudoisocytidine, 4-thio-1-methyl-pseudoisocytidine, 4-thio-1-methyl-1-deaza-pseudoisocytidine, 1-methyl-1-deaza-pseudoisocytidine, zebularine, 5-aza-zebularine, 5-methyl-zebularine, 5-aza-2-thio-zebularine, 2-thio-zebularine, 2-methoxy-cytidine, 2-methoxy-5-methyl-cytidine, 4-methoxy-pseudoisocytidine, and 4-methoxy-1-methyl-pseudoisocytidine.</div>
    </li> <li> <para-num num="[0161]"> </para-num> <div id="p-0166" num="0161" class="description-line">In other embodiments, modified nucleosides include 2-aminopurine, 2,6-diaminopurine, 7-deaza-adenine, 7-deaza-8-aza-adenine, 7-deaza-2-aminopurine, 7-deaza-8-aza-2-aminopurine, 7-deaza-2,6-diaminopurine, 7-deaza-8-aza-2,6-diaminopurine, 1-methyl adenosine, N6-methyladenosine, N6-isopentenyladenosine, N6-(cis-hydroxyisopentenyl)adenosine, 2-methylthio-N6-(cis-hydroxyisopentenyl) adenosine, N6-glycinylcarbamoyladenosine, N6-threonylcarbamoyladenosine, 2-methylthio-N6-threonyl carbamoyladenosine, N6,N6-dimethyladenosine, 7-methyladenine, 2-methylthio-adenine, and 2-methoxy-adenine.</div>
    </li> <li> <para-num num="[0162]"> </para-num> <div id="p-0167" num="0162" class="description-line">In specific embodiments, a modified nucleoside is 5â²-0-(1-Thiophosphate)-Adenosine, 5â²-0-(1-Thiophosphate)-Cytidine, 5â²-0-(1-Thiophosphate)-Guanosine, 5â²-0-(1-Thiophosphate)-Uridine or 5â²-0-(1-Thiophosphate)-Pseudouridine. The Î±-thio substituted phosphate moiety is provided to confer stability to RNA polymers through the unnatural phosphorothioate backbone linkages. Phosphorothioate RNA have increased nuclease resistance and subsequently a longer half-life in a cellular environment. Phosphorothioate linked nucleic acids are expected to also reduce the innate immune response through weaker binding/activation of cellular innate immune molecules.</div>
    </li> <li> <para-num num="[0163]"> </para-num> <div id="p-0168" num="0163" class="description-line">In certain embodiments it is desirable to intracellularly degrade a modified nucleic acid introduced into the cell, for example if precise timing of protein production is desired. Thus, the invention provides a modified nucleic acid containing a degradation domain, which is capable of being acted on in a directed manner within a cell.</div>
    </li> <li> <para-num num="[0164]"> </para-num> <div id="p-0169" num="0164" class="description-line">In other embodiments, modified nucleosides include inosine, 1-methyl-inosine, wyosine, wybutosine, 7-deaza-guanosine, 7-deaza-8-aza-guanosine, 6-thio-guanosine, 6-thio-7-deaza-guanosine, 6-thio-7-deaza-8-aza-guanosine, 7-methyl-guanosine, 6-thio-7-methyl-guanosine, 7-methylinosine, 6-methoxy-guanosine, 1-methylguanosine, N2-methylguanosine, N2,N2-dimethylguanosine, 8-oxo-guanosine, 7-methyl-8-oxo-guanosine, 1-methyl-6-thio-guanosine, N2-methyl-6-thio-guanosine, and N2,N2-dimethyl-6-thio-guanosine.</div>
    </li> <heading id="h-0006">Optional Components of the Modified Nucleic Acids</heading>
    <li> <para-num num="[0165]"> </para-num> <div id="p-0170" num="0165" class="description-line">In further embodiments, the modified nucleic acids may include other optional components, which can be beneficial in some embodiments. These optional components include, but are not limited to, untranslated regions, kozak sequences, intronic nucleotide sequences, internal ribosome entry site (IRES), caps and polyA tails. For example, a 5â² untranslated region (UTR) and/or a 3â² UTR may be provided, wherein either or both may independently contain one or more different nucleoside modifications. In such embodiments, nucleoside modifications may also be present in the translatable region. Also provided are nucleic acids containing a Kozak sequence.</div>
    </li> <li> <para-num num="[0166]"> </para-num> <div id="p-0171" num="0166" class="description-line">Additionally, provided are nucleic acids containing one or more intronic nucleotide sequences capable of being excised from the nucleic acid.</div>
    </li> <heading id="h-0007">Untranslated Regions (UTRs)</heading>
    <li> <para-num num="[0167]"> </para-num> <div id="p-0172" num="0167" class="description-line">Untranslated regions (UTRs) of a gene are transcribed but not translated. The 5â²UTR starts at the transcription start site and continues to the start codon but does not include the start codon; whereas, the 3â²UTR starts immediately following the stop codon and continues until the transcriptional termination signal. There is growing body of evidence about the regulatory roles played by the UTRs in terms of stability of the nucleic acid molecule and translation. The regulatory features of a UTR can be incorporated into the mRNA used in the present invention to increase the stability of the molecule. The specific features can also be incorporated to ensure controlled down-regulation of the transcript in case they are misdirected to undesired organs sites.</div>
    </li> <heading id="h-0008">5â² Capping</heading>
    <li> <para-num num="[0168]"> </para-num> <div id="p-0173" num="0168" class="description-line">The 5â² cap structure of an mRNA is involved in nuclear export, increasing mRNA stability and binds the mRNA Cap Binding Protein (CBP), which is responsible for mRNA stability in the cell and translation competency through the association of CBP with poly(A) binding protein to form the mature cyclic mRNA species. The cap further assists the removal of 5â² proximal introns removal during mRNA splicing.</div>
    </li> <li> <para-num num="[0169]"> </para-num> <div id="p-0174" num="0169" class="description-line">Endogenous mRNA molecules may be 5â²-end capped generating a 5â²-ppp-5â²-triphosphate linkage between a terminal guanosine cap residue and the 5â²-terminal transcribed sense nucleotide of the mRNA molecule. This 5â²-guanylate cap may then be methylated to generate an N7-methyl-guanylate residue. The ribose sugars of the terminal and/or anteterminal transcribed nucleotides of the 5â² end of the mRNA may optionally also be 2â²-0-methylated. 5â²-decapping through hydrolysis and cleavage of the guanylate cap structure may target a nucleic acid molecule, such as an mRNA molecule, for degradation.</div>
    </li> <heading id="h-0009">IRES Sequences</heading>
    <li> <para-num num="[0170]"> </para-num> <div id="p-0175" num="0170" class="description-line">mRNA containing an internal ribosome entry site (IRES) are also useful in the practice of the present invention. An IRES may act as the sole ribosome binding site, or may serve as one of multiple ribosome binding sites of an mRNA. An mRNA containing more than one functional ribosome binding site may encode several peptides or polypeptides that are translated independently by the ribosomes (âmulticistronic mRNAâ). When mRNA are provided with an IRES, further optionally provided is a second translatable region. Examples of IRES sequences that can be used according to the invention include without limitation, those from picornaviruses (e.g. FMDV), pest viruses (CFFV), polio viruses (PV), encephalomyocarditis viruses (ECMV), foot-and-mouth disease viruses (FMDV), hepatitis C viruses (HCV), classical swine fever viruses (CSFV), murine leukemia virus (MLV), simian immune deficiency viruses (S1V) or cricket paralysis viruses (CrPV).</div>
    </li> <heading id="h-0010">Poly-A Tails</heading>
    <li> <para-num num="[0171]"> </para-num> <div id="p-0176" num="0171" class="description-line">During RNA processing, a long chain of adenine nucleotides (poly-A tail) may be added to a polynucleotide such as an mRNA molecules in order to increase stability. Immediately after transcription, the 3â² end of the transcript may be cleaved to free a 3â² hydroxyl. Then poly-A polymerase adds a chain of adenine nucleotides to the RNA. The process, called polyadenylation, adds a poly-A tail that can be between 100 and 250 residues long.</div>
    </li> <li> <para-num num="[0172]"> </para-num> <div id="p-0177" num="0172" class="description-line">Generally, the length of a poly-A tail is greater than 30 nucleotides in length. In another embodiment, the poly-A tail is greater than 35 nucleotides in length (e.g., at least or greater than about 35, 40, 45, 50, 55, 60, 70, 80, 90, 100, 120, 140, 160, 180, 200, 250, 300, 350, 400, 450, 500, 600, 700, 800, 900, 1000, 1100, 1200, 1300, 1400, 1500, 1600, 1700, 1800, 1900, 2,000, 2,500, and 3,000 nucleotides).</div>
    </li> <li> <para-num num="[0173]"> </para-num> <div id="p-0178" num="0173" class="description-line">In this context the poly-A tail may be 10, 20, 30, 40, 50, 60, 70, 80, 90, or 100% greater in length than the modified mRNA. The poly-A tail may also be designed as a fraction of modified nucleic acids to which it belongs. In this context, the poly-A tail may be 10, 20, 30, 40, 50, 60, 70, 80, or 90% or more of the total length of the modified mRNA or the total length of the modified mRNA minus the poly-A tail.</div>
    </li> <li> <div id="p-0179" num="0000" class="description-line">Generating mRNA Molecules</div>
    </li> <li> <para-num num="[0174]"> </para-num> <div id="p-0180" num="0174" class="description-line">Methods for isolating RNA, synthesizing RNA, hybridizing nucleic acids, making and screening cDNA libraries, and performing PCR are well known in the art (see, e.g., Gubler and Hoffman, <i>Gene, </i>25:263-269 (1983); Sambrook et al., <i>Molecular Cloning, A Laboratory Manual </i>(2nd ed. 1989)); as are PCR methods (see, U.S. Pat. Nos. 4,683,195 and 4,683,202; <i>PCR Protocols: A Guide to Methods and Applications </i>(Innis et al., eds, 1990)). Expression libraries are also well known to those of skill in the art. Additional basic texts disclosing the general methods of use in this invention include Kriegler, <i>Gene Transfer and Expression: A Laboratory Manual </i>(1990); and <i>Current Protocols in Molecular Biology </i>(Ausubel et al., eds., 1994). The disclosures of these references are herein incorporated by reference in their entirety for all purposes.</div>
    </li> <li> <div id="p-0181" num="0000" class="description-line">Generating siRNA Molecules</div>
    </li> <li> <para-num num="[0175]"> </para-num> <div id="p-0182" num="0175" class="description-line">siRNA can be provided in several forms including, e.g., as one or more isolated small-interfering RNA (siRNA) duplexes, as longer double-stranded RNA (dsRNA), or as siRNA or dsRNA transcribed from a transcriptional cassette in a DNA plasmid. In some embodiments, siRNA may be produced enzymatically or by partial/total organic synthesis, and modified ribonucleotides can be introduced by in vitro enzymatic or organic synthesis. In certain instances, each strand is prepared chemically. Methods of synthesizing RNA molecules are known in the art, e.g., the chemical synthesis methods as described in Verma and Eckstein (1998) or as described herein.</div>
    </li> <li> <para-num num="[0176]"> </para-num> <div id="p-0183" num="0176" class="description-line">Methods for isolating RNA, synthesizing RNA, hybridizing nucleic acids, making and screening cDNA libraries, and performing PCR are well known in the art (see, e.g., Gubler and Hoffman, <i>Gene, </i>25:263-269 (1983); Sambrook et al., supra; Ausubel et al., supra), as are PCR methods (see, U.S. Pat. Nos. 4,683,195 and 4,683,202; <i>PCR Protocols: A Guide to Methods and Applications </i>(Innis et al., eds, 1990)). Expression libraries are also well known to those of skill in the art. Additional basic texts disclosing the general methods of use in this invention include Sambrook et al., <i>Molecular Cloning, A Laboratory Manual </i>(2nd ed. 1989); Kriegler, <i>Gene Transfer and Expression: A Laboratory Manual </i>(1990); and <i>Current Protocols in Molecular Biology </i>(Ausubel et al., eds., 1994). The disclosures of these references are herein incorporated by reference in their entirety for all purposes.</div>
    </li> <li> <para-num num="[0177]"> </para-num> <div id="p-0184" num="0177" class="description-line">Preferably, siRNA are chemically synthesized. The oligonucleotides that comprise the siRNA molecules of the invention can be synthesized using any of a variety of techniques known in the art, such as those described in Usman et al., <i>J. Am. Chem. Soc., </i>109:7845 (1987); Scaringe et al., <i>Nucl. Acids Res., </i>18:5433 (1990); Wincott et al., <i>Nucl. Acids Res., </i>23:2677-2684 (1995); and Wincott et al., <i>Methods Mol. Bio., </i>74:59 (1997). The synthesis of oligonucleotides makes use of common nucleic acid protecting and coupling groups, such as dimethoxytrityl at the 5â²-end and phosphoramidites at the 3â²-end. As a non-limiting example, small scale syntheses can be conducted on an Applied Biosystems synthesizer using a 0.2 Î¼mol scale protocol. Alternatively, syntheses at the 0.2 Î¼mol scale can be performed on a 96-well plate synthesizer from Protogene (Palo Alto, Calif.). However, a larger or smaller scale of synthesis is also within the scope of this invention. Suitable reagents for oligonucleotide synthesis, methods for RNA deprotection, and methods for RNA purification are known to those of skill in the art.</div>
    </li> <li> <para-num num="[0178]"> </para-num> <div id="p-0185" num="0178" class="description-line">siRNA molecules can be assembled from two distinct oligonucleotides, wherein one oligonucleotide comprises the sense strand and the other comprises the antisense strand of the siRNA. For example, each strand can be synthesized separately and joined together by hybridization or ligation following synthesis and/or deprotection.</div>
    </li> <heading id="h-0011">Lipid Particles</heading>
    <li> <para-num num="[0179]"> </para-num> <div id="p-0186" num="0179" class="description-line">In certain aspects, the present invention provides lipid particles comprising one or more therapeutic mRNA molecules encapsulated within the lipid particles.</div>
    </li> <li> <para-num num="[0180]"> </para-num> <div id="p-0187" num="0180" class="description-line">In some embodiments, the mRNA is fully encapsulated within the lipid portion of the lipid particle such that the mRNA in the lipid particle is resistant in aqueous solution to nuclease degradation. In other embodiments, the lipid particles described herein are substantially non-toxic to mammals such as humans. The lipid particles of the invention typically have a mean diameter of from about 30 nm to about 150 nm, from about 40 nm to about 150 nm, from about 50 nm to about 150 nm, from about 60 nm to about 130 nm, from about 70 nm to about 110 nm, or from about 70 to about 90 nm. The lipid particles of the invention also typically have a lipid:mRNA ratio (mass/mass ratio) of from about 1:1 to about 100:1, from about 1:1 to about 50:1, from about 2:1 to about 25:1, from about 3:1 to about 20:1, from about 5:1 to about 15:1, or from about 5:1 to about 10:1, or from about 10:1 to about 14:1, or from about 9:1 to about 20:1. In one embodiment, the lipid particles of the invention have a lipid:mRNA ratio (mass/mass ratio) of about 12:1, such as 12:1. In another embodiment, the lipid particles of the invention have a lipid:mRNA ratio (mass/mass ratio) of about 13:1, such as 13:1.</div>
    </li> <li> <para-num num="[0181]"> </para-num> <div id="p-0188" num="0181" class="description-line">In preferred embodiments, the lipid particles of the invention are serum-stable nucleic acid-lipid particles (SNALP) which comprise an mRNA, a cationic lipid (e.g., one or more cationic lipids of Formula I-III or salts thereof as set forth herein), a phospholipid, and a conjugated lipid that inhibits aggregation of the particles (e.g., one or more PEG-lipid conjugates). The lipid particles can also include cholesterol. The SNALP may comprise at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more unmodified and/or modified mRNA that express one or more polypeptides. Nucleic acid-lipid particles and their method of preparation are described in, e.g., U.S. Pat. Nos. 5,753,613; 5,785,992; 5,705,385; 5,976,567; 5,981,501; 6,110,745; and 6,320,017; and PCT Publication No. WO 96/40964, the disclosures of which are each herein incorporated by reference in their entirety for all purposes.</div>
    </li> <li> <para-num num="[0182]"> </para-num> <div id="p-0189" num="0182" class="description-line">In the nucleic acid-lipid particles of the invention, the mRNA may be fully encapsulated within the lipid portion of the particle, thereby protecting the nucleic acid from nuclease degradation. In preferred embodiments, a SNALP comprising an mRNA is fully encapsulated within the lipid portion of the particle, thereby protecting the nucleic acid from nuclease degradation. In certain instances, the mRNA in the SNALP is not substantially degraded after exposure of the particle to a nuclease at 37Â° C. for at least about 20, 30, 45, or 60 minutes. In certain other instances, the mRNA in the SNALP is not substantially degraded after incubation of the particle in serum at 37Â° C. for at least about 30, 45, or 60 minutes or at least about 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, or 36 hours. In other embodiments, the mRNA is complexed with the lipid portion of the particle. One of the benefits of the formulations of the present invention is that the nucleic acid-lipid particle compositions are substantially non-toxic to mammals such as humans.</div>
    </li> <li> <para-num num="[0183]"> </para-num> <div id="p-0190" num="0183" class="description-line">The term âfully encapsulatedâ indicates that the nucleic acid (mRNA) in the nucleic acid-lipid particle is not significantly degraded after exposure to serum or a nuclease assay that would significantly degrade free RNA. In a fully encapsulated system, preferably less than about 25% of the nucleic acid in the particle is degraded in a treatment that would normally degrade 100% of free nucleic acid, more preferably less than about 10%, and most preferably less than about 5% of the nucleic acid in the particle is degraded. âFully encapsulatedâ also indicates that the nucleic acid-lipid particles are serum-stable, that is, that they do not rapidly decompose into their component parts upon in vivo administration.</div>
    </li> <li> <para-num num="[0184]"> </para-num> <div id="p-0191" num="0184" class="description-line">In the context of nucleic acids, full encapsulation may be determined by performing a membrane-impermeable fluorescent dye exclusion assay, which uses a dye that has enhanced fluorescence when associated with nucleic acid. Specific dyes such as OliGreenÂ® and RiboGreenÂ® (Invitrogen Corp.; Carlsbad, Calif.) are available for the quantitative determination of plasmid DNA, single-stranded deoxyribonucleotides, and/or single- or double-stranded ribonucleotides. Encapsulation is determined by adding the dye to a liposomal formulation, measuring the resulting fluorescence, and comparing it to the fluorescence observed upon addition of a small amount of nonionic detergent. Detergent-mediated disruption of the liposomal bilayer releases the encapsulated nucleic acid, allowing it to interact with the membrane-impermeable dye. Nucleic acid encapsulation may be calculated as E=(I<sub>o</sub>âI)/I<sub>o</sub>, where I and I<sub>o </sub>refer to the fluorescence intensities before and after the addition of detergent (see, Wheeler et al., <i>Gene Ther., </i>6:271-281 (1999)).</div>
    </li> <li> <para-num num="[0185]"> </para-num> <div id="p-0192" num="0185" class="description-line">In other embodiments, the present invention provides a nucleic acid-lipid particle (e.g., SNALP) composition comprising a plurality of nucleic acid-lipid particles.</div>
    </li> <li> <para-num num="[0186]"> </para-num> <div id="p-0193" num="0186" class="description-line">In some instances, the SNALP composition comprises mRNA that is fully encapsulated within the lipid portion of the particles, such that from about 30% to about 100%, from about 40% to about 100%, from about 50% to about 100%, from about 60% to about 100%, from about 70% to about 100%, from about 80% to about 100%, from about 90% to about 100%, from about 30% to about 95%, from about 40% to about 95%, from about 50% to about 95%, from about 60% to about 95%, from about 70% to about 95%, from about 80% to about 95%, from about 85% to about 95%, from about 90% to about 95%, from about 30% to about 90%, from about 40% to about 90%, from about 50% to about 90%, from about 60% to about 90%, from about 70% to about 90%, from about 80% to about 90%, or at least about 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% (or any fraction thereof or range therein) of the particles have the mRNA encapsulated therein.</div>
    </li> <li> <para-num num="[0187]"> </para-num> <div id="p-0194" num="0187" class="description-line">Depending on the intended use of the lipid particles of the invention, the proportions of the components can be varied and the delivery efficiency of a particular formulation can be measured using, e.g., an endosomal release parameter (ERP) assay.</div>
    </li> <heading id="h-0012">Cationic Lipids</heading>
    <li> <para-num num="[0188]"> </para-num> <div id="p-0195" num="0188" class="description-line">Any of a variety of cationic lipids or salts thereof may be used in the lipid particles of the present invention (e.g., SNALP), either alone or in combination with one or more other cationic lipid species or non-cationic lipid species. The cationic lipids include the (R) and/or (S) enantiomers thereof. Typically, the cationic lipids contain a portion (i.e. a hydrophobic moiety) that comprises unsaturated and/or saturated hydrocarbon chains.</div>
    </li> <li> <para-num num="[0189]"> </para-num> <div id="p-0196" num="0189" class="description-line">In one aspect, cationic lipids of Formula I having the following structure are useful in the present invention:</div>
    </li> <li> <div id="p-0197" num="0000" class="description-line">
      <chemistry id="CHEM-US-00002" num="00002">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/69/66/b4/25e30d4bfba823/US20190240354A1-20190808-C00002.png"><img id="EMI-C00002" he="21.34mm" wi="69.93mm" file="US20190240354A1-20190808-C00002.TIF" alt="Figure US20190240354A1-20190808-C00002" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="280" height="85" alt="Figure US20190240354A1-20190808-C00002" class="patent-full-image" src="https://patentimages.storage.googleapis.com/69/66/b4/25e30d4bfba823/US20190240354A1-20190808-C00002.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00002" attachment-type="cdx" file="US20190240354A1-20190808-C00002.CDX"> </attachment>
          <attachment idref="CHEM-US-00002" attachment-type="mol" file="US20190240354A1-20190808-C00002.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0190]"> </para-num> <div id="p-0198" num="0190" class="description-line">or salts thereof, wherein:</div>
    </li> <li> <para-num num="[0191]"> </para-num> <div id="p-0199" num="0191" class="description-line">R<sup>1 </sup>and R<sup>2 </sup>are either the same or different and are independently hydrogen (H) or an optionally substituted C<sub>1</sub>-C<sub>6 </sub>alkyl, C<sub>2</sub>-C<sub>6 </sub>alkenyl, or C<sub>2</sub>-C<sub>6 </sub>alkynyl, or R<sup>1 </sup>and R<sup>2 </sup>may join to form an optionally substituted heterocyclic ring of 4 to 6 carbon atoms and 1 or 2 heteroatoms selected from the group consisting of nitrogen (N), oxygen (O), and mixtures thereof;</div>
    </li> <li> <para-num num="[0192]"> </para-num> <div id="p-0200" num="0192" class="description-line">R<sup>3 </sup>is either absent or is hydrogen (H) or a C<sub>1</sub>-C<sub>6 </sub>alkyl to provide a quaternary amine; R<sup>4 </sup>and R<sup>5 </sup>are either the same or different and are independently an optionally substituted C<sub>10</sub>-C<sub>24 </sub>alkyl, C<sub>10</sub>-C<sub>24 </sub>alkenyl, C<sub>10</sub>-C<sub>24 </sub>alkynyl, or C<sub>10</sub>-C<sub>24 </sub>acyl, wherein at least one of R<sup>4 </sup>and R<sup>5 </sup>comprises at least two sites of unsaturation; and</div>
    </li> <li> <para-num num="[0193]"> </para-num> <div id="p-0201" num="0193" class="description-line">n is 0, 1, 2, 3, or 4.</div>
    </li> <li> <para-num num="[0194]"> </para-num> <div id="p-0202" num="0194" class="description-line">In some embodiments, R<sup>1 </sup>and R<sup>2 </sup>are independently an optionally substituted C<sub>1</sub>-C<sub>4 </sub>alkyl, C<sub>2</sub>-C<sub>4 </sub>alkenyl, or C<sub>2</sub>-C<sub>4 </sub>alkynyl. In one preferred embodiment, R<sup>1 </sup>and R<sup>2 </sup>are both methyl groups. In other preferred embodiments, n is 1 or 2. In other embodiments, R<sup>3 </sup>is absent when the pH is above the pK<sub>a </sub>of the cationic lipid and R<sup>3 </sup>is hydrogen when the pH is below the pK<sub>a </sub>of the cationic lipid such that the amino head group is protonated. In an alternative embodiment, R<sup>3 </sup>is an optionally substituted C<sub>1</sub>-C<sub>4 </sub>alkyl to provide a quaternary amine. In further embodiments, R<sup>4 </sup>and R<sup>5 </sup>are independently an optionally substituted C<sub>12</sub>-C<sub>20 </sub>or C<sub>14</sub>-C<sub>22 </sub>alkyl, C<sub>12</sub>-C<sub>20 </sub>or C<sub>14</sub>-C<sub>22 </sub>alkenyl, C<sub>12</sub>-C<sub>20 </sub>or C<sub>14</sub>-C<sub>22 </sub>alkynyl, or C<sub>12</sub>-C<sub>20 </sub>or C<sub>14</sub>-C<sub>22 </sub>acyl, wherein at least one of R<sup>4 </sup>and R<sup>5 </sup>comprises at least two sites of unsaturation.</div>
    </li> <li> <para-num num="[0195]"> </para-num> <div id="p-0203" num="0195" class="description-line">In certain embodiments, R<sup>4 </sup>and R<sup>5 </sup>are independently selected from the group consisting of a dodecadienyl moiety, a tetradecadienyl moiety, a hexadecadienyl moiety, an octadecadienyl moiety, an icosadienyl moiety, a dodecatrienyl moiety, a tetradectrienyl moiety, a hexadecatrienyl moiety, an octadecatrienyl moiety, an icosatrienyl moiety, an arachidonyl moiety, and a docosahexaenoyl moiety, as well as acyl derivatives thereof (e.g., linoleoyl, linolenoyl, Î³-linolenoyl, etc.). In some instances, one of R<sup>4 </sup>and R<sup>5 </sup>comprises a branched alkyl group (e.g., a phytanyl moiety) or an acyl derivative thereof (e.g., a phytanoyl moiety). In certain instances, the octadecadienyl moiety is a linoleyl moiety. In certain other instances, the octadecatrienyl moiety is a linolenyl moiety or a Î³-linolenyl moiety. In certain embodiments, R<sup>4 </sup>and R<sup>5 </sup>are both linoleyl moieties, linolenyl moieties, or Î³-linolenyl moieties. In particular embodiments, the cationic lipid of Formula I is 1,2-dilinoleyloxy-N,N-dimethylaminopropane (DLinDMA), 1,2-dilinolenyloxy-N,N-dimethylaminopropane (DLenDMA), 1,2-dilinoleyloxy-(N,N-dimethyl)-butyl-4-amine (C2-DLinDMA), 1,2-dilinoleoyloxy-(N,N-dimethyl)-butyl-4-amine (C2-DLinDAP), or mixtures thereof.</div>
    </li> <li> <para-num num="[0196]"> </para-num> <div id="p-0204" num="0196" class="description-line">In some embodiments, the cationic lipid of Formula I forms a salt (preferably a crystalline salt) with one or more anions. In one particular embodiment, the cationic lipid of Formula I is the oxalate (e.g., hemioxalate) salt thereof, which is preferably a crystalline salt.</div>
    </li> <li> <para-num num="[0197]"> </para-num> <div id="p-0205" num="0197" class="description-line">The synthesis of cationic lipids such as DLinDMA and DLenDMA, as well as additional cationic lipids, is described in U.S. Patent Publication No. 20060083780, the disclosure of which is herein incorporated by reference in its entirety for all purposes. The synthesis of cationic lipids such as C2-DLinDMA and C2-DLinDAP, as well as additional cationic lipids, is described in international patent application number WO2011/000106 the disclosure of which is herein incorporated by reference in its entirety for all purposes.</div>
    </li> <li> <para-num num="[0198]"> </para-num> <div id="p-0206" num="0198" class="description-line">In another aspect, cationic lipids of Formula II having the following structure (or salts thereof) are useful in the present invention:</div>
    </li> <li> <div id="p-0207" num="0000" class="description-line">
      <chemistry id="CHEM-US-00003" num="00003">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/fc/f1/2f/be034283124296/US20190240354A1-20190808-C00003.png"><img id="EMI-C00003" he="17.27mm" wi="69.93mm" file="US20190240354A1-20190808-C00003.TIF" alt="Figure US20190240354A1-20190808-C00003" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="280" height="69" alt="Figure US20190240354A1-20190808-C00003" class="patent-full-image" src="https://patentimages.storage.googleapis.com/fc/f1/2f/be034283124296/US20190240354A1-20190808-C00003.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00003" attachment-type="cdx" file="US20190240354A1-20190808-C00003.CDX"> </attachment>
          <attachment idref="CHEM-US-00003" attachment-type="mol" file="US20190240354A1-20190808-C00003.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <div id="p-0208" num="0000" class="description-line">wherein R<sup>1 </sup>and R<sup>2 </sup>are either the same or different and are independently an optionally substituted C<sub>12</sub>-C<sub>24 </sub>alkyl, C<sub>12</sub>-C<sub>24 </sub>alkenyl, C<sub>12</sub>-C<sub>24 </sub>alkynyl, or C<sub>12</sub>-C<sub>24 </sub>acyl; R<sup>3 </sup>and R<sup>4 </sup>are either the same or different and are independently an optionally substituted C<sub>1</sub>-C<sub>6 </sub>alkyl, C<sub>2</sub>-C<sub>6 </sub>alkenyl, or C<sub>2</sub>-C<sub>6 </sub>alkynyl, or R<sup>3 </sup>and R<sup>4 </sup>may join to form an optionally substituted heterocyclic ring of 4 to 6 carbon atoms and 1 or 2 heteroatoms chosen from nitrogen and oxygen; R<sup>5 </sup>is either absent or is hydrogen (H) or a C<sub>1</sub>-C<sub>6 </sub>alkyl to provide a quaternary amine; m, n, and p are either the same or different and are independently either 0, 1, or 2, with the proviso that m, n, and p are not simultaneously 0; q is 0, 1, 2, 3, or 4; and Y and Z are either the same or different and are independently O, S, or NH. In a preferred embodiment, q is 2.</div>
    </li> <li> <para-num num="[0199]"> </para-num> <div id="p-0209" num="0199" class="description-line">In some embodiments, the cationic lipid of Formula II is 2,2-dilinoleyl-4-(2-dimethylaminoethyl)-[1,3]-dioxolane, 2,2-dilinoleyl-4-(3-dimethylaminopropyl)-[1,3]-dioxolane, 2,2-dilinoleyl-4-(4-dimethylaminobutyl)-[1,3]-dioxolane, 2,2-dilinoleyl-5-dimethylaminomethyl-[1,3]-dioxane, 2,2-dilinoleyl-4-N-methylpepiazino-[1,3]-dioxolane, 2,2-dilinoleyl-4-dimethylaminomethyl-[1,3]-dioxolane, 2,2-dioleoyl-4-dimethylaminomethyl-[1,3]-dioxolane, 2,2-distearoyl-4-dimethylaminomethyl-[1,3]-dioxolane, 2,2-dilinoleyl-4-N-morpholino-[1,3]-dioxolane, 2,2-Dilinoleyl-4-trimethylamino-[1,3]-dioxolane chloride, 2,2-dilinoleyl-4,5-bis(dimethylaminomethyl)-[1,3]-dioxolane, 2,2-dilinoleyl-4-methylpiperzine-[1,3]-dioxolane, or mixtures thereof. In preferred embodiments, the cationic lipid of Formula II is 2,2-dilinoleyl-4-(2-dimethylaminoethyl)-[1,3]-dioxolane.</div>
    </li> <li> <para-num num="[0200]"> </para-num> <div id="p-0210" num="0200" class="description-line">In some embodiments, the cationic lipid of Formula II forms a salt (preferably a crystalline salt) with one or more anions. In one particular embodiment, the cationic lipid of Formula II is the oxalate (e.g., hemioxalate) salt thereof, which is preferably a crystalline salt.</div>
    </li> <li> <para-num num="[0201]"> </para-num> <div id="p-0211" num="0201" class="description-line">The synthesis of cationic lipids such as 2,2-dilinoleyl-4-dimethylaminomethyl-[1,3]-dioxolane, as well as additional cationic lipids, is described in PCT Publication No. WO 09/086558, the disclosure of which is herein incorporated by reference in its entirety for all purposes, and in PCT Application No. PCT/US2009/060251, entitled âImproved Amino Lipids and Methods for the Delivery of Nucleic Acids,â the disclosure of which is incorporated herein by reference in its entirety for all purposes.</div>
    </li> <li> <para-num num="[0202]"> </para-num> <div id="p-0212" num="0202" class="description-line">In a further aspect, cationic lipids of Formula III having the following structure are useful in the present invention:</div>
    </li> <li> <div id="p-0213" num="0000" class="description-line">
      <chemistry id="CHEM-US-00004" num="00004">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/0f/5a/2b/42e9bd46146d6d/US20190240354A1-20190808-C00004.png"><img id="EMI-C00004" he="20.66mm" wi="113.28mm" file="US20190240354A1-20190808-C00004.TIF" alt="Figure US20190240354A1-20190808-C00004" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="453" height="83" alt="Figure US20190240354A1-20190808-C00004" class="patent-full-image" src="https://patentimages.storage.googleapis.com/0f/5a/2b/42e9bd46146d6d/US20190240354A1-20190808-C00004.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00004" attachment-type="cdx" file="US20190240354A1-20190808-C00004.CDX"> </attachment>
          <attachment idref="CHEM-US-00004" attachment-type="mol" file="US20190240354A1-20190808-C00004.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <div id="p-0214" num="0000" class="description-line">or salts thereof, wherein: R<sup>1 </sup>and R<sup>2 </sup>are either the same or different and are independently an optionally substituted C<sub>1</sub>-C<sub>6 </sub>alkyl, C<sub>2</sub>-C<sub>6 </sub>alkenyl, or C<sub>2</sub>-C<sub>6 </sub>alkynyl, or R<sup>1 </sup>and R<sup>2 </sup>may join to form an optionally substituted heterocyclic ring of 4 to 6 carbon atoms and 1 or 2 heteroatoms selected from the group consisting of nitrogen (N), oxygen (O), and mixtures thereof; R<sup>3 </sup>is either absent or is hydrogen (H) or a C<sub>1</sub>-C<sub>6 </sub>alkyl to provide a quaternary amine; R<sup>4 </sup>and R<sup>5 </sup>are either absent or present and when present are either the same or different and are independently an optionally substituted C<sub>1</sub>-C<sub>10 </sub>alkyl or C<sub>2</sub>-C<sub>10 </sub>alkenyl; and n is 0, 1, 2, 3, or 4.</div>
    </li> <li> <para-num num="[0203]"> </para-num> <div id="p-0215" num="0203" class="description-line">In some embodiments, R<sup>1 </sup>and R<sup>2 </sup>are independently an optionally substituted C<sub>1</sub>-C<sub>4 </sub>alkyl, C<sub>2</sub>-C<sub>4 </sub>alkenyl, or C<sub>2</sub>-C<sub>4 </sub>alkynyl. In a preferred embodiment, R<sup>1 </sup>and R<sup>2 </sup>are both methyl groups. In another preferred embodiment, R<sup>4 </sup>and R<sup>5 </sup>are both butyl groups. In yet another preferred embodiment, n is 1. In other embodiments, R<sup>3 </sup>is absent when the pH is above the pK<sub>a </sub>of the cationic lipid and R<sup>3 </sup>is hydrogen when the pH is below the pK<sub>a </sub>of the cationic lipid such that the amino head group is protonated. In an alternative embodiment, R<sup>3 </sup>is an optionally substituted C<sub>1</sub>-C<sub>4 </sub>alkyl to provide a quaternary amine. In further embodiments, R<sup>4 </sup>and R<sup>5 </sup>are independently an optionally substituted C<sub>2</sub>-C<sub>6 </sub>or C<sub>2</sub>-C<sub>4 </sub>alkyl or C<sub>2</sub>-C<sub>6 </sub>or C<sub>2</sub>-C<sub>4 </sub>alkenyl.</div>
    </li> <li> <para-num num="[0204]"> </para-num> <div id="p-0216" num="0204" class="description-line">In an alternative embodiment, the cationic lipid of Formula III comprises ester linkages between the amino head group and one or both of the alkyl chains. In some embodiments, the cationic lipid of Formula III forms a salt (preferably a crystalline salt) with one or more anions. In one particular embodiment, the cationic lipid of Formula III is the oxalate (e.g., hemioxalate) salt thereof, which is preferably a crystalline salt.</div>
    </li> <li> <para-num num="[0205]"> </para-num> <div id="p-0217" num="0205" class="description-line">Although each of the alkyl chains in Formula III contains cis double bonds at positions 6, 9, and 12 (i.e., cis,cis,cis-Î<sup>6</sup>,Î<sup>9</sup>,Î<sup>12</sup>), in an alternative embodiment, one, two, or three of these double bonds in one or both alkyl chains may be in the trans configuration.</div>
    </li> <li> <para-num num="[0206]"> </para-num> <div id="p-0218" num="0206" class="description-line">In one embodiment, the cationic lipid of Formula III has the structure:</div>
    </li> <li> <div id="p-0219" num="0000" class="description-line">
      <chemistry id="CHEM-US-00005" num="00005">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/46/22/3c/0af2342274f4e6/US20190240354A1-20190808-C00005.png"><img id="EMI-C00005" he="21.51mm" wi="122.60mm" file="US20190240354A1-20190808-C00005.TIF" alt="Figure US20190240354A1-20190808-C00005" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="490" height="86" alt="Figure US20190240354A1-20190808-C00005" class="patent-full-image" src="https://patentimages.storage.googleapis.com/46/22/3c/0af2342274f4e6/US20190240354A1-20190808-C00005.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00005" attachment-type="cdx" file="US20190240354A1-20190808-C00005.CDX"> </attachment>
          <attachment idref="CHEM-US-00005" attachment-type="mol" file="US20190240354A1-20190808-C00005.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0207]"> </para-num> <div id="p-0220" num="0207" class="description-line">The synthesis of cationic lipids such as Î³-DLenDMA, as well as additional cationic lipids, is described in International Patent Application WO2011/000106, the disclosure of which is herein incorporated by reference in its entirety for all purposes.</div>
    </li> <li> <para-num num="[0208]"> </para-num> <div id="p-0221" num="0208" class="description-line">In particular embodiments, a cationic lipid having the following structure is useful in the present invention:</div>
    </li> <li> <div id="p-0222" num="0000" class="description-line">
      <chemistry id="CHEM-US-00006" num="00006">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/50/2c/aa/6559eb819d676b/US20190240354A1-20190808-C00006.png"><img id="EMI-C00006" he="15.24mm" wi="127.76mm" file="US20190240354A1-20190808-C00006.TIF" alt="Figure US20190240354A1-20190808-C00006" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="511" height="61" alt="Figure US20190240354A1-20190808-C00006" class="patent-full-image" src="https://patentimages.storage.googleapis.com/50/2c/aa/6559eb819d676b/US20190240354A1-20190808-C00006.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00006" attachment-type="cdx" file="US20190240354A1-20190808-C00006.CDX"> </attachment>
          <attachment idref="CHEM-US-00006" attachment-type="mol" file="US20190240354A1-20190808-C00006.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0209]"> </para-num> <div id="p-0223" num="0209" class="description-line">The synthesis of cationic lipids such as compound 7, as well as additional cationic lipids, are described in U.S. Pat. No. 8,158,601, and in International Patent Application serial number PCT/GB2011/000723, the disclosures of which are herein incorporated by reference in their entirety for all purposes.</div>
    </li> <li> <para-num num="[0210]"> </para-num> <div id="p-0224" num="0210" class="description-line">Examples of other cationic lipids or salts thereof which may be included in the lipid particles of the present invention include, but are not limited to, cationic lipids such as those described in WO2011/000106, the disclosure of which is herein incorporated by reference in its entirety for all purposes, as well as cationic lipids such as N,N-dioleyl-N,N-dimethylammonium chloride (DODAC), 1,2-dioleyloxy-N,N-dimethylaminopropane (DODMA), 1,2-distearyloxy-N,N-dimethylaminopropane (DSDMA), N-(1-(2,3-dioleyloxy)propyl)-N,N,N-trimethylammonium chloride (DOTMA), N,N-distearyl-N,N-dimethylammonium bromide (DDAB), N-(1-(2,3-dioleoyloxy)propyl)-N,N,N-trimethylammonium chloride (DOTAP), 3-(N-(Nâ²,Nâ²-dimethylaminoethane)-carbamoyl)cholesterol (DC-Chol), N-(1,2-dimyristyloxyprop-3-yl)-N,N-dimethyl-N-hydroxyethyl ammonium bromide (DMRIE), 2,3-dioleyloxy-N-[2(spermine-carboxamido)ethyl]-N,N-dimethyl-1-propanaminiumtrifluoroacetate (DOSPA), dioctadecylamidoglycyl spermine (DOGS), 3-dimethylamino-2-(cholest-5-en-3-beta-oxybutan-4-oxy)-1-(cis,cis-9,12-octadecadienoxy)propane (CLinDMA), 2-[5â²-(cholest-5-en-3-beta-oxy)-3â²-oxapentoxy)-3-dimethy-1-(cis,cis-9â²,1-2â²-octadecadienoxy)propane (CpLinDMA), N,N-dimethyl-3,4-dioleyloxybenzylamine (DMOBA), 1,2-N,Nâ²-dioleylcarbamyl-3-dimethylaminopropane (DOcarbDAP), 1,2-N,Nâ²-dilinoleylcarbamyl-3-dimethylaminopropane (DLincarbDAP), 1,2-dilinoleylcarbamoyloxy-3-dimethylaminopropane (DLin-C-DAP), 1,2-dilinoleyoxy-3-(dimethylamino)acetoxypropane (DLin-DAC), 1,2-dilinoleyoxy-3-morpholinopropane (DLin-MA), 1,2-dilinoleoyl-3-dimethylaminopropane (DLinDAP), 1,2-dilinoleylthio-3-dimethylaminopropane (DLin-S-DMA), 1-linoleoyl-2-linoleyloxy-3-dimethylaminopropane (DLin-2-DMAP), 1,2-dilinoleyloxy-3-trimethylaminopropane chloride salt (DLin-TMA.Cl), 1,2-dilinoleoyl-3-trimethylaminopropane chloride salt (DLin-TAP.Cl), 1,2-dilinoleyloxy-3-(N-methylpiperazino)propane (DLin-MPZ), 3-(N,N-dilinoleylamino)-1,2-propanediol (DLinAP), 3-(N,N-dioleylamino)-1,2-propanedio (DOAP), 1,2-dilinoleyloxo-3-(2-N,N-dimethylamino)ethoxypropane (DLin-EG-DMA), 1,2-dioeylcarbamoyloxy-3-dimethylaminopropane (DO-C-DAP), 1,2-dimyristoleoyl-3-dimethylaminopropane (DMDAP), 1,2-dioleoyl-3-trimethylaminopropane chloride (DOTAP.Cl), dilinoleylmethyl-3-dimethylaminopropionate (DLin-M-C2-DMA; also known as DLin-M-K-DMA or DLin-M-DMA), and mixtures thereof. Additional cationic lipids or salts thereof which may be included in the lipid particles of the present invention are described in U.S. Patent Publication No. 20090023673, the disclosure of which is herein incorporated by reference in its entirety for all purposes.</div>
    </li> <li> <para-num num="[0211]"> </para-num> <div id="p-0225" num="0211" class="description-line">In another embodiment, a trialkyl cationic lipid can be used to prepare the lipid particles described herein. Such trialkyl cationic lipids typically comprise three saturated or unsaturated hydrocarbon chains having six or more carbons in each chain. Trialkyl cationic lipids that can be incorporated into the compositions described herein can be prepared as described in International Patent Application Publication Number WO 2013/126803.</div>
    </li> <li> <para-num num="[0212]"> </para-num> <div id="p-0226" num="0212" class="description-line">For example, a trialkyl cationic lipid of the following Formula B can be used to make lipid particles of the present invention:</div>
    </li> <li> <div id="p-0227" num="0000" class="description-line"> <br/>X-A-YâZ; ââ(Formula B)
</div>
    </li> <li> <para-num num="[0213]"> </para-num> <div id="p-0228" num="0213" class="description-line">or salts thereof, wherein:</div>
    </li> <li> <para-num num="[0214]"> </para-num> <div id="p-0229" num="0214" class="description-line">X is âN(H)R or âNR<sub>2</sub>;</div>
    </li> <li> <para-num num="[0215]"> </para-num> <div id="p-0230" num="0215" class="description-line">A is absent, C<sub>1 </sub>to C<sub>6</sub>alkyl, C<sub>2 </sub>to C<sub>6</sub>alkenyl, or C<sub>2 </sub>to C<sub>6</sub>alkynyl, which C<sub>1 </sub>to C<sub>6</sub>alkyl, C<sub>2 </sub>to C<sub>6</sub>alkenyl, and C<sub>2 </sub>to C<sub>6</sub>alkynyl is optionally substituted with one or more groups independently selected from oxo, halogen, heterocycle, âCN, âOR<sup>x</sup>, âNR<sup>x</sup>R<sup>y</sup>, âNR<sup>x</sup>C(âO)R<sup>y</sup>, âNR<sup>x</sup>SO<sub>2</sub>R<sup>y</sup>, âC(âO)R<sup>x</sup>, âC(âO)OR<sup>x</sup>, âC(âO)NR<sup>x</sup>R<sup>y</sup>, âSO<sub>n</sub>R<sup>x</sup>, and âSO<sub>n</sub>NR<sup>x</sup>R<sup>y</sup>, wherein n is 0, 1, or 2, and R<sup>x </sup>and R<sup>y </sup>are each independently hydrogen, alkyl, or heterocycle, wherein each alkyl and heterocycle of R<sup>x </sup>and R<sup>y </sup>may be further substituted with one or more groups independently selected from oxo, halogen, âOH, âCN, alkyl, âOR<sup>xâ²</sup>, heterocycle, âNR<sup>xâ²</sup>R<sup>yâ²</sup>, âNR<sup>xâ²</sup>C(âO)R<sup>yâ²</sup>, âNR<sup>xâ²</sup>SO<sub>2</sub>R<sup>yâ²</sup>, âC(âO)R<sup>xâ²</sup>, âC(âO)OR<sup>xâ²</sup>, âC(âO)NR<sup>xâ²</sup>R<sup>yâ²</sup>, âSO<sub>nâ²</sub>R<sup>xâ²</sup>, and âSO<sub>nâ²</sub>NR<sup>xâ²</sup>R<sup>yâ²</sup>, wherein nâ² is 0, 1, or 2, and R<sup>xâ²</sup> and R<sup>yâ²</sup> are each independently hydrogen, alkyl, or heterocycle;</div>
    </li> <li> <para-num num="[0216]"> </para-num> <div id="p-0231" num="0216" class="description-line">Y is selected from the group consisting of absent, âC(âO)â, âOâ, âOC(âO)â, âC(âO)Oâ, âN(R<sup>b</sup>)C(âO)â, âC(âO)N(R<sup>b</sup>)â, âN(R<sup>b</sup>)C(âO)Oâ, and âOC(âO)N(R<sup>b</sup>)â;</div>
    </li> <li> <para-num num="[0217]"> </para-num> <div id="p-0232" num="0217" class="description-line">Z is a hydrophobic moiety comprising three chains wherein each of the chains is independently selected from C<sub>8 </sub>to C<sub>11</sub>alkyl, C<sub>8 </sub>to C<sub>11</sub>alkenyl, and C<sub>8 </sub>to C<sub>11</sub>alkynyl, which C<sub>8 </sub>to C<sub>11</sub>alkyl, C<sub>8 </sub>to C<sub>11</sub>alkenyl, and C<sub>8 </sub>to C<sub>11</sub>alkynyl is optionally substituted with one or more groups independently selected from oxo, halogen, heterocycle, âCN, âOR<sup>x</sup>, âNR<sup>x</sup>R<sup>y</sup>, âNR<sup>x</sup>C(âO)R<sup>y</sup>, âNR<sup>x</sup>SO<sub>2</sub>R<sup>y</sup>, âC(âO)R<sup>x</sup>, âC(âO)OR<sup>x</sup>, âC(âO)NR<sup>x</sup>R<sup>y</sup>, âSO<sub>n</sub>R<sup>x</sup>, and âSO<sub>n</sub>NR<sup>x</sup>R<sup>y</sup>, wherein n is 0, 1, or 2, and R<sup>x </sup>and R<sup>y </sup>are each independently hydrogen, alkyl, or heterocycle, wherein any alkyl and heterocycle of R<sup>x </sup>and R<sup>y </sup>may be further substituted with one or more groups independently selected from oxo, halogen, âOH, âCN, alkyl, âOR<sup>xâ²</sup>, heterocycle, âNR<sup>xâ²</sup>R<sup>yâ²</sup>, âNR<sup>xâ²</sup>C(âO)R<sup>yâ²</sup>, âNR<sup>xâ²</sup>SO<sub>2</sub>R<sup>yâ²</sup>, âC(âO)R<sup>xâ²</sup>, âC(âO)OR<sup>xâ²</sup>, âC(âO)NR<sup>xâ²</sup>R<sup>yâ²</sup>, âSO<sub>n</sub>R<sup>xâ²</sup>, and âSO<sub>nâ²</sub>NR<sup>xâ²</sup>R<sup>yâ²</sup>, wherein nâ² is 0, 1, or 2, and R<sup>xâ²</sup> and R<sup>yâ²</sup> are each independently hydrogen, alkyl, or heterocycle;</div>
    </li> <li> <para-num num="[0218]"> </para-num> <div id="p-0233" num="0218" class="description-line">each R is independently alkyl, alkenyl, or alkynyl, that is optionally substituted with one or more groups independently selected from oxo, halogen, heterocycle, âCN, âOR<sup>x</sup>, âNR<sup>x</sup>R<sup>y</sup>, âNR<sup>x</sup>C(âO)R<sup>y</sup>, âNR<sup>x</sup>SO<sub>2</sub>R<sup>y</sup>, âC(âO)R<sup>x</sup>, âC(âO)OR<sup>x</sup>, âC(âO)NR<sup>x</sup>R<sup>y</sup>, âSO<sub>n</sub>R<sup>x</sup>, and âSO<sub>n</sub>NR<sup>x</sup>R<sup>y</sup>, wherein n is 0, 1, or 2, and R<sup>x </sup>and R<sup>y </sup>are each independently hydrogen, alkyl, or heterocycle, wherein any alkyl and heterocycle of R<sup>x </sup>and R<sup>y </sup>may be further substituted with one or more groups independently selected from oxo, halogen, âOH, âCN, alkyl, âOR<sup>xâ²</sup>, heterocycle, âNR<sup>xâ²</sup>R<sup>yâ²</sup>, âNR<sup>xâ²</sup>C(âO)R<sup>yâ²</sup>, âNR<sup>xâ²</sup>SO<sub>2</sub>R<sup>yâ²</sup>, âC(âO)R<sup>xâ²</sup>, âC(âO)OR<sup>xâ²</sup>, âC(âO)NR<sup>xâ²</sup>R<sup>yâ²</sup>, âSO<sub>nâ²</sub>R<sup>xâ²</sup>, and âSO<sub>nâ²</sub>NR<sup>xâ²</sup>R<sup>yâ²</sup>, wherein nâ² is 0, 1, or 2, and R<sup>xâ²</sup> and R<sup>yâ²</sup> are each independently hydrogen, alkyl, or heterocycle; and</div>
    </li> <li> <para-num num="[0219]"> </para-num> <div id="p-0234" num="0219" class="description-line">each R<sup>b </sup>is H or C<sub>1 </sub>to C<sub>6</sub>alkyl.</div>
    </li> <li> <para-num num="[0220]"> </para-num> <div id="p-0235" num="0220" class="description-line">In some embodiments, Z in Formula B has the structure:</div>
    </li> <li> <div id="p-0236" num="0000" class="description-line">
      <chemistry id="CHEM-US-00007" num="00007">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/dc/0b/f9/3b936aedfb536c/US20190240354A1-20190808-C00007.png"><img id="EMI-C00007" he="16.43mm" wi="28.70mm" file="US20190240354A1-20190808-C00007.TIF" alt="Figure US20190240354A1-20190808-C00007" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="115" height="66" alt="Figure US20190240354A1-20190808-C00007" class="patent-full-image" src="https://patentimages.storage.googleapis.com/dc/0b/f9/3b936aedfb536c/US20190240354A1-20190808-C00007.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00007" attachment-type="cdx" file="US20190240354A1-20190808-C00007.CDX"> </attachment>
          <attachment idref="CHEM-US-00007" attachment-type="mol" file="US20190240354A1-20190808-C00007.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <div id="p-0237" num="0000" class="description-line">wherein, R<sub>1</sub>, R<sub>2</sub>, and R<sub>3 </sub>are each independently C<sub>8 </sub>to C<sub>11</sub>alkyl, C<sub>8 </sub>to C<sub>11</sub>alkenyl, or C<sub>8 </sub>to C<sub>11</sub>alkynyl, which C<sub>8 </sub>to C<sub>11</sub>alkyl, C<sub>8 </sub>to C<sub>11</sub>alkenyl, and C<sub>8 </sub>to C<sub>11</sub>alkynyl is optionally substituted with one or more groups independently selected from oxo, halogen, heterocycle, âCN, âOR<sup>x</sup>, âNR<sup>x</sup>R<sup>y</sup>, âNR<sup>x</sup>C(âO)R<sup>y</sup>, âNR<sup>x</sup>SO<sub>2</sub>R<sup>y</sup>, âC(âO)R<sup>x</sup>, âC(âO)OR<sup>x</sup>, âC(âO)NR<sup>x</sup>R<sup>y</sup>, âSO<sub>n</sub>R<sup>x</sup>, and âSO<sub>n</sub>NR<sup>x</sup>R<sup>y</sup>, wherein n is 0, 1, or 2, and R<sup>x </sup>and R<sup>y </sup>are each independently hydrogen, alkyl, or heterocycle, wherein any alkyl and heterocycle of R<sup>x </sup>and R<sup>y </sup>may be further substituted with one or more groups independently selected from oxo, halogen, âOH, âCN, alkyl, âOR<sup>xâ²</sup>, heterocycle, âNR<sup>xâ²</sup>R<sup>yâ²</sup>, âNR<sup>xâ²</sup>C(âO)R<sup>yâ²</sup>, âNR<sup>xâ²</sup>SO<sub>2</sub>R<sup>yâ²</sup>, âC(âO)R<sup>xâ²</sup>, âC(âO)OR<sup>xâ²</sup>, âC(âO)NR<sup>xâ²</sup>R<sup>yâ²</sup>, âSO<sub>nâ²</sub>R<sup>xâ²</sup>, and âSO<sub>nâ²</sub>NR<sup>xâ²</sup>R<sup>yâ²</sup>, wherein nâ² is 0, 1, or 2, and R<sup>xâ²</sup> and R<sup>yâ²</sup> are each independently hydrogen, alkyl, or heterocycle.</div>
    </li> <li> <para-num num="[0221]"> </para-num> <div id="p-0238" num="0221" class="description-line">In another embodiment, cationic lipids of the following Formula C are used to make lipid particles of the present invention:</div>
    </li> <li> <div id="p-0239" num="0000" class="description-line"> <br/>X-A-YâZ<sup>1</sup>; ââ(Formula C)
</div>
    </li> <li> <para-num num="[0222]"> </para-num> <div id="p-0240" num="0222" class="description-line">or salts thereof, wherein:</div>
    </li> <li> <para-num num="[0223]"> </para-num> <div id="p-0241" num="0223" class="description-line">X is âN(H)R or âNR<sub>2</sub>;</div>
    </li> <li> <para-num num="[0224]"> </para-num> <div id="p-0242" num="0224" class="description-line">A is absent, C<sub>1 </sub>to C<sub>6</sub>alkyl, C<sub>2 </sub>to C<sub>6</sub>alkenyl, or C<sub>2 </sub>to C<sub>6</sub>alkynyl, which C<sub>1 </sub>to C<sub>6</sub>alkyl, C<sub>2 </sub>to C<sub>6</sub>alkenyl, and C<sub>2 </sub>to C<sub>6</sub>alkynyl is optionally substituted with one or more groups independently selected from oxo, halogen, heterocycle, âCN, âOR<sup>x</sup>, âNR<sup>x</sup>R<sup>y</sup>, âNR<sup>x</sup>C(âO)R<sup>y</sup>, âNR<sup>x</sup>SO<sub>2</sub>R<sup>y</sup>, âC(âO)R<sup>x</sup>, âC(âO)OR<sup>x</sup>, âC(âO)NR<sup>x</sup>R<sup>y</sup>, âSO<sub>n</sub>R<sup>x</sup>, and âSO<sub>n</sub>NR<sup>x</sup>R<sup>y</sup>, wherein n is 0, 1, or 2, and R<sup>x </sup>and R<sup>y </sup>are each independently hydrogen, alkyl, or heterocycle, wherein each alkyl and heterocycle of R<sup>x </sup>and R<sup>y </sup>may be further substituted with one or more groups independently selected from oxo, halogen, âOH, âCN, alkyl, âOR<sup>xâ²</sup>, heterocycle, âNR<sup>xâ²</sup>R<sup>yâ²</sup>, âNR<sup>xâ²</sup>C(âO)R<sup>yâ²</sup>, âNR<sup>xâ²</sup>SO<sub>2</sub>R<sup>yâ²</sup>, âC(âO)R<sup>xâ²</sup>, âC(âO)OR<sup>xâ²</sup>, âC(âO)NR<sup>xâ²</sup>R<sup>yâ²</sup>, âSO<sub>nâ²</sub>R<sup>xâ²</sup>, and âSO<sub>nâ²</sub>NR<sup>xâ²</sup>R<sup>yâ²</sup>, wherein nâ² is 0, 1, or 2, and R<sup>xâ²</sup> and R<sup>yâ²</sup> are each independently hydrogen, alkyl, or heterocycle;</div>
    </li> <li> <para-num num="[0225]"> </para-num> <div id="p-0243" num="0225" class="description-line">Y is selected from the group consisting of absent, âC(âO)â, âOâ, âOC(âO)â, âC(âO)Oâ, âN(R<sup>b</sup>)C(âO)â, âC(âO)N(R<sup>b</sup>)â, âN(R<sup>b</sup>)C(âO)Oâ, and âOC(âO)N(R<sup>b</sup>)â;</div>
    </li> <li> <para-num num="[0226]"> </para-num> <div id="p-0244" num="0226" class="description-line">Z<sup>1 </sup>is a C<sub>1 </sub>to C<sub>6</sub>alkyl that is substituted with three or four R<sup>x </sup>groups, wherein each R<sup>x </sup>is independently selected from C<sub>6 </sub>to C<sub>11</sub>alkyl, C<sub>6 </sub>to C<sub>11</sub>alkenyl, and C<sub>6 </sub>to C<sub>11</sub>alkynyl, which C<sub>6 </sub>to C<sub>11</sub>alkyl, C<sub>6 </sub>to C<sub>11</sub>alkenyl, and C<sub>6 </sub>to C<sub>11</sub>alkynyl is optionally substituted with one or more groups independently selected from oxo, halogen, heterocycle, âCN, âOR<sup>x</sup>, âNR<sup>x</sup>R<sup>y</sup>, âNR<sup>x</sup>C(âO)R<sup>y</sup>, âNR<sup>x</sup>SO<sub>2</sub>R<sup>y</sup>, âC(âO)R<sup>x</sup>, âC(âO)OR<sup>x</sup>, âC(âO)NR<sup>x</sup>R<sup>y</sup>, âSO<sub>n</sub>R<sup>x</sup>, and âSO<sub>n</sub>NR<sup>x</sup>R<sup>y</sup>, wherein n is 0, 1, or 2, and R<sup>x </sup>and R<sup>y </sup>are each independently hydrogen, alkyl, or heterocycle, wherein any alkyl and heterocycle of R<sup>x </sup>and R<sup>y </sup>may be further substituted with one or more groups independently selected from oxo, halogen, âOH, âCN, alkyl, âOR<sup>xâ²</sup>, heterocycle, âNR<sup>xâ²</sup>R<sup>yâ²</sup>, âNR<sup>xâ²</sup>C(âO)R<sup>yâ²</sup>, âNR<sup>xâ²</sup>SO<sub>2</sub>R<sup>yâ²</sup>, âC(âO)R<sup>xâ²</sup>, âC(âO)OR<sup>xâ²</sup>, âC(âO)NR<sup>xâ²</sup>R<sup>yâ²</sup>, âSO<sub>nâ²</sub>R<sup>xâ²</sup>, and âSO<sub>nâ²</sub>NR<sup>xâ²</sup>R<sup>yâ²</sup>, wherein nâ² is 0, 1, or 2, and R<sup>xâ²</sup> and R<sup>yâ²</sup> are each independently hydrogen, alkyl, or heterocycle;</div>
    </li> <li> <para-num num="[0227]"> </para-num> <div id="p-0245" num="0227" class="description-line">each R is independently alkyl, alkenyl, or alkynyl, that is optionally substituted with one or more groups independently selected from oxo, halogen, heterocycle, âCN, âOR<sup>x</sup>, âNR<sup>x</sup>R<sup>y</sup>, âNR<sup>x</sup>C(âO)R<sup>y</sup>, âNR<sup>x</sup>SO<sub>2</sub>R<sup>y</sup>, âC(âO)R<sup>x</sup>, âC(âO)OR<sup>x</sup>, âC(âO)NR<sup>x</sup>R<sup>y</sup>, âSO<sub>n</sub>R<sup>x</sup>, and âSO<sub>n</sub>NR<sup>x</sup>R<sup>y</sup>, wherein n is 0, 1, or 2, and R<sup>x </sup>and R<sup>y </sup>are each independently hydrogen, alkyl, or heterocycle, wherein any alkyl and heterocycle of R<sup>x </sup>and R<sup>y </sup>may be further substituted with one or more groups independently selected from oxo, halogen, âOH, âCN, alkyl, âOR<sup>xâ²</sup>, heterocycle, âNR<sup>xâ²</sup>R<sup>yâ²</sup>, âNR<sup>xâ²</sup>C(âO)R<sup>yâ²</sup>, âNR<sup>xâ²</sup>SO<sub>2</sub>R<sup>yâ²</sup>, âC(âO)R<sup>xâ²</sup>, âC(âO)OR<sup>xâ²</sup>, âC(âO)NR<sup>xâ²</sup>R<sup>yâ²</sup>, âSO<sub>nâ²</sub>R<sup>xâ²</sup>, and âSO<sub>nâ²</sub>NR<sup>xâ²</sup>R<sup>yâ²</sup>, wherein nâ² is 0, 1, or 2, and R<sup>xâ²</sup> and R<sup>yâ²</sup> are each independently hydrogen, alkyl, or heterocycle; and</div>
    </li> <li> <para-num num="[0228]"> </para-num> <div id="p-0246" num="0228" class="description-line">each R<sup>b </sup>is H or C<sub>1 </sub>to C<sub>6</sub>alkyl.</div>
    </li> <li> <para-num num="[0229]"> </para-num> <div id="p-0247" num="0229" class="description-line">In some embodiments, Z<sup>1 </sup>in Formula C has the structure:</div>
    </li> <li> <div id="p-0248" num="0000" class="description-line">
      <chemistry id="CHEM-US-00008" num="00008">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/f0/4c/74/b4b06d56e765be/US20190240354A1-20190808-C00008.png"><img id="EMI-C00008" he="16.43mm" wi="28.70mm" file="US20190240354A1-20190808-C00008.TIF" alt="Figure US20190240354A1-20190808-C00008" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="115" height="66" alt="Figure US20190240354A1-20190808-C00008" class="patent-full-image" src="https://patentimages.storage.googleapis.com/f0/4c/74/b4b06d56e765be/US20190240354A1-20190808-C00008.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00008" attachment-type="cdx" file="US20190240354A1-20190808-C00008.CDX"> </attachment>
          <attachment idref="CHEM-US-00008" attachment-type="mol" file="US20190240354A1-20190808-C00008.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <div id="p-0249" num="0000" class="description-line">wherein, R<sub>1</sub>, R<sub>2</sub>, and R<sub>3 </sub>are each independently C<sub>8 </sub>to C<sub>11</sub>alkyl, C<sub>8 </sub>to C<sub>11</sub>alkenyl, or C<sub>8 </sub>to C<sub>11</sub>alkynyl, which C<sub>8 </sub>to C<sub>11</sub>alkyl, C<sub>8 </sub>to C<sub>11</sub>alkenyl, and C<sub>8 </sub>to C<sub>11</sub>alkynyl is optionally substituted with one or more groups independently selected from oxo, halogen, heterocycle, âCN, âOR<sup>x</sup>, âNR<sup>x</sup>R<sup>y</sup>, âNR<sup>x</sup>C(âO)R<sup>y</sup>, âNR<sup>x</sup>SO<sub>2</sub>R<sup>y</sup>, âC(âO)R<sup>x</sup>, âC(âO)OR<sup>x</sup>, âC(âO)NR<sup>x</sup>R<sup>y</sup>, âSO<sub>n</sub>R<sup>x</sup>, and âSO<sub>n</sub>NR<sup>x</sup>R<sup>y</sup>, wherein n is 0, 1, or 2, and R<sup>x </sup>and R<sup>y </sup>are each independently hydrogen, alkyl, or heterocycle, wherein any alkyl and heterocycle of R<sup>x </sup>and R<sup>y </sup>may be further substituted with one or more groups independently selected from oxo, halogen, âOH, âCN, alkyl, âOR<sup>xâ²</sup>, heterocycle, âNR<sup>xâ²</sup>R<sup>yâ²</sup>, âNR<sup>xâ²</sup>C(âO)R<sup>yâ²</sup>, âNR<sup>xâ²</sup>SO<sub>2</sub>R<sup>yâ²</sup>, âC(âO)R<sup>xâ²</sup>, âC(âO)OR<sup>xâ²</sup>, âC(âO)NR<sup>xâ²</sup>R<sup>yâ²</sup>, âSO<sub>nâ²</sub>R<sup>xâ²</sup>, and âSO<sub>nâ²</sub>NR<sup>xâ²</sup>R<sup>yâ²</sup>, wherein nâ² is 0, 1, or 2, and R<sup>xâ²</sup> and R<sup>yâ²</sup> are each independently hydrogen, alkyl, or heterocycle.</div>
    </li> <li> <para-num num="[0230]"> </para-num> <div id="p-0250" num="0230" class="description-line">In some embodiments, Z<sup>1 </sup>in Formula C has the structure:</div>
    </li> <li> <div id="p-0251" num="0000" class="description-line">
      <chemistry id="CHEM-US-00009" num="00009">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/b8/ca/fa/2ad3a22824ecd8/US20190240354A1-20190808-C00009.png"><img id="EMI-C00009" he="14.82mm" wi="17.27mm" file="US20190240354A1-20190808-C00009.TIF" alt="Figure US20190240354A1-20190808-C00009" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="69" height="59" alt="Figure US20190240354A1-20190808-C00009" class="patent-full-image" src="https://patentimages.storage.googleapis.com/b8/ca/fa/2ad3a22824ecd8/US20190240354A1-20190808-C00009.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00009" attachment-type="cdx" file="US20190240354A1-20190808-C00009.CDX"> </attachment>
          <attachment idref="CHEM-US-00009" attachment-type="mol" file="US20190240354A1-20190808-C00009.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <div id="p-0252" num="0000" class="description-line">wherein one of R<sup>1z </sup>and R<sup>2z </sup>is selected from the group consisting of:</div>
    </li> <li> <div id="p-0253" num="0000" class="description-line">
      <chemistry id="CHEM-US-00010" num="00010">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/1e/9b/12/5cf7868e2b0dc1/US20190240354A1-20190808-C00010.png"><img id="EMI-C00010" he="16.93mm" wi="45.04mm" file="US20190240354A1-20190808-C00010.TIF" alt="Figure US20190240354A1-20190808-C00010" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="180" height="68" alt="Figure US20190240354A1-20190808-C00010" class="patent-full-image" src="https://patentimages.storage.googleapis.com/1e/9b/12/5cf7868e2b0dc1/US20190240354A1-20190808-C00010.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00010" attachment-type="cdx" file="US20190240354A1-20190808-C00010.CDX"> </attachment>
          <attachment idref="CHEM-US-00010" attachment-type="mol" file="US20190240354A1-20190808-C00010.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <div id="p-0254" num="0000" class="description-line">and
<br/>
the other of R<sup>1z </sup>and R<sup>2z </sup>is selected from the group consisting of:
</div>
    </li> <li> <div id="p-0255" num="0000" class="description-line">
      <chemistry id="CHEM-US-00011" num="00011">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/75/29/76/5e9a67c7c5e097/US20190240354A1-20190808-C00011.png"><img id="EMI-C00011" he="16.93mm" wi="65.02mm" file="US20190240354A1-20190808-C00011.TIF" alt="Figure US20190240354A1-20190808-C00011" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="260" height="68" alt="Figure US20190240354A1-20190808-C00011" class="patent-full-image" src="https://patentimages.storage.googleapis.com/75/29/76/5e9a67c7c5e097/US20190240354A1-20190808-C00011.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00011" attachment-type="cdx" file="US20190240354A1-20190808-C00011.CDX"> </attachment>
          <attachment idref="CHEM-US-00011" attachment-type="mol" file="US20190240354A1-20190808-C00011.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <div id="p-0256" num="0000" class="description-line">wherein each R<sup>3z</sup>, R<sup>4z</sup>, R<sup>5z</sup>, R<sup>6z</sup>, and R<sup>7z </sup>is independently selected from C<sub>6 </sub>to C<sub>11</sub>alkyl, C<sub>6 </sub>to C<sub>11</sub>alkenyl, and C<sub>6 </sub>to C<sub>11</sub>alkynyl, which C<sub>6 </sub>to C<sub>11</sub>alkyl, C<sub>6 </sub>to C<sub>11</sub>alkenyl, and C<sub>6 </sub>to C<sub>11</sub>alkynyl is optionally substituted with one or more groups independently selected from oxo, halogen, heterocycle, âCN, âOR<sup>x</sup>, âNR<sup>x</sup>R<sup>y</sup>, âNR<sup>x</sup>C(âO)R<sup>y</sup>, âNR<sup>x</sup>SO<sub>2</sub>R<sup>y</sup>, âC(âO)R<sup>x</sup>, âC(âO)OR<sup>x</sup>, âC(âO)NR<sup>x</sup>R<sup>y</sup>, âSO<sub>n</sub>R<sup>x</sup>, and âSO<sub>n</sub>NR<sup>x</sup>R<sup>y</sup>, wherein n is 0, 1, or 2, and R<sup>x </sup>and R<sup>y </sup>are each independently hydrogen, alkyl, or heterocycle, wherein any alkyl and heterocycle of R<sup>x </sup>and R<sup>y </sup>may be further substituted with one or more groups independently selected from oxo, halogen, âOH, âCN, alkyl, âOR<sup>xâ²</sup>, heterocycle, âNR<sup>xâ²</sup>R<sup>yâ²</sup>, âNR<sup>xâ²</sup>C(âO)R<sup>yâ²</sup>, âNR<sup>xâ²</sup>SO<sub>2</sub>R<sup>yâ²</sup>, âC(âO)R<sup>xâ²</sup>, âC(âO)OR<sup>xâ²</sup>, âC(âO)NR<sup>xâ²</sup>R<sup>yâ²</sup>, âSO<sub>nâ²</sub>R<sup>xâ²</sup>, and âSO<sub>nâ²</sub>NR<sup>xâ²</sup>R<sup>yâ²</sup>, wherein nâ² is 0, 1, or 2, and R<sup>xâ²</sup> and R<sup>yâ²</sup> are each independently hydrogen, alkyl, or heterocycle.</div>
    </li> <li> <para-num num="[0231]"> </para-num> <div id="p-0257" num="0231" class="description-line">In some embodiments, Z<sup>1 </sup>in Formula C has the structure:</div>
    </li> <li> <div id="p-0258" num="0000" class="description-line">
      <chemistry id="CHEM-US-00012" num="00012">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/3e/69/f3/0035f4bd904867/US20190240354A1-20190808-C00012.png"><img id="EMI-C00012" he="57.32mm" wi="56.64mm" file="US20190240354A1-20190808-C00012.TIF" alt="Figure US20190240354A1-20190808-C00012" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="227" height="229" alt="Figure US20190240354A1-20190808-C00012" class="patent-full-image" src="https://patentimages.storage.googleapis.com/3e/69/f3/0035f4bd904867/US20190240354A1-20190808-C00012.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00012" attachment-type="cdx" file="US20190240354A1-20190808-C00012.CDX"> </attachment>
          <attachment idref="CHEM-US-00012" attachment-type="mol" file="US20190240354A1-20190808-C00012.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <div id="p-0259" num="0000" class="description-line">wherein each R<sup>3z</sup>, R<sup>4z</sup>, R<sup>5z</sup>, and R<sup>6z </sup>is independently selected from C<sub>6 </sub>to C<sub>11</sub>alkyl, C<sub>6 </sub>to C<sub>11</sub>alkenyl, and C<sub>6 </sub>to C<sub>11</sub>alkynyl, which C<sub>6 </sub>to C<sub>11</sub>alkyl, C<sub>6 </sub>to C<sub>11</sub>alkenyl, and C<sub>6 </sub>to C<sub>11</sub>alkynyl is optionally substituted with one or more groups independently selected from oxo, halogen, heterocycle, âCN, âOR<sup>x</sup>, âNR<sup>x</sup>R<sup>y</sup>, âNR<sup>x</sup>C(âO)R<sup>y</sup>, âNR<sup>x</sup>SO<sub>2</sub>R<sup>y</sup>, âC(âO)R<sup>x</sup>, âC(âO)OR<sup>x</sup>, âC(âO)NR<sup>x</sup>R<sup>y</sup>, âSO<sub>n</sub>R<sup>x</sup>, and âSO<sub>n</sub>NR<sup>x</sup>R<sup>y</sup>, wherein n is 0, 1, or 2, and R<sup>x </sup>and R<sup>y </sup>are each independently hydrogen, alkyl, or heterocycle, wherein any alkyl and heterocycle of R<sup>x </sup>and R<sup>y </sup>may be further substituted with one or more groups independently selected from oxo, halogen, âOH, âCN, alkyl, âOR<sup>xâ²</sup>, heterocycle, âNR<sup>xâ²</sup>R<sup>yâ²</sup>, âNR<sup>xâ²</sup>C(âO)R<sup>yâ²</sup>, âNR<sup>xâ²</sup>SO<sub>2</sub>R<sup>yâ²</sup>, âC(âO)R<sup>xâ²</sup>, âC(âO)OR<sup>xâ²</sup>, âC(âO)NR<sup>xâ²</sup>R<sup>yâ²</sup>, âSO<sub>nâ²</sub>R<sup>xâ²</sup>, and âSO<sub>nâ²</sub>NR<sup>xâ²</sup>R<sup>yâ²</sup>, wherein nâ² is 0, 1, or 2, and R<sup>xâ²</sup> and R<sup>yâ²</sup> are each independently hydrogen, alkyl, or heterocycle.</div>
    </li> <li> <para-num num="[0232]"> </para-num> <div id="p-0260" num="0232" class="description-line">In some embodiments the cationic lipid is selected from the group consisting of:</div>
    </li> <li> <div id="p-0261" num="0000" class="description-line">
      <chemistry id="CHEM-US-00013" num="00013">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/51/0f/12/462de70edb17e8/US20190240354A1-20190808-C00013.png"><img id="EMI-C00013" he="156.72mm" wi="76.03mm" file="US20190240354A1-20190808-C00013.TIF" alt="Figure US20190240354A1-20190808-C00013" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="304" height="627" alt="Figure US20190240354A1-20190808-C00013" class="patent-full-image" src="https://patentimages.storage.googleapis.com/51/0f/12/462de70edb17e8/US20190240354A1-20190808-C00013.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00013" attachment-type="cdx" file="US20190240354A1-20190808-C00013.CDX"> </attachment>
          <attachment idref="CHEM-US-00013" attachment-type="mol" file="US20190240354A1-20190808-C00013.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <div id="p-0262" num="0000" class="description-line">and salts thereof.</div>
    </li> <li> <para-num num="[0233]"> </para-num> <div id="p-0263" num="0233" class="description-line">The synthesis of cationic lipids such as CLinDMA, as well as additional cationic lipids, is described in U.S. Patent Publication No. 20060240554, the disclosure of which is herein incorporated by reference in its entirety for all purposes. The synthesis of cationic lipids such as DLin-C-DAP, DLinDAC, DLinMA, DLinDAP, DLin-S-DMA, DLin-2-DMAP, DLinTMA.Cl, DLinTAP.Cl, DLinMPZ, DLinAP, DOAP, and DLin-EG-DMA, as well as additional cationic lipids, is described in PCT Publication No. WO 09/086558, the disclosure of which is herein incorporated by reference in its entirety for all purposes. The synthesis of cationic lipids such as DO-C-DAP, DMDAP, DOTAP.Cl, DLin-M-C2-DMA, as well as additional cationic lipids, is described in PCT Application No. PCT/US2009/060251, entitled âImproved Amino Lipids and Methods for the Delivery of Nucleic Acids,â filed Oct. 9, 2009, the disclosure of which is incorporated herein by reference in its entirety for all purposes. The synthesis of a number of other cationic lipids and related analogs has been described in U.S. Pat. Nos. 5,208,036; 5,264,618; 5,279,833; 5,283,185; 5,753,613; and 5,785,992; and PCT Publication No. WO 96/10390, the disclosures of which are each herein incorporated by reference in their entirety for all purposes. Additionally, a number of commercial preparations of cationic lipids can be used, such as, e.g., LIPOFECTINÂ® (including DOTMA and DOPE, available from Invitrogen); LIPOFECTAMINEÂ® (including DOSPA and DOPE, available from Invitrogen); and TRANSFECTAMÂ® (including DOGS, available from Promega Corp.).</div>
    </li> <li> <para-num num="[0234]"> </para-num> <div id="p-0264" num="0234" class="description-line">In some embodiments, the cationic lipid comprises from about 50 mol % to about 90 mol %, from about 50 mol % to about 85 mol %, from about 50 mol % to about 80 mol %, from about 50 mol % to about 75 mol %, from about 50 mol % to about 70 mol %, from about 50 mol % to about 65 mol %, from about 50 mol % to about 60 mol %, from about 55 mol % to about 65 mol %, or from about 55 mol % to about 70 mol % (or any fraction thereof or range therein) of the total lipid present in the particle. In particular embodiments, the cationic lipid comprises about 50 mol %, 51 mol %, 52 mol %, 53 mol %, 54 mol %, 55 mol %, 56 mol %, 57 mol %, 58 mol %, 59 mol %, 60 mol %, 61 mol %, 62 mol %, 63 mol %, 64 mol %, or 65 mol % (or any fraction thereof) of the total lipid present in the particle.</div>
    </li> <li> <para-num num="[0235]"> </para-num> <div id="p-0265" num="0235" class="description-line">In other embodiments, the cationic lipid comprises from about 2 mol % to about 60 mol %, from about 5 mol % to about 50 mol %, from about 10 mol % to about 50 mol %, from about 20 mol % to about 50 mol %, from about 20 mol % to about 40 mol %, from about 30 mol % to about 40 mol %, or about 40 mol % (or any fraction thereof or range therein) of the total lipid present in the particle.</div>
    </li> <li> <para-num num="[0236]"> </para-num> <div id="p-0266" num="0236" class="description-line">Additional percentages and ranges of cationic lipids suitable for use in the lipid particles of the present invention are described in PCT Publication No. WO 09/127060, U.S. Published Application No. US 2011/0071208, PCT Publication No. WO2011/000106, and U.S. Published Application No. US 2011/0076335, the disclosures of which are herein incorporated by reference in their entirety for all purposes.</div>
    </li> <li> <para-num num="[0237]"> </para-num> <div id="p-0267" num="0237" class="description-line">It should be understood that the percentage of cationic lipid present in the lipid particles of the invention is a target amount, and that the actual amount of cationic lipid present in the formulation may vary, for example, by Â±5 mol %. For example, in the 1:57 lipid particle (e.g., SNALP) formulation, the target amount of cationic lipid is 57.1 mol %, but the actual amount of cationic lipid may be Â±5 mol %, Â±4 mol %, Â±3 mol %, Â±2 mol %, 1 mol %, 0.75 mol %, 0.5 mol %, Â±0.25 mol %, or Â±0.1 mol % of that target amount, with the balance of the formulation being made up of other lipid components (adding up to 100 mol % of total lipids present in the particle).</div>
    </li> <li> <para-num num="[0238]"> </para-num> <div id="p-0268" num="0238" class="description-line">By way of non-limiting example, cationic lipids include the following compounds:</div>
    </li> <li> <div id="p-0269" num="0000" class="description-line">
      <chemistry id="CHEM-US-00014" num="00014">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/1a/1b/49/265b52bbfe1c1c/US20190240354A1-20190808-C00014.png"><img id="EMI-C00014" he="11.51mm" wi="114.05mm" file="US20190240354A1-20190808-C00014.TIF" alt="Figure US20190240354A1-20190808-C00014" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="456" height="46" alt="Figure US20190240354A1-20190808-C00014" class="patent-full-image" src="https://patentimages.storage.googleapis.com/1a/1b/49/265b52bbfe1c1c/US20190240354A1-20190808-C00014.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00014" attachment-type="cdx" file="US20190240354A1-20190808-C00014.CDX"> </attachment>
          <attachment idref="CHEM-US-00014" attachment-type="mol" file="US20190240354A1-20190808-C00014.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <heading id="h-0013">N,N-dimethyl-2,3-bis((9Z,12Z)-octadeca-9,12-dienyloxy)propan-1-amine (5)</heading>
    <li> <para-num num="[0239]"> </para-num> <div id="p-0270" num="0239" class="description-line">
      <chemistry id="CHEM-US-00015" num="00015">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/9b/e9/41/365a02ed5eddd3/US20190240354A1-20190808-C00015.png"><img id="EMI-C00015" he="22.10mm" wi="116.84mm" file="US20190240354A1-20190808-C00015.TIF" alt="Figure US20190240354A1-20190808-C00015" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="467" height="88" alt="Figure US20190240354A1-20190808-C00015" class="patent-full-image" src="https://patentimages.storage.googleapis.com/9b/e9/41/365a02ed5eddd3/US20190240354A1-20190808-C00015.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00015" attachment-type="cdx" file="US20190240354A1-20190808-C00015.CDX"> </attachment>
          <attachment idref="CHEM-US-00015" attachment-type="mol" file="US20190240354A1-20190808-C00015.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <heading id="h-0014">2-(2,2-di((9Z,12Z)-octadeca-9,12-dienyl)-1,3-dioxolan-4-yl)-N,N-dimethylethanamine (6)</heading>
    <li> <para-num num="[0240]"> </para-num> <div id="p-0271" num="0240" class="description-line">
      <chemistry id="CHEM-US-00016" num="00016">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/55/9d/0b/e393d636f49b0d/US20190240354A1-20190808-C00016.png"><img id="EMI-C00016" he="12.28mm" wi="123.87mm" file="US20190240354A1-20190808-C00016.TIF" alt="Figure US20190240354A1-20190808-C00016" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="495" height="49" alt="Figure US20190240354A1-20190808-C00016" class="patent-full-image" src="https://patentimages.storage.googleapis.com/55/9d/0b/e393d636f49b0d/US20190240354A1-20190808-C00016.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00016" attachment-type="cdx" file="US20190240354A1-20190808-C00016.CDX"> </attachment>
          <attachment idref="CHEM-US-00016" attachment-type="mol" file="US20190240354A1-20190808-C00016.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <heading id="h-0015">(6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-tetraen-19-yl 4-(dimethylamino)butanoate (7)</heading>
    <li> <para-num num="[0241]"> </para-num> <div id="p-0272" num="0241" class="description-line">
      <chemistry id="CHEM-US-00017" num="00017">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/48/3f/fc/2d6d36c8de6b6c/US20190240354A1-20190808-C00017.png"><img id="EMI-C00017" he="17.10mm" wi="118.96mm" file="US20190240354A1-20190808-C00017.TIF" alt="Figure US20190240354A1-20190808-C00017" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="476" height="68" alt="Figure US20190240354A1-20190808-C00017" class="patent-full-image" src="https://patentimages.storage.googleapis.com/48/3f/fc/2d6d36c8de6b6c/US20190240354A1-20190808-C00017.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00017" attachment-type="cdx" file="US20190240354A1-20190808-C00017.CDX"> </attachment>
          <attachment idref="CHEM-US-00017" attachment-type="mol" file="US20190240354A1-20190808-C00017.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <heading id="h-0016">3-((6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-tetraen-19-yloxy)-N,N-dimethylpropan-1-amine (8)</heading>
    <li> <para-num num="[0242]"> </para-num> <div id="p-0273" num="0242" class="description-line">
      <chemistry id="CHEM-US-00018" num="00018">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/73/eb/41/2ffda7cb2e4915/US20190240354A1-20190808-C00018.png"><img id="EMI-C00018" he="16.00mm" wi="74.93mm" file="US20190240354A1-20190808-C00018.TIF" alt="Figure US20190240354A1-20190808-C00018" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="300" height="64" alt="Figure US20190240354A1-20190808-C00018" class="patent-full-image" src="https://patentimages.storage.googleapis.com/73/eb/41/2ffda7cb2e4915/US20190240354A1-20190808-C00018.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00018" attachment-type="cdx" file="US20190240354A1-20190808-C00018.CDX"> </attachment>
          <attachment idref="CHEM-US-00018" attachment-type="mol" file="US20190240354A1-20190808-C00018.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <heading id="h-0017">(Z)-12-((Z)-dec-4-enyl)docos-16-en-11-yl 5-(dimethylamino)pentanoate (53)</heading>
    <li> <para-num num="[0243]"> </para-num> <div id="p-0274" num="0243" class="description-line">
      <chemistry id="CHEM-US-00019" num="00019">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/72/23/8a/20fcd321ea705c/US20190240354A1-20190808-C00019.png"><img id="EMI-C00019" he="15.32mm" wi="75.18mm" file="US20190240354A1-20190808-C00019.TIF" alt="Figure US20190240354A1-20190808-C00019" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="301" height="61" alt="Figure US20190240354A1-20190808-C00019" class="patent-full-image" src="https://patentimages.storage.googleapis.com/72/23/8a/20fcd321ea705c/US20190240354A1-20190808-C00019.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00019" attachment-type="cdx" file="US20190240354A1-20190808-C00019.CDX"> </attachment>
          <attachment idref="CHEM-US-00019" attachment-type="mol" file="US20190240354A1-20190808-C00019.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <heading id="h-0018">(6Z,16Z)-12-((Z)-dec-4-enyl)docosa-6,16-dien-11-yl 6-(dimethylamino)hexanoate (11)</heading>
    <li> <para-num num="[0244]"> </para-num> <div id="p-0275" num="0244" class="description-line">
      <chemistry id="CHEM-US-00020" num="00020">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/59/f7/7b/bb54029d3e9fe6/US20190240354A1-20190808-C00020.png"><img id="EMI-C00020" he="16.09mm" wi="74.85mm" file="US20190240354A1-20190808-C00020.TIF" alt="Figure US20190240354A1-20190808-C00020" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="299" height="64" alt="Figure US20190240354A1-20190808-C00020" class="patent-full-image" src="https://patentimages.storage.googleapis.com/59/f7/7b/bb54029d3e9fe6/US20190240354A1-20190808-C00020.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00020" attachment-type="cdx" file="US20190240354A1-20190808-C00020.CDX"> </attachment>
          <attachment idref="CHEM-US-00020" attachment-type="mol" file="US20190240354A1-20190808-C00020.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <heading id="h-0019">(6Z,16Z)-12-((Z)-dec-4-enyl)docosa-6,16-dien-11-yl 5-(dimethylamino)pentanoate (13)</heading>
    <li> <para-num num="[0245]"> </para-num> <div id="p-0276" num="0245" class="description-line">
      <chemistry id="CHEM-US-00021" num="00021">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/fc/4e/22/1cd67956dbe8e5/US20190240354A1-20190808-C00021.png"><img id="EMI-C00021" he="16.09mm" wi="74.85mm" file="US20190240354A1-20190808-C00021.TIF" alt="Figure US20190240354A1-20190808-C00021" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="299" height="64" alt="Figure US20190240354A1-20190808-C00021" class="patent-full-image" src="https://patentimages.storage.googleapis.com/fc/4e/22/1cd67956dbe8e5/US20190240354A1-20190808-C00021.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00021" attachment-type="cdx" file="US20190240354A1-20190808-C00021.CDX"> </attachment>
          <attachment idref="CHEM-US-00021" attachment-type="mol" file="US20190240354A1-20190808-C00021.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <heading id="h-0020">12-decyldocosan-11-yl 5-(dimethylamino)pentanoate (14)</heading>
    <li> <para-num num="[0246]"> </para-num> <div id="p-0277" num="0246" class="description-line">
      <chemistry id="CHEM-US-00022" num="00022">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/3b/de/89/f2919307ddd9e1/US20190240354A1-20190808-C00022.png"><img id="EMI-C00022" he="181.86mm" wi="75.95mm" file="US20190240354A1-20190808-C00022.TIF" alt="Figure US20190240354A1-20190808-C00022" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="304" height="727" alt="Figure US20190240354A1-20190808-C00022" class="patent-full-image" src="https://patentimages.storage.googleapis.com/3b/de/89/f2919307ddd9e1/US20190240354A1-20190808-C00022.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00022" attachment-type="cdx" file="US20190240354A1-20190808-C00022.CDX"> </attachment>
          <attachment idref="CHEM-US-00022" attachment-type="mol" file="US20190240354A1-20190808-C00022.MOL"> </attachment>
        </attachments>
      </chemistry>
      <chemistry id="CHEM-US-00023" num="00023">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/55/c4/08/8fd30bbe6867b1/US20190240354A1-20190808-C00023.png"><img id="EMI-C00023" he="187.54mm" wi="75.52mm" file="US20190240354A1-20190808-C00023.TIF" alt="Figure US20190240354A1-20190808-C00023" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="302" height="750" alt="Figure US20190240354A1-20190808-C00023" class="patent-full-image" src="https://patentimages.storage.googleapis.com/55/c4/08/8fd30bbe6867b1/US20190240354A1-20190808-C00023.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00023" attachment-type="cdx" file="US20190240354A1-20190808-C00023.CDX"> </attachment>
          <attachment idref="CHEM-US-00023" attachment-type="mol" file="US20190240354A1-20190808-C00023.MOL"> </attachment>
        </attachments>
      </chemistry>
      <chemistry id="CHEM-US-00024" num="00024">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/50/32/fc/6ee077f1d7ae14/US20190240354A1-20190808-C00024.png"><img id="EMI-C00024" he="180.00mm" wi="76.03mm" file="US20190240354A1-20190808-C00024.TIF" alt="Figure US20190240354A1-20190808-C00024" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="304" height="720" alt="Figure US20190240354A1-20190808-C00024" class="patent-full-image" src="https://patentimages.storage.googleapis.com/50/32/fc/6ee077f1d7ae14/US20190240354A1-20190808-C00024.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00024" attachment-type="cdx" file="US20190240354A1-20190808-C00024.CDX"> </attachment>
          <attachment idref="CHEM-US-00024" attachment-type="mol" file="US20190240354A1-20190808-C00024.MOL"> </attachment>
        </attachments>
      </chemistry>
      <chemistry id="CHEM-US-00025" num="00025">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/e9/45/f3/072dffccb94cd2/US20190240354A1-20190808-C00025.png"><img id="EMI-C00025" he="91.95mm" wi="75.27mm" file="US20190240354A1-20190808-C00025.TIF" alt="Figure US20190240354A1-20190808-C00025" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="301" height="368" alt="Figure US20190240354A1-20190808-C00025" class="patent-full-image" src="https://patentimages.storage.googleapis.com/e9/45/f3/072dffccb94cd2/US20190240354A1-20190808-C00025.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00025" attachment-type="cdx" file="US20190240354A1-20190808-C00025.CDX"> </attachment>
          <attachment idref="CHEM-US-00025" attachment-type="mol" file="US20190240354A1-20190808-C00025.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <heading id="h-0021">Non-Cationic Lipids</heading>
    <li> <para-num num="[0247]"> </para-num> <div id="p-0278" num="0247" class="description-line">The non-cationic lipids used in the lipid particles of the invention (e.g., SNALP) can be any of a variety of neutral uncharged, zwitterionic, or anionic lipids capable of producing a stable complex.</div>
    </li> <li> <para-num num="[0248]"> </para-num> <div id="p-0279" num="0248" class="description-line">Non-limiting examples of non-cationic lipids include phospholipids such as lecithin, phosphatidylethanolamine, lysolecithin, lysophosphatidylethanolamine, phosphatidylserine, phosphatidylinositol, sphingomyelin, egg sphingomyelin (ESM), cephalin, cardiolipin, phosphatidic acid, cerebrosides, dicetylphosphate, di stearoylphosphatidylcholine (DSPC), dioleoylphosphatidylcholine (DOPC), dipalmitoylphosphatidylcholine (DPPC), dioleoylphosphatidylglycerol (DOPG), dipalmitoylphosphatidylglycerol (DPPG), dioleoylphosphatidylethanolamine (DOPE), palmitoyloleoyl-phosphatidylcholine (POPC), palmitoyloleoyl-phosphatidylethanolamine (POPE), palmitoyloleyol-phosphatidylglycerol (POPG), dioleoylphosphatidylethanolamine 4-(N-maleimidomethyl)-cyclohexane-1-carboxylate (DOPE-mal), dipalmitoyl-phosphatidylethanolamine (DPPE), dimyristoyl-phosphatidylethanolamine (DMPE), distearoyl-phosphatidylethanolamine (DSPE), monomethyl-phosphatidylethanolamine, dimethyl-phosphatidylethanolamine, dielaidoyl-phosphatidylethanolamine (DEPE), stearoyloleoyl-phosphatidylethanolamine (SOPE), lysophosphatidylcholine, dilinoleoylphosphatidylcholine, and mixtures thereof. Other diacylphosphatidylcholine and diacylphosphatidylethanolamine phospholipids can also be used. The acyl groups in these lipids are preferably acyl groups derived from fatty acids having C<sub>10</sub>-C<sub>24 </sub>carbon chains, e.g., lauroyl, myristoyl, palmitoyl, stearoyl, or oleoyl.</div>
    </li> <li> <para-num num="[0249]"> </para-num> <div id="p-0280" num="0249" class="description-line">Additional examples of non-cationic lipids include sterols such as cholesterol and derivatives thereof. Non-limiting examples of cholesterol derivatives include polar analogues such as 5Î±-cholestanol, 5Î²-coprostanol, cholesteryl-(2â²-hydroxy)-ethyl ether, cholesteryl-(4â²-hydroxy)-butyl ether, and 6-ketocholestanol; non-polar analogues such as 5Î±-cholestane, cholestenone, 5Î±-cholestanone, 5Î²-cholestanone, and cholesteryl decanoate; and mixtures thereof. In preferred embodiments, the cholesterol derivative is a polar analogue such as cholesteryl-(4â²-hydroxy)-butyl ether. The synthesis of cholesteryl-(2â²-hydroxy)-ethyl ether is described in PCT Publication No. WO 09/127060, the disclosure of which is herein incorporated by reference in its entirety for all purposes.</div>
    </li> <li> <para-num num="[0250]"> </para-num> <div id="p-0281" num="0250" class="description-line">In some embodiments, the non-cationic lipid present in the lipid particles (e.g., SNALP) comprises or consists of a mixture of one or more phospholipids and cholesterol or a derivative thereof. In other embodiments, the non-cationic lipid present in the lipid particles (e.g., SNALP) comprises or consists of one or more phospholipids, e.g., a cholesterol-free lipid particle formulation. In yet other embodiments, the non-cationic lipid present in the lipid particles (e.g., SNALP) comprises or consists of cholesterol or a derivative thereof, e.g., a phospholipid-free lipid particle formulation.</div>
    </li> <li> <para-num num="[0251]"> </para-num> <div id="p-0282" num="0251" class="description-line">Other examples of non-cationic lipids suitable for use in the present invention include nonphosphorous containing lipids such as, e.g., stearylamine, dodecylamine, hexadecylamine, acetyl palmitate, glycerolricinoleate, hexadecyl stereate, isopropyl myristate, amphoteric acrylic polymers, triethanolamine-lauryl sulfate, alkyl-aryl sulfate polyethyloxylated fatty acid amides, dioctadecyldimethyl ammonium bromide, ceramide, sphingomyelin, and the like.</div>
    </li> <li> <para-num num="[0252]"> </para-num> <div id="p-0283" num="0252" class="description-line">In some embodiments, the non-cationic lipid comprises from about 10 mol % to about 60 mol %, from about 20 mol % to about 55 mol %, from about 20 mol % to about 45 mol %, from about 20 mol % to about 40 mol %, from about 25 mol % to about 50 mol %, from about 25 mol % to about 45 mol %, from about 30 mol % to about 50 mol %, from about 30 mol % to about 45 mol %, from about 30 mol % to about 40 mol %, from about 35 mol % to about 45 mol %, from about 37 mol % to about 42 mol %, or about 35 mol %, 36 mol %, 37 mol %, 38 mol %, 39 mol %, 40 mol %, 41 mol %, 42 mol %, 43 mol %, 44 mol %, or 45 mol % (or any fraction thereof or range therein) of the total lipid present in the particle.</div>
    </li> <li> <para-num num="[0253]"> </para-num> <div id="p-0284" num="0253" class="description-line">In embodiments where the lipid particles contain a mixture of phospholipid and cholesterol or a cholesterol derivative, the mixture may comprise up to about 40 mol %, 45 mol %, 50 mol %, 55 mol %, or 60 mol % of the total lipid present in the particle.</div>
    </li> <li> <para-num num="[0254]"> </para-num> <div id="p-0285" num="0254" class="description-line">In some embodiments, the phospholipid component in the mixture may comprise from about 2 mol % to about 20 mol %, from about 2 mol % to about 15 mol %, from about 2 mol % to about 12 mol %, from about 4 mol % to about 15 mol %, or from about 4 mol % to about 10 mol % (or any fraction thereof or range therein) of the total lipid present in the particle. In certain preferred embodiments, the phospholipid component in the mixture comprises from about 5 mol % to about 10 mol %, from about 5 mol % to about 9 mol %, from about 5 mol % to about 8 mol %, from about 6 mol % to about 9 mol %, from about 6 mol % to about 8 mol %, or about 5 mol %, 6 mol %, 7 mol %, 8 mol %, 9 mol %, or 10 mol % (or any fraction thereof or range therein) of the total lipid present in the particle. As a non-limiting example, a 1:57 lipid particle formulation comprising a mixture of phospholipid and cholesterol may comprise a phospholipid such as DPPC or DSPC at about 7 mol % (or any fraction thereof), e.g., in a mixture with cholesterol or a cholesterol derivative at about 34 mol % (or any fraction thereof) of the total lipid present in the particle. As another non-limiting example, a 7:54 lipid particle formulation comprising a mixture of phospholipid and cholesterol may comprise a phospholipid such as DPPC or DSPC at about 7 mol % (or any fraction thereof), e.g., in a mixture with cholesterol or a cholesterol derivative at about 32 mol % (or any fraction thereof) of the total lipid present in the particle.</div>
    </li> <li> <para-num num="[0255]"> </para-num> <div id="p-0286" num="0255" class="description-line">In other embodiments, the cholesterol component in the mixture may comprise from about 25 mol % to about 45 mol %, from about 25 mol % to about 40 mol %, from about 30 mol % to about 45 mol %, from about 30 mol % to about 40 mol %, from about 27 mol % to about 37 mol %, from about 25 mol % to about 30 mol %, or from about 35 mol % to about 40 mol % (or any fraction thereof or range therein) of the total lipid present in the particle. In certain preferred embodiments, the cholesterol component in the mixture comprises from about 25 mol % to about 35 mol %, from about 27 mol % to about 35 mol %, from about 29 mol % to about 35 mol %, from about 30 mol % to about 35 mol %, from about 30 mol % to about 34 mol %, from about 31 mol % to about 33 mol %, or about 30 mol %, 31 mol %, 32 mol %, 33 mol %, 34 mol %, or 35 mol % (or any fraction thereof or range therein) of the total lipid present in the particle. Typically, a 1:57 lipid particle formulation comprising a mixture of phospholipid and cholesterol may comprise cholesterol or a cholesterol derivative at about 34 mol % (or any fraction thereof), e.g., in a mixture with a phospholipid such as DPPC or DSPC at about 7 mol % (or any fraction thereof) of the total lipid present in the particle. Typically, a 7:54 lipid particle formulation comprising a mixture of phospholipid and cholesterol may comprise cholesterol or a cholesterol derivative at about 32 mol % (or any fraction thereof), e.g., in a mixture with a phospholipid such as DPPC or DSPC at about 7 mol % (or any fraction thereof) of the total lipid present in the particle.</div>
    </li> <li> <para-num num="[0256]"> </para-num> <div id="p-0287" num="0256" class="description-line">In embodiments where the lipid particles are phospholipid-free, the cholesterol or derivative thereof may comprise up to about 25 mol %, 30 mol %, 35 mol %, 40 mol %, 45 mol %, 50 mol %, 55 mol %, or 60 mol % of the total lipid present in the particle.</div>
    </li> <li> <para-num num="[0257]"> </para-num> <div id="p-0288" num="0257" class="description-line">In some embodiments, the cholesterol or derivative thereof in the phospholipid-free lipid particle formulation may comprise from about 25 mol % to about 45 mol %, from about 25 mol % to about 40 mol %, from about 30 mol % to about 45 mol %, from about 30 mol % to about 40 mol %, from about 31 mol % to about 39 mol %, from about 32 mol % to about 38 mol %, from about 33 mol % to about 37 mol %, from about 35 mol % to about 45 mol %, from about 30 mol % to about 35 mol %, from about 35 mol % to about 40 mol %, or about 30 mol %, 31 mol %, 32 mol %, 33 mol %, 34 mol %, 35 mol %, 36 mol %, 37 mol %, 38 mol %, 39 mol %, or 40 mol % (or any fraction thereof or range therein) of the total lipid present in the particle. As a non-limiting example, a 1:62 lipid particle formulation may comprise cholesterol at about 37 mol % (or any fraction thereof) of the total lipid present in the particle. As another non-limiting example, a 7:58 lipid particle formulation may comprise cholesterol at about 35 mol % (or any fraction thereof) of the total lipid present in the particle.</div>
    </li> <li> <para-num num="[0258]"> </para-num> <div id="p-0289" num="0258" class="description-line">In other embodiments, the non-cationic lipid comprises from about 5 mol % to about 90 mol %, from about 10 mol % to about 85 mol %, from about 20 mol % to about 80 mol %, about 10 mol % (e.g., phospholipid only), or about 60 mol % (e.g., phospholipid and cholesterol or derivative thereof) (or any fraction thereof or range therein) of the total lipid present in the particle.</div>
    </li> <li> <para-num num="[0259]"> </para-num> <div id="p-0290" num="0259" class="description-line">Additional percentages and ranges of non-cationic lipids suitable for use in the lipid particles of the present invention are described in PCT Publication No. WO 09/127060, U.S. Published Application No. US 2011/0071208, PCT Publication No. WO2011/000106, and U.S. Published Application No. US 2011/0076335, the disclosures of which are herein incorporated by reference in their entirety for all purposes.</div>
    </li> <li> <para-num num="[0260]"> </para-num> <div id="p-0291" num="0260" class="description-line">It should be understood that the percentage of non-cationic lipid present in the lipid particles of the invention is a target amount, and that the actual amount of non-cationic lipid present in the formulation may vary, for example, by Â±5 mol %. For example, in the 1:57 lipid particle (e.g., SNALP) formulation, the target amount of phospholipid is 7.1 mol % and the target amount of cholesterol is 34.3 mol %, but the actual amount of phospholipid may be Â±2 mol %, 1.5 mol %, 1 mol %, 0.75 mol %, 0.5 mol %, 0.25 mol %, or Â±0.1 mol % of that target amount, and the actual amount of cholesterol may be Â±3 mol %, Â±2 mol %, Â±1 mol %, Â±0.75 mol %, Â±0.5 mol %, Â±0.25 mol %, or Â±0.1 mol % of that target amount, with the balance of the formulation being made up of other lipid components (adding up to 100 mol % of total lipids present in the particle). Similarly, in the 7:54 lipid particle (e.g., SNALP) formulation, the target amount of phospholipid is 6.75 mol % and the target amount of cholesterol is 32.43 mol %, but the actual amount of phospholipid may be Â±2 mol %, Â±1.5 mol %, Â±1 mol %, Â±0.75 mol %, Â±0.5 mol %, Â±0.25 mol %, or Â±0.1 mol % of that target amount, and the actual amount of cholesterol may be Â±3 mol %, Â±2 mol %, Â±1 mol %, Â±0.75 mol %, Â±0.5 mol %, Â±0.25 mol %, or Â±0.1 mol % of that target amount, with the balance of the formulation being made up of other lipid components (adding up to 100 mol % of total lipids present in the particle).</div>
    </li> <heading id="h-0022">Lipid Conjugates</heading>
    <li> <para-num num="[0261]"> </para-num> <div id="p-0292" num="0261" class="description-line">In addition to cationic and non-cationic lipids, the lipid particles of the invention (e.g., SNALP) may further comprise a lipid conjugate. The conjugated lipid is useful in that it prevents the aggregation of particles. Suitable conjugated lipids include, but are not limited to, PEG-lipid conjugates, POZ-lipid conjugates, ATTA-lipid conjugates, cationic-polymer-lipid conjugates (CPLs), and mixtures thereof. In certain embodiments, the particles comprise either a PEG-lipid conjugate or an ATTA-lipid conjugate together with a CPL.</div>
    </li> <li> <para-num num="[0262]"> </para-num> <div id="p-0293" num="0262" class="description-line">In a preferred embodiment, the lipid conjugate is a PEG-lipid. Examples of PEG-lipids include, but are not limited to, PEG coupled to dialkyloxypropyls (PEG-DAA) as described in, e.g., PCT Publication No. WO 05/026372, PEG coupled to diacylglycerol (PEG-DAG) as described in, e.g., U.S. Patent Publication Nos. 20030077829 and 2005008689, PEG coupled to phospholipids such as phosphatidylethanolamine (PEG-PE), PEG conjugated to ceramides as described in, e.g., U.S. Pat. No. 5,885,613, PEG conjugated to cholesterol or a derivative thereof, and mixtures thereof. The disclosures of these patent documents are herein incorporated by reference in their entirety for all purposes. Additional PEG-lipids suitable for use in the invention include, without limitation, mPEG2000-1,2-di-O-alkyl-sn3-carbomoylglyceride (PEG-C-DOMG). The synthesis of PEG-C-DOMG is described in PCT Publication No. WO 09/086558, the disclosure of which is herein incorporated by reference in its entirety for all purposes. Yet additional suitable PEG-lipid conjugates include, without limitation, 1-[8â²-(1,2-dimyristoyl-3-propanoxy)-carboxamido-3â²,6â²-dioxaoctanyl]carbamoyl-Ï-methyl-poly(ethylene glycol) (2KPEG-DMG). The synthesis of 2KPEG-DMG is described in U.S. Pat. No. 7,404,969, the disclosure of which is herein incorporated by reference in its entirety for all purposes.</div>
    </li> <li> <para-num num="[0263]"> </para-num> <div id="p-0294" num="0263" class="description-line">PEG is a linear, water-soluble polymer of ethylene PEG repeating units with two terminal hydroxyl groups. PEGs are classified by their molecular weights; for example, PEG 2000 has an average molecular weight of about 2,000 daltons, and PEG 5000 has an average molecular weight of about 5,000 daltons. PEGs are commercially available from Sigma Chemical Co. and other companies and include, but are not limited to, the following: monomethoxypolyethylene glycol (MePEG-OH), monomethoxypolyethylene glycol-succinate (MePEG-S), monomethoxypolyethylene glycol-succinimidyl succinate (MePEG-S-NHS), monomethoxypolyethylene glycol-amine (MePEG-NH<sub>2</sub>), monomethoxypolyethylene glycol-tresylate (MePEG-TRES), monomethoxypolyethylene glycol-imidazolyl-carbonyl (MePEG-IM), as well as such compounds containing a terminal hydroxyl group instead of a terminal methoxy group (e.g., HO-PEG-S, HO-PEG-S-NHS, HO-PEG-NH<sub>2</sub>, etc.). Other PEGs such as those described in U.S. Pat. Nos. 6,774,180 and 7,053,150 (e.g., mPEG (20 KDa) amine) are also useful for preparing the PEG-lipid conjugates of the present invention. The disclosures of these patents are herein incorporated by reference in their entirety for all purposes. In addition, monomethoxypolyethyleneglycol-acetic acid (MePEG-CH<sub>2</sub>COOH) is particularly useful for preparing PEG-lipid conjugates including, e.g., PEG-DAA conjugates.</div>
    </li> <li> <para-num num="[0264]"> </para-num> <div id="p-0295" num="0264" class="description-line">The PEG moiety of the PEG-lipid conjugates described herein may comprise an average molecular weight ranging from about 550 daltons to about 10,000 daltons. In certain instances, the PEG moiety has an average molecular weight of from about 750 daltons to about 5,000 daltons (e.g., from about 1,000 daltons to about 5,000 daltons, from about 1,500 daltons to about 3,000 daltons, from about 750 daltons to about 3,000 daltons, from about 750 daltons to about 2,000 daltons, etc.). In preferred embodiments, the PEG moiety has an average molecular weight of about 2,000 daltons or about 750 daltons.</div>
    </li> <li> <para-num num="[0265]"> </para-num> <div id="p-0296" num="0265" class="description-line">In certain instances, the PEG can be optionally substituted by an alkyl, alkoxy, acyl, or aryl group. The PEG can be conjugated directly to the lipid or may be linked to the lipid via a linker moiety. Any linker moiety suitable for coupling the PEG to a lipid can be used including, e.g., non-ester containing linker moieties and ester-containing linker moieties. In a preferred embodiment, the linker moiety is a non-ester containing linker moiety. As used herein, the term ânon-ester containing linker moietyâ refers to a linker moiety that does not contain a carboxylic ester bond (âOC(O)â). Suitable non-ester containing linker moieties include, but are not limited to, amido (âC(O)NHâ), amino (âNRâ), carbonyl (âC(O)â), carbamate (âNHC(O)Oâ), urea (âNHC(O)NHâ), disulphide (âSâSâ), ether (âOâ), succinyl (â(O)CCH<sub>2</sub>CH<sub>2</sub>C(O)â), succinamidyl (âNHC(O)CH<sub>2</sub>CH<sub>2</sub>C(O)NHâ), ether, disulphide, as well as combinations thereof (such as a linker containing both a carbamate linker moiety and an amido linker moiety). In a preferred embodiment, a carbamate linker is used to couple the PEG to the lipid.</div>
    </li> <li> <para-num num="[0266]"> </para-num> <div id="p-0297" num="0266" class="description-line">In other embodiments, an ester containing linker moiety is used to couple the PEG to the lipid. Suitable ester containing linker moieties include, e.g., carbonate (âOC(O)Oâ), succinoyl, phosphate esters (âOâ(O)POHâOâ), sulfonate esters, and combinations thereof.</div>
    </li> <li> <para-num num="[0267]"> </para-num> <div id="p-0298" num="0267" class="description-line">Phosphatidylethanolamines having a variety of acyl chain groups of varying chain lengths and degrees of saturation can be conjugated to PEG to form the lipid conjugate. Such phosphatidylethanolamines are commercially available, or can be isolated or synthesized using conventional techniques known to those of skilled in the art. Phosphatidyl-ethanolamines containing saturated or unsaturated fatty acids with carbon chain lengths in the range of C<sub>10 </sub>to C<sub>20 </sub>are preferred. Phosphatidylethanolamines with mono- or diunsaturated fatty acids and mixtures of saturated and unsaturated fatty acids can also be used. Suitable phosphatidylethanolamines include, but are not limited to, dimyristoyl-phosphatidylethanolamine (DMPE), dipalmitoyl-phosphatidylethanolamine (DPPE), dioleoylphosphatidylethanolamine (DOPE), and distearoyl-phosphatidylethanolamine (DSPE).</div>
    </li> <li> <para-num num="[0268]"> </para-num> <div id="p-0299" num="0268" class="description-line">The term âATTAâ or âpolyamideâ includes, without limitation, compounds described in U.S. Pat. Nos. 6,320,017 and 6,586,559, the disclosures of which are herein incorporated by reference in their entirety for all purposes. These compounds include a compound having the formula:</div>
    </li> <li> <div id="p-0300" num="0000" class="description-line">
      <chemistry id="CHEM-US-00026" num="00026">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/79/44/ff/b3c018048f9a22/US20190240354A1-20190808-C00026.png"><img id="EMI-C00026" he="20.32mm" wi="75.95mm" file="US20190240354A1-20190808-C00026.TIF" alt="Figure US20190240354A1-20190808-C00026" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="304" height="81" alt="Figure US20190240354A1-20190808-C00026" class="patent-full-image" src="https://patentimages.storage.googleapis.com/79/44/ff/b3c018048f9a22/US20190240354A1-20190808-C00026.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00026" attachment-type="cdx" file="US20190240354A1-20190808-C00026.CDX"> </attachment>
          <attachment idref="CHEM-US-00026" attachment-type="mol" file="US20190240354A1-20190808-C00026.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <div id="p-0301" num="0000" class="description-line">wherein R is a member selected from the group consisting of hydrogen, alkyl and acyl; R<sup>1 </sup>is a member selected from the group consisting of hydrogen and alkyl; or optionally, R and R<sup>1 </sup>and the nitrogen to which they are bound form an azido moiety; R<sup>2 </sup>is a member of the group selected from hydrogen, optionally substituted alkyl, optionally substituted aryl and a side chain of an amino acid; R<sup>3 </sup>is a member selected from the group consisting of hydrogen, halogen, hydroxy, alkoxy, mercapto, hydrazino, amino and NR<sup>4</sup>R<sup>5</sup>, wherein R<sup>4 </sup>and R<sup>5 </sup>are independently hydrogen or alkyl; n is 4 to 80; m is 2 to 6; p is 1 to 4; and q is 0 or 1. It will be apparent to those of skill in the art that other polyamides can be used in the compounds of the present invention.</div>
    </li> <li> <para-num num="[0269]"> </para-num> <div id="p-0302" num="0269" class="description-line">The term âdiacylglycerolâ or âDAGâ includes a compound having 2 fatty acyl chains, R<sup>1 </sup>and R<sup>2</sup>, both of which have independently between 2 and 30 carbons bonded to the 1- and 2-position of glycerol by ester linkages. The acyl groups can be saturated or have varying degrees of unsaturation. Suitable acyl groups include, but are not limited to, lauroyl (C<sub>12</sub>), myristoyl (C<sub>14</sub>), palmitoyl (C<sub>16</sub>), stearoyl (C<sub>18</sub>), and icosoyl (C<sub>20</sub>). In preferred embodiments, R<sup>1 </sup>and R<sup>2 </sup>are the same, i.e., R<sup>1 </sup>and R<sup>2 </sup>are both myristoyl (i.e., dimyristoyl), R<sup>1 </sup>and R<sup>2 </sup>are both stearoyl (i.e., distearoyl), etc. Diacylglycerols have the following general formula:</div>
    </li> <li> <div id="p-0303" num="0000" class="description-line">
      <chemistry id="CHEM-US-00027" num="00027">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/75/67/1c/7b08f8f68747ed/US20190240354A1-20190808-C00027.png"><img id="EMI-C00027" he="40.56mm" wi="69.93mm" file="US20190240354A1-20190808-C00027.TIF" alt="Figure US20190240354A1-20190808-C00027" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="280" height="162" alt="Figure US20190240354A1-20190808-C00027" class="patent-full-image" src="https://patentimages.storage.googleapis.com/75/67/1c/7b08f8f68747ed/US20190240354A1-20190808-C00027.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00027" attachment-type="cdx" file="US20190240354A1-20190808-C00027.CDX"> </attachment>
          <attachment idref="CHEM-US-00027" attachment-type="mol" file="US20190240354A1-20190808-C00027.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0270]"> </para-num> <div id="p-0304" num="0270" class="description-line">The term âdialkyloxypropylâ or âDAAâ includes a compound having 2 alkyl chains, R<sup>1 </sup>and R<sup>2</sup>, both of which have independently between 2 and 30 carbons. The alkyl groups can be saturated or have varying degrees of unsaturation. Dialkyloxypropyls have the following general formula:</div>
    </li> <li> <div id="p-0305" num="0000" class="description-line">
      <chemistry id="CHEM-US-00028" num="00028">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/1a/ba/87/526dd699447c74/US20190240354A1-20190808-C00028.png"><img id="EMI-C00028" he="17.10mm" wi="69.93mm" file="US20190240354A1-20190808-C00028.TIF" alt="Figure US20190240354A1-20190808-C00028" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="280" height="68" alt="Figure US20190240354A1-20190808-C00028" class="patent-full-image" src="https://patentimages.storage.googleapis.com/1a/ba/87/526dd699447c74/US20190240354A1-20190808-C00028.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00028" attachment-type="cdx" file="US20190240354A1-20190808-C00028.CDX"> </attachment>
          <attachment idref="CHEM-US-00028" attachment-type="mol" file="US20190240354A1-20190808-C00028.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0271]"> </para-num> <div id="p-0306" num="0271" class="description-line">In a preferred embodiment, the PEG-lipid is a PEG-DAA conjugate having the following formula:</div>
    </li> <li> <div id="p-0307" num="0000" class="description-line">
      <chemistry id="CHEM-US-00029" num="00029">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/94/f4/9e/acfa9f70eaf10c/US20190240354A1-20190808-C00029.png"><img id="EMI-C00029" he="17.02mm" wi="69.93mm" file="US20190240354A1-20190808-C00029.TIF" alt="Figure US20190240354A1-20190808-C00029" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="280" height="68" alt="Figure US20190240354A1-20190808-C00029" class="patent-full-image" src="https://patentimages.storage.googleapis.com/94/f4/9e/acfa9f70eaf10c/US20190240354A1-20190808-C00029.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00029" attachment-type="cdx" file="US20190240354A1-20190808-C00029.CDX"> </attachment>
          <attachment idref="CHEM-US-00029" attachment-type="mol" file="US20190240354A1-20190808-C00029.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <div id="p-0308" num="0000" class="description-line">wherein R<sup>1 </sup>and R<sup>2 </sup>are independently selected and are long-chain alkyl groups having from about 10 to about 22 carbon atoms; PEG is a polyethyleneglycol; and L is a non-ester containing linker moiety or an ester containing linker moiety as described above. The long-chain alkyl groups can be saturated or unsaturated. Suitable alkyl groups include, but are not limited to, decyl (C<sub>10</sub>), lauryl (C<sub>12</sub>), myristyl (C<sub>14</sub>), palmityl (C<sub>16</sub>), stearyl (C<sub>18</sub>), and icosyl (C<sub>20</sub>). In preferred embodiments, R<sup>1 </sup>and R<sup>2 </sup>are the same, i.e., R<sup>1 </sup>and R<sup>2 </sup>are both myristyl (i.e., dimyristyl), R<sup>1 </sup>and R<sup>2 </sup>are both stearyl (i.e., distearyl), etc.</div>
    </li> <li> <para-num num="[0272]"> </para-num> <div id="p-0309" num="0272" class="description-line">In Formula VII above, the PEG has an average molecular weight ranging from about 550 daltons to about 10,000 daltons. In certain instances, the PEG has an average molecular weight of from about 750 daltons to about 5,000 daltons (e.g., from about 1,000 daltons to about 5,000 daltons, from about 1,500 daltons to about 3,000 daltons, from about 750 daltons to about 3,000 daltons, from about 750 daltons to about 2,000 daltons, etc.). In preferred embodiments, the PEG has an average molecular weight of about 2,000 daltons or about 750 daltons. The PEG can be optionally substituted with alkyl, alkoxy, acyl, or aryl groups. In certain embodiments, the terminal hydroxyl group is substituted with a methoxy or methyl group.</div>
    </li> <li> <para-num num="[0273]"> </para-num> <div id="p-0310" num="0273" class="description-line">In a preferred embodiment, âLâ is a non-ester containing linker moiety. Suitable non-ester containing linkers include, but are not limited to, an amido linker moiety, an amino linker moiety, a carbonyl linker moiety, a carbamate linker moiety, a urea linker moiety, an ether linker moiety, a disulphide linker moiety, a succinamidyl linker moiety, and combinations thereof. In a preferred embodiment, the non-ester containing linker moiety is a carbamate linker moiety (i.e., a PEG-C-DAA conjugate). In another preferred embodiment, the non-ester containing linker moiety is an amido linker moiety (i.e., a PEG-A-DAA conjugate). In yet another preferred embodiment, the non-ester containing linker moiety is a succinamidyl linker moiety (i.e., a PEG-S-DAA conjugate).</div>
    </li> <li> <para-num num="[0274]"> </para-num> <div id="p-0311" num="0274" class="description-line">In particular embodiments, the PEG-lipid conjugate is selected from:</div>
    </li> <li> <div id="p-0312" num="0000" class="description-line">
      <chemistry id="CHEM-US-00030" num="00030">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/16/03/74/a45fd3908ff7da/US20190240354A1-20190808-C00030.png"><img id="EMI-C00030" he="57.32mm" wi="140.38mm" file="US20190240354A1-20190808-C00030.TIF" alt="Figure US20190240354A1-20190808-C00030" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="562" height="229" alt="Figure US20190240354A1-20190808-C00030" class="patent-full-image" src="https://patentimages.storage.googleapis.com/16/03/74/a45fd3908ff7da/US20190240354A1-20190808-C00030.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00030" attachment-type="cdx" file="US20190240354A1-20190808-C00030.CDX"> </attachment>
          <attachment idref="CHEM-US-00030" attachment-type="mol" file="US20190240354A1-20190808-C00030.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0275]"> </para-num> <div id="p-0313" num="0275" class="description-line">The PEG-DAA conjugates are synthesized using standard techniques and reagents known to those of skill in the art. It will be recognized that the PEG-DAA conjugates will contain various amide, amine, ether, thio, carbamate, and urea linkages. Those of skill in the art will recognize that methods and reagents for forming these bonds are well known and readily available. See, e.g., March, ADVANCED ORGANIC CHEMISTRY (Wiley 1992); Larock, COMPREHENSIVE ORGANIC TRANSFORMATIONS (VCH 1989); and Furniss, VOGEL&#39;S TEXTBOOK OF PRACTICAL ORGANIC CHEMISTRY, 5th ed. (Longman 1989). It will also be appreciated that any functional groups present may require protection and deprotection at different points in the synthesis of the PEG-DAA conjugates. Those of skill in the art will recognize that such techniques are well known. See, e.g., Green and Wuts, PROTECTIVE GROUPS IN ORGANIC SYNTHESIS (Wiley 1991).</div>
    </li> <li> <para-num num="[0276]"> </para-num> <div id="p-0314" num="0276" class="description-line">Preferably, the PEG-DAA conjugate is a PEG-didecyloxypropyl (C<sub>10</sub>) conjugate, a PEG-dilauryloxypropyl (C<sub>12</sub>) conjugate, a PEG-dimyristyloxypropyl (C<sub>14</sub>) conjugate, a PEG-dipalmityloxypropyl (C<sub>16</sub>) conjugate, or a PEG-distearyloxypropyl (C<sub>18</sub>) conjugate. In these embodiments, the PEG preferably has an average molecular weight of about 750 or about 2,000 daltons. In one particularly preferred embodiment, the PEG-lipid conjugate comprises PEG2000-C-DMA, wherein the â2000â denotes the average molecular weight of the PEG, the âCâ denotes a carbamate linker moiety, and the âDMAâ denotes dimyristyloxypropyl. In another particularly preferred embodiment, the PEG-lipid conjugate comprises PEG750-C-DMA, wherein the â750â denotes the average molecular weight of the PEG, the âCâ denotes a carbamate linker moiety, and the âDMAâ denotes dimyristyloxypropyl. In particular embodiments, the terminal hydroxyl group of the PEG is substituted with a methyl group. Those of skill in the art will readily appreciate that other dialkyloxypropyls can be used in the PEG-DAA conjugates of the present invention.</div>
    </li> <li> <para-num num="[0277]"> </para-num> <div id="p-0315" num="0277" class="description-line">In addition to the foregoing, it will be readily apparent to those of skill in the art that other hydrophilic polymers can be used in place of PEG. Examples of suitable polymers that can be used in place of PEG include, but are not limited to, polyvinylpyrrolidone, polymethyloxazoline, polyethyloxazoline, polyhydroxypropyl methacrylamide, polymethacrylamide and polydimethylacrylamide, polylactic acid, polyglycolic acid, and derivatized celluloses such as hydroxymethylcellulose or hydroxyethylcellulose.</div>
    </li> <li> <para-num num="[0278]"> </para-num> <div id="p-0316" num="0278" class="description-line">In addition to the foregoing components, the lipid particles (e.g., SNALP) of the present invention can further comprise cationic poly(ethylene glycol) (PEG) lipids or CPLs (see, e.g., Chen et al., <i>Bioconj. Chem., </i>11:433-437 (2000); U.S. Pat. No. 6,852,334; PCT Publication No. WO 00/62813, the disclosures of which are herein incorporated by reference in their entirety for all purposes).</div>
    </li> <li> <para-num num="[0279]"> </para-num> <div id="p-0317" num="0279" class="description-line">Suitable CPLs include compounds of Formula VIII:</div>
    </li> <li> <div id="p-0318" num="0000" class="description-line"> <br/>A-WâY ââ(VIII),
</div>
    </li> <li> <div id="p-0319" num="0000" class="description-line">wherein A, W, and Y are as described below.</div>
    </li> <li> <para-num num="[0280]"> </para-num> <div id="p-0320" num="0280" class="description-line">With reference to Formula VIII, âAâ is a lipid moiety such as an amphipathic lipid, a neutral lipid, or a hydrophobic lipid that acts as a lipid anchor. Suitable lipid examples include, but are not limited to, diacylglycerolyls, dialkylglycerolyls, N-N-dialkylaminos, 1,2-diacyloxy-3-aminopropanes, and 1,2-dialkyl-3-aminopropanes.</div>
    </li> <li> <para-num num="[0281]"> </para-num> <div id="p-0321" num="0281" class="description-line">âWâ is a polymer or an oligomer such as a hydrophilic polymer or oligomer. Preferably, the hydrophilic polymer is a biocompatible polymer that is nonimmunogenic or possesses low inherent immunogenicity. Alternatively, the hydrophilic polymer can be weakly antigenic if used with appropriate adjuvants. Suitable nonimmunogenic polymers include, but are not limited to, PEG, polyamides, polylactic acid, polyglycolic acid, polylactic acid/polyglycolic acid copolymers, and combinations thereof. In a preferred embodiment, the polymer has a molecular weight of from about 250 to about 7,000 daltons.</div>
    </li> <li> <para-num num="[0282]"> </para-num> <div id="p-0322" num="0282" class="description-line">âYâ is a polycationic moiety. The term polycationic moiety refers to a compound, derivative, or functional group having a positive charge, preferably at least 2 positive charges at a selected pH, preferably physiological pH. Suitable polycationic moieties include basic amino acids and their derivatives such as arginine, asparagine, glutamine, lysine, and histidine; spermine; spermidine; cationic dendrimers; polyamines; polyamine sugars; and amino polysaccharides. The polycationic moieties can be linear, such as linear tetralysine, branched or dendrimeric in structure. Polycationic moieties have between about 2 to about 15 positive charges, preferably between about 2 to about 12 positive charges, and more preferably between about 2 to about 8 positive charges at selected pH values. The selection of which polycationic moiety to employ may be determined by the type of particle application which is desired.</div>
    </li> <li> <para-num num="[0283]"> </para-num> <div id="p-0323" num="0283" class="description-line">The charges on the polycationic moieties can be either distributed around the entire particle moiety, or alternatively, they can be a discrete concentration of charge density in one particular area of the particle moiety e.g., a charge spike. If the charge density is distributed on the particle, the charge density can be equally distributed or unequally distributed. All variations of charge distribution of the polycationic moiety are encompassed by the present invention.</div>
    </li> <li> <para-num num="[0284]"> </para-num> <div id="p-0324" num="0284" class="description-line">The lipid âAâ and the nonimmunogenic polymer âWâ can be attached by various methods and preferably by covalent attachment. Methods known to those of skill in the art can be used for the covalent attachment of âAâ and âW.â Suitable linkages include, but are not limited to, amide, amine, carboxyl, carbonate, carbamate, ester, and hydrazone linkages. It will be apparent to those skilled in the art that âAâ and âWâ must have complementary functional groups to effectuate the linkage. The reaction of these two groups, one on the lipid and the other on the polymer, will provide the desired linkage. For example, when the lipid is a diacylglycerol and the terminal hydroxyl is activated, for instance with NHS and DCC, to form an active ester, and is then reacted with a polymer which contains an amino group, such as with a polyamide (see, e.g., U.S. Pat. Nos. 6,320,017 and 6,586,559, the disclosures of which are herein incorporated by reference in their entirety for all purposes), an amide bond will form between the two groups.</div>
    </li> <li> <para-num num="[0285]"> </para-num> <div id="p-0325" num="0285" class="description-line">In certain instances, the polycationic moiety can have a ligand attached, such as a targeting ligand or a chelating moiety for complexing calcium. Preferably, after the ligand is attached, the cationic moiety maintains a positive charge. In certain instances, the ligand that is attached has a positive charge. Suitable ligands include, but are not limited to, a compound or device with a reactive functional group and include lipids, amphipathic lipids, carrier compounds, bioaffinity compounds, biomaterials, biopolymers, biomedical devices, analytically detectable compounds, therapeutically active compounds, enzymes, peptides, proteins, antibodies, immune stimulators, radiolabels, fluorogens, biotin, drugs, haptens, DNA, RNA, polysaccharides, liposomes, virosomes, micelles, immunoglobulins, functional groups, other targeting moieties, or toxins.</div>
    </li> <li> <para-num num="[0286]"> </para-num> <div id="p-0326" num="0286" class="description-line">In some embodiments, the lipid conjugate (e.g., PEG-lipid) comprises from about 0.1 mol % to about 2 mol %, from about 0.5 mol % to about 2 mol %, from about 1 mol % to about 2 mol %, from about 0.6 mol % to about 1.9 mol %, from about 0.7 mol % to about 1.8 mol %, from about 0.8 mol % to about 1.7 mol %, from about 0.9 mol % to about 1.6 mol %, from about 0.9 mol % to about 1.8 mol %, from about 1 mol % to about 1.8 mol %, from about 1 mol % to about 1.7 mol %, from about 1.2 mol % to about 1.8 mol %, from about 1.2 mol % to about 1.7 mol %, from about 1.3 mol % to about 1.6 mol %, or from about 1.4 mol % to about 1.5 mol % (or any fraction thereof or range therein) of the total lipid present in the particle.</div>
    </li> <li> <para-num num="[0287]"> </para-num> <div id="p-0327" num="0287" class="description-line">In other embodiments, the lipid conjugate (e.g., PEG-lipid) comprises from about 0 mol % to about 20 mol %, from about 0.5 mol % to about 20 mol %, from about 2 mol % to about 20 mol %, from about 1.5 mol % to about 18 mol %, from about 2 mol % to about 15 mol %, from about 4 mol % to about 15 mol %, from about 2 mol % to about 12 mol %, from about 5 mol % to about 12 mol %, or about 2 mol % (or any fraction thereof or range therein) of the total lipid present in the particle.</div>
    </li> <li> <para-num num="[0288]"> </para-num> <div id="p-0328" num="0288" class="description-line">In further embodiments, the lipid conjugate (e.g., PEG-lipid) comprises from about 4 mol % to about 10 mol %, from about 5 mol % to about 10 mol %, from about 5 mol % to about 9 mol %, from about 5 mol % to about 8 mol %, from about 6 mol % to about 9 mol %, from about 6 mol % to about 8 mol %, or about 5 mol %, 6 mol %, 7 mol %, 8 mol %, 9 mol %, or 10 mol % (or any fraction thereof or range therein) of the total lipid present in the particle.</div>
    </li> <li> <para-num num="[0289]"> </para-num> <div id="p-0329" num="0289" class="description-line">Additional percentages and ranges of lipid conjugates suitable for use in the lipid particles of the present invention are described in PCT Publication No. WO 09/127060, U.S. Published Application No. US 2011/0071208, PCT Publication No. WO2011/000106, and U.S. Published Application No. US 2011/0076335, the disclosures of which are herein incorporated by reference in their entirety for all purposes.</div>
    </li> <li> <para-num num="[0290]"> </para-num> <div id="p-0330" num="0290" class="description-line">It should be understood that the percentage of lipid conjugate (e.g., PEG-lipid) present in the lipid particles of the invention is a target amount, and that the actual amount of lipid conjugate present in the formulation may vary, for example, by Â±2 mol %. For example, in the 1:57 lipid particle (e.g., SNALP) formulation, the target amount of lipid conjugate is 1.4 mol %, but the actual amount of lipid conjugate may be Â±0.5 mol %, Â±0.4 mol %, Â±0.3 mol %, Â±0.2 mol %, Â±0.1 mol %, or Â±0.05 mol % of that target amount, with the balance of the formulation being made up of other lipid components (adding up to 100 mol % of total lipids present in the particle). Similarly, in the 7:54 lipid particle (e.g., SNALP) formulation, the target amount of lipid conjugate is 6.76 mol %, but the actual amount of lipid conjugate may be Â±2 mol %, Â±1.5 mol %, Â±1 mol %, Â±0.75 mol %, Â±0.5 mol %, Â±0.25 mol %, or Â±0.1 mol % of that target amount, with the balance of the formulation being made up of other lipid components (adding up to 100 mol % of total lipids present in the particle).</div>
    </li> <li> <para-num num="[0291]"> </para-num> <div id="p-0331" num="0291" class="description-line">One of ordinary skill in the art will appreciate that the concentration of the lipid conjugate can be varied depending on the lipid conjugate employed and the rate at which the lipid particle is to become fusogenic.</div>
    </li> <li> <para-num num="[0292]"> </para-num> <div id="p-0332" num="0292" class="description-line">By controlling the composition and concentration of the lipid conjugate, one can control the rate at which the lipid conjugate exchanges out of the lipid particle and, in turn, the rate at which the lipid particle becomes fusogenic. For instance, when a PEG-DAA conjugate is used as the lipid conjugate, the rate at which the lipid particle becomes fusogenic can be varied, for example, by varying the concentration of the lipid conjugate, by varying the molecular weight of the PEG, or by varying the chain length and degree of saturation of the alkyl groups on the PEG-DAA conjugate. In addition, other variables including, for example, pH, temperature, ionic strength, etc. can be used to vary and/or control the rate at which the lipid particle becomes fusogenic. Other methods which can be used to control the rate at which the lipid particle becomes fusogenic will become apparent to those of skill in the art upon reading this disclosure. Also, by controlling the composition and concentration of the lipid conjugate, one can control the lipid particle (e.g., SNALP) size.</div>
    </li> <heading id="h-0023">Preparation of Lipid Particles</heading>
    <li> <para-num num="[0293]"> </para-num> <div id="p-0333" num="0293" class="description-line">The lipid particles of the present invention, e.g., SNALP, in which an mRNA is entrapped within the lipid portion of the particle and is protected from degradation, can be formed by any method known in the art including, but not limited to, a continuous mixing method, a direct dilution process, and an in-line dilution process.</div>
    </li> <li> <para-num num="[0294]"> </para-num> <div id="p-0334" num="0294" class="description-line">In certain embodiments, the present invention provides nucleic acid-lipid particles (e.g., SNALP) produced via a continuous mixing method, e.g., a process that includes providing an aqueous solution comprising a nucleic acid (e.g., mRNA) in a first reservoir, providing an organic lipid solution in a second reservoir (wherein the lipids present in the organic lipid solution are solubilized in an organic solvent, e.g., a lower alkanol such as ethanol), and mixing the aqueous solution with the organic lipid solution such that the organic lipid solution mixes with the aqueous solution so as to substantially instantaneously produce a lipid vesicle (e.g., liposome) encapsulating the nucleic acid within the lipid vesicle. This process and the apparatus for carrying out this process are described in detail in U.S. Patent Publication No. 20040142025, the disclosure of which is herein incorporated by reference in its entirety for all purposes.</div>
    </li> <li> <para-num num="[0295]"> </para-num> <div id="p-0335" num="0295" class="description-line">The action of continuously introducing lipid and buffer solutions into a mixing environment, such as in a mixing chamber, causes a continuous dilution of the lipid solution with the buffer solution, thereby producing a lipid vesicle substantially instantaneously upon mixing. As used herein, the phrase âcontinuously diluting a lipid solution with a buffer solutionâ (and variations) generally means that the lipid solution is diluted sufficiently rapidly in a hydration process with sufficient force to effectuate vesicle generation. By mixing the aqueous solution comprising a nucleic acid with the organic lipid solution, the organic lipid solution undergoes a continuous stepwise dilution in the presence of the buffer solution (i.e., aqueous solution) to produce a nucleic acid-lipid particle.</div>
    </li> <li> <para-num num="[0296]"> </para-num> <div id="p-0336" num="0296" class="description-line">The nucleic acid-lipid particles formed using the continuous mixing method typically have a size of from about 30 nm to about 150 nm, from about 40 nm to about 150 nm, from about 50 nm to about 150 nm, from about 60 nm to about 130 nm, from about 70 nm to about 110 nm, from about 70 nm to about 100 nm, from about 80 nm to about 100 nm, from about 90 nm to about 100 nm, from about 70 to about 90 nm, from about 80 nm to about 90 nm, from about 70 nm to about 80 nm, less than about 120 nm, 110 nm, 100 nm, 90 nm, or 80 nm, or about 30 nm, 35 nm, 40 nm, 45 nm, 50 nm, 55 nm, 60 nm, 65 nm, 70 nm, 75 nm, 80 nm, 85 nm, 90 nm, 95 nm, 100 nm, 105 nm, 110 nm, 115 nm, 120 nm, 125 nm, 130 nm, 135 nm, 140 nm, 145 nm, or 150 nm (or any fraction thereof or range therein). The particles thus formed do not aggregate and are optionally sized to achieve a uniform particle size.</div>
    </li> <li> <para-num num="[0297]"> </para-num> <div id="p-0337" num="0297" class="description-line">In another embodiment, the present invention provides nucleic acid-lipid particles (e.g., SNALP) produced via a direct dilution process that includes forming a lipid vesicle (e.g., liposome) solution and immediately and directly introducing the lipid vesicle solution into a collection vessel containing a controlled amount of dilution buffer. In preferred aspects, the collection vessel includes one or more elements configured to stir the contents of the collection vessel to facilitate dilution. In one aspect, the amount of dilution buffer present in the collection vessel is substantially equal to the volume of lipid vesicle solution introduced thereto. As a non-limiting example, a lipid vesicle solution in 45% ethanol when introduced into the collection vessel containing an equal volume of dilution buffer will advantageously yield smaller particles.</div>
    </li> <li> <para-num num="[0298]"> </para-num> <div id="p-0338" num="0298" class="description-line">In yet another embodiment, the present invention provides nucleic acid-lipid particles (e.g., SNALP) produced via an in-line dilution process in which a third reservoir containing dilution buffer is fluidly coupled to a second mixing region. In this embodiment, the lipid vesicle (e.g., liposome) solution formed in a first mixing region is immediately and directly mixed with dilution buffer in the second mixing region. In preferred aspects, the second mixing region includes a T-connector arranged so that the lipid vesicle solution and the dilution buffer flows meet as opposing 180Â° flows; however, connectors providing shallower angles can be used, e.g., from about 27Â° to about 180Â° (e.g., about 90Â°). A pump mechanism delivers a controllable flow of buffer to the second mixing region. In one aspect, the flow rate of dilution buffer provided to the second mixing region is controlled to be substantially equal to the flow rate of lipid vesicle solution introduced thereto from the first mixing region. This embodiment advantageously allows for more control of the flow of dilution buffer mixing with the lipid vesicle solution in the second mixing region, and therefore also the concentration of lipid vesicle solution in buffer throughout the second mixing process. Such control of the dilution buffer flow rate advantageously allows for small particle size formation at reduced concentrations.</div>
    </li> <li> <para-num num="[0299]"> </para-num> <div id="p-0339" num="0299" class="description-line">These processes and the apparatuses for carrying out these direct dilution and in-line dilution processes are described in detail in U.S. Patent Publication No. 20070042031, the disclosure of which is herein incorporated by reference in its entirety for all purposes.</div>
    </li> <li> <para-num num="[0300]"> </para-num> <div id="p-0340" num="0300" class="description-line">The nucleic acid-lipid particles formed using the direct dilution and in-line dilution processes typically have a size of from about 30 nm to about 150 nm, from about 40 nm to about 150 nm, from about 50 nm to about 150 nm, from about 60 nm to about 130 nm, from about 70 nm to about 110 nm, from about 70 nm to about 100 nm, from about 80 nm to about 100 nm, from about 90 nm to about 100 nm, from about 70 to about 90 nm, from about 80 nm to about 90 nm, from about 70 nm to about 80 nm, less than about 120 nm, 110 nm, 100 nm, 90 nm, or 80 nm, or about 30 nm, 35 nm, 40 nm, 45 nm, 50 nm, 55 nm, 60 nm, 65 nm, 70 nm, 75 nm, 80 nm, 85 nm, 90 nm, 95 nm, 100 nm, 105 nm, 110 nm, 115 nm, 120 nm, 125 nm, 130 nm, 135 nm, 140 nm, 145 nm, or 150 nm (or any fraction thereof or range therein). The particles thus formed do not aggregate and are optionally sized to achieve a uniform particle size.</div>
    </li> <li> <para-num num="[0301]"> </para-num> <div id="p-0341" num="0301" class="description-line">If needed, the lipid particles of the invention (e.g., SNALP) can be sized by any of the methods available for sizing liposomes. The sizing may be conducted in order to achieve a desired size range and relatively narrow distribution of particle sizes.</div>
    </li> <li> <para-num num="[0302]"> </para-num> <div id="p-0342" num="0302" class="description-line">Several techniques are available for sizing the particles to a desired size. One sizing method, used for liposomes and equally applicable to the present particles, is described in U.S. Pat. No. 4,737,323, the disclosure of which is herein incorporated by reference in its entirety for all purposes. Sonicating a particle suspension either by bath or probe sonication produces a progressive size reduction down to particles of less than about 50 nm in size. Homogenization is another method which relies on shearing energy to fragment larger particles into smaller ones. In a typical homogenization procedure, particles are recirculated through a standard emulsion homogenizer until selected particle sizes, typically between about 60 and about 80 nm, are observed. In both methods, the particle size distribution can be monitored by conventional laser-beam particle size discrimination, or QELS.</div>
    </li> <li> <para-num num="[0303]"> </para-num> <div id="p-0343" num="0303" class="description-line">Extrusion of the particles through a small-pore polycarbonate membrane or an asymmetric ceramic membrane is also an effective method for reducing particle sizes to a relatively well-defined size distribution. Typically, the suspension is cycled through the membrane one or more times until the desired particle size distribution is achieved. The particles may be extruded through successively smaller-pore membranes, to achieve a gradual reduction in size.</div>
    </li> <li> <para-num num="[0304]"> </para-num> <div id="p-0344" num="0304" class="description-line">In other embodiments, the methods may further comprise adding non-lipid polycations which are useful to effect the lipofection of cells using the present compositions. Examples of suitable non-lipid polycations include, hexadimethrine bromide (sold under the brand name POLYBRENEÂ®, from Aldrich Chemical Co., Milwaukee, Wis., USA) or other salts of hexadimethrine. Other suitable polycations include, for example, salts of poly-L-ornithine, poly-L-arginine, poly-L-lysine, poly-D-lysine, polyallylamine, and polyethyleneimine. Addition of these salts is preferably after the particles have been formed.</div>
    </li> <li> <para-num num="[0305]"> </para-num> <div id="p-0345" num="0305" class="description-line">In some embodiments, the nucleic acid to lipid ratios (mass/mass ratios) in a formed nucleic acid-lipid particle (e.g., SNALP) will range from about 0.01 to about 0.2, from about 0.05 to about 0.2, from about 0.02 to about 0.1, from about 0.03 to about 0.1, or from about 0.01 to about 0.08. The ratio of the starting materials (input) also falls within this range. In other embodiments, the particle preparation uses about 400 Î¼g nucleic acid per 10 mg total lipid or a nucleic acid to lipid mass ratio of about 0.01 to about 0.08 and, more preferably, about 0.04, which corresponds to 1.25 mg of total lipid per 50 Î¼g of nucleic acid. In other preferred embodiments, the particle has a nucleic acid:lipid mass ratio of about 0.08.</div>
    </li> <li> <para-num num="[0306]"> </para-num> <div id="p-0346" num="0306" class="description-line">In other embodiments, the lipid to nucleic acid ratios (mass/mass ratios) in a formed nucleic acid-lipid particle (e.g., SNALP) will range from about 1 (1:1) to about 100 (100:1), from about 5 (5:1) to about 100 (100:1), from about 1 (1:1) to about 50 (50:1), from about 2 (2:1) to about 50 (50:1), from about 3 (3:1) to about 50 (50:1), from about 4 (4:1) to about 50 (50:1), from about 5 (5:1) to about 50 (50:1), from about 1 (1:1) to about 25 (25:1), from about 2 (2:1) to about 25 (25:1), from about 3 (3:1) to about 25 (25:1), from about 4 (4:1) to about 25 (25:1), from about 5 (5:1) to about 25 (25:1), from about 5 (5:1) to about 20 (20:1), from about 5 (5:1) to about 15 (15:1), from about 5 (5:1) to about 10 (10:1), or about 5 (5:1), 6 (6:1), 7 (7:1), 8 (8:1), 9 (9:1), 10 (10:1), 11 (11:1), 12 (12:1), 13 (13:1), 14 (14:1), 15 (15:1), 16 (16:1), 17 (17:1), 18 (18:1), 19 (19:1), 20 (20:1), 21 (21:1), 22 (22:1), 23 (23:1), 24 (24:1), or 25 (25:1), or any fraction thereof or range therein. The ratio of the starting materials (input) also falls within this range.</div>
    </li> <li> <para-num num="[0307]"> </para-num> <div id="p-0347" num="0307" class="description-line">As previously discussed, the conjugated lipid may further include a CPL. A variety of general methods for making SNALP-CPLs (CPL-containing SNALP) are discussed herein. Two general techniques include the âpost-insertionâ technique, that is, insertion of a CPL into, for example, a pre-formed SNALP, and the âstandardâ technique, wherein the CPL is included in the lipid mixture during, for example, the SNALP formation steps. The post-insertion technique results in SNALP having CPLs mainly in the external face of the SNALP bilayer membrane, whereas standard techniques provide SNALP having CPLs on both internal and external faces. The method is especially useful for vesicles made from phospholipids (which can contain cholesterol) and also for vesicles containing PEG-lipids (such as PEG-DAAs and PEG-DAGs). Methods of making SNALP-CPLs are taught, for example, in U.S. Pat. Nos. 5,705,385; 6,586,410; 5,981,501; 6,534,484; and 6,852,334; U.S. Patent Publication No. 20020072121; and PCT Publication No. WO 00/62813, the disclosures of which are herein incorporated by reference in their entirety for all purposes.</div>
    </li> <heading id="h-0024">Administration of Lipid Particles</heading>
    <li> <para-num num="[0308]"> </para-num> <div id="p-0348" num="0308" class="description-line">Once formed, the lipid particles of the invention (e.g., SNALP) are particularly useful for the introduction of nucleic acids (e.g., mRNA) into cells. Accordingly, the present invention also provides methods for introducing a nucleic acid (e.g., mRNA) into a cell. In particular embodiments, the nucleic acid (e.g., mRNA) is introduced into an infected cell such as reticuloendothelial cells (e.g., macrophages, monocytes, etc.) as well as other cell types, including fibroblasts, endothelial cells (such as those lining the interior surface of blood vessels), and/or platelet cells. The methods may be carried out in vitro or in vivo by first forming the particles as described herein and then contacting the particles with the cells for a period of time sufficient for delivery of the mRNA to the cells to occur.</div>
    </li> <li> <para-num num="[0309]"> </para-num> <div id="p-0349" num="0309" class="description-line">The lipid particles of the invention (e.g., SNALP) can be adsorbed to almost any cell type with which they are mixed or contacted. Once adsorbed, the particles can either be endocytosed by a portion of the cells, exchange lipids with cell membranes, or fuse with the cells. Transfer or incorporation of the nucleic acid (e.g., mRNA) portion of the particle can take place via any one of these pathways. In particular, when fusion takes place, the particle membrane is integrated into the cell membrane and the contents of the particle combine with the intracellular fluid.</div>
    </li> <li> <para-num num="[0310]"> </para-num> <div id="p-0350" num="0310" class="description-line">The lipid particles of the invention (e.g., SNALP) can be administered either alone or in a mixture with a pharmaceutically acceptable carrier (e.g., physiological saline or phosphate buffer) selected in accordance with the route of administration and standard pharmaceutical practice. Generally, normal buffered saline (e.g., 135-150 mM NaCl) will be employed as the pharmaceutically acceptable carrier. Other suitable carriers include, e.g., water, buffered water, 0.4% saline, 0.3% glycine, and the like, including glycoproteins for enhanced stability, such as albumin, lipoprotein, globulin, etc. Additional suitable carriers are described in, e.g., REMINGTON&#39;S PHARMACEUTICAL SCIENCES, Mack Publishing Company, Philadelphia, Pa., 17th ed. (1985). As used herein, âcarrierâ includes any and all solvents, dispersion media, vehicles, coatings, diluents, antibacterial and antifungal agents, isotonic and absorption delaying agents, buffers, carrier solutions, suspensions, colloids, and the like. The phrase âpharmaceutically acceptableâ refers to molecular entities and compositions that do not produce an allergic or similar untoward reaction when administered to a human.</div>
    </li> <li> <para-num num="[0311]"> </para-num> <div id="p-0351" num="0311" class="description-line">The pharmaceutically acceptable carrier is generally added following lipid particle formation. Thus, after the lipid particle (e.g., SNALP) is formed, the particle can be diluted into pharmaceutically acceptable carriers such as normal buffered saline.</div>
    </li> <li> <para-num num="[0312]"> </para-num> <div id="p-0352" num="0312" class="description-line">The concentration of particles in the pharmaceutical formulations can vary widely, i.e., from less than about 0.05%, usually at or at least about 2 to 5%, to as much as about 10 to 90% by weight, and will be selected primarily by fluid volumes, viscosities, etc., in accordance with the particular mode of administration selected. For example, the concentration may be increased to lower the fluid load associated with treatment. This may be particularly desirable in patients having atherosclerosis-associated congestive heart failure or severe hypertension. Alternatively, particles composed of irritating lipids may be diluted to low concentrations to lessen inflammation at the site of administration.</div>
    </li> <li> <para-num num="[0313]"> </para-num> <div id="p-0353" num="0313" class="description-line">The pharmaceutical compositions of the present invention may be sterilized by conventional, well-known sterilization techniques. Aqueous solutions can be packaged for use or filtered under aseptic conditions and lyophilized, the lyophilized preparation being combined with a sterile aqueous solution prior to administration. The compositions can contain pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions, such as pH adjusting and buffering agents, tonicity adjusting agents and the like, for example, sodium acetate, sodium lactate, sodium chloride, potassium chloride, and calcium chloride. Additionally, the particle suspension may include lipid-protective agents which protect lipids against free-radical and lipid-peroxidative damages on storage. Lipophilic free-radical quenchers, such as alphatocopherol, and water-soluble iron-specific chelators, such as ferrioxamine, are suitable.</div>
    </li> <li> <para-num num="[0314]"> </para-num> <div id="p-0354" num="0314" class="description-line">In some embodiments, the lipid particles of the invention (e.g., SNALP) are particularly useful in methods for the therapeutic delivery of one or more mRNA.</div>
    </li> <heading id="h-0025">In Vivo Administration</heading>
    <li> <para-num num="[0315]"> </para-num> <div id="p-0355" num="0315" class="description-line">Systemic delivery for in vivo therapy, e.g., delivery of a therapeutic nucleic acid to a distal target cell via body systems such as the circulation, has been achieved using nucleic acid-lipid particles such as those described in PCT Publication Nos. WO 05/007196, WO 05/121348, WO 05/120152, and WO 04/002453, the disclosures of which are herein incorporated by reference in their entirety for all purposes. The present invention also provides fully encapsulated lipid particles that protect the nucleic acid from nuclease degradation in serum, are non-immunogenic, are small in size, and are suitable for repeat dosing.</div>
    </li> <li> <para-num num="[0316]"> </para-num> <div id="p-0356" num="0316" class="description-line">For in vivo administration, administration can be in any manner known in the art, e.g., by injection, oral administration, inhalation (e.g., intransal or intratracheal), transdermal application, or rectal administration. Administration can be accomplished via single or divided doses. The pharmaceutical compositions can be administered parenterally, i.e., intraarticularly, intravenously, intraperitoneally, subcutaneously, or intramuscularly. In some embodiments, the pharmaceutical compositions are administered intravenously or intraperitoneally by a bolus injection (see, e.g., U.S. Pat. No. 5,286,634). Intracellular nucleic acid delivery has also been discussed in Straubringer et al., <i>Methods Enzymol., </i>101:512 (1983); Mannino et al., <i>Biotechniques, </i>6:682 (1988); Nicolau et al., <i>Crit. Rev. Ther. Drug Carrier Syst., </i>6:239 (1989); and Behr, <i>Acc. Chem. Res., </i>26:274 (1993). Still other methods of administering lipid-based therapeutics are described in, for example, U.S. Pat. Nos. 3,993,754; 4,145,410; 4,235,871; 4,224,179; 4,522,803; and 4,588,578. The lipid particles can be administered by direct injection at the site of disease or by injection at a site distal from the site of disease (see, e.g., Culver, HUMAN GENE THERAPY, MaryAnn Liebert, Inc., Publishers, New York. pp. 70-71 (1994)). The disclosures of the above-described references are herein incorporated by reference in their entirety for all purposes.</div>
    </li> <li> <para-num num="[0317]"> </para-num> <div id="p-0357" num="0317" class="description-line">In embodiments where the lipid particles of the present invention (e.g., SNALP) are administered intravenously, at least about 5%, 10%, 15%, 20%, or 25% of the total injected dose of the particles is present in plasma about 8, 12, 24, 36, or 48 hours after injection. In other embodiments, more than about 20%, 30%, 40% and as much as about 60%, 70% or 80% of the total injected dose of the lipid particles is present in plasma about 8, 12, 24, 36, or 48 hours after injection. In certain instances, more than about 10% of a plurality of the particles is present in the plasma of a mammal about 1 hour after administration. In certain other instances, the presence of the lipid particles is detectable at least about 1 hour after administration of the particle. In some embodiments, the presence of a therapeutic nucleic acid such as an mRNA molecule is detectable in cells at about 8, 12, 24, 36, 48, 60, 72 or 96 hours after administration. In other embodiments, expression of a polypeptide encoded by an mRNA introduced into a living body in accordance with the present invention is detectable at about 8, 12, 24, 36, 48, 60, 72 or 96 hours after administration. In further embodiments, the presence or effect of an mRNA in cells at a site proximal or distal to the site of administration is detectable at about 12, 24, 48, 72, or 96 hours, or at about 6, 8, 10, 12, 14, 16, 18, 19, 20, 22, 24, 26, or 28 days after administration. In additional embodiments, the lipid particles (e.g., SNALP) of the invention are administered parenterally or intraperitoneally.</div>
    </li> <li> <para-num num="[0318]"> </para-num> <div id="p-0358" num="0318" class="description-line">The compositions of the present invention, either alone or in combination with other suitable components, can be made into aerosol formulations (i.e., they can be ânebulizedâ) to be administered via inhalation (e.g., intranasally or intratracheally) (see, Brigham et al., <i>Am. J. Sci., </i>298:278 (1989)). Aerosol formulations can be placed into pressurized acceptable propellants, such as dichlorodifluoromethane, propane, nitrogen, and the like.</div>
    </li> <li> <para-num num="[0319]"> </para-num> <div id="p-0359" num="0319" class="description-line">In certain embodiments, the pharmaceutical compositions may be delivered by intranasal sprays, inhalation, and/or other aerosol delivery vehicles. Methods for delivering nucleic acid compositions directly to the lungs via nasal aerosol sprays have been described, e.g., in U.S. Pat. Nos. 5,756,353 and 5,804,212. Likewise, the delivery of drugs using intranasal microparticle resins and lysophosphatidyl-glycerol compounds (U.S. Pat. No. 5,725,871) are also known in the pharmaceutical arts. Similarly, transmucosal drug delivery in the form of a polytetrafluoroetheylene support matrix is described in U.S. Pat. No. 5,780,045. The disclosures of the above-described patents are herein incorporated by reference in their entirety for all purposes.</div>
    </li> <li> <para-num num="[0320]"> </para-num> <div id="p-0360" num="0320" class="description-line">Formulations suitable for parenteral administration, such as, for example, by intraarticular (in the joints), intravenous, intramuscular, intradermal, intraperitoneal, and subcutaneous routes, include aqueous and non-aqueous, isotonic sterile injection solutions, which can contain antioxidants, buffers, bacteriostats, and solutes that render the formulation isotonic with the blood of the intended recipient, and aqueous and non-aqueous sterile suspensions that can include suspending agents, solubilizers, thickening agents, stabilizers, and preservatives. In the practice of this invention, compositions are preferably administered, for example, by intravenous infusion, orally, topically, intraperitoneally, intravesically, or intrathecally.</div>
    </li> <li> <para-num num="[0321]"> </para-num> <div id="p-0361" num="0321" class="description-line">Generally, when administered intravenously, the lipid particle formulations are formulated with a suitable pharmaceutical carrier. Many pharmaceutically acceptable carriers may be employed in the compositions and methods of the present invention. Suitable formulations for use in the present invention are found, for example, in REMINGTON&#39;S PHARMACEUTICAL SCIENCES, Mack Publishing Company, Philadelphia, Pa., 17th ed. (1985). A variety of aqueous carriers may be used, for example, water, buffered water, 0.4% saline, 0.3% glycine, and the like, and may include glycoproteins for enhanced stability, such as albumin, lipoprotein, globulin, etc. Generally, normal buffered saline (135-150 mM NaCl) will be employed as the pharmaceutically acceptable carrier, but other suitable carriers will suffice. These compositions can be sterilized by conventional liposomal sterilization techniques, such as filtration. The compositions may contain pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions, such as pH adjusting and buffering agents, tonicity adjusting agents, wetting agents and the like, for example, sodium acetate, sodium lactate, sodium chloride, potassium chloride, calcium chloride, sorbitan monolaurate, triethanolamine oleate, etc. These compositions can be sterilized using the techniques referred to above or, alternatively, they can be produced under sterile conditions. The resulting aqueous solutions may be packaged for use or filtered under aseptic conditions and lyophilized, the lyophilized preparation being combined with a sterile aqueous solution prior to administration.</div>
    </li> <li> <para-num num="[0322]"> </para-num> <div id="p-0362" num="0322" class="description-line">In certain applications, the lipid particles disclosed herein may be delivered via oral administration to the individual. The particles may be incorporated with excipients and used in the form of ingestible tablets, buccal tablets, troches, capsules, pills, lozenges, elixirs, mouthwash, suspensions, oral sprays, syrups, wafers, and the like (see, e.g., U.S. Pat. Nos. 5,641,515, 5,580,579, and 5,792,451, the disclosures of which are herein incorporated by reference in their entirety for all purposes). These oral dosage forms may also contain the following: binders, gelatin; excipients, lubricants, and/or flavoring agents. When the unit dosage form is a capsule, it may contain, in addition to the materials described above, a liquid carrier. Various other materials may be present as coatings or to otherwise modify the physical form of the dosage unit. Of course, any material used in preparing any unit dosage form should be pharmaceutically pure and substantially non-toxic in the amounts employed.</div>
    </li> <li> <para-num num="[0323]"> </para-num> <div id="p-0363" num="0323" class="description-line">Typically, these oral formulations may contain at least about 0.1% of the lipid particles or more, although the percentage of the particles may, of course, be varied and may conveniently be between about 1% or 2% and about 60% or 70% or more of the weight or volume of the total formulation. Naturally, the amount of particles in each therapeutically useful composition may be prepared is such a way that a suitable dosage will be obtained in any given unit dose of the compound. Factors such as solubility, bioavailability, biological half-life, route of administration, product shelf life, as well as other pharmacological considerations will be contemplated by one skilled in the art of preparing such pharmaceutical formulations, and as such, a variety of dosages and treatment regimens may be desirable.</div>
    </li> <li> <para-num num="[0324]"> </para-num> <div id="p-0364" num="0324" class="description-line">Formulations suitable for oral administration can consist of: (a) liquid solutions, such as an effective amount of a packaged therapeutic nucleic acid (e.g., mRNA) suspended in diluents such as water, saline, or PEG 400; (b) capsules, sachets, or tablets, each containing a predetermined amount of a therapeutic nucleic acid (e.g., mRNA), as liquids, solids, granules, or gelatin; (c) suspensions in an appropriate liquid; and (d) suitable emulsions. Tablet forms can include one or more of lactose, sucrose, mannitol, sorbitol, calcium phosphates, corn starch, potato starch, microcrystalline cellulose, gelatin, colloidal silicon dioxide, talc, magnesium stearate, stearic acid, and other excipients, colorants, fillers, binders, diluents, buffering agents, moistening agents, preservatives, flavoring agents, dyes, disintegrating agents, and pharmaceutically compatible carriers. Lozenge forms can comprise a therapeutic nucleic acid (e.g., mRNA) in a flavor, e.g., sucrose, as well as pastilles comprising the therapeutic nucleic acid in an inert base, such as gelatin and glycerin or sucrose and acacia emulsions, gels, and the like containing, in addition to the therapeutic nucleic acid, carriers known in the art.</div>
    </li> <li> <para-num num="[0325]"> </para-num> <div id="p-0365" num="0325" class="description-line">In another example of their use, lipid particles can be incorporated into a broad range of topical dosage forms. For instance, a suspension containing nucleic acid-lipid particles such as SNALP can be formulated and administered as gels, oils, emulsions, topical creams, pastes, ointments, lotions, foams, mousses, and the like.</div>
    </li> <li> <para-num num="[0326]"> </para-num> <div id="p-0366" num="0326" class="description-line">When preparing pharmaceutical preparations of the lipid particles of the invention, it is preferable to use quantities of the particles which have been purified to reduce or eliminate empty particles or particles with therapeutic agents such as nucleic acid associated with the external surface.</div>
    </li> <li> <para-num num="[0327]"> </para-num> <div id="p-0367" num="0327" class="description-line">The methods of the present invention may be practiced in a variety of hosts. Preferred hosts include mammalian species, such as primates (e.g., humans and chimpanzees as well as other nonhuman primates), canines, felines, equines, bovines, ovines, caprines, rodents (e.g., rats and mice), lagomorphs, and swine.</div>
    </li> <li> <para-num num="[0328]"> </para-num> <div id="p-0368" num="0328" class="description-line">The amount of particles administered will depend upon the ratio of therapeutic nucleic acid (e.g., mRNA) to lipid, the particular therapeutic nucleic acid used, the disease or disorder being treated, the age, weight, and condition of the patient, and the judgment of the clinician, but will generally be between about 0.01 and about 50 mg per kilogram of body weight, preferably between about 0.1 and about 5 mg/kg of body weight, or about 10<sup>8</sup>-10<sup>10 </sup>particles per administration (e.g., injection).</div>
    </li> <heading id="h-0026">In Vitro Administration</heading>
    <li> <para-num num="[0329]"> </para-num> <div id="p-0369" num="0329" class="description-line">For in vitro applications, the delivery of therapeutic nucleic acids (e.g., mRNA) can be to any cell grown in culture, whether of plant or animal origin, vertebrate or invertebrate, and of any tissue or type. In preferred embodiments, the cells are animal cells, more preferably mammalian cells, and most preferably human cells.</div>
    </li> <li> <para-num num="[0330]"> </para-num> <div id="p-0370" num="0330" class="description-line">Contact between the cells and the lipid particles, when carried out in vitro, takes place in a biologically compatible medium. The concentration of particles varies widely depending on the particular application, but is generally between about 1 Î¼mol and about 10 mmol. Treatment of the cells with the lipid particles is generally carried out at physiological temperatures (about 37Â° C.) for periods of time of from about 1 to 48 hours, preferably of from about 2 to 4 hours.</div>
    </li> <li> <para-num num="[0331]"> </para-num> <div id="p-0371" num="0331" class="description-line">In one group of preferred embodiments, a lipid particle suspension is added to 60-80% confluent plated cells having a cell density of from about 10<sup>3 </sup>to about 10<sup>5 </sup>cells/ml, more preferably about 2Ã10<sup>4 </sup>cells/ml. The concentration of the suspension added to the cells is preferably of from about 0.01 to 0.2 Î¼g/ml, more preferably about 0.1 Î¼g/ml.</div>
    </li> <li> <para-num num="[0332]"> </para-num> <div id="p-0372" num="0332" class="description-line">To the extent that tissue culture of cells may be required, it is well-known in the art. For example, Freshney, Culture of Animal Cells, a Manual of Basic Technique, 3rd Ed., Wiley-Liss, New York (1994), Kuchler et al., Biochemical Methods in Cell Culture and Virology, Dowden, Hutchinson and Ross, Inc. (1977), and the references cited therein provide a general guide to the culture of cells. Cultured cell systems often will be in the form of monolayers of cells, although cell suspensions are also used.</div>
    </li> <li> <para-num num="[0333]"> </para-num> <div id="p-0373" num="0333" class="description-line">Using an Endosomal Release Parameter (ERP) assay, the delivery efficiency of the SNALP or other lipid particle of the invention can be optimized. An ERP assay is described in detail in U.S. Patent Publication No. 20030077829, the disclosure of which is herein incorporated by reference in its entirety for all purposes. More particularly, the purpose of an ERP assay is to distinguish the effect of various cationic lipids and helper lipid components of SNALP or other lipid particle based on their relative effect on binding/uptake or fusion with/destabilization of the endosomal membrane. This assay allows one to determine quantitatively how each component of the SNALP or other lipid particle affects delivery efficiency, thereby optimizing the SNALP or other lipid particle. Usually, an ERP assay measures expression of a reporter protein (e.g., luciferase, Î²-galactosidase, green fluorescent protein (GFP), etc.), and in some instances, a SNALP formulation optimized for an expression plasmid will also be appropriate for encapsulating an mRNA. By comparing the ERPs for each of the various SNALP or other lipid particles, one can readily determine the optimized system, e.g., the SNALP or other lipid particle that has the greatest uptake in the cell.</div>
    </li> <heading id="h-0027">Cells for Delivery of Lipid Particles</heading>
    <li> <para-num num="[0334]"> </para-num> <div id="p-0374" num="0334" class="description-line">The present invention can be practiced on a wide variety of cell types from any vertebrate species, including mammals, such as, e.g, canines, felines, equines, bovines, ovines, caprines, rodents (e.g., mice, rats, and guinea pigs), lagomorphs, swine, and primates (e.g. monkeys, chimpanzees, and humans).</div>
    </li> <heading id="h-0028">Detection of Lipid Particles</heading>
    <li> <para-num num="[0335]"> </para-num> <div id="p-0375" num="0335" class="description-line">In some embodiments, the lipid particles of the present invention (e.g., SNALP) are detectable in the subject at about 1, 2, 3, 4, 5, 6, 7, 8 or more hours. In other embodiments, the lipid particles of the present invention (e.g., SNALP) are detectable in the subject at about 8, 12, 24, 48, 60, 72, or 96 hours, or about 6, 8, 10, 12, 14, 16, 18, 19, 22, 24, 25, or 28 days after administration of the particles. The presence of the particles can be detected in the cells, tissues, or other biological samples from the subject. The particles may be detected, e.g., by direct detection of the particles, and/or detection of an mRNA sequence encapsulated within the lipid particles, and/or detection of a polypeptide expressed from an mRNA.</div>
    </li> <heading id="h-0029">Detection of Particles</heading>
    <li> <para-num num="[0336]"> </para-num> <div id="p-0376" num="0336" class="description-line">Lipid particles of the invention such as SNALP can be detected using any method known in the art. For example, a label can be coupled directly or indirectly to a component of the lipid particle using methods well-known in the art. A wide variety of labels can be used, with the choice of label depending on sensitivity required, ease of conjugation with the lipid particle component, stability requirements, and available instrumentation and disposal provisions. Suitable labels include, but are not limited to, spectral labels such as fluorescent dyes (e.g., fluorescein and derivatives, such as fluorescein isothiocyanate (FITC) and Oregon Greenâ¢; rhodamine and derivatives such Texas red, tetrarhodimine isothiocynate (TRITC), etc., digoxigenin, biotin, phycoerythrin, AMCA, CyDyesâ¢, and the like; radiolabels such as <sup>3</sup>H, <sup>125</sup>I, <sup>35</sup>S, <sup>14</sup>C, <sup>32</sup>P, <sup>33</sup>P, etc.; enzymes such as horse radish peroxidase, alkaline phosphatase, etc.; spectral colorimetric labels such as colloidal gold or colored glass or plastic beads such as polystyrene, polypropylene, latex, etc. The label can be detected using any means known in the art.</div>
    </li> <heading id="h-0030">Detection of Nucleic Acids</heading>
    <li> <para-num num="[0337]"> </para-num> <div id="p-0377" num="0337" class="description-line">Nucleic acids (e.g., mRNA) are detected and quantified herein by any of a number of means well-known to those of skill in the art. The detection of nucleic acids may proceed by well-known methods such as Southern analysis, Northern analysis, gel electrophoresis, PCR, radiolabeling, scintillation counting, and affinity chromatography. Additional analytic biochemical methods such as spectrophotometry, radiography, electrophoresis, capillary electrophoresis, high performance liquid chromatography (HPLC), thin layer chromatography (TLC), and hyperdiffusion chromatography may also be employed.</div>
    </li> <li> <para-num num="[0338]"> </para-num> <div id="p-0378" num="0338" class="description-line">The selection of a nucleic acid hybridization format is not critical. A variety of nucleic acid hybridization formats are known to those skilled in the art. For example, common formats include sandwich assays and competition or displacement assays. Hybridization techniques are generally described in, e.g., âNucleic Acid Hybridization, A Practical Approach,â Eds. Hames and Higgins, IRL Press (1985).</div>
    </li> <li> <para-num num="[0339]"> </para-num> <div id="p-0379" num="0339" class="description-line">The sensitivity of the hybridization assays may be enhanced through the use of a nucleic acid amplification system which multiplies the target nucleic acid being detected. In vitro amplification techniques suitable for amplifying sequences for use as molecular probes or for generating nucleic acid fragments for subsequent subcloning are known. Examples of techniques sufficient to direct persons of skill through such in vitro amplification methods, including the polymerase chain reaction (PCR), the ligase chain reaction (LCR), QÎ²-replicase amplification, and other RNA polymerase mediated techniques (e.g., NASBAâ¢) are found in Sambrook et al., In <i>Molecular Cloning: A Laboratory Manual, </i>Cold Spring Harbor Laboratory Press (2000); and Ausubel et al., S<smallcaps>HORT </smallcaps>P<smallcaps>ROTOCOLS IN </smallcaps>M<smallcaps>OLECULAR </smallcaps>B<smallcaps>IOLOGY, </smallcaps>eds., Current Protocols, Greene Publishing Associates, Inc. and John Wiley &amp; Sons, Inc. (2002); as well as U.S. Pat. No. 4,683,202; PCR Protocols, A Guide to Methods and Applications (Innis et al. eds.) Academic Press Inc. San Diego, Calif. (1990); Arnheim &amp; Levinson (Oct. 1, 1990), <i>C</i>&amp;<i>EN </i>36; The <i>Journal Of NIH Research, </i>3:81 (1991); Kwoh et al., <i>Proc. Natl. Acad. Sci. USA, </i>86:1173 (1989); Guatelli et al., <i>Proc. Natl. Acad. Sci. USA, </i>87:1874 (1990); Lomell et al., <i>J. Clin. Chem., </i>35:1826 (1989); Landegren et al., <i>Science, </i>241:1077 (1988); Van Brunt, <i>Biotechnology, </i>8:291 (1990); Wu and Wallace, <i>Gene, </i>4:560 (1989); Barringer et al., <i>Gene, </i>89:117 (1990); and Sooknanan and Malek, <i>Biotechnology, </i>13:563 (1995). Improved methods of cloning in vitro amplified nucleic acids are described in U.S. Pat. No. 5,426,039. Other methods described in the art are the nucleic acid sequence based amplification (NASBAâ¢, Cangene, Mississauga, Ontario) and QÎ²-replicase systems. These systems can be used to directly identify mutants where the PCR or LCR primers are designed to be extended or ligated only when a select sequence is present. Alternatively, the select sequences can be generally amplified using, for example, nonspecific PCR primers and the amplified target region later probed for a specific sequence indicative of a mutation. The disclosures of the above-described references are herein incorporated by reference in their entirety for all purposes.</div>
    </li> <li> <para-num num="[0340]"> </para-num> <div id="p-0380" num="0340" class="description-line">Nucleic acids for use as probes, e.g., in in vitro amplification methods, for use as gene probes, or as inhibitor components are typically synthesized chemically according to the solid phase phosphoramidite triester method described by Beaucage et al., <i>Tetrahedron Letts., </i>22:1859 1862 (1981), e.g., using an automated synthesizer, as described in Needham VanDevanter et al., <i>Nucleic Acids Res., </i>12:6159 (1984). Purification of polynucleotides, where necessary, is typically performed by either native acrylamide gel electrophoresis or by anion exchange HPLC as described in Pearson et al., <i>J. Chrom., </i>255:137 149 (1983). The sequence of the synthetic polynucleotides can be verified using the chemical degradation method of Maxam and Gilbert (1980) in Grossman and Moldave (eds.) Academic Press, New York, <i>Methods in Enzymology, </i>65:499.</div>
    </li> <li> <para-num num="[0341]"> </para-num> <div id="p-0381" num="0341" class="description-line">An alternative means for determining the level of transcription is in situ hybridization. In situ hybridization assays are well-known and are generally described in Angerer et al., <i>Methods Enzymol., </i>152:649 (1987). In an in situ hybridization assay, cells are fixed to a solid support, typically a glass slide. If DNA is to be probed, the cells are denatured with heat or alkali. The cells are then contacted with a hybridization solution at a moderate temperature to permit annealing of specific probes that are labeled. The probes are preferably labeled with radioisotopes or fluorescent reporters.</div>
    </li> <heading id="h-0031">EXAMPLES</heading>
    <li> <para-num num="[0342]"> </para-num> <div id="p-0382" num="0342" class="description-line">The present invention will be described in greater detail by way of specific examples. The following examples are offered for illustrative purposes, and are not intended to limit the invention in any manner. Those of skill in the art will readily recognize a variety of noncritical parameters which can be changed or modified to yield essentially the same results. The art worker will also understand the while a âTable 1â may be included in more than one Example, references to a âTable 1â in Example 1 refer to the Table 1 present in Example 1.</div>
    </li> <heading id="h-0032">Examples 1-13</heading>
    <heading id="h-0033">Co-Delivery of a Nucleic Acid Payload with a Steroid in Lipid Nanoparticles</heading>
    <li> <para-num num="[0343]"> </para-num> <div id="p-0383" num="0343" class="description-line">Corticosteroids are a class of steroid hormones that are produced in the adrenal cortex of vertebrates, as well as the synthetic analogues of these hormones. Corticosteroids are involved in a wide range of physiological processes, including stress response, immune response, and regulation of inflammation, carbohydrate metabolism, protein catabolism, blood electrolyte levels, and behavior.</div>
    </li> <li> <para-num num="[0344]"> </para-num> <div id="p-0384" num="0344" class="description-line">There are two classes of corticosteroids. Glucocorticoids such as cortisol control carbohydrate, fat and protein metabolism, and are anti-inflammatory by preventing phospholipid release, decreasing eosinophil action and a number of other mechanisms. Mineralocorticoids such as aldosterone control electrolyte and water levels, mainly by promoting sodium retention in the kidney.</div>
    </li> <li> <para-num num="[0345]"> </para-num> <div id="p-0385" num="0345" class="description-line">The term âglucocorticoidâ refers to any of a group of natural or synthetic steroid hormones that control carbohydrate, protein, and fat metabolism and have anti-inflammatory and/or immunosuppressive properties. Suitable glucocorticoids for use in certain embodiments of the present invention include, but are not limited to, hydrocortisone, cortisone, corticosterone, deoxycorticosterone, prednisone, prednisolone, methylprednisolone, dexamethasone, betamethasone, mometasone, triamcinolone, beclomethasone, fludrocortisone, aldosterone, fluticasone, clobetasone, clobetasol, and loteprednol, and pharmaceutically acceptable salts thereof, and mixtures thereof.â</div>
    </li> <li> <para-num num="[0346]"> </para-num> <div id="p-0386" num="0346" class="description-line">Steroids are often used in the treatment of various diseases as they can help with treatment in a number of ways. In cancer treatment, for example, steroids can reduce nausea associated with chemotherapy and radiation, decrease inflammation, reduce allergic reactions (before transfusions, for example), or simply to help improve quality of life by enabling the patient to sleep, eat, and feel better.</div>
    </li> <li> <para-num num="[0347]"> </para-num> <div id="p-0387" num="0347" class="description-line">While the use of lipid nanoparticles is a proven delivery platform, it is necessary to further expand on the therapeutic utility and patient convenience of LNP by overcoming a number of safety and tolerability concerns. In the clinic, and the absence of premedication, most LNP treatment related adverse events are consistent with infusion-type reactions associated with increases in certain inflammatory biomarkers that may represent dose limiting toxicities. (see, e.g., Judge et al., Review: Overcoming the Innate Immune Response to Small Interfering RNA, <i>Human Gene Therapy, </i>19, 2008)</div>
    </li> <li> <para-num num="[0348]"> </para-num> <div id="p-0388" num="0348" class="description-line">The effects of co-formulating glucocorticoids into LNP have been investigated, to see if inflammatory response following intravenous administration could be dampened, and the therapeutic index of the platform broadened. Preclinical data generated in murine models have indicated that steroid co-formulation with LNP is a viable strategy to achieve reduced immune stimulation, while maintaining the same level of gene silencing ability. Furthermore, early preclinical data in NHP and porcine models correlated well with murine data, providing additional assurance to this novel strategy.</div>
    </li> <heading id="h-0034">General Procedures</heading>
    <heading id="h-0035">Lipid Nanoparticle Formulating</heading>
    <li> <para-num num="[0349]"> </para-num> <div id="p-0389" num="0349" class="description-line">Lipid nanoparticles were made by either direct dilution or in-line dilution methods described by Jeffs et al. (see U.S. Pat. No. 9,005,654). Lipid composition typically contained the following lipids in the respective molar ratios, except where otherwise noted: PEG-lipid (PEG2000-C-DMA, 1.1 mol %); Cationic lipid (Compound 13, 54.9 mol %); cholesterol (33.0 mol %); and 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC, 11.0 mol %). Nucleic acid was solubilized in 20 mM EDTA, pH 4.5. The solutions were combined in a T-connector at a flow rate of 400 mL/min, diluting (in-line or directly into) with PBS at pH 7.4. Ethanol was then removed and carrier buffer replaced with PBS, pH 7.4 by tangential flow ultrafilitration using Midgee hoop cartridges (MW cut off of 500K, GE Healthcare). The LNP were sterile filtered (0.2 Î¼m syringe filter) and sample concentration determined by either DENAX-HPLC or RiboGreen Assay. Particle size and polydispersity were determined using a Malvern Nano Series Zetasizer. Final lipid and steroid concentrations were determined by UPLC.</div>
    </li> <heading id="h-0036">Animal Models</heading>
    <heading id="h-0037">LPS-Primed Cytokine Mouse Model</heading>
    <li> <para-num num="[0350]"> </para-num> <div id="p-0390" num="0350" class="description-line">Female ICR mice (n=5 per group, 5-6 weeks old) are pre-treated with 0.05 mg/kg of lipopolysaccharide (LPS) at time=0 to prime the immune system. At t=2 h they receive LNP at a 1 mg/kg dose by intravenous administration. Blood samples are collected into sodium EDTA microtainer tubes at 4 h post-LNP treatment (terminal bleed) and are processed to plasma by centrifugation at 16000Ãg for 5 min at 16Â° C. Plasma samples are analyzed for Interleukin-1 beta (IL-1Î²), Interleukin-6 (IL-6), and Monocyte Chemotactic Protein 1 (MCP-1) cytokine levels by ELISA.</div>
    </li> <heading id="h-0038">Acute Cytokine Mouse Model</heading>
    <li> <para-num num="[0351]"> </para-num> <div id="p-0391" num="0351" class="description-line">Female ICR mice (n=5 per group, 5-6 weeks old) are treated with 10 mg/kg of LNP by intravenous administration. At 2 h post-treatment, blood is collected into tubes containing 50 mM EDTA via tail nicks and processed to plasma by centrifugation at 16000Ãg for 5 min at 16Â° C. At 6 h post-treatment, terminal blood samples are collected into sodium EDTA microtainer tubes and are processed to plasma using the same procedure as above. Plasma samples are analyzed by ELISA for Interleukin-6 (IL-6) and Monocyte Chemotactic Protein 1 (MCP-1) cytokine levels.</div>
    </li> <heading id="h-0039">Activity Mouse Model</heading>
    <li> <para-num num="[0352]"> </para-num> <div id="p-0392" num="0352" class="description-line">LNP formulated with a siRNA targeting Apolipoprotein B (ApoB) were administered IV to generate dose response curve (typical doses: 0.01 mg/kg to 0.05 mg/kg total siRNA) in female Balb/C mice (n=3 per group, 5-6 weeks old). Terminal time point is at 48 hours post-intravenous administration of LNP. The left liver lobe is collected into RNAlater and assayed for ApoB levels by QuantiGene 2.0 analysis. Results are normalized to the house keeping gene GAPDH.</div>
    </li> <heading id="h-0040">Example 1</heading>
    <heading id="h-0041">LNP Containing Dexamethasone 21-Palmitate in LPS-Primed Cytokine Mouse Model</heading>
    <li> <para-num num="[0353]"> </para-num> <div id="p-0393" num="0353" class="description-line">Dexamethasone 21-palmitate (Dex-P) is effectively a pro-drug of dexamethasone, requiring enzymatic action to release the steroid (Dexamethasone). This is less favorable compared to the steroid in its free form (since it requires conversion to the active form in vivo); however, dexamethasone 21-palmitate has a higher log P than free dexamethasone, facilitating better incorporation into LNP.</div>
    </li> <li> <para-num num="[0354]"> </para-num> <div id="p-0394" num="0354" class="description-line">Using the base composition described in General Procedures, a titration series of compositions was prepared with a steadily increasing Dex-P content (0.5 mol %, 2 mol %, or 5 mol % Dex-P). Dex-P was simply included as an additional lipid component in the 90% ethanol lipid stock. Particle characteristics were essentially identical to the base composition (Table 1).</div>
    </li> <li> <div id="p-0395" num="0000" class="description-line">
      <tables id="TABLE-US-00001" num="00001">
        <patent-tables frame="none" colsep="0" rowsep="0">
          <table align="left" colsep="0" rowsep="0" cols="1" class="description-table" width="100%">
            <thead>
              <tr class="description-tr">
                <td namest="1" nameend="1" rowsep="1" class="description-td" colspan="1">TABLE 1</td>
              </tr>
            </thead>
            
              <tbody><tr class="description-tr">
                <td namest="1" nameend="1" align="center" rowsep="1" class="description-td" colspan="1"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Formulation characteristics of Base Formulation vs Dex-P LNP</td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="5" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td"> </td>
                <td class="description-td">Z avg</td>
                <td class="description-td"> </td>
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">Formulation</td>
                <td class="description-td">(nm)</td>
                <td class="description-td">PDI</td>
                <td class="description-td">% Encap</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td namest="offset" nameend="4" align="center" rowsep="1" class="description-td" colspan="5"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">Base Formulation</td>
                <td class="description-td">77</td>
                <td class="description-td">0.04</td>
                <td class="description-td">98</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">Base + 5% DexP</td>
                <td class="description-td">77</td>
                <td class="description-td">0.03</td>
                <td class="description-td">98</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">Base + 2% DexP</td>
                <td class="description-td">77</td>
                <td class="description-td">0.02</td>
                <td class="description-td">99</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">Base + 0.5% DexP</td>
                <td class="description-td">74</td>
                <td class="description-td">0.03</td>
                <td class="description-td">98</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td namest="offset" nameend="4" align="center" rowsep="1" class="description-td" colspan="5"> </td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    </li> <li> <para-num num="[0355]"> </para-num> <div id="p-0396" num="0355" class="description-line">The above formulations were tested in the LPS-primed mouse cytokine model described in General Procedures. As an additional control, the Base Formulation was co-administered with free Dexamethasone. The free steroid was administered intravenously at a dose of 0.3 mg/kg (a clinically relevant dose).</div>
    </li> <li> <para-num num="[0356]"> </para-num> <div id="p-0397" num="0356" class="description-line">ICR mice pre-treated with lipopolysaccharide (LPS) at 0.05 mg/kg induced cytokine response compared to animals pre-treated with PBS. Following intravenous administration of LNP, there were further increases in all 3 cytokines. Representative cytokine data (MCP-1) is shown in Table 2. The cytokine levels were highest for the group treated with the Base Formulation in the absence of steroid. Co-formulating Dex-P with the LNP reduced cytokine levels significantly. Furthermore, the cytokine levels were similar between the low (0.5 mol %) and high (5 mol %) steroid doses when co-formulated in LNP, indicating a potentially saturating effect. With 5 mol % Dex-P incorporated into the LNP, the equivalent dose of free dexamethasone administered in a single intravenous injection was 0.3 mg/kg. The cytokine levels achieved with Dex-P LNP at this dose was similar to co-administering the control LNP with 0.3 mg/kg of free dexamethasone in two separate, consecutive injections.</div>
    </li> <li> <div id="p-0398" num="0000" class="description-line">
      <tables id="TABLE-US-00002" num="00002">
        <patent-tables frame="none" colsep="0" rowsep="0">
          <table align="left" colsep="0" rowsep="0" cols="1" class="description-table" width="100%">
            <thead>
              <tr class="description-tr">
                <td namest="1" nameend="1" rowsep="1" class="description-td" colspan="1">TABLE 2</td>
              </tr>
            </thead>
            
              <tbody><tr class="description-tr">
                <td namest="1" nameend="1" align="center" rowsep="1" class="description-td" colspan="1"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">MCP-1 ELISA Results of Base Composition vs Dex-P</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">LNP in LPS-primed Cytokine Mouse Model</td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="4" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td"> </td>
                <td class="description-td">Average MCP-1</td>
                <td class="description-td">Stdev</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Pre-Treatment</td>
                <td class="description-td">Treatment</td>
                <td class="description-td">(pg/mL)</td>
                <td class="description-td">(pg/mL)</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="4" align="center" rowsep="1" class="description-td" colspan="4"> </td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="4" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td">PBS</td>
                <td class="description-td">PBS</td>
                <td class="description-td">95</td>
                <td class="description-td">35</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">LPS</td>
                <td class="description-td">PBS</td>
                <td class="description-td">4170</td>
                <td class="description-td">2345</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">LPS</td>
                <td class="description-td">1.1:55 (âBaseâ)</td>
                <td class="description-td">39403</td>
                <td class="description-td">12135</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">LPS</td>
                <td class="description-td">Base + 5% DexP</td>
                <td class="description-td">8978</td>
                <td class="description-td">5817</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">LPS</td>
                <td class="description-td">Base + 2% DexP</td>
                <td class="description-td">13039</td>
                <td class="description-td">4824</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">LPS</td>
                <td class="description-td">Base + 0.5% DexP</td>
                <td class="description-td">12899</td>
                <td class="description-td">4705</td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="5" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td">LPS</td>
                <td class="description-td">1.1:55</td>
                <td class="description-td">0.3 mg/kg</td>
                <td class="description-td">8801</td>
                <td class="description-td">4327</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">(âBaseâ)</td>
                <td class="description-td">Free Dex</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="5" align="center" rowsep="1" class="description-td" colspan="5"> </td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    </li> <heading id="h-0042">Example 2</heading>
    <heading id="h-0043">LNP Containing Dexamethasone 21-Palmitate in Acute Cytokine Mouse Model</heading>
    <li> <para-num num="[0357]"> </para-num> <div id="p-0399" num="0357" class="description-line">The concept of corticosteroid co-formulation was further supported with data from the acute cytokine model. The same formulation panel was tested (dosed at 10 mg/kg in this model) and data again indicated that co-formulated Dex-P LNP is an effective means of reducing immune-stimulation, achieving similar cytokine levels to co-administering LNP with free dexamethasone, at the same or lower doses (Table 3).</div>
    </li> <li> <div id="p-0400" num="0000" class="description-line">
      <tables id="TABLE-US-00003" num="00003">
        <patent-tables frame="none" colsep="0" rowsep="0">
          <table align="left" colsep="0" rowsep="0" cols="1" class="description-table" width="100%">
            <thead>
              <tr class="description-tr">
                <td namest="1" nameend="1" rowsep="1" class="description-td" colspan="1">TABLE 3</td>
              </tr>
            </thead>
            
              <tbody><tr class="description-tr">
                <td namest="1" nameend="1" align="center" rowsep="1" class="description-td" colspan="1"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">MCP-1 ELISA Results of Base Composition vs</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Dex-P LNP in Acute Cytokine Mouse Model</td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="3" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">2 h</td>
                <td class="description-td">6 h</td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="5" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">Average</td>
                <td class="description-td"> </td>
                <td class="description-td">Average</td>
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">MCP-1</td>
                <td class="description-td">Stdev</td>
                <td class="description-td">MCP-1</td>
                <td class="description-td">Stdev</td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="5" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td">Treatment</td>
                <td class="description-td">(pg/mL)</td>
                <td class="description-td">(pg/mL)</td>
                <td class="description-td">(pg/mL)</td>
                <td class="description-td">(pg/mL)</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="5" align="center" rowsep="1" class="description-td" colspan="5"> </td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="5" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td">PBS</td>
                <td class="description-td">88</td>
                <td class="description-td">14</td>
                <td class="description-td">104</td>
                <td class="description-td">18</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">1.1:55 (âBaseâ)</td>
                <td class="description-td">3804</td>
                <td class="description-td">1145</td>
                <td class="description-td">1377</td>
                <td class="description-td">553</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Base + 5% DexP</td>
                <td class="description-td">104</td>
                <td class="description-td">24</td>
                <td class="description-td">118</td>
                <td class="description-td">43</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Base + 2% DexP</td>
                <td class="description-td">148</td>
                <td class="description-td">66</td>
                <td class="description-td">139</td>
                <td class="description-td">84</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Base + 0.5% DexP</td>
                <td class="description-td">193</td>
                <td class="description-td">62</td>
                <td class="description-td">203</td>
                <td class="description-td">61</td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="6" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td">1.1:55</td>
                <td class="description-td">0.3 mg/kg</td>
                <td class="description-td">190</td>
                <td class="description-td">132</td>
                <td class="description-td">252</td>
                <td class="description-td">155</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">(âBaseâ)</td>
                <td class="description-td">FreeDex</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="6" align="center" rowsep="1" class="description-td" colspan="6"> </td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    </li> <heading id="h-0044">Example 3</heading>
    <heading id="h-0045">LNP Containing Reduced Dexamethasone 21-Palmitate in LPS Primed Model</heading>
    <li> <para-num num="[0358]"> </para-num> <div id="p-0401" num="0358" class="description-line">The concentrations of Dex-P were titrated down further (to 0.5 mol %, 0.1 mol % and 0.01 mol %). Post-formulation analysis by UPLC indicated that Dex-P was readily incorporated into the particles. Particle characteristics were comparable between LNP formulations (Table 4).</div>
    </li> <li> <div id="p-0402" num="0000" class="description-line">
      <tables id="TABLE-US-00004" num="00004">
        <patent-tables frame="none" colsep="0" rowsep="0">
          <table align="left" colsep="0" rowsep="0" cols="1" class="description-table" width="100%">
            <thead>
              <tr class="description-tr">
                <td namest="1" nameend="1" rowsep="1" class="description-td" colspan="1">TABLE 4</td>
              </tr>
            </thead>
            
              <tbody><tr class="description-tr">
                <td namest="1" nameend="1" align="center" rowsep="1" class="description-td" colspan="1"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Formulation characteristics of Base Formulation vs Dex-P LNP</td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="5" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td"> </td>
                <td class="description-td">Z-avg</td>
                <td class="description-td"> </td>
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">Formulation</td>
                <td class="description-td">(nm)</td>
                <td class="description-td">PDI</td>
                <td class="description-td">% Encap</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td namest="offset" nameend="4" align="center" rowsep="1" class="description-td" colspan="5"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">Base Formulation</td>
                <td class="description-td">75</td>
                <td class="description-td">0.10</td>
                <td class="description-td">99</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">Base + 0.5% DexP</td>
                <td class="description-td">74</td>
                <td class="description-td">0.03</td>
                <td class="description-td">99</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">Base + 0.1% DexP</td>
                <td class="description-td">75</td>
                <td class="description-td">0.07</td>
                <td class="description-td">98</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">Base + 0.01% DexP</td>
                <td class="description-td">74</td>
                <td class="description-td">0.01</td>
                <td class="description-td">98</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td namest="offset" nameend="4" align="center" rowsep="1" class="description-td" colspan="5"> </td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    </li> <li> <para-num num="[0359]"> </para-num> <div id="p-0403" num="0359" class="description-line">Results for a representative cytokine readout (MCP-1) are shown in Table 5. A correlation between Dex-P concentration and cytokine levels was observed (more Dex-P gave a better reduction in cytokines). The 0.5% Dex-P LNP is equivalent to approximately a 0.03 mg/kg dose of free Dexamethasone. Data comparing these two groups showed that the reduction in cytokines is significantly better when the corticosteroid was incorporated in the LNP. In fact, this LNP (0.5% Dex-P) actually performed as well as a 0.3 mg/kg dose of free Dexamethasoneâa 10-fold greater dose of corticosteroid. It was hypothesized that this surprising result may be due to much more effective, âtargeted deliveryâ of the corticosteroid. Immune cells which take up LNP, and may otherwise have triggered an immune response, are simultaneously receiving the immune suppressive corticosteroid.</div>
    </li> <li> <div id="p-0404" num="0000" class="description-line">
      <tables id="TABLE-US-00005" num="00005">
        <patent-tables frame="none" colsep="0" rowsep="0">
          <table align="left" colsep="0" rowsep="0" cols="1" class="description-table" width="100%">
            <thead>
              <tr class="description-tr">
                <td namest="1" nameend="1" rowsep="1" class="description-td" colspan="1">TABLE 5</td>
              </tr>
            </thead>
            
              <tbody><tr class="description-tr">
                <td namest="1" nameend="1" align="center" rowsep="1" class="description-td" colspan="1"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">MCP-1 ELISA Results of Base Composition vs Dex-P</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">LNP in LPS-primed Cytokine Mouse Model</td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="4" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td"> </td>
                <td class="description-td">Average MCP-1</td>
                <td class="description-td">Stdev</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Pre-Treatment</td>
                <td class="description-td">Treatment</td>
                <td class="description-td">(pg/mL)</td>
                <td class="description-td">(pg/mL)</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="4" align="center" rowsep="1" class="description-td" colspan="4"> </td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="4" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td">PBS</td>
                <td class="description-td">PBS</td>
                <td class="description-td">135</td>
                <td class="description-td">21</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">LPS</td>
                <td class="description-td">PBS</td>
                <td class="description-td">3821</td>
                <td class="description-td">432</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">LPS</td>
                <td class="description-td">1.1:55 (âBaseâ)</td>
                <td class="description-td">28020</td>
                <td class="description-td">6224</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">LPS</td>
                <td class="description-td">Base + 0.5% DexP</td>
                <td class="description-td">12304</td>
                <td class="description-td">7171</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">LPS</td>
                <td class="description-td">Base + 0.1% DexP</td>
                <td class="description-td">24119</td>
                <td class="description-td">9935</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">LPS</td>
                <td class="description-td">Base + 0.01% DexP</td>
                <td class="description-td">29276</td>
                <td class="description-td">5392</td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="5" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td">LPS</td>
                <td class="description-td">1.1:55</td>
                <td class="description-td">0.3 mg/kg</td>
                <td class="description-td">13982</td>
                <td class="description-td">4350</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">(âBaseâ)</td>
                <td class="description-td">Free Dex</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">LPS</td>
                <td class="description-td">1.1:55</td>
                <td class="description-td">0.03 mg/kg</td>
                <td class="description-td">27893</td>
                <td class="description-td">7566</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">(âBaseâ)</td>
                <td class="description-td">Free Dex</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">LPS</td>
                <td class="description-td">1.1:55</td>
                <td class="description-td">0.006 mg/kg</td>
                <td class="description-td">23901</td>
                <td class="description-td">4254</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">(âBaseâ)</td>
                <td class="description-td">Free Dex</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="5" align="center" rowsep="1" class="description-td" colspan="5"> </td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    </li> <heading id="h-0046">Example 4</heading>
    <heading id="h-0047">Activity of LNP Co-Formulated with Dex-P</heading>
    <li> <para-num num="[0360]"> </para-num> <div id="p-0405" num="0360" class="description-line">To verify that incorporation of Dex-P into LNP did not impact potency, formulations were assessed in the Activity Mouse Model described in General Procedures. Samples containing various amounts of Dex-P were tested at 2 doses; 0.025 mg/kg and 0.05 mg/kg. Similar silencing activity was observed for all formulations at each dose. The Base Formulation containing 0.5% Dex-P and a non-targeting control siRNA (siLuc-2) was included as a negative control. No silencing is expected or observed with this payload. Results are shown in Table 6.</div>
    </li> <li> <div id="p-0406" num="0000" class="description-line">
      <tables id="TABLE-US-00006" num="00006">
        <patent-tables frame="none" colsep="0" rowsep="0">
          <table align="left" colsep="0" rowsep="0" cols="1" class="description-table" width="100%">
            <thead>
              <tr class="description-tr">
                <td namest="1" nameend="1" rowsep="1" class="description-td" colspan="1">TABLE 6</td>
              </tr>
            </thead>
            
              <tbody><tr class="description-tr">
                <td namest="1" nameend="1" align="center" rowsep="1" class="description-td" colspan="1"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">ApoB Silencing Activity of 1.1:55 Base vs</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">LNP co-formulated with Dex-P in Mouse Model</td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="5" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td"> </td>
                <td class="description-td">Dose</td>
                <td class="description-td"> </td>
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">Treatment</td>
                <td class="description-td">(mg/kg)</td>
                <td class="description-td">% PBS</td>
                <td class="description-td">% Error</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td namest="offset" nameend="4" align="center" rowsep="1" class="description-td" colspan="5"> </td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="5" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">PBS</td>
                <td class="description-td">n/a<sup>1</sup> </td>
                <td class="description-td">100</td>
                <td class="description-td">21</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">1.1:55 (âBaseâ)</td>
                <td class="description-td">0.025</td>
                <td class="description-td">55</td>
                <td class="description-td">6</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td"> </td>
                <td class="description-td">0.05</td>
                <td class="description-td">47</td>
                <td class="description-td">7</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">Base + 5% Dex-P</td>
                <td class="description-td">0.025</td>
                <td class="description-td">81</td>
                <td class="description-td">12</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td"> </td>
                <td class="description-td">0.05</td>
                <td class="description-td">46</td>
                <td class="description-td">5</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">Base + 2.5% Dex-P</td>
                <td class="description-td">0.025</td>
                <td class="description-td">57</td>
                <td class="description-td">19</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td"> </td>
                <td class="description-td">0.05</td>
                <td class="description-td">34</td>
                <td class="description-td">6</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">Base + 0.5% Dex-P</td>
                <td class="description-td">0.025</td>
                <td class="description-td">54</td>
                <td class="description-td">8</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td"> </td>
                <td class="description-td">0.05</td>
                <td class="description-td">35</td>
                <td class="description-td">10</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">Base + 0.1% Dex-P</td>
                <td class="description-td">0.025</td>
                <td class="description-td">67</td>
                <td class="description-td">8</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td"> </td>
                <td class="description-td">0.05</td>
                <td class="description-td">36</td>
                <td class="description-td">14</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">Base + Free Dex</td>
                <td class="description-td">0.025</td>
                <td class="description-td">64</td>
                <td class="description-td">15</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td"> </td>
                <td class="description-td">0.05</td>
                <td class="description-td">29</td>
                <td class="description-td">6</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">Base + 0.5% Dex-P (siLuc-2)</td>
                <td class="description-td">0.025</td>
                <td class="description-td">86</td>
                <td class="description-td">8</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td"> </td>
                <td class="description-td">0.05</td>
                <td class="description-td">92</td>
                <td class="description-td">20</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td namest="offset" nameend="4" align="center" rowsep="1" class="description-td" colspan="5"> </td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
      </div> </li> <ul>
        <li id="ul0001-0001" num="0361"> <sup>1</sup>PBS administered intravenously at 10 mL/kg.</li>
      </ul>
    
    <heading id="h-0048">Example 5</heading>
    <heading id="h-0049">LNP Containing Clobetasol in LPS Primed Mouse Model</heading>
    <li> <para-num num="[0362]"> </para-num> <div id="p-0407" num="0362" class="description-line">It was then attempted to co-formulate the corticosteroid clobetasol-17-propionate (clobetasol) into LNP, again to study its ability to suppress inflammatory responses to the particle. A 40 mM acetate, pH 4.5 buffer was used to solubilize the nucleic acid. Final lipid composition is shown in Table 7. Clobetasol, having a lower log P (Ë3.5), didn&#39;t incorporate as readily into the LNP as Dex-P (log P Ë9). Therefore an 8-fold greater concentration of clobetasol than was actually desired in the end product was input into the process. Analysis by UPLC confirmed incorporation of clobetasol.</div>
    </li> <li> <div id="p-0408" num="0000" class="description-line">
      <tables id="TABLE-US-00007" num="00007">
        <patent-tables frame="none" colsep="0" rowsep="0">
          <table align="left" colsep="0" rowsep="0" cols="1" class="description-table" width="100%">
            <thead>
              <tr class="description-tr">
                <td namest="1" nameend="1" rowsep="1" class="description-td" colspan="1">TABLE 7</td>
              </tr>
            </thead>
            
              <tbody><tr class="description-tr">
                <td namest="1" nameend="1" align="center" rowsep="1" class="description-td" colspan="1"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Lipid composition of 1.1:55 Base vs LNP containing Clobetasol</td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="2" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">Lipid Composition (mol %)</td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="6" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">PEG2000-</td>
                <td class="description-td">Compound</td>
                <td class="description-td">Chole-</td>
                <td class="description-td">Phospho-</td>
                <td class="description-td">Clobe-</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">C-DMA</td>
                <td class="description-td">13</td>
                <td class="description-td">sterol</td>
                <td class="description-td">lipid <sup>1</sup> </td>
                <td class="description-td">tasol</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td namest="offset" nameend="5" align="center" rowsep="1" class="description-td" colspan="6"> </td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="6" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td">1.1:55 (âBaseâ)</td>
                <td class="description-td">1.1</td>
                <td class="description-td">55</td>
                <td class="description-td">33</td>
                <td class="description-td">11</td>
                <td class="description-td">â</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Base + 1%</td>
                <td class="description-td">1.1</td>
                <td class="description-td">55</td>
                <td class="description-td">33</td>
                <td class="description-td">11</td>
                <td class="description-td">1</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Clobetasol</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="6" align="center" rowsep="1" class="description-td" colspan="6"> </td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="6" align="left" id="FOO-00001" class="description-td" colspan="6"> <sup>1 </sup>1,2-di-O-octadecyl-sn-glycero-3-phosphocholine used instead of DSPC in LNP containing Clobetasol</td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    </li> <li> <para-num num="[0363]"> </para-num> <div id="p-0409" num="0363" class="description-line">As outlined in Table 8, formulation characteristics were comparable between the two compositions. Particle size, polydispersity and payload encapsulation indicated uniform particle populations.</div>
    </li> <li> <div id="p-0410" num="0000" class="description-line">
      <tables id="TABLE-US-00008" num="00008">
        <patent-tables frame="none" colsep="0" rowsep="0">
          <table align="left" colsep="0" rowsep="0" cols="1" class="description-table" width="100%">
            <thead>
              <tr class="description-tr">
                <td namest="1" nameend="1" rowsep="1" class="description-td" colspan="1">TABLE 8</td>
              </tr>
            </thead>
            
              <tbody><tr class="description-tr">
                <td namest="1" nameend="1" align="center" rowsep="1" class="description-td" colspan="1"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Characterization of 1.1:55 Base vs LNP containing Clobetasol</td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="5" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td"> </td>
                <td class="description-td">Z avg</td>
                <td class="description-td"> </td>
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">Formulation</td>
                <td class="description-td">(nm)</td>
                <td class="description-td">PDI</td>
                <td class="description-td">% Encap</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td namest="offset" nameend="4" align="center" rowsep="1" class="description-td" colspan="5"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">Base Formulation</td>
                <td class="description-td">79</td>
                <td class="description-td">0.04</td>
                <td class="description-td">96</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">Base + 1%</td>
                <td class="description-td">65</td>
                <td class="description-td">0.04</td>
                <td class="description-td">98</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">clobetasol</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td namest="offset" nameend="4" align="center" rowsep="1" class="description-td" colspan="5"> </td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    </li> <li> <para-num num="[0364]"> </para-num> <div id="p-0411" num="0364" class="description-line">The two compositions were assessed in the LPS-primed mouse model. A representative cytokine readout (MCP-1) is shown in Table 9. The inflammatory response to the LNP is significantly reduced with the clobetasol LNP. The MCP-1 levels are similar to LNP containing Dex-P; however, clobetasol is not a pro-drug, and does not rely on enzymatic action for activation. This is a significant advantage over Dex-P as this corticosteroid would work spontaneously upon delivery of the LNP to its targeted site of action.</div>
    </li> <li> <div id="p-0412" num="0000" class="description-line">
      <tables id="TABLE-US-00009" num="00009">
        <patent-tables frame="none" colsep="0" rowsep="0">
          <table align="left" colsep="0" rowsep="0" cols="1" class="description-table" width="100%">
            <thead>
              <tr class="description-tr">
                <td namest="1" nameend="1" rowsep="1" class="description-td" colspan="1">TABLE 9</td>
              </tr>
            </thead>
            
              <tbody><tr class="description-tr">
                <td namest="1" nameend="1" align="center" rowsep="1" class="description-td" colspan="1"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">MCP-1 ELISA Results of Base Composition vs LNP containing</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Clobetasol in LPS-primed Cytokine Mouse Model</td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="4" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td"> </td>
                <td class="description-td">Average MCP-1</td>
                <td class="description-td">Stdev</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Pre-Treatment</td>
                <td class="description-td">Treatment</td>
                <td class="description-td">(pg/mL)</td>
                <td class="description-td">(pg/mL)</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="4" align="center" rowsep="1" class="description-td" colspan="4"> </td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="4" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td">PBS</td>
                <td class="description-td">PBS</td>
                <td class="description-td">201</td>
                <td class="description-td">13</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">LPS</td>
                <td class="description-td">PBS</td>
                <td class="description-td">3877</td>
                <td class="description-td">2138</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">LPS</td>
                <td class="description-td">1.1:55 (âBaseâ)</td>
                <td class="description-td">49069</td>
                <td class="description-td">9784</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">LPS</td>
                <td class="description-td">Base + 1% Clobetasol</td>
                <td class="description-td">11550</td>
                <td class="description-td">7598</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="4" align="center" rowsep="1" class="description-td" colspan="4"> </td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    </li> <heading id="h-0050">Example 6</heading>
    <heading id="h-0051">LNP Containing Clobetasol in Acute Cytokine Mouse Model</heading>
    <li> <para-num num="[0365]"> </para-num> <div id="p-0413" num="0365" class="description-line">The same LNP compositions (Base and Base+Clobetasol) were tested in the acute cytokine model. MCP-1 and IL-6 cytokine levels were measured at both 2 h and 6 h time points. Both cytokines reported significantly lower levels for the co-formulated clobetasol LNP. The latter formulation reported only baseline levels of IL-6 at both time points (Table 10).</div>
    </li> <li> <div id="p-0414" num="0000" class="description-line">
      <tables id="TABLE-US-00010" num="00010">
        <patent-tables frame="none" colsep="0" rowsep="0">
          <table align="left" colsep="0" rowsep="0" cols="1" class="description-table" width="100%">
            <thead>
              <tr class="description-tr">
                <td namest="1" nameend="1" rowsep="1" class="description-td" colspan="1">TABLE 10</td>
              </tr>
            </thead>
            
              <tbody><tr class="description-tr">
                <td namest="1" nameend="1" align="center" rowsep="1" class="description-td" colspan="1"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">IL-6 ELISA Results of Base Composition vs LNP containing</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Clobetasol in Acute Cytokine Mouse Model</td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="3" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">2 h</td>
                <td class="description-td">6 h</td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="5" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">Average IL-6</td>
                <td class="description-td">Stdev</td>
                <td class="description-td">Average IL-6</td>
                <td class="description-td">Stdev</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Treatment</td>
                <td class="description-td">(pg/mL)</td>
                <td class="description-td">(pg/mL)</td>
                <td class="description-td">(pg/mL)</td>
                <td class="description-td">(pg/mL)</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="5" align="center" rowsep="1" class="description-td" colspan="5"> </td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="5" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td">PBS</td>
                <td class="description-td">17</td>
                <td class="description-td">4</td>
                <td class="description-td">10</td>
                <td class="description-td">7</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">1.1:55 (âBaseâ)</td>
                <td class="description-td">2232</td>
                <td class="description-td">493</td>
                <td class="description-td">152</td>
                <td class="description-td">137</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Base + 1%</td>
                <td class="description-td">27</td>
                <td class="description-td">13</td>
                <td class="description-td">5</td>
                <td class="description-td">2</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Clobetasol</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="5" align="center" rowsep="1" class="description-td" colspan="5"> </td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    </li> <li> <para-num num="[0366]"> </para-num> <div id="p-0415" num="0366" class="description-line">An expanded acute cytokine study was performed with more time points, to ensure that the peak cytokine response had not simply shifted to an earlier or later time point with the clobetasol LNP. Peak cytokine response is usually observed at 2 h post-LNP treatment in this model. Results confirmed that this steroid was effective at suppressing the immune response throughout the time course of the study (Table 11).</div>
    </li> <li> <div id="p-0416" num="0000" class="description-line">
      <tables id="TABLE-US-00011" num="00011">
        <patent-tables frame="none" colsep="0" rowsep="0">
          <table align="left" colsep="0" rowsep="0" cols="1" class="description-table" width="100%">
            <thead>
              <tr class="description-tr">
                <td namest="1" nameend="1" rowsep="1" class="description-td" colspan="1">TABLE 11</td>
              </tr>
            </thead>
            
              <tbody><tr class="description-tr">
                <td namest="1" nameend="1" align="center" rowsep="1" class="description-td" colspan="1"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">MCP-1 ELISA Results of Base Composition vs LNP containing</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Clobetasol in an Expanded Time Course Study, Acute</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Cytokine Mouse Model</td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="4" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td"> </td>
                <td class="description-td">1.1:55</td>
                <td class="description-td">Base + 1%</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">PBS</td>
                <td class="description-td">(âBaseâ)</td>
                <td class="description-td">Clobetasol</td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="7" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">Avg</td>
                <td class="description-td"> </td>
                <td class="description-td">Avg</td>
                <td class="description-td"> </td>
                <td class="description-td">Avg</td>
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Time Point</td>
                <td class="description-td">MCP-1</td>
                <td class="description-td">Stdev</td>
                <td class="description-td">MCP-1</td>
                <td class="description-td">Stdev</td>
                <td class="description-td">MCP-</td>
                <td class="description-td">Stdev</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">(h)</td>
                <td class="description-td">(pg/mL)</td>
                <td class="description-td">(pg/mL)</td>
                <td class="description-td">(pg/mL)</td>
                <td class="description-td">(pg/mL)</td>
                <td class="description-td">1 (pg/mL)</td>
                <td class="description-td">(pg/mL)</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="7" align="center" rowsep="1" class="description-td" colspan="7"> </td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="7" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td">0.25</td>
                <td class="description-td">74</td>
                <td class="description-td">10</td>
                <td class="description-td">83</td>
                <td class="description-td">13</td>
                <td class="description-td">68</td>
                <td class="description-td">5</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">0.5</td>
                <td class="description-td">150</td>
                <td class="description-td">52</td>
                <td class="description-td">314</td>
                <td class="description-td">196</td>
                <td class="description-td">75</td>
                <td class="description-td">9</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">1</td>
                <td class="description-td">91</td>
                <td class="description-td">7</td>
                <td class="description-td">356</td>
                <td class="description-td">202</td>
                <td class="description-td">99</td>
                <td class="description-td">7</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">2</td>
                <td class="description-td">100</td>
                <td class="description-td">12</td>
                <td class="description-td">1447</td>
                <td class="description-td">602</td>
                <td class="description-td">248</td>
                <td class="description-td">198</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">3</td>
                <td class="description-td">98</td>
                <td class="description-td">21</td>
                <td class="description-td">946</td>
                <td class="description-td">815</td>
                <td class="description-td">186</td>
                <td class="description-td">156</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">4</td>
                <td class="description-td">113</td>
                <td class="description-td">22</td>
                <td class="description-td">646</td>
                <td class="description-td">411</td>
                <td class="description-td">191</td>
                <td class="description-td">99</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">6</td>
                <td class="description-td">84</td>
                <td class="description-td">16</td>
                <td class="description-td">735</td>
                <td class="description-td">561</td>
                <td class="description-td">106</td>
                <td class="description-td">24</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="7" align="center" rowsep="1" class="description-td" colspan="7"> </td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    </li> <heading id="h-0052">Example 7</heading>
    <heading id="h-0053">Activity of LNP Containing Clobetasol in a Mouse Dose Response Study</heading>
    <li> <para-num num="[0367]"> </para-num> <div id="p-0417" num="0367" class="description-line">To verify that incorporation of clobetasol into LNP and the slight modifications to the process did not impact potency, formulations were assessed in the Activity Model described in General Procedures. Similar silencing activity was observed for both formulations at each dose (Table 12). This highlights that the clobetasol LNP have a dramatically improved Therapeutic Index; they have equal potency, but far superior tolerability.</div>
    </li> <li> <div id="p-0418" num="0000" class="description-line">
      <tables id="TABLE-US-00012" num="00012">
        <patent-tables frame="none" colsep="0" rowsep="0">
          <table align="left" colsep="0" rowsep="0" cols="1" class="description-table" width="100%">
            <thead>
              <tr class="description-tr">
                <td namest="1" nameend="1" rowsep="1" class="description-td" colspan="1">TABLE 12</td>
              </tr>
            </thead>
            
              <tbody><tr class="description-tr">
                <td namest="1" nameend="1" align="center" rowsep="1" class="description-td" colspan="1"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">ApoB Silencing Activity of 1.1:55 Base Composition</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">vs LNP containing Clobetasol</td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="5" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td"> </td>
                <td class="description-td">Dose</td>
                <td class="description-td"> </td>
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">Treatment</td>
                <td class="description-td">(mg/kg)</td>
                <td class="description-td">% PBS</td>
                <td class="description-td">% Error</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td namest="offset" nameend="4" align="center" rowsep="1" class="description-td" colspan="5"> </td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="5" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">PBS</td>
                <td class="description-td">n/a<sup>1</sup> </td>
                <td class="description-td">100</td>
                <td class="description-td">20</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">1.1:55 (âBaseâ)</td>
                <td class="description-td">0.01</td>
                <td class="description-td">45</td>
                <td class="description-td">7</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td"> </td>
                <td class="description-td">0.025</td>
                <td class="description-td">21</td>
                <td class="description-td">1</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td"> </td>
                <td class="description-td">0.05</td>
                <td class="description-td">12</td>
                <td class="description-td">1</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">Base + 1%</td>
                <td class="description-td">0.01</td>
                <td class="description-td">44</td>
                <td class="description-td">11</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">Clobetasol</td>
                <td class="description-td">0.025</td>
                <td class="description-td">18</td>
                <td class="description-td">5</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td"> </td>
                <td class="description-td">0.05</td>
                <td class="description-td">9</td>
                <td class="description-td">1</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td namest="offset" nameend="4" align="center" rowsep="1" class="description-td" colspan="5"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td namest="offset" nameend="4" align="left" id="FOO-00002" class="description-td" colspan="5"> <sup>1</sup>PBS administered intravenously at 10 mL/kg.</td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    </li> <heading id="h-0054">Example 8</heading>
    <heading id="h-0055">Immune Suppression with LNP Containing Ciclesonide</heading>
    <li> <para-num num="[0368]"> </para-num> <div id="p-0419" num="0368" class="description-line">Next the corticosteroid Ciclesonide was tested. Final lipid composition is shown in Table 13. Analysis by UPLC confirmed incorporation of Ciclesonide. Ciclesonide has a log P of Ë5.3 and incorporated readily into the particle.</div>
    </li> <li> <div id="p-0420" num="0000" class="description-line">
      <tables id="TABLE-US-00013" num="00013">
        <patent-tables frame="none" colsep="0" rowsep="0">
          <table align="left" colsep="0" rowsep="0" cols="1" class="description-table" width="100%">
            <thead>
              <tr class="description-tr">
                <td namest="1" nameend="1" rowsep="1" class="description-td" colspan="1">TABLE 13</td>
              </tr>
            </thead>
            
              <tbody><tr class="description-tr">
                <td namest="1" nameend="1" align="center" rowsep="1" class="description-td" colspan="1"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Lipid composition of 1.1:55 Base vs LNP containing Clobetasol</td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="2" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">Lipid Composition (mol %)</td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="6" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">PEG2000-</td>
                <td class="description-td">Compound</td>
                <td class="description-td">Choles-</td>
                <td class="description-td"> </td>
                <td class="description-td">Cicleso-</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">C-DMA</td>
                <td class="description-td">13</td>
                <td class="description-td">terol</td>
                <td class="description-td">DSPC</td>
                <td class="description-td">nide</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td namest="offset" nameend="5" align="center" rowsep="1" class="description-td" colspan="6"> </td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="6" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td">Base Formulation</td>
                <td class="description-td">1.1</td>
                <td class="description-td">55</td>
                <td class="description-td">33</td>
                <td class="description-td">11</td>
                <td class="description-td">â</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Base + 2%</td>
                <td class="description-td">1.1</td>
                <td class="description-td">55</td>
                <td class="description-td">33</td>
                <td class="description-td">11</td>
                <td class="description-td">2</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Ciclesonide</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="6" align="center" rowsep="1" class="description-td" colspan="6"> </td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    </li> <li> <para-num num="[0369]"> </para-num> <div id="p-0421" num="0369" class="description-line">As outlined in Table 14, formulation characteristics were comparable between the two compositions. Particle size, polydispersity and payload encapsulation indicated uniform particle populations.</div>
    </li> <li> <div id="p-0422" num="0000" class="description-line">
      <tables id="TABLE-US-00014" num="00014">
        <patent-tables frame="none" colsep="0" rowsep="0">
          <table align="left" colsep="0" rowsep="0" cols="1" class="description-table" width="100%">
            <thead>
              <tr class="description-tr">
                <td namest="1" nameend="1" rowsep="1" class="description-td" colspan="1">TABLE 14</td>
              </tr>
            </thead>
            
              <tbody><tr class="description-tr">
                <td namest="1" nameend="1" align="center" rowsep="1" class="description-td" colspan="1"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Characterization of 1.1:55 Base vs LNP containing Clobetasol</td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="5" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td"> </td>
                <td class="description-td">Z-avg</td>
                <td class="description-td"> </td>
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">Formulation</td>
                <td class="description-td">(nm)</td>
                <td class="description-td">PDI</td>
                <td class="description-td">% Encap</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td namest="offset" nameend="4" align="center" rowsep="1" class="description-td" colspan="5"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">Base Formulation</td>
                <td class="description-td">78</td>
                <td class="description-td">0.06</td>
                <td class="description-td">96</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">Base + 2%</td>
                <td class="description-td">77</td>
                <td class="description-td">0.04</td>
                <td class="description-td">97</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">Ciclesonide</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td namest="offset" nameend="4" align="center" rowsep="1" class="description-td" colspan="5"> </td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    </li> <li> <para-num num="[0370]"> </para-num> <div id="p-0423" num="0370" class="description-line">The Ciclesonide LNP were tested in the LPS-primed mouse model, and compared to the Base formulation as well as Dex-P LNP. The Ciclesonide LNP also exhibited a significantly reduced inflammatory cytokine response, compared to the Base formulation. Data for a representative cytokine (MCP-1) is shown in Table 15.</div>
    </li> <li> <div id="p-0424" num="0000" class="description-line">
      <tables id="TABLE-US-00015" num="00015">
        <patent-tables frame="none" colsep="0" rowsep="0">
          <table align="left" colsep="0" rowsep="0" cols="1" class="description-table" width="100%">
            <thead>
              <tr class="description-tr">
                <td namest="1" nameend="1" rowsep="1" class="description-td" colspan="1">TABLE 15</td>
              </tr>
            </thead>
            
              <tbody><tr class="description-tr">
                <td namest="1" nameend="1" align="center" rowsep="1" class="description-td" colspan="1"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">MCP-1 ELISA Results of Base Composition vs LNP containing</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Steroid in LPS-primed Cytokine Mouse Model</td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="4" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td"> </td>
                <td class="description-td">Average MCP-1</td>
                <td class="description-td">Stdev</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Pre-Treatment</td>
                <td class="description-td">Treatment</td>
                <td class="description-td">(pg/mL)</td>
                <td class="description-td">(pg/mL)</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="4" align="center" rowsep="1" class="description-td" colspan="4"> </td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="4" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td">PBS</td>
                <td class="description-td">PBS</td>
                <td class="description-td">170</td>
                <td class="description-td">9</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">LPS</td>
                <td class="description-td">PBS</td>
                <td class="description-td">6012</td>
                <td class="description-td">2774</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">LPS</td>
                <td class="description-td">1.1:55 (âBaseâ)</td>
                <td class="description-td">54909</td>
                <td class="description-td">18542</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">LPS</td>
                <td class="description-td">Base + 2% Dex-P</td>
                <td class="description-td">26468</td>
                <td class="description-td">4561</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">LPS</td>
                <td class="description-td">Base + 2% Ciclesonide</td>
                <td class="description-td">17913</td>
                <td class="description-td">4352</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="4" align="center" rowsep="1" class="description-td" colspan="4"> </td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    </li> <heading id="h-0056">Example 9</heading>
    <heading id="h-0057">Activity of LNP Containing Ciclesonide</heading>
    <li> <para-num num="[0371]"> </para-num> <div id="p-0425" num="0371" class="description-line">Ciclesonide LNP were also assessed in the Activity Model described in General Procedures. Like Dex-P LNP, the Ciclesonide LNP exhibited similar potency to the Base Formulation (Table 16).</div>
    </li> <li> <div id="p-0426" num="0000" class="description-line">
      <tables id="TABLE-US-00016" num="00016">
        <patent-tables frame="none" colsep="0" rowsep="0">
          <table align="left" colsep="0" rowsep="0" cols="1" class="description-table" width="100%">
            <thead>
              <tr class="description-tr">
                <td namest="1" nameend="1" rowsep="1" class="description-td" colspan="1">TABLE 16</td>
              </tr>
            </thead>
            
              <tbody><tr class="description-tr">
                <td namest="1" nameend="1" align="center" rowsep="1" class="description-td" colspan="1"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">ApoB Silencing Activity of 1.1:55 Base Composition</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">vs LNP containing Ciclesonide and Dex-P</td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="5" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td"> </td>
                <td class="description-td">Dose</td>
                <td class="description-td"> </td>
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">Treatment</td>
                <td class="description-td">(mg/kg)</td>
                <td class="description-td">% PBS</td>
                <td class="description-td">% Error</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td namest="offset" nameend="4" align="center" rowsep="1" class="description-td" colspan="5"> </td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="5" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">PBS</td>
                <td class="description-td">n/a<sup>1</sup> </td>
                <td class="description-td">100</td>
                <td class="description-td">17</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">1.1:55 (âBaseâ)</td>
                <td class="description-td">0.01</td>
                <td class="description-td">31</td>
                <td class="description-td">3</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td"> </td>
                <td class="description-td">0.025</td>
                <td class="description-td">16</td>
                <td class="description-td">2</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td"> </td>
                <td class="description-td">0.05</td>
                <td class="description-td">12</td>
                <td class="description-td">2</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">Base + 2% Dex-P</td>
                <td class="description-td">0.01</td>
                <td class="description-td">43</td>
                <td class="description-td">11</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td"> </td>
                <td class="description-td">0.025</td>
                <td class="description-td">17</td>
                <td class="description-td">9</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td"> </td>
                <td class="description-td">0.05</td>
                <td class="description-td">17</td>
                <td class="description-td">3</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">Base + 2%</td>
                <td class="description-td">0.01</td>
                <td class="description-td">48</td>
                <td class="description-td">16</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">Ciclesonide</td>
                <td class="description-td">0.025</td>
                <td class="description-td">27</td>
                <td class="description-td">2</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td"> </td>
                <td class="description-td">0.05</td>
                <td class="description-td">13</td>
                <td class="description-td">4</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td namest="offset" nameend="4" align="center" rowsep="1" class="description-td" colspan="5"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td namest="offset" nameend="4" align="left" id="FOO-00003" class="description-td" colspan="5"> <sup>1</sup>PBS administered intravenously at 10 mL/kg.</td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    </li> <heading id="h-0058">Example 10</heading>
    <heading id="h-0059">LNP Containing Clobetasol Reduced Immune-Stimulation in Non-Human Primates</heading>
    <li> <para-num num="[0372]"> </para-num> <div id="p-0427" num="0372" class="description-line">An intravenous pharmacology study was conducted in cynomolgus monkeys to evaluate a clobetasol LNP formulation, and compared to a control formulation (the âBase Formulationâ used previously). Similar to Example 5, an 8-fold greater concentration of clobetasol was input into the process to get the desired 1 mol % in the final composition (Table 17). A 40 mM acetate, pH 4.5 buffer was used to solubilize the nucleic acid.</div>
    </li> <li> <div id="p-0428" num="0000" class="description-line">
      <tables id="TABLE-US-00017" num="00017">
        <patent-tables frame="none" colsep="0" rowsep="0">
          <table align="left" colsep="0" rowsep="0" cols="1" class="description-table" width="100%">
            <thead>
              <tr class="description-tr">
                <td namest="1" nameend="1" rowsep="1" class="description-td" colspan="1">TABLE 17</td>
              </tr>
            </thead>
            
              <tbody><tr class="description-tr">
                <td namest="1" nameend="1" align="center" rowsep="1" class="description-td" colspan="1"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Lipid composition of 1.1:55 Base vs LNP containing Clobetasol</td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="2" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">Lipid Composition (mol %)</td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="6" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">PEG-2000-</td>
                <td class="description-td">Compound</td>
                <td class="description-td">Choles-</td>
                <td class="description-td"> </td>
                <td class="description-td">Clobe-</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">C-DMA</td>
                <td class="description-td">13</td>
                <td class="description-td">terol</td>
                <td class="description-td">DSPC</td>
                <td class="description-td">tasol</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td namest="offset" nameend="5" align="center" rowsep="1" class="description-td" colspan="6"> </td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="6" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td">1.1:55 (âBaseâ)</td>
                <td class="description-td">1.1</td>
                <td class="description-td">55</td>
                <td class="description-td">33</td>
                <td class="description-td">11</td>
                <td class="description-td">â</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Base + 1%</td>
                <td class="description-td">1.0</td>
                <td class="description-td">61</td>
                <td class="description-td">18.5</td>
                <td class="description-td">18.5</td>
                <td class="description-td">1</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Clobetasol</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="6" align="center" rowsep="1" class="description-td" colspan="6"> </td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    </li> <li> <para-num num="[0373]"> </para-num> <div id="p-0429" num="0373" class="description-line">LNP formulation was administered to a group of four cynomolgus monkeys (Cambodian origin; 2 males, 2 females, 2-5 years of age) via a 60 minute intravenous infusion at a dose of 2.0 mg/kg total siRNA. Blood draws at pre-dose and 2, 6, and 24 h post-infusion were tested for a panel of inflammatory markers. The clobetasol LNP demonstrated a significant reduction in a number of inflammatory markers, further confirming the effectiveness of this strategy. Table 18 compares MCP-1, IL-6, and IL-1ra (Interleukin-1 receptor antagonist) levels between the two compositions at 6 hours post-infusion.</div>
    </li> <li> <div id="p-0430" num="0000" class="description-line">
      <tables id="TABLE-US-00018" num="00018">
        <patent-tables frame="none" colsep="0" rowsep="0">
          <table align="left" colsep="0" rowsep="0" cols="1" class="description-table" width="100%">
            <thead>
              <tr class="description-tr">
                <td namest="1" nameend="1" rowsep="1" class="description-td" colspan="1">TABLE 18</td>
              </tr>
            </thead>
            
              <tbody><tr class="description-tr">
                <td namest="1" nameend="1" align="center" rowsep="1" class="description-td" colspan="1"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Comparison of Inflammatory Response (at 6 hours post-infusion)</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">to Base Composition vs LNP containing Clobetasol in</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Cynomolgus Monkeys</td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="7" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">Avg</td>
                <td class="description-td"> </td>
                <td class="description-td"> </td>
                <td class="description-td"> </td>
                <td class="description-td">Avg IL-</td>
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">MCP-1</td>
                <td class="description-td">Stdev</td>
                <td class="description-td">Avg IL-6</td>
                <td class="description-td">Stdev</td>
                <td class="description-td">1ra</td>
                <td class="description-td">Stdev</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Treatment</td>
                <td class="description-td">(pg/mL)</td>
                <td class="description-td">(pg/mL)</td>
                <td class="description-td">(pg/mL)</td>
                <td class="description-td">(pg/mL)</td>
                <td class="description-td">(pg/mL)</td>
                <td class="description-td">(pg/mL)</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="7" align="center" rowsep="1" class="description-td" colspan="7"> </td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="7" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td">Saline</td>
                <td class="description-td">660</td>
                <td class="description-td">334</td>
                <td class="description-td">26</td>
                <td class="description-td">31</td>
                <td class="description-td">420</td>
                <td class="description-td">344</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">1.1:55</td>
                <td class="description-td">5548</td>
                <td class="description-td">7280</td>
                <td class="description-td">703</td>
                <td class="description-td">1164</td>
                <td class="description-td">2571</td>
                <td class="description-td">3114</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">(âBaseâ)</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Base + 1%</td>
                <td class="description-td">214</td>
                <td class="description-td">28</td>
                <td class="description-td">7</td>
                <td class="description-td">3</td>
                <td class="description-td">204</td>
                <td class="description-td">160</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Clobetasol</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="7" align="center" rowsep="1" class="description-td" colspan="7"> </td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    </li> <heading id="h-0060">Example 11</heading>
    <heading id="h-0061">An Examination of the Cardiovascular Effects of a Single Infusion of LNP Formulations in Anesthetized Female Gottingen Mini-Pigs</heading>
    <li> <para-num num="[0374]"> </para-num> <div id="p-0431" num="0374" class="description-line">Test article-related effects of a single 1-hour infusion of LNP formulations on hemodynamic parameters and inflammatory biomarkers were evaluated in anesthetized female Gottingen mini-pigs. LNP were formulated with the compositions in Table 19. Similar to Example 5, an 8-fold greater concentration of clobetasol was input into the process to get the desired 1 mol % in the final composition. A 40 mM acetate, pH 4.5 buffer was used to solubilize the nucleic acid.</div>
    </li> <li> <div id="p-0432" num="0000" class="description-line">
      <tables id="TABLE-US-00019" num="00019">
        <patent-tables frame="none" colsep="0" rowsep="0">
          <table align="left" colsep="0" rowsep="0" cols="1" class="description-table" width="100%">
            <thead>
              <tr class="description-tr">
                <td namest="1" nameend="1" rowsep="1" class="description-td" colspan="1">TABLE 19</td>
              </tr>
            </thead>
            
              <tbody><tr class="description-tr">
                <td namest="1" nameend="1" align="center" rowsep="1" class="description-td" colspan="1"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Lipid composition of 1.1:55 Base vs LNP containing Clobetasol</td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="2" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">Lipid Composition (mol %)</td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="6" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">PEG-2000-</td>
                <td class="description-td">Compound</td>
                <td class="description-td">Choles-</td>
                <td class="description-td"> </td>
                <td class="description-td">Clobe-</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">C-DMA</td>
                <td class="description-td">13</td>
                <td class="description-td">terol</td>
                <td class="description-td">DSPC</td>
                <td class="description-td">tasol</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td namest="offset" nameend="5" align="center" rowsep="1" class="description-td" colspan="6"> </td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="6" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td">1.1:55 (âBaseâ)</td>
                <td class="description-td">1.1</td>
                <td class="description-td">55</td>
                <td class="description-td">33</td>
                <td class="description-td">11</td>
                <td class="description-td">â</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Base + 1%</td>
                <td class="description-td">1.0</td>
                <td class="description-td">61</td>
                <td class="description-td">18.5</td>
                <td class="description-td">18.5</td>
                <td class="description-td">1</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Clobetasol</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="6" align="center" rowsep="1" class="description-td" colspan="6"> </td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    </li> <li> <para-num num="[0375]"> </para-num> <div id="p-0433" num="0375" class="description-line">Three (3) naÃ¯ve mini-pigs were surgically instrumented and baseline data was collected prior to a single administration of vehicle (saline), base LNP, or clobetasol LNP via a 60 minute intravenous infusion. LNP formulations were administered at a dose of 0.3 mg/kg total nucleic acid. Just prior to the first infusion, and at approximately 5, 60, 90, 120, 180, and 240 minutes after the start of infusion, a blood sample was taken, processed to plasma and serum, and analyzed for cytokines and thromboxane (11-dehydrothromboxane B2). Hemodynamic data was collected continuously throughout the experiment, for a total time period of 4 hours. At 4 hours post-infusion, pigs were euthanized under anesthesia via barbiturate overdose.</div>
    </li> <li> <para-num num="[0376]"> </para-num> <div id="p-0434" num="0376" class="description-line">Treatment with the Base Formulation resulted in considerable, measureable increases in thromboxane (Table 20) and cytokines (Table 21) with the Base Formulation. Furthermore, hemodynamic changes such as increases in pulmonary artery pressure were observed (Table 22). These parameters are all indicative of an inflammatory response to the Base LNP that is suppressed by incorporation of clobetasol into the LNP formulation. This is likely a glucocorticoid-mediated inhibition of phospholipase A2 and transrepression of inflammatory cytokine transcription when the animals are treated with co-formulated steroid LNP.</div>
    </li> <li> <div id="p-0435" num="0000" class="description-line">
      <tables id="TABLE-US-00020" num="00020">
        <patent-tables frame="none" colsep="0" rowsep="0">
          <table align="left" colsep="0" rowsep="0" cols="1" class="description-table" width="100%">
            <thead>
              <tr class="description-tr">
                <td namest="1" nameend="1" rowsep="1" class="description-td" colspan="1">TABLE 20</td>
              </tr>
            </thead>
            
              <tbody><tr class="description-tr">
                <td namest="1" nameend="1" align="center" rowsep="1" class="description-td" colspan="1"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Comparison of Thromboxane Levels between 1.1:55 Base and</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">LNP containing Clobetasol in Anesthetized Mini-Pigs</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">TXB2 Change from Baseline (pg/mL)</td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="2" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">Time Relative to Start of Infusion (minutes)</td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="8" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">â15</td>
                <td class="description-td">5</td>
                <td class="description-td">60</td>
                <td class="description-td">90</td>
                <td class="description-td">120</td>
                <td class="description-td">180</td>
                <td class="description-td">240</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td namest="offset" nameend="7" align="center" rowsep="1" class="description-td" colspan="8"> </td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="9" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td">Saline</td>
                <td class="description-td">Mean</td>
                <td class="description-td">0.0</td>
                <td class="description-td">â9.2</td>
                <td class="description-td">1.5</td>
                <td class="description-td">â13.0</td>
                <td class="description-td">â13.0</td>
                <td class="description-td">â7.0</td>
                <td class="description-td">â9.0</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">sem</td>
                <td class="description-td">0.0</td>
                <td class="description-td">3.5</td>
                <td class="description-td">3.6</td>
                <td class="description-td">2.3</td>
                <td class="description-td">2.3</td>
                <td class="description-td">1.5</td>
                <td class="description-td">2.2</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">1.1:55 (âBaseâ)</td>
                <td class="description-td">Mean</td>
                <td class="description-td">0.0</td>
                <td class="description-td">4.8</td>
                <td class="description-td">21.5</td>
                <td class="description-td">24.4</td>
                <td class="description-td">19.4</td>
                <td class="description-td">14.0</td>
                <td class="description-td">4.8</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">sem</td>
                <td class="description-td">0.0</td>
                <td class="description-td">2.0</td>
                <td class="description-td">1.4</td>
                <td class="description-td">8.1</td>
                <td class="description-td">7.2</td>
                <td class="description-td">6.6</td>
                <td class="description-td">2.7</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Base + 1%</td>
                <td class="description-td">Mean</td>
                <td class="description-td">0.0</td>
                <td class="description-td">â7.3</td>
                <td class="description-td">9.9</td>
                <td class="description-td">â0.9</td>
                <td class="description-td">â0.1</td>
                <td class="description-td">â7.3</td>
                <td class="description-td">â7.3</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Clobetasol</td>
                <td class="description-td">sem</td>
                <td class="description-td">0.0</td>
                <td class="description-td">7.3</td>
                <td class="description-td">8.5</td>
                <td class="description-td">0.9</td>
                <td class="description-td">7.3</td>
                <td class="description-td">7.3</td>
                <td class="description-td">7.3</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="9" align="center" rowsep="1" class="description-td" colspan="9"> </td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    </li> <li> <div id="p-0436" num="0000" class="description-line">
      <tables id="TABLE-US-00021" num="00021">
        <patent-tables frame="none" colsep="0" rowsep="0">
          <table align="left" colsep="0" rowsep="0" cols="1" class="description-table" width="100%">
            <thead>
              <tr class="description-tr">
                <td namest="1" nameend="1" rowsep="1" class="description-td" colspan="1">TABLE 21</td>
              </tr>
            </thead>
            
              <tbody><tr class="description-tr">
                <td namest="1" nameend="1" align="center" rowsep="1" class="description-td" colspan="1"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Comparison of IL-6 Cytokine Levels between 1.1:55 Base and</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">LNP containing Clobetasol in Anesthetized Mini-Pigs</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Fold Change in IL-6 from Baseline</td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="2" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">Time Relative to Start of Infusion (minutes)</td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="8" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">â15</td>
                <td class="description-td">5</td>
                <td class="description-td">60</td>
                <td class="description-td">90</td>
                <td class="description-td">120</td>
                <td class="description-td">180</td>
                <td class="description-td">240</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td namest="offset" nameend="7" align="center" rowsep="1" class="description-td" colspan="8"> </td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="9" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td">Saline</td>
                <td class="description-td">Mean</td>
                <td class="description-td">1.0</td>
                <td class="description-td">0.9</td>
                <td class="description-td">3.3</td>
                <td class="description-td">5.4</td>
                <td class="description-td">8.0</td>
                <td class="description-td">16.6</td>
                <td class="description-td">40.3</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">sem</td>
                <td class="description-td">0.0</td>
                <td class="description-td">0.1</td>
                <td class="description-td">1.5</td>
                <td class="description-td">2.3</td>
                <td class="description-td">1.6</td>
                <td class="description-td">1.4</td>
                <td class="description-td">20.0</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">1.1:55 (âBaseâ)</td>
                <td class="description-td">Mean</td>
                <td class="description-td">1.0</td>
                <td class="description-td">1.0</td>
                <td class="description-td">4.2</td>
                <td class="description-td">9.0</td>
                <td class="description-td">21.4</td>
                <td class="description-td">76.5</td>
                <td class="description-td">210.5</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">sem</td>
                <td class="description-td">0.0</td>
                <td class="description-td">0.0</td>
                <td class="description-td">3.2</td>
                <td class="description-td">8.0</td>
                <td class="description-td">15.9</td>
                <td class="description-td">39.9</td>
                <td class="description-td">58.9</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Base + 1%</td>
                <td class="description-td">Mean</td>
                <td class="description-td">1.0</td>
                <td class="description-td">0.9</td>
                <td class="description-td">3.9</td>
                <td class="description-td">10.0</td>
                <td class="description-td">15.8</td>
                <td class="description-td">1.0</td>
                <td class="description-td">0.4</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Clobetasol</td>
                <td class="description-td">sem</td>
                <td class="description-td">0.0</td>
                <td class="description-td">0.5</td>
                <td class="description-td">2.9</td>
                <td class="description-td">9.0</td>
                <td class="description-td">14.7</td>
                <td class="description-td">0.6</td>
                <td class="description-td">0.3</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="9" align="center" rowsep="1" class="description-td" colspan="9"> </td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    </li> <li> <div id="p-0437" num="0000" class="description-line">
      <tables id="TABLE-US-00022" num="00022">
        <patent-tables frame="none" colsep="0" rowsep="0" pgwide="1">
          <table align="left" colsep="0" rowsep="0" cols="1" class="description-table" width="100%">
            <thead>
              <tr class="description-tr">
                <td namest="1" nameend="1" rowsep="1" class="description-td" colspan="1">TABLE 22</td>
              </tr>
            </thead>
            
              <tbody><tr class="description-tr">
                <td namest="1" nameend="1" align="center" rowsep="1" class="description-td" colspan="1"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Comparison of Mean Pulmonary Artery Pressure (PAP) between 1.1:55 Base</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">and LNP containing Clobetasol in Anesthetized Mini-Pigs</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Mean PAP - Change from Baseline (mmHg)</td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="2" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">Time Relative to Start of Infusion (minutes)</td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="11" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">â15</td>
                <td class="description-td">0</td>
                <td class="description-td">15</td>
                <td class="description-td">30</td>
                <td class="description-td">60</td>
                <td class="description-td">90</td>
                <td class="description-td">120</td>
                <td class="description-td">150</td>
                <td class="description-td">180</td>
                <td class="description-td">240</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td namest="offset" nameend="10" align="center" rowsep="1" class="description-td" colspan="11"> </td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="12" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td">Saline</td>
                <td class="description-td">Mean</td>
                <td class="description-td">0</td>
                <td class="description-td">0</td>
                <td class="description-td">0</td>
                <td class="description-td">0</td>
                <td class="description-td">0</td>
                <td class="description-td">0</td>
                <td class="description-td">0</td>
                <td class="description-td">0</td>
                <td class="description-td">0</td>
                <td class="description-td">0</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">sem</td>
                <td class="description-td">0</td>
                <td class="description-td">0</td>
                <td class="description-td">0</td>
                <td class="description-td">1</td>
                <td class="description-td">1</td>
                <td class="description-td">1</td>
                <td class="description-td">1</td>
                <td class="description-td">1</td>
                <td class="description-td">1</td>
                <td class="description-td">1</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">1.1:55 (âBaseâ)</td>
                <td class="description-td">Mean</td>
                <td class="description-td">0</td>
                <td class="description-td">0</td>
                <td class="description-td">4</td>
                <td class="description-td">1</td>
                <td class="description-td">4</td>
                <td class="description-td">6</td>
                <td class="description-td">4</td>
                <td class="description-td">3</td>
                <td class="description-td">2</td>
                <td class="description-td">1</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">sem</td>
                <td class="description-td">0</td>
                <td class="description-td">0</td>
                <td class="description-td">2</td>
                <td class="description-td">0</td>
                <td class="description-td">2</td>
                <td class="description-td">3</td>
                <td class="description-td">2</td>
                <td class="description-td">2</td>
                <td class="description-td">1</td>
                <td class="description-td">1</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Base + 1%</td>
                <td class="description-td">Mean</td>
                <td class="description-td">0</td>
                <td class="description-td">0</td>
                <td class="description-td">4</td>
                <td class="description-td">1</td>
                <td class="description-td">1</td>
                <td class="description-td">1</td>
                <td class="description-td">1</td>
                <td class="description-td">1</td>
                <td class="description-td">0</td>
                <td class="description-td">1</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Clobetasol</td>
                <td class="description-td">sem</td>
                <td class="description-td">0</td>
                <td class="description-td">0</td>
                <td class="description-td">0</td>
                <td class="description-td">0</td>
                <td class="description-td">1</td>
                <td class="description-td">1</td>
                <td class="description-td">1</td>
                <td class="description-td">0</td>
                <td class="description-td">0</td>
                <td class="description-td">1</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="12" align="center" rowsep="1" class="description-td" colspan="12"> </td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    </li> <heading id="h-0062">Example 12</heading>
    <heading id="h-0063">Co-Formulated Clobetasol is Effective at Reducing Immune Response to LNP Bearing mRNA Payloads</heading>
    <li> <para-num num="[0377]"> </para-num> <div id="p-0438" num="0377" class="description-line">The concept of steroid co-formulation with LNP was further tested bearing an mRNA payload. This example demonstrates how a reduction in mRNA-LNP immune stimulation can be achieved by incorporation of the corticosteroid clobetasol.</div>
    </li> <li> <para-num num="[0378]"> </para-num> <div id="p-0439" num="0378" class="description-line">LNP (PL-containing &amp; PL-free) were prepared by the direct dilution method described by Jeffs et al. In brief, lipid stocks were prepared in 100% ethanol at a total lipid concentration of 6-7 mg/mL. An mRNA transcript encoding Luciferase (TriLink BioTechnologies), a reporter gene, was solubilized in 40 mM EDTA, pH 4.5 at 0.366 mg/mL. Equal volumes of these solutions were combined in a T-connector at a flow rate of 250 mL/min, immediately diluting into PBS (4Ã volume of lipid stock) at pH 7.4. Ethanol was then removed and carrier buffer was replaced with PBS by dialysis (Slide-A-Lyzer unit, MWCO 10 k), dialyzing overnight against 100 volumes of PBS. Following dialysis the formulations were concentrated to Ë0.3 mg/mL using VivaSpin concentrator units (MWCO 100,000). As with siRNA formulations, the low log P of clobetasol necessitated it being input at Ë8Ã the amount desired in the final composition, as only Ë15% incorporates in the LNP particles. The remainder is lost during dialysis. The LNP samples were sterile filtered (0.2 Î¼m syringe filter) and sample concentration determined by RiboGreen Assay. Particle size and polydispersity were determined using a Malvern Nano Series Zetasizer. The amount of clobetasol and other lipids in the final composition was determined by UPLC and is displayed in Table 23.</div>
    </li> <li> <div id="p-0440" num="0000" class="description-line">
      <tables id="TABLE-US-00023" num="00023">
        <patent-tables frame="none" colsep="0" rowsep="0" pgwide="1">
          <table align="left" colsep="0" rowsep="0" cols="1" class="description-table" width="100%">
            <thead>
              <tr class="description-tr">
                <td namest="1" nameend="1" rowsep="1" class="description-td" colspan="1">TABLE 23</td>
              </tr>
            </thead>
            
              <tbody><tr class="description-tr">
                <td namest="1" nameend="1" align="center" rowsep="1" class="description-td" colspan="1"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Formulation characteristics of Base Formulation vs LNP containing Clobetasol</td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="3" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">Lipid Composition (mol %)</td>
                <td class="description-td">Characterization</td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="9" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">PEG2000-</td>
                <td class="description-td">Cmpd</td>
                <td class="description-td"> </td>
                <td class="description-td"> </td>
                <td class="description-td"> </td>
                <td class="description-td">Size</td>
                <td class="description-td"> </td>
                <td class="description-td">%</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">C-DMA</td>
                <td class="description-td">13</td>
                <td class="description-td">Cholesterol</td>
                <td class="description-td">Phospholipid<sup>1</sup> </td>
                <td class="description-td">Clobetasol</td>
                <td class="description-td">(nm)</td>
                <td class="description-td">PDI</td>
                <td class="description-td">Encap</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td namest="offset" nameend="8" align="center" rowsep="1" class="description-td" colspan="9"> </td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="9" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td">1.6:55</td>
                <td class="description-td">1.6</td>
                <td class="description-td">55</td>
                <td class="description-td">33</td>
                <td class="description-td">11</td>
                <td class="description-td">0</td>
                <td class="description-td">73</td>
                <td class="description-td">0.07</td>
                <td class="description-td">97</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Base</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Base +</td>
                <td class="description-td">1.6</td>
                <td class="description-td">55</td>
                <td class="description-td">33</td>
                <td class="description-td">11</td>
                <td class="description-td">1</td>
                <td class="description-td">67</td>
                <td class="description-td">0.04</td>
                <td class="description-td">96</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">1.0%</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Clobetasol</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="9" align="center" rowsep="1" class="description-td" colspan="9"> </td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="9" align="left" id="FOO-00004" class="description-td" colspan="9"> <sup>1</sup>1,2-di-O-octadecyl-sn-glycero-3-phosphocholine</td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    </li> <li> <para-num num="[0379]"> </para-num> <div id="p-0441" num="0379" class="description-line">Prior to injection formulations were diluted to 0.05 mg/mL. Balb/c mice (n=5) were injected at 0.5 mg/kg (mRNA) via the intravenous route through the lateral tail. Four hours following injection the animals were euthanized with a lethal dose of ketamine/xylazine. A small amount (20 Î¼L) of the terminal blood was collected into a tube containing 5 Î¼L of 50 mg/L heparin, while the rest of the blood was collected into sodium EDTA microtainer tubes. All of these tubes were centrifuged for 5 min at 16000Ãg &amp; 16Â° C. to isolate plasma. A small portion (Ë200 mg) of the left lateral lobe of the liver was collected and stored overnight in RNALater @4Â° C.</div>
    </li> <li> <para-num num="[0380]"> </para-num> <div id="p-0442" num="0380" class="description-line">The heparin plasma (diluted 1:4000 with ELISA Diluent) was used in a standard Murine EPO ELISA analysis (kit from R&amp;D Systems). As shown in Table 24, the incorporation of clobetasol within the mRNA-LNP possibly resulted in a slight reduction in potency, though likely within the boundary of experimental variability. The regular level of EPO seen within the plasma of these mice is 0.1-0.2 ng/mL. Therefore, the incorporation of clobetasol within the mRNA-LNP does not really affect the efficacy of the formulation.</div>
    </li> <li> <div id="p-0443" num="0000" class="description-line">
      <tables id="TABLE-US-00024" num="00024">
        <patent-tables frame="none" colsep="0" rowsep="0">
          <table align="left" colsep="0" rowsep="0" cols="1" class="description-table" width="100%">
            <thead>
              <tr class="description-tr">
                <td namest="1" nameend="1" rowsep="1" class="description-td" colspan="1">TABLE 24</td>
              </tr>
            </thead>
            
              <tbody><tr class="description-tr">
                <td namest="1" nameend="1" align="center" rowsep="1" class="description-td" colspan="1"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Efficacy of Murine mEPO-LNP in Liver 4 h Post-IV Administration</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">of Base Composition vs LNP containing Clobetasol</td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="4" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td"> </td>
                <td class="description-td">mEPO</td>
                <td class="description-td">Stdev</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">Treatment</td>
                <td class="description-td">(ng/mL)</td>
                <td class="description-td">(ng/mL)</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td namest="offset" nameend="3" align="center" rowsep="1" class="description-td" colspan="4"> </td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="4" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">1.6:55 (âBaseâ)</td>
                <td class="description-td">6041</td>
                <td class="description-td">1305</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">Base + Clobetasol</td>
                <td class="description-td">4438</td>
                <td class="description-td">781</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td namest="offset" nameend="3" align="center" rowsep="1" class="description-td" colspan="4"> </td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    </li> <li> <para-num num="[0381]"> </para-num> <div id="p-0444" num="0381" class="description-line">To assess the effect on immune stimulation, EDTA plasma samples were diluted (1:8) and analyzed for cytokines (MCP-1 and IL-6) by ELISA (ELISA assays and capture &amp; detection antibodies from BD Biosciences). Table 25 demonstrates that cytokine production is significantly reduced when clobetasol is incorporated in the formulation.</div>
    </li> <li> <div id="p-0445" num="0000" class="description-line">
      <tables id="TABLE-US-00025" num="00025">
        <patent-tables frame="none" colsep="0" rowsep="0">
          <table align="left" colsep="0" rowsep="0" cols="1" class="description-table" width="100%">
            <thead>
              <tr class="description-tr">
                <td namest="1" nameend="1" rowsep="1" class="description-td" colspan="1">TABLE 25</td>
              </tr>
            </thead>
            
              <tbody><tr class="description-tr">
                <td namest="1" nameend="1" align="center" rowsep="1" class="description-td" colspan="1"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">MCP-1 and IL-6 ELISA Results of Base Compositions</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">vs LNP containing Clobetasol</td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="5" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">MCP-1</td>
                <td class="description-td"> </td>
                <td class="description-td">IL-6</td>
                <td class="description-td"> </td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="6" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td"> </td>
                <td class="description-td">Average</td>
                <td class="description-td">Stdev</td>
                <td class="description-td">Average</td>
                <td class="description-td">Stdev</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">Treatment</td>
                <td class="description-td">(pg/mL)</td>
                <td class="description-td">(pg/mL)</td>
                <td class="description-td">(pg/mL)</td>
                <td class="description-td">(pg/mL)</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td namest="offset" nameend="5" align="center" rowsep="1" class="description-td" colspan="6"> </td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="6" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">PBS</td>
                <td class="description-td">57</td>
                <td class="description-td">4</td>
                <td class="description-td">15</td>
                <td class="description-td">3</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">1.6:55 (âBaseâ)</td>
                <td class="description-td">5911</td>
                <td class="description-td">3592</td>
                <td class="description-td">353</td>
                <td class="description-td">194</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">Base + Clobetasol</td>
                <td class="description-td">479</td>
                <td class="description-td">146</td>
                <td class="description-td">78</td>
                <td class="description-td">24</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td namest="offset" nameend="5" align="center" rowsep="1" class="description-td" colspan="6"> </td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    </li> <li> <para-num num="[0382]"> </para-num> <div id="p-0446" num="0382" class="description-line">The liver IFIT (Interferon Induced proteins with Tetratricopeptide repeats) response to the two formulations was also measured. The IFIT biomarker indicates a type I interferon response to the payload. Liver samples (20-25 mg) were homogenized and the QuantiGene 2.0 assay (Affymetrix) used to assess IFIT levels in the liver (normalized to the housekeeping gene GAPDH). Results are plotted as a fold increase over the PBS control group, and demonstrate that clobetasol co-formulation is also effective in suppressing the IFIT response to the mRNA payload (Table 26).</div>
    </li> <li> <div id="p-0447" num="0000" class="description-line">
      <tables id="TABLE-US-00026" num="00026">
        <patent-tables frame="none" colsep="0" rowsep="0">
          <table align="left" colsep="0" rowsep="0" cols="1" class="description-table" width="100%">
            <thead>
              <tr class="description-tr">
                <td namest="1" nameend="1" rowsep="1" class="description-td" colspan="1">TABLE 26</td>
              </tr>
            </thead>
            
              <tbody><tr class="description-tr">
                <td namest="1" nameend="1" align="center" rowsep="1" class="description-td" colspan="1"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Hepatic IFIT Induction of Base Composition</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">vs LNP containing Clobetasol</td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="4" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td"> </td>
                <td class="description-td">Fold Increase</td>
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">Treatment</td>
                <td class="description-td">Over PBS</td>
                <td class="description-td">Stdev</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td namest="offset" nameend="3" align="center" rowsep="1" class="description-td" colspan="4"> </td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="4" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">1.6:55 (âBaseâ)</td>
                <td class="description-td">591</td>
                <td class="description-td">116</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">Base + Clobetasol</td>
                <td class="description-td">334</td>
                <td class="description-td">31</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td namest="offset" nameend="3" align="center" rowsep="1" class="description-td" colspan="4"> </td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    </li> <li> <para-num num="[0383]"> </para-num> <div id="p-0448" num="0383" class="description-line">Taken together these results demonstrate that the incorporation of clobetasol into the LNP particle significantly abrogates the immune stimulation to mRNA-LNP, and an increase in the Therapeutic Index is observed.</div>
    </li> <heading id="h-0064">Example 13</heading>
    <heading id="h-0065">Co-Formulated Dexamethasone Palmitate is Effective at Reducing Immune Response to LNP Bearing mRNA Payloads</heading>
    <li> <para-num num="[0384]"> </para-num> <div id="p-0449" num="0384" class="description-line">This example demonstrates how a steroid pro-drug, dexamethasone 21-palmitate (Dex-P), can also be used to reduce inflammatory responses to LNP bearing and mRNA payload. An mRNA-LNP containing Dex-P was formulated as described in Example 12, with the compositions described in Table 27. A murine EPO mRNA transcript (TriLink BioTechnologies) was used for the payload.</div>
    </li> <li> <div id="p-0450" num="0000" class="description-line">
      <tables id="TABLE-US-00027" num="00027">
        <patent-tables frame="none" colsep="0" rowsep="0" pgwide="1">
          <table align="left" colsep="0" rowsep="0" cols="1" class="description-table" width="100%">
            <thead>
              <tr class="description-tr">
                <td namest="1" nameend="1" rowsep="1" class="description-td" colspan="1">TABLE 27</td>
              </tr>
            </thead>
            
              <tbody><tr class="description-tr">
                <td namest="1" nameend="1" align="center" rowsep="1" class="description-td" colspan="1"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Formulation characteristics of Base Formulation vs LNP containing Dex-P</td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="3" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">Lipid Composition (mol %)</td>
                <td class="description-td">Characterization</td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="9" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">PEG2000-</td>
                <td class="description-td">Cmpd</td>
                <td class="description-td"> </td>
                <td class="description-td"> </td>
                <td class="description-td"> </td>
                <td class="description-td">Size</td>
                <td class="description-td"> </td>
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">C-DMA</td>
                <td class="description-td">13</td>
                <td class="description-td">Cholesterol</td>
                <td class="description-td">DSPC</td>
                <td class="description-td">Dex-P</td>
                <td class="description-td">(nm)</td>
                <td class="description-td">PDI</td>
                <td class="description-td">% Encap</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td namest="offset" nameend="8" align="center" rowsep="1" class="description-td" colspan="9"> </td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="9" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td">1.1:55</td>
                <td class="description-td">1.1</td>
                <td class="description-td">55</td>
                <td class="description-td">33</td>
                <td class="description-td">11</td>
                <td class="description-td">0</td>
                <td class="description-td">85</td>
                <td class="description-td">0.06</td>
                <td class="description-td">97</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Base</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Base + 2%</td>
                <td class="description-td">1.1</td>
                <td class="description-td">55</td>
                <td class="description-td">33</td>
                <td class="description-td">11</td>
                <td class="description-td">2</td>
                <td class="description-td">81</td>
                <td class="description-td">0.05</td>
                <td class="description-td">97</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Dex-P</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="9" align="center" rowsep="1" class="description-td" colspan="9"> </td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    </li> <li> <para-num num="[0385]"> </para-num> <div id="p-0451" num="0385" class="description-line">The formulations were injected intravenously at a dose of 0.5 mg/kg (total mRNA) into Balb/C mice (n=5). Six hours following injection, the animals were euthanized with a lethal dose of ketamine/xylazine. A small amount (75 Î¼L) of the terminal blood was collected into a tube containing 5 Î¼L of 50 mg/L heparin, while the rest of the blood was collected into sodium EDTA microtainer tubes. Blood samples were centrifuged for 5 min at 16000Ãg &amp; 16Â° C. to isolate plasma.</div>
    </li> <li> <para-num num="[0386]"> </para-num> <div id="p-0452" num="0386" class="description-line">The heparin plasma (diluted 1:4000 with ELISA Diluent) was analyzed by ELISA for EPO levels (kit from R&amp;D Systems). As shown in Table 28, the incorporation of Dex-P within the mRNA-LNP possibly resulted in an increase in potency, though possibly within experimental variability.</div>
    </li> <li> <div id="p-0453" num="0000" class="description-line">
      <tables id="TABLE-US-00028" num="00028">
        <patent-tables frame="none" colsep="0" rowsep="0">
          <table align="left" colsep="0" rowsep="0" cols="1" class="description-table" width="100%">
            <thead>
              <tr class="description-tr">
                <td namest="1" nameend="1" rowsep="1" class="description-td" colspan="1">TABLE 28</td>
              </tr>
            </thead>
            
              <tbody><tr class="description-tr">
                <td namest="1" nameend="1" align="center" rowsep="1" class="description-td" colspan="1"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Efficacy of Murine mEPO-LNP in Liver 4 h Post-IV Administration</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">of Base Composition vs LNP containing Dex-P</td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="4" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td"> </td>
                <td class="description-td">mEPO</td>
                <td class="description-td">Stdev</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">Treatment</td>
                <td class="description-td">(ng/mL)</td>
                <td class="description-td">(ng/mL)</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td namest="offset" nameend="3" align="center" rowsep="1" class="description-td" colspan="4"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">1.1:55 (âBaseâ)</td>
                <td class="description-td">2009</td>
                <td class="description-td">1179</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">Base + 2% Dex-P</td>
                <td class="description-td">3659</td>
                <td class="description-td">1313</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td namest="offset" nameend="3" align="center" rowsep="1" class="description-td" colspan="4"> </td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    </li> <li> <para-num num="[0387]"> </para-num> <div id="p-0454" num="0387" class="description-line">EDTA plasma was analyzed by ELISA (BD Biosciences) for cytokine levels (MCP-1 &amp; IL-6). Table 29 demonstrates that incorporation of Dex-P into the mRNA-LNP yields a marked reduction in cytokine levels.</div>
    </li> <li> <div id="p-0455" num="0000" class="description-line">
      <tables id="TABLE-US-00029" num="00029">
        <patent-tables frame="none" colsep="0" rowsep="0">
          <table align="left" colsep="0" rowsep="0" cols="1" class="description-table" width="100%">
            <thead>
              <tr class="description-tr">
                <td namest="1" nameend="1" rowsep="1" class="description-td" colspan="1">TABLE 29</td>
              </tr>
            </thead>
            
              <tbody><tr class="description-tr">
                <td namest="1" nameend="1" align="center" rowsep="1" class="description-td" colspan="1"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">MCP-1 and IL-6 ELISA Results of Base</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Composition vs LNP containing Dex-P</td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="5" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">MCP-1</td>
                <td class="description-td"> </td>
                <td class="description-td">IL-6</td>
                <td class="description-td"> </td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="6" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td"> </td>
                <td class="description-td">Average</td>
                <td class="description-td">Stdev</td>
                <td class="description-td">Average</td>
                <td class="description-td">Stdev</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">Treatment</td>
                <td class="description-td">(pg/mL)</td>
                <td class="description-td">(pg/mL)</td>
                <td class="description-td">(pg/mL)</td>
                <td class="description-td">(pg/mL)</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td namest="offset" nameend="5" align="center" rowsep="1" class="description-td" colspan="6"> </td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="6" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">PBS</td>
                <td class="description-td">36</td>
                <td class="description-td">15</td>
                <td class="description-td">27</td>
                <td class="description-td">13</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">1.1:55 (âBaseâ)</td>
                <td class="description-td">4471</td>
                <td class="description-td">1279</td>
                <td class="description-td">515</td>
                <td class="description-td">194</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">Base + 2% Dex-P</td>
                <td class="description-td">1281</td>
                <td class="description-td">737</td>
                <td class="description-td">83</td>
                <td class="description-td">16</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td namest="offset" nameend="5" align="center" rowsep="1" class="description-td" colspan="6"> </td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
      </div> </li> <ul>
        <li id="ul0002-0001" num="0388">This data demonstrates that incorporation of dexamethasone-palmitate reduced the inflammatory response to mRNA-LNP, and results significantly improved therapeutic index for mRNA-LNP.</li>
      </ul>
    
    <heading id="h-0066">Examples 14-20</heading>
    <heading id="h-0067">Reduced or Absent Phospholipid and High PEG in LNP</heading>
    <li> <para-num num="[0389]"> </para-num> <div id="p-0456" num="0389" class="description-line">The presence of phospholipid can reduce the shelf-life of lipid nanoparticles (LNPs) because the phosphate ester bond is thought to be quite labile. Most or all the phospholipid was removed from LNPs to test the effect on shelf-life of LNP comprising mRNA. During these experiments, it was discovered that the immunogenicity of the formulations was greatly reduced without affecting potency. As described herein, certain embodiments of the present invention are directed to LNPs possessing the combination of low or absent phospholipid and higher than usual PEG. Interestingly, the combination of low phospholipid and high mol percent PEG reduces immunostimulation for mRNA more effectively than for siRNA.</div>
    </li> <li> <para-num num="[0390]"> </para-num> <div id="p-0457" num="0390" class="description-line">In certain embodiments, the amount of PEG is at least 3 mole percent (e.g., at least 3.1 mole percent, at least 3.2 mole percent, at least 3.3 mole percent, at least 3.4 mole percent, at least 3.5 mole percent, at least 3.6 mole percent, at least 3.7 mole percent, at least 3.8 mole percent, at least 3.9 mole percent, at least 4 mole percent).With respect to phospholipid, in certain embodiments, no phospholipid is used in the practice of the invention. In certain embodiments, the lipid particle comprises less than 2 mole percent phospholipid, e.g., 1.9 mol % phospholipid, 1.8 mol % phospholipid, 1.7 mol % phospholipid, 1.6 mol % phospholipid, 1.5 mol % phospholipid, 1.4 mol % phospholipid, 1.3 mol % phospholipid, 1.2 mol % phospholipid, 1.1 mol % phospholipid, 1.0 mol % phospholipid, 0.9 mol % phospholipid, 0.8 mol % phospholipid, 0.7 mol % phospholipid, 0.6 mol % phospholipid, 0.5 mol % phospholipid, 0.4 mol % phospholipid, 0.3 mol % phospholipid, 0.2 mol % phospholipid, 0.1 mol % phospholipid, or 0.0% phospholipid, e.g., less than 1.9 mol % phospholipid, less than 1.8 mol % phospholipid, less than 1.7 mol % phospholipid, less than 1.6 mol % phospholipid, less than 1.5 mol % phospholipid, less than 1.4 mol % phospholipid, less than 1.3 mol % phospholipid, less than 1.2 mol % phospholipid, less than 1.1 mol % phospholipid, less than 1.0 mol % phospholipid, less than 0.9 mol % phospholipid, less than 0.8 mol % phospholipid, less than 0.7 mol % phospholipid, less than 0.6 mol % phospholipid, less than 0.5 mol % phospholipid, less than 0.4 mol % phospholipid, less than 0.3 mol % phospholipid, less than 0.2 mol % phospholipid, less than 0.1 mol % phospholipid.</div>
    </li> <heading id="h-0068">General Procedures</heading>
    <li> <para-num num="[0391]"> </para-num> <div id="p-0458" num="0391" class="description-line">Lipid Nanoparticle Formulating</div>
    </li> <li> <para-num num="[0392]"> </para-num> <div id="p-0459" num="0392" class="description-line">LNP formulations were prepared by the LipoMixer method described by Jeffs et al, using either direct dilution or in-line dilution. Lipid compositions were as described, typically comprising 3 or 4 lipids in the molar ratios described. Lipids were solubilized in 100% ethanol at a total lipid concentration of approx. 12 mg/mL. Nucleic acid was solubilized in 20 mM EDTA, pH 4.5 when phospholipid is present in the LNP and in 40 mM EDTA, pH 4.5 in the absence of phospholipid. Equal volumes of these solutions were combined in a T-connector at a flow rate of 400 mL/min, immediately diluting (in-line or directly into) with PBS (4Ã volume of lipid stock) at pH 7.4. Ethanol was then removed and carrier buffer was replaced with PBS by either dialysis (Slide-A-Lyzer unit, MWCO 10 k) or tangential flow ultrafilitration using Midgee hoop cartridges (MWCO 500 k, GE Healthcare). The LNP samples were sterile filtered (0.2 Î¼m syringe filter) and sample concentration determined by either DENAX-HPLC or RiboGreen Assay. Particle size and polydispersity were determined using a Malvern Nano Series Zetasizer. Final lipid were determined by UPLC.</div>
    </li> <heading id="h-0069">Animal Models</heading>
    <li> <para-num num="[0393]"> </para-num> <div id="p-0460" num="0393" class="description-line">3 animal models were used to assess formulations; two models of immune stimulation, and one of potency. Descriptions as follows:</div>
    </li> <li> <para-num num="[0394]"> </para-num> <div id="p-0461" num="0394" class="description-line">LPS-Primed Cytokine Mouse Model</div>
    </li> <li> <para-num num="[0395]"> </para-num> <div id="p-0462" num="0395" class="description-line">Female ICR mice (n=5, 5-6 weeks old) are pre-treated with 0.05 mg/kg of lipopolysaccharide (LPS) at time=0 to prime the immune system. At t=2 h they receive LNP at a 1 mg/kg dose by intravenous administration. Blood samples are collected into sodium EDTA microtainer tubes at 4 h post-LNP treatment (terminal bleed) and are processed to plasma by centrifugation at 16000Ãg for 5 min at 16Â° C. Plasma samples are analyzed for IL-10, IL-6, and MCP-1 cytokine levels by ELISA.</div>
    </li> <li> <para-num num="[0396]"> </para-num> <div id="p-0463" num="0396" class="description-line">Acute Cytokine Mouse Model</div>
    </li> <li> <para-num num="[0397]"> </para-num> <div id="p-0464" num="0397" class="description-line">Female ICR mice (n=5, 5-6 weeks old) are treated with 10 mg/kg of LNP by intravenous administration. At 2 h post-treatment, blood is collected into tubes containing 50 mM EDTA via tail nicks and processed to plasma by centrifugation at 16000Ãg for 5 min at 16Â° C. At 6 h post-treatment, terminal blood samples are collected into sodium EDTA microtainer tubes and are processed to plasma using the same procedure as above. Plasma samples are analyzed by ELISA for IL-6 and MCP-1 cytokine levels.</div>
    </li> <li> <para-num num="[0398]"> </para-num> <div id="p-0465" num="0398" class="description-line">Activity Mouse Model</div>
    </li> <li> <para-num num="[0399]"> </para-num> <div id="p-0466" num="0399" class="description-line">LNP formulated with a siRNA targeting Apolipoprotein B. Administered IV to generate dose response curve (typical doses: 0.01 mg/kg to 0.05 mg/kg total siRNA encapsulated in LNP) in female Balb/C mice (n=3, 5-6 weeks old). Terminal time point is at 48 hours post-intravenous administration of LNP. The left liver lobe is collected into RNAlater and assayed for ApoB levels by QuantiGene 2.0 analysis. Results are normalized to the house keeping gene GAPDH, and expressed as a % of the PBS control. A group with an ApoB readout that is â20% of PBSâ has experienced more profound gene silencing activity than one with â80% of PBSâ.</div>
    </li> <heading id="h-0070">Example 14</heading>
    <heading id="h-0071">Removing Phospholipid from LNP Formulation Reduces Immune Stimulation without Impairing Potency</heading>
    <li> <para-num num="[0400]"> </para-num> <div id="p-0467" num="0400" class="description-line">Two LNP formulations were made with an oligonucleotide siRNA payload targeting Apolipoprotein B (ApoB). A âbaseâ composition, and another with the phospholipid omitted (âphospholipid freeâ, or âPL-freeâ). Composition details are outlined in Table 30.</div>
    </li> <li> <div id="p-0468" num="0000" class="description-line">
      <tables id="TABLE-US-00030" num="00030">
        <patent-tables frame="none" colsep="0" rowsep="0">
          <table align="left" colsep="0" rowsep="0" cols="1" class="description-table" width="100%">
            <thead>
              <tr class="description-tr">
                <td namest="1" nameend="1" rowsep="1" class="description-td" colspan="1">TABLE 30</td>
              </tr>
            </thead>
            
              <tbody><tr class="description-tr">
                <td namest="1" nameend="1" align="center" rowsep="1" class="description-td" colspan="1"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Lipid composition of a 1.6:55 (âBaseâ)</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">and 1.8:61 (âPL-freeâ) Formulation</td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="2" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">Lipid Composition (mol %)</td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="5" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">PEG-2000-C-</td>
                <td class="description-td">Cationic</td>
                <td class="description-td">Choles-</td>
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">DMA</td>
                <td class="description-td">Compound 13</td>
                <td class="description-td">terol</td>
                <td class="description-td">DSPC</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td namest="offset" nameend="4" align="center" rowsep="1" class="description-td" colspan="5"> </td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="5" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td">1.6:55 (âBaseâ)</td>
                <td class="description-td">1.6</td>
                <td class="description-td">55</td>
                <td class="description-td">33</td>
                <td class="description-td">11</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">1.8:61 (âPL-freeâ)</td>
                <td class="description-td">1.8</td>
                <td class="description-td">61</td>
                <td class="description-td">37</td>
                <td class="description-td">0</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="5" align="center" rowsep="1" class="description-td" colspan="5"> </td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    </li> <li> <para-num num="[0401]"> </para-num> <div id="p-0469" num="0401" class="description-line">In the LPS-primed mouse cytokine model, results clearly indicate that the PL-free LNP is less stimulatory than its parent composition that contains phospholipid (Table 31).</div>
    </li> <li> <div id="p-0470" num="0000" class="description-line">
      <tables id="TABLE-US-00031" num="00031">
        <patent-tables frame="none" colsep="0" rowsep="0">
          <table align="left" colsep="0" rowsep="0" cols="1" class="description-table" width="100%">
            <thead>
              <tr class="description-tr">
                <td namest="1" nameend="1" rowsep="1" class="description-td" colspan="1">TABLE 31</td>
              </tr>
            </thead>
            
              <tbody><tr class="description-tr">
                <td namest="1" nameend="1" align="center" rowsep="1" class="description-td" colspan="1"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">MCP-1 ELISA Results of Base Composition vs PL-free</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Composition in LPS-Primed Cytokine Mouse Model</td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="4" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td"> </td>
                <td class="description-td">Average MCP-1</td>
                <td class="description-td">Stdev</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Pre-Treatment</td>
                <td class="description-td">Treatment</td>
                <td class="description-td">(pg/mL)</td>
                <td class="description-td">(pg/mL)</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="4" align="center" rowsep="1" class="description-td" colspan="4"> </td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="4" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td">PBS</td>
                <td class="description-td">PBS</td>
                <td class="description-td">160</td>
                <td class="description-td">11</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">LPS</td>
                <td class="description-td">PBS</td>
                <td class="description-td">3237</td>
                <td class="description-td">782</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">LPS</td>
                <td class="description-td">1.6:55 (âBaseâ)</td>
                <td class="description-td">35691</td>
                <td class="description-td">17620</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">LPS</td>
                <td class="description-td">1.8:61 (âPL-freeâ)</td>
                <td class="description-td">10485</td>
                <td class="description-td">3545</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="4" align="center" rowsep="1" class="description-td" colspan="4"> </td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    </li> <li> <para-num num="[0402]"> </para-num> <div id="p-0471" num="0402" class="description-line">While reducing inflammatory responses is an important objective, it is also important that potency is not simultaneously impaired. The same panel of LNP were therefore assessed in the ApoB Silencing Activity Model (described under General Procedures). Gene silencing data (Table 32) reveals that removing the phospholipid does not impair potency.</div>
    </li> <li> <div id="p-0472" num="0000" class="description-line">
      <tables id="TABLE-US-00032" num="00032">
        <patent-tables frame="none" colsep="0" rowsep="0">
          <table align="left" colsep="0" rowsep="0" cols="1" class="description-table" width="100%">
            <thead>
              <tr class="description-tr">
                <td namest="1" nameend="1" rowsep="1" class="description-td" colspan="1">TABLE 32</td>
              </tr>
            </thead>
            
              <tbody><tr class="description-tr">
                <td namest="1" nameend="1" align="center" rowsep="1" class="description-td" colspan="1"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">ApoB Silencing Activity of Base Composition vs</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">PL-free Composition in Activity Mouse Model</td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="5" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td"> </td>
                <td class="description-td">Dose</td>
                <td class="description-td"> </td>
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">Treatment</td>
                <td class="description-td">(mg/kg)</td>
                <td class="description-td">% PBS</td>
                <td class="description-td">% Error</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td namest="offset" nameend="4" align="center" rowsep="1" class="description-td" colspan="5"> </td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="5" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">PBS</td>
                <td class="description-td">n/a<sup>1</sup> </td>
                <td class="description-td">100</td>
                <td class="description-td">9.2</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">1.6:55 (âBaseâ)</td>
                <td class="description-td">0.01</td>
                <td class="description-td">45</td>
                <td class="description-td">8.6</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td"> </td>
                <td class="description-td">0.025</td>
                <td class="description-td">17</td>
                <td class="description-td">2.1</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td"> </td>
                <td class="description-td">0.05</td>
                <td class="description-td">11</td>
                <td class="description-td">1.3</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">1.8:61 (âPL-freeâ)</td>
                <td class="description-td">0.01</td>
                <td class="description-td">43</td>
                <td class="description-td">8.6</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td"> </td>
                <td class="description-td">0.025</td>
                <td class="description-td">29</td>
                <td class="description-td">1.5</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td"> </td>
                <td class="description-td">0.05</td>
                <td class="description-td">20</td>
                <td class="description-td">5.2</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td namest="offset" nameend="4" align="center" rowsep="1" class="description-td" colspan="5"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td namest="offset" nameend="4" align="left" id="FOO-00005" class="description-td" colspan="5"> <sup>1</sup>PBS administered intravenously at 10 mL/kg.</td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    </li> <heading id="h-0072">Example 15</heading>
    <heading id="h-0073">Increasing PEG Lipid Content in Phospholipid-Free LNP Resulted in Further Reductions in Cytokine Levels, without Significantly Impacting Potency</heading>
    <li> <para-num num="[0403]"> </para-num> <div id="p-0473" num="0403" class="description-line">The following LNP were formulated using an ApoB siRNA payload. Starting from a âbaseâ composition, the phospholipid was first removed, and then PEG content either doubled or tripled (Table 33):</div>
    </li> <li> <div id="p-0474" num="0000" class="description-line"> <tables id="TABLE-US-00033" num="00033"> <patent-tables frame="none" colsep="0" rowsep="0"> <table align="left" colsep="0" rowsep="0" cols="1" class="description-table" width="100%"> <thead> <tr class="description-tr"> <td namest="1" nameend="1" rowsep="1" class="description-td" colspan="1">TABLE 33</td> </tr> </thead>  <tbody><tr class="description-tr"> <td namest="1" nameend="1" align="center" rowsep="1" class="description-td" colspan="1"> </td> </tr> <tr class="description-tr"> <td class="description-td">Lipid composition of a 1.1:55 Base and PL-</td> </tr> <tr class="description-tr"> <td class="description-td">free Formulations with Increasing PEG Content</td> </tr>  </tbody></table> <table align="left" colsep="0" rowsep="0" cols="2" class="description-table" width="100%"> <tbody><tr class="description-tr"> <td class="description-td"> </td> <td class="description-td">Lipid Composition (mol %)</td> </tr>  </tbody></table> <table align="left" colsep="0" rowsep="0" cols="5" class="description-table" width="100%"> <tbody><tr class="description-tr"> <td class="description-td"> </td> <td class="description-td">PEG-2000-C-</td> <td class="description-td">Cationic</td> <td class="description-td">Choles-</td> <td class="description-td"> </td> </tr> <tr class="description-tr"> <td class="description-td"> </td> <td class="description-td">DMA</td> <td class="description-td">Compound 13</td> <td class="description-td">terol</td> <td class="description-td">DSPC</td> </tr> <tr class="description-tr"> <td class="description-td"> </td> <td namest="offset" nameend="4" align="center" rowsep="1" class="description-td" colspan="5"> </td> </tr>  </tbody></table> <table align="left" colsep="0" rowsep="0" cols="5" class="description-table" width="100%"> <tbody><tr class="description-tr"> <td class="description-td">1.1:55 (âBaseâ)</td> <td class="description-td">1.1</td> <td class="description-td">55</td> <td class="description-td">33</td> <td class="description-td">11</td> </tr> <tr class="description-tr"> <td class="description-td">1.1:57 (PL-free)</td> <td class="description-td">1.1</td> <td class="description-td">57</td> <td class="description-td">42</td> <td class="description-td">0</td> </tr> <tr class="description-tr"> <td class="description-td">2.2:56 (PL-free)</td> <td class="description-td">2.2</td> <td class="description-td">56</td> <td class="description-td">42</td> <td class="description-td">0</td> </tr> <tr class="description-tr"> <td class="description-td">3.3:55 (PL-free)</td> <td class="description-td">3.3</td> <td class="description-td">55</td> <td class="description-td">41</td> <td class="description-td">0</td> </tr> <tr class="description-tr"> <td namest="1" nameend="5" align="center" rowsep="1" class="description-td" colspan="5"> </td> </tr>  </tbody></table> </patent-tables> </tables> <br/>
This panel of LNP was evaluated in the acute mouse cytokine model, with time points at 2 h and 6 h. Again a reduction in cytokines was observed when phospholipid was removed from the composition. Representative cytokine data (MCP-1) is displayed in Table 34. Subsequently, as the PEG content was increased, an even more pronounced reduction in cytokines was observed.
</div>
    </li> <li> <div id="p-0475" num="0000" class="description-line">
      <tables id="TABLE-US-00034" num="00034">
        <patent-tables frame="none" colsep="0" rowsep="0">
          <table align="left" colsep="0" rowsep="0" cols="1" class="description-table" width="100%">
            <thead>
              <tr class="description-tr">
                <td namest="1" nameend="1" rowsep="1" class="description-td" colspan="1">TABLE 34</td>
              </tr>
            </thead>
            
              <tbody><tr class="description-tr">
                <td namest="1" nameend="1" align="center" rowsep="1" class="description-td" colspan="1"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">MCP-1 ELISA Results of 1.1:55 Base Composition</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">vs PL-free Compositions with Increasing PEG Lipid</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Content in Acute Cytokine Mouse Model</td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="5" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">2 h</td>
                <td class="description-td"> </td>
                <td class="description-td">6 h</td>
                <td class="description-td"> </td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="6" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td"> </td>
                <td class="description-td">Average</td>
                <td class="description-td"> </td>
                <td class="description-td">Average</td>
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td"> </td>
                <td class="description-td">MCP-1</td>
                <td class="description-td">Stdev</td>
                <td class="description-td">MCP-1</td>
                <td class="description-td">Stdev</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">Treatment</td>
                <td class="description-td">(pg/mL)</td>
                <td class="description-td">(pg/mL)</td>
                <td class="description-td">(pg/mL)</td>
                <td class="description-td">(pg/mL)</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td namest="offset" nameend="5" align="center" rowsep="1" class="description-td" colspan="6"> </td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="6" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">PBS</td>
                <td class="description-td">29</td>
                <td class="description-td">4</td>
                <td class="description-td">36</td>
                <td class="description-td">6</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">1.1:55 (âBaseâ)</td>
                <td class="description-td">1967</td>
                <td class="description-td">916</td>
                <td class="description-td">973</td>
                <td class="description-td">801</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">1.1:57 (PL-free)</td>
                <td class="description-td">1072</td>
                <td class="description-td">317</td>
                <td class="description-td">745</td>
                <td class="description-td">342</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">2.2:56 (PL-free)</td>
                <td class="description-td">704</td>
                <td class="description-td">147</td>
                <td class="description-td">183</td>
                <td class="description-td">73</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">3.3:55 (PL-free)</td>
                <td class="description-td">157</td>
                <td class="description-td">72</td>
                <td class="description-td">45</td>
                <td class="description-td">7</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td namest="offset" nameend="5" align="center" rowsep="1" class="description-td" colspan="6"> </td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
      </div> </li> <ul>
        <li id="ul0003-0001" num="0404">Interestingly, the potency of these high PEG, PL-free compositions was not significantly impacted (Table 35). In previous experience, formulations with higher PEG content were often found to have compromised activity. For example three (3) related LNP in a similar PEG titration series (Table 36), but with a standard phospholipid content, were evaluated and representative activity data is shown in Table 37. A significant attenuation of activity if observed as PEG content increases. It is therefore surprising to see the significant reduction in cytokines without a more profound, commensurate loss of potency with the high PEG, PL-free systems above.</li>
      </ul>
    
    <li> <div id="p-0476" num="0000" class="description-line">
      <tables id="TABLE-US-00035" num="00035">
        <patent-tables frame="none" colsep="0" rowsep="0">
          <table align="left" colsep="0" rowsep="0" cols="1" class="description-table" width="100%">
            <thead>
              <tr class="description-tr">
                <td namest="1" nameend="1" rowsep="1" class="description-td" colspan="1">TABLE 35</td>
              </tr>
            </thead>
            
              <tbody><tr class="description-tr">
                <td namest="1" nameend="1" align="center" rowsep="1" class="description-td" colspan="1"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">ApoB Silencing Activity of 1.1:55 Base Composition</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">vs PL-free Compositions with Increasing PEG</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Lipid Content in Activity Mouse Model</td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="5" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td"> </td>
                <td class="description-td">Dose</td>
                <td class="description-td"> </td>
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">Treatment</td>
                <td class="description-td">(mg/kg)</td>
                <td class="description-td">% PBS</td>
                <td class="description-td">% Error</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td namest="offset" nameend="4" align="center" rowsep="1" class="description-td" colspan="5"> </td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="5" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">PBS</td>
                <td class="description-td">n/a<sup>1</sup> </td>
                <td class="description-td">100</td>
                <td class="description-td">13</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">1.1:55 (âBaseâ)</td>
                <td class="description-td">0.01</td>
                <td class="description-td">37</td>
                <td class="description-td">2</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td"> </td>
                <td class="description-td">0.025</td>
                <td class="description-td">15</td>
                <td class="description-td">2</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td"> </td>
                <td class="description-td">0.05</td>
                <td class="description-td">9</td>
                <td class="description-td">3</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">1.1:57 (âPL-freeâ)</td>
                <td class="description-td">0.01</td>
                <td class="description-td">37</td>
                <td class="description-td">7</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td"> </td>
                <td class="description-td">0.025</td>
                <td class="description-td">21</td>
                <td class="description-td">5</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td"> </td>
                <td class="description-td">0.05</td>
                <td class="description-td">12</td>
                <td class="description-td">2</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">2.2:56 (âPL-free)</td>
                <td class="description-td">0.01</td>
                <td class="description-td">45</td>
                <td class="description-td">7</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td"> </td>
                <td class="description-td">0.025</td>
                <td class="description-td">20</td>
                <td class="description-td">5</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td"> </td>
                <td class="description-td">0.05</td>
                <td class="description-td">11</td>
                <td class="description-td">2</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">3.3:55 (âPL-freeâ)</td>
                <td class="description-td">0.01</td>
                <td class="description-td">48</td>
                <td class="description-td">7</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td"> </td>
                <td class="description-td">0.025</td>
                <td class="description-td">31</td>
                <td class="description-td">8</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td"> </td>
                <td class="description-td">0.05</td>
                <td class="description-td">22</td>
                <td class="description-td">6</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td namest="offset" nameend="4" align="center" rowsep="1" class="description-td" colspan="5"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td namest="offset" nameend="4" align="left" id="FOO-00006" class="description-td" colspan="5"> <sup>1</sup>PBS administered intravenously at 10 mL/kg.</td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    </li> <li> <div id="p-0477" num="0000" class="description-line">
      <tables id="TABLE-US-00036" num="00036">
        <patent-tables frame="none" colsep="0" rowsep="0">
          <table align="left" colsep="0" rowsep="0" cols="1" class="description-table" width="100%">
            <thead>
              <tr class="description-tr">
                <td namest="1" nameend="1" rowsep="1" class="description-td" colspan="1">TABLE 36</td>
              </tr>
            </thead>
            
              <tbody><tr class="description-tr">
                <td namest="1" nameend="1" align="center" rowsep="1" class="description-td" colspan="1"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Lipid composition of a 1.1:55 Base and PL-</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">containing LNP with Increasing PEG Content</td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="2" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">Lipid Composition (mol %)</td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="5" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">PEG-2000-C-</td>
                <td class="description-td">Cationic</td>
                <td class="description-td">Choles-</td>
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">DMA</td>
                <td class="description-td">Compound 13</td>
                <td class="description-td">terol</td>
                <td class="description-td">DSPC</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td namest="offset" nameend="4" align="center" rowsep="1" class="description-td" colspan="5"> </td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="5" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td">1.1:55 (âBaseâ)</td>
                <td class="description-td">1.1</td>
                <td class="description-td">55</td>
                <td class="description-td">33</td>
                <td class="description-td">11</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">2.2:54</td>
                <td class="description-td">2.2</td>
                <td class="description-td">54</td>
                <td class="description-td">33</td>
                <td class="description-td">11</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">4.3:53</td>
                <td class="description-td">4.3</td>
                <td class="description-td">53</td>
                <td class="description-td">32</td>
                <td class="description-td">11</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="5" align="center" rowsep="1" class="description-td" colspan="5"> </td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    </li> <li> <div id="p-0478" num="0000" class="description-line">
      <tables id="TABLE-US-00037" num="00037">
        <patent-tables frame="none" colsep="0" rowsep="0">
          <table align="left" colsep="0" rowsep="0" cols="1" class="description-table" width="100%">
            <thead>
              <tr class="description-tr">
                <td namest="1" nameend="1" rowsep="1" class="description-td" colspan="1">TABLE 37</td>
              </tr>
            </thead>
            
              <tbody><tr class="description-tr">
                <td namest="1" nameend="1" align="center" rowsep="1" class="description-td" colspan="1"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">ApoB Silencing Activity of 1.1:55 Base and PL-containing</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">LNP with Increasing PEG content in Activity Mouse Model</td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="5" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td"> </td>
                <td class="description-td">Dose</td>
                <td class="description-td"> </td>
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">Treatment</td>
                <td class="description-td">(mg/kg)</td>
                <td class="description-td">% PBS</td>
                <td class="description-td">% Error</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td namest="offset" nameend="4" align="center" rowsep="1" class="description-td" colspan="5"> </td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="5" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">PBS</td>
                <td class="description-td">n/a<sup>1</sup> </td>
                <td class="description-td">100</td>
                <td class="description-td">30</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">1.1:55 (âBaseâ)</td>
                <td class="description-td">0.05</td>
                <td class="description-td">16</td>
                <td class="description-td">5</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">2.2:55</td>
                <td class="description-td">0.05</td>
                <td class="description-td">33</td>
                <td class="description-td">3</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">4.4:55</td>
                <td class="description-td">0.05</td>
                <td class="description-td">100</td>
                <td class="description-td">38</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td namest="offset" nameend="4" align="center" rowsep="1" class="description-td" colspan="5"> </td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    </li> <heading id="h-0074">Example 16</heading>
    <heading id="h-0075">Reduction in Phospholipid Content also Effective at Reducing Inflammatory Response</heading>
    <li> <para-num num="[0405]"> </para-num> <div id="p-0479" num="0405" class="description-line">It was hypothesized that it may not be necessary to completely remove phospholipid from the LNP formulation to abrogate immune stimulation, and that this effect can be achieved by simply reducing the PL content. A panel of compositions was prepared (Table 38), using reduced PL content (3 mol % or 8 mol %) vs the parent composition (11 mol %):</div>
    </li> <li> <div id="p-0480" num="0000" class="description-line"> <tables id="TABLE-US-00038" num="00038"> <patent-tables frame="none" colsep="0" rowsep="0"> <table align="left" colsep="0" rowsep="0" cols="1" class="description-table" width="100%"> <thead> <tr class="description-tr"> <td namest="1" nameend="1" rowsep="1" class="description-td" colspan="1">TABLE 38</td> </tr> </thead>  <tbody><tr class="description-tr"> <td namest="1" nameend="1" align="center" rowsep="1" class="description-td" colspan="1"> </td> </tr> <tr class="description-tr"> <td class="description-td">Lipid composition of a 1.1:55 Base and PL-</td> </tr> <tr class="description-tr"> <td class="description-td">containing LNP with Reduced PL Content</td> </tr>  </tbody></table> <table align="left" colsep="0" rowsep="0" cols="2" class="description-table" width="100%"> <tbody><tr class="description-tr"> <td class="description-td"> </td> <td class="description-td">Lipid Composition (mol %)</td> </tr>  </tbody></table> <table align="left" colsep="0" rowsep="0" cols="5" class="description-table" width="100%"> <tbody><tr class="description-tr"> <td class="description-td"> </td> <td class="description-td">PEG-2000-C-</td> <td class="description-td">Cationic</td> <td class="description-td">Choles-</td> <td class="description-td"> </td> </tr> <tr class="description-tr"> <td class="description-td"> </td> <td class="description-td">DMA</td> <td class="description-td">Compound 13</td> <td class="description-td">terol</td> <td class="description-td">DSPC</td> </tr> <tr class="description-tr"> <td class="description-td"> </td> <td namest="offset" nameend="4" align="center" rowsep="1" class="description-td" colspan="5"> </td> </tr>  </tbody></table> <table align="left" colsep="0" rowsep="0" cols="5" class="description-table" width="100%"> <tbody><tr class="description-tr"> <td class="description-td">1.1:55 (âBaseâ)</td> <td class="description-td">1.1</td> <td class="description-td">55</td> <td class="description-td">33</td> <td class="description-td">11</td> </tr> <tr class="description-tr"> <td class="description-td">1.1:57</td> <td class="description-td">1.1</td> <td class="description-td">57</td> <td class="description-td">34</td> <td class="description-td">8</td> </tr> <tr class="description-tr"> <td class="description-td">1.1:55</td> <td class="description-td">1.1</td> <td class="description-td">55</td> <td class="description-td">41</td> <td class="description-td">3</td> </tr> <tr class="description-tr"> <td class="description-td">1.6:52</td> <td class="description-td">1.6</td> <td class="description-td">52</td> <td class="description-td">39</td> <td class="description-td">8</td> </tr> <tr class="description-tr"> <td class="description-td">1.6:55</td> <td class="description-td">1.6</td> <td class="description-td">55</td> <td class="description-td">41</td> <td class="description-td">3</td> </tr> <tr class="description-tr"> <td namest="1" nameend="5" align="center" rowsep="1" class="description-td" colspan="5"> </td> </tr>  </tbody></table> </patent-tables> </tables> <br/>
These compositions were assessed for immune stimulation in the acute cytokine model. As seen in Table 39, the compositions with reduced phospholipid had a reduced tendency to stimulate the production of cytokines. Further, reduction of phospholipid content had no significant impact on potency (Table 40).
</div>
    </li> <li> <div id="p-0481" num="0000" class="description-line">
      <tables id="TABLE-US-00039" num="00039">
        <patent-tables frame="none" colsep="0" rowsep="0">
          <table align="left" colsep="0" rowsep="0" cols="1" class="description-table" width="100%">
            <thead>
              <tr class="description-tr">
                <td namest="1" nameend="1" rowsep="1" class="description-td" colspan="1">TABLE 39</td>
              </tr>
            </thead>
            
              <tbody><tr class="description-tr">
                <td namest="1" nameend="1" align="center" rowsep="1" class="description-td" colspan="1"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">MCP-1 ELISA Results of 1.1:55 Base vs PL-containing LNP</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">with Reduced PL Content in Acute Cytokine Mouse Model</td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="5" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">2 h</td>
                <td class="description-td"> </td>
                <td class="description-td">6 h</td>
                <td class="description-td"> </td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="6" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td"> </td>
                <td class="description-td">Average</td>
                <td class="description-td"> </td>
                <td class="description-td">Average</td>
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td"> </td>
                <td class="description-td">MCP-1</td>
                <td class="description-td">Stdev</td>
                <td class="description-td">MCP-1</td>
                <td class="description-td">Stdev</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">Treatment</td>
                <td class="description-td">(pg/mL)</td>
                <td class="description-td">(pg/mL)</td>
                <td class="description-td">(pg/mL)</td>
                <td class="description-td">(pg/mL)</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td namest="offset" nameend="5" align="center" rowsep="1" class="description-td" colspan="6"> </td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="6" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">PBS</td>
                <td class="description-td">721</td>
                <td class="description-td">487</td>
                <td class="description-td">85</td>
                <td class="description-td">23</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">1.1:55 (âBaseâ)</td>
                <td class="description-td">3644</td>
                <td class="description-td">3250</td>
                <td class="description-td">894</td>
                <td class="description-td">759</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">1.1:57</td>
                <td class="description-td">831</td>
                <td class="description-td">786</td>
                <td class="description-td">388</td>
                <td class="description-td">295</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">1.1:55</td>
                <td class="description-td">335</td>
                <td class="description-td">213</td>
                <td class="description-td">117</td>
                <td class="description-td">39</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">1.6:52</td>
                <td class="description-td">447</td>
                <td class="description-td">174</td>
                <td class="description-td">76</td>
                <td class="description-td">14</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">1.6:55</td>
                <td class="description-td">221</td>
                <td class="description-td">159</td>
                <td class="description-td">91</td>
                <td class="description-td">35</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td namest="offset" nameend="5" align="center" rowsep="1" class="description-td" colspan="6"> </td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    </li> <li> <div id="p-0482" num="0000" class="description-line">
      <tables id="TABLE-US-00040" num="00040">
        <patent-tables frame="none" colsep="0" rowsep="0">
          <table align="left" colsep="0" rowsep="0" cols="1" class="description-table" width="100%">
            <thead>
              <tr class="description-tr">
                <td namest="1" nameend="1" rowsep="1" class="description-td" colspan="1">TABLE 40</td>
              </tr>
            </thead>
            
              <tbody><tr class="description-tr">
                <td namest="1" nameend="1" align="center" rowsep="1" class="description-td" colspan="1"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">ApoB Silencing Activity of 1.1:55 Base Composition vs PL-</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">containing LNP with Reduced PL Content in Mouse Model</td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="5" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td"> </td>
                <td class="description-td">Dose</td>
                <td class="description-td"> </td>
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">Treatment</td>
                <td class="description-td">(mg/kg)</td>
                <td class="description-td">% PBS</td>
                <td class="description-td">% Error</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td namest="offset" nameend="4" align="center" rowsep="1" class="description-td" colspan="5"> </td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="5" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">PBS</td>
                <td class="description-td">n/a<sup>1</sup> </td>
                <td class="description-td">100</td>
                <td class="description-td">6</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">1.1:55 (âBaseâ)</td>
                <td class="description-td">0.01</td>
                <td class="description-td">47</td>
                <td class="description-td">4</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td"> </td>
                <td class="description-td">0.025</td>
                <td class="description-td">18</td>
                <td class="description-td">2</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">1.1:57</td>
                <td class="description-td">0.01</td>
                <td class="description-td">37</td>
                <td class="description-td">4</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td"> </td>
                <td class="description-td">0.025</td>
                <td class="description-td">15</td>
                <td class="description-td">2</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">1.1:55</td>
                <td class="description-td">0.01</td>
                <td class="description-td">60</td>
                <td class="description-td">13</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td"> </td>
                <td class="description-td">0.025</td>
                <td class="description-td">20</td>
                <td class="description-td">5</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">1.6:52</td>
                <td class="description-td">0.01</td>
                <td class="description-td">66</td>
                <td class="description-td">14</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td"> </td>
                <td class="description-td">0.025</td>
                <td class="description-td">27</td>
                <td class="description-td">3</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">1.6:55</td>
                <td class="description-td">0.01</td>
                <td class="description-td">46</td>
                <td class="description-td">10</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td"> </td>
                <td class="description-td">0.025</td>
                <td class="description-td">28</td>
                <td class="description-td">2</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td namest="offset" nameend="4" align="center" rowsep="1" class="description-td" colspan="5"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td namest="offset" nameend="4" align="left" id="FOO-00007" class="description-td" colspan="5"> <sup>1</sup>PBS administered intravenously at 10 mL/kg.</td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    </li> <heading id="h-0076">Example 17</heading>
    <heading id="h-0077">Removing Phospholipid Reduces Immune Stimulation of LNP Containing mRNA without Impairing Potency</heading>
    <li> <para-num num="[0406]"> </para-num> <div id="p-0483" num="0406" class="description-line">This example demonstrates how a reduction in mRNA-LNP immune stimulation can be achieved by removing the phospholipid from the LNP composition (i.e. production of a PL-free mRNA-LNP). The mRNA-LNP formulations were made with the lipid compositions shown in Table 41. Two different base formulations (1.1:55 and 1.6:55) had their phospholipid content removed (âPL-freeâ compositions), whilst either maintaining or slightly increasing the cholesterol content.</div>
    </li> <li> <div id="p-0484" num="0000" class="description-line">
      <tables id="TABLE-US-00041" num="00041">
        <patent-tables frame="none" colsep="0" rowsep="0" pgwide="1">
          <table align="left" colsep="0" rowsep="0" cols="1" class="description-table" width="100%">
            <thead>
              <tr class="description-tr">
                <td namest="1" nameend="1" rowsep="1" class="description-td" colspan="1">TABLE 41</td>
              </tr>
            </thead>
            
              <tbody><tr class="description-tr">
                <td namest="1" nameend="1" align="center" rowsep="1" class="description-td" colspan="1"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Formulation characteristics of Base Formulations vs PL-free mLuc-LNP</td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="3" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">Lipid Composition (mol %)</td>
                <td class="description-td">Characterization</td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="8" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">PEG-2000-C-</td>
                <td class="description-td">Cmpd</td>
                <td class="description-td"> </td>
                <td class="description-td"> </td>
                <td class="description-td">Size</td>
                <td class="description-td"> </td>
                <td class="description-td">%</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">DMA</td>
                <td class="description-td">13</td>
                <td class="description-td">Cholesterol</td>
                <td class="description-td">DSPC</td>
                <td class="description-td">(nm)</td>
                <td class="description-td">PDI</td>
                <td class="description-td">Encap</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td namest="offset" nameend="7" align="center" rowsep="1" class="description-td" colspan="8"> </td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="8" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td">1.1:55 (âBaseâ)</td>
                <td class="description-td">1.1</td>
                <td class="description-td">55</td>
                <td class="description-td">33</td>
                <td class="description-td">11</td>
                <td class="description-td">104</td>
                <td class="description-td">0.01</td>
                <td class="description-td">96</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">1.6:55 (âBaseâ)</td>
                <td class="description-td">1.6</td>
                <td class="description-td">55</td>
                <td class="description-td">33</td>
                <td class="description-td">11</td>
                <td class="description-td">80</td>
                <td class="description-td">0.11</td>
                <td class="description-td">99</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">1.1:57 (âPL-freeâ)</td>
                <td class="description-td">1.1</td>
                <td class="description-td">57</td>
                <td class="description-td">42</td>
                <td class="description-td">0</td>
                <td class="description-td">106</td>
                <td class="description-td">0.08</td>
                <td class="description-td">96</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">1.7:57 (âPL-freeâ)</td>
                <td class="description-td">1.7</td>
                <td class="description-td">57</td>
                <td class="description-td">42</td>
                <td class="description-td">0</td>
                <td class="description-td">94</td>
                <td class="description-td">0.08</td>
                <td class="description-td">98</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">1.8:61 (âPL-freeâ)</td>
                <td class="description-td">1.8</td>
                <td class="description-td">61</td>
                <td class="description-td">37</td>
                <td class="description-td">0</td>
                <td class="description-td">99</td>
                <td class="description-td">0.09</td>
                <td class="description-td">95</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="8" align="center" rowsep="1" class="description-td" colspan="8"> </td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
      </div> </li> <ul>
        <li id="ul0004-0001" num="0407">LNP (PL-containing &amp; PL-free) were prepared by the direct dilution method described by Jeffs et al. In brief, lipid stocks were prepared in 100% ethanol at a total lipid concentration of 6-7 mg/mL. An mRNA transcript encoding Luciferase, a reporter gene, was solubilized in 40 mM EDTA, pH 4.5 at 0.366 mg/mL. Equal volumes of these solutions were combined in a T-connector at a flow rate of 250 mL/min, immediately diluting into PBS (4Ã volume of lipid stock) at pH 7.4. Ethanol was then removed and carrier buffer was replaced with PBS by dialysis (Slide-A-Lyzer unit, MWCO 10 k), dialyzing overnight against 100 volumes of PBS. Following dialysis the formulations were concentrated to Ë0.6 mg/mL using VivaSpin concentrator units (MWCO 100,000). The LNP samples were sterile filtered (0.2 Î¼m syringe filter) and sample concentration determined by RiboGreen Assay. Particle size and polydispersity were determined using a Malvern Nano Series Zetasizer.</li>
      </ul>
    
    <li> <para-num num="[0408]"> </para-num> <div id="p-0485" num="0408" class="description-line">Prior to injection, LNP were diluted to 0.05 mg/mL. Balb/c mice (n=4) were administered doses (using a volume dose of 10 mL/kg) of 0.5 mg/kg (total mRNA) via lateral tail vein. Animals were euthanized at 4 h post-treatment with ketamine/xylazine. Terminal blood was collected into sodium EDTA microtainer tubes and centrifuged for 5 min at 16000Ãg &amp; 16Â° C. to isolate plasma. Liver sections were collected into FastPrep tubes and stored at â80Â° C. until analysis.</div>
    </li> <li> <para-num num="[0409]"> </para-num> <div id="p-0486" num="0409" class="description-line">To assess potency, livers were homogenized in 1Ã Cell Culture Lysis Reagent (CCLR) buffer, then analyzed for luciferase activity using the Luciferase Assay (Promega). As seen in Table 42, there is no detrimental effect on potency when phospholipid was removed from the compositions.</div>
    </li> <li> <div id="p-0487" num="0000" class="description-line">
      <tables id="TABLE-US-00042" num="00042">
        <patent-tables frame="none" colsep="0" rowsep="0">
          <table align="left" colsep="0" rowsep="0" cols="1" class="description-table" width="100%">
            <thead>
              <tr class="description-tr">
                <td namest="1" nameend="1" rowsep="1" class="description-td" colspan="1">TABLE 42</td>
              </tr>
            </thead>
            
              <tbody><tr class="description-tr">
                <td namest="1" nameend="1" align="center" rowsep="1" class="description-td" colspan="1"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Luciferase Gene Expression in Liver 6 h Post-IV Administration</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">of Base Compositions vs PL-free mLuc-LNP</td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="4" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td"> </td>
                <td class="description-td">Luciferase Activity</td>
                <td class="description-td">Stdev</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">Treatment</td>
                <td class="description-td">(ng/g liver)</td>
                <td class="description-td">(ng/g)</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td namest="offset" nameend="3" align="center" rowsep="1" class="description-td" colspan="4"> </td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="4" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">1.1:55 (âBaseâ)</td>
                <td class="description-td">849</td>
                <td class="description-td">33</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">1.6:55 (âBaseâ)</td>
                <td class="description-td">1092</td>
                <td class="description-td">42</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">1.1:57 (âPL-freeâ)</td>
                <td class="description-td">991</td>
                <td class="description-td">27</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">1.7:57 (âPL-freeâ)</td>
                <td class="description-td">846</td>
                <td class="description-td">22</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">1.8:61 (âPL-freeâ)</td>
                <td class="description-td">1156</td>
                <td class="description-td">65</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td namest="offset" nameend="3" align="center" rowsep="1" class="description-td" colspan="4"> </td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    </li> <li> <para-num num="[0410]"> </para-num> <div id="p-0488" num="0410" class="description-line">To assess the effect on immune stimulation, plasma samples were diluted (1:8) and analyzed for cytokines (MCP-1 and IL-6) by ELISA (ELISA assays and capture &amp; detection antibodies from BD Biosciences). Table 43 demonstrates that cytokine production is significantly reduced for both of the âBaseâ formulations when the phospholipid is removed. The effect on the 1.1:55 Base is particularly profound.</div>
    </li> <li> <div id="p-0489" num="0000" class="description-line">
      <tables id="TABLE-US-00043" num="00043">
        <patent-tables frame="none" colsep="0" rowsep="0">
          <table align="left" colsep="0" rowsep="0" cols="1" class="description-table" width="100%">
            <thead>
              <tr class="description-tr">
                <td namest="1" nameend="1" rowsep="1" class="description-td" colspan="1">TABLE 43</td>
              </tr>
            </thead>
            
              <tbody><tr class="description-tr">
                <td namest="1" nameend="1" align="center" rowsep="1" class="description-td" colspan="1"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">MCP-1 and IL-6 ELISA Results of Base</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Compositions vs PL-free mLuc-LNP</td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="5" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">MCP-1</td>
                <td class="description-td"> </td>
                <td class="description-td">IL-6</td>
                <td class="description-td"> </td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="6" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td"> </td>
                <td class="description-td">Average</td>
                <td class="description-td">Stdev</td>
                <td class="description-td">Average</td>
                <td class="description-td">Stdev</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">Treatment</td>
                <td class="description-td">(pg/mL)</td>
                <td class="description-td">(pg/mL)</td>
                <td class="description-td">(pg/mL)</td>
                <td class="description-td">(pg/mL)</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td namest="offset" nameend="5" align="center" rowsep="1" class="description-td" colspan="6"> </td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="6" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">PBS</td>
                <td class="description-td">28</td>
                <td class="description-td">7</td>
                <td class="description-td">14</td>
                <td class="description-td">5</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">1.1:55 (âBaseâ)</td>
                <td class="description-td">8022</td>
                <td class="description-td">3166</td>
                <td class="description-td">566</td>
                <td class="description-td">177</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">1.6:55 (âBaseâ)</td>
                <td class="description-td">2293</td>
                <td class="description-td">293</td>
                <td class="description-td">136</td>
                <td class="description-td">23</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">1.1:57 (âPL-freeâ)</td>
                <td class="description-td">1434</td>
                <td class="description-td">657</td>
                <td class="description-td">41</td>
                <td class="description-td">29</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">1.7:57 (âPL-freeâ)</td>
                <td class="description-td">705</td>
                <td class="description-td">144</td>
                <td class="description-td">28</td>
                <td class="description-td">6</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">1.8:61 (âPL-freeâ)</td>
                <td class="description-td">540</td>
                <td class="description-td">82</td>
                <td class="description-td">23</td>
                <td class="description-td">6</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td namest="offset" nameend="5" align="center" rowsep="1" class="description-td" colspan="6"> </td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    </li> <li> <para-num num="[0411]"> </para-num> <div id="p-0490" num="0411" class="description-line">Taken together these results demonstrate that the use of PL-free formulations results in a reduction in the immune stimulation of the formulation compared to PL-containing formulations. Given that the efficacy does not seem to be affected this should result in an increase in the therapeutic index of the mRNA-LNP.</div>
    </li> <heading id="h-0078">Example 18</heading>
    <heading id="h-0079">Removing Phospholipid Reduces Immune Stimulation of LNP Containing mRNA without Impairing Potency</heading>
    <li> <para-num num="[0412]"> </para-num> <div id="p-0491" num="0412" class="description-line">The result in Example 17 was further corroborated with a subset of the compositions formulated with two different mRNA transcripts, mLuc (Table 44a) &amp; mEPO (Table 44b). Transcripts used encoded either luciferase (reporter gene) or erythropoietin (a hormone that controls erythropoiesis, or red blood cell production).</div>
    </li> <li> <div id="p-0492" num="0000" class="description-line">
      <tables id="TABLE-US-00044" num="00044">
        <patent-tables frame="none" colsep="0" rowsep="0" pgwide="1">
          <table align="left" colsep="0" rowsep="0" cols="1" class="description-table" width="100%">
            <thead>
              <tr class="description-tr">
                <td namest="1" nameend="1" rowsep="1" class="description-td" colspan="1">TABLE 44a</td>
              </tr>
            </thead>
            
              <tbody><tr class="description-tr">
                <td namest="1" nameend="1" align="center" rowsep="1" class="description-td" colspan="1"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Formulation characteristics of 1.6:55 Base Formulation vs PL-free mLuc-LNP</td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="3" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">Lipid Composition (mol %)</td>
                <td class="description-td">Characterization</td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="8" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">PEG-2000-C-</td>
                <td class="description-td">Compound</td>
                <td class="description-td"> </td>
                <td class="description-td"> </td>
                <td class="description-td">Size</td>
                <td class="description-td"> </td>
                <td class="description-td">%</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">DMA</td>
                <td class="description-td">13</td>
                <td class="description-td">Cholesterol</td>
                <td class="description-td">DSPC</td>
                <td class="description-td">(nm)</td>
                <td class="description-td">PDI</td>
                <td class="description-td">Encap</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td namest="offset" nameend="7" align="center" rowsep="1" class="description-td" colspan="8"> </td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="8" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td">1.6:55</td>
                <td class="description-td">1.6</td>
                <td class="description-td">55</td>
                <td class="description-td">33</td>
                <td class="description-td">11</td>
                <td class="description-td">77</td>
                <td class="description-td">0.10</td>
                <td class="description-td">95</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">(âBaseâ)</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">1.7:57 (âPL-</td>
                <td class="description-td">1.7</td>
                <td class="description-td">57</td>
                <td class="description-td">42</td>
                <td class="description-td">0</td>
                <td class="description-td">80</td>
                <td class="description-td">0.06</td>
                <td class="description-td">93</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">freeâ)</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">1.8:61 (âPL-</td>
                <td class="description-td">1.8</td>
                <td class="description-td">61</td>
                <td class="description-td">37</td>
                <td class="description-td">0</td>
                <td class="description-td">90</td>
                <td class="description-td">0.06</td>
                <td class="description-td">91</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">freeâ)</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="8" align="center" rowsep="1" class="description-td" colspan="8"> </td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    </li> <li> <div id="p-0493" num="0000" class="description-line">
      <tables id="TABLE-US-00045" num="00045">
        <patent-tables frame="none" colsep="0" rowsep="0" pgwide="1">
          <table align="left" colsep="0" rowsep="0" cols="1" class="description-table" width="100%">
            <thead>
              <tr class="description-tr">
                <td namest="1" nameend="1" rowsep="1" class="description-td" colspan="1">TABLE 44b</td>
              </tr>
            </thead>
            
              <tbody><tr class="description-tr">
                <td namest="1" nameend="1" align="center" rowsep="1" class="description-td" colspan="1"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Formulation characteristics of 1.6:55 Base Formulation vs PL-free mEPO-LNP</td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="3" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">Lipid Composition (mol %)</td>
                <td class="description-td"> </td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="4" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">PEG-</td>
                <td class="description-td"> </td>
                <td class="description-td">Characterization</td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="8" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">2000-C-</td>
                <td class="description-td">Compound</td>
                <td class="description-td"> </td>
                <td class="description-td"> </td>
                <td class="description-td">Size</td>
                <td class="description-td"> </td>
                <td class="description-td">%</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">DMA</td>
                <td class="description-td">13</td>
                <td class="description-td">Cholesterol</td>
                <td class="description-td">DSPC</td>
                <td class="description-td">(nm)</td>
                <td class="description-td">PDI</td>
                <td class="description-td">Encap</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td namest="offset" nameend="7" align="center" rowsep="1" class="description-td" colspan="8"> </td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="8" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td">1.6:55 (âBaseâ)</td>
                <td class="description-td">1.6</td>
                <td class="description-td">55</td>
                <td class="description-td">33</td>
                <td class="description-td">11</td>
                <td class="description-td">76</td>
                <td class="description-td">0.10</td>
                <td class="description-td">95</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">1.7:57 (âPL-freeâ)</td>
                <td class="description-td">1.7</td>
                <td class="description-td">57</td>
                <td class="description-td">42</td>
                <td class="description-td">0</td>
                <td class="description-td">78</td>
                <td class="description-td">0.09</td>
                <td class="description-td">95</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">1.8:61 (âPL-freeâ)</td>
                <td class="description-td">1.8</td>
                <td class="description-td">61</td>
                <td class="description-td">37</td>
                <td class="description-td">0</td>
                <td class="description-td">82</td>
                <td class="description-td">0.02</td>
                <td class="description-td">93</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="8" align="center" rowsep="1" class="description-td" colspan="8"> </td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    </li> <li> <para-num num="[0413]"> </para-num> <div id="p-0494" num="0413" class="description-line">The mRNA-LNP were prepared as described in Example 17. Female Balb/C (n=4) received a 0.5 mg/kg (mRNA) intravenous dose of LNP. Six hours later, animals were euthanized with ketamine/xylazine. A small amount (75 Î¼L) of the terminal blood was collected into a tube containing 18.8 Î¼L of 50 mg/L heparin, while the rest of the blood was collected into sodium EDTA microtainer tubes. All of these tubes were centrifuged for 5 min at 16000Ãg &amp; 16Â° C. and plasma was isolated. Also, part of the liver was collected into FastPrep tubes which were placed at â80Â° C. until analysis.</div>
    </li> <li> <para-num num="[0414]"> </para-num> <div id="p-0495" num="0414" class="description-line">The livers were homogenized in 1ÃCCLR buffer and were analyzed for luciferase activity using the Luciferase Assay (Promega). As can be seen in Table 45 the efficacy of the PL-free mRNA-LNP formulations are similar to those of the Base (PL-containing) formulation.</div>
    </li> <li> <div id="p-0496" num="0000" class="description-line">
      <tables id="TABLE-US-00046" num="00046">
        <patent-tables frame="none" colsep="0" rowsep="0">
          <table align="left" colsep="0" rowsep="0" cols="1" class="description-table" width="100%">
            <thead>
              <tr class="description-tr">
                <td namest="1" nameend="1" rowsep="1" class="description-td" colspan="1">TABLE 45</td>
              </tr>
            </thead>
            
              <tbody><tr class="description-tr">
                <td namest="1" nameend="1" align="center" rowsep="1" class="description-td" colspan="1"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Luciferase Gene Expression in Liver 6 h Post-IV Administration</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">of Base Compositions vs PL-free mLuc-LNP</td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="4" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td"> </td>
                <td class="description-td">Luciferase Activity</td>
                <td class="description-td">Stdev</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">Treatment</td>
                <td class="description-td">(ng/g liver)</td>
                <td class="description-td">(ng/g liver)</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td namest="offset" nameend="3" align="center" rowsep="1" class="description-td" colspan="4"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">1.6:55 (âBaseâ)</td>
                <td class="description-td">1708</td>
                <td class="description-td">73</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">1.7:57 (âPL-freeâ)</td>
                <td class="description-td">1651</td>
                <td class="description-td">70</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">1.8:61 (âPL-freeâ)</td>
                <td class="description-td">1867</td>
                <td class="description-td">62</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td namest="offset" nameend="3" align="center" rowsep="1" class="description-td" colspan="4"> </td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    </li> <li> <para-num num="[0415]"> </para-num> <div id="p-0497" num="0415" class="description-line">The heparin plasma (diluted 1:4000 with ELISA Diluent) was used in a standard Murine EPO ELISA analysis (R&amp;D Systems). As seen in Table 46, the efficacy trend for the mEPO-LNP was similar to that seen with the mLuc-LNP where the efficacies of the PL-free Luc mRNA-LNP are similar to those of the Base (PL-containing) formulation.</div>
    </li> <li> <div id="p-0498" num="0000" class="description-line">
      <tables id="TABLE-US-00047" num="00047">
        <patent-tables frame="none" colsep="0" rowsep="0">
          <table align="left" colsep="0" rowsep="0" cols="1" class="description-table" width="100%">
            <thead>
              <tr class="description-tr">
                <td namest="1" nameend="1" rowsep="1" class="description-td" colspan="1">TABLE 46</td>
              </tr>
            </thead>
            
              <tbody><tr class="description-tr">
                <td namest="1" nameend="1" align="center" rowsep="1" class="description-td" colspan="1"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Efficacy of Murine mEPO-LNP in Liver 6 h Post-IV Administration</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">of Base Compositions vs PL-free mEPO-LNP</td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="4" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td"> </td>
                <td class="description-td">mEPO</td>
                <td class="description-td">Stdev</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">Treatment</td>
                <td class="description-td">(ng/mL)</td>
                <td class="description-td">(ng/mL)</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td namest="offset" nameend="3" align="center" rowsep="1" class="description-td" colspan="4"> </td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="4" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">PBS</td>
                <td class="description-td">0.124</td>
                <td class="description-td">0.009</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">1.6:55 (âBaseâ)</td>
                <td class="description-td">2839</td>
                <td class="description-td">313</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">1.7:57 (âPL-freeâ)</td>
                <td class="description-td">2460</td>
                <td class="description-td">611</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">1.8:61 (âPL-freeâ)</td>
                <td class="description-td">3986</td>
                <td class="description-td">426</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td namest="offset" nameend="3" align="center" rowsep="1" class="description-td" colspan="4"> </td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    </li> <li> <para-num num="[0416]"> </para-num> <div id="p-0499" num="0416" class="description-line">To assess immune stimulation, plasma samples were analyzed by ELISA for cytokines MCP-1 and IL-6 (ELISA assays and capture/detection antibodies from BD Biosciences). Results in Table 47a (mEPO) and Table 47b (mLuc) show again how the inflammatory response to the PL-free LNP compositions markedly reduced compared to the Base composition. This is true for both sets of LNP (luciferase and EPO). Given that the efficacy of these PL-free compositions has not been impaired, their reduced cytokine induction furnishes a significantly improved therapeutic index.</div>
    </li> <li> <div id="p-0500" num="0000" class="description-line">
      <tables id="TABLE-US-00048" num="00048">
        <patent-tables frame="none" colsep="0" rowsep="0">
          <table align="left" colsep="0" rowsep="0" cols="1" class="description-table" width="100%">
            <thead>
              <tr class="description-tr">
                <td namest="1" nameend="1" rowsep="1" class="description-td" colspan="1">TABLE 47a</td>
              </tr>
            </thead>
            
              <tbody><tr class="description-tr">
                <td namest="1" nameend="1" align="center" rowsep="1" class="description-td" colspan="1"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">MCP-1 and IL-6 ELISA Results of Base</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Compositions vs PL-free mEPO-LNP</td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="5" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">MCP-1</td>
                <td class="description-td"> </td>
                <td class="description-td">IL-6</td>
                <td class="description-td"> </td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="6" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td"> </td>
                <td class="description-td">Average</td>
                <td class="description-td">Stdev</td>
                <td class="description-td">Average</td>
                <td class="description-td">Stdev</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">Treatment</td>
                <td class="description-td">(pg/mL)</td>
                <td class="description-td">(pg/mL)</td>
                <td class="description-td">(pg/mL)</td>
                <td class="description-td">(pg/mL)</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td namest="offset" nameend="5" align="center" rowsep="1" class="description-td" colspan="6"> </td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="6" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">PBS</td>
                <td class="description-td">47</td>
                <td class="description-td">3</td>
                <td class="description-td">15</td>
                <td class="description-td">3</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">1.6:55 (âBaseâ)</td>
                <td class="description-td">3947</td>
                <td class="description-td">440</td>
                <td class="description-td">236</td>
                <td class="description-td">29</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">1.7:57 (âPL-freeâ)</td>
                <td class="description-td">873</td>
                <td class="description-td">431</td>
                <td class="description-td">39</td>
                <td class="description-td">14</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">1.8:61 (âPL-freeâ)</td>
                <td class="description-td">851</td>
                <td class="description-td">110</td>
                <td class="description-td">43</td>
                <td class="description-td">17</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td namest="offset" nameend="5" align="center" rowsep="1" class="description-td" colspan="6"> </td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    </li> <li> <div id="p-0501" num="0000" class="description-line">
      <tables id="TABLE-US-00049" num="00049">
        <patent-tables frame="none" colsep="0" rowsep="0">
          <table align="left" colsep="0" rowsep="0" cols="1" class="description-table" width="100%">
            <thead>
              <tr class="description-tr">
                <td namest="1" nameend="1" rowsep="1" class="description-td" colspan="1">TABLE 47b</td>
              </tr>
            </thead>
            
              <tbody><tr class="description-tr">
                <td namest="1" nameend="1" align="center" rowsep="1" class="description-td" colspan="1"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">MCP-1 and IL-6 ELISA Results of Base</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Compositions vs PL-free mLuc-LNP</td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="5" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">MCP-1</td>
                <td class="description-td"> </td>
                <td class="description-td">IL-6</td>
                <td class="description-td"> </td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="6" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td"> </td>
                <td class="description-td">Average</td>
                <td class="description-td">Stdev</td>
                <td class="description-td">Average</td>
                <td class="description-td">Stdev</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">Treatment</td>
                <td class="description-td">(pg/mL)</td>
                <td class="description-td">(pg/mL)</td>
                <td class="description-td">(pg/mL)</td>
                <td class="description-td">(pg/mL)</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td namest="offset" nameend="5" align="center" rowsep="1" class="description-td" colspan="6"> </td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="6" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">PBS</td>
                <td class="description-td">47</td>
                <td class="description-td">5</td>
                <td class="description-td">14</td>
                <td class="description-td">3</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">1.6:55 (âBaseâ)</td>
                <td class="description-td">2474</td>
                <td class="description-td">446</td>
                <td class="description-td">208</td>
                <td class="description-td">31</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">1.7:57 (âPL-freeâ)</td>
                <td class="description-td">1231</td>
                <td class="description-td">687</td>
                <td class="description-td">27</td>
                <td class="description-td">6</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">1.8:61 (âPL-freeâ)</td>
                <td class="description-td">856</td>
                <td class="description-td">745</td>
                <td class="description-td">30</td>
                <td class="description-td">8</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td namest="offset" nameend="5" align="center" rowsep="1" class="description-td" colspan="6"> </td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    </li> <heading id="h-0080">Example 19</heading>
    <heading id="h-0081">PL-Free LNP with Increased PEG Content are Less Stimulatory</heading>
    <li> <para-num num="[0417]"> </para-num> <div id="p-0502" num="0417" class="description-line">This example demonstrates how a further reduction in mRNA-LNP immune stimulation can be achieved by increasing the PEG component of the PL-free mRNA-LNP, again without impairing activity. The following mRNA-LNP compositions (Table 48) were prepared as described in Example 17, with an EPO mRNA payload:</div>
    </li> <li> <div id="p-0503" num="0000" class="description-line">
      <tables id="TABLE-US-00050" num="00050">
        <patent-tables frame="none" colsep="0" rowsep="0" pgwide="1">
          <table align="left" colsep="0" rowsep="0" cols="1" class="description-table" width="100%">
            <thead>
              <tr class="description-tr">
                <td namest="1" nameend="1" rowsep="1" class="description-td" colspan="1">TABLE 48</td>
              </tr>
            </thead>
            
              <tbody><tr class="description-tr">
                <td namest="1" nameend="1" align="center" rowsep="1" class="description-td" colspan="1"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Formulation characteristics of 1.6:55 Base Formulation vs PL-free mRNA-LNP</td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="3" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">Lipid Composition (mol %)</td>
                <td class="description-td">Characterization</td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="8" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">PEG-2000-C-</td>
                <td class="description-td">Compound</td>
                <td class="description-td"> </td>
                <td class="description-td"> </td>
                <td class="description-td">Size</td>
                <td class="description-td"> </td>
                <td class="description-td">%</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">DMA</td>
                <td class="description-td">13</td>
                <td class="description-td">Cholesterol</td>
                <td class="description-td">DSPC</td>
                <td class="description-td">(nm)</td>
                <td class="description-td">PDI</td>
                <td class="description-td">Encap</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td namest="offset" nameend="7" align="center" rowsep="1" class="description-td" colspan="8"> </td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="8" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td">1.6:55 (âBaseâ)</td>
                <td class="description-td">1.6</td>
                <td class="description-td">55</td>
                <td class="description-td">33</td>
                <td class="description-td">11</td>
                <td class="description-td">73</td>
                <td class="description-td">0.07</td>
                <td class="description-td">97</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">1.8:61 (âPL-</td>
                <td class="description-td">1.8</td>
                <td class="description-td">61</td>
                <td class="description-td">37</td>
                <td class="description-td">0</td>
                <td class="description-td">86</td>
                <td class="description-td">0.06</td>
                <td class="description-td">96</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">freeâ)</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">3.3:55 (âPL-</td>
                <td class="description-td">3.3</td>
                <td class="description-td">55</td>
                <td class="description-td">41</td>
                <td class="description-td">0</td>
                <td class="description-td">59</td>
                <td class="description-td">0.06</td>
                <td class="description-td">96</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">freeâ)</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="8" align="center" rowsep="1" class="description-td" colspan="8"> </td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    </li> <li> <para-num num="[0418]"> </para-num> <div id="p-0504" num="0418" class="description-line">Female Balb/C (n=4) then received a 0.5 mg/kg (mRNA) intravenous administration of LNP. Six hours later, animals were euthanized with ketamine/xylazine. Blood was collected into sodium EDTA microtainer tubes. All of these tubes were centrifuged for 5 min at 16000Ãg &amp; 16Â° C. and plasma was isolated. Plasma samples were analyzed by ELISA for cytokines MCP-1 and IL-6 (ELISA assays and capture/detection antibodies from BD Biosciences). Results in Table 49 shows again how inflammatory response to the PL-free LNP compositions markedly reduced compared to the Base composition. Given that the efficacy of these PL-free compositions has not been impaired, their reduced cytokine induction furnishes a significantly improved therapeutic index.</div>
    </li> <li> <div id="p-0505" num="0000" class="description-line">
      <tables id="TABLE-US-00051" num="00051">
        <patent-tables frame="none" colsep="0" rowsep="0">
          <table align="left" colsep="0" rowsep="0" cols="1" class="description-table" width="100%">
            <thead>
              <tr class="description-tr">
                <td namest="1" nameend="1" rowsep="1" class="description-td" colspan="1">TABLE 49</td>
              </tr>
            </thead>
            
              <tbody><tr class="description-tr">
                <td namest="1" nameend="1" align="center" rowsep="1" class="description-td" colspan="1"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">MCP-1 and IL-6 ELISA Results of Base Compositions</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">vs High PEG, PL-free mEPO-LNP</td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="5" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">MCP-1</td>
                <td class="description-td"> </td>
                <td class="description-td">IL-6</td>
                <td class="description-td"> </td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="6" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td"> </td>
                <td class="description-td">Average</td>
                <td class="description-td">Stdev</td>
                <td class="description-td">Average</td>
                <td class="description-td">Stdev</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">Treatment</td>
                <td class="description-td">(pg/mL)</td>
                <td class="description-td">(pg/mL)</td>
                <td class="description-td">(pg/mL)</td>
                <td class="description-td">(pg/mL)</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td namest="offset" nameend="5" align="center" rowsep="1" class="description-td" colspan="6"> </td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="6" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">PBS</td>
                <td class="description-td">57</td>
                <td class="description-td">4</td>
                <td class="description-td">15</td>
                <td class="description-td">3</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">1.6:55 (âBaseâ)</td>
                <td class="description-td">2875</td>
                <td class="description-td">2317</td>
                <td class="description-td">244</td>
                <td class="description-td">112</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">1.8:61 (âPL-freeâ)</td>
                <td class="description-td">1204</td>
                <td class="description-td">460</td>
                <td class="description-td">77</td>
                <td class="description-td">22</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">3.3:55 (âPL-freeâ)</td>
                <td class="description-td">712</td>
                <td class="description-td">186</td>
                <td class="description-td">37</td>
                <td class="description-td">11</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td namest="offset" nameend="5" align="center" rowsep="1" class="description-td" colspan="6"> </td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    </li> <li> <para-num num="[0419]"> </para-num> <div id="p-0506" num="0419" class="description-line">These results demonstrate that by increasing the amount of PEG lipid to 3.3 mol % within the PL-free formulation (3.3:55 Compound 13 PL-free mRNA-LNP), a further reduction in the immune stimulation of the mRNA-LNP can be achieved. The potency of the 3.3:55 composition was next examined.</div>
    </li> <heading id="h-0082">Example 20</heading>
    <heading id="h-0083">High PEG, PL-Free mRNA-LNP Remain Surprisingly Potent, and Exhibit a Larger Therapeutic Index</heading>
    <li> <para-num num="[0420]"> </para-num> <div id="p-0507" num="0420" class="description-line">This example demonstrates that the high PEG, PL-free 3.3:55 mRNA-LNP composition is just as efficacious as the Base, PL-containing composition. It again shows the reduced immune stimulation of the 3.3:55 composition and therefore the improved Therapeutic Index. The following LNP were prepared using the process described in Example 17 (Table 50), with an EPO payload:</div>
    </li> <li> <div id="p-0508" num="0000" class="description-line">
      <tables id="TABLE-US-00052" num="00052">
        <patent-tables frame="none" colsep="0" rowsep="0" pgwide="1">
          <table align="left" colsep="0" rowsep="0" cols="1" class="description-table" width="100%">
            <thead>
              <tr class="description-tr">
                <td namest="1" nameend="1" rowsep="1" class="description-td" colspan="1">TABLE 50</td>
              </tr>
            </thead>
            
              <tbody><tr class="description-tr">
                <td namest="1" nameend="1" align="center" rowsep="1" class="description-td" colspan="1"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Formulation characteristics of 1.6:55 Base Formulation vs High PEG, PL-free mEPO-LNP</td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="3" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">Lipid Composition (mol %)</td>
                <td class="description-td">Characterization</td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="8" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">PEG-2000-C-</td>
                <td class="description-td">Compound</td>
                <td class="description-td"> </td>
                <td class="description-td"> </td>
                <td class="description-td">Size</td>
                <td class="description-td"> </td>
                <td class="description-td">%</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">DMA</td>
                <td class="description-td">13</td>
                <td class="description-td">Cholesterol</td>
                <td class="description-td">DSPC</td>
                <td class="description-td">(nm)</td>
                <td class="description-td">PDI</td>
                <td class="description-td">Encap</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td namest="offset" nameend="7" align="center" rowsep="1" class="description-td" colspan="8"> </td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="8" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td">1.6:55 (âBaseâ)</td>
                <td class="description-td">1.6</td>
                <td class="description-td">55</td>
                <td class="description-td">33</td>
                <td class="description-td">11</td>
                <td class="description-td">74</td>
                <td class="description-td">0.07</td>
                <td class="description-td">97</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">3.3:55 (âPL-</td>
                <td class="description-td">3.3</td>
                <td class="description-td">55</td>
                <td class="description-td">41</td>
                <td class="description-td">0</td>
                <td class="description-td">63</td>
                <td class="description-td">0.06</td>
                <td class="description-td">96</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">freeâ)</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="8" align="center" rowsep="1" class="description-td" colspan="8"> </td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    </li> <li> <para-num num="[0421]"> </para-num> <div id="p-0509" num="0421" class="description-line">Female Balb/C (n=4) then received a 0.5 mg/kg (mRNA) intravenous administration of LNP. Six hours later, animals were euthanized with ketamine/xylazine. At time points of 2 h, 3 h, 4 h &amp; 5 h blood draws were performed and 20 Î¼L of the blood was collected into a tube containing 5 Î¼L of 50 mg/L heparin. Then at 6 hour time point, the animals were euthanized with a lethal dose of ketamine/xylazine. A small amount (20 Î¼L) of the terminal blood was collected into a tube containing 5 Î¼L of 50 mg/L heparin, while the rest of the blood was collected into sodium EDTA microtainer tubes. Tubes were centrifuged for 5 min at 16000Ãg &amp; 16Â° C. and to isolate plasma.</div>
    </li> <li> <para-num num="[0422]"> </para-num> <div id="p-0510" num="0422" class="description-line">Heparin plasma analyzed by ELISA (kit from R&amp;D Systems) for EPO concentrations. As seen in Table 51, at all the time points the efficacy of the PL-containing mRNA-LNP and the 3.3:55 PL-free formulation are equivalent.</div>
    </li> <li> <div id="p-0511" num="0000" class="description-line">
      <tables id="TABLE-US-00053" num="00053">
        <patent-tables frame="none" colsep="0" rowsep="0">
          <table align="left" colsep="0" rowsep="0" cols="1" class="description-table" width="100%">
            <thead>
              <tr class="description-tr">
                <td namest="1" nameend="1" rowsep="1" class="description-td" colspan="1">TABLE 51</td>
              </tr>
            </thead>
            
              <tbody><tr class="description-tr">
                <td namest="1" nameend="1" align="center" rowsep="1" class="description-td" colspan="1"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Efficacy of Murine mEPO-LNP in Liver 6 h Post-IV Administration</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">of Base Compositions vs High PEG, PL-free mEPO-LNP</td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="5" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">1.6:55 (âBaseâ)</td>
                <td class="description-td"> </td>
                <td class="description-td">3.3:55 (âPL-freeâ)</td>
                <td class="description-td"> </td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="5" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td">Time Point</td>
                <td class="description-td">EPO</td>
                <td class="description-td">Stdev</td>
                <td class="description-td">EPO</td>
                <td class="description-td">Stdev</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">(h)</td>
                <td class="description-td">(ng/mL)</td>
                <td class="description-td">(ng/mL)</td>
                <td class="description-td">(ng/mL)</td>
                <td class="description-td">(ng/mL)</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="5" align="center" rowsep="1" class="description-td" colspan="5"> </td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="5" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td">2</td>
                <td class="description-td">5065</td>
                <td class="description-td">773</td>
                <td class="description-td">4832</td>
                <td class="description-td">843</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">3</td>
                <td class="description-td">6174</td>
                <td class="description-td">514</td>
                <td class="description-td">6412</td>
                <td class="description-td">1188</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">4</td>
                <td class="description-td">5194</td>
                <td class="description-td">485</td>
                <td class="description-td">5902</td>
                <td class="description-td">1093</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">5</td>
                <td class="description-td">3961</td>
                <td class="description-td">643</td>
                <td class="description-td">4313</td>
                <td class="description-td">768</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">6</td>
                <td class="description-td">2936</td>
                <td class="description-td">528</td>
                <td class="description-td">3055</td>
                <td class="description-td">521</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="5" align="center" rowsep="1" class="description-td" colspan="5"> </td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    </li> <li> <para-num num="[0423]"> </para-num> <div id="p-0512" num="0423" class="description-line">Plasma samples were analyzed by ELISA for cytokines MCP-1 and IL-6 (ELISA assays and capture/detection antibodies from BD Biosciences). Results in Table 52 corroborate the data in Example 19, and show again how the inflammatory response to the high PEG, PL-free LNP compositions is markedly reduced compared to the Base composition.</div>
    </li> <li> <div id="p-0513" num="0000" class="description-line">
      <tables id="TABLE-US-00054" num="00054">
        <patent-tables frame="none" colsep="0" rowsep="0">
          <table align="left" colsep="0" rowsep="0" cols="1" class="description-table" width="100%">
            <thead>
              <tr class="description-tr">
                <td namest="1" nameend="1" rowsep="1" class="description-td" colspan="1">TABLE 52</td>
              </tr>
            </thead>
            
              <tbody><tr class="description-tr">
                <td namest="1" nameend="1" align="center" rowsep="1" class="description-td" colspan="1"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">MCP-1 and IL-6 ELISA Results of Base Compositions</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">vs High PEG, PL-free mEPO-LNP</td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="5" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">MCP-1</td>
                <td class="description-td"> </td>
                <td class="description-td">IL-6</td>
                <td class="description-td"> </td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="6" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td"> </td>
                <td class="description-td">Average</td>
                <td class="description-td">Stdev</td>
                <td class="description-td">Average</td>
                <td class="description-td">Stdev</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">Treatment</td>
                <td class="description-td">(pg/mL)</td>
                <td class="description-td">(pg/mL)</td>
                <td class="description-td">(pg/mL)</td>
                <td class="description-td">(pg/mL)</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td namest="offset" nameend="5" align="center" rowsep="1" class="description-td" colspan="6"> </td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="6" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">PBS</td>
                <td class="description-td">67</td>
                <td class="description-td">3</td>
                <td class="description-td">22</td>
                <td class="description-td">4</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">1.6:55 (âBaseâ)</td>
                <td class="description-td">2402</td>
                <td class="description-td">1317</td>
                <td class="description-td">163</td>
                <td class="description-td">74</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">3.3:55 (âPL-freeâ)</td>
                <td class="description-td">485</td>
                <td class="description-td">210</td>
                <td class="description-td">36</td>
                <td class="description-td">12</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td namest="offset" nameend="5" align="center" rowsep="1" class="description-td" colspan="6"> </td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    </li> <li> <para-num num="[0424]"> </para-num> <div id="p-0514" num="0424" class="description-line">Taken together these results demonstrate that by using a PL-free formulation the therapeutic index of an mRNA-LNP formulation can be increased and further by changing the formulation to include higher amounts of PEG (e.g., 3.3 mol %) the therapeutic index can be further advanced.</div>
    </li> <heading id="h-0084">Example 21</heading>
    <heading id="h-0085">Use of HPLC Purified mRNA for Immune Stimulation Abrogation of mRNA-LNP</heading>
    <li> <para-num num="[0425]"> </para-num> <div id="p-0515" num="0425" class="description-line">This example demonstrates how a reduction in mRNA-LNP immune stimulation can be achieved by replacing regular silica membrane purified mRNA with Reverse Phase (RP) HPLC-purified mRNA in LNP. Murine erythropoietin (EPO) mRNA purified by either method was formulated in LNP and injected via the iv route into Balb/C mice. Four hours following injection the animals were sacrificed and plasma &amp; liver tissue were analyzed for efficacy and immune stimulation.</div>
    </li> <li> <para-num num="[0426]"> </para-num> <div id="p-0516" num="0426" class="description-line">LNP were prepared by the regular LipoMixer technology. In brief, a 7.36 mg/mL lipid solution in 100% ethanol was prepared containing the lipids DSPC:Chol:PEG<sub>2000</sub>-C-DMA:Compound 13 in the following molar ratios: 10.9:32.8:1.64:54.6, mol %. The mRNA payload was solubilized in 40 mM EDTA (pH 4.5) at a concentration of 0.366 mg/mL. Equal volumes of each solution (1.6 mL) were blended at 250 mL/min through a T-connector using the Direct Dilution method described by Jeffs et al. The resulting mixture was subsequently collected directly into a tube containing Ë4 volumes (5.9 mL) of PBS, pH 7.4. These formulations were placed in Slide-A-Lyzer dialysis units (MWCO 10,000) and were dialyzed overnight against 100 volumes of PBS, pH 7.4. Following dialysis the formulations were concentrated to Ë0.6 mg/mL using VivaSpin concentrator units (MWCO 100,000).</div>
    </li> <li> <para-num num="[0427]"> </para-num> <div id="p-0517" num="0427" class="description-line">Female Balb/C mice (n=5) received an intravenous (tail vein) administration of either PBS, or LNP bearing either a regularly purified (silica membrane) or HPLC-purified mRNA payload. The mRNA transcript encoded mouse erythropoietin (EPO). Each animal received a dose corresponding to 0.5 mg/kg mRNA. Four hours following injection the animals were euthanized with a lethal dose of ketamine/xylazine. A small amount (20 Î¼L) of the terminal blood was collected into a tube containing 5 Î¼L of 50 mg/L heparin, while the rest of the blood was collected into Na EDTA microtainer tubes. All tubes were centrifuged for 5 min at 16000Ãg &amp; 16Â° C. to isolate plasma. Half of the left lateral lobe was collected into 1.5 mL of RNALater and stored at 4Â° C. for at least 16 h.</div>
    </li> <li> <para-num num="[0428]"> </para-num> <div id="p-0518" num="0428" class="description-line">The heparin plasma (diluted 1:4000 with ELISA Diluent) was used in a standard Murine EPO ELISA analysis (kit from R&amp;D Systems). As can be seen in Table 53 the efficacy of the LNP containing the highly (HPLC) purified EPO mRNA is very similar to that of the regular (Silica Membrane) purified EPO mRNA. The regular level of EPO seen within the plasma of mice treated with PBS is 100-200 pg/mL. Therefore, regardless of the purity of the EPO mRNA incorporated the level of liver gene expression of EPO from the encapsulated mEPO is extremely high.</div>
    </li> <li> <para-num num="[0429]"> </para-num> <div id="p-0519" num="0429" class="description-line">To determine the level of immune stimulation caused by mRNA-LNP, the fold increase of IFIT mRNA within the livers for the LNP treated animals (over the PBS treated animals) was determined. This is one example of an assay the art worker can use to assess the the level of immune stimulation caused by mRNA-LNP. In certain embodiments, the HPLC-purified mRNA-LNP induces significantly less immune stimulation than a control, which in certain embodiments is characterized by the IFIT response. The IFN-inducible IFIT1 mRNA, the most strongly induced mRNA in response to type I IFN, was used as a more sensitive measure of immune stimulation. Strong IFIT1 mRNA induction in both liver and spleen can be observed in mice treated with LNP bearing nucleic acids, even in the absence of detectable plasma IFN protein. This likely reflects local IFN induction that does not manifest as a systemic cytokine response. In the IFIT1 assay, the amount of IFIT1 mRNA in hepatocytes was quantified and normalized to mRNA levels of a housekeeping gene (usually GAPD), which typically remains constant. A QuantiGene 2.0 kit (a branched DNA based assay) from Affymetrix was used to determine mRNA levels of both genes.</div>
    </li> <li> <para-num num="[0430]"> </para-num> <div id="p-0520" num="0430" class="description-line">Approximately 20-25 mg of the left lateral lobe of the livers (stored in RNALater) were homogenized. Relative mRNA levels of both IFIT &amp; and the house keeping gene GAPD were determined using the QuantiGene 2.0 Assay. IFIT readouts were normalized to GAPD for each group of animals, and expressed as a fold increase over the PBS control group. The results in Table 54 demonstrate that LNP bearing an mRNA payload purified by silica membrane yielded a 627-fold increase in IFIT, vs the PBS group. Mice treated with LNP bearing an HPLC-purified payload exhibited only a 21-fold increase vs PBS. Thus they are approx. 30-fold less stimulatory than particles bearing silica-membrane purified mRNA. In certain embodiments, the lipid nanoparticle formulation having HPLC-purified mRNA has an IFIT response that is no more than 30 fold greater than a reference IFIT response of phosphate buffered saline. In certain embodiments, the lipid nanoparticle formulation having HPLC-purified mRNA has an IFIT response that is no more than 10 or 20 or 30 or 40 or 50 or 60 or 70 or 80 or 90 or 100 fold greater than a reference IFIT response of phosphate buffered saline.</div>
    </li> <li> <para-num num="[0431]"> </para-num> <div id="p-0521" num="0431" class="description-line">Further comparison of immune stimulatory capacity was afforded by analysis of the EDTA plasma in cytokine (MCP-1 and IL-6) ELISA assays. Plasma was diluted (1:8 or 1:80) in ELISA diluent and was analyzed for levels of MCP-1 &amp; IL-6 presence using ELISA assays with capture &amp; detection antibodies from BD Biosciences. The level of MCP-1 is dramatically reduced (37106 pg/mL down to 105 pg/mL) with the incorporation of the HPLC purified mRNA. Similarly, another cytokine (IL-6) is also dramatically reduced (4805 pg/mL reduced to 22 pg/mL) when using the HPLC purified mRNA. Results are shown in Table 55.</div>
    </li> <li> <para-num num="[0432]"> </para-num> <div id="p-0522" num="0432" class="description-line">Taken together these results demonstrate that LNP particles bearing an HPLC-purified mRNA payload are significantly less stimulatory than those with a less refined (e.g. regular silica membrane purified) mRNA payload. Given that the efficacy is not adversely affected, this represents a dramatic increase in the therapeutic index of the mRNA-LNP.</div>
    </li> <li> <div id="p-0523" num="0000" class="description-line">
      <tables id="TABLE-US-00055" num="00055">
        <patent-tables frame="none" colsep="0" rowsep="0">
          <table align="left" colsep="0" rowsep="0" cols="1" class="description-table" width="100%">
            <thead>
              <tr class="description-tr">
                <td namest="1" nameend="1" rowsep="1" class="description-td" colspan="1">TABLE 53</td>
              </tr>
            </thead>
            
              <tbody><tr class="description-tr">
                <td namest="1" nameend="1" align="center" rowsep="1" class="description-td" colspan="1"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">EPO Efficacy of 0.5 mg/kg 1.6:55 Compound 13 Containing</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Regular Silica Membrane Purified or HPLC Purified Murine</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">mEPO 4 h Following IV Dosing in Balb/C Mice (n = 5)</td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="4" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td"> </td>
                <td class="description-td">EPO</td>
                <td class="description-td">Stdev</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">Treatment</td>
                <td class="description-td">(ng/mL)</td>
                <td class="description-td">(ng/mL)</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td namest="offset" nameend="3" align="center" rowsep="1" class="description-td" colspan="4"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">1.6:55 (âBaseâ) with Regular</td>
                <td class="description-td">4050</td>
                <td class="description-td">450</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">Purified Murine mEPO</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">1.6:55 (âBaseâ) with HPLC</td>
                <td class="description-td">4525</td>
                <td class="description-td">385</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">Purified Murine mEPO</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td namest="offset" nameend="3" align="center" rowsep="1" class="description-td" colspan="4"> </td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    </li> <li> <div id="p-0524" num="0000" class="description-line">
      <tables id="TABLE-US-00056" num="00056">
        <patent-tables frame="none" colsep="0" rowsep="0">
          <table align="left" colsep="0" rowsep="0" cols="1" class="description-table" width="100%">
            <thead>
              <tr class="description-tr">
                <td namest="1" nameend="1" rowsep="1" class="description-td" colspan="1">TABLE 54</td>
              </tr>
            </thead>
            
              <tbody><tr class="description-tr">
                <td namest="1" nameend="1" align="center" rowsep="1" class="description-td" colspan="1"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">IFIT Induction of 0.5 mg/kg 1.6:55 Compound 13 Containing</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Regular Silica Membrane Purified or HPLC Purified Murine</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">mEPO 4 h Following IV Dosing in Balb/C Mice (n = 5)</td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="3" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">IFIT (Fold Increase Over PBS)</td>
                <td class="description-td"> </td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="3" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td">Treatment</td>
                <td class="description-td">Average</td>
                <td class="description-td">Stdev</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="3" align="center" rowsep="1" class="description-td" colspan="3"> </td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="3" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td">PBS</td>
                <td class="description-td">1.0</td>
                <td class="description-td">0.3</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">1.6:55 (âBaseâ) with Regular</td>
                <td class="description-td">627</td>
                <td class="description-td">52</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Purified Murine mEPO</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">1.6:55 (âBaseâ) with HPLC</td>
                <td class="description-td">21</td>
                <td class="description-td">12</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Purified Murine mEPO</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="3" align="center" rowsep="1" class="description-td" colspan="3"> </td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    </li> <li> <div id="p-0525" num="0000" class="description-line">
      <tables id="TABLE-US-00057" num="00057">
        <patent-tables frame="none" colsep="0" rowsep="0">
          <table align="left" colsep="0" rowsep="0" cols="1" class="description-table" width="100%">
            <thead>
              <tr class="description-tr">
                <td namest="1" nameend="1" rowsep="1" class="description-td" colspan="1">TABLE 55</td>
              </tr>
            </thead>
            
              <tbody><tr class="description-tr">
                <td namest="1" nameend="1" align="center" rowsep="1" class="description-td" colspan="1"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">MCP-1 and IL-6 ELISA Results in Balb/C Mice 4 h Following IV</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Dosing of 0.5 mg/kg of 1.6:55 Compound 13 Containing Regular</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Silica Membrane Purified or HPLC Purified Murine mEPO (n = 5)</td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="3" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">MCP-1</td>
                <td class="description-td">IL-6</td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="5" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">Average</td>
                <td class="description-td">Stdev</td>
                <td class="description-td">Average</td>
                <td class="description-td">Stdev</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Treatment</td>
                <td class="description-td">(pg/mL)</td>
                <td class="description-td">(pg/mL)</td>
                <td class="description-td">(pg/mL)</td>
                <td class="description-td">(pg/mL)</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="5" align="center" rowsep="1" class="description-td" colspan="5"> </td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="5" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td">PBS</td>
                <td class="description-td">56</td>
                <td class="description-td">3</td>
                <td class="description-td">17</td>
                <td class="description-td">2</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">1.6:55 (âBaseâ) with Regular</td>
                <td class="description-td">37106</td>
                <td class="description-td">12621</td>
                <td class="description-td">4805</td>
                <td class="description-td">1075</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Purified Murine mEPO</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">1.6:55 (âBaseâ) with HPLC</td>
                <td class="description-td">105</td>
                <td class="description-td">18</td>
                <td class="description-td">22</td>
                <td class="description-td">6</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Purified Murine mEPO</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="5" align="center" rowsep="1" class="description-td" colspan="5"> </td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    </li> <li> <para-num num="[0433]"> </para-num> <div id="p-0526" num="0433" class="description-line">All documents cited herein are incorporated by reference. While certain embodiments of invention are described, and many details have been set forth for purposes of illustration, certain of the details can be varied without departing from the basic principles of the invention.</div>
    </li> <li> <para-num num="[0434]"> </para-num> <div id="p-0527" num="0434" class="description-line">The use of the terms âaâ and âanâ and âtheâ and similar terms in the context of describing embodiments of invention are to be construed to cover both the singular and the plural, unless otherwise indicated herein or clearly contradicted by context. The terms âcomprising,â âhaving,â âincluding,â and âcontainingâ are to be construed as open-ended terms (i.e., meaning âincluding, but not limited toâ) unless otherwise noted. Recitation of ranges of values herein are merely intended to serve as a shorthand method of referring individually to each separate value falling within the range, unless otherwise indicated herein, and each separate value is incorporated into the specification as if it were individually recited herein. In addition to the order detailed herein, the methods described herein can be performed in any suitable order unless otherwise indicated herein or otherwise clearly contradicted by context. The use of any and all examples, or exemplary language (e.g., âsuch asâ) provided herein, is intended merely to better illuminate embodiments of invention and does not necessarily impose a limitation on the scope of the invention unless otherwise specifically recited in the claims. No language in the specification should be construed as indicating that any non-claimed element is essential to the practice of the invention.</div>
    
  </li> </ul>
  </div>
  </section>

  <section itemprop="claims" itemscope>
    <h2>Claims (<span itemprop="count">31</span>)</h2>
    
    <div itemprop="content" html><div mxw-id="PCLM191711201" lang="EN" load-source="patent-office" class="claims">
    <claim-statement>What is claimed is:</claim-statement>
    <div class="claim"> <div id="CLM-00001" num="00001" class="claim">
      <div class="claim-text"> <b>1</b>. A lipid nanoparticle comprising:
<div class="claim-text">(a) a cationic lipid;</div> <div class="claim-text">(b) a non-cationic lipid;</div> <div class="claim-text">(c) a corticosteroid and;</div> <div class="claim-text">(d) a nucleic acid, wherein the nucleic acid and the corticosteroid are encapsulated within the lipid nanoparticle.</div> </div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00002" num="00002" class="claim">
      <div class="claim-text"> <b>2</b>. A population of lipid nanoparticles comprising the lipid nanoparticle of <claim-ref idref="CLM-00001">claim 1</claim-ref>.</div>
    </div>
    </div> <div class="claim"> <div id="CLM-00003" num="00003" class="claim">
      <div class="claim-text"> <b>3</b>. A population of lipid nanoparticles, comprising at least one population of lipid nanoparticles selected from:
<div class="claim-text">(a) a first population of lipid nanoparticles that each comprise a cationic lipid, a non-cationic lipid, and a corticosteroid; and</div> <div class="claim-text">(b) a second population of lipid nanoparticles that each comprise a cationic lipid, a non-cationic lipid, and a nucleic acid,</div> <div class="claim-text">wherein the first population of lipid nanoparticles does not comprise a nucleic acid, and wherein the second population of lipid nanoparticles does not comprise a corticosteroid.</div> </div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00004" num="00004" class="claim">
      <div class="claim-text"> <b>4</b>. A population of lipid nanoparticles comprising the first and second populations of lipid nanoparticles of <claim-ref idref="CLM-00003">claim 3</claim-ref>.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00005" num="00005" class="claim">
      <div class="claim-text"> <b>5</b>. The lipid nanoparticle or population thereof of any one of <claim-ref idref="CLM-00001">claims 1</claim-ref>-<claim-ref idref="CLM-00004">4</claim-ref>, wherein the nucleic acid is mRNA.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00006" num="00006" class="claim">
      <div class="claim-text"> <b>6</b>. The lipid nanoparticle or population thereof of any one of <claim-ref idref="CLM-00001">claims 1</claim-ref>-<claim-ref idref="CLM-00005">5</claim-ref>, wherein the corticosteroid has a logP greater than 3.0.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00007" num="00007" class="claim">
      <div class="claim-text"> <b>7</b>. The lipid nanoparticle or population thereof of any one of <claim-ref idref="CLM-00001">claims 1</claim-ref>-<claim-ref idref="CLM-00006">6</claim-ref>, wherein the corticosteroid is a glucocorticoid.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00008" num="00008" class="claim">
      <div class="claim-text"> <b>8</b>. The lipid nanoparticle or population thereof of any one of <claim-ref idref="CLM-00001">claims 1</claim-ref>-<claim-ref idref="CLM-00006">6</claim-ref>, wherein the corticosteroid is a mineralocorticoid.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00009" num="00009" class="claim">
      <div class="claim-text"> <b>9</b>. The lipid nanoparticle or population thereof of any one of <claim-ref idref="CLM-00001">claims 1</claim-ref>-<claim-ref idref="CLM-00006">6</claim-ref>, wherein the corticosteroid is a clobetasol.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00010" num="00010" class="claim">
      <div class="claim-text"> <b>10</b>. The lipid nanoparticle or population thereof of any one of <claim-ref idref="CLM-00001">claims 1</claim-ref>-<claim-ref idref="CLM-00009">9</claim-ref>, wherein the non-cationic lipid is selected from a PEG-lipid conjugate and a phospholipid.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00011" num="00011" class="claim">
      <div class="claim-text"> <b>11</b>. The lipid nanoparticle or population thereof of any one of <claim-ref idref="CLM-00001">claims 1</claim-ref>-<claim-ref idref="CLM-00010">10</claim-ref>, wherein the lipid nanoparticle further comprises cholesterol.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00012" num="00012" class="claim">
      <div class="claim-text"> <b>12</b>. The lipid nanoparticle or population thereof of any one of <claim-ref idref="CLM-00010">claims 10</claim-ref> and <claim-ref idref="CLM-00011">11</claim-ref>, wherein the phospholipid comprises dipalmitoylphosphatidylcholine (DPPC), distearoylphosphatidylcholine (DSPC), or a mixture thereof.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00013" num="00013" class="claim">
      <div class="claim-text"> <b>13</b>. The lipid nanoparticle or population thereof of any one of <claim-ref idref="CLM-00010">claims 10</claim-ref> and <claim-ref idref="CLM-00011">11</claim-ref>, wherein the PEG-lipid conjugate is selected from the group consisting of a PEG-diacylglycerol (PEG-DAG) conjugate, a PEG-dialkyloxypropyl (PEG-DAA) conjugate, a PEG-phospholipid conjugate, a PEG-ceramide (PEG-Cer) conjugate, and a mixture thereof.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00014" num="00014" class="claim">
      <div class="claim-text"> <b>14</b>. The lipid nanoparticle or population thereof of <claim-ref idref="CLM-00013">claim 13</claim-ref>, wherein the PEG-lipid conjugate is a PEG-DAA conjugate.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00015" num="00015" class="claim">
      <div class="claim-text"> <b>15</b>. The lipid nanoparticle or population thereof of <claim-ref idref="CLM-00014">claim 14</claim-ref>, wherein the PEG-DAA conjugate is selected from the group consisting of a PEG-didecyloxypropyl (C<sub>10</sub>) conjugate, a PEG-dilauryloxypropyl (C<sub>12</sub>) conjugate, a PEG-dimyristyloxypropyl (C<sub>14</sub>) conjugate, a PEG-dipalmityloxypropyl (C<sub>16</sub>) conjugate, a PEG-distearyloxypropyl (C<sub>18</sub>) conjugate, and a mixture thereof.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00016" num="00016" class="claim">
      <div class="claim-text"> <b>16</b>. The lipid nanoparticle or population thereof of any one of <claim-ref idref="CLM-00001">claims 1</claim-ref>-<claim-ref idref="CLM-00015">15</claim-ref>, wherein the lipid nanoparticle has a lipid:nucleic mass ratio of from about 9:1 to about 20:1.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00017" num="00017" class="claim">
      <div class="claim-text"> <b>17</b>. The lipid nanoparticle or population thereof of any one of <claim-ref idref="CLM-00001">claims 1</claim-ref>-<claim-ref idref="CLM-00016">16</claim-ref>, wherein the mRNA is chemically modified.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00018" num="00018" class="claim">
      <div class="claim-text"> <b>18</b>. The lipid nanoparticle or population thereof of any one of <claim-ref idref="CLM-00001">claims 1</claim-ref>-<claim-ref idref="CLM-00017">17</claim-ref>, wherein the lipid nanoparticle comprises an electron dense core.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00019" num="00019" class="claim">
      <div class="claim-text"> <b>19</b>. The lipid nanoparticle or population thereof of any one of <claim-ref idref="CLM-00001">claims 1</claim-ref>-<claim-ref idref="CLM-00017">17</claim-ref>, wherein the lipid nanoparticle comprises an electron dense core and wherein the mRNA is located within the electron dense core.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00020" num="00020" class="claim">
      <div class="claim-text"> <b>20</b>. A population of lipid particles comprising a multiplicity of lipid nanoparticles of <claim-ref idref="CLM-00001">claim 1</claim-ref>.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00021" num="00021" class="claim">
      <div class="claim-text"> <b>21</b>. The lipid nanoparticle or population thereof of any one of <claim-ref idref="CLM-00001">claims 1</claim-ref>-<claim-ref idref="CLM-00018">18</claim-ref>, which has an IFIT response that is no more than 30 fold greater than a reference IFIT response of phosphate buffered saline.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00022" num="00022" class="claim">
      <div class="claim-text"> <b>22</b>. The lipid nanoparticle or population thereof of any one of <claim-ref idref="CLM-00001">claims 1</claim-ref>-<claim-ref idref="CLM-00021">21</claim-ref>, which has a PEG-lipid conjugate present in an amount of at least 3 mole percent; and mRNA encapsulated within the lipid particle; provided that the lipid particle comprises less than 0.5 mole percent phospholipid.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00023" num="00023" class="claim">
      <div class="claim-text"> <b>23</b>. A pharmaceutical composition comprising the lipid nanoparticle or population thereof of any one of <claim-ref idref="CLM-00001">claims 1</claim-ref>-<claim-ref idref="CLM-00022">22</claim-ref>, and a pharmaceutically acceptable carrier.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00024" num="00024" class="claim">
      <div class="claim-text"> <b>24</b>. A method for introducing an mRNA that encodes a protein into a cell, the method comprising contacting the cell with the lipid nanoparticle or population thereof of any one of <claim-ref idref="CLM-00005">claims 5</claim-ref>-<claim-ref idref="CLM-00023">23</claim-ref>, under conditions whereby the mRNA is introduced into the cell and expressed therein to produce the protein.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00025" num="00025" class="claim">
      <div class="claim-text"> <b>25</b>. A method for treating and/or ameliorating one or more symptoms associated with a disease in a human, caused by impaired expression of a protein in the human, the method comprising administering to the human a therapeutically effective amount of the lipid nanoparticle or population thereof of any one of <claim-ref idref="CLM-00005">claims 5</claim-ref>-<claim-ref idref="CLM-00023">23</claim-ref>, wherein the mRNA encapsulated within the lipid nanoparticle encodes the protein.</div>
    </div>
    </div> <div class="claim"> <div id="CLM-00026" num="00026" class="claim">
      <div class="claim-text"> <b>26</b>. A lipid nanoparticle formulation comprising a multiplicity of lipid nanoparticles, wherein each lipid nanoparticle comprises:
<div class="claim-text">(a) a cationic lipid;</div> <div class="claim-text">(b) a non-cationic lipid; and</div> <div class="claim-text">(c) mRNA encapsulated within the lipid particle,</div> <div class="claim-text">wherein the lipid nanoparticle formulation has an IFIT response that is no more than 30 fold greater than a reference IFIT response of phosphate buffered saline.</div> </div>
    </div>
    </div> <div class="claim"> <div id="CLM-00027" num="00027" class="claim">
      <div class="claim-text"> <b>27</b>. A method of making a lipid nanoparticle, comprising combining:
<div class="claim-text">(a) a cationic lipid;</div> <div class="claim-text">(b) a non-cationic lipid; and</div> <div class="claim-text">(c) purified mRNA so as to form a lipid nanoparticle, wherein the mRNA is encapsulated within the lipid nanoparticle, and wherein the lipid nanoparticle has an IFIT response that is no more than 30 fold greater than a reference IFIT response of phosphate buffered saline.</div> </div>
    </div>
    </div> <div class="claim"> <div id="CLM-00028" num="00028" class="claim">
      <div class="claim-text"> <b>28</b>. A method of making a lipid nanoparticle formulation comprising a multiplicity of lipid nanoparticles, the method comprising the step of combining:
<div class="claim-text">(a) a cationic lipid;</div> <div class="claim-text">(b) a non-cationic lipid; and</div> <div class="claim-text">(c) purified mRNA so as to form a lipid nanoparticle formulation comprising a multiplicity of lipid nanoparticles, wherein the mRNA is encapsulated within the lipid particles in the lipid nanoparticle formulation, and wherein the lipid nanoparticle formulation has an IFIT response that is no more than 30 fold greater than a reference IFIT response of phosphate buffered saline.</div> </div>
    </div>
    </div> <div class="claim"> <div id="CLM-00029" num="00029" class="claim">
      <div class="claim-text"> <b>29</b>. A lipid nanoparticle formulation comprising a multiplicity of lipid nanoparticles made by a process comprising the steps of combining:
<div class="claim-text">(a) a cationic lipid;</div> <div class="claim-text">(b) a non-cationic lipid; and</div> <div class="claim-text">(c) purified mRNA so as to form a lipid nanoparticle formulation comprising a multiplicity of lipid nanoparticles, wherein the mRNA is encapsulated within the lipid particles in the lipid nanoparticle formulation, and wherein the lipid nanoparticle formulation has an IFIT response that is no more than 30 fold greater than a reference IFIT response of phosphate buffered saline.</div> </div>
    </div>
    </div> <div class="claim"> <div id="CLM-00030" num="00030" class="claim">
      <div class="claim-text"> <b>30</b>. A lipid nanoparticle comprising:
<div class="claim-text">(a) a cationic lipid;</div> <div class="claim-text">(b) a PEG-lipid conjugate present in an amount of at least 3 mole percent; and</div> <div class="claim-text">(c) mRNA encapsulated within the lipid particle;</div> <div class="claim-text">provided that the lipid particle comprises less than 0.5 mole percent phospholipid.</div> </div>
    </div>
    </div> <div class="claim"> <div id="CLM-00031" num="00031" class="claim">
      <div class="claim-text"> <b>31</b>. A population of lipid nanoparticles wherein each lipid nanoparticle in the population comprises:
<div class="claim-text">(a) a cationic lipid;</div> <div class="claim-text">(b) a PEG-lipid conjugate present in an amount of at least 3 mole percent; and</div> <div class="claim-text">(c) mRNA encapsulated within the lipid nanoparticle;</div> <div class="claim-text">provided that the lipid nanoparticle comprises less than 0.5 mole percent phospholipid.</div> </div>
    </div>
  </div> </div>
  </div>
  </section>

  <section itemprop="application" itemscope>

    <section itemprop="metadata" itemscope>
      <span itemprop="applicationNumber">US16/312,162</span>
      <span itemprop="priorityDate">2016-06-30</span>
      <span itemprop="filingDate">2017-06-30</span>
      <span itemprop="title">Compositions and methods for delivering messenger RNA 
       </span>
      <span itemprop="ifiStatus">Active</span>
      
      <a href="/patent/US11191849B2/en">
        <span itemprop="representativePublication">US11191849B2</span>
        (<span itemprop="primaryLanguage">en</span>)
      </a>
    </section>

    <h2>Priority Applications (1)</h2>
    <table>
      <thead>
        <tr>
          <th>Application Number</th>
          <th>Priority Date</th>
          <th>Filing Date</th>
          <th>Title</th>
        </tr>
      </thead>
      <tbody>
        <tr itemprop="priorityApps" itemscope repeat>
          <td>
            <span itemprop="applicationNumber">US16/312,162</span>
            
            <a href="/patent/US11191849B2/en">
              <span itemprop="representativePublication">US11191849B2</span>
                (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="priorityDate">2016-06-30</td>
          <td itemprop="filingDate">2017-06-30</td>
          <td itemprop="title">Compositions and methods for delivering messenger RNA 
       </td>
        </tr>
      </tbody>
    </table>

    <h2>Applications Claiming Priority (4)</h2>
    <table>
      <thead>
        <tr>
          <th>Application Number</th>
          <th>Priority Date</th>
          <th>Filing Date</th>
          <th>Title</th>
        </tr>
      </thead>
      <tbody>
        <tr itemprop="appsClaimingPriority" itemscope repeat>
          <td>
            <span itemprop="applicationNumber">US201662357189P</span>
            
          </td>
          <td itemprop="priorityDate">2016-06-30</td>
          <td itemprop="filingDate">2016-06-30</td>
          <td itemprop="title"></td>
        </tr>
        <tr itemprop="appsClaimingPriority" itemscope repeat>
          <td>
            <span itemprop="applicationNumber">US201662375292P</span>
            
          </td>
          <td itemprop="priorityDate">2016-08-15</td>
          <td itemprop="filingDate">2016-08-15</td>
          <td itemprop="title"></td>
        </tr>
        <tr itemprop="appsClaimingPriority" itemscope repeat>
          <td>
            <span itemprop="applicationNumber">PCT/US2017/040446</span>
            <a href="/patent/WO2018006052A1/en">
              <span itemprop="representativePublication">WO2018006052A1</span>
                (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="priorityDate">2016-06-30</td>
          <td itemprop="filingDate">2017-06-30</td>
          <td itemprop="title">Compositions and methods for delivering messenger rna 
       </td>
        </tr>
        <tr itemprop="appsClaimingPriority" itemscope repeat>
          <td>
            <span itemprop="applicationNumber">US16/312,162</span>
            <a href="/patent/US11191849B2/en">
              <span itemprop="representativePublication">US11191849B2</span>
                (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="priorityDate">2016-06-30</td>
          <td itemprop="filingDate">2017-06-30</td>
          <td itemprop="title">Compositions and methods for delivering messenger RNA 
       </td>
        </tr>
      </tbody>
    </table>

    <h2>Related Parent Applications (1)</h2>
    <table>
      <thead>
        <tr>
          <th>Application Number</th>
          <th>Title</th>
          <th>Priority Date</th>
          <th>Filing Date</th>
        </tr>
      </thead>
      <tbody>
        <tr itemprop="parentApps" itemscope repeat>
          <td>
            <span itemprop="applicationNumber">PCT/US2017/040446</span>
            <span itemprop="relationType">A-371-Of-International</span>
            <a href="/patent/WO2018006052A1/en">
              <span itemprop="representativePublication">WO2018006052A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="priorityDate">2016-06-30</td>
          <td itemprop="filingDate">2017-06-30</td>
          <td itemprop="title">Compositions and methods for delivering messenger rna 
       </td>
        </tr>
      </tbody>
    </table>

    <h2>Related Child Applications (1)</h2>
    <table>
      <thead>
        <tr>
          <th>Application Number</th>
          <th>Title</th>
          <th>Priority Date</th>
          <th>Filing Date</th>
        </tr>
      </thead>
      <tbody>
        <tr itemprop="childApps" itemscope repeat>
          <td>
            <span itemprop="applicationNumber">US17/515,859</span>
            <span itemprop="relationType">Continuation</span>
            <a href="/patent/US20220160899A1/en">
              <span itemprop="representativePublication">US20220160899A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="priorityDate">2016-06-30</td>
          <td itemprop="filingDate">2021-11-01</td>
          <td itemprop="title">Compositions and methods for delivering messenger rna 
       </td>
        </tr>
      </tbody>
    </table>

    <h2>Publications (2)</h2>
    <table>
      <thead>
        <tr>
          <th>Publication Number</th>
          <th>Publication Date</th>
        </tr>
      </thead>
      <tbody>
        <tr itemprop="pubs" itemscope repeat>
          <td>
            <span itemprop="publicationNumber">US20190240354A1</span>
            
            <span itemprop="thisPatent">true</span>
            <a href="/patent/US20190240354A1/en">
              US20190240354A1
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="publicationDate">2019-08-08</td>
        </tr>
        <tr itemprop="pubs" itemscope repeat>
          <td>
            <span itemprop="publicationNumber">US11191849B2</span>
            
            <a href="/patent/US11191849B2/en">
              US11191849B2
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="publicationDate">2021-12-07</td>
        </tr>
      </tbody>
    </table>

  </section>

  <section itemprop="family" itemscope>
    <h1>Family</h1>
    <h2>ID=59363246</h2>

    <h2>Family Applications (2)</h2>
    <table>
      <thead>
        <tr>
          <th>Application Number</th>
          <th>Title</th>
          <th>Priority Date</th>
          <th>Filing Date</th>
        </tr>
      </thead>
      <tbody>
        <tr itemprop="applications" itemscope repeat>
          <td>
            <span itemprop="applicationNumber">US16/312,162</span>
            <span itemprop="ifiStatus">Active</span>
            
            <a href="/patent/US11191849B2/en">
              <span itemprop="representativePublication">US11191849B2</span>
                (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="priorityDate">2016-06-30</td>
          <td itemprop="filingDate">2017-06-30</td>
          <td itemprop="title">Compositions and methods for delivering messenger RNA 
       </td>
        </tr>
        <tr itemprop="applications" itemscope repeat>
          <td>
            <span itemprop="applicationNumber">US17/515,859</span>
            <span itemprop="ifiStatus">Abandoned</span>
            
            <a href="/patent/US20220160899A1/en">
              <span itemprop="representativePublication">US20220160899A1</span>
                (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="priorityDate">2016-06-30</td>
          <td itemprop="filingDate">2021-11-01</td>
          <td itemprop="title">Compositions and methods for delivering messenger rna 
       </td>
        </tr>
      </tbody>
    </table>

    

    <h2>Family Applications After (1)</h2>
    <table>
      <thead>
        <tr>
          <th>Application Number</th>
          <th>Title</th>
          <th>Priority Date</th>
          <th>Filing Date</th>
        </tr>
      </thead>
      <tbody>
        <tr itemprop="afterApplications" itemscope repeat>
          <td>
            <span itemprop="applicationNumber">US17/515,859</span>
            <span itemprop="ifiStatus">Abandoned</span>
            
            <a href="/patent/US20220160899A1/en">
                <span itemprop="representativePublication">US20220160899A1</span>
                  (<span itemprop="primaryLanguage">en</span>)
              </a>
          </td>
          <td itemprop="priorityDate">2016-06-30</td>
          <td itemprop="filingDate">2021-11-01</td>
          <td itemprop="title">Compositions and methods for delivering messenger rna 
       </td>
        </tr>
      </tbody>
    </table>

    <h2>Country Status (8)</h2>
    <table>
      <thead>
        <tr>
          <th>Country</th>
          <th>Link</th>
        </tr>
      </thead>
      <tbody>
        <tr itemprop="countryStatus" itemscope repeat>
          <td>
            <span itemprop="countryCode">US</span>
            (<span itemprop="num">2</span>)
            <meta itemprop="thisCountry" content="true">
          </td>
          <td>
            <a href="/patent/US11191849B2/en">
              <span itemprop="representativePublication">US11191849B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
        </tr>
        <tr itemprop="countryStatus" itemscope repeat>
          <td>
            <span itemprop="countryCode">EP</span>
            (<span itemprop="num">1</span>)
            
          </td>
          <td>
            <a href="/patent/EP3478838A1/en">
              <span itemprop="representativePublication">EP3478838A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
        </tr>
        <tr itemprop="countryStatus" itemscope repeat>
          <td>
            <span itemprop="countryCode">JP</span>
            (<span itemprop="num">3</span>)
            
          </td>
          <td>
            <a href="/patent/JP7086870B2/en">
              <span itemprop="representativePublication">JP7086870B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
        </tr>
        <tr itemprop="countryStatus" itemscope repeat>
          <td>
            <span itemprop="countryCode">CN</span>
            (<span itemprop="num">1</span>)
            
          </td>
          <td>
            <a href="/patent/CN109563511A/en">
              <span itemprop="representativePublication">CN109563511A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
        </tr>
        <tr itemprop="countryStatus" itemscope repeat>
          <td>
            <span itemprop="countryCode">AU</span>
            (<span itemprop="num">2</span>)
            
          </td>
          <td>
            <a href="/patent/AU2017286980B2/en">
              <span itemprop="representativePublication">AU2017286980B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
        </tr>
        <tr itemprop="countryStatus" itemscope repeat>
          <td>
            <span itemprop="countryCode">CA</span>
            (<span itemprop="num">1</span>)
            
          </td>
          <td>
            <a href="/patent/CA3034681A1/en">
              <span itemprop="representativePublication">CA3034681A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
        </tr>
        <tr itemprop="countryStatus" itemscope repeat>
          <td>
            <span itemprop="countryCode">MX</span>
            (<span itemprop="num">2</span>)
            
          </td>
          <td>
            <a href="/patent/MX2018016389A/en">
              <span itemprop="representativePublication">MX2018016389A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
        </tr>
        <tr itemprop="countryStatus" itemscope repeat>
          <td>
            <span itemprop="countryCode">WO</span>
            (<span itemprop="num">1</span>)
            
          </td>
          <td>
            <a href="/patent/WO2018006052A1/en">
              <span itemprop="representativePublication">WO2018006052A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
        </tr>
      </tbody>
    </table>

    <h2>Cited By (31)</h2>
    <table>
      <caption>* Cited by examiner, â  Cited by third party</caption>
      <thead>
        <tr>
          <th>Publication number</th>
          <th>Priority date</th>
          <th>Publication date</th>
          <th>Assignee</th>
          <th>Title</th>
        </tr>
      </thead>
      <tbody>
        <tr itemprop="forwardReferencesOrig" itemscope repeat>
          <td>
            <a href="/patent/WO2021061707A1/en">
              <span itemprop="publicationNumber">WO2021061707A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2019-09-23</td>
          <td itemprop="publicationDate">2021-04-01</td>
          <td><span itemprop="assigneeOriginal">Omega Therapeutics, Inc.</span></td>
          <td itemprop="title">Compositions and methods for modulating apolipoprotein b (apob) gene expression 
       </td>
        </tr>
        <tr itemprop="forwardReferencesOrig" itemscope repeat>
          <td>
            <a href="/patent/WO2021061815A1/en">
              <span itemprop="publicationNumber">WO2021061815A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2019-09-23</td>
          <td itemprop="publicationDate">2021-04-01</td>
          <td><span itemprop="assigneeOriginal">Omega Therapeutics, Inc.</span></td>
          <td itemprop="title">COMPOSITIONS AND METHODS FOR MODULATING HEPATOCYTE NUCLEAR FACTOR 4-ALPHA (HNF4Î±) GENE EXPRESSION 
       </td>
        </tr>
        <tr itemprop="forwardReferencesOrig" itemscope repeat>
          <td>
            <a href="/patent/WO2021183720A1/en">
              <span itemprop="publicationNumber">WO2021183720A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2020-03-11</td>
          <td itemprop="publicationDate">2021-09-16</td>
          <td><span itemprop="assigneeOriginal">Omega Therapeutics, Inc.</span></td>
          <td itemprop="title">Compositions and methods for modulating forkhead box p3 (foxp3) gene expression 
       </td>
        </tr>
        <tr itemprop="forwardReferencesOrig" itemscope repeat>
          <td>
            <a href="/patent/WO2021207020A1/en">
              <span itemprop="publicationNumber">WO2021207020A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2020-04-06</td>
          <td itemprop="publicationDate">2021-10-14</td>
          <td><span itemprop="assigneeOriginal">Tiba Biotech Llc</span></td>
          <td itemprop="title">Carriers for efficient nucleic acid delivery 
       </td>
        </tr>
        <tr itemprop="forwardReferencesOrig" itemscope repeat>
          <td>
            <a href="/patent/US20210378962A1/en">
              <span itemprop="publicationNumber">US20210378962A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2018-10-19</td>
          <td itemprop="publicationDate">2021-12-09</td>
          <td><span itemprop="assigneeOriginal">Translate Bio, Inc.</span></td>
          <td itemprop="title">Pumpless encapsulation of messenger rna 
       </td>
        </tr>
        <tr itemprop="forwardReferencesOrig" itemscope repeat>
          <td>
            <a href="/patent/WO2022166814A1/en">
              <span itemprop="publicationNumber">WO2022166814A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2021-02-07</td>
          <td itemprop="publicationDate">2022-08-11</td>
          <td><span itemprop="assigneeOriginal">ä¸­ç¾çåº·æ ¸é¸ææ¯(åé)ç ç©¶é¢æéå¬å¸</span></td>
          <td itemprop="title">Chemically modified small activating rna 
       </td>
        </tr>
        <tr itemprop="forwardReferencesOrig" itemscope repeat>
          <td>
            <a href="/patent/WO2023283359A2/en">
              <span itemprop="publicationNumber">WO2023283359A2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2021-07-07</td>
          <td itemprop="publicationDate">2023-01-12</td>
          <td><span itemprop="assigneeOriginal">Omega Therapeutics, Inc.</span></td>
          <td itemprop="title">Compositions and methods for modulating secreted frizzled receptor protein 1 (sfrp1) gene expression 
       </td>
        </tr>
        <tr itemprop="forwardReferencesOrig" itemscope repeat>
          <td>
            <a href="/patent/CN115703714A/en">
              <span itemprop="publicationNumber">CN115703714A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2021-08-13</td>
          <td itemprop="publicationDate">2023-02-17</td>
          <td><span itemprop="assigneeOriginal">å¹¿å·è°·æ£®å¶è¯æéå¬å¸</span></td>
          <td itemprop="title">
        Novel Cationic Lipid Compounds
       
       </td>
        </tr>
        <tr itemprop="forwardReferencesOrig" itemscope repeat>
          <td>
            <a href="/patent/WO2023023055A1/en">
              <span itemprop="publicationNumber">WO2023023055A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2021-08-16</td>
          <td itemprop="publicationDate">2023-02-23</td>
          <td><span itemprop="assigneeOriginal">Renagade Therapeutics Management Inc.</span></td>
          <td itemprop="title">Compositions and methods for optimizing tropism of delivery systems for rna 
       </td>
        </tr>
        <tr itemprop="forwardReferencesOrig" itemscope repeat>
          <td>
            <a href="/patent/WO2023044343A1/en">
              <span itemprop="publicationNumber">WO2023044343A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2021-09-14</td>
          <td itemprop="publicationDate">2023-03-23</td>
          <td><span itemprop="assigneeOriginal">Renagade Therapeutics Management Inc.</span></td>
          <td itemprop="title">Acyclic lipids and methods of use thereof 
       </td>
        </tr>
        <tr itemprop="forwardReferencesOrig" itemscope repeat>
          <td>
            <a href="/patent/WO2023044333A1/en">
              <span itemprop="publicationNumber">WO2023044333A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2021-09-14</td>
          <td itemprop="publicationDate">2023-03-23</td>
          <td><span itemprop="assigneeOriginal">Renagade Therapeutics Management Inc.</span></td>
          <td itemprop="title">Cyclic lipids and methods of use thereof 
       </td>
        </tr>
        <tr itemprop="forwardReferencesOrig" itemscope repeat>
          <td>
            <a href="/patent/WO2023081756A1/en">
              <span itemprop="publicationNumber">WO2023081756A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2021-11-03</td>
          <td itemprop="publicationDate">2023-05-11</td>
          <td><span itemprop="assigneeOriginal">The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone</span></td>
          <td itemprop="title">Precise genome editing using retrons 
       </td>
        </tr>
        <tr itemprop="forwardReferencesOrig" itemscope repeat>
          <td>
            <a href="/patent/WO2023122752A1/en">
              <span itemprop="publicationNumber">WO2023122752A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2021-12-23</td>
          <td itemprop="publicationDate">2023-06-29</td>
          <td><span itemprop="assigneeOriginal">Renagade Therapeutics Management Inc.</span></td>
          <td itemprop="title">Constrained lipids and methods of use thereof 
       </td>
        </tr>
        <tr itemprop="forwardReferencesOrig" itemscope repeat>
          <td>
            <a href="/patent/WO2023141602A2/en">
              <span itemprop="publicationNumber">WO2023141602A2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2022-01-21</td>
          <td itemprop="publicationDate">2023-07-27</td>
          <td><span itemprop="assigneeOriginal">Renagade Therapeutics Management Inc.</span></td>
          <td itemprop="title">Engineered retrons and methods of use 
       </td>
        </tr>
        <tr itemprop="forwardReferencesOrig" itemscope repeat>
          <td>
            <a href="/patent/WO2023196931A1/en">
              <span itemprop="publicationNumber">WO2023196931A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2022-04-07</td>
          <td itemprop="publicationDate">2023-10-12</td>
          <td><span itemprop="assigneeOriginal">Renagade Therapeutics Management Inc.</span></td>
          <td itemprop="title">Cyclic lipids and lipid nanoparticles (lnp) for the delivery of nucleic acids or peptides for use in vaccinating against infectious agents 
       </td>
        </tr>
        <tr itemprop="forwardReferencesOrig" itemscope repeat>
          <td>
            <a href="/patent/US11859201B2/en">
              <span itemprop="publicationNumber">US11859201B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2021-08-16</td>
          <td itemprop="publicationDate">2024-01-02</td>
          <td><span itemprop="assigneeOriginal">Tiba Biotech Llc</span></td>
          <td itemprop="title">Nanoparticle compositions containing sugar functionalized nucleic acid carriers 
       </td>
        </tr>
        <tr itemprop="forwardReferencesOrig" itemscope repeat>
          <td>
            <a href="/patent/WO2024020346A2/en">
              <span itemprop="publicationNumber">WO2024020346A2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2022-07-18</td>
          <td itemprop="publicationDate">2024-01-25</td>
          <td><span itemprop="assigneeOriginal">Renagade Therapeutics Management Inc.</span></td>
          <td itemprop="title">Gene editing components, systems, and methods of use 
       </td>
        </tr>
        <tr itemprop="forwardReferencesOrig" itemscope repeat>
          <td>
            <a href="/patent/WO2024044723A1/en">
              <span itemprop="publicationNumber">WO2024044723A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2022-08-25</td>
          <td itemprop="publicationDate">2024-02-29</td>
          <td><span itemprop="assigneeOriginal">Renagade Therapeutics Management Inc.</span></td>
          <td itemprop="title">Engineered retrons and methods of use 
       </td>
        </tr>
        <tr itemprop="forwardReferencesOrig" itemscope repeat>
          <td>
            <a href="/patent/WO2024192277A2/en">
              <span itemprop="publicationNumber">WO2024192277A2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2023-03-15</td>
          <td itemprop="publicationDate">2024-09-19</td>
          <td><span itemprop="assigneeOriginal">Renagade Therapeutics Management Inc.</span></td>
          <td itemprop="title">Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents 
       </td>
        </tr>
        <tr itemprop="forwardReferencesOrig" itemscope repeat>
          <td>
            <a href="/patent/WO2024192291A1/en">
              <span itemprop="publicationNumber">WO2024192291A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2023-03-15</td>
          <td itemprop="publicationDate">2024-09-19</td>
          <td><span itemprop="assigneeOriginal">Renagade Therapeutics Management Inc.</span></td>
          <td itemprop="title">Delivery of gene editing systems and methods of use thereof 
       </td>
        </tr>
        <tr itemprop="forwardReferencesOrig" itemscope repeat>
          <td>
            <a href="/patent/WO2024243438A2/en">
              <span itemprop="publicationNumber">WO2024243438A2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2023-05-23</td>
          <td itemprop="publicationDate">2024-11-28</td>
          <td><span itemprop="assigneeOriginal">Omega Therapeutics, Inc.</span></td>
          <td itemprop="title">Compositions and methods for reducing cxcl9, cxcl10, and cxcl11 gene expression 
       </td>
        </tr>
        <tr itemprop="forwardReferencesOrig" itemscope repeat>
          <td>
            <a href="/patent/WO2025007148A1/en">
              <span itemprop="publicationNumber">WO2025007148A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2023-06-30</td>
          <td itemprop="publicationDate">2025-01-02</td>
          <td><span itemprop="assigneeOriginal">Orna Therapeutics, Inc.</span></td>
          <td itemprop="title">Polymer lipid nanoparticle compositions for delivering circular polynucleotides 
       </td>
        </tr>
        <tr itemprop="forwardReferencesOrig" itemscope repeat>
          <td>
            <a href="/patent/WO2025049959A2/en">
              <span itemprop="publicationNumber">WO2025049959A2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2023-09-01</td>
          <td itemprop="publicationDate">2025-03-06</td>
          <td><span itemprop="assigneeOriginal">Renagade Therapeutics Management Inc.</span></td>
          <td itemprop="title">Gene editing systems, compositions, and methods for treatment of vexas syndrome 
       </td>
        </tr>
        <tr itemprop="forwardReferencesOrig" itemscope repeat>
          <td>
            <a href="/patent/WO2025081042A1/en">
              <span itemprop="publicationNumber">WO2025081042A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2023-10-12</td>
          <td itemprop="publicationDate">2025-04-17</td>
          <td><span itemprop="assigneeOriginal">Renagade Therapeutics Management Inc.</span></td>
          <td itemprop="title">Nickase-retron template-based precision editing system and methods of use 
       </td>
        </tr>
        <tr itemprop="forwardReferencesOrig" itemscope repeat>
          <td>
            <a href="/patent/WO2025128871A2/en">
              <span itemprop="publicationNumber">WO2025128871A2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2023-12-13</td>
          <td itemprop="publicationDate">2025-06-19</td>
          <td><span itemprop="assigneeOriginal">Renagade Therapeutics Management Inc.</span></td>
          <td itemprop="title">Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents 
       </td>
        </tr>
        <tr itemprop="forwardReferencesOrig" itemscope repeat>
          <td>
            <a href="/patent/WO2025144938A1/en">
              <span itemprop="publicationNumber">WO2025144938A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2023-12-26</td>
          <td itemprop="publicationDate">2025-07-03</td>
          <td><span itemprop="assigneeOriginal">Emmune, Inc.</span></td>
          <td itemprop="title">Systems for nucleic acid transfer 
       </td>
        </tr>
        <tr itemprop="forwardReferencesOrig" itemscope repeat>
          <td>
            <a href="/patent/WO2025155753A2/en">
              <span itemprop="publicationNumber">WO2025155753A2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2024-01-17</td>
          <td itemprop="publicationDate">2025-07-24</td>
          <td><span itemprop="assigneeOriginal">Renagade Therapeutics Management Inc.</span></td>
          <td itemprop="title">Improved gene editing system, guides, and methods 
       </td>
        </tr>
        <tr itemprop="forwardReferencesOrig" itemscope repeat>
          <td>
            <a href="/patent/WO2025166238A1/en">
              <span itemprop="publicationNumber">WO2025166238A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2024-01-31</td>
          <td itemprop="publicationDate">2025-08-07</td>
          <td><span itemprop="assigneeOriginal">Orna Therapeutics, Inc.</span></td>
          <td itemprop="title">Fast-shedding polyethylene glycol lipids 
       </td>
        </tr>
        <tr itemprop="forwardReferencesOrig" itemscope repeat>
          <td>
            <a href="/patent/WO2025174765A1/en">
              <span itemprop="publicationNumber">WO2025174765A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2024-02-12</td>
          <td itemprop="publicationDate">2025-08-21</td>
          <td><span itemprop="assigneeOriginal">Renagade Therapeutics Management Inc.</span></td>
          <td itemprop="title">Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents 
       </td>
        </tr>
        <tr itemprop="forwardReferencesOrig" itemscope repeat>
          <td>
            <a href="/patent/US12491262B2/en">
              <span itemprop="publicationNumber">US12491262B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2023-10-31</td>
          <td itemprop="publicationDate">2025-12-09</td>
          <td><span itemprop="assigneeOriginal">Tiba Biotech Llc</span></td>
          <td itemprop="title">Gene delivery agents 
       </td>
        </tr>
        <tr itemprop="forwardReferencesOrig" itemscope repeat>
          <td>
            <a href="/patent/WO2026003582A2/en">
              <span itemprop="publicationNumber">WO2026003582A2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2024-06-27</td>
          <td itemprop="publicationDate">2026-01-02</td>
          <td><span itemprop="assigneeOriginal">Axelyf ehf.</span></td>
          <td itemprop="title">Lipids and lipid nanoparticles 
       </td>
        </tr>
      </tbody>
    </table>

    <h2>Families Citing this family (35)</h2>
    <table>
      <caption>* Cited by examiner, â  Cited by third party</caption>
      <thead>
        <tr>
          <th>Publication number</th>
          <th>Priority date</th>
          <th>Publication date</th>
          <th>Assignee</th>
          <th>Title</th>
        </tr>
      </thead>
      <tbody>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/HUE057800T2/en">
              <span itemprop="publicationNumber">HUE057800T2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2014-04-23</td>
          <td itemprop="publicationDate">2022-06-28</td>
          <td><span itemprop="assigneeOriginal">Modernatx Inc</span></td>
          <td itemprop="title">
        Nucleic acid vaccines
       
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/ES2922760T3/en">
              <span itemprop="publicationNumber">ES2922760T3</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2015-10-22</td>
          <td itemprop="publicationDate">2022-09-20</td>
          <td><span itemprop="assigneeOriginal">Modernatx Inc</span></td>
          <td itemprop="title">
        Respiratory virus vaccines
       
     </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2018232357A1/en">
              <span itemprop="publicationNumber">WO2018232357A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2017-06-15</td>
          <td itemprop="publicationDate">2018-12-20</td>
          <td><span itemprop="assigneeOriginal">Modernatx, Inc.</span></td>
          <td itemprop="title">Rna formulations 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/CN111315359A/en">
              <span itemprop="publicationNumber">CN111315359A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2017-08-31</td>
          <td itemprop="publicationDate">2020-06-19</td>
          <td><span itemprop="assigneeOriginal">æ©ç»çº³ç¹æ¯æéå¬å¸</span></td>
          <td itemprop="title">
        Methods of preparing lipid nanoparticles
       
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US20240254252A1/en">
              <span itemprop="publicationNumber">US20240254252A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2018-07-13</td>
          <td itemprop="publicationDate">2024-08-01</td>
          <td><span itemprop="assigneeOriginal">Genmab A/S</span></td>
          <td itemprop="title">Trogocytosis-mediated therapy using cd38 antibodies 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/CR20210081A/en">
              <span itemprop="publicationNumber">CR20210081A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2018-07-13</td>
          <td itemprop="publicationDate">2021-06-24</td>
          <td><span itemprop="assigneeOriginal">Genmab As</span></td>
          <td itemprop="title">Variants of cd38 antibody and uses thereof 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/CA3108920A1/en">
              <span itemprop="publicationNumber">CA3108920A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2018-08-29</td>
          <td itemprop="publicationDate">2020-03-05</td>
          <td><span itemprop="assigneeOriginal">Translate Bio, Inc.</span></td>
          <td itemprop="title">Improved process of preparing mrna-loaded lipid nanoparticles 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/CN113271926A/en">
              <span itemprop="publicationNumber">CN113271926A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2018-09-20</td>
          <td itemprop="publicationDate">2021-08-17</td>
          <td><span itemprop="assigneeOriginal">æ©ç»çº³ç¹æ¯æéå¬å¸</span></td>
          <td itemprop="title">Preparation of lipid nanoparticles and methods of administration thereof 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/BR112021008982A2/en">
              <span itemprop="publicationNumber">BR112021008982A2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2018-11-09</td>
          <td itemprop="publicationDate">2021-08-10</td>
          <td><span itemprop="assigneeOriginal">Arbutus Biopharma Corporation</span></td>
          <td itemprop="title">
  lipid nanoparticles, pharmaceutical composition, method of delivering a nucleic acid to a cell and methods of treating a disease
 
     </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/MA55766A/en">
              <span itemprop="publicationNumber">MA55766A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2019-04-26</td>
          <td itemprop="publicationDate">2022-03-02</td>
          <td><span itemprop="assigneeOriginal">Genevant Sciences Gmbh</span></td>
          <td itemprop="title">
  LIPID NANOPARTICLES
 
     </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/AU2020329166A1/en">
              <span itemprop="publicationNumber">AU2020329166A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2019-08-09</td>
          <td itemprop="publicationDate">2022-03-03</td>
          <td><span itemprop="assigneeOriginal">Nutcracker Therapeutics, Inc.</span></td>
          <td itemprop="title">Microfluidic apparatus and methods of use thereof 
     </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2021148511A1/en">
              <span itemprop="publicationNumber">WO2021148511A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2020-01-21</td>
          <td itemprop="publicationDate">2021-07-29</td>
          <td><span itemprop="assigneeOriginal">Etherna Immunotherapies Nv</span></td>
          <td itemprop="title">Lipid nanoparticles 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/KR20220154740A/en">
              <span itemprop="publicationNumber">KR20220154740A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2020-03-17</td>
          <td itemprop="publicationDate">2022-11-22</td>
          <td><span itemprop="assigneeOriginal">ì ë¤ë°í¸ ì¬ì´ì¸ìì¦ ê²ì ë² í</span></td>
          <td itemprop="title">
        Cationic lipids for lipid nanoparticle delivery of therapeutics to hepatic stellate cells
       
     </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2022081750A1/en">
              <span itemprop="publicationNumber">WO2022081750A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2020-10-14</td>
          <td itemprop="publicationDate">2022-04-21</td>
          <td><span itemprop="assigneeOriginal">George Mason Research Foundation, Inc.</span></td>
          <td itemprop="title">Ionizable lipids and methods of manufacture and use thereof 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US11771652B2/en">
              <span itemprop="publicationNumber">US11771652B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2020-11-06</td>
          <td itemprop="publicationDate">2023-10-03</td>
          <td><span itemprop="assigneeOriginal">Sanofi</span></td>
          <td itemprop="title">Lipid nanoparticles for delivering mRNA vaccines 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/AU2021403156A1/en">
              <span itemprop="publicationNumber">AU2021403156A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2020-12-18</td>
          <td itemprop="publicationDate">2023-07-13</td>
          <td><span itemprop="assigneeOriginal">Genevant Sciences Gmbh</span></td>
          <td itemprop="title">Peg lipids and lipid nanoparticles 
     </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/EP4399227A1/en">
              <span itemprop="publicationNumber">EP4399227A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2021-09-06</td>
          <td itemprop="publicationDate">2024-07-17</td>
          <td><span itemprop="assigneeOriginal">Genmab A/S</span></td>
          <td itemprop="title">Antibodies capable of binding to cd27, variants thereof and uses thereof 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/CA3234153A1/en">
              <span itemprop="publicationNumber">CA3234153A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2021-10-08</td>
          <td itemprop="publicationDate">2023-04-13</td>
          <td><span itemprop="assigneeOriginal">David Satijn</span></td>
          <td itemprop="title">Antibodies binding to cd30 and cd3 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/EP4419082A1/en">
              <span itemprop="publicationNumber">EP4419082A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2021-10-20</td>
          <td itemprop="publicationDate">2024-08-28</td>
          <td><span itemprop="assigneeOriginal">ModernaTX, Inc.</span></td>
          <td itemprop="title">Drug product surrogate solutions 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/ES3017428T3/en">
              <span itemprop="publicationNumber">ES3017428T3</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2022-01-31</td>
          <td itemprop="publicationDate">2025-05-12</td>
          <td><span itemprop="assigneeOriginal">Genevant Sciences Gmbh</span></td>
          <td itemprop="title">Ionizable cationic lipids for lipid nanoparticles 
     </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US20250134825A1/en">
              <span itemprop="publicationNumber">US20250134825A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2022-02-02</td>
          <td itemprop="publicationDate">2025-05-01</td>
          <td><span itemprop="assigneeOriginal">Mslsolutions Gmbh</span></td>
          <td itemprop="title">Method for producing medications and vaccines 
     </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/EP4496565A1/en">
              <span itemprop="publicationNumber">EP4496565A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2022-03-23</td>
          <td itemprop="publicationDate">2025-01-29</td>
          <td><span itemprop="assigneeOriginal">Nanovation Therapeutics Inc.</span></td>
          <td itemprop="title">High sterol-containing lipid nanoparticles 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US12011507B2/en">
              <span itemprop="publicationNumber">US12011507B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2022-04-01</td>
          <td itemprop="publicationDate">2024-06-18</td>
          <td><span itemprop="assigneeOriginal">Nanovation Therapeutics Inc.</span></td>
          <td itemprop="title">MRNA delivery composition 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/CA3246384A1/en">
              <span itemprop="publicationNumber">CA3246384A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2022-04-13</td>
          <td itemprop="publicationDate">2023-10-19</td>
          <td><span itemprop="assigneeOriginal">FundaciÃ³ Hospital Universitari Vall D&#39;hebron - Institut De Recerca</span></td>
          <td itemprop="title">Treatment of neuromuscular diseases via gene therapy that expresses klotho protein 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2024028492A1/en">
              <span itemprop="publicationNumber">WO2024028492A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2022-08-04</td>
          <td itemprop="publicationDate">2024-02-08</td>
          <td><span itemprop="assigneeOriginal">Sanofi</span></td>
          <td itemprop="title">Quantitative assessment of rna encapsulation 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2024037577A1/en">
              <span itemprop="publicationNumber">WO2024037577A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2022-08-18</td>
          <td itemprop="publicationDate">2024-02-22</td>
          <td><span itemprop="assigneeOriginal">Suzhou Abogen Biosciences Co., Ltd.</span></td>
          <td itemprop="title">Composition of lipid nanoparticles 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/JP2025527583A/en">
              <span itemprop="publicationNumber">JP2025527583A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2022-08-18</td>
          <td itemprop="publicationDate">2025-08-22</td>
          <td><span itemprop="assigneeOriginal">ã¹ã¼ã¸ã§ã¦ã»ã¢ãã¸ã§ã³ã»ãã¤ãªãµã¤ã¨ã³ã·ãºã»ã«ã³ããã¼ã»ãªãããã</span></td>
          <td itemprop="title">
        Lipid nanoparticle composition
       
     </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2024102954A1/en">
              <span itemprop="publicationNumber">WO2024102954A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2022-11-10</td>
          <td itemprop="publicationDate">2024-05-16</td>
          <td><span itemprop="assigneeOriginal">Massachusetts Institute Of Technology</span></td>
          <td itemprop="title">Activation induced clipping system (aics) 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US12410258B2/en">
              <span itemprop="publicationNumber">US12410258B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2023-05-12</td>
          <td itemprop="publicationDate">2025-09-09</td>
          <td><span itemprop="assigneeOriginal">Ganmab A/S</span></td>
          <td itemprop="title">Antibodies capable of binding to OX40, variants thereof and uses thereof 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/TW202509077A/en">
              <span itemprop="publicationNumber">TW202509077A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2023-06-30</td>
          <td itemprop="publicationDate">2025-03-01</td>
          <td><span itemprop="assigneeOriginal">ä¸¹éº¥åçç¾å¯¶è¡ä»½æéå¬å¸</span></td>
          <td itemprop="title">Antibodies binding to fibroblast activation protein alpha and death receptor 4 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2025052278A1/en">
              <span itemprop="publicationNumber">WO2025052278A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2023-09-05</td>
          <td itemprop="publicationDate">2025-03-13</td>
          <td><span itemprop="assigneeOriginal">Genevant Sciences Gmbh</span></td>
          <td itemprop="title">Pyrrolidine based cationic lipids for lipid nanoparticle delivery of therapeutics to hepatic stellate cells 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2025133951A1/en">
              <span itemprop="publicationNumber">WO2025133951A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2023-12-21</td>
          <td itemprop="publicationDate">2025-06-26</td>
          <td><span itemprop="assigneeOriginal">Genevant Sciences Gmbh</span></td>
          <td itemprop="title">Ionizable lipids suitable for lipid nanoparticles 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2025210521A1/en">
              <span itemprop="publicationNumber">WO2025210521A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2024-04-04</td>
          <td itemprop="publicationDate">2025-10-09</td>
          <td><span itemprop="assigneeOriginal">Genevant Sciences Gmbh</span></td>
          <td itemprop="title">Lipid nanoparticles for stimulating t cells 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2025210520A1/en">
              <span itemprop="publicationNumber">WO2025210520A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2024-04-04</td>
          <td itemprop="publicationDate">2025-10-09</td>
          <td><span itemprop="assigneeOriginal">Genevant Sciences Gmbh</span></td>
          <td itemprop="title">Lipid nanoparticles for inducing an immunological response 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2025235862A1/en">
              <span itemprop="publicationNumber">WO2025235862A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2024-05-10</td>
          <td itemprop="publicationDate">2025-11-13</td>
          <td><span itemprop="assigneeOriginal">Inndura Therapeutics Inc.</span></td>
          <td itemprop="title">A modified immune cell receptor comprising a target-binding domain and the extracellular domain of cd16a 
       </td>
        </tr>
      </tbody>
    </table>

    

    <h2>Family Cites Families (81)</h2>
    <table>
      <caption>* Cited by examiner, â  Cited by third party</caption>
      <thead>
        <tr>
          <th>Publication number</th>
          <th>Priority date</th>
          <th>Publication date</th>
          <th>Assignee</th>
          <th>Title</th>
        </tr>
      </thead>
      <tbody>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US3993754A/en">
              <span itemprop="publicationNumber">US3993754A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">1974-10-09</td>
          <td itemprop="publicationDate">1976-11-23</td>
          <td><span itemprop="assigneeOriginal">The United States Of America As Represented By The United States Energy Research And Development Administration</span></td>
          <td itemprop="title">Liposome-encapsulated actinomycin for cancer chemotherapy 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US4086257A/en">
              <span itemprop="publicationNumber">US4086257A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">1976-10-12</td>
          <td itemprop="publicationDate">1978-04-25</td>
          <td><span itemprop="assigneeOriginal">Sears Barry D</span></td>
          <td itemprop="title">Phosphatidyl quaternary ammonium compounds 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/CH624011A5/en">
              <span itemprop="publicationNumber">CH624011A5</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">1977-08-05</td>
          <td itemprop="publicationDate">1981-07-15</td>
          <td><span itemprop="assigneeOriginal">Battelle Memorial Institute</span></td>
          <td itemprop="title"></td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US4235871A/en">
              <span itemprop="publicationNumber">US4235871A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">1978-02-24</td>
          <td itemprop="publicationDate">1980-11-25</td>
          <td><span itemprop="assigneeOriginal">Papahadjopoulos Demetrios P</span></td>
          <td itemprop="title">Method of encapsulating biologically active materials in lipid vesicles 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US4522803A/en">
              <span itemprop="publicationNumber">US4522803A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">1983-02-04</td>
          <td itemprop="publicationDate">1985-06-11</td>
          <td><span itemprop="assigneeOriginal">The Liposome Company, Inc.</span></td>
          <td itemprop="title">Stable plurilamellar vesicles, their preparation and use 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US4588578A/en">
              <span itemprop="publicationNumber">US4588578A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">1983-08-08</td>
          <td itemprop="publicationDate">1986-05-13</td>
          <td><span itemprop="assigneeOriginal">The Liposome Company, Inc.</span></td>
          <td itemprop="title">Lipid vesicles prepared in a monophase 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US5208036A/en">
              <span itemprop="publicationNumber">US5208036A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">1985-01-07</td>
          <td itemprop="publicationDate">1993-05-04</td>
          <td><span itemprop="assigneeOriginal">Syntex (U.S.A.) Inc.</span></td>
          <td itemprop="title">N-(Ï, (Ï-1)-dialkyloxy)- and N-(Ï, (Ï-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US4683195A/en">
              <span itemprop="publicationNumber">US4683195A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">1986-01-30</td>
          <td itemprop="publicationDate">1987-07-28</td>
          <td><span itemprop="assigneeOriginal">Cetus Corporation</span></td>
          <td itemprop="title">Process for amplifying, detecting, and/or-cloning nucleic acid sequences 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US4683202A/en">
              <span itemprop="publicationNumber">US4683202A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">1985-03-28</td>
          <td itemprop="publicationDate">1987-07-28</td>
          <td><span itemprop="assigneeOriginal">Cetus Corporation</span></td>
          <td itemprop="title">Process for amplifying nucleic acid sequences 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US4737323A/en">
              <span itemprop="publicationNumber">US4737323A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">1986-02-13</td>
          <td itemprop="publicationDate">1988-04-12</td>
          <td><span itemprop="assigneeOriginal">Liposome Technology, Inc.</span></td>
          <td itemprop="title">Liposome extrusion method 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US5725871A/en">
              <span itemprop="publicationNumber">US5725871A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">1989-08-18</td>
          <td itemprop="publicationDate">1998-03-10</td>
          <td><span itemprop="assigneeOriginal">Danbiosyst Uk Limited</span></td>
          <td itemprop="title">Drug delivery compositions comprising lysophosphoglycerolipid 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US5286634A/en">
              <span itemprop="publicationNumber">US5286634A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">1989-09-28</td>
          <td itemprop="publicationDate">1994-02-15</td>
          <td><span itemprop="assigneeOriginal">Stadler Joan K</span></td>
          <td itemprop="title">Synergistic method for host cell transformation 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US5707644A/en">
              <span itemprop="publicationNumber">US5707644A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">1989-11-04</td>
          <td itemprop="publicationDate">1998-01-13</td>
          <td><span itemprop="assigneeOriginal">Danbiosyst Uk Limited</span></td>
          <td itemprop="title">Small particle compositions for intranasal drug delivery 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US5279833A/en">
              <span itemprop="publicationNumber">US5279833A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">1990-04-04</td>
          <td itemprop="publicationDate">1994-01-18</td>
          <td><span itemprop="assigneeOriginal">Yale University</span></td>
          <td itemprop="title">Liposomal transfection of nucleic acids into animal cells 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US5264618A/en">
              <span itemprop="publicationNumber">US5264618A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">1990-04-19</td>
          <td itemprop="publicationDate">1993-11-23</td>
          <td><span itemprop="assigneeOriginal">Vical, Inc.</span></td>
          <td itemprop="title">Cationic lipids for intracellular delivery of biologically active molecules 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US5283185A/en">
              <span itemprop="publicationNumber">US5283185A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">1991-08-28</td>
          <td itemprop="publicationDate">1994-02-01</td>
          <td><span itemprop="assigneeOriginal">University Of Tennessee Research Corporation</span></td>
          <td itemprop="title">Method for delivering nucleic acids into cells 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US5756353A/en">
              <span itemprop="publicationNumber">US5756353A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">1991-12-17</td>
          <td itemprop="publicationDate">1998-05-26</td>
          <td><span itemprop="assigneeOriginal">The Regents Of The University Of California</span></td>
          <td itemprop="title">Expression of cloned genes in the lung by aerosol-and liposome-based delivery 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/EP0641192B1/en">
              <span itemprop="publicationNumber">EP0641192B1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">1992-05-18</td>
          <td itemprop="publicationDate">1997-07-23</td>
          <td><span itemprop="assigneeOriginal">Minnesota Mining And Manufacturing Company</span></td>
          <td itemprop="title">Transmucosal drug delivery device 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US5792451A/en">
              <span itemprop="publicationNumber">US5792451A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">1994-03-02</td>
          <td itemprop="publicationDate">1998-08-11</td>
          <td><span itemprop="assigneeOriginal">Emisphere Technologies, Inc.</span></td>
          <td itemprop="title">Oral drug delivery compositions and methods 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US5426039A/en">
              <span itemprop="publicationNumber">US5426039A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">1993-09-08</td>
          <td itemprop="publicationDate">1995-06-20</td>
          <td><span itemprop="assigneeOriginal">Bio-Rad Laboratories, Inc.</span></td>
          <td itemprop="title">Direct molecular cloning of primer extended DNA containing an alkane diol 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US5753613A/en">
              <span itemprop="publicationNumber">US5753613A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">1994-09-30</td>
          <td itemprop="publicationDate">1998-05-19</td>
          <td><span itemprop="assigneeOriginal">Inex Pharmaceuticals Corporation</span></td>
          <td itemprop="title">Compositions for the introduction of polyanionic materials into cells 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US5885613A/en">
              <span itemprop="publicationNumber">US5885613A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">1994-09-30</td>
          <td itemprop="publicationDate">1999-03-23</td>
          <td><span itemprop="assigneeOriginal">The University Of British Columbia</span></td>
          <td itemprop="title">Bilayer stabilizing components and their use in forming programmable fusogenic liposomes 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/CA2200952C/en">
              <span itemprop="publicationNumber">CA2200952C</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">1994-09-30</td>
          <td itemprop="publicationDate">2006-04-11</td>
          <td><span itemprop="assigneeOriginal">Inex Pharmaceuticals Corp.</span></td>
          <td itemprop="title">Novel compositions comprising quaternary ammonium compounds and neutral lipids for the introduction of polyanionic materials into cells 
     </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US5580579A/en">
              <span itemprop="publicationNumber">US5580579A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">1995-02-15</td>
          <td itemprop="publicationDate">1996-12-03</td>
          <td><span itemprop="assigneeOriginal">Nano Systems L.L.C.</span></td>
          <td itemprop="title">Site-specific adhesion within the GI tract using nanoparticles stabilized by high molecular weight, linear poly (ethylene oxide) polymers 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/IE80468B1/en">
              <span itemprop="publicationNumber">IE80468B1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">1995-04-04</td>
          <td itemprop="publicationDate">1998-07-29</td>
          <td><span itemprop="assigneeOriginal">Elan Corp Plc</span></td>
          <td itemprop="title">Controlled release biodegradable nanoparticles containing insulin 
     </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US5705385A/en">
              <span itemprop="publicationNumber">US5705385A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">1995-06-07</td>
          <td itemprop="publicationDate">1998-01-06</td>
          <td><span itemprop="assigneeOriginal">Inex Pharmaceuticals Corporation</span></td>
          <td itemprop="title">Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US5981501A/en">
              <span itemprop="publicationNumber">US5981501A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">1995-06-07</td>
          <td itemprop="publicationDate">1999-11-09</td>
          <td><span itemprop="assigneeOriginal">Inex Pharmaceuticals Corp.</span></td>
          <td itemprop="title">Methods for encapsulating plasmids in lipid bilayers 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/EP1489184A1/en">
              <span itemprop="publicationNumber">EP1489184A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">1995-06-07</td>
          <td itemprop="publicationDate">2004-12-22</td>
          <td><span itemprop="assigneeOriginal">Inex Pharmaceutical Corp.</span></td>
          <td itemprop="title">Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US7422902B1/en">
              <span itemprop="publicationNumber">US7422902B1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">1995-06-07</td>
          <td itemprop="publicationDate">2008-09-09</td>
          <td><span itemprop="assigneeOriginal">The University Of British Columbia</span></td>
          <td itemprop="title">Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/DE69841002D1/en">
              <span itemprop="publicationNumber">DE69841002D1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">1997-05-14</td>
          <td itemprop="publicationDate">2009-09-03</td>
          <td><span itemprop="assigneeOriginal">Univ British Columbia</span></td>
          <td itemprop="title">
        Highly effective encapsulation of nucleic acids in lipid vesicles
       
     </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/AU8428998A/en">
              <span itemprop="publicationNumber">AU8428998A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">1997-07-24</td>
          <td itemprop="publicationDate">1999-02-16</td>
          <td><span itemprop="assigneeOriginal">Inex Pharmaceuticals Corporation</span></td>
          <td itemprop="title">Preparation of lipid-nucleic acid particles using a solvent extraction and direct hydration method 
     </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US6320017B1/en">
              <span itemprop="publicationNumber">US6320017B1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">1997-12-23</td>
          <td itemprop="publicationDate">2001-11-20</td>
          <td><span itemprop="assigneeOriginal">Inex Pharmaceuticals Corp.</span></td>
          <td itemprop="title">Polyamide oligomers 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/AU747597B2/en">
              <span itemprop="publicationNumber">AU747597B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">1998-07-20</td>
          <td itemprop="publicationDate">2002-05-16</td>
          <td><span itemprop="assigneeOriginal">Inex Pharmaceuticals Corporation</span></td>
          <td itemprop="title">Liposomal encapsulated nucleic acid-complexes 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US6852334B1/en">
              <span itemprop="publicationNumber">US6852334B1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">1999-04-20</td>
          <td itemprop="publicationDate">2005-02-08</td>
          <td><span itemprop="assigneeOriginal">The University Of British Columbia</span></td>
          <td itemprop="title">Cationic peg-lipids and methods of use 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2000062813A2/en">
              <span itemprop="publicationNumber">WO2000062813A2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">1999-04-20</td>
          <td itemprop="publicationDate">2000-10-26</td>
          <td><span itemprop="assigneeOriginal">The University Of British Columbia</span></td>
          <td itemprop="title">Cationic peg-lipids and methods of use 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US7189705B2/en">
              <span itemprop="publicationNumber">US7189705B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2000-04-20</td>
          <td itemprop="publicationDate">2007-03-13</td>
          <td><span itemprop="assigneeOriginal">The University Of British Columbia</span></td>
          <td itemprop="title">Methods of enhancing SPLP-mediated transfection using endosomal membrane destabilizers 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US7053150B2/en">
              <span itemprop="publicationNumber">US7053150B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2000-12-18</td>
          <td itemprop="publicationDate">2006-05-30</td>
          <td><span itemprop="assigneeOriginal">Nektar Therapeutics Al, Corporation</span></td>
          <td itemprop="title">Segmented polymers and their conjugates 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/TW593427B/en">
              <span itemprop="publicationNumber">TW593427B</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2000-12-18</td>
          <td itemprop="publicationDate">2004-06-21</td>
          <td><span itemprop="assigneeOriginal">Nektar Therapeutics Al Corp</span></td>
          <td itemprop="title">Synthesis of high molecular weight non-peptidic polymer derivatives 
     </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US20030077829A1/en">
              <span itemprop="publicationNumber">US20030077829A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2001-04-30</td>
          <td itemprop="publicationDate">2003-04-24</td>
          <td><span itemprop="assigneeOriginal">Protiva Biotherapeutics Inc..</span></td>
          <td itemprop="title">Lipid-based formulations 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/EP1519714B1/en">
              <span itemprop="publicationNumber">EP1519714B1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2002-06-28</td>
          <td itemprop="publicationDate">2010-10-20</td>
          <td><span itemprop="assigneeOriginal">Protiva Biotherapeutics Inc.</span></td>
          <td itemprop="title">Method and apparatus for producing liposomes 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/CA2524634A1/en">
              <span itemprop="publicationNumber">CA2524634A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2003-05-09</td>
          <td itemprop="publicationDate">2004-11-25</td>
          <td><span itemprop="assigneeOriginal">Novosom Ag</span></td>
          <td itemprop="title">Injectable liposomal depots for delivering active ingredients 
     </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/AU2004257373B2/en">
              <span itemprop="publicationNumber">AU2004257373B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2003-07-16</td>
          <td itemprop="publicationDate">2011-03-24</td>
          <td><span itemprop="assigneeOriginal">Arbutus Biopharma Corporation</span></td>
          <td itemprop="title">Lipid encapsulated interfering RNA 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2005026372A1/en">
              <span itemprop="publicationNumber">WO2005026372A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2003-09-15</td>
          <td itemprop="publicationDate">2005-03-24</td>
          <td><span itemprop="assigneeOriginal">Protiva Biotherapeutics, Inc.</span></td>
          <td itemprop="title">Polyethyleneglycol-modified lipid compounds and uses thereof 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/ATE537263T1/en">
              <span itemprop="publicationNumber">ATE537263T1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2004-06-07</td>
          <td itemprop="publicationDate">2011-12-15</td>
          <td><span itemprop="assigneeOriginal">Protiva Biotherapeutics Inc</span></td>
          <td itemprop="title">
  CATIONIC LIPIDS AND METHODS OF USE
 
     </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2005121348A1/en">
              <span itemprop="publicationNumber">WO2005121348A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2004-06-07</td>
          <td itemprop="publicationDate">2005-12-22</td>
          <td><span itemprop="assigneeOriginal">Protiva Biotherapeutics, Inc.</span></td>
          <td itemprop="title">Lipid encapsulated interfering rna 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US7404969B2/en">
              <span itemprop="publicationNumber">US7404969B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2005-02-14</td>
          <td itemprop="publicationDate">2008-07-29</td>
          <td><span itemprop="assigneeOriginal">Sirna Therapeutics, Inc.</span></td>
          <td itemprop="title">Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/CA2597724A1/en">
              <span itemprop="publicationNumber">CA2597724A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2005-02-14</td>
          <td itemprop="publicationDate">2007-08-02</td>
          <td><span itemprop="assigneeOriginal">Sirna Therapeutics, Inc.</span></td>
          <td itemprop="title">Cationic lipids and formulated molecular compositions containing them 
     </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2007012191A1/en">
              <span itemprop="publicationNumber">WO2007012191A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2005-07-27</td>
          <td itemprop="publicationDate">2007-02-01</td>
          <td><span itemprop="assigneeOriginal">Protiva Biotherapeutics, Inc.</span></td>
          <td itemprop="title">Systems and methods for manufacturing liposomes 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US20070054873A1/en">
              <span itemprop="publicationNumber">US20070054873A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2005-08-26</td>
          <td itemprop="publicationDate">2007-03-08</td>
          <td><span itemprop="assigneeOriginal">Protiva Biotherapeutics, Inc.</span></td>
          <td itemprop="title">Glucocorticoid modulation of nucleic acid-mediated immune stimulation 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/CA2848238C/en">
              <span itemprop="publicationNumber">CA2848238C</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2006-10-03</td>
          <td itemprop="publicationDate">2016-07-19</td>
          <td><span itemprop="assigneeOriginal">Tekmira Pharmaceuticals Corporation</span></td>
          <td itemprop="title">Lipid containing formulations 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/MX2009012568A/en">
              <span itemprop="publicationNumber">MX2009012568A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2007-05-22</td>
          <td itemprop="publicationDate">2009-12-08</td>
          <td><span itemprop="assigneeOriginal">Mdrna Inc</span></td>
          <td itemprop="title">Hydroxymethyl substituted rna oligonucleotides and rna complexes. 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2009082817A1/en">
              <span itemprop="publicationNumber">WO2009082817A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2007-12-27</td>
          <td itemprop="publicationDate">2009-07-09</td>
          <td><span itemprop="assigneeOriginal">Protiva Biotherapeutics, Inc.</span></td>
          <td itemprop="title">Silencing of polo-like kinase expression using interfering rna 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US20110117125A1/en">
              <span itemprop="publicationNumber">US20110117125A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2008-01-02</td>
          <td itemprop="publicationDate">2011-05-19</td>
          <td><span itemprop="assigneeOriginal">Tekmira Pharmaceuticals Corporation</span></td>
          <td itemprop="title">Compositions and methods for the delivery of nucleic acids 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/NZ588583A/en">
              <span itemprop="publicationNumber">NZ588583A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2008-04-15</td>
          <td itemprop="publicationDate">2012-08-31</td>
          <td><span itemprop="assigneeOriginal">Protiva Biotherapeutics Inc</span></td>
          <td itemprop="title">Novel lipid formulations for nucleic acid delivery 
     </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/CN102149749B/en">
              <span itemprop="publicationNumber">CN102149749B</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2008-07-10</td>
          <td itemprop="publicationDate">2014-06-25</td>
          <td><span itemprop="assigneeOriginal">å¡ççº³æ²»çå¬å¸</span></td>
          <td itemprop="title">
        Polyoxazolines with inert end groups, polyoxazolines prepared from protected initiator groups, and related compounds
       
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/ES2475065T3/en">
              <span itemprop="publicationNumber">ES2475065T3</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2008-10-09</td>
          <td itemprop="publicationDate">2014-07-10</td>
          <td><span itemprop="assigneeOriginal">Tekmira Pharmaceuticals Corporation</span></td>
          <td itemprop="title">
        Enhanced amino acids and methods for nucleic acid administration
       
     </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US20110071208A1/en">
              <span itemprop="publicationNumber">US20110071208A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2009-06-05</td>
          <td itemprop="publicationDate">2011-03-24</td>
          <td><span itemprop="assigneeOriginal">Protiva Biotherapeutics, Inc.</span></td>
          <td itemprop="title">Lipid encapsulated dicer-substrate interfering rna 
     </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/NZ712719A/en">
              <span itemprop="publicationNumber">NZ712719A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2009-06-10</td>
          <td itemprop="publicationDate">2017-03-31</td>
          <td><span itemprop="assigneeOriginal">Arbutus Biopharma Corp</span></td>
          <td itemprop="title">Improved lipid formulation 
     </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/CA2767127A1/en">
              <span itemprop="publicationNumber">CA2767127A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2009-07-01</td>
          <td itemprop="publicationDate">2011-01-06</td>
          <td><span itemprop="assigneeOriginal">Protiva Biotherapeutics, Inc.</span></td>
          <td itemprop="title">Novel lipid formulations for delivery of therapeutic agents to solid tumors 
     </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2011000106A1/en">
              <span itemprop="publicationNumber">WO2011000106A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2009-07-01</td>
          <td itemprop="publicationDate">2011-01-06</td>
          <td><span itemprop="assigneeOriginal">Protiva Biotherapeutics, Inc.</span></td>
          <td itemprop="title">Improved cationic lipids and methods for the delivery of therapeutic agents 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/EP2512487A4/en">
              <span itemprop="publicationNumber">EP2512487A4</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2009-12-15</td>
          <td itemprop="publicationDate">2013-08-07</td>
          <td></td>
          <td itemprop="title">Therapeutic polymeric nanoparticles comprising corticosteroids and methods of making and using same 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2012000104A1/en">
              <span itemprop="publicationNumber">WO2012000104A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2010-06-30</td>
          <td itemprop="publicationDate">2012-01-05</td>
          <td><span itemprop="assigneeOriginal">Protiva Biotherapeutics, Inc.</span></td>
          <td itemprop="title">Non-liposomal systems for nucleic acid delivery 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/RU2625546C2/en">
              <span itemprop="publicationNumber">RU2625546C2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2010-07-06</td>
          <td itemprop="publicationDate">2017-07-14</td>
          <td><span itemprop="assigneeOriginal">ÐÐ¾Ð²Ð°ÑÑÐ¸Ñ ÐÐ³</span></td>
          <td itemprop="title">Cationic emulsions &#34;oil-in-water&#34; 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US8466122B2/en">
              <span itemprop="publicationNumber">US8466122B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2010-09-17</td>
          <td itemprop="publicationDate">2013-06-18</td>
          <td><span itemprop="assigneeOriginal">Protiva Biotherapeutics, Inc.</span></td>
          <td itemprop="title">Trialkyl cationic lipids and methods of use thereof 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/EP2621480B1/en">
              <span itemprop="publicationNumber">EP2621480B1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2010-09-30</td>
          <td itemprop="publicationDate">2018-08-15</td>
          <td><span itemprop="assigneeOriginal">Sirna Therapeutics, Inc.</span></td>
          <td itemprop="title">Low molecular weight cationic lipids for oligonucleotide delivery 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US9339513B2/en">
              <span itemprop="publicationNumber">US9339513B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2010-11-09</td>
          <td itemprop="publicationDate">2016-05-17</td>
          <td><span itemprop="assigneeOriginal">Alnylam Pharmaceuticals, Inc.</span></td>
          <td itemprop="title">Lipid formulated compositions and methods for inhibiting expression of Eg5 and VEGF genes 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/ES2740248T3/en">
              <span itemprop="publicationNumber">ES2740248T3</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2011-06-08</td>
          <td itemprop="publicationDate">2020-02-05</td>
          <td><span itemprop="assigneeOriginal">Translate Bio Inc</span></td>
          <td itemprop="title">
        Lipid nanoparticle compositions and methods for mRNA administration
       
     </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US9126966B2/en">
              <span itemprop="publicationNumber">US9126966B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2011-08-31</td>
          <td itemprop="publicationDate">2015-09-08</td>
          <td><span itemprop="assigneeOriginal">Protiva Biotherapeutics, Inc.</span></td>
          <td itemprop="title">Cationic lipids and methods of use thereof 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/RS58562B1/en">
              <span itemprop="publicationNumber">RS58562B1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2011-11-04</td>
          <td itemprop="publicationDate">2019-05-31</td>
          <td><span itemprop="assigneeOriginal">Nitto Denko Corp</span></td>
          <td itemprop="title">Method for sterilely producing lipid-nucleic acid particles 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US9579338B2/en">
              <span itemprop="publicationNumber">US9579338B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2011-11-04</td>
          <td itemprop="publicationDate">2017-02-28</td>
          <td><span itemprop="assigneeOriginal">Nitto Denko Corporation</span></td>
          <td itemprop="title">Method of producing lipid nanoparticles for drug delivery 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/HRP20220717T1/en">
              <span itemprop="publicationNumber">HRP20220717T1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2011-12-16</td>
          <td itemprop="publicationDate">2022-07-22</td>
          <td><span itemprop="assigneeOriginal">Modernatx, Inc.</span></td>
          <td itemprop="title">Modified mrna compositions 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US9035039B2/en">
              <span itemprop="publicationNumber">US9035039B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2011-12-22</td>
          <td itemprop="publicationDate">2015-05-19</td>
          <td><span itemprop="assigneeOriginal">Protiva Biotherapeutics, Inc.</span></td>
          <td itemprop="title">Compositions and methods for silencing SMAD4 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/SG11201405157PA/en">
              <span itemprop="publicationNumber">SG11201405157PA</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2012-02-24</td>
          <td itemprop="publicationDate">2014-10-30</td>
          <td><span itemprop="assigneeOriginal">Protiva Biotherapeutics Inc</span></td>
          <td itemprop="title">Trialkyl cationic lipids and methods of use thereof 
     </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US9546128B2/en">
              <span itemprop="publicationNumber">US9546128B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2012-03-29</td>
          <td itemprop="publicationDate">2017-01-17</td>
          <td><span itemprop="assigneeOriginal">Shire Human Genetic Therapies, Inc.</span></td>
          <td itemprop="title">Ionizable cationic lipids 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2013151665A2/en">
              <span itemprop="publicationNumber">WO2013151665A2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2012-04-02</td>
          <td itemprop="publicationDate">2013-10-10</td>
          <td><span itemprop="assigneeOriginal">modeRNA Therapeutics</span></td>
          <td itemprop="title">Modified polynucleotides for the production of proteins associated with human disease 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2013158579A1/en">
              <span itemprop="publicationNumber">WO2013158579A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2012-04-19</td>
          <td itemprop="publicationDate">2013-10-24</td>
          <td><span itemprop="assigneeOriginal">Merck Sharp &amp; Dohme Corp.</span></td>
          <td itemprop="title">Novel diester and triester based low molecular weight, biodegradable cationic lipids for oligonucleotide delivery 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/CN104519915A/en">
              <span itemprop="publicationNumber">CN104519915A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2012-06-08</td>
          <td itemprop="publicationDate">2015-04-15</td>
          <td><span itemprop="assigneeOriginal">å¤å°äººç±»éä¼ æ§æ²»çå¬å¸</span></td>
          <td itemprop="title">Pulmonary delivery of mRNA to non-lung target cells 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2014089486A1/en">
              <span itemprop="publicationNumber">WO2014089486A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2012-12-07</td>
          <td itemprop="publicationDate">2014-06-12</td>
          <td><span itemprop="assigneeOriginal">Shire Human Genetic Therapies, Inc.</span></td>
          <td itemprop="title">Lipidic nanoparticles for mrna delivering 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/CA2919226C/en">
              <span itemprop="publicationNumber">CA2919226C</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2013-07-23</td>
          <td itemprop="publicationDate">2024-05-14</td>
          <td><span itemprop="assigneeOriginal">Protiva Biotherapeutics, Inc.</span></td>
          <td itemprop="title">Compositions and methods for delivering messenger rna 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/BR112016013213A2/en">
              <span itemprop="publicationNumber">BR112016013213A2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2013-12-12</td>
          <td itemprop="publicationDate">2017-12-05</td>
          <td><span itemprop="assigneeOriginal">Massachusetts Inst Technology</span></td>
          <td itemprop="title">
  administration, use and therapeutic applications of crisper systems and compositions for targeting disorders and diseases using particle delivery components
 
     </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/JP6767976B2/en">
              <span itemprop="publicationNumber">JP6767976B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2014-12-05</td>
          <td itemprop="publicationDate">2020-10-14</td>
          <td><span itemprop="assigneeOriginal">ãã©ã³ã¹ã¬ã¤ã ãã¤ãªï¼ ã¤ã³ã³ã¼ãã¬ã¤ããã</span></td>
          <td itemprop="title">
        Messenger RNA therapy for the treatment of joint diseases
       
     </td>
        </tr>
      </tbody>
    </table>

    <ul>
      <li itemprop="applicationsByYear" itemscope repeat>
        <span itemprop="year">2017</span>
        <ul>
          <li itemprop="application" itemscope repeat>
            <span itemprop="filingDate">2017-06-30</span>
            <span itemprop="countryCode">AU</span>
            <span itemprop="applicationNumber">AU2017286980A</span>
            <a href="/patent/AU2017286980B2/en"><span itemprop="documentId">patent/AU2017286980B2/en</span></a>
            <span itemprop="legalStatusCat">active</span>
            <span itemprop="legalStatus">Active</span>
            
          </li>
          <li itemprop="application" itemscope repeat>
            <span itemprop="filingDate">2017-06-30</span>
            <span itemprop="countryCode">MX</span>
            <span itemprop="applicationNumber">MX2018016389A</span>
            <a href="/patent/MX2018016389A/en"><span itemprop="documentId">patent/MX2018016389A/en</span></a>
            <span itemprop="legalStatusCat">unknown</span>
            <span itemprop="legalStatus"></span>
            
          </li>
          <li itemprop="application" itemscope repeat>
            <span itemprop="filingDate">2017-06-30</span>
            <span itemprop="countryCode">US</span>
            <span itemprop="applicationNumber">US16/312,162</span>
            <a href="/patent/US11191849B2/en"><span itemprop="documentId">patent/US11191849B2/en</span></a>
            <span itemprop="legalStatusCat">active</span>
            <span itemprop="legalStatus">Active</span>
            <span itemprop="thisApp" content="true" bool></span>
          </li>
          <li itemprop="application" itemscope repeat>
            <span itemprop="filingDate">2017-06-30</span>
            <span itemprop="countryCode">JP</span>
            <span itemprop="applicationNumber">JP2018567951A</span>
            <a href="/patent/JP7086870B2/en"><span itemprop="documentId">patent/JP7086870B2/en</span></a>
            <span itemprop="legalStatusCat">active</span>
            <span itemprop="legalStatus">Active</span>
            
          </li>
          <li itemprop="application" itemscope repeat>
            <span itemprop="filingDate">2017-06-30</span>
            <span itemprop="countryCode">WO</span>
            <span itemprop="applicationNumber">PCT/US2017/040446</span>
            <a href="/patent/WO2018006052A1/en"><span itemprop="documentId">patent/WO2018006052A1/en</span></a>
            <span itemprop="legalStatusCat">not_active</span>
            <span itemprop="legalStatus">Ceased</span>
            
          </li>
          <li itemprop="application" itemscope repeat>
            <span itemprop="filingDate">2017-06-30</span>
            <span itemprop="countryCode">CN</span>
            <span itemprop="applicationNumber">CN201780049850.2A</span>
            <a href="/patent/CN109563511A/en"><span itemprop="documentId">patent/CN109563511A/en</span></a>
            <span itemprop="legalStatusCat">active</span>
            <span itemprop="legalStatus">Pending</span>
            
          </li>
          <li itemprop="application" itemscope repeat>
            <span itemprop="filingDate">2017-06-30</span>
            <span itemprop="countryCode">EP</span>
            <span itemprop="applicationNumber">EP17740546.1A</span>
            <a href="/patent/EP3478838A1/en"><span itemprop="documentId">patent/EP3478838A1/en</span></a>
            <span itemprop="legalStatusCat">active</span>
            <span itemprop="legalStatus">Pending</span>
            
          </li>
          <li itemprop="application" itemscope repeat>
            <span itemprop="filingDate">2017-06-30</span>
            <span itemprop="countryCode">CA</span>
            <span itemprop="applicationNumber">CA3034681A</span>
            <a href="/patent/CA3034681A1/en"><span itemprop="documentId">patent/CA3034681A1/en</span></a>
            <span itemprop="legalStatusCat">active</span>
            <span itemprop="legalStatus">Pending</span>
            
          </li>
        </ul>
      </li>
      <li itemprop="applicationsByYear" itemscope repeat>
        <span itemprop="year">2018</span>
        <ul>
          <li itemprop="application" itemscope repeat>
            <span itemprop="filingDate">2018-12-19</span>
            <span itemprop="countryCode">MX</span>
            <span itemprop="applicationNumber">MX2024000327A</span>
            <a href="/patent/MX2024000327A/en"><span itemprop="documentId">patent/MX2024000327A/en</span></a>
            <span itemprop="legalStatusCat">unknown</span>
            <span itemprop="legalStatus"></span>
            
          </li>
        </ul>
      </li>
      <li itemprop="applicationsByYear" itemscope repeat>
        <span itemprop="year">2021</span>
        <ul>
          <li itemprop="application" itemscope repeat>
            <span itemprop="filingDate">2021-11-01</span>
            <span itemprop="countryCode">US</span>
            <span itemprop="applicationNumber">US17/515,859</span>
            <a href="/patent/US20220160899A1/en"><span itemprop="documentId">patent/US20220160899A1/en</span></a>
            <span itemprop="legalStatusCat">not_active</span>
            <span itemprop="legalStatus">Abandoned</span>
            
          </li>
        </ul>
      </li>
      <li itemprop="applicationsByYear" itemscope repeat>
        <span itemprop="year">2022</span>
        <ul>
          <li itemprop="application" itemscope repeat>
            <span itemprop="filingDate">2022-06-07</span>
            <span itemprop="countryCode">JP</span>
            <span itemprop="applicationNumber">JP2022092262A</span>
            <a href="/patent/JP2022111231A/en"><span itemprop="documentId">patent/JP2022111231A/en</span></a>
            <span itemprop="legalStatusCat">active</span>
            <span itemprop="legalStatus">Pending</span>
            
          </li>
        </ul>
      </li>
      <li itemprop="applicationsByYear" itemscope repeat>
        <span itemprop="year">2024</span>
        <ul>
          <li itemprop="application" itemscope repeat>
            <span itemprop="filingDate">2024-01-22</span>
            <span itemprop="countryCode">AU</span>
            <span itemprop="applicationNumber">AU2024200392A</span>
            <a href="/patent/AU2024200392A1/en"><span itemprop="documentId">patent/AU2024200392A1/en</span></a>
            <span itemprop="legalStatusCat">not_active</span>
            <span itemprop="legalStatus">Abandoned</span>
            
          </li>
        </ul>
      </li>
      <li itemprop="applicationsByYear" itemscope repeat>
        <span itemprop="year">2025</span>
        <ul>
          <li itemprop="application" itemscope repeat>
            <span itemprop="filingDate">2025-02-07</span>
            <span itemprop="countryCode">JP</span>
            <span itemprop="applicationNumber">JP2025019358A</span>
            <a href="/patent/JP2025065390A/en"><span itemprop="documentId">patent/JP2025065390A/en</span></a>
            <span itemprop="legalStatusCat">active</span>
            <span itemprop="legalStatus">Pending</span>
            
          </li>
        </ul>
      </li>
    </ul>

    </section>

  

  

  <h2>Cited By (32)</h2>
  <table>
    <caption>* Cited by examiner, â  Cited by third party</caption>
    <thead>
      <tr>
        <th>Publication number</th>
        <th>Priority date</th>
        <th>Publication date</th>
        <th>Assignee</th>
        <th>Title</th>
      </tr>
    </thead>
    <tbody>
      <tr itemprop="forwardReferences" itemscope repeat>
        <td>
          <a href="/patent/US20210378962A1/en">
            <span itemprop="publicationNumber">US20210378962A1</span>
            (<span itemprop="primaryLanguage">en</span>)
          </a>
          <span itemprop="examinerCited">*</span>
          
        </td>
        <td itemprop="priorityDate">2018-10-19</td>
        <td itemprop="publicationDate">2021-12-09</td>
        <td><span itemprop="assigneeOriginal">Translate Bio, Inc.</span></td>
        <td itemprop="title">Pumpless encapsulation of messenger rna 
       </td>
      </tr>
      <tr itemprop="forwardReferences" itemscope repeat>
        <td>
          <a href="/patent/WO2021061707A1/en">
            <span itemprop="publicationNumber">WO2021061707A1</span>
            (<span itemprop="primaryLanguage">en</span>)
          </a>
          
          
        </td>
        <td itemprop="priorityDate">2019-09-23</td>
        <td itemprop="publicationDate">2021-04-01</td>
        <td><span itemprop="assigneeOriginal">Omega Therapeutics, Inc.</span></td>
        <td itemprop="title">Compositions and methods for modulating apolipoprotein b (apob) gene expression 
       </td>
      </tr>
      <tr itemprop="forwardReferences" itemscope repeat>
        <td>
          <a href="/patent/WO2021061815A1/en">
            <span itemprop="publicationNumber">WO2021061815A1</span>
            (<span itemprop="primaryLanguage">en</span>)
          </a>
          
          
        </td>
        <td itemprop="priorityDate">2019-09-23</td>
        <td itemprop="publicationDate">2021-04-01</td>
        <td><span itemprop="assigneeOriginal">Omega Therapeutics, Inc.</span></td>
        <td itemprop="title">COMPOSITIONS AND METHODS FOR MODULATING HEPATOCYTE NUCLEAR FACTOR 4-ALPHA (HNF4Î±) GENE EXPRESSION 
       </td>
      </tr>
      <tr itemprop="forwardReferences" itemscope repeat>
        <td>
          <a href="/patent/WO2021183720A1/en">
            <span itemprop="publicationNumber">WO2021183720A1</span>
            (<span itemprop="primaryLanguage">en</span>)
          </a>
          
          
        </td>
        <td itemprop="priorityDate">2020-03-11</td>
        <td itemprop="publicationDate">2021-09-16</td>
        <td><span itemprop="assigneeOriginal">Omega Therapeutics, Inc.</span></td>
        <td itemprop="title">Compositions and methods for modulating forkhead box p3 (foxp3) gene expression 
       </td>
      </tr>
      <tr itemprop="forwardReferences" itemscope repeat>
        <td>
          <a href="/patent/WO2021207020A1/en">
            <span itemprop="publicationNumber">WO2021207020A1</span>
            (<span itemprop="primaryLanguage">en</span>)
          </a>
          <span itemprop="examinerCited">*</span>
          
        </td>
        <td itemprop="priorityDate">2020-04-06</td>
        <td itemprop="publicationDate">2021-10-14</td>
        <td><span itemprop="assigneeOriginal">Tiba Biotech Llc</span></td>
        <td itemprop="title">Carriers for efficient nucleic acid delivery 
       </td>
      </tr>
      <tr itemprop="forwardReferences" itemscope repeat>
        <td>
          <a href="/patent/WO2022166814A1/en">
            <span itemprop="publicationNumber">WO2022166814A1</span>
            (<span itemprop="primaryLanguage">en</span>)
          </a>
          
          
        </td>
        <td itemprop="priorityDate">2021-02-07</td>
        <td itemprop="publicationDate">2022-08-11</td>
        <td><span itemprop="assigneeOriginal">ä¸­ç¾çåº·æ ¸é¸ææ¯(åé)ç ç©¶é¢æéå¬å¸</span></td>
        <td itemprop="title">Chemically modified small activating rna 
       </td>
      </tr>
      <tr itemprop="forwardReferences" itemscope repeat>
        <td>
          <a href="/patent/WO2023283359A2/en">
            <span itemprop="publicationNumber">WO2023283359A2</span>
            (<span itemprop="primaryLanguage">en</span>)
          </a>
          
          
        </td>
        <td itemprop="priorityDate">2021-07-07</td>
        <td itemprop="publicationDate">2023-01-12</td>
        <td><span itemprop="assigneeOriginal">Omega Therapeutics, Inc.</span></td>
        <td itemprop="title">Compositions and methods for modulating secreted frizzled receptor protein 1 (sfrp1) gene expression 
       </td>
      </tr>
      <tr itemprop="forwardReferences" itemscope repeat>
        <td>
          <a href="/patent/CN115703714A/en">
            <span itemprop="publicationNumber">CN115703714A</span>
            (<span itemprop="primaryLanguage">en</span>)
          </a>
          <span itemprop="examinerCited">*</span>
          
        </td>
        <td itemprop="priorityDate">2021-08-13</td>
        <td itemprop="publicationDate">2023-02-17</td>
        <td><span itemprop="assigneeOriginal">å¹¿å·è°·æ£®å¶è¯æéå¬å¸</span></td>
        <td itemprop="title">
        Novel Cationic Lipid Compounds
       
       </td>
      </tr>
      <tr itemprop="forwardReferences" itemscope repeat>
        <td>
          <a href="/patent/WO2023023055A1/en">
            <span itemprop="publicationNumber">WO2023023055A1</span>
            (<span itemprop="primaryLanguage">en</span>)
          </a>
          
          
        </td>
        <td itemprop="priorityDate">2021-08-16</td>
        <td itemprop="publicationDate">2023-02-23</td>
        <td><span itemprop="assigneeOriginal">Renagade Therapeutics Management Inc.</span></td>
        <td itemprop="title">Compositions and methods for optimizing tropism of delivery systems for rna 
       </td>
      </tr>
      <tr itemprop="forwardReferences" itemscope repeat>
        <td>
          <a href="/patent/US11859201B2/en">
            <span itemprop="publicationNumber">US11859201B2</span>
            (<span itemprop="primaryLanguage">en</span>)
          </a>
          
          
        </td>
        <td itemprop="priorityDate">2021-08-16</td>
        <td itemprop="publicationDate">2024-01-02</td>
        <td><span itemprop="assigneeOriginal">Tiba Biotech Llc</span></td>
        <td itemprop="title">Nanoparticle compositions containing sugar functionalized nucleic acid carriers 
       </td>
      </tr>
      <tr itemprop="forwardReferences" itemscope repeat>
        <td>
          <a href="/patent/US12410448B2/en">
            <span itemprop="publicationNumber">US12410448B2</span>
            (<span itemprop="primaryLanguage">en</span>)
          </a>
          
          
        </td>
        <td itemprop="priorityDate">2021-08-16</td>
        <td itemprop="publicationDate">2025-09-09</td>
        <td><span itemprop="assigneeOriginal">Tiba Biotech Llc</span></td>
        <td itemprop="title">Nanoparticle compositions containing sugar functionalized nucleic acid carriers 
       </td>
      </tr>
      <tr itemprop="forwardReferences" itemscope repeat>
        <td>
          <a href="/patent/WO2023044343A1/en">
            <span itemprop="publicationNumber">WO2023044343A1</span>
            (<span itemprop="primaryLanguage">en</span>)
          </a>
          
          
        </td>
        <td itemprop="priorityDate">2021-09-14</td>
        <td itemprop="publicationDate">2023-03-23</td>
        <td><span itemprop="assigneeOriginal">Renagade Therapeutics Management Inc.</span></td>
        <td itemprop="title">Acyclic lipids and methods of use thereof 
       </td>
      </tr>
      <tr itemprop="forwardReferences" itemscope repeat>
        <td>
          <a href="/patent/WO2023044333A1/en">
            <span itemprop="publicationNumber">WO2023044333A1</span>
            (<span itemprop="primaryLanguage">en</span>)
          </a>
          
          
        </td>
        <td itemprop="priorityDate">2021-09-14</td>
        <td itemprop="publicationDate">2023-03-23</td>
        <td><span itemprop="assigneeOriginal">Renagade Therapeutics Management Inc.</span></td>
        <td itemprop="title">Cyclic lipids and methods of use thereof 
       </td>
      </tr>
      <tr itemprop="forwardReferences" itemscope repeat>
        <td>
          <a href="/patent/WO2023081756A1/en">
            <span itemprop="publicationNumber">WO2023081756A1</span>
            (<span itemprop="primaryLanguage">en</span>)
          </a>
          
          
        </td>
        <td itemprop="priorityDate">2021-11-03</td>
        <td itemprop="publicationDate">2023-05-11</td>
        <td><span itemprop="assigneeOriginal">The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone</span></td>
        <td itemprop="title">Precise genome editing using retrons 
       </td>
      </tr>
      <tr itemprop="forwardReferences" itemscope repeat>
        <td>
          <a href="/patent/WO2023122752A1/en">
            <span itemprop="publicationNumber">WO2023122752A1</span>
            (<span itemprop="primaryLanguage">en</span>)
          </a>
          
          
        </td>
        <td itemprop="priorityDate">2021-12-23</td>
        <td itemprop="publicationDate">2023-06-29</td>
        <td><span itemprop="assigneeOriginal">Renagade Therapeutics Management Inc.</span></td>
        <td itemprop="title">Constrained lipids and methods of use thereof 
       </td>
      </tr>
      <tr itemprop="forwardReferences" itemscope repeat>
        <td>
          <a href="/patent/WO2023141602A2/en">
            <span itemprop="publicationNumber">WO2023141602A2</span>
            (<span itemprop="primaryLanguage">en</span>)
          </a>
          
          
        </td>
        <td itemprop="priorityDate">2022-01-21</td>
        <td itemprop="publicationDate">2023-07-27</td>
        <td><span itemprop="assigneeOriginal">Renagade Therapeutics Management Inc.</span></td>
        <td itemprop="title">Engineered retrons and methods of use 
       </td>
      </tr>
      <tr itemprop="forwardReferences" itemscope repeat>
        <td>
          <a href="/patent/WO2023196931A1/en">
            <span itemprop="publicationNumber">WO2023196931A1</span>
            (<span itemprop="primaryLanguage">en</span>)
          </a>
          
          
        </td>
        <td itemprop="priorityDate">2022-04-07</td>
        <td itemprop="publicationDate">2023-10-12</td>
        <td><span itemprop="assigneeOriginal">Renagade Therapeutics Management Inc.</span></td>
        <td itemprop="title">Cyclic lipids and lipid nanoparticles (lnp) for the delivery of nucleic acids or peptides for use in vaccinating against infectious agents 
       </td>
      </tr>
      <tr itemprop="forwardReferences" itemscope repeat>
        <td>
          <a href="/patent/WO2024020346A2/en">
            <span itemprop="publicationNumber">WO2024020346A2</span>
            (<span itemprop="primaryLanguage">en</span>)
          </a>
          
          
        </td>
        <td itemprop="priorityDate">2022-07-18</td>
        <td itemprop="publicationDate">2024-01-25</td>
        <td><span itemprop="assigneeOriginal">Renagade Therapeutics Management Inc.</span></td>
        <td itemprop="title">Gene editing components, systems, and methods of use 
       </td>
      </tr>
      <tr itemprop="forwardReferences" itemscope repeat>
        <td>
          <a href="/patent/WO2024044723A1/en">
            <span itemprop="publicationNumber">WO2024044723A1</span>
            (<span itemprop="primaryLanguage">en</span>)
          </a>
          
          
        </td>
        <td itemprop="priorityDate">2022-08-25</td>
        <td itemprop="publicationDate">2024-02-29</td>
        <td><span itemprop="assigneeOriginal">Renagade Therapeutics Management Inc.</span></td>
        <td itemprop="title">Engineered retrons and methods of use 
       </td>
      </tr>
      <tr itemprop="forwardReferences" itemscope repeat>
        <td>
          <a href="/patent/WO2024192291A1/en">
            <span itemprop="publicationNumber">WO2024192291A1</span>
            (<span itemprop="primaryLanguage">en</span>)
          </a>
          
          
        </td>
        <td itemprop="priorityDate">2023-03-15</td>
        <td itemprop="publicationDate">2024-09-19</td>
        <td><span itemprop="assigneeOriginal">Renagade Therapeutics Management Inc.</span></td>
        <td itemprop="title">Delivery of gene editing systems and methods of use thereof 
       </td>
      </tr>
      <tr itemprop="forwardReferences" itemscope repeat>
        <td>
          <a href="/patent/WO2024192277A2/en">
            <span itemprop="publicationNumber">WO2024192277A2</span>
            (<span itemprop="primaryLanguage">en</span>)
          </a>
          
          
        </td>
        <td itemprop="priorityDate">2023-03-15</td>
        <td itemprop="publicationDate">2024-09-19</td>
        <td><span itemprop="assigneeOriginal">Renagade Therapeutics Management Inc.</span></td>
        <td itemprop="title">Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents 
       </td>
      </tr>
      <tr itemprop="forwardReferences" itemscope repeat>
        <td>
          <a href="/patent/WO2024243438A2/en">
            <span itemprop="publicationNumber">WO2024243438A2</span>
            (<span itemprop="primaryLanguage">en</span>)
          </a>
          
          
        </td>
        <td itemprop="priorityDate">2023-05-23</td>
        <td itemprop="publicationDate">2024-11-28</td>
        <td><span itemprop="assigneeOriginal">Omega Therapeutics, Inc.</span></td>
        <td itemprop="title">Compositions and methods for reducing cxcl9, cxcl10, and cxcl11 gene expression 
       </td>
      </tr>
      <tr itemprop="forwardReferences" itemscope repeat>
        <td>
          <a href="/patent/WO2025007148A1/en">
            <span itemprop="publicationNumber">WO2025007148A1</span>
            (<span itemprop="primaryLanguage">en</span>)
          </a>
          
          
        </td>
        <td itemprop="priorityDate">2023-06-30</td>
        <td itemprop="publicationDate">2025-01-02</td>
        <td><span itemprop="assigneeOriginal">Orna Therapeutics, Inc.</span></td>
        <td itemprop="title">Polymer lipid nanoparticle compositions for delivering circular polynucleotides 
       </td>
      </tr>
      <tr itemprop="forwardReferences" itemscope repeat>
        <td>
          <a href="/patent/WO2025049959A2/en">
            <span itemprop="publicationNumber">WO2025049959A2</span>
            (<span itemprop="primaryLanguage">en</span>)
          </a>
          
          
        </td>
        <td itemprop="priorityDate">2023-09-01</td>
        <td itemprop="publicationDate">2025-03-06</td>
        <td><span itemprop="assigneeOriginal">Renagade Therapeutics Management Inc.</span></td>
        <td itemprop="title">Gene editing systems, compositions, and methods for treatment of vexas syndrome 
       </td>
      </tr>
      <tr itemprop="forwardReferences" itemscope repeat>
        <td>
          <a href="/patent/WO2025081042A1/en">
            <span itemprop="publicationNumber">WO2025081042A1</span>
            (<span itemprop="primaryLanguage">en</span>)
          </a>
          
          
        </td>
        <td itemprop="priorityDate">2023-10-12</td>
        <td itemprop="publicationDate">2025-04-17</td>
        <td><span itemprop="assigneeOriginal">Renagade Therapeutics Management Inc.</span></td>
        <td itemprop="title">Nickase-retron template-based precision editing system and methods of use 
       </td>
      </tr>
      <tr itemprop="forwardReferences" itemscope repeat>
        <td>
          <a href="/patent/US12491262B2/en">
            <span itemprop="publicationNumber">US12491262B2</span>
            (<span itemprop="primaryLanguage">en</span>)
          </a>
          
          
        </td>
        <td itemprop="priorityDate">2023-10-31</td>
        <td itemprop="publicationDate">2025-12-09</td>
        <td><span itemprop="assigneeOriginal">Tiba Biotech Llc</span></td>
        <td itemprop="title">Gene delivery agents 
       </td>
      </tr>
      <tr itemprop="forwardReferences" itemscope repeat>
        <td>
          <a href="/patent/WO2025128871A2/en">
            <span itemprop="publicationNumber">WO2025128871A2</span>
            (<span itemprop="primaryLanguage">en</span>)
          </a>
          
          
        </td>
        <td itemprop="priorityDate">2023-12-13</td>
        <td itemprop="publicationDate">2025-06-19</td>
        <td><span itemprop="assigneeOriginal">Renagade Therapeutics Management Inc.</span></td>
        <td itemprop="title">Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents 
       </td>
      </tr>
      <tr itemprop="forwardReferences" itemscope repeat>
        <td>
          <a href="/patent/WO2025144938A1/en">
            <span itemprop="publicationNumber">WO2025144938A1</span>
            (<span itemprop="primaryLanguage">en</span>)
          </a>
          
          
        </td>
        <td itemprop="priorityDate">2023-12-26</td>
        <td itemprop="publicationDate">2025-07-03</td>
        <td><span itemprop="assigneeOriginal">Emmune, Inc.</span></td>
        <td itemprop="title">Systems for nucleic acid transfer 
       </td>
      </tr>
      <tr itemprop="forwardReferences" itemscope repeat>
        <td>
          <a href="/patent/WO2025155753A2/en">
            <span itemprop="publicationNumber">WO2025155753A2</span>
            (<span itemprop="primaryLanguage">en</span>)
          </a>
          
          
        </td>
        <td itemprop="priorityDate">2024-01-17</td>
        <td itemprop="publicationDate">2025-07-24</td>
        <td><span itemprop="assigneeOriginal">Renagade Therapeutics Management Inc.</span></td>
        <td itemprop="title">Improved gene editing system, guides, and methods 
       </td>
      </tr>
      <tr itemprop="forwardReferences" itemscope repeat>
        <td>
          <a href="/patent/WO2025166238A1/en">
            <span itemprop="publicationNumber">WO2025166238A1</span>
            (<span itemprop="primaryLanguage">en</span>)
          </a>
          
          
        </td>
        <td itemprop="priorityDate">2024-01-31</td>
        <td itemprop="publicationDate">2025-08-07</td>
        <td><span itemprop="assigneeOriginal">Orna Therapeutics, Inc.</span></td>
        <td itemprop="title">Fast-shedding polyethylene glycol lipids 
       </td>
      </tr>
      <tr itemprop="forwardReferences" itemscope repeat>
        <td>
          <a href="/patent/WO2025174765A1/en">
            <span itemprop="publicationNumber">WO2025174765A1</span>
            (<span itemprop="primaryLanguage">en</span>)
          </a>
          
          
        </td>
        <td itemprop="priorityDate">2024-02-12</td>
        <td itemprop="publicationDate">2025-08-21</td>
        <td><span itemprop="assigneeOriginal">Renagade Therapeutics Management Inc.</span></td>
        <td itemprop="title">Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents 
       </td>
      </tr>
      <tr itemprop="forwardReferences" itemscope repeat>
        <td>
          <a href="/patent/WO2026003582A2/en">
            <span itemprop="publicationNumber">WO2026003582A2</span>
            (<span itemprop="primaryLanguage">en</span>)
          </a>
          
          
        </td>
        <td itemprop="priorityDate">2024-06-27</td>
        <td itemprop="publicationDate">2026-01-02</td>
        <td><span itemprop="assigneeOriginal">Axelyf ehf.</span></td>
        <td itemprop="title">Lipids and lipid nanoparticles 
       </td>
      </tr>
    </tbody>
  </table>

  <section>
    <h2>Also Published As</h2>
    <table>
      <thead>
        <tr>
          <th>Publication number</th>
          <th>Publication date</th>
        </tr>
      </thead>
      <tbody>
        <tr itemprop="docdbFamily" itemscope repeat>
          <td>
            <a href="/patent/JP2022111231A/en">
              <span itemprop="publicationNumber">JP2022111231A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="publicationDate">2022-07-29</td>
        </tr>
        <tr itemprop="docdbFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2018006052A1/en">
              <span itemprop="publicationNumber">WO2018006052A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="publicationDate">2018-01-04</td>
        </tr>
        <tr itemprop="docdbFamily" itemscope repeat>
          <td>
            <a href="/patent/AU2024200392A1/en">
              <span itemprop="publicationNumber">AU2024200392A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="publicationDate">2024-02-08</td>
        </tr>
        <tr itemprop="docdbFamily" itemscope repeat>
          <td>
            <a href="/patent/EP3478838A1/en">
              <span itemprop="publicationNumber">EP3478838A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="publicationDate">2019-05-08</td>
        </tr>
        <tr itemprop="docdbFamily" itemscope repeat>
          <td>
            <a href="/patent/US11191849B2/en">
              <span itemprop="publicationNumber">US11191849B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="publicationDate">2021-12-07</td>
        </tr>
        <tr itemprop="docdbFamily" itemscope repeat>
          <td>
            <a href="/patent/US20220160899A1/en">
              <span itemprop="publicationNumber">US20220160899A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="publicationDate">2022-05-26</td>
        </tr>
        <tr itemprop="docdbFamily" itemscope repeat>
          <td>
            <a href="/patent/CN109563511A/en">
              <span itemprop="publicationNumber">CN109563511A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="publicationDate">2019-04-02</td>
        </tr>
        <tr itemprop="docdbFamily" itemscope repeat>
          <td>
            <a href="/patent/MX2024000327A/en">
              <span itemprop="publicationNumber">MX2024000327A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="publicationDate">2024-01-25</td>
        </tr>
        <tr itemprop="docdbFamily" itemscope repeat>
          <td>
            <a href="/patent/JP7086870B2/en">
              <span itemprop="publicationNumber">JP7086870B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="publicationDate">2022-06-20</td>
        </tr>
        <tr itemprop="docdbFamily" itemscope repeat>
          <td>
            <a href="/patent/JP2019519568A/en">
              <span itemprop="publicationNumber">JP2019519568A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="publicationDate">2019-07-11</td>
        </tr>
        <tr itemprop="docdbFamily" itemscope repeat>
          <td>
            <a href="/patent/CA3034681A1/en">
              <span itemprop="publicationNumber">CA3034681A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="publicationDate">2018-01-04</td>
        </tr>
        <tr itemprop="docdbFamily" itemscope repeat>
          <td>
            <a href="/patent/MX2018016389A/en">
              <span itemprop="publicationNumber">MX2018016389A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="publicationDate">2019-08-16</td>
        </tr>
        <tr itemprop="docdbFamily" itemscope repeat>
          <td>
            <a href="/patent/AU2017286980B2/en">
              <span itemprop="publicationNumber">AU2017286980B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="publicationDate">2023-10-26</td>
        </tr>
        <tr itemprop="docdbFamily" itemscope repeat>
          <td>
            <a href="/patent/AU2017286980A1/en">
              <span itemprop="publicationNumber">AU2017286980A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="publicationDate">2019-01-17</td>
        </tr>
        <tr itemprop="docdbFamily" itemscope repeat>
          <td>
            <a href="/patent/JP2025065390A/en">
              <span itemprop="publicationNumber">JP2025065390A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="publicationDate">2025-04-17</td>
        </tr>
      </tbody>
    </table>
  </section>

  <section>
    <h2>Similar Documents</h2>
    <table>
      <thead>
        <tr>
          <th>Publication</th>
          <th>Publication Date</th>
          <th>Title</th>
        </tr>
      </thead>
      <tbody>
        <tr itemprop="similarDocuments" itemscope repeat>
          <td>
            <meta itemprop="isPatent" content="true">
              <a href="/patent/US11191849B2/en">
                <span itemprop="publicationNumber">US11191849B2</span>
                (<span itemprop="primaryLanguage">en</span>)
              </a>
            
            
          </td>
          <td>
            <time itemprop="publicationDate" datetime="2021-12-07">2021-12-07</time>
            
            
          </td>
          <td itemprop="title">Compositions and methods for delivering messenger RNA 
       </td>
        </tr>
        <tr itemprop="similarDocuments" itemscope repeat>
          <td>
            <meta itemprop="isPatent" content="true">
              <a href="/patent/US20230165973A1/en">
                <span itemprop="publicationNumber">US20230165973A1</span>
                (<span itemprop="primaryLanguage">en</span>)
              </a>
            
            
          </td>
          <td>
            <time itemprop="publicationDate" datetime="2023-06-01">2023-06-01</time>
            
            
          </td>
          <td itemprop="title">Compositions and methods for delivering messenger rna 
     </td>
        </tr>
        <tr itemprop="similarDocuments" itemscope repeat>
          <td>
            <meta itemprop="isPatent" content="true">
              <a href="/patent/US20230212578A1/en">
                <span itemprop="publicationNumber">US20230212578A1</span>
                (<span itemprop="primaryLanguage">en</span>)
              </a>
            
            
          </td>
          <td>
            <time itemprop="publicationDate" datetime="2023-07-06">2023-07-06</time>
            
            
          </td>
          <td itemprop="title">Compositions and methods for treating hypertriglyceridemia 
     </td>
        </tr>
        <tr itemprop="similarDocuments" itemscope repeat>
          <td>
            <meta itemprop="isPatent" content="true">
              <a href="/patent/US10626393B2/en">
                <span itemprop="publicationNumber">US10626393B2</span>
                (<span itemprop="primaryLanguage">en</span>)
              </a>
            
            
          </td>
          <td>
            <time itemprop="publicationDate" datetime="2020-04-21">2020-04-21</time>
            
            
          </td>
          <td itemprop="title">Delivering CRISPR therapeutics with lipid nanoparticles 
       </td>
        </tr>
        <tr itemprop="similarDocuments" itemscope repeat>
          <td>
            <meta itemprop="isPatent" content="true">
              <a href="/patent/EP3201338B1/en">
                <span itemprop="publicationNumber">EP3201338B1</span>
                (<span itemprop="primaryLanguage">en</span>)
              </a>
            
            
          </td>
          <td>
            <time itemprop="publicationDate" datetime="2021-11-03">2021-11-03</time>
            
            
          </td>
          <td itemprop="title">Compositions and methods for silencing hepatitis b virus gene expression 
       </td>
        </tr>
        <tr itemprop="similarDocuments" itemscope repeat>
          <td>
            <meta itemprop="isPatent" content="true">
              <a href="/patent/EP3329003A2/en">
                <span itemprop="publicationNumber">EP3329003A2</span>
                (<span itemprop="primaryLanguage">en</span>)
              </a>
            
            
          </td>
          <td>
            <time itemprop="publicationDate" datetime="2018-06-06">2018-06-06</time>
            
            
          </td>
          <td itemprop="title">Compositions and methods for silencing hepatitis b virus gene expression 
       </td>
        </tr>
        <tr itemprop="similarDocuments" itemscope repeat>
          <td>
            <meta itemprop="isPatent" content="true">
              <a href="/patent/WO2016183366A2/en">
                <span itemprop="publicationNumber">WO2016183366A2</span>
                (<span itemprop="primaryLanguage">en</span>)
              </a>
            
            
          </td>
          <td>
            <time itemprop="publicationDate" datetime="2016-11-17">2016-11-17</time>
            
            
          </td>
          <td itemprop="title">Compositions and methods for silencing expression of hepatitis d virus rna 
       </td>
        </tr>
        <tr itemprop="similarDocuments" itemscope repeat>
          <td>
            <meta itemprop="isPatent" content="true">
              <a href="/patent/HK40023090A/en">
                <span itemprop="publicationNumber">HK40023090A</span>
                (<span itemprop="primaryLanguage">en</span>)
              </a>
            
            
          </td>
          <td>
            <time itemprop="publicationDate" datetime="2020-11-27">2020-11-27</time>
            
            
          </td>
          <td itemprop="title">Compositions and methods for delivering messenger rna 
       </td>
        </tr>
        <tr itemprop="similarDocuments" itemscope repeat>
          <td>
            <meta itemprop="isPatent" content="true">
              <a href="/patent/HK1219719B/en">
                <span itemprop="publicationNumber">HK1219719B</span>
                (<span itemprop="primaryLanguage">en</span>)
              </a>
            
            
          </td>
          <td>
            <time itemprop="publicationDate" datetime="2020-11-06">2020-11-06</time>
            
            
          </td>
          <td itemprop="title">Compositions and methods for delivering messenger rna 
       </td>
        </tr>
        <tr itemprop="similarDocuments" itemscope repeat>
          <td>
            <meta itemprop="isPatent" content="true">
              <a href="/patent/HK1234102B/en">
                <span itemprop="publicationNumber">HK1234102B</span>
                (<span itemprop="primaryLanguage">en</span>)
              </a>
            
            
          </td>
          <td>
            <time itemprop="publicationDate" datetime="2022-02-25">2022-02-25</time>
            
            
          </td>
          <td itemprop="title">Compositions and methods for silencing hepatitis b virus gene expression 
       </td>
        </tr>
      </tbody>
    </table>
  </section>

  <section>
    <h2>Legal Events</h2>
    <table>
      <thead>
        <tr>
          <th>Date</th>
          <th>Code</th>
          <th>Title</th>
          <th>Description</th>
        </tr>
      </thead>
      <tbody>
        <tr itemprop="legalEvents" itemscope repeat>
          <td><time itemprop="date" datetime="2018-12-20">2018-12-20</time></td>
          <td itemprop="code">FEPP</td>
          <td itemprop="title">Fee payment procedure</td>
          <td>
            <p itemprop="attributes" itemscope repeat>
              <strong itemprop="label">Free format text</strong>:
              <span itemprop="value">ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: BIG.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY</span>
            </p>
          </td>
        </tr>
        <tr itemprop="legalEvents" itemscope repeat>
          <td><time itemprop="date" datetime="2019-03-05">2019-03-05</time></td>
          <td itemprop="code">AS</td>
          <td itemprop="title">Assignment</td>
          <td>
            <p itemprop="attributes" itemscope repeat>
              <strong itemprop="label">Owner name</strong>:
              <span itemprop="value">ARBUTUS BIOPHARMA CORPORATION, CANADA</span>
            </p>
            <p itemprop="attributes" itemscope repeat>
              <strong itemprop="label">Free format text</strong>:
              <span itemprop="value">ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ABRAMS, MICHAEL J.;HEYES, JAMES;JUDGE, ADAM;AND OTHERS;SIGNING DATES FROM 20180823 TO 20180914;REEL/FRAME:048510/0276</span>
            </p>
          </td>
        </tr>
        <tr itemprop="legalEvents" itemscope repeat>
          <td><time itemprop="date" datetime="2019-08-16">2019-08-16</time></td>
          <td itemprop="code">STPP</td>
          <td itemprop="title">Information on status: patent application and granting procedure in general</td>
          <td>
            <p itemprop="attributes" itemscope repeat>
              <strong itemprop="label">Free format text</strong>:
              <span itemprop="value">APPLICATION DISPATCHED FROM PREEXAM, NOT YET DOCKETED</span>
            </p>
          </td>
        </tr>
        <tr itemprop="legalEvents" itemscope repeat>
          <td><time itemprop="date" datetime="2019-11-27">2019-11-27</time></td>
          <td itemprop="code">STPP</td>
          <td itemprop="title">Information on status: patent application and granting procedure in general</td>
          <td>
            <p itemprop="attributes" itemscope repeat>
              <strong itemprop="label">Free format text</strong>:
              <span itemprop="value">DOCKETED NEW CASE - READY FOR EXAMINATION</span>
            </p>
          </td>
        </tr>
        <tr itemprop="legalEvents" itemscope repeat>
          <td><time itemprop="date" datetime="2021-01-13">2021-01-13</time></td>
          <td itemprop="code">STPP</td>
          <td itemprop="title">Information on status: patent application and granting procedure in general</td>
          <td>
            <p itemprop="attributes" itemscope repeat>
              <strong itemprop="label">Free format text</strong>:
              <span itemprop="value">NON FINAL ACTION MAILED</span>
            </p>
          </td>
        </tr>
        <tr itemprop="legalEvents" itemscope repeat>
          <td><time itemprop="date" datetime="2021-07-21">2021-07-21</time></td>
          <td itemprop="code">STPP</td>
          <td itemprop="title">Information on status: patent application and granting procedure in general</td>
          <td>
            <p itemprop="attributes" itemscope repeat>
              <strong itemprop="label">Free format text</strong>:
              <span itemprop="value">RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER</span>
            </p>
          </td>
        </tr>
        <tr itemprop="legalEvents" itemscope repeat>
          <td><time itemprop="date" datetime="2021-08-06">2021-08-06</time></td>
          <td itemprop="code">STPP</td>
          <td itemprop="title">Information on status: patent application and granting procedure in general</td>
          <td>
            <p itemprop="attributes" itemscope repeat>
              <strong itemprop="label">Free format text</strong>:
              <span itemprop="value">NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS</span>
            </p>
          </td>
        </tr>
        <tr itemprop="legalEvents" itemscope repeat>
          <td><time itemprop="date" datetime="2021-10-29">2021-10-29</time></td>
          <td itemprop="code">STPP</td>
          <td itemprop="title">Information on status: patent application and granting procedure in general</td>
          <td>
            <p itemprop="attributes" itemscope repeat>
              <strong itemprop="label">Free format text</strong>:
              <span itemprop="value">PUBLICATIONS -- ISSUE FEE PAYMENT RECEIVED</span>
            </p>
          </td>
        </tr>
        <tr itemprop="legalEvents" itemscope repeat>
          <td><time itemprop="date" datetime="2021-11-01">2021-11-01</time></td>
          <td itemprop="code">STPP</td>
          <td itemprop="title">Information on status: patent application and granting procedure in general</td>
          <td>
            <p itemprop="attributes" itemscope repeat>
              <strong itemprop="label">Free format text</strong>:
              <span itemprop="value">PUBLICATIONS -- ISSUE FEE PAYMENT VERIFIED</span>
            </p>
          </td>
        </tr>
        <tr itemprop="legalEvents" itemscope repeat>
          <td><time itemprop="date" datetime="2021-11-17">2021-11-17</time></td>
          <td itemprop="code">STCF</td>
          <td itemprop="title">Information on status: patent grant</td>
          <td>
            <p itemprop="attributes" itemscope repeat>
              <strong itemprop="label">Free format text</strong>:
              <span itemprop="value">PATENTED CASE</span>
            </p>
          </td>
        </tr>
        <tr itemprop="legalEvents" itemscope repeat>
          <td><time itemprop="date" datetime="2025-06-09">2025-06-09</time></td>
          <td itemprop="code">MAFP</td>
          <td itemprop="title">Maintenance fee payment</td>
          <td>
            <p itemprop="attributes" itemscope repeat>
              <strong itemprop="label">Free format text</strong>:
              <span itemprop="value">PAYMENT OF MAINTENANCE FEE, 4TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1551); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY</span>
            </p>
            <p itemprop="attributes" itemscope repeat>
              <strong itemprop="label">Year of fee payment</strong>:
              <span itemprop="value">4</span>
            </p>
          </td>
        </tr>
      </tbody>
    </table>
  </section>

</article>

    </search-app>
    
    <script></script>
    <script type="text/javascript" src="//www.gstatic.com/feedback/api.js"></script>
    <script type="text/javascript" src="//www.gstatic.com/feedback/js/help/prod/service/lazy.min.js"></script>
    <script type="text/javascript">
      if (window.help && window.help.service) {
        helpApi = window.help.service.Lazy.create(0, {apiKey: 'AIzaSyDTEI_0tLX4varJ7bwK8aT-eOI5qr3BmyI', locale: 'en-US'});
        window.requestedSurveys = new Set();
        window.requestSurvey = function(triggerId) {
          if (window.requestedSurveys.has(triggerId)) {
            return;
          }
          window.requestedSurveys.add(triggerId);
          helpApi.requestSurvey({
            triggerId: triggerId,
            enableTestingMode: false,
            callback: (requestSurveyCallbackParam) => {
              if (!requestSurveyCallbackParam.surveyData) {
                return;
              }
              helpApi.presentSurvey({
                productData: {
                  productVersion: window.version,
                  customData: {
                    "experiments": "",
                  },
                },
                surveyData: requestSurveyCallbackParam.surveyData,
                colorScheme: 1,
                customZIndex: 10000,
              });
            }
          });
        };

        window.requestSurvey('YXTwAsvoW0kedxbuTdH0RArc9VhT');
      }
    </script>
    <script src="/sw/null_loader.js"></script>
  </body>
</html>
